<SEC-DOCUMENT>0001193125-22-257577.txt : 20221004
<SEC-HEADER>0001193125-22-257577.hdr.sgml : 20221004
<ACCEPTANCE-DATETIME>20221004160317
ACCESSION NUMBER:		0001193125-22-257577
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		20
FILED AS OF DATE:		20221004
DATE AS OF CHANGE:		20221004

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Amylyx Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001658551
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				464600503
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-267730
		FILM NUMBER:		221291426

	BUSINESS ADDRESS:	
		STREET 1:		43 THORNDIKE STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
		BUSINESS PHONE:		617-683-0917

	MAIL ADDRESS:	
		STREET 1:		43 THORNDIKE STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>d383770ds1.htm
<DESCRIPTION>S-1
<TEXT>
<HTML><HEAD>
<TITLE>S-1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>As filed with the Securities and Exchange Commission on October&nbsp;4, 2022. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-</FONT> </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE
COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B><I>THE SECURITIES ACT OF 1933
</I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL" ALIGN="center"><B>Amylyx Pharmaceuticals, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Exact name of
registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">46-4600503</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>43 Thorndike St. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cambridge, Massachusetts 02141 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(617) <FONT
STYLE="white-space:nowrap">682-0917</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s
principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Joshua B. Cohen, <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Justin B. Klee, <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Amylyx Pharmaceuticals, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>43 Thorndike St.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cambridge, Massachusetts 02141 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(617) <FONT
STYLE="white-space:nowrap">682-0917</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service)
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>Copies to: </I></B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Mitchell S. Bloom, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Benjamin K. Marsh, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Goodwin Procter
LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>100 Northern Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Boston,
Massachusetts 02210</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">570-1000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Lisa Firenze, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Stuart M. Falber, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Jeffries <FONT
STYLE="white-space:nowrap">Oliver-Li,</FONT> Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Wilmer Cutler Pickering Hale and Dorr LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>7 World Trade Center</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>250 Greenwich
Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>New York, New York 10007</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(212) <FONT
STYLE="white-space:nowrap">230-8800</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as practicable after this Registration Statement is declared effective.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities
Act of 1933 check the following box.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If this form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT
STYLE="font-family:Times New Roman">&#9744;</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act,
check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company,&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging growth company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant
shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective
on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#de1a1e">The information in this prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where
the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#de1a1e">Subject To
Completion. Dated October 4, 2022. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><U>6,000,000</U> Shares </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383770g92x08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are offering 6,000,000
shares of our common stock. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our common stock is listed on the Nasdaq Global Select Stock Market, or Nasdaq, under the symbol &#147;AMLX.&#148; On
October&nbsp;3, 2022, the last reported sale price of our common stock, as reported on Nasdaq, was $29.75 per share. The final public offering price will be determined through negotiation between us and the lead underwriters in the offering, and the
recent market price used throughout the prospectus may not be indicative of the actual offering price. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth
company&#148; as defined under U.S. federal securities laws and, as such, will be subject to reduced public company reporting requirements for this prospectus and future filings. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Investing in our common stock involves risks. See &#147;<A HREF="#toc383770_3">Risk Factors</A>&#148; beginning on page&nbsp;13 of this prospectus
and under similar headings in documents incorporated by reference into this prospectus to read about factors you should consider before buying shares of our common stock. </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities nor passed upon
the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Per&nbsp;Share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discounts(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds, before expenses, to Amylyx Pharmaceuticals, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">See the section titled &#147;Underwriting&#148; for a description of the compensation payable to the underwriters.
</P></TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters have the option to purchase up to an additional 900,000 shares from us at the price to the public less the
underwriting discount. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters expect to deliver the shares against payment in New York, New York on or about
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:14pt">
<TD VALIGN="top" ALIGN="center"><B>Goldman&nbsp;Sachs&nbsp;&amp; Co. LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>BofA&nbsp;Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>SVB&nbsp;Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Evercore&nbsp;ISI</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>H.C. Wainwright&nbsp;&amp; Co. </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Prospectus dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022 </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc383770_1">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc383770_2">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc383770_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc383770_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc383770_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc383770_6">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc383770_7">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc383770_8">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc383770_9">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc383770_10">PRINCIPAL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc383770_11">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc383770_12">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc383770_13">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <FONT STYLE="white-space:nowrap">NON-U.S.
</FONT> HOLDERS OF COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc383770_14">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc383770_15">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc383770_16">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc383770_17">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc383770_18">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We incorporate by reference important information into this prospectus. You may obtain the information incorporated by
reference without charge by following the instructions under &#147;Where You Can Find More Information.&#148; You should carefully read this prospectus as well as additional information described under &#147;Incorporation of Certain Information by
Reference,&#148; before deciding to invest in our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Neither we nor the underwriters have authorized anyone to provide you with any
information or to make any representations other than those contained in this prospectus, any amendment or supplement to this prospectus, or in any free writing prospectus we may authorize to be delivered or made available to you. Neither we nor the
underwriters take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where
offers and sales are permitted. The information contained in this prospectus is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or any sale of shares of our common stock. Our
business, financial condition, results of operations and prospects may have changed since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For investors outside the United States: We
have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside
the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In this prospectus, unless otherwise stated or the context otherwise requires, references to &#147;Amylyx,&#148; &#147;the Company,&#148;
&#147;we,&#148; &#147;us,&#148; &#147;our&#148; and similar references refer to Amylyx Pharmaceuticals, Inc. Amylyx and other trademarks or service marks of Amylyx appearing in this prospectus, including RELYVRIO<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> and ALBRIOZA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, are the property of Amylyx. The other trademarks, trade names and service marks appearing in this prospectus are the
property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and
<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc383770_1"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>This summary highlights, and is qualified in its entirety by, the more detailed information included elsewhere in this prospectus and the other
documents incorporated by reference herein. This summary does not contain all of the information that may be important to you. You should carefully consider, among other things, the matters discussed in &#147;Risk Factors&#148; and &#147;Special
Note Regarding Forward-Looking Statements&#148; in this prospectus and the information in our filings with the U.S. Securities and Exchange Commission, or the SEC, incorporated by reference in this prospectus. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our mission is to one day end the
suffering caused by neurodegenerative diseases. Unlike most other cells in the body that regularly die and are replaced as part of healthy function, mature neurons are normally resistant to cell death and generally cannot regenerate. We believe
AMX0035 is the first drug candidate to show both a functional and survival benefit in a large-scale clinical trial of patients with Amyotrophic Lateral Sclerosis, or ALS. On September 29, 2022, the U.S. Food and Drug Administration, or FDA, approved
AMX0035, known as RELYVRIO in the United States, for the treatment of ALS in adults, and we are preparing for commercial launch of this product. AMX0035 also received marketing authorization with conditions as ALBRIOZA by Health Canada for the
treatment of ALS in June 2022, and we commenced Canadian commercial sales of ALBRIOZA in the third quarter of 2022. We submitted a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, in the first quarter of 2022,
which was validated in the same quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">AMX0035 is a dual <FONT STYLE="white-space:nowrap">UPR-Bax</FONT> apoptosis inhibitor composed of sodium
phenylbutyrate, or PB, and TURSO (also known as tauroursodeoxycholic acid, or TUDCA). Through the resolution of the unfolded protein response, or UPR, and by inhibiting translocation of the <FONT STYLE="white-space:nowrap">Bcl-2</FONT> Associated <FONT
STYLE="white-space:nowrap">X-protein,</FONT> or Bax, to the outer mitochondrial membrane, we have shown in multiple models that AMX0035 can keep neurons alive under a variety of different conditions and stresses, including in in vitro models of
neurodegeneration, endoplasmic reticulum stress, mitochondrial dysfunction, oxidative stress and disease-specific models of a variety of other conditions, as well as in vivo models of Alzheimer&#146;s Disease, or AD, and multiple sclerosis. We are
pursuing ALS as our first indication as it is a disease of rapid and profound neurodegeneration, and we are focused on the development and potential commercialization of AMX0035 for ALS globally. We believe AMX0035 has the potential to be a
foundational therapy, meaning that it could be used alone or in conjunction with other therapies, to change the treatment paradigm across a broad range of neurodegenerative diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2021, we initiated a global Phase 3 clinical trial of AMX0035 for the treatment of ALS, known as the PHOENIX trial, at clinical trial sites
in the United States and Europe. Enrollment in this trial was completed in March 2022 in the United States and remains ongoing in Europe. We anticipate topline results from the PHOENIX trial in 2024. This trial is designed to provide further data
evaluating the safety and efficacy of AMX0035 for the treatment of ALS and to further support our global regulatory efforts and approvals. In July 2022, we announced a planned open label extension, or OLE, for the PHOENIX trial, which will allow all
participants who complete the PHOENIX trial, regardless of original treatment assignment, to receive AMX0035 following the trial. In March 2022, we announced the launch of an expanded access program, or EAP, in the United States that the FDA has
authorized for people with ALS who meet eligibility criteria for participation. The EAP will be wound down alongside the commercial launch of RELYVRIO in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA approval on September 29, 2022 of AMX0035 as RELYVRIO for the treatment of ALS in adults was granted following the second virtual meeting of the
FDA&#146;s Peripheral and Central Nervous System Drugs Advisory Committee, or the Advisory Committee, held on September 7, 2022. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
The Advisory Committee initially met on March 30, 2022 and voted 4 (yes) and 6 (no) on the question of whether the data from our randomized, controlled Phase 2 CENTAUR trial and OLE established a
conclusion that AMX0035 is effective in the treatment of patients with ALS. At the second meeting of the Advisory Committee, the Advisory Committee voted 7 (yes) to 2 (no) in response to the question of whether available evidence of effectiveness is
sufficient to support approval of AMX0035 for the treatment of ALS, taking into account the unmet need in ALS, the status of the ongoing PHOENIX trial and the seriousness of ALS. At this meeting and the previous Advisory Committee meeting, the FDA
presented concerns regarding choices of statistical models for the prespecified primary analysis and the interpretability of the survival results. In both Advisory Committee meetings, we presented scientific arguments and analyses, together with
experts in the field, which we believe sufficiently addressed these concerns. In describing its basis for approval, the FDA acknowledged this scientific debate but concluded that the data met the substantial evidence standard, noting the limitations
of exploratory and post hoc analyses. As a result of the FDA&#146;s approval of AMX0035 for the treatment of ALS in adults, we are preparing for a commercial launch of RELYVRIO in the United&nbsp;States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are also developing AMX0035 for other neurodegenerative diseases by leveraging our deep knowledge of and relationships in the neurodegenerative
space. We believe the approach of a dual <FONT STYLE="white-space:nowrap">UPR-Bax</FONT> apoptosis inhibitor designed to help keep neurons alive could be clinically meaningful for the treatment of other neurodegenerative disease indications in
addition to ALS. Many common and rare neurodegenerative diseases are characterized by substantial neuronal cellular loss, including AD and Wolfram syndrome, as well as Parkinson&#146;s Disease, Huntington&#146;s Disease, Progressive Supranuclear
Palsy, Multi-System Atrophy, and others. We conducted a Phase 2 clinical trial in AD, known as the PEGASUS trial, to obtain safety data along with initial efficacy and biomarker data which could help us prioritize additional indications to pursue
with AMX0035. We believe the topline results from the PEGASUS trial, reported in November 2021, provide further biological knowledge about AMX0035 which will help inform future clinical development of AMX0035 for the treatment of AD and in other
potential indications. Based on these topline results, AMX0035 met the PEGASUS trial&#146;s primary endpoint of safety and tolerability. The <FONT STYLE="white-space:nowrap">6-month</FONT> trial was not powered to evaluate differences between groups
in efficacy outcomes and no differences were seen in a newly developed composite outcome of cognitive, functional, and imaging measures, or in secondary efficacy endpoints of cognition, function, and imaging. In this trial, AMX0035 showed
significant effects on biomarkers including neurogranin, YKL-40 or Chitinase 3-like 1 (CHI3L1), and fatty acid binding protein 3 (FABP3). These results build on previously reported findings that AMX0035 exhibited significant effects on the total tau
protein, tau phosphorylated at threonine 181, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">8-hydroxy-2&#146;&#151;deoxyguanosine,</FONT></FONT> or <FONT STYLE="white-space:nowrap">8-OHdG,</FONT> and the amyloid beta 42 to 40 <FONT
STYLE="white-space:nowrap">(amyloid-&szlig;1-42,</FONT> <FONT STYLE="white-space:nowrap">amyloid-&szlig;1-40)</FONT> ratio in cerebrospinal fluid. We will continue to evaluate these data and discuss the results of the PEGASUS trial with scientific
advisors as we consider potential next steps for the development of AMX0035 for the treatment of AD within our clinical development strategy. Based on preclinical evidence, we are continuing to evaluate plans to explore the use of AMX0035 in
patients with Wolfram syndrome. We intend to prioritize our development efforts around neurodegenerative diseases that result in substantial disability, and ultimately death, and where unmet medical needs are greatest. Neurodegeneration represents
one of today&#146;s most significant unmet medical needs. The development of therapies that preserve neuron health has historically presented unique challenges, including an imperfect understanding of underlying biology and a lack of translation of
activity observed in preclinical studies to results in clinical trials. Currently approved therapies for many neurodegenerative diseases are generally only symptom modifying and have demonstrated limited efficacy. There remains an urgent need for
novel approaches to address most neurodegenerative diseases, especially for progressive and severe conditions such as ALS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since our founding in
2013, our goal has been to improve the quality of, and extend, life for patients suffering from neurodegenerative diseases. One of our key strategies towards achieving this goal has been to form direct relationships with patients, their families,
advocacy groups, and healthcare </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
professionals to bring much needed innovation to patients. Throughout the development of AMX0035, we have partnered with members of the disease communities we serve, including the ALS
Association, the Northeast ALS Consortium, or NEALS, ALS Finding a Cure, the Healey Center at Massachusetts General Hospital, the Cure Alzheimer&#146;s Fund, the Alzheimer&#146;s Association and the Alzheimer&#146;s Drug Discovery Foundation, to
ensure our goals are aligned with patient needs. In addition, many of the key opinion leaders in the ALS community were and are investigators in our recent and ongoing trials. These relationships are a cornerstone of our culture and corporate
strategy. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Pipeline Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">AMX0035 is
a proprietary oral fixed-dose combination of two small molecules: PB, which is a small molecular chaperone that reduces the UPR, preventing cell death resulting from the UPR, and TURSO, which is a Bax inhibitor that reduces cell death through
apoptosis. While the PB and TURSO molecules individually are not proprietary to us, we own patents and patent applications covering AMX0035, including the fixed-dose combination of AMX0035 itself. We believe that our proprietary combination of these
two molecules will allow us to target abnormal cell death to better prevent neurodegeneration than treatment with either mechanism of action alone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our current pipeline, including the stage of development and approvals of AMX0035 in our target indications, is represented in the table below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383770g05v33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The results of our CENTAUR trial were published in September 2020 in the New England Journal of Medicine and in
October 2020 in the Journal of Muscle and Nerve. Trial results showed that patients receiving AMX0035 experienced statistically significant benefit in retention of function, as measured by the Revised ALS Functional Rating Scale, or <FONT
STYLE="white-space:nowrap">ALSFRS-R,</FONT> as well as nominally significant improvement in overall survival, or OS, when analyzing the full randomized population through the OLE trial in a post hoc analysis (July 20, 2020 and March 1, 2021 data
cutoffs). AMX0035 was shown to be generally well-tolerated with the prevalence of adverse events comparable across placebo and treatment groups. We believe AMX0035 is the first drug candidate in ALS to demonstrate a statistically significant benefit
in function as measured by a prespecified mean rate change in <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> and a nominally significant benefit in a longer-term post hoc analysis of OS, which are both important outcomes for people with ALS. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Our Strategy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our mission is to one day end the suffering caused by neurodegenerative diseases. Key elements of our strategy to achieve this mission include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Effectively and efficiently commercializing RELYVRIO for ALS in the United States and ALBRIOZA for ALS in Canada.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Obtaining additional regulatory approvals of AMX0035 for ALS, with an initial focus on Europe. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Effectively and efficiently commercializing AMX0035 in other key territories, if approved. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Maximizing the therapeutic potential of AMX0035 by expanding into additional neurodegenerative diseases.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Continuing to cultivate a network of patient advocacy groups, key opinion leaders, research institutions, and healthcare
professionals to inform our patient-centric approach. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Deploying a strategic approach to design, acquire and develop new therapies. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Our Company and Team </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Amylyx was founded with
the ambitious goal of improving the quality and length of life for patients suffering from neurodegenerative diseases. From a dorm room at Brown University in 2013, our <FONT STYLE="white-space:nowrap">Co-CEOs</FONT> and <FONT
STYLE="white-space:nowrap">Co-Founders,</FONT> Josh Cohen and Justin Klee set out to determine why neurons die, and have ever since been working to develop AMX0035, which we believe is the first drug candidate to show a function and survival benefit
in patients with ALS, and other novel therapies. To help realize our goal, we have assembled a team with deep scientific, clinical, business and leadership experience, bolstered by expertise in biotechnology. Our Chief Financial Officer, James
Frates, brings over 20 years of experience as the Chief Financial Officer of Alkermes. Our Chief Commercial Officer, Margaret Olinger, brings three decades of expertise in commercial launches and operations, most recently at Alexion. Our Chief
Technical Operations Officer, Tom Holmes, brings more than 25 years of leadership experience at Biogen in supply chain, pharmaceutical manufacturing and program management. Our Chief Medical Officer, Patrick D. Yeramian, brings over 30 years of
medical and pharmaceutical industry experience. Our Head of Regulatory Affairs, Tammy Sarnelli, brings more than 30 years of experience from Biogen and other companies in early and late-stage neurology and rare disease development. Our Chief Human
Resources Officer, Debra Canner, brings over 30 years of experience, having served as the Chief of Human Resources Officer at Akamai and as part of Genzyme. Our Chief Legal Officer and General Counsel, Gina M. Mazzariello, brings more than 20 years
of corporate and commercial legal experience in the healthcare industry, including holding leadership positions at Boehringer Ingelheim USA, Inc. This team brings a diverse set of skills uniquely suited to drive successful commercialization of
AMX0035 in ALS while continuing to advance AMX0035 in other indications. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully in
the &#147;Risk Factors&#148; section of this prospectus immediately following this prospectus summary. These risks include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Risks Related to Our Financial Position and Need for Capital </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have incurred significant losses since our inception. Until we are able to generate sufficient revenue from approved
products, we anticipate that we will continue to incur significant losses. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have only recently obtained regulatory approval for RELYVRIO in the United States and launched ALBRIOZA in Canada and,
prior to their launch, have never generated revenue from product sales. If the commercial launches of RELYVRIO in the United States and ALBRIOZA in Canada are unsuccessful, and AMX0035 is not approved in other jurisdictions or for other indications,
we may never be profitable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have a limited operating history and our only product, AMX0035, has only recently been approved by the FDA in the United
States and only recently received marketing authorization with conditions in Canada, which may make it difficult to evaluate the prospects for our future viability. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Risks Related to Commercialization of AMX0035 or Future Product Candidates </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have limited experience as a commercial company and we may not be successful in commercializing AMX0035 or any future
product candidates in the United States, Canada or anywhere else, if and when approved, and we may be unable to generate meaningful product revenue. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">AMX0035 may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the
medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">If the FDA, Health Canada, the EMA or other comparable foreign regulatory authorities approve generic versions of AMX0035
or any future product candidate of ours that receives regulatory approval, or such authorities do not grant our products appropriate periods of non-patent exclusivity before approving generic versions of such products, the sales of such products
could be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Healthcare insurance coverage and reimbursement, both from public drug plans and private health care insurers, may be
limited or unavailable for RELYVRIO in the United States and ALBRIOZA in Canada, and for AMX0035 and any future product candidates, if approved anywhere else, which could make it difficult for us to sell any product candidates or therapies
profitably. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Risks Related to the Discovery and Development of Our Current or Future Product Candidates </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We currently depend on the success of AMX0035. If we are unable to maintain, or obtain additional, regulatory approvals
for, and successfully commercialize, AMX0035, or experience significant delays in doing so, our business may be materially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The delay or denial of regulatory approval, inability to maintain regulatory approval, inability to complete post-marketing
requirements, or the requirement to resubmit any marketing application with additional data or information for AMX0035 in any jurisdiction could mean that we need to delay or even cease operations, and a delay in obtaining or inability to maintain
such approval would delay commercialization of AMX0035 and adversely impact our ability to generate revenue, our business and our results of operations. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">AMX0035 is a fixed-dose combination drug product and certain regulatory authorities may require a demonstration that each
component makes a contribution to the claimed effects in addition to demonstrating that the combination is safe and effective for the intended population. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have concentrated our research and development efforts on the treatment of neurodegenerative and central nervous system,
or CNS, disorders, a field that has seen very limited success in product development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The regulatory approval processes of the FDA, Health Canada, the EMA and other comparable foreign authorities are lengthy,
time-consuming and inherently unpredictable, and if we are ultimately unable to obtain or maintain regulatory approval for AMX0035 or any future product candidates, our business will be substantially harmed. Any finding that our global Phase 3
PHOENIX trial is insufficient to support current or additional marketing authorizations in ALS could lead the FDA or Health Canada to withdraw prior regulatory approvals for RELYVRIO or ALBRIOZA, respectively, or we could decide, after consultation
with regulatory authorities, to voluntarily withdraw RELYVRIO or ALBRIOZA from the marketplace. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Competitive products may reduce or eliminate the commercial opportunity for AMX0035 for our current or future indications.
If our competitors develop technologies or product candidates more rapidly than we do, or their technologies or product candidates are more effective or safer than ours, our ability to develop and successfully commercialize AMX0035 may be adversely
affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Risks Related to Our Dependence on Third Parties </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have entered and may in the future enter into collaborations with third parties for the development and
commercialization of AMX0035 or any future product candidates, and our prospects with respect to those product candidates will depend in significant part on the success of those collaborations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our use of third parties to manufacture AMX0035 and approved products in compliance with current good manufacturing
practices may increase the risk that we will not have sufficient cGMP-compliant quantities of AMX0035, products, or necessary quantities of such materials on time or at an acceptable cost. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Risks Related to Our Intellectual Property </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our commercial success depends on our ability to protect our intellectual property and proprietary technology and to
achieve data and market exclusivities in applicable markets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Risks Related to Our Business Operations, Employee Matters and Managing Growth </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">A pandemic, epidemic, or outbreak of an infectious disease, such as the ongoing and evolving
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, may materially and adversely affect our business, including our preclinical studies, clinical trials, third parties on whom we rely, our supply chain, our ability to raise capital, our
ability to conduct regular business and our financial results. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We depend heavily on our executive officers, principal consultants and others, and the loss of their services would
materially harm our business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Risks Related to Our Common Stock and This Offering </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">If you purchase shares of our common stock in this offering, you will incur immediate and substantial dilution.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Unstable market, economic, political and geographical conditions may have serious adverse consequences on our business,
financial condition and stock price. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Our Corporate Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We were incorporated under the laws of the State of Delaware on January&nbsp;10, 2014 under the name Amylyx Pharmaceuticals, Inc. Our executive offices
are located at 43 Thorndike Street, Cambridge, Massachusetts 02141, and our telephone number is (617) <FONT STYLE="white-space:nowrap">682-0917.</FONT> Our website address is www.amylyx.com. The information contained on, or that can be accessed
through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a company with less than $1.235&nbsp;billion of revenue during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as defined
in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of
$1.235&nbsp;billion or more; (ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public offering, or IPO; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in
nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the SEC. For so long as we remain an emerging growth company, we are permitted and intend to rely on
exemptions from certain disclosure and other requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">only two years of audited financial statements in addition to any required unaudited interim financial statements with
correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reduced disclosure about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on executive compensation or golden parachute
arrangements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In particular, we have not included or incorporated herein all of the executive compensation-related information that would be
required if we were not an emerging growth company. Accordingly, the information contained or incorporated herein may be different than the information you receive from other public companies in which you hold stock. We have elected not to &#147;opt
out&#148; of the exemption for the delayed adoption of certain accounting standards and, therefore, we will adopt new or revised accounting standards only at the time private companies adopt the new or revised accounting standard and will do so
until such time that we either (i)&nbsp;irrevocably elect to &#147;opt out&#148; of such extended transition period or (ii)&nbsp;no longer qualify as an emerging growth company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are also a &#147;smaller reporting company&#148;, meaning that the market value of our stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million and our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either
(i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250&nbsp;million or (ii)&nbsp;our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year and
the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on
exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our annual reports on Form <FONT STYLE="white-space:nowrap">10-K</FONT>
and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc383770_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock offered by us </P></TD>
<TD>6,000,000&nbsp;shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Option to purchase additional shares </P></TD>
<TD>We have granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to&nbsp;900,000 additional shares of our common stock at the public offering price, less the underwriting discounts and commissions.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock to be outstanding immediately following this offering </P></TD>
<TD>64,533,226&nbsp;shares (65,433,226&nbsp;shares if the underwriters exercise their option to purchase additional shares of common stock in full). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Use of Proceeds </P></TD>
<TD>We estimate that the net proceeds to us from this offering, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately $167.0&nbsp;million, or approximately
$192.2&nbsp;million if the underwriters exercise their option to purchase additional shares from us in full, assuming a public offering price of $29.75 per share, which is the last reported trading price of our common stock on the Nasdaq Global
Select Market on&nbsp;October&nbsp;3, 2022. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD>We intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and investments, to fund: (i)&nbsp;production and commercialization activities for AMX0035 for the treatment of ALS in the United States and
Canada and the regulatory approval process and market preparation in Europe for AMX0035 for the treatment of ALS; (ii)&nbsp;the completion of our ongoing Phase 3 PHOENIX clinical trial for the treatment of ALS; (iii)&nbsp;the development and
expansion of our pipeline to address other neurodegenerative indications, and for formulations and derivatives of AMX0035; and (iv)&nbsp;working capital and other general corporate activities, including the continued build out of our organization.
See the &#147;Use of Proceeds&#148; section in this prospectus for a more complete description of the intended use of proceeds from this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Risk factors </P></TD>
<TD> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">You should read the &#147;Risk Factors&#148; section of this prospectus and under similar headings in
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="52%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:ARIAL">
documents incorporated by reference into this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Exchange symbol </P></TD>
<TD>&#147;AMLX&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The number of shares of our common stock to be outstanding after this offering is based on 58,533,226 shares of
our common stock outstanding as of June&nbsp;30, 2022, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">8,528,039 shares of our common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30, 2022, at a
weighted average exercise price of $12.08 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">670,013 shares of our common stock issuable upon vesting of restricted stock units outstanding as of June 30, 2022 under
our 2022 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">3,121,919 shares of our common stock that are available for future issuance as of June&nbsp;30, 2022 under our 2022 Stock
Option and Incentive Plan, or the 2022 Plan, as well as any future increases, including annual automatic evergreen increases, in the number of shares of common stock reserved for issuance thereunder in accordance with the terms of such plan; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">605,000 shares of our common stock that are available for future issuance under our 2022 Employee Stock Purchase Plan, or
the 2022 ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless otherwise indicated, all information in this prospectus assumes no exercise of the outstanding options
described above and no exercise by the underwriters of their option to purchase additional shares of our common stock. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">You should read the following summary consolidated financial data together with &#147;Management&#146;s Discussion and Analysis of Financial Condition
and Results of Operations&#148; and our consolidated financial statements, related notes and other financial information incorporated by reference from our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2021 and our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2022. The summary consolidated financial data in this section are not intended to replace the consolidated
financial statements and are qualified in their entirety by the consolidated financial statements and related notes incorporated by reference in this prospectus. We have derived the consolidated statement of operations data for the years ended
December&nbsp;31, 2021 and 2020 from our audited consolidated financial statements, incorporated by reference into this prospectus from our Annual Report on Form 10-K for the year ended December 31, 2021. The consolidated statements of operations
data for the six months ended June&nbsp;30, 2022 and 2021 and the consolidated balance sheet data as of June&nbsp;30, 2022 have been derived from our unaudited condensed consolidated financial statements, incorporated by reference into this
prospectus from our Quarterly Report on Form 10-Q for the six months ended June 30, 2022, and have been prepared on the same basis as the audited consolidated financial statements. In the opinion of management, the unaudited data reflects all
adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the financial information in those statements. Our historical results are not necessarily indicative of results that may be expected in the future. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except per share and per share amount)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Consolidated Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,455</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82,688</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other (expense) income, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,990</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(101,595</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87,931</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(101,915</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36,445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(87,931</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(42,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders&#151;basic and diluted&nbsp;(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13.35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6.96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average common shares used to compute net loss per share attributable to common
stockholders&#151;basic and diluted&nbsp;(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,958,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,334,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,586,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,077,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">See Notes 2 and 14 to our audited consolidated financial statements, incorporated by reference into this prospectus from
our Annual Report on Form 10-K for the year ended December 31, 2021, </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
and Note 11 to our unaudited condensed consolidated financial statements, incorporated by reference into this prospectus from our Quarterly Report on Form 10-Q for the six months ended June 30,
2022, for an explanation of the method used to calculate historical basic and diluted net loss per share attributable to common stockholders and the weighted-average common shares outstanding used in the computation of the per share amount.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;adjusted&nbsp;(2)&nbsp;(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Consolidated balance sheet data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash, cash equivalents, and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">206,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$373,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Working capital (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">356,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">617,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(257,760</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(257,760</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated other comprehensive (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">We define working capital as current assets less current liabilities. See our consolidated financial statements included
in our Annual Report on Form 10-K for the year ended December 31, 2021 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, each of which is incorporated by reference in this prospectus, for further details regarding our
current assets and current liabilities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">As adjusted balance sheet data give effect to the sale of&nbsp;6,000,000 shares of our common stock in this offering
based on an assumed public offering price of $29.75 per share, which is the last reported trading price of our common stock on the Nasdaq Global Select Market on October&nbsp;3, 2022, after deducting the estimated underwriting discounts and
commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Each $1.00 increase (decrease) in the assumed public offering price of $29.75<U></U> per share, which is the last
reported trading price of our common stock on the Nasdaq Global Select Market on October&nbsp;3, 2022, would increase (decrease) the as adjusted amount of each of cash, cash equivalents and short-term investments, working capital, total assets and
total stockholders&#146; equity by approximately $5.6 million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us. Similarly, each increase (decrease) of 1.0 million shares offered by us would increase (decrease) the as adjusted amount of each of cash, cash equivalents and short-term investments, working capital, total
assets and total stockholders&#146; equity by approximately $28.0 million, assuming the assumed public offering price per share remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses
payable by us. The as adjusted information is illustrative only, and will be adjusted based on the actual public offering price and other terms of this offering determined at pricing. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc383770_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Investing in our common stock involves a high degree of risk. Before you decide to invest in our common stock, you should consider carefully the
risks described below, together with the other information contained in this prospectus and the documents incorporated by reference into this prospectus. We believe the risks described below are the risks that are material to us as of the date of
this prospectus. If any of the following risks actually occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. In these circumstances, the market price of our common
stock could decline, and you may lose all or part of your investment. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Risks Related to Our Financial Position and Need for Capital </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have incurred significant losses since our inception. Until we are able to generate sufficient revenue from approved products, we anticipate that we will
continue to incur significant losses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Investment in pharmaceutical product development is highly speculative because it entails substantial
upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We have invested substantial
resources into our product development efforts and toward the commercialization of RELYVRIO, which has been recently approved by the FDA, and ALBRIOZA, which has received marketing authorization with conditions from Health Canada, but we have not
yet generated any significant revenue from product sales to date in the United States, Canada or elsewhere. We will continue to incur significant research and development and other expenses related to clinical development, commercialization,
approvals in additional jurisdictions and ongoing operations. As a result, we are not profitable and have incurred losses in each period since our inception. Since our inception, we have devoted the majority of our financial resources and efforts to
research and development, including preclinical studies and our clinical trials, and preparation for commercialization. Our financial condition and operating results, including our expenses and net losses, may fluctuate significantly from quarter to
quarter and year to year. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance. Additionally, net losses and negative cash flows have had, and will continue to have, an
adverse effect on our stockholders&#146; equity and working capital. Our net losses were $54.1&nbsp;million and $101.9&nbsp;million for the three and six months ended June&nbsp;30, 2022, respectively, and $21.9&nbsp;million and $36.4&nbsp;million
for the three and six months ended June&nbsp;30, 2021, respectively. As of June&nbsp;30, 2022, we had an accumulated deficit of $257.8&nbsp;million. For the years ended December&nbsp;31, 2021 and 2020, we incurred net losses of $87.9&nbsp;million
and $42.3&nbsp;million, respectively. We may continue to incur significant losses and our financial results will be highly dependent upon the successful launch of RELYVRIO in the United States. We will continue to incur expenses related to our
research and development activities and pre-commercialization activities in Europe, among other things. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We anticipate that our expenses will
increase substantially if and as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">further build out our sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to
commercialize AMX0035 for which we obtained regulatory approval from FDA and marketing authorization with conditions from Health Canada and any product candidate for which we may obtain approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue to develop and conduct clinical trials for AMX0035 for the treatment of ALS, AD and potential additional
indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">initiate and continue research, preclinical and clinical development efforts for any future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seek to identify additional product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seek to maintain regulatory approvals in the United States and Canada and obtain regulatory approvals in the European
Union, or the EU, and other geographies for AMX0035 for the treatment of ALS, AD and other indications that successfully complete clinical development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">experience any delays or encounter any issues with any of the above, including but not limited to completion of
post-marketing requirements, the potential that the EMA or other regulators require additional data to support the approval of AMX0035 for ALS, failed studies, negative or mixed clinical trial results, safety issues or other regulatory challenges,
the risk of which in each case may be exacerbated by the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establish sales, marketing, distribution, manufacturing, supply chain and other commercial infrastructure to commercialize
any products for which we may in the future obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">add operational, financial and management information systems and personnel, including personnel to support our product
candidate development and help us comply with our obligations as a public company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">hire and retain additional personnel, such as clinical, quality control, scientific, commercial and administrative
personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintain, expand and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">add equipment and physical infrastructure to support our research and development; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and technologies.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are continuing to build out our infrastructure, including sales and marketing and production capabilities, for
commercialization of AMX0035 in the United States and Canada. As of June&nbsp;30, 2022, we had 226 full-time employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our expenses could increase
beyond our expectations if we are required by the FDA, Health Canada, the EMA, or other regulatory authorities to perform clinical trials or conduct other studies in addition to those that we currently expect, or if there are any delays in
establishing appropriate manufacturing arrangements for or in completing our clinical trials or the development of AMX0035 or any future product candidates we may develop. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have only recently obtained regulatory approval for RELYVRIO in the United States and launched ALBRIOZA in Canada and, prior to their launch, we have never
generated revenue from product sales. If the commercial launches of RELYVRIO in the United States and ALBRIOZA in Canada are unsuccessful, and AMX0035 is not approved in other jurisdictions or for other indications, we may never be profitable.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ability to become and remain profitable depends on our ability to generate revenue from our approved products, RELYVRIO in the United
States and ALBRIOZA in Canada. Other than ALBRIOZA in Canada, we have not yet launched any other approved products for commercial sale and have not yet generated any significant revenue from product sales. Successful commercialization will require
achievement of many key milestones, which vary by jurisdiction and may include demonstrating safety and efficacy in clinical trials, obtaining and maintaining regulatory, including marketing, approval for these product candidates, manufacturing,
marketing and selling those products for which we, or any of our future collaborators, may obtain regulatory approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government
payors. Even if we successfully launch and commercialize RELYVRIO in the United States and ALBRIOZA in Canada, we may be unable to achieve or maintain profitability, unless AMX0035 is approved in other jurisdictions or for additional indications.
Because of the uncertainties and risks associated with these activities, we are unable to accurately and precisely predict the timing and amount of revenues, the extent of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
further losses or if or when we might achieve profitability. We and any future collaborators may never succeed in these activities and, even if we do, or any future collaborators do, we may never
generate revenues that are large enough for us to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our failure to become and remain profitable may depress the market price of our common stock and could impair our ability to raise capital, expand our
business, diversify our product offerings or continue our operations. If we continue to suffer losses as we have in the past, investors may not receive any return on their investment and may lose their entire investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have a limited operating history and our only product, AMX0035, has only recently been approved by the FDA in the United States and only recently received
marketing authorization with conditions in Canada, which may make it difficult to evaluate the prospects for our future viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have
only recently commenced our transition from a clinical-stage to a commercial-stage company. Our operations to date have been limited to organizing, staffing and financing our company, raising capital, conducting research and development activities,
including preclinical studies and clinical trials and preparing for and commencing commercialization of AMX0035. We have not yet demonstrated an ability to generate significant revenues, or clearly conduct sales and marketing activities necessary
for successful product commercialization. In June 2022, AMX0035 received marketing authorization with conditions from Health Canada for the treatment of ALS. One of the conditions of the marketing authorization in Canada is the provision of data
from our ongoing PHOENIX trial and other additional planned or ongoing studies. We also have a pending MAA before the EMA, and we expect a decision in the first half of 2023. Accordingly, you should consider our prospects in light of the costs,
uncertainties, delays and difficulties frequently encountered by companies in the early commercial stage, especially pharmaceutical companies such as ours. Any predictions you make about our future success or viability may not be as accurate as they
could be if we had a longer operating history with these activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At a second meeting of the FDA&#146;s Peripheral and Central Nervous System
Drugs Advisory Committee, or the Advisory Committee, on September 7, 2022, relating to AMX0035 for the treatment of ALS, we stated that if our PHOENIX trial is not successful then we will do what is right for patients, which includes voluntarily
removing the product from the market. We will work in consultation with regulatory authorities when the PHOENIX data are available. We could also be required by regulatory authorities to withdraw AMX0035 from the marketplace. The outcomes of the
PHOENIX trial and any potential withdrawal could have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may not satisfy all of the conditions imposed
by Health Canada for marketing authorization of ALBRIOZA for the treatment of ALS. If we fail to do so, we may be subject to additional conditions imposed by Health Canada or we may have to cease commercialization of ALBRIOZA, which may impact our
prospectus for profitability. We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. We are transitioning from a company with a development focus to a
company capable of supporting commercial activities. We may not be successful in such a transition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We will require substantial additional funding to meet
our financial needs and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product discovery and development activities or commercialization efforts. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to commercialize AMX0035 in
jurisdictions in which it has received regulatory approval and to continue the clinical development of AMX0035 and the preclinical and clinical development of any future product candidates. If we are unable to obtain and maintain
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
marketing approvals for AMX0035 or any future product candidates that we develop, including any indication for which we are developing or may develop AMX0035, we will require significant
additional amounts of cash in order to continue to develop AMX0035 and any future product candidates and fund our operations. In addition, other unanticipated costs may arise in the course of our development and commercialization efforts. Because
the design and outcome of our ongoing and anticipated clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any product candidate we develop.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our future capital requirements depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope, progress, results and costs of researching and developing AMX0035 for the treatment of ALS, AD and potential
additional indications, as well as any future product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing of, and the costs involved in, obtaining and maintaining marketing approvals for AMX0035 for the treatment of
ALS, AD and potential additional indications, and any future product candidates we may develop and pursue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of future product candidates that we may pursue and their development requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of commercialization activities for AMX0035 for any approved indications, or any other product candidate that
receives regulatory approval to the extent such costs are not the responsibility of any future collaborators, including the costs and timing of establishing sufficient product sales, marketing, distribution and manufacturing capabilities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">subject to receipt of regulatory approval on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">jurisdiction-by-jurisdiction</FONT></FONT> basis, revenue, if any, received from commercial sales of AMX0035 for any approved indications or any future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire rights to other products, product
candidates or technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our headcount growth and associated costs as we expand our research and development, increase our office space, and
establish a commercial infrastructure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property
rights, including enforcing and defending intellectual property related claims; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ongoing costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot be certain that additional funding will be available on acceptable terms, or at all. As a result of the ongoing
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and actions taken to slow its spread, global economic instability and geopolitical events, including the conflict in Ukraine, the global credit and financial markets have experienced extreme
volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, and uncertainty about economic stability. If the equity and credit
markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly or more dilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have no committed source
of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of AMX0035 or any future
product candidates or other research and development initiatives. We may need to seek collaborators for AMX0035 and any future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might
otherwise be available or relinquish or license on unfavorable terms our rights to AMX0035 and any future product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves. Any of the above events could
significantly harm our business, prospects, financial condition, and results of operations and cause the price of our common stock to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe that the net proceeds from this offering, together with our existing cash, cash
equivalents, and short-term investments, will be sufficient to meet our anticipated operating and capital expenditure requirements for at least twelve months after the date of this prospectus. Our estimate may prove to be wrong, and we could use our
available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek
additional funds sooner than planned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish
rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect our expenses to continue to increase in connection with our planned operations.
Unless and until we can generate a substantial amount of revenue from AMX0035 or any future product candidates, we expect to finance our future cash needs through public or private equity offerings, royalty-based or debt financings, collaborations,
licensing arrangements or other sources, or any combination of the foregoing. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our
current or future operating plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent that we raise additional capital through the sale of common stock, convertible securities or other
equity securities, your ownership interest may be diluted, and the terms of these securities could include liquidation or other preferences and anti-dilution protections that could adversely affect your rights as a common stockholder. In addition,
debt financing, if available, may result in fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures,
creating liens, redeeming stock or declaring dividends, that could adversely impact our ability to conduct our business. In addition, securing financing could require a substantial amount of time and attention from our management and may divert a
disproportionate amount of their attention away from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our management&#146;s ability to oversee the development and
commercialization of AMX0035 or any future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we raise additional funds through collaborations or marketing, distribution or
licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in tax law could adversely affect our business and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by
the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and
changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax
advisers regarding the implications of potential changes in tax laws on an investment in our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Risks Related to Commercialization of
AMX0035 or Future Product Candidates </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have limited experience as a commercial company and we may not be successful in commercializing AMX0035 or any
future product candidates in the United States, Canada or anywhere else if and when approved, and we may be unable to generate meaningful product revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We recently launched ALBRIOZA in Canada and are preparing to launch RELYVRIO, which was approved by the FDA in September 2022, in the United States, and
if approved, we also intend to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
commercialize AMX0035 in the EU with specialized teams, given the relative rarity of ALS and certain of the other indications we are targeting. We are currently continuing to build the global
marketing and sales team for the marketing, sales and distribution of AMX0035 and any future product candidates, if approved. In order to commercialize AMX0035 for the treatment of ALS, AD and other indications, or any of our future product
candidates that may be approved, we must build, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">territory-by-territory</FONT></FONT> basis, marketing, sales, distribution, managerial and other capabilities or make arrangements
with third parties to perform these services, and we may not be successful in doing so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are risks involved with both establishing our own
sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, we have recruited and trained a U.S. commercial organization which is expensive and time-consuming. If the commercial launch
of AMX0035 (RELYVRIO) in the United States is delayed or does not occur for any reason, we will have prematurely or unnecessarily incurred these commercialization expenses. If we fail to obtain or maintain approval or if for any reason a potential
commercial launch is otherwise delayed, we would not realize the benefits of any <FONT STYLE="white-space:nowrap">pre-commercial</FONT> activity expenditures made to date. This may be costly and our investment would be lost if we cannot retain or
reposition our sales and marketing personnel. These same circumstances could apply globally, and to any future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Factors that may
inhibit our efforts to commercialize AMX0035 or any future product candidates, if approved, on our own include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability of sales personnel to obtain access to physicians to prescribe AMX0035 or any future product that we may
develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any views or opinions expressed by ALS or AD community organizations about the safety or efficacy of AMX0035;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the lack of complementary treatments to be offered by sales personnel, which may put us at a competitive disadvantage
relative to companies with more extensive product lines; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the availability of adequate coverage by and reimbursement from government and third-party payors; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or
profitability from these revenue streams is likely to be lower than if we were to market and sell any product candidates that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and
market AMX0035 or any of our future product candidates or may be unable to do so on terms that are favorable to us. We likely will have limited control over such third parties, and any of them may fail to devote the necessary resources and attention
to sell and market AMX0035 or any future product candidates effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we may not be successful in commercializing
AMX0035 or any future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our efforts to educate the ALS, AD and other neurodegenerative disease medical communities and payors on
the benefits of AMX0035 or any future product candidates may require significant resources and may never be successful. Such efforts may require more resources than are typically required due to the complexity and uniqueness of AMX0035 or any future
product candidates, and the indications we are targeting. Even if AMX0035 or any future product candidates are approved in any jurisdiction, if we are unable to successfully market our products successfully, we will not be able to generate
significant revenues from such products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to expand our marketing and distribution capabilities or enter into agreements with third
parties to market and sell any of AMX0035 or future product candidates for which we obtain marketing approval, we will be unable to generate any product revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To successfully commercialize any products that may result from our development activities, we need to continue to expand our marketing and distribution
capabilities, either on our own or with others. The development of our own marketing and distribution effort is, and will continue to be, expensive and time-consuming and could delay any further product launch. Moreover, we cannot be certain that we
will be able to develop this capability successfully. We may enter into collaborations regarding any approved product candidates with other entities to utilize their established marketing and distribution capabilities, however, we may be unable to
enter into such agreements on favorable terms, if at all. If any future collaborators do not commit sufficient resources to commercialize AMX0035 or any future product candidates, or we are unable to develop the necessary capabilities on our own, we
will be unable to generate sufficient product revenue to sustain our business. We compete with many companies that currently have extensive, experienced and well-funded sales, distribution and marketing operations to recruit, hire, train and retain
marketing and sales personnel. We also face competition in our search for third parties to assist us with the sales and marketing efforts of AMX0035 and any future product candidates, if approved. Without an internal team or the support of a
third-party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The market for
AMX0035 for ALS, AD and other neurodegenerative diseases and for any future product candidates we may develop may be smaller than we expect. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We focus our research and product development on treatments of neurodegenerative diseases. We base our market opportunity estimates on a variety of
factors, including our estimates of the number of people who have these diseases, the potential scope of our approved product labels, the subset of people with these diseases who have the potential to benefit from treatment with AMX0035 or any
future product candidates, various pricing scenarios, and our understanding of reimbursement policies for rare diseases in particular countries. These estimates are based on many assumptions and may prove incorrect, and new studies may reduce the
estimated incidence or prevalence of these diseases. Estimating market opportunities can be particularly challenging for rare indications, such as the ones we currently address, as epidemiological data is often more limited than for more prevalent
indications and can require additional assumptions to assess potential patient populations. For example, as we begin to commercialize RELYVRIO in the United States, ALBRIOZA in Canada and AMX0035, if approved, in other jurisdictions, and learn more
about market dynamics and engage with regulators on additional potential marketing approvals, our view of our products&#146; initial potential market opportunity will become more refined. For example, we are now initially focused primarily on the
annual incidence of ALS. This means the initial market opportunity for AMX0035 and any future product candidates may be smaller than the total addressable market opportunity that could be achieved over time. If we are unable to successfully
commercialize AMX0035 or any future product candidates with attractive market opportunities, our future product revenues may be smaller than anticipated, and our business may suffer. Patient identification efforts also influence the ability to
address a patient population. If efforts in patient identification are unsuccessful or less impactful than anticipated, for instance, because of a lack of diagnostic initiatives, inadequate disease awareness among healthcare professionals, or
otherwise, we may not address the entirety of the opportunity we are seeking. As a result, patients may be difficult to identify and access, the addressable patient population in the United States, Canada, the EU and elsewhere may turn out to be
lower than expected, or patients may not be otherwise amenable to treatment with our products, all of which would adversely affect our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>AMX0035 may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and
others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if AMX0035 for the treatment of any indication, or any future product candidate of ours, is approved by the appropriate regulatory authorities for
marketing and sale, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. Physicians may be reluctant to add AMX0035 to their patients&#146; treatment regimen.
Further, patients often acclimate to the treatment regime they are currently taking and do not want to add additional treatments unless their physicians recommend it. Further, they may be unable to add AMX0035 to their treatment regimen due to lack
of coverage and adequate reimbursement. In addition, even if we are able to demonstrate our product candidates&#146; safety and efficacy to Health Canada, the FDA, the EMA and other regulators, safety or efficacy concerns in the medical community
may hinder market acceptance. Our ability to proactively educate health care professionals and patients may be limited based on the marketing restrictions in a given jurisdiction, specifically as they relate to the particular labeling approved by
the applicable health authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Efforts to educate the medical community and third-party payors on the benefits of our current and any future
product candidates may require significant resources, including management time and financial resources, and may not be successful. If AMX0035 or any future product candidate is approved but does not achieve an adequate level of market acceptance,
we may not generate significant revenues and we may not become profitable. The degree of market acceptance of AMX0035 and any future product candidates, if approved for commercial sale, will depend on a number of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the efficacy and safety of the product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential advantages of the product compared to competitive therapies and our ability to successfully publicize these
advantages or highlight them in any marketing materials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">whether the product is designated under physician treatment guidelines as a first-, second- or third-line therapy;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability, or the ability of any future collaborators, to offer the product for sale at competitive prices;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the product&#146;s convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the willingness of the target patient population to try, and of physicians to prescribe, the product;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">limitations or warnings, including distribution or use restrictions contained in the product&#146;s approved labeling;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the strength of sales, marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in the standard of care for the targeted indications for the product; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">availability and adequacy of coverage and reimbursement from government payors, managed care plans and other third-party
payors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any failure by AMX0035 or any other potential product candidate of ours that obtains regulatory approval to achieve
market acceptance or commercial success would adversely affect our business prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Off-label</FONT> use for the
treatment of ALS of PB, which is available as a generic drug, along with the potential sale in some jurisdictions of TURSO, which preparations are of unknown identity and may not be legally sold for the treatment of ALS, expose us to additional
risks that could reduce or eliminate the commercial opportunity for AMX0035. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are developing and advancing AMX0035 as a combination of
TURSO and PB. PB has been approved by the FDA and other regulatory authorities for the treatment of patients with certain urea cycle disorders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">TURSO is being marketed in preparations of unknown identity and without approval for the treatment of
ALS in some jurisdictions, including the United States. We face the risk that healthcare professionals may prescribe PB for the treatment of ALS and recommend that patients obtain a commercial preparation of TURSO not approved, labeled, or marketed
for the treatment of ALS on the belief that this combination could replicate the benefits of AMX0035. Patient-directed treatment with TURSO for ALS may also arise in certain jurisdictions if the Phase 3 clinical trial to assess the safety and
efficacy of TURSO in patients with ALS conducted by Humanitas Mirasole SpA in the EU reports positive results. While these practices are not recommended by the medical community and have not been approved by any regulatory authority, they may
nonetheless impact our sales of RELYVRIO in the United States, ALBRIOZA in Canada and AMX0035, if approved in other jurisdictions, and/or public perception of AMX0035 in the United States or abroad. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If the FDA, Health Canada, the EMA or other comparable foreign regulatory authorities approve generic versions of AMX0035 or any future product candidate of ours
that receives regulatory approval, or such authorities do not grant our products appropriate periods of <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity before approving generic versions of such products, the sales of such products
could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States, once an NDA is approved, the product covered thereby becomes a &#147;reference listed
drug&#148; in the FDA&#146;s publication, &#147;Approved Drug Products with Therapeutic Equivalence Evaluations,&#148; or the Orange Book. Manufacturers may seek approval of generic versions of reference listed drugs through submission of
abbreviated new drug applications, or ANDAs, in the United States. In support of an ANDA, a generic manufacturer generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration, and adequate
labeling as the reference listed drug and that the generic version is bioequivalent to the reference listed drug, meaning, in part, that it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less
costly to bring to market than the reference listed drug and companies that produce generic products are generally able to offer them at lower prices. Moreover, many states allow or require substitution of therapeutically equivalent generic drugs at
the pharmacy level even if the branded drug is prescribed. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug may be lost to the generic product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA may not finally approve an ANDA for a generic product until any applicable period of <FONT STYLE="white-space:nowrap">non-patent</FONT>
exclusivity for the reference listed drug has expired. The FDCA provides a period of five years of <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity for a new drug containing a new chemical entity, or NCE. For the purposes of this
provision, an NCE is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance.
Specifically, in cases where such exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification that a patent covering the listed drug is
invalid, unenforceable or will not be infringed by the generic product. In that case, the applicant may submit its application four years following approval of the listed drug and seek to launch its generic product even if we still have patent
protection for our product unless an infringement suit is timely filed by the NDA or patent holder in which case the FDA cannot approve the ANDA for 30 months unless a court decision in favor of the generic manufacturer is issued earlier. For fixed
dose combination products, the FDA has taken the position that a combination product will be eligible for NCE exclusivity (also known as data exclusivity) if it contains a new active moiety, even if the fixed-combination also contains a drug
substance with a previously approved active moiety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While we believe, based on the applicable requirements and FDA&#146;s designation of RELYVRIO
as&nbsp;a &#147;New Molecular Entity,&#148; that RELYVRIO qualifies for NCE exclusivity, there can be no assurance until&nbsp;we receive official confirmation. In addition, in connection with our Health Canada marketing
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
authorization with conditions, ALBRIOZA was added to the Register of Innovative Drugs, which provides an eight year period of market exclusivity. The regulatory authorities in the United States
and Europe may reach different conclusions from Health Canada with respect to exclusivity for AMX0035. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If any product we develop does not receive
five years of NCE exclusivity, the FDA may approve generic versions of such product three years after its date of approval, subject to the requirement that the ANDA applicant certifies to the invalidity or
<FONT STYLE="white-space:nowrap">non-infringement</FONT> of any patents listed for our products in the Orange Book. If an infringement suit is timely filed by the NDA or patent holder, the FDA cannot finally approve the ANDA for 30 months unless a
court decision in favor of the generic manufacturer is issued earlier. Three-year exclusivity is given to a drug if it contains an active moiety that has previously been approved, and the NDA includes reports of one or more new clinical
investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are determined by the FDA to be essential to the approval of the NDA. This form of data exclusivity is known as New Clinical
Investigation, or NCI, exclusivity. If AMX0035 is approved or if future candidates are approved with only NCI exclusivity, generic manufacturers may file their ANDAs anytime following approval of AMX0035 and seek to launch their generic products
following the expiration of the three year market exclusivity period, even if we still have patent protection for our product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, in the
United States the FDCA provides a period of seven years of orphan drug exclusivity for drugs that treat small patient populations less than 200,000 patients or for which there are more than 200,000 patients but there is no reasonable expectation
that the cost of developing and making the drug for such disease or condition will be recovered from sales in the United States of such drug. AMX0035 has been granted orphan drug designation for the treatment of ALS, and with the approval of AMX0035
(RELYVRIO) by the FDA in September 2022 for the treatment of ALS in adults, the product is entitled to orphan drug exclusivity and the FDA cannot approve a generic or a brand product that contains the same active moiety for the same orphan
indication as AMX0035, for a period of seven years, subject to certain exceptions. This period runs concurrent with any NCE exclusivity period awarded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Canada&#146;s data protection regime provides an eight year period of market exclusivity for &#147;innovative drugs&#148;, which is independent from
patent protection. An innovative drug is a drug that contains a medicinal ingredient not previously approved by Health Canada and that is not a variation of a previously approved medicinal ingredient such as a salt, ester, enantiomer, solvate or
polymorph. If a drug qualifies as an &#147;innovative drug&#148; in Canada, generic/and manufacturers are not permitted to seek approval for their product on the basis of a direct or indirect comparison to an innovative drug for the first six years
of the data protection period, and Health Canada cannot issue a Notice of Compliance (NOC or marketing approval) for eight years. One of the components of ALBRIOZA (ursodoxicoltaurine) is an innovative drug, and therefore ALBRIOZA was added to the
Register of Innovative Drugs upon its approval. The data protection period for ALBRIOZA runs until June 10, 2030 which is eight years from the date its NOC was issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There is no regulatory provision in Canada that provides orphan drug exclusivity to approved products for rare diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the EU, innovative medicinal products (including both small molecules and biological medicinal products), sometimes referred to as new active
substances, or NAS, qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. The data exclusivity, if granted, prevents generic or biosimilar applicants from referencing the
innovator&#146;s preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization, for a period of eight years from the date on which the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
reference product was first authorized in the EU. During the additional <FONT STYLE="white-space:nowrap">two-year</FONT> period of market exclusivity, a generic or biosimilar marketing
authorization can be submitted, and the innovator&#146;s data may be referenced, but no generic or biosimilar product can be marketed until the expiration of the market exclusivity period. This <FONT STYLE="white-space:nowrap">10-year</FONT>
marketing exclusivity period may be extended to 11 years if, during the first eight of those 10 years, the marketing authorization holder obtains an approval for one or more new therapeutic indications that bring significant clinical benefits
compared with existing therapies. However, even if an innovative medicinal product gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained a marketing authorization based on
an application with a complete and independent data package of pharmaceutical tests, preclinical tests and clinical trials. We have applied for NAS status for AMX0035 in the EU. Irrespective of the NAS status, we expect that AMX0035 will be eligible
for Regulatory Data Protection and/or Orphan Market Exclusivity if the orphan designation is maintained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Competition that AMX0035 or any future
products, if approved, may face from generic versions of such products could negatively impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on our investments in those product candidates.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>AMX0035 or any future product candidates for which we, or any future collaborators, obtain regulatory approval will be subject to ongoing obligations and
continued regulatory review, which may result in significant additional expense. AMX0035 and any future product candidates, if approved, could be subject to post-marketing restrictions, requirements or withdrawal from the market and we, or any
future collaborators, may be subject to substantial penalties if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our products following approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">AMX0035 received approval by the FDA for the treatment of ALS in adults (known as RELYVRIO) in September 2022 and marketing authorization with conditions
by Health Canada for the treatment of ALS (known as ALBRIOZA) in June 2022. We have a pending MAA before the EMA for AMX0035 for the treatment of ALS and we may seek approval of AMX0035 in additional jurisdictions and in additional indications.
AMX0035 or any future product candidates for which we, or any future collaborators, obtain regulatory approval, as well as the manufacturing processes, post-approval studies, labeling, advertising and promotional activities for such product, among
other things, will be subject to ongoing requirements of and review by the FDA, Health Canada, the EMA and other applicable regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports,
registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and
recordkeeping. For certain commercial prescription drug products, manufacturers and other parties involved in the supply chain must also meet chain of distribution requirements and build electronic, interoperable systems for product tracking and
tracing and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or other products that are otherwise unfit for distribution in the United States. We and our contract manufacturers will also be subject to
user fees and periodic inspection by regulatory authorities to monitor compliance with these requirements and the terms of any product approval we may obtain. Even if regulatory approval of a product candidate is granted, the approval may be subject
to limitations on the indications or uses for which the product may be marketed or to the conditions of approval, including the requirement in the United States to implement a Risk Evaluation and Mitigation Strategy, or REMS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA, Health Canada, the EMA and other regulatory authorities may also impose requirements for costly post-marketing studies or clinical trials and
surveillance to monitor the safety or efficacy of a product. For example, as part of our approval of RELYVRIO in the United States, we have post-marketing requirements to conduct carcinogenicity studies in mice and rats, drug-drug interaction
studies, and studies in patients with kidney or liver impairment. Additionally, the FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. Regulatory
authorities impose stringent restrictions on manufacturers&#146; communications regarding <FONT STYLE="white-space:nowrap">off-label</FONT> use. However, companies generally may share truthful and not misleading information that is otherwise
consistent with a product&#146;s approved labeling. If we, or any future collaborators, do not market AMX0035 or any of our future product candidates for which we, or they, receive regulatory approval for only their approved indications, we, or
they, may be subject to warnings or enforcement action for <FONT STYLE="white-space:nowrap">off-label</FONT> marketing if it is alleged that we are doing so. Violation of laws and regulations relating to the promotion and advertising of prescription
drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws, including the False Claims Act and any comparable foreign laws. In the EU, the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising of prescription-only medicinal products is prohibited. Violations of the rules governing the promotion of medicinal products in the EU could be
penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public, and may also impose limitations on our promotional activities with health
care professionals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Post-marketing requirements in Canada are similar to those in the United States. Following the approval of our New Drug
Submission, or NDS with conditions, Health Canada requires that we submit a Risk Management Plan, or RMP. Health Canada may, as part of the RMP, require that we conduct additional clinical studies. For example, one of the conditions of the marketing
authorization in Canada of AMX0035 (ALBRIOZA) is the provision of data from our ongoing PHOENIX trial and other additional planned or ongoing studies. Standard pharmacovigilance activities are also required for any marketed drug product. Any
labelling changes or changes in the product supply chain would require a submission to Health Canada for approval before the change may be implemented. Our advertising may be scrutinized by competitors or by health care providers, and complaints
could be made to Health Canada or other agencies. Reimbursement in Canada is complex and requires submissions to both public and private payors to gain access to prescription drug formulary lists. In addition, if there are any patents associated
with AMX0035, the product will be subject to price regulation by the Patented Medicine Prices Review Board, or the PMPRB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, later
discovery of previously unknown adverse events or other problems with our products or their manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on the manufacturing of such products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on the labeling or marketing of such products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on product distribution or use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">requirements to conduct post-marketing studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">warning letters or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">withdrawal of the products from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal to approve pending applications or supplements to approved applications that we submit; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">recall of products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on coverage by third-party payors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">fines, restitution or disgorgement of profits or revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">exclusion from federal health care programs such as Medicare and Medicaid; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">suspension or withdrawal of regulatory approvals; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product seizure; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are not able to comply with post-approval regulatory requirements, we could have the marketing approvals for AMX0035 or any future approved
products withdrawn by regulatory authorities, or we may voluntarily do so, and our ability to market AMX0035 or any future approved products, to develop AMX0035 in the United States, Canada or additional jurisdictions or for additional indications,
and to develop and seek approval for additional product candidates could become limited, which could adversely affect our ability to achieve or sustain profitability. As a result, the cost of compliance with post-approval regulatory requirements may
have a negative effect on our operating results and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Healthcare insurance coverage and reimbursement, both from public drug plans and
private health care insurers, may be limited or unavailable for RELYVRIO in the United States and ALBRIOZA in Canada, and for AMX0035 and any future product candidates, if approved anywhere else, which could make it difficult for us to sell any
product candidates or therapies profitably. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The success of AMX0035 and any future product candidates, if approved, depends on the
availability of adequate coverage and reimbursement from third-party payors. Because AMX0035 and any future product candidates represent new approaches to the treatment of the diseases they target, we cannot be sure that coverage and reimbursement
will be available for, or accurately estimate the potential revenue from, AMX0035 and any future product candidates or for any product that we may develop. If we are unable to obtain adequate levels of reimbursement, our ability to successfully
market and sell any such product candidates will be adversely affected. The manner and level at which reimbursement is provided for services related to any current or future product candidates we may develop (e.g., for the administration of our
product candidate to patients) is also important. Inadequate reimbursement for such services may lead to physician and payor resistance and adversely affect our ability to market or sell AMX0035 or any future product candidates we may develop. In
addition, we may need to develop new reimbursement models, in order to realize adequate value. Payors may not be able or willing to adopt such new models and patients may be unable to afford that portion of the cost that such models may require them
to bear. If we determine such new models are necessary, but we are unsuccessful in developing them, or if payors do not adopt such models, our business, financial condition, results of operations and prospects could be adversely affected. For
additional information on coverage and reimbursement, see the section entitled &#147;Business&#151;Government Regulation&#151;Coverage and Reimbursement&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated
with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors, such as private health insurers and health maintenance organizations, are critical to new product
acceptance. Government authorities and other third-party payors decide which drugs and treatments they will cover and the reimbursement amount. Coverage and reimbursement by a third-party payor may depend upon a number of factors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. As a result, obtaining coverage and
reimbursement approval of a product from a government or other third-party payor is a time consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our
products on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis, with no assurance that coverage and adequate reimbursement from third-party payors will be obtained. There is significant uncertainty
related to the insurance coverage and reimbursement of newly approved products, which uncertainty may be heightened where </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the product is subject to post-marketing conditions or requirements to provide additional clinical data. In the United States, the principal decisions about reimbursement for new medicines are
typically made by the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under
Medicare. Private payors tend to follow CMS to a substantial degree. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require <FONT
STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. Future coverage and reimbursement may be subject to increased restrictions, such as prior authorization requirements, both in the United States and in international
markets. Orphan drugs are typically placed on the highest cost-sharing tier and a substantial percentage are subject to prior authorization requirements. Reimbursement agencies in the EU may be more conservative than CMS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we
believe the increasing emphasis on cost-containment initiatives in Canada, the EU and other countries has and will continue to put pressure on the pricing and usage of drug products such as AMX0035 and any future product candidates we may develop,
if approved. We may also incur additional challenges when seeking reimbursement from public and private payers where AMX0035 or any future product candidate has been approved subject to post-marketing conditions. In many countries, particularly the
countries of the EU, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after the
receipt of marketing approval for a product. For example, in Canada, price negotiations with provincial authorities can take more than 18 months before there are agreed-upon pricing and reimbursement rates. Prior to these negotiations, a review by
agencies known as the Canadian Agency for Drugs and Technologies in Health, or CADTH, and l&#146;Institut national d&#146;excellence en sant&eacute; et en services sociaux, or INESSS, are conducted to assess the value that a medicine will provide to
the health system. For patented medicines, the PMPRB has jurisdiction over the price at which the medicine is sold, and PMPRB&#146;s assessment of an acceptable price can impact negotiations with payors. Such negotiations may also result in
additional studies and rationale required for combination products before reimbursement will be granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay or
might even prevent our commercial launch of the product, possibly for lengthy periods of time. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our
product candidate to other available therapies. In general, the prices of products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products but monitor and control
company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for product candidates. Accordingly, in markets outside the United States, the reimbursement for AMX0035
and any future product candidates we may develop may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term <FONT STYLE="white-space:nowrap">follow-up</FONT>
evaluations required following the use of product candidates. Patients are unlikely to use AMX0035 or any future product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of AMX0035 or
any future product candidates. Because AMX0035 and any future product candidates may have a higher cost of goods than conventional therapies and may require long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> evaluations, the risk that
coverage and reimbursement rates may be inadequate for us to achieve profitability may be greater. While we have received a positive response from some providers in Canada following Health Canada&#146;s approval with conditions of AMX0035 for the
treatment of ALS, there is significant uncertainty related to insurance coverage and reimbursement. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for AMX0035 and any future
product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, increasing efforts by governmental and other third-party payors in Canada, the EU, the
United States and other foreign jurisdictions to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate
payment for AMX0035 or any future product candidates. There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. We expect to experience pricing pressures in connection with
the sale of AMX0035 or any future product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example:
(i)&nbsp;changes to our manufacturing arrangements; (ii)&nbsp;additions or modifications to product labeling; (iii)&nbsp;the recall or discontinuation of our products; or (iv)&nbsp;additional record-keeping requirements. If any such changes were to
be imposed, they could adversely affect the operation of our business. For more information, see the section entitled <I>&#147;</I>Business&#151;Government Regulation&#151;Current and Future U.S. Healthcare Reform Legislation&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These laws and future state and federal healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and
other healthcare funding and otherwise affect the prices we may obtain for AMX0035 or any future product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. Any
reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to
generate revenue, attain profitability or commercialize our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, increasing efforts by governmental and third-party payors
in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our
product candidates. There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and
enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and
reform government program reimbursement methodologies for drugs. On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which among other things, allows for CMS to negotiate prices for certain single-source drugs
and biologics reimbursed under Medicare Part B and Part D, beginning with ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029
and beyond. The legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#147;maximum fair
price&#148; under the law or for taking price increases that exceed inflation. The legislation also caps Medicare beneficiaries&#146; annual <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> drug expenses
at $2,000. The effect of Inflation Reduction Act of 2022 on our business and the healthcare industry in general is not yet known. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additional state and federal healthcare reform measures are expected to be adopted in the future, any
of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for certain pharmaceutical products or additional pricing pressures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While some of these and other proposed measures may require additional authorization to become effective, Congress and the Biden administration have
each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Governments outside the United States may
impose strict price controls, which may adversely affect our revenues, if any. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In some countries, including Canada and certain Member States
of the EU, the pricing of prescription drugs is, in part, subject to governmental control. Additional countries may adopt similar approaches to the pricing of prescription drugs. In such countries, pricing negotiations with governmental authorities
can take considerable time after receipt of regulatory approval for a product. The EU provides options for the EU Member States to restrict the range of drug products for which their national health insurance systems provide reimbursement and to
control the prices of medicinal products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the
market. Other EU Member States allow companies to fix their own prices for drug products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. In addition, there can be considerable pressure by
governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue
after coverage and reimbursement have been obtained. Reference pricing used by various countries and parallel distribution, or arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced countries, can further reduce prices.
In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of AMX0035 or any future product candidates to other available therapies in order to obtain or maintain reimbursement or pricing
approval, which is time-consuming and costly. We cannot be sure that such prices and reimbursement will be acceptable to us. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement
levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales by us or our strategic partners and
the potential profitability of AMX0035 or any future product candidates in those countries would be negatively affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our relationships with healthcare
providers, physicians, patients and third-party payors may be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages,
reputational harm and diminished profits and future earnings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Healthcare providers, physicians and third-party payors in the United States
and elsewhere play a primary role in the recommendation and prescription of pharmaceutical products. Arrangements with third-party payors and customers can expose pharmaceutical manufacturers to broadly applicable fraud and abuse and other
healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, or FCA, which may constrain the business or financial arrangements and relationships through which such companies
conduct research, sell, market and distribute pharmaceutical products. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive
laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of
information obtained in the course of patient recruitment for clinical trials. For more information, see &#147;Business&#151;Government Regulation&#151;Other U.S. Healthcare Laws&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States, to help patients afford our approved product, we may implement programs to assist them, including patient assistance programs and
co-pay coupon programs for eligible patients. Government enforcement agencies have shown increased interest in pharmaceutical companies&#146; product and patient assistance programs, including reimbursement support services, and a number of
investigations into these programs have resulted in significant civil and criminal settlements. In addition, at least one insurer has directed its network pharmacies to no longer accept co-pay coupons for certain specialty drugs the insurer
identified. Our co-pay coupon programs could become the target of similar insurer actions. In September 2014, the HHS Office of Inspector General, or OIG, issued a Special Advisory Bulletin warning manufacturers that they may be subject to sanctions
under the federal anti-kickback statute and/or civil monetary penalty laws if they do not take appropriate steps to exclude Part D beneficiaries from using co-pay coupons. Accordingly, companies exclude these Part D beneficiaries from using co-pay
coupons and the same is true for our Amylyx Care Team. It is possible that changes in insurer policies regarding co-pay coupons and/or the introduction and enactment of new legislation or regulatory action could restrict or otherwise negatively
affect these patient support programs, which could result in fewer patients using affected products, such as RELYVRIO in the United States, and therefore could have a material adverse effect on our sales, business, and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Third party patient assistance programs that receive financial support from companies have also become the subject of enhanced government and regulatory
scrutiny. The OIG has established guidelines that suggest that it is lawful for pharmaceutical manufacturers to make donations to charitable organizations who provide co-pay assistance to Medicare patients. However, donations to patient assistance
programs have received some negative publicity and have been the subject of multiple government enforcement actions, related to allegations regarding their misuse to promote branded pharmaceutical products over other less costly alternatives.
Specifically, in recent years, there have been multiple settlements resulting out of government claims challenging the legality of third party patient assistance programs under a variety of federal and state laws. We may, from time to time, make
charitable grants to independent charitable foundations that help financially needy patients with their premium, co-pay, and co-insurance obligations. If we choose to do so, and if we or our vendors or donation recipients are deemed to fail to
comply with relevant laws, regulations or evolving government guidance in the provision of charitable donations or operation of these programs, we could be subject to damages, fines, penalties, or other criminal, civil, or administrative sanctions
or enforcement actions. We cannot ensure that our compliance controls, policies, and procedures will be sufficient to protect against acts of our employees, business partners, vendors or charitable foundations that may violate the laws or
regulations of the jurisdictions in which we operate. Regardless of whether we have complied with the law, a government investigation, including of any business partners, vendors or charitable foundations, could impact our business practices, harm
our reputation, divert the attention of management, increase our expenses, and reduce the availability of foundation support for our patients who need assistance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The distribution of pharmaceutical products is also subject to additional requirements and regulations, including extensive recordkeeping, licensing,
storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations
will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or
other healthcare laws and regulations. The scope and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. If our operations are found to be in violation of any of the laws
described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government-funded healthcare
programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits, additional reporting requirements and oversight if we become
subject to a corporate integrity agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws and the delay, reduction, termination or restructuring of our operations. Further,
defending against any such actions can be costly and time-consuming, and may require significant financial and personnel resources. Therefore, even if we successfully defend against any such actions that may be brought against us, our business may
be impaired. If any of the physicians or other providers or entities with whom we expect to do business is found to not comply with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions
from government-funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process
data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other information processing worldwide is rapidly evolving and is
likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure,
transfer, or other processing of personal data regarding individuals in the EU, including personal health data, is subject to the EU General Data Protection Regulation, or the GDPR, which took effect across all member states of the EEA in May 2018.
The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining the consent of the individuals to whom the personal
data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when
engaging third-party processors. The GDPR increases our obligations with respect to clinical trials conducted in the EEA by expanding the definition of personal data to include coded data and requiring changes to informed consent practices and more
detailed notices for clinical trial subjects and investigators. In addition, the GDPR also imposes strict rules on the transfer of personal data to countries outside the EU, including the United States, and, as a result, increases the scrutiny that
clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection, such as the United States. The GDPR also permits data protection
authorities to require the destruction of improperly gathered or used personal information and or impose substantial fines for violations of the GDPR, which can be up to four percent of global revenues or 20&nbsp;million Euros, whichever is greater
and it also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In
addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Similar actions are either in place or underway in the United States. There are a broad variety of data protection laws that are applicable to our
activities, and a wide range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
based on general consumer protection laws. The Federal Trade Commission and state Attorneys General are all aggressive in reviewing consumers&#146; privacy and data security protections. New laws
also are being considered at both the state and federal levels. For example, the California Consumer Privacy Act&#151;which went into effect on January&nbsp;1, 2020&#151;is creating similar risks and obligations as those created by GDPR, though the
Act does exempt certain information collected as part of a clinical trial subject to the Federal Policy for the Protection of Human Subjects, or the Common Rule. Many other states are considering similar legislation. A broad range of legislative
measures also has been introduced at the federal level. Accordingly, failure to comply with federal and state laws (both those currently in effect and future legislation) regarding the privacy and security of personal information could expose us to
fines and penalties under such laws. There also is the threat of consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined to have violated these laws, government investigations into
these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Given the breadth and depth of changes in data protection obligations, preparing for and complying with these requirements is rigorous and
time-intensive and requires significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data
collected in the EU. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to
change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement
actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our business, financial condition or results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Risks Related to the Discovery and Development of Our Current or Future Product Candidates </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We currently depend on the success of AMX0035. If we are unable to maintain, or obtain additional, regulatory approvals for, and successfully commercialize,
AMX0035, or experience significant delays in doing so, our business may be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently only have one product candidate,
AMX0035, and our current business and future success depends entirely on our ability to develop, maintain, or obtain additional, regulatory approvals for, and then successfully commercialize, AMX0035, which we are developing for patients with ALS,
AD and other neurological diseases. To date, we have obtained limited clinical trial data supporting AMX0035, having only completed a clinical trial of 137 patients with ALS and a clinical trial in 95 patients with AD. We are conducting a global
Phase 3 clinical trial of AMX0035 in ALS and intend to conduct additional clinical trials for other indications in the future. This may make an investment in our company riskier than similar companies that have multiple product candidates in active
development that may be able to better sustain failure of a lead product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We recently received approval from the FDA for RELYVRIO for the
treatment of ALS in adults and marketing authorization with conditions from Health Canada for ALBRIOZA for the treatment of ALS and we have a MAA pending before the EMA for AMX0035. Accordingly, we are investing the majority of our efforts and
financial resources in the further development and commercialization of our product candidate, AMX0035, for the treatment of ALS, AD and other diseases. Successful continued development and additional regulatory approvals of AMX0035 for our initial
and potential additional indications is critical to the future success of our business. We will need to raise sufficient funds for, and successfully enroll and complete, our clinical development of AMX0035 for the treatment of ALS,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
AD and other indications. The future regulatory and commercial success of AMX0035 or any future product candidates are subject to a number of risks, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">successful completion of preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">successful patient enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">successful data from our preclinical studies and clinical trials that supports an acceptable risk-benefit profile of
AMX0035 or any future product candidates in the intended populations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">satisfaction of applicable regulatory requirements, including to satisfy applicable rules governing fixed dose combination
products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the interpretation of our preclinical and clinical data by regulatory authorities to support marketing approvals;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">potential unforeseen safety issues or adverse side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">receipt and maintenance of marketing approvals from applicable regulatory authorities, including with any expected NCE and
new clinical investigation data exclusivity and orphan drug market exclusivity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for AMX0035 or any future product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and
commercial supplies of AMX0035 or any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">entry into collaborations to further the development of AMX0035 or any future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, including of
RELYVRIO in the United States, ALBRIOZA in Canada and AMX0035, if and when approved in other jurisdictions, whether alone or in collaboration with others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">successfully launching commercial sales of RELYVRIO in the United States, ALBRIOZA in Canada and AMX0035 or any future
product candidates, if and when approved in other jurisdictions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acceptance of AMX0035, or any other products if and when approved, by patients, the medical community and third-party
payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining and maintaining third-party coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintaining a continued acceptable safety profile of the products following approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">effectively competing with other therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">ensuring that we promote and distribute our products consistent with all applicable healthcare laws; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">enforcing and defending intellectual property rights and claims. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many of these risks are beyond our control, including the risks related to clinical development, the regulatory submission process, potential threats to
our intellectual property rights and the manufacturing, marketing and sales efforts of any future collaborator. If we are unable to develop, obtain or maintain additional regulatory approvals for, or successfully commercialize AMX0035 for the
indications we are developing it for, or if we experience delays as a result of any of these risks or otherwise, our business could be materially harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, of the large number of drugs in development in the pharmaceutical industry, only a small
percentage result in the submission of marketing applications to regulatory authorities, and even fewer are approved for commercialization. Furthermore, even if we do receive regulatory approval for AMX0035 for any indication, any such approval may
be subject to limitations on the indications or uses or the patient populations for which we may market the product. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development activities, we cannot assure
you that we will successfully develop or commercialize AMX0035 for any indication in any jurisdiction. If we or any of our future collaborators are unable to develop, maintain, or obtain additional, regulatory approvals for, or, if approved,
successfully commercialize AMX0035 for our initial or potential additional indications, we may not be able to generate sufficient revenue to continue our business. In addition, our failure to demonstrate positive results in our clinical trials in
any indication for which we are developing AMX0035, or to satisfy other regulatory requirements could adversely affect our development efforts for AMX0035 in other indications. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The delay or denial of regulatory approval, inability to maintain regulatory approval, inability to complete post-marketing requirements, or the requirement to
resubmit any marketing application with additional data or information for AMX0035 in any jurisdiction could mean that we need to delay or even cease operations, and a delay in obtaining or inability to maintain such approval would delay
commercialization of AMX0035 and adversely impact our ability to generate revenue, our business and our results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are not
successful in commercializing AMX0035, or are significantly delayed in doing so, our business will be materially harmed, and we may need to curtail or cease operations. The research, testing, manufacturing, labeling, approval, sale, marketing and
distribution of drug products are subject to extensive regulation by the FDA, Health Canada, the EMA, and other regulatory agencies in the United States and other countries, and such regulations differ from country to country. We are not permitted
to market AMX0035 until we receive approval or marketing authorization from the relevant regulatory authority. We recently received approval from the FDA for AMX0035 (RELYVRIO) for the treatment of ALS in adults and, as part of our approval of
RELYVRIO in the United States, we have post-marketing requirements to conduct carcinogenicity studies in mice and rats, drug-drug interaction studies, and studies in patients with kidney or liver impairment. We also received marketing authorization
with conditions from Health Canada for AMX0035 (ALBRIOZA) for the treatment of ALS. One of the conditions of the approval in Canada is the provision of data from our ongoing PHOENIX trial and additional planned or ongoing studies. We also have a
pending MAA before the EMA. The FDA, Health Canada, the EMA or any other foreign regulatory agency can delay, limit, deny or withdraw approval to market AMX0035 for many reasons, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to demonstrate to the satisfaction of, the FDA, Health Canada, the EMA or any other applicable foreign
regulatory agency that AMX0035 is safe and effective for the requested indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to gain agreement from applicable foreign regulatory authorities that AMX0035 is appropriate for approval
under applicable regulatory pathways; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA&#146;s, Health Canada&#146;s, the EMA&#146;s or any other applicable foreign regulatory agency&#146;s disagreement
with the interpretation of data from nonclinical and clinical studies and trials, such as the FDA&#146;s differing interpretations of certain data, including sensitivity and statistical analyses, from our CENTAUR trial and OLE as presented at the
meetings of the FDA&#146;s Advisory Committee on March&nbsp;30, 2022 and September 7, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to demonstrate that the clinical and other benefits of AMX0035 outweigh any safety or other perceived risks;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to enroll an adequate number of patients in and successfully complete our ongoing global Phase 3 PHOENIX trial;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA&#146;s, Health Canada&#146;s, the EMA&#146;s or any other applicable foreign regulatory agency&#146;s requirement
for additional nonclinical or clinical studies or trials, including studies to satisfy applicable rules governing fixed dose combination products or post-market requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA&#146;s, Health Canada&#146;s, the EMA&#146;s or any other applicable foreign regulatory agency&#146;s having
differing requirements for the trial protocols used in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA&#146;s, Health Canada&#146;s, the EMA&#146;s or any other applicable foreign regulatory agency&#146;s <FONT
STYLE="white-space:nowrap">non-approval</FONT> of the formulation, labeling and/or the specifications of AMX0035; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA&#146;s, Health Canada&#146;s, the EMA&#146;s or any other applicable foreign regulatory agency&#146;s failure to
accept the manufacturing processes or third-party manufacturers with which we contract; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential for approval policies or regulations the FDA, of Health Canada, the EMA or any other applicable foreign
regulatory agencies to significantly change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Of the large
number of drugs in development, only a small percentage successfully complete the FDA, Health Canada, the EMA or other regulatory approval processes and are commercialized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even when we complete clinical testing and receive any regulatory approvals for AMX0035, the FDA or the applicable foreign regulatory agency may grant
approval contingent on the performance of costly additional preclinical studies and clinical trials, which may be required after approval. The FDA or the applicable foreign regulatory agency may also approve AMX0035 for a more limited indication
and/or a narrower patient population than we originally request, and the FDA, Health Canada, the EMA or any other applicable foreign regulatory agency may not approve the labeling that we believe is necessary or desirable for the successful
commercialization of AMX0035. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of AMX0035 and would materially adversely impact our business and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>AMX0035 is a fixed-dose combination drug product and certain regulatory authorities may require a demonstration that each component makes a contribution to the
claimed effects in addition to demonstrating that the combination is safe and effective for the intended population. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the FDA&#146;s
combination rule, the FDA may not file or approve an NDA for a fixed-dose combination product unless each component of a proposed drug product is shown to make a contribution to the claimed effects and the dosage of each component (amount,
frequency, duration) is safe and effective for the intended population. To satisfy these requirements, the FDA typically requires a clinical factorial study, designed to assess the effects attributable to each drug in the combination product. This
is particularly true when the ingredients are directed at the same sign or symptom of the disease or condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA has accepted a variety of
approaches to satisfy the combination rule. In December 2015, the FDA proposed regulations that would allow the agency to waive the requirements of the combination rule for certain drug products under particular circumstances. The FDA has not, to
date, finalized these regulations, but the FDA has stated that factorial studies may be unethical (e.g., omitting a drug known to improve survival) or impractical (there may be too many components to conduct a factorial study, meaning the trial
cannot be conducted). The FDA has also stated that it may be possible to use other types of clinical and nonclinical data and mechanistic information available to demonstrate the contributions of the individual active ingredients to the effect of
the combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Similar requirements may be imposed on us by the EMA in the EU and comparable regulatory authorities in other jurisdictions where
we intend to seek regulatory approval. In the EU, we have only </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
submitted preclinical data to demonstrate the clinical effects of each component in AMX0035, PB and TURSO (also known as TUDCA), in our MAA. There can be no assurance that the EMA will conclude
that our preclinical data are sufficient for these purposes or, even if they are, that the results from our preclinical studies demonstrate the clinical effects of each component in AMX0035 for the treatment of ALS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While the FDA has approved AMX0035 (known as RELYVRIO) as a fixed-dose combination product for the treatment of ALS in adults, we may be required by the
FDA and comparable foreign regulatory authorities to satisfy the fixed-dose combination rule for AMX0035 or any other fixed-dose combination products we may develop for the treatment of any other indications we may pursue in advance of approval.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the FDA, the EMA or other comparable foreign regulatory authorities require us to conduct one or more clinical trials to support such a
demonstration, such as a factorial study, the design, duration, and scope of such clinical trials will be decided upon after further discussions with those agencies and other comparable foreign regulatory authorities. As a result, we are unable to
predict with certainty the estimated timing or scope of any future clinical trials of AMX0035 we may be required to conduct to satisfy these requirements governing fixed dose combination products in various jurisdictions. Ongoing third-party data in
neurology, specifically within ALS, on our products or other products may influence regulatory decision making, including for fixed-dose combinations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We
have concentrated our research and development efforts on the treatment of neurodegenerative and CNS disorders, a field that has seen very limited success in product development. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have focused our research and development efforts on addressing neurodegenerative and CNS disorders. Historically, efforts by pharmaceutical companies
in the field of neurodegenerative and CNS disorders have experienced limited successes in product development. The development of neurodegenerative and CNS therapies presents unique challenges, including an imperfect understanding of the biology,
the presence of the blood brain barrier that can restrict the flow of drugs to the brain, a frequent lack of translatability of preclinical study results in subsequent clinical trials and dose selection, and the product candidate having an effect
that may be too small to be detected using the outcome measures selected in clinical trials or if the outcomes measured do not reach statistical significance. There are few approved therapeutic options available for patients with ALS, AD and other
neurodegenerative disorders. Our future success is highly dependent on the successful development and commercialization of AMX0035 and any future product candidates for treating neurodegenerative and CNS disorders. Developing and commercializing
AMX0035 and any future product candidates for treatment of neurodegenerative and CNS disorders subjects us to a number of challenges, including ensuring that we have selected the optimal doses, executing an appropriate clinical trial to test for
efficacy and obtaining and maintaining regulatory approval from Health Canada, the FDA, the EMA and other comparable foreign regulatory authorities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The
regulatory approval processes of the FDA, Health Canada, the EMA and other comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain or maintain regulatory approval for AMX0035
or any future product candidates, our business will be substantially harmed. Any finding that our global Phase 3 PHOENIX trial is insufficient to support current or additional marketing authorizations in ALS could lead the FDA or Health Canada to
withdraw prior regulatory approvals for RELYVRIO or ALBRIOZA, respectively, or we could decide, after consultation with regulatory authorities, to voluntarily withdraw RELYVRIO or ALBRIOZA from the marketplace. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We, and any future collaborators, are not permitted to commercialize, market, promote or sell any product candidate in the United States, Canada, or the
EU without obtaining regulatory approval from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the FDA, Health Canada, or the EMA, respectively. Regulatory authorities in other jurisdictions may have similar requirements. The time required to obtain approval by the FDA, Health Canada, the
EMA and other comparable foreign regulatory authorities is unpredictable, and typically takes many years following the commencement of clinical trials and depends upon numerous factors, including substantial discretion of such regulatory
authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions. The FDA in
any approval needs to determine that there is substantial evidence of effectiveness. This finding can be substantiated based on two adequate and well-controlled studies, or in certain circumstances on a single, large, multicenter, adequate and
well-controlled study that is very persuasive or from a single adequate and well-controlled study together with confirmatory evidence. FDA regulations and guidance also allow for greater flexibility and tolerance for uncertainty in the context of
rare and fatal diseases. In June 2022, we obtained marketing authorization with conditions for AMX0035 (ALBRIOZA) in Canada and in September 2022, we received approval from the FDA for AMX0035 (RELYVRIO) in the United States. While we have received
approval from the FDA and marketing authorization with conditions from Health Canada, and have submitted an MAA to the EMA, to date, we have not submitted any other similar drug approval submissions to comparable foreign regulatory authorities for
AMX0035 or any other product candidate. We have not obtained approval of our MAA from the EMA, and there can be no assurance that we will receive such approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">One of the conditions of the marketing authorization in Canada is the provision of data from our ongoing PHOENIX trial. There is no guarantee that
Health Canada will accept the data from our PHOENIX trial as satisfying the conditions and grant a marketing authorization without conditions for ALBRIOZA for the treatment of ALS. Health Canada could require us to make further undertakings with
respect to confirmatory clinical trials if it is not satisfied with the data from the PHOENIX trial, in order for AMX0035 to continue to be marketed in Canada. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our approval of RELYVRIO by the FDA was granted following a positive recommendation for approval at the second virtual meeting of the Advisory Committee
held on September 7, 2022. The Advisory Committee initially met on March 30, 2022 and voted 4 (yes) and 6 (no) on the question of whether the data from our randomized, controlled Phase 2 CENTAUR trial and OLE established a conclusion that AMX0035 is
effective in the treatment of patients with ALS. At the second meeting of the Advisory Committee, the Advisory Committee voted 7 (yes) to 2 (no) in response to the question of whether available evidence of effectiveness is sufficient to support
approval of AMX0035 for the treatment of ALS, taking into account the unmet need in ALS, the status of the ongoing PHOENIX trial and the seriousness of ALS. Although the FDA subsequently approved RELYVRIO for the treatment of ALS in adults, at this
meeting and the previous Advisory Committee meeting, the FDA presented concerns regarding choices of statistical models for the prespecified primarily analysis and the interpretability of the survival results included in our marketing application.
Other regulatory authorities may present similar concerns regarding our data when reviewed to support marketing applications for AMX0035 for the treatment of ALS. If we experience delays in obtaining and maintaining regulatory approval or if we fail
to obtain or maintain such approvals, the commercial prospects for AMX0035 may be harmed and our ability to generate revenues and the value of our common stock will be materially impaired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. We cannot
guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. The clinical development of AMX0035 for our initial and potential additional indications or any future product candidates is susceptible to the risk
of failure inherent at any stage of development, including failure to demonstrate efficacy in a clinical trial or across a broad population of patients, the occurrence of adverse events that are severe or medically or commercially unacceptable,
failure to comply with protocols or applicable regulatory requirements, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and determination by the FDA, Health Canada, the EMA or any other comparable foreign regulatory authority that a product candidate may not continue development or is not approvable. Additionally,
our expenses could increase if we are required by the FDA, Health Canada, the EMA or any other comparable foreign regulatory authority to perform clinical trials in addition to those currently expected, or if there are any delays in completing our
clinical trials or the development of AMX0035 in additional indications. It is possible that even if AMX0035 or any future product candidate has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or
more of a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of AMX0035 or any
future product candidate that is greater than the actual positive effect, if any. Similarly, in our clinical trials we may fail to detect toxicity of or intolerability caused by AMX0035 or any future product candidate, or mistakenly believe that
AMX0035 or any future product candidates are toxic or not well-tolerated when that is not in fact the case. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">AMX0035 could fail to obtain additional
regulatory approvals, and any of our future product candidates could fail to obtain regulatory approvals, for many reasons, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA, Health Canada, the EMA or other comparable foreign regulatory authorities may disagree as to the design or
implementation of our clinical trials and may require additional data to support regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA, Health Canada, the EMA or other comparable foreign
regulatory authorities that a product candidate is safe and effective for its proposed indication and, if necessary, that a product candidate and any active components thereof are safe and effective for the proposed indication;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA, Health Canada, the
EMA or other comparable foreign regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be unable to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety risks;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA, Health Canada, the EMA and comparable authorities in other countries may disagree with our interpretation of data
from clinical trials or preclinical studies and may require additional trials or studies to support marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the data collected from clinical trials of AMX0035 or any future product candidates may not be sufficient to support the
submission of an NDA or other submission to the FDA or other comparable foreign regulatory authority to obtain regulatory approval in the United States, Canada, the EU or elsewhere; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA, Health Canada, the EMA or other comparable foreign regulatory authorities may find deficiencies with clinical
trial sites or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the approval policies or regulations of the FDA, Health Canada, the EMA or other comparable foreign regulatory authorities
may significantly change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This lengthy approval process as well
as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval to market AMX0035 or any future product candidate we develop, which would significantly harm our business, results of operations and prospects.
There is no assurance that the endpoints and trial designs used for the approval of currently approved drugs for the treatment of neurodegenerative diseases will be acceptable for future approvals, including for AMX0035. The FDA, Health Canada, the
EMA and other comparable foreign authorities have substantial discretion in the approval process and determining when or whether regulatory approval will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
be obtained for any product candidate that we develop. Even if we believe the data collected from past or future clinical trials of AMX0035 or any future product candidates are promising, such
data may not be sufficient to support approval by the FDA or any other regulatory authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA reviews an NDA to determine whether the
product is safe and effective for its intended use(s), with the latter determination being made on the basis of substantial evidence. This finding can be substantiated based on two adequate and well-controlled studies, or in certain circumstances on
a single, large, multicenter, adequate and well-controlled study that is very persuasive or from a single adequate and well-controlled study together with confirmatory evidence. The FDA may not agree that this standard is met. Accordingly, there can
be no assurance that for AMX0035 or future product candidates the FDA and other regulatory agencies, including Health Canada and the EMA, will not require additional clinical trials beyond what we may plan to conduct. This may be the case
particularly as these regulatory authorities may consult with one another or as we may be required to apprise the respective agencies of studies we are conducting of AMX0035 for ALS in conjunction with our requests for marketing approval or in
response to post-marketing requirements from the respective agency. In September 2022, we received approval for AMX0035 from the FDA for the treatment of ALS in adults, and as a part of our approval, we have post-marketing requirements to conduct
carcinogenicity studies in mice and rats, drug-drug interaction studies, and studies in patients with kidney or liver impairment. In July 2022, we received marketing authorization for AMX0035 from Health Canada, with conditions, for the treatment of
ALS. One of the conditions of the approval is the provision of data from our ongoing PHOENIX trial. There is no guarantee that Health Canada will accept the data from our PHOENIX trial and grant authorization without conditions for AMX0035 for the
treatment of ALS. Additionally, the EMA may also find that our CENTAUR trial, together with any data from our global Phase 3 PHOENIX trial that may be provided during or after the review period for these applications, is not sufficient to support
our request for marketing authorization in the EU. It is typically the case not just in the United States, but also in Canada and Europe, that marketing approvals are based on two Phase 3 clinical studies. Moreover, any finding by another regulatory
authority that our global Phase 3 PHOENIX trial is insufficient to support additional marketing authorizations in ALS could lead the FDA or Health Canada to withdraw prior regulatory approvals for RELYVRIO and ALBRIOZA, respectively. At the second
meeting of the Advisory Committee on September 7, 2022, we stated that if our PHOENIX trial is not successful then we will do what is right for patients, which includes voluntarily removing the product from the market. Any such findings by a
regulatory authority or decision to voluntarily withdraw AMX0035 from the marketplace would materially harm our ability to generate revenue and become profitable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, disruptions caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may increase the likelihood that we encounter
difficulties or delays in initiating, screening, enrolling, conducting, or completing our ongoing and planned preclinical studies and clinical trials. Clinical site initiation and patient screening and enrollment may be delayed due to prioritization
of hospital resources toward the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Investigators and patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services.
Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> could be limited, which in turn could
adversely impact our clinical trial operations. Additionally, we may experience interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed
or recommended by federal or state governments, employers and others in connection with the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. As a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we may face
delays in meeting our anticipated timelines for our ongoing and planned clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA has noted it is continuing to ensure timely
reviews of applications for medical products during the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic in line with its user fee performance goals and conducting mission critical domestic and foreign inspections to ensure
compliance of manufacturing facilities with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
FDA quality standards. However, the FDA may not be able to continue its current pace and approval timelines could be extended, including where a
<FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection or an inspection of clinical sites is required and due to the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and travel restrictions the FDA is unable to complete
such required inspections during the review period. Since March 2020, when foreign and domestic inspections were largely placed on hold due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the FDA has been working to resume
pre-pandemic levels of inspection activities, including routine surveillance, bioresearch monitoring and <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections on a prioritized basis. Should the FDA determine that an inspection is
necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the agency has stated that it generally intends to
issue, depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed. Further, if there is inadequate information to make a determination on the acceptability of a facility, the
FDA may defer action on the application until an inspection can be completed. During the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, a number of companies announced receipt of complete response letters due to the FDA&#146;s inability
to complete required inspections for their applications. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and may
experience delays in their regulatory activities. For example, with respect to new sites or facilities in the European Economic Area, or EEA, which have never had a current Good Manufacturing Practices, or cGMP, inspection or authorization, the EMA
has stated that a distant assessment may be conducted in order to evaluate if the site could be authorized without an <FONT STYLE="white-space:nowrap">on-site</FONT> <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection. If an approval is
granted, it should be indicated that the certificate has been granted on the basis of a distant assessment and an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection should be conducted when circumstances permit. If a cGMP certificate cannot
be granted as a result of the distant assessment, a clock-stop in the regulatory approval process will be imposed until an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection is possible. In addition, even if we were to obtain approval,
regulatory authorities may approve AMX0035 or any future product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of
costly post-marketing preclinical studies and clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of
the foregoing scenarios could materially harm the commercial prospects for AMX0035 or any future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In Canada, <FONT
STYLE="white-space:nowrap">pre-approval</FONT> GMP inspections are not performed in association with the NDS. Instead, Health Canada relies on a Drug Establishment License, or DEL, to determine the site&#146;s compliance with GMP. DELs can only be
held by companies in Canada, and that company becomes the importer of record for the drug. To import, the sites of manufacture, testing and packaging of the Drug Substance and Drug Product are required to be listed on the DEL. Listing is dependent
on having an inspection report from a recognized sister regulatory agency such as the EMA or the FDA. As a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, inspection reports can now be up to three years old. The site of
manufacture of the drug product for AMX0035 is in Canada and is subject to routine inspections from Health Canada. These Canadian inspections are currently being performed remotely as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of
AMX0035 or any future product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To obtain regulatory approval to commercialize AMX0035 and any future product candidates, we must
demonstrate through extensive preclinical studies and clinical trials that such product candidates are safe and effective in humans. Preclinical and clinical testing are expensive and can take many years to complete, and their outcome is inherently
uncertain. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful, which could impact our ability to obtain additional regulatory approvals for AMX0035, to satisfy any applicable
post-market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
conditions or requirements or to continue marketing AMX0035 in the United States and Canada. We could also be required by regulatory authorities to withdraw AMX0035 from the marketplace. This
could impact our development plans for AMX0035 for other indications and future product candidates and could impact our results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We
may experience delays in completing our clinical trials or preclinical studies and initiating or completing additional clinical trials. We may also experience numerous unforeseen events during our clinical trials that could delay or prevent our
ability to receive marketing approval or commercialize AMX0035 or any future product candidates we develop, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulators, or institutional review boards, or IRBs, or other reviewing bodies may not authorize us or our investigators to
commence a clinical trial, or to conduct or continue a clinical trial at a prospective or specific trial site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may not reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical
trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of subjects or patients required for clinical trials of AMX0035 in an indication or any future product candidate
may be larger than we anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate, and the number of clinical trials being conducted at any given time may be high and result in fewer available patients for any
given clinical trial, or patients may drop out of these clinical trials at a higher rate than we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our third-party contractors, including those manufacturing AMX0035 or any future product candidates or conducting clinical
trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may have to amend clinical trial protocol submitted to regulatory authorities or conduct additional studies to reflect
changes in regulatory requirements or guidance, which we may be required to resubmit to an IRB and regulatory authorities for <FONT STYLE="white-space:nowrap">re-examination;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unforeseen safety events may occur during the course of a clinical trial and these events may result in the temporary
suspension or termination of a clinical trial, or require urgent safety measures or restrictions to protect human subjects during the conduct of a clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulators, IRBs or other reviewing bodies may fail to approve or subsequently find fault with the manufacturing processes
or facilities of third-party manufacturers with which we enter into agreement for clinical and commercial supplies, or the supply or quality of AMX0035 or any future product candidate or other materials necessary to conduct clinical trials of
AMX0035 or any future product candidates may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential for approval policies or regulations of Health Canada, the FDA, the EMA or any other applicable foreign
regulatory agencies to significantly change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Regulators, IRBs
of the institutions in which clinical trials are being conducted or data monitoring committees may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory
requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to
demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Negative or inconclusive impressions of the results from our earlier clinical trials of AMX0035 for the treatment of ALS or AD, or any other clinical
trial or preclinical studies in animals that we have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
conducted, could mandate repeated or additional preclinical studies or clinical trials and could delay marketing approvals or result in changes to or delays in preclinical studies or clinical
trials of AMX0035 in other indications. We do not know whether any clinical trials that we may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market AMX0035 for our initial or potential additional
indications, or any future product candidate. If later stage clinical trials, including our ongoing global Phase 3 PHOENIX trial in ALS, do not produce favorable results with very strong statistical significance, our ability to obtain or maintain
any prior-issued regulatory approval for AMX0035 for ALS (including our FDA approval and our marketing authorization with conditions from Health Canada) or potential additional indications, or any future product candidate, may be adversely impacted.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our failure to successfully initiate and complete clinical trials of AMX0035 for ALS, AD or potential additional indications and to demonstrate the
efficacy and safety of AMX0035, including each component thereof, necessary to obtain and maintain regulatory approval to market AMX0035, including if our global Phase 3 PHOENIX trial is not successful, would significantly harm our business and
ability to continue developing and marketing AMX0035 for any indications. Our product candidate development costs will also increase if we experience delays in testing or obtaining and maintaining regulatory approvals and we may be required to
obtain additional funds to complete clinical trials. We cannot assure you that our clinical trials will begin as planned or be completed on schedule, if at all, or that we will not need to restructure our trials after they have begun. Significant
clinical trial delays or the need for additional data from our clinical trials also could shorten any periods during which we may have the exclusive right to commercialize AMX0035 or any future product candidates or allow our competitors to bring
products to market before we do and impair our ability to successfully commercialize such product candidates, which may harm our business and results of operations. In addition, many of the factors that cause, or lead to, delays of clinical trials
may ultimately lead to the denial of regulatory approval of AMX0035 or any future product candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if we complete the necessary preclinical studies
and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us or any future collaboration partners from obtaining or maintaining approvals for the commercialization of AMX0035 for our initial or
potential additional indications as well as for any future product candidate we develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any product candidate we may develop and the
activities associated with its development and commercialization, including its design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject to comprehensive
regulation by Health Canada, the FDA, the EMA and other regulatory authorities in the United States and in other countries. Failure to obtain marketing approval for a product candidate will prevent us from commercializing that product candidate in a
given jurisdiction. Although we have invested substantial time and resources to date in pursuit of regulatory approval and toward potential commercialization, we have only received regulatory approval for AMX0035 (RELYVRIO) in the United States and
marketing authorization with conditions for AMX0035 (ALBRIOZA) in Canada and have not received any other regulatory approvals to market any product candidates from regulatory authorities in any jurisdiction and it is possible that none of the
product candidates we may seek to develop in the future will ever obtain regulatory approval. We have no experience in filing and supporting the applications necessary to gain marketing approvals and rely on third-party CROs or regulatory
consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish
the biologic product candidate&#146;s safety, purity, efficacy and potency. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the
relevant regulatory authority. Any product candidates we develop may not be effective, may be only moderately effective, or may prove to have undesirable or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The process of obtaining marketing approvals, in the United States, Canada, EU and other foreign jurisdictions, is expensive, may take many years if
additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity, and novelty of the product candidates involved. Changes in marketing approval
policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The
FDA, Health Canada, the EMA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide during the review process that our data are insufficient for
approval and require additional preclinical, clinical or other studies. For example, during the review of our NDA for AMX0035 for the treatment of ALS, the FDA requested clarifying information regarding our preclinical and clinical data and during
the Advisory Committee meetings noted certain concerns with interpretation of our clinical data. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent marketing approval of, or
limit the approved labeling for, a product candidate. For example, while we have conducted preclinical studies in various models of neurodegenerative diseases, it is the view of the FDA that the mechanism by which RELYVRIO exerts its therapeutic
effects in patients with ALS is unknown. In addition, in the approved labeling for RELYVRIO, the FDA noted that the post hoc, long-term exploratory survival analysis should be interpreted with caution given the limitations of data collected outside
of a controlled study. Additionally, the FDA has discretion to refer an application for a novel drug or a drug that presents difficult questions of safety or efficacy to an advisory committee. For example, our approval of RELYVRIO by the FDA was
granted following the second virtual meeting of the Advisory Committee held on September 7, 2022. The Advisory Committee initially met on March 30, 2022 and voted 4 (yes) and 6 (no) on the question of whether the data from our randomized, controlled
Phase 2 CENTAUR trial and OLE established a conclusion that AMX0035 is effective in the treatment of patients with ALS. At the second meeting of the Advisory Committee, the Advisory Committee voted 7 (yes) to 2 (no) in response to the question of
whether available evidence of effectiveness is sufficient to support approval of AMX0035 for the treatment of ALS, taking into account the unmet need in ALS, the status of the ongoing PHOENIX trial and the seriousness of ALS. At this meeting and the
previous Advisory Committee meeting, the FDA presented concerns regarding choices of statistical models for the prespecified primarily analysis and the interpretability of the survival results. Additionally, in July 2022 we received marketing
authorization with conditions of AMX0035 (ALBRIOZA) from Health Canada for the treatment of ALS. One of the conditions of the marketing authorization in Canada is the provision of data from our ongoing PHOENIX trial. There is no guarantee that
Health Canada will accept the data from our PHOENIX trial as satisfying the conditions and grant a marketing authorization without conditions for ALBRIOZA for the treatment of ALS or that the PHOENIX trial will be successful. Health Canada could
require us to make further undertakings with respect to confirmatory clinical trials if it is not satisfied with the data from the PHOENIX trial, in order for AMX0035 to continue to be marketed in Canada. As such, we may be unable to obtain or to
maintain the marketing approvals we are pursuing and any marketing approvals we ultimately obtain, including any conditional approvals, may be denied, limited, withdrawn, or subject to restrictions or post-approval commitments that could render the
approved product not commercially viable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we experience delays in obtaining and maintaining approval or if we fail to obtain approval of any
product candidates we may develop, the commercial prospects for those product candidates, including for AMX0035 in other indications, may be harmed, and our ability to generate revenues will be materially impaired. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The results of early-stage clinical trials and preclinical studies may not be predictive of future results.
Initial data in our clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
results of preclinical studies may not be predictive of the results of clinical trials, and the results of any early-stage clinical trials we commence may not be predictive of the results of the later-stage clinical trials. In addition, initial data
in clinical trials may not be indicative of results obtained when such trials are completed. There can be no assurance that any of our clinical trials will ultimately be successful or support further clinical development of AMX0035 or any future
product candidates. In addition, the clinical results seen in the CENTAUR trial may not be repeated in our global Phase 3 PHOENIX clinical trial, which may materially impact our ability to obtain authorization without conditions for ALBRIOZA in
Canada, to maintain our approval for RELYVRIO in the United States, and to continue development of AMX0035 for additional indications or of future product candidates. There is a high failure rate for drugs and biologics proceeding through clinical
trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies, and any such setbacks in our clinical development
could have a material adverse effect on our business and operating results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, we have in the past utilized and may in the future
utilize an &#147;open-label&#148; clinical trial design. An &#147;open-label&#148; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing
approved drug or placebo. Most open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any
therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#147;patient bias&#148; where patients perceive their symptoms to have improved merely due to
their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#147;investigator bias&#148; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of
which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with AMX0035 or any future
product candidates when studied in a controlled environment with a placebo or active control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Interim topline and preliminary data from our clinical trials
that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From time to time, we may publish interim topline or preliminary data from our clinical trials. Interim data from clinical trials that we may complete
are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or topline results also remain subject to audit and verification procedures
that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between
preliminary or interim data and final data could significantly harm our reputation and business prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Enrollment and retention of patients in clinical
trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Patient enrollment is a significant factor in the timing of clinical trials, and the timing of our clinical trials depends, in part, on the speed at
which we can recruit patients to participate in our trials, as well </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
as completion of required <FONT STYLE="white-space:nowrap">follow-up</FONT> periods. We may not be able to initiate or continue clinical trials for AMX0035 or any future product candidates if we
are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trial&#146;s conclusion as required by Health Canada, the FDA, the EMA or other comparable foreign regulatory authorities. Additionally,
certain clinical trials for AMX0035 and any future product candidates may be focused on indications with relatively small patient populations, which may further limit enrollment of eligible patients or may result in slower enrollment than we
anticipate. The eligibility criteria of our clinical trials, once established, may further limit the pool of available trial participants. For example the number of patients suffering from ALS, is small and, in some cases, has not been established
with precision. If the actual number of patients with these diseases is smaller than we anticipate, we may encounter difficulties in enrolling patients in our clinical trials, thereby delaying or preventing development and approval of AMX0035 or any
future product candidates. Even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. For example, ALS patients have significant mobility issues, morbidities and other complications that have
historically made retention in ALS trials, more challenging. These challenges are also present with many other neurodegenerative indications, including indications for which we may run clinical trials in the future. In the past, we have had
discontinuations in our clinical trials, including in our CENTAUR trial and CENTAUR OLE trial. Discontinuations may occur in the future and could result in delays of our clinical trials and affect our ability to enroll additional patients in our
clinical trials and impact the integrity of data from our clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Patient enrollment and retention in clinical trials depends on many
factors, including the size of the patient population, the severity of the disease under investigation, the nature of the trial protocol, the existing body of safety and efficacy data for the product candidate, the number and nature of competing
treatments and ongoing clinical trials of or expanded access to competing therapies for the same indication, the proximity of patients to clinical sites, the eligibility criteria for the trial, the ability to adequately monitor patients during a
trial, clinicians&#146; and patients&#146; perceptions as to the potential advantages of the product candidate being studied, and the risk that patients will drop out of a trial before completing all site visits. There are limited patient pools from
which to draw in order to complete our clinical trials in a timely and cost-effective manner, including due to the fact that the neurological diseases we target are rare. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore, our efforts to build relationships with patient communities may not succeed, which could result in delays in patient enrollment in our
clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any negative results we may report in clinical trials of AMX0035 or any future product candidate may also make it difficult or
impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect
on our ability to develop AMX0035 in ALS, AD and additional indications and any future product candidates, or could render further development impossible. For example, the impact of public health epidemics, such as the ongoing <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, may delay or prevent patients from enrolling or from receiving treatment in accordance with the protocol and the required timelines, which could delay our clinical trials, or prevent us or our
partners from completing our clinical trials at all, and harm our ability to obtain and maintain approval for such product candidate. Further, if patients drop out of our clinical trials, miss scheduled doses or
<FONT STYLE="white-space:nowrap">follow-up</FONT> visits, or otherwise fail to follow clinical trial protocols, whether as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and related illness or actions taken to slow the
spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> or otherwise, the integrity of data from our clinical trials may be compromised or not accepted by Health Canada, the FDA, the EMA or other regulatory authorities, which would represent a
significant setback for the applicable program. In addition, we may rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we
will be limited in our ability to compel their actual performance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it
is common that various aspects of the development activities, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Any of these changes could cause AMX0035 or any future product
candidates to perform differently and affect the results of ongoing clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. For example, in seeking approval of AMX0035 in Europe, we
submitted data supporting a different formulation of AMX0035 from the formulation evaluated in the CENTAUR trial. Changes to commercial formulations from those studied clinically could lead regulatory authorities to delay the approval of our
marketing applications until we can demonstrate through additional clinical data that there is comparability in the bioavailability of the two different formulations or may require us to revert to the prior formulation evaluated clinically. Should
we have to conduct comparability testing to bridge earlier clinical data obtained from product candidates produced under earlier manufacturing methods or formulations with the planned commercial formulation, regulatory authorities may disagree on
the interpretation of results from this testing. This could delay completion of clinical trials, require the repetition of one or more clinical trials, increase clinical trial costs, delay approval of AMX0035 or any future product candidates and
jeopardize our ability to commence sales and generate revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>AMX0035 or any future product candidate may cause undesirable side effects or have other
properties that could delay or prevent its regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if obtained. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Undesirable side effects caused by AMX0035, or any future product candidate, could cause us or regulatory authorities to interrupt, delay or halt
clinical trials and could result in a more restrictive label or the delay, denial or withdrawal of regulatory approval by the FDA, Health Canada, the EMA or comparable foreign regulatory authorities. Results of our preclinical studies or clinical
trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. In clinical trials of AMX0035 to date, AMX0035 has been generally well-tolerated, with most common treatment-emergent adverse events
including diarrhea, abdominal pain, nausea, upper respiratory infection, constipation, headache, fatigue, proteinuria, and decreased appetite. In animal studies, administration of AMX0035 to rats throughout pregnancy and lactation resulted in
increased offspring mortality at all doses tested, which were less than or similar to the clinical doses tested in our clinical trials. However, there can be no guarantee that we would observe a similar tolerability profile of AMX0035 in our ongoing
global Phase 3 PHOENIX clinical trial or in other future clinical trials. Many compounds that initially showed promise in clinical or earlier stage testing are later found to cause undesirable or unexpected side effects that prevented further
development of the compound. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If unacceptable side effects arise in the development of AMX0035 or any future product candidates, we, the FDA, Health
Canada, the EMA or comparable foreign regulatory authorities, the IRBs, or independent ethics committees at the institutions in which our trials are conducted, or the independent safety monitoring committee could suspend or terminate our clinical
trials or regulatory authorities could order us to cease clinical trials or deny approval of AMX0035 or any future product candidates for any or all targeted indications. Treatment-emergent side effects that are deemed to be drug-related could also
affect subject recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Undesirable side effects in one of our clinical trials for AMX0035 in one indication could adversely affect
enrollment in clinical trials, regulatory approval and commercialization of AMX0035 in other indications. Additionally, there may be negative findings regarding components of AMX0035 or future product candidates by other parties. For example,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Humanitas Mirasole SpA, or Humanitas, is conducting a Phase 3 clinical trial in the EU to assess the safety and efficacy of TURSO in patients with ALS which may lead to additional findings as to
the safety profile of TURSO. Any negative findings by third parties may impact the future approvability or labeling of AMX0035 or other product candidates we may develop. In addition, side effects may not be appropriately recognized or managed by
the treating medical staff. We have no relationship with Humanitas. If their Phase 3 clinical trial is successful and TURSO is approved by the FDA or any other regulatory agency, TURSO may become a commercialized product competitive with AMX0035,
unless our intellectual property protections and any regulatory exclusivities we possess or may possess in the future prevent such commercialization. Inadequate training in recognizing or managing the potential side effects of AMX0035 or any future
product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Bitter taste was frequently observed in our clinical trials of AMX0035. While bitter taste, by itself, does not present a safety risk for patients, it
may lead to higher levels of patient <FONT STYLE="white-space:nowrap">non-compliance,</FONT> which could have the effect of reducing the observed efficacy of AMX0035 in our clinical trials, including our ongoing global Phase 3 PHOENIX trial, or
limit its commercial adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, clinical trials of AMX0035 are conducted in carefully defined sets of patients who have agreed to enter
into clinical trials. Consequently, it is possible that our clinical trials, or those of any future collaborator, may indicate an apparent positive effect of AMX0035 or a future product candidate that is greater than the actual positive effect, if
any, or alternatively fail to identify undesirable side effects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Finally, AMX0035 is a combination of TURSO and PB. PB has been approved by the FDA
and other regulatory authorities for the treatment of patients with certain urea cycle disorders and TURSO has been approved in Italy for diseases of cirrhotic liver disorders such as primary biliary cirrhosis. It is possible that one or more of the
active moieties in AMX0035 has also been approved by FDA or other regulatory authorities. Even if AMX0035 receives marketing approval and is commercialized in a jurisdiction, we would continue to be subject to the risks that the applicable
regulatory authorities could revoke approval of PB or TURSO or any active moiety in AMX0035, if applicable, or that efficacy, manufacturing or supply issues could arise with PB or TURSO or any active moiety in AMX0035, if applicable. This could
result in our own products being removed from the market or being less commercially successful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Increasing demand for expanded access to AMX0035 could
negatively affect our reputation and harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are developing AMX0035 for the treatment of ALS, AD and other potential future
indications for which there are currently limited or no available therapeutic options. It is possible for individuals or groups to target companies with disruptive social media campaigns related to a request for access to unapproved drugs for
patients with significant unmet medical need. If we experience a similar social media campaign regarding our decision to provide or not provide access to AMX0035 or any of our future product candidates under an expanded access policy, our reputation
may be negatively affected and our business may be harmed. On March&nbsp;18, 2022, we launched an <FONT STYLE="white-space:nowrap">FDA-authorized</FONT> expanded access program in the United States for AMX0035 for certain adults with ALS and this
program will be wound down alongside the commercial launch of RELYVRIO in the United States. We may launch additional expanded access programs of AMX0035 in the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the past, media attention to individual patients&#146; expanded access requests has resulted in the introduction and enactment of legislation at the
local and national level, including the Accelerating Access to Critical Therapies for ALS Act and prior &#147;Right to Try&#148; laws, such as the federal Right to Try Act of 2017, which are intended to allow patients access to unapproved therapies
earlier than </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
traditional expanded access programs and the former of which is intended to support research and development related to ALS, specifically. A possible consequence of both activism and legislation
in this area may be the need for us to initiate an expanded access program beyond that which we have submitted to the FDA or to make AMX0035 or any future product candidates more widely available sooner than anticipated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, some patients who receive access to drugs prior to their commercial approval through compassionate use, expanded access programs or right
to try access have life-threatening illnesses and have exhausted all other available therapies. The risk for SAEs in this patient population is high, which could have a negative impact on the safety profile of AMX0035 or future product candidates,
which could cause significant delays or an inability to successfully commercialize AMX0035 or future product candidates, which could materially harm our business. We may in the future need to restructure or pause any future compassionate use and/or
expanded access program we initiate in order to perform the controlled clinical trials required for regulatory approval and successful commercialization of AMX0035 or future product candidates, which could prompt adverse publicity or other
disruptions related to current or potential participants in such programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The increasing use of social media platforms presents new risks and challenges.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Social media is increasingly being used to communicate about our clinical development activities and the diseases AMX0035 is being developed
to treat, and we intend to continue to utilize appropriate social media in connection with our commercialization efforts for RELYVRIO in the United States and ALBRIOZA in Canada, and in any other jurisdictions where we obtain regulatory approvals.
Social media practices in the biotechnology and pharmaceutical industries continue to evolve and regulations and regulatory guidance relating to such use are evolving and not always clear. This evolution creates uncertainty and risk of noncompliance
with regulations applicable to our business, resulting in potential regulatory actions against us, along with the potential for litigation related to <FONT STYLE="white-space:nowrap">off-label</FONT> marketing or other prohibited activities and
heightened scrutiny by the FDA, the SEC and other regulators. For example, patients may use social media channels to comment on their experience on treatment with AMX0035 or their experience in an ongoing blinded clinical trial or to report an
alleged adverse event. If such disclosures occur, there is a risk that trial enrollment may be adversely impacted, that we may fail to monitor and comply with applicable adverse event reporting obligations or that we may not be able to defend our
business or the public&#146;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our product candidates. There is also a risk of inappropriate disclosure of
sensitive or confidential information or negative or inaccurate posts or comments about us on any social networking website. In addition, we may encounter attacks on social media regarding our company, management, AMX0035 or future product
candidates. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we fail to develop and commercialize AMX0035 for additional indications or fail to discover, develop and commercialize other product candidates, we may be
unable to grow our business and our ability to achieve our strategic objectives would be impaired. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although the development and
commercialization of AMX0035 for the treatment of ALS is our current primary focus, as part of our longer-term growth strategy, we plan to evaluate AMX0035 in other indications and develop other product candidates. We intend to evaluate internal
opportunities from AMX0035 or other potential product candidates, and also may choose to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other product candidates as well as commercial products to treat patients suffering from
neurodegenerative diseases and CNS or other disorders with significant unmet medical needs and limited treatment options. These other potential product candidates will require additional, time-consuming development efforts prior to commercial sale,
including preclinical studies, clinical trials and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
approval by the FDA, Health Canada, the EMA and/or other applicable foreign regulatory authorities. All product candidates are prone to the risks of failure that are inherent in pharmaceutical
product development, including the possibility that the product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot assure you that any such products that are approved will
be manufactured or produced economically, successfully commercialized or widely accepted in the marketplace or be more effective than other commercially available alternatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Research activities to identify product candidates require substantial technical, financial and human resources, whether or not any product candidates
are ultimately identified. Our research activities may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the research methodology used may not be successful in identifying potential product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">competitors may develop alternatives that render our potential product candidates obsolete; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product candidates that we develop may nevertheless be covered by third parties&#146; patents or other exclusive rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a product candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it
is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are unsuccessful in identifying and developing additional product candidates, our potential for growth and achieving our
strategic objectives may be impaired. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be successful in our efforts to expand our pipeline by identifying additional indications and modifications
for which to investigate AMX0035 in the future. We may expend our limited resources to pursue a particular indication or formulation for AMX0035 and fail to capitalize on product candidates, indications or formulations that may be more profitable or
for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Because we have limited financial and managerial resources, we are focused on specific
indications and modifications for AMX0035. As a result, we may fail to generate additional clinical development opportunities for AMX0035 for a number of reasons, including, that AMX0035 may in certain indications, on further study, be shown to have
harmful side effects, limited to no efficacy, or other characteristics that suggest it is unlikely to receive marketing approval and achieve market acceptance in such additional indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We plan to conduct several clinical trials for AMX0035 in parallel over the next several years, including multiple clinical trials in patients with ALS
and other indications, which may make our decision as to which indication to focus on more difficult. As a result, we may forgo or delay pursuit of opportunities with other indications that could have had greater commercial potential or likelihood
of success. In addition, we are continuing to evaluate plans to explore the use of AMX0035 in patients with AD, Wolfram syndrome and other indications. However, we may focus on or pursue one or more of our target indications over other potential
indications and such development efforts may not be successful, which would cause us to delay the clinical development and approval of AMX0035. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Furthermore, research activities to identify additional indications for AMX0035 require substantial technical, financial, and human resources. We may not successfully develop these additional
modifications for chemistry-related, stability-related, or other reasons. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future
research and development activities for specific indications may not yield any commercially viable products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, we may pursue <FONT
STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions of development-stage assets or programs, which entails additional risk to us. Identifying, selecting and acquiring promising product candidates requires substantial technical, financial,
and human resources expertise. Efforts to do so may not result in the actual acquisition or license of a particular product candidate, potentially resulting in a diversion of our management&#146;s time and the expenditure of our resources with no
resulting benefit. For example, if we are unable to identify programs that ultimately result in approved products, we may spend material amounts of our capital and other resources evaluating, acquiring and developing products that ultimately do not
provide a return on our investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Competitive products may reduce or eliminate the commercial opportunity for AMX0035 for our current or future
indications. If our competitors develop technologies or product candidates more rapidly than we do, or their technologies or product candidates are more effective or safer than ours, our ability to develop and successfully commercialize AMX0035 may
be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The clinical and commercial landscape for the treatment of ALS and other neurodegenerative diseases, including AD is
highly competitive and subject to rapid and significant technological change. We face competition with respect to our current indications for AMX0035 and will face competition with respect to any future indications of AMX0035 or other drug
candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. For example, Humanitas Mirasole SpA is currently conducting a Phase
3 clinical trial in the EU to assess the safety and efficacy of TURSO in patients with ALS, which, if approved, may be commercialized as a competitor to AMX0035. If this study meets its clinical endpoints, this monotherapy treatment could be
approved by the FDA, the EMA and other regulatory authorities, and TURSO may become a commercialized product competitive with AMX0035, unless our intellectual property protections and any regulatory exclusivities we possess or may possess in the
future prevent such commercialization. There are also a number of large pharmaceutical and biotechnology companies that currently market and sell drugs or are pursuing the development of drug candidates for the treatment of the indications that we
are pursuing. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research,
development, manufacturing and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Several large pharmaceutical companies market
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> drugs for the treatment of ALS. These drugs include: Riluzole, marketed by Sanofi-Aventis U.S. LLC, and Radicava, marketed by Mitsubishi Tanabe Pharma America, Inc. Additionally, Mitsubishi Tanabe
Pharma America, Inc., or MTPA, is developing an oral alternative to Radicava. In the first quarter of 2022, the FDA accepted MTPA&#146;s application for priority review of its oral alternative to Radicava and in May 2022, the FDA approved its oral
alternative to Radicava. Our potential competitors include pharmaceutical and biotechnology companies, such as Biogen, Inc., Orphazyme A/S, Biohaven Pharmaceutical Holding Co Ltd., UCB S.A., Alexion Pharmaceuticals, Inc. and Apellis Pharmaceuticals,
Inc., specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions. In the third quarter of 2022, the FDA accepted Biogen, Inc.&#146;s NDA for toferson, an investigational drug for
superoxide dismutase 1 (SOD1) ALS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many of our competitors have significantly greater financial resources, established presence in the
market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. Accordingly, our competitors may be more successful than we
may be in obtaining regulatory approval for therapies and achieving widespread market acceptance. Our competitors&#146; products may be more effective, or more effectively marketed and sold, than any product candidate we may commercialize and may
render AMX0035 or any future product candidates obsolete or <FONT STYLE="white-space:nowrap">non-competitive</FONT> before we can recover development and commercialization expenses. If AMX0035 is approved for the indications we are currently
pursuing, it could compete with a range of therapeutic treatments that are in development. In addition, our competitors may succeed in developing, acquiring or licensing technologies and drug products that are more effective or less costly than
AMX0035 or any future product candidates that we may develop, which could render such product candidates obsolete and noncompetitive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following
approval for AMX0035 or any other future product candidate, we may face competition based on many different factors, including the efficacy, safety and tolerability of our products, the ease with which our products can be administered, the timing
and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Existing and future competing products could present superior
treatment alternatives, including being more effective, safer, less expensive or marketed and sold more effectively than any products we commercialize. Competitive products may make any products we commercialize obsolete or noncompetitive before we
recover the expense of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, our competitors may obtain patent protection, regulatory exclusivities or regulatory approval and commercialize products more rapidly than
we do, which may impact future approvals or sales of any of our product candidates that receive regulatory approval. We expect to face competition with respect to our commercialization of RELYVRIO in the United States and ALBRIOZA in Canada and any
future product candidates, if approved. Following approval by Health Canada, the FDA or the EMA for the commercial sale of AMX0035 or any future product candidates, we will also be competing with respect to marketing capabilities and manufacturing
efficiency. We expect competition among products will be based on product efficacy and safety, the timing and scope of regulatory approvals, availability of supply, marketing and sales capabilities, product price, reimbursement coverage by
government and private third-party payors, regulatory exclusivities and patent position. Our profitability and financial position will suffer if our product candidates receive regulatory approval, but cannot compete effectively in the marketplace.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller
number of our competitors. Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting
and retaining qualified scientific and management personnel and establishing clinical trial sites, as well as in acquiring technologies complementary to, or necessary for, our activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Obtaining and maintaining regulatory approval of AMX0035 or any future product candidates in one jurisdiction does not mean that we will be successful in
obtaining regulatory approval of those product candidates in other jurisdictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Obtaining and maintaining regulatory approval of AMX0035
and any future product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have
a negative effect on the regulatory approval process in others. For example, even though the FDA has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
approved AMX0035 (RELYVRIO) and Health Canada has granted marketing authorization with conditions of AMX0035 (ALBRIOZA), comparable regulatory authorities in the EU and other foreign
jurisdictions must also approve the manufacturing, marketing and promotion of AMX0035 in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than,
those in the United States, Canada or the EU, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions
outside the United States, including Canada, and certain jurisdictions in the EU, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for
our products is also subject to approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have received approval for AMX0035 (RELYVRIO) in the United States and marketing authorization with
conditions for AMX0035 (ALBRIOZA) in Canada and have submitted a marketing application in the EU. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply
prior to marketing in those jurisdictions and such regulatory requirements can vary widely from country to country. Obtaining other regulatory approvals and compliance with other regulatory requirements could result in significant delays,
difficulties and costs for us and could require additional preclinical studies or clinical trials, which could be costly and time-consuming and could delay or prevent the introduction of our products in certain countries. The foreign regulatory
approval process involves all of the risks associated with FDA approval. We do not have any product candidates approved for sale in any jurisdiction except the United States and Canada, and we do not have experience in obtaining regulatory approval
in international markets outside of Canada. If we fail to comply with the regulatory requirements in international markets and/or obtain and maintain applicable marketing approvals, our target market will be reduced and our ability to realize the
full market potential of AMX0035 or any future product candidates will be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even though we have obtained orphan drug designation for AMX0035 for the
treatment of ALS in the United States and the EU and for the treatment of Wolfram syndrome in the United States, we may not be able to obtain or maintain the benefits associated with orphan drug status, including market exclusivity. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Regulatory authorities in some jurisdictions, including the United States and the EU, may designate drugs for relatively small patient populations as
orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 people in the United States, or
a patient population of greater than 200,000 people in the United States, but for which there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, the EMA Committee for
Orphan Medicinal Products grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in
10,000 people in the EU. Additionally, designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition when, without incentives, it is unlikely that sales of the
drug in the EU would be sufficient to justify the necessary investment in developing the drug or biologic product. In either case, the applicant for orphan designation must also demonstrate that no satisfactory method of diagnosis, prevention, or
treatment for the condition has been authorized (or, if such a method exists, the new product would be a significant benefit to those affected compared to the product available). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In September 2017, the FDA granted orphan drug status to AMX0035 for the treatment of patients with ALS in the United States, and with the approval of
AMX0035 (RELYVRIO) by the FDA in September 2022 for the treatment of ALS in adults, the product is entitled to orphan drug exclusivity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and the FDA cannot approve a generic or a brand product that contains the same active moiety for the same orphan indication as AMX0035 for a period of seven years, subject to certain exceptions.
In addition, in June 2020, the EMA granted orphan drug status to AMX0035 for the treatment of patients with ALS in the EU. We also received orphan drug status for AMX0035 for the treatment of patients with Wolfram syndrome in the United States in
November 2020. Generally, if a drug with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug may be entitled to a period of marketing exclusivity, which
precludes the FDA or the EMA from approving another marketing application for the same drug for that time period. Another drug may receive marketing approval prior to AMX0035. The applicable period is seven years in the United States and ten years
in the EU, which may be extended by six months and two years, respectively, in the case of product candidates that have complied with the respective regulatory agency&#146;s agreed upon pediatric investigation plan. The exclusivity period in the EU
can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. In the EU, during the
<FONT STYLE="white-space:nowrap">ten-year</FONT> period of orphan marketing exclusivity, neither the competent authorities of the EU Member States, the EMA, or the European Commission are permitted to accept applications or grant marketing
authorization for other similar medicinal products. A &#147;similar medicinal product&#148; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is
intended for the same therapeutic indication. Orphan drug exclusivity may be lost if the FDA or the EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug
to meet the needs of patients with the rare disease or condition. In addition, even after a drug is granted orphan exclusivity and approved, the FDA and the EMA can subsequently approve another drug for the same condition before the expiration of
the seven-year (or <FONT STYLE="white-space:nowrap">ten-year</FONT> in the EU) exclusivity period if the FDA or the EMA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major
contribution to patient care. In addition, if an orphan designated product receives marketing approval for an indication broader than or different from what is designated, such product may not be entitled to orphan exclusivity. Even though the FDA
has granted orphan drug designation to AMX0035 for the treatment of Wolfram syndrome, if we receive approval for AMX0035 for a modified or different indication, our current orphan designation may not provide us with exclusivity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process. Also, regulatory
approval for any product candidate may be withdrawn, and other product candidates may obtain approval before us and receive orphan drug exclusivity, which could block us from entering the market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if we obtain orphan drug exclusivity for AMX0035, that exclusivity may not effectively protect us from competition because different drugs can be
approved for the same condition before the expiration of the orphan drug exclusivity period. For example, even though AMX0035 is entitled to orphan drug exclusivity, that exclusivity may not prevent the approval of TURSO by the FDA, the EMA or other
regulatory authorities as a monotherapy treatment for ALS if those regulatory agencies determine that TURSO is a different drug product from AMX0035. In addition, the regulatory authorities may find that this monotherapy treatment is clinically
superior to our fixed dose product and approve it even if we are granted orphan drug exclusivity. U.S. lawmakers have also recently raised the possibility that regulatory or legislative changes might need to be made to the Orphan Drug Act to foster
competition. This includes the introduction of legislation that, if adopted into law, would require us to demonstrate to the FDA that AMX0035 would be economically unviable when facing competition to maintain our exclusivity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may pursue orphan drug designation for AMX0035 for the treatment of additional indications. The incidence and
prevalence of the target patient populations for these indications will be based on our estimates and third-party data. If the market opportunity for these target populations is larger than we estimate, we may be unable to receive orphan drug
designation. Additionally, if orphan drug designation is granted, we may be unable to maintain any benefits associated with orphan drug designation, including market exclusivity. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Periodically, we make estimates regarding the incidence and prevalence of target patient populations based on various third-party sources and internally
generated analysis. Our estimates may be inaccurate or based on imprecise data. As described above, under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is intended to treat a rare disease or condition, which is generally
defined as a patient population of fewer than 200,000 people in the United States, or a patient population of greater than 200,000 people in the United States, but for which there is no reasonable expectation that the cost of developing the drug
will be recovered from sales in the United States. If our incidence or prevalence estimates for future indications for which we may seek orphan drug designation are incorrect, we may be unable to receive orphan drug designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if the FDA grants orphan drug designation for AMX0035 for other indications, exclusive marketing rights in the United States may be limited if we
seek FDA marketing approval for an indication broader than the orphan designated indication. Additionally, any product candidate that initially receives orphan drug status designation, may lose such designation if the FDA later determines that the
request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. In addition, others may obtain orphan drug status for
products addressing the same diseases or conditions as products we are developing, thus limiting our ability to compete in the markets addressing such diseases or conditions for a significant period of time. As a result, our business and prospects
could suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may pursue priority review designation for product candidates that we may develop, but we might not receive such designations, and priority
review designations may not lead to a faster development or regulatory review or approval process. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the FDA determines that a product
candidate offers a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation
means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months. For example, we received priority review for AMX0035 for the treatment of ALS, and we may in the future request priority
review designation for any future product candidates, however, we cannot assume that any application for future indications of AMX0035 or any other product candidate we may develop will meet the criteria for that designation. The FDA has broad
discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a
priority review designation does not necessarily mean a faster development or regulatory review or approval process or necessarily confer any advantage with respect to approval compared to standard FDA review and approval. For example, the FDA
originally set the PDUFA date for AMX0035 for the treatment of ALS, for June&nbsp;29, 2022, and then extended the review timeline for our NDA to September 2022. Receiving priority review from the FDA does not guarantee approval within the <FONT
STYLE="white-space:nowrap">six-month</FONT> review cycle or at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may seek Fast Track Designation by the FDA for a product candidate that we develop, and we may be
unsuccessful. If we are successful, the designation may not actually lead to a faster development or regulatory review or approval process. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may seek Fast Track Designation for future product candidates we develop. If a product is intended for the treatment of a serious or life-threatening
condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this
designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development
process, review or approval compared to conventional FDA procedures. The FDA may rescind the Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may seek Breakthrough Therapy Designation by the FDA for a product candidate that we develop, and we may be unsuccessful. If we are successful, the designation
may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may seek Breakthrough Therapy Designation for any product candidate that we develop. A breakthrough therapy is defined as a drug that is intended,
alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over currently approved therapies on
one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor
of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for
accelerated approval and priority review. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we
believe a product candidate we develop meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of Breakthrough Therapy Designation for a product
candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if any product candidate we
develop qualifies as a breakthrough therapy, the FDA may later decide that the drug no longer meets the conditions for qualification and rescind the designation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Product liability lawsuits against us or any of our future collaborators could divert our resources and attention, cause us to incur substantial liabilities and
limit commercialization of AMX0035 or any future product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are exposed to potential product liability and professional
indemnity risks that are inherent in the research, development, manufacturing, marketing and use of pharmaceutical products. The use of AMX0035 by us and any collaborators in clinical trials, and the sale of AMX0035 in the United States, Canada and
in other jurisdictions, if approved, in the future, may expose us to liability claims. Product liability claims may be brought against us or our partners by participants enrolled in our clinical trials, patients, health care providers,
pharmaceutical companies, our collaborators or others using, administering or selling any of our future approved products. If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities or be required to
limit commercialization of AMX0035 or any future product candidates. Regardless of the merits or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">decreased demand for any of our future approved products; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">injury to our reputation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">termination of clinical trial sites or entire trial programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">significant litigation costs, including with respect to potential class action lawsuits; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">substantial monetary awards to, or costly settlements with, patients or other claimants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product recalls or a change in the indications for which they may be used; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">diversion of management and scientific resources from our business operations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability to commercialize AMX0035 or any future product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although the clinical trial process is designed to identify and assess potential side effects, clinical development does not always fully characterize
the safety and efficacy profile of a new drug, and it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If AMX0035 was to cause adverse side effects during clinical trials or after approval, we may
be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use AMX0035 or any of our future product candidates. If any of our current or
future product candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety and quality of our products. We could be adversely affected if we are subject to negative publicity associated
with illness or other adverse effects resulting from patients&#146; use or misuse of our products or any similar products distributed by other companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although we maintain product liability insurance coverage in the amount of up to $5.0&nbsp;million in the aggregate, including clinical trial liability,
this insurance may not fully cover potential liabilities that we may incur. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. We will need to increase our insurance coverage as we
commercialize AMX0035 in the United States, Canada and other jurisdictions, if approved, or any future product candidate that receives regulatory approval. In addition, insurance coverage is becoming increasingly expensive. If we are unable to
maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and sale of AMX0035 or any future product
candidates, which could harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if we, or any future collaborators, obtain and
maintain regulatory approvals for AMX0035 or any future product candidate, the terms of approvals and ongoing regulation of our products may limit how we manufacture and market our products, which could impair our ability to generate revenue.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Once regulatory approval has been granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive
regulation. We, and any future collaborators, must therefore comply with requirements concerning advertising and promotion for AMX0035 or any future product candidate for which we or they obtain regulatory approval. Promotional communications with
respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#146;s approved labeling. Thus, we and any future collaborators will not be able to promote any
products we develop for indications or uses for which they are not approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, manufacturers of approved products and those
manufacturers&#146; facilities are required to comply with extensive FDA, Health Canada and EMA requirements, including ensuring that quality </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
control and manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and
documentation and reporting requirements. We, our contract manufacturers, any future collaborators and their contract manufacturers could fail to conform to cGMPs and be subject to periodic unannounced inspections by the FDA, Health Canada and the
EMA to monitor and ensure compliance with cGMPs. Despite our efforts to inspect and verify regulatory compliance, one or more of our third-party manufacturing vendors may be found on regulatory inspection by the FDA, Health Canada, the EMA or other
authorities to be not in compliance with cGMP regulations, which may result in shutdown of the third-party vendor or invalidation of drug product lots or processes. In some cases, a product recall may be warranted or required, which would materially
affect our ability to supply and market our drug products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Accordingly, in any jurisdiction where we or any future collaborators, receive
regulatory approval for AMX0035 or one or more future product candidates, we, and any future collaborators, and our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including
manufacturing, production, product surveillance and quality control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we, and any future collaborators, are not able to comply with post-approval
regulatory requirements, we, and any future collaborators, could have the regulatory approvals for AMX0035 or any future products withdrawn by regulatory authorities and our, or any future collaborators&#146;, ability to market any future products
could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Laws and regulations governing any international operations we expect to have in the future may preclude us from developing, manufacturing and selling certain
products outside of the United States and will require us to develop and implement costly compliance programs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have operations in the
United States and Canada and expect to engage in operations in other jurisdictions, including the EU, as well as other potential jurisdictions, and we must dedicate additional resources to comply with numerous laws and regulations in each
jurisdiction in which we currently or plan to operate. The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any
foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose
securities are listed in the United States to comply with certain accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to
devise and maintain an adequate system of internal accounting controls for international operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Compliance with the FCPA is expensive and
difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors
and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Various laws, regulations and executive orders, including export control and trade sanctions laws, also restrict the use and dissemination outside
of the United States, or the sharing with certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we
expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development
costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and
suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#146;s accounting provisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our
business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures
and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and
may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event
of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or
criminal fines and penalties for failure to comply with such laws and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We maintain workers&#146; compensation insurance to cover us for
costs and expenses we may incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be
asserted against us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws
and regulations. Environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Risks Related to Our Dependence on Third Parties </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We
may seek to establish collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The advancement of AMX0035, and any future product candidates and development programs or activities, as well as the commercialization of RELYVRIO in the
United States and ALBRIOZA in Canada and the potential commercialization of AMX0035 in other jurisdictions and of any future product candidates will require substantial additional cash to fund expenses. For some indications of AMX0035 or future
product candidates, we may decide to collaborate with additional pharmaceutical and biotechnology companies with respect to development and potential commercialization. Likely collaborators may include large and
<FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. In addition, if we are able to obtain regulatory approval for product candidates from foreign
regulatory authorities, we may enter into collaborations with international biotechnology or pharmaceutical companies for the commercialization of such product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among
other things, upon our assessment of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors. Those factors may
include the potential differentiation of our product candidate from competing product candidates, design or results of clinical trials, the likelihood of approval by Health Canada, the FDA, the EMA or other comparable foreign regulatory authorities
and the regulatory pathway for any such approval, the potential market for the product candidate, the costs and complexities of manufacturing and delivering the product to patients and the potential of competing products. The collaborator may also
consider alternative product candidates or technologies for similar indications that may be available for collaboration and whether such a collaboration could be more attractive than the one with us for our product candidate. If we elect to increase
our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to
further develop AMX0035 or any future product candidates or bring them to market and generate product revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Collaborations are complex and
time-consuming to negotiate and document. Further, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Any collaboration
agreements that we enter into in the future may contain restrictions on our ability to enter into potential collaborations or to otherwise develop specified product candidates. We may not be able to negotiate collaborations on a timely basis, on
acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs
or activities, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have entered and may in the future enter into collaborations with third parties for the development and commercialization of AMX0035 or any future product
candidates, and our prospects with respect to those product candidates will depend in significant part on the success of those collaborations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may rely on collaborations for the development and commercialization of AMX0035 and any future product candidates. For example, we may utilize a
variety of distribution, collaboration and other marketing arrangements with one or more third parties to facilitate commercialization of AMX0035 or to identify novel drug candidates for neurodegenerative diseases as with our partnership with
Sunnybrook Research Institute. Our likely collaborators for any distribution, development, sales, marketing, licensing or broader collaboration arrangements include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies,
regional and national pharmaceutical companies and biotechnology companies. If we enter into such collaborations, we may have limited control over the amount and timing of resources that our collaborators dedicate to the development or
commercialization of AMX0035 or any future product candidates. Our ability to generate revenues from these arrangements will depend on any future collaborators&#146; abilities to successfully perform the functions assigned to them in these
arrangements. In addition, any future collaborators may have the right to abandon research or development projects and terminate applicable agreements, including funding obligations, prior to or upon the expiration of the agreed upon terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Collaborations involving AMX0035 and any future product candidates pose a number of risks, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these
collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may not perform their obligations as expected; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may not pursue development and commercialization of AMX0035 or any future product candidates or may elect not
to continue or renew development or commercialization programs, based on clinical trial results, changes in the collaborators&#146; strategic focus or available funding or external factors, such as an acquisition, that divert resources or create
competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial
or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with
AMX0035 or any of our future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the
marketing and distribution of such product or products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">disagreements with collaborators, including disagreements over proprietary rights, including trade secrets and intellectual
property rights, contract interpretation, or the preferred course of development might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect
to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information
in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and
potential liability; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further
development or commercialization of the applicable product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Collaboration agreements may not lead to development or
commercialization of product candidates in the most efficient manner or at all. If any future collaborator of ours is involved in a business combination, it could decide to delay, diminish or terminate the development or commercialization of any
product candidate licensed to it by us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We rely on third parties to assist in conducting our clinical trials. If they do not perform satisfactorily, we may
not be able to obtain or maintain regulatory approval or successfully commercialize AMX0035 or any future product candidates, or such approval or commercialization may be delayed, and our business could be substantially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have relied upon and plan to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions and
clinical investigators, to conduct our clinical trials and expect to rely on these third parties to conduct clinical trials of any future product candidate that we develop. Any of these third parties may terminate their engagements with us under
certain circumstances. We may not be able to enter into alternative arrangements or do so on commercially reasonable terms. In addition, there is a natural transition period when a new CRO begins work. As a result, delays may occur, which could
negatively impact our ability to meet our expected clinical development timelines and harm our business, financial condition and prospects. Clinical trials involve multiple clinical sites, vendors and other third parties and we are dependent on
these vendors to ensure appropriate study conduct, statistical analysis and randomization. Errors or deviations they make in any of these activities could impact the usefulness and interpretability of clinical trial results by regulatory
authorities. For example, at the Advisory Committee meetings on March&nbsp;30, 2022 and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
September 7, 2022, the FDA noted a number of concerns that, in the FDA&#146;s view, impacted the interpretability of the results from the CENTAUR trial. Clinical trials from time to time have
deviations where a protocol or standard operating procedure is not perfectly carried out and where corrective actions are taken. While we may perceive these events as low risk, our perception of risk and appropriate corrective actions may differ
from that of the regulators&#146; view. Deviations from protocols or standard operating procedures during studies could result in negative regulatory opinions and outcomes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, although our reliance on these third parties for clinical development activities limits our control over these activities, we remain
responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards. Moreover, the FDA, the EMA and competent authorities of the EU Member States
require us to comply with Good Clinical Practices, or GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality
of trial participants are protected. The FDA enforces these GCPs through periodic inspections of trial sponsors, principal investigators, clinical trial sites and IRBs. If we or our third-party contractors fail to comply with applicable GCPs, the
clinical data generated in our clinical trials may be deemed unreliable and the FDA or the EMA may require us to perform additional clinical trials before approving AMX0035, including for additional indications, or any future product candidates,
which would delay the regulatory approval process. We cannot be certain that, upon inspection, the FDA or the EMA will determine that any of our clinical trials comply with GCPs. For example, our clinical trial sites and investigators have in the
past and may in the future engage in protocol deviations which could impact the overall interpretability of the outcomes of our clinical trials. We are also required to register certain clinical trials and post the results of completed clinical
trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore, the third parties conducting clinical trials on our behalf are not our employees, and except for remedies available to us under our
agreements with such contractors, we cannot control whether or not they devote sufficient time, skill and resources to our ongoing development activities. These contractors may also have relationships with other commercial entities, including our
competitors, for whom they may also be conducting clinical trials or other drug development activities, which could impede their ability to devote appropriate time to our clinical activities. If these third parties, including clinical investigators,
do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may not be able to obtain, or may be delayed in obtaining, clinical
data necessary for regulatory approvals for AMX0035 or any future product candidates. If that occurs, we will not be able to, or may be delayed in our efforts to, successfully commercialize AMX0035 or any future product candidates. In such an event,
our financial results and the commercial prospects for AMX0035 or any future product candidates that we seek to develop could be harmed, our costs could increase and our ability to generate revenues could be delayed, impaired or foreclosed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, quarantines, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place,</FONT></FONT> and similar government
orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or other infectious diseases could impact
personnel at our CROs, which could disrupt our clinical timelines, which could have a material adverse impact on our business, prospects, financial condition, and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We also rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our
distributors could delay clinical development or regulatory approval of AMX0035 or any future product candidates or commercialization of any resulting products, producing additional losses and depriving us of potential product revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our use of third parties to manufacture AMX0035 and approved products in compliance with current good
manufacturing practices may increase the risk that we will not have sufficient cGMP-compliant quantities of AMX0035, products, or necessary quantities of such materials on time or at an acceptable cost. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We do not own or operate manufacturing facilities for the production of clinical or commercial quantities of AMX0035, and we currently lack the resources
and the capabilities to do so. As a result, we currently rely on third parties for the manufacture and supply of the active pharmaceutical ingredients, or APIs, in AMX0035, and for the blending and packaging of AMX0035. Our current strategy is to
outsource all manufacturing of AMX0035 and any future product candidates to third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently engage third-party manufacturers to provide
the APIs of AMX0035 and for the final drug product formulation of AMX0035 that is being used in our clinical trials and for expanded access and commercial supply, and we engage separate third-parties for the blending and packaging of finished
clinical materials. We must be able to demonstrate comparability of drug substance across suppliers along with stability data across suppliers. We currently rely on a single manufacturer to supply one of our APIs and a separate manufacturer to
supply the other. Although we believe that there are several potential alternative manufacturers who could manufacture each of the APIs in AMX0035, we may incur added costs and delays in identifying and qualifying any such replacement. In addition,
we typically order raw materials and services on a purchase order basis and do not enter into long-term dedicated capacity or minimum supply arrangements with any commercial manufacturer. Moreover, the extent to which the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacts our ability to procure sufficient supplies for the development of AMX0035, and any future products and product candidates will depend on the severity and duration of the spread of the
virus, and the actions undertaken to contain <FONT STYLE="white-space:nowrap">COVID-19</FONT> or treat its effects. There is no assurance that we will be able to timely secure needed supply arrangements on satisfactory terms, or at all. Our failure
to secure these arrangements as needed could have a material adverse effect on our ability to complete the development of AMX0035 or any future product candidates or, to commercialize them, if approved. We may be unable to conclude agreements for
commercial supply with third-party manufacturers, or may be unable to do so on acceptable terms. There may be difficulties in scaling up to commercial quantities and formulation of AMX0035, and the costs of manufacturing could be prohibitive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if we are able to establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers entails additional
risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the failure of the third-party manufacturer to comply with applicable regulatory requirements, including cGMPs, and
reliance on third-parties for manufacturing process development, regulatory compliance and quality assurance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">manufacturing delays if our third-party manufacturers give greater priority to the supply of other products over AMX0035 or
any future product candidates or otherwise do not satisfactorily perform according to the terms of the agreement between us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">limitations on supply availability resulting from capacity and scheduling constraints of third-parties, or as a result of
economic or political developments, including the ongoing conflict in Ukraine and global economic instability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the possible breach of manufacturing agreements by third-parties because of factors beyond our control;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the possible termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> of the manufacturing agreements by a
third-party, at a time that is costly or inconvenient to us; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the possible misappropriation of our proprietary information, including our trade secrets and <FONT
STYLE="white-space:nowrap">know-how.</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we do not maintain our key manufacturing relationships, or if any of our contract manufacturers
fail to perform their obligations, we may fail to find replacement manufacturers or develop our own manufacturing capabilities, which could adversely impact our ability to commercialize AMX0035 in the United States and Canada, and delay or impair
our ability to obtain regulatory approval for our products. If we do find replacement manufacturers, we may not be able to enter into agreements with them on terms and conditions favorable to us and there could be a substantial delay before new
facilities could be qualified and registered with the FDA, Health Canada, the EMA and other foreign regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any change in
manufacturer may also involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. In addition, we
will need to verify that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA, Health Canada, the EMA or another regulatory authority. We may be unsuccessful in
demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In some cases, the technical
skills required to manufacture AMX0035, or any future products or product candidates may be unique or proprietary to the original contract manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from,
transferring such skills to a <FONT STYLE="white-space:nowrap">back-up</FONT> or alternate supplier, or we may be unable to transfer such skills at all. Furthermore, a contract manufacturer may possess or acquire technology related to the
manufacture of AMX0035 or any future product candidate that such contract manufacturer owns independently. This would increase our reliance on such contract manufacturer or require us to obtain a license from such contract manufacturer in order to
have another contract manufacturer manufacture AMX0035 or any future product candidates. If AMX0035 for any of our initial or potential additional indications or any future product candidate is approved by any regulatory agency, we intend to utilize
arrangements with third-party contract manufacturers for the commercial production of those products. This process is difficult and time consuming and we may face competition for access to manufacturing facilities as there are a limited number of
contract manufacturers operating under cGMPs that are capable of manufacturing AMX0035 or any future product candidates. Consequently, we may not be able to reach agreement with third-party manufacturers on satisfactory terms, which could delay our
commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions
being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or voluntary recalls of AMX0035 or any future product candidates, operating restrictions and criminal
prosecutions, any of which could significantly affect supplies of AMX0035 or any future product candidates. The facilities used by our contract manufacturers to manufacture AMX0035 or any future product candidates must be evaluated by the FDA,
Health Canada, the EMA and certain other foreign regulatory authorities. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with cGMPs. If our contract manufacturers
cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, Health Canada, the EMA or others, we may not be able to secure and/or maintain regulatory approval for our product
manufactured at these facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, Health Canada, the EMA or other comparable
foreign regulatory authority finds deficiencies or does not approve these facilities for the manufacture of AMX0035 or any future product candidates, or if it withdraws any such approval in the future, we may need to find alternative manufacturing
facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market AMX0035 or any future product candidates, if approved. Furthermore, if we are required to change contract manufacturers, we will be
required to verify that the new contract manufacturer maintains </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
facilities and procedures that comply with quality standards and with all applicable regulations, which could result in further costs and delays. Contract manufacturers may face manufacturing or
quality control problems causing drug substance production and shipment delays or a situation where the contractor may not be able to maintain compliance with the applicable cGMP requirements. Any failure to comply with cGMP requirements or other
FDA, Health Canada, EMA and comparable foreign regulatory requirements could adversely affect our clinical research activities and our ability to develop AMX0035 or any future product candidates and market our products, if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA, Health Canada, the EMA and other foreign regulatory authorities require manufacturers to register manufacturing facilities. The FDA, Health
Canada, the EMA and corresponding foreign regulators also inspect these facilities to confirm compliance with cGMPs. Contract manufacturers may face manufacturing or quality control problems causing drug substance production and shipment delays or a
situation where the contractor may not be able to maintain compliance with the applicable cGMP requirements. Any failure to comply with cGMP requirements or other FDA, Health Canada, EMA and comparable foreign regulatory requirements could adversely
affect our clinical research activities and our ability to develop AMX0035 or any future product candidates and market our products following approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If
any third-party manufacturer of AMX0035 or any future product candidates is unable to increase the scale of its production of such product candidates, and/or increase the product yield of its manufacturing, then our costs to manufacture the product
may increase and commercialization may be delayed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In order to produce sufficient quantities to meet the demand for clinical trials,
expanded access and, commercialization of AMX0035 in the United States and Canada, and any subsequent commercialization of AMX0035 in other jurisdictions, if approved, or any future product candidates that we may develop, our third-party
manufacturers will be required to increase their production and optimize their manufacturing processes while maintaining the quality of the product. The transition to larger scale production could prove difficult. In addition, if our third party
manufacturers are not able to optimize their manufacturing processes to increase the product yield for AMX0035 or any future product candidates, or if they are unable to produce increased amounts of such product candidates while maintaining the
quality of the product and compliance with cGMPs, then we may not be able to meet the demands of clinical trials or market demands, which could decrease our ability to generate profits and have a material adverse impact on our business and results
of operation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since the beginning of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, several vaccines for <FONT
STYLE="white-space:nowrap">COVID-19</FONT> have received Emergency Use Authorization by the FDA and a number of those later received marketing approval. Additional vaccines may be authorized or approved in the future. The resultant demand for
vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, is having rippling effects across the contract manufacturing industry, which may make
it more difficult to obtain materials or manufacturing slots for the production needed for our clinical trials and, if approved, our future commercial supply, which could lead to delays in our trials and commercial distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may need to maintain licenses for active ingredients from third parties to develop and commercialize AMX0035 or a future product candidate, which could
increase our development costs and delay our ability to commercialize such product candidate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Should we decide to use API in any of AMX0035
or any future product candidates that are proprietary to one or more third parties, we would need to maintain licenses to those active ingredients from those third parties. If we are unable to gain or continue to access rights to these active
ingredients prior to conducting preclinical toxicology studies intended to support clinical trials, we may need to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
develop alternate product candidates from these programs by either accessing or developing alternate active ingredients, resulting in increased development costs and delays in commercialization
of these product candidates. If we are unable to gain or maintain continued access rights to the desired active ingredients on commercially reasonable terms or develop suitable alternate active ingredients, we may not be able to commercialize
product candidates from these programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our commercial success depends on our ability to protect our intellectual property and proprietary technology. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our commercial success depends in large part on our ability to obtain and maintain intellectual property rights protection through patents, trademarks
and trade secrets in the United States and other countries with respect to our proprietary product candidate, AMX0035, and any future proprietary product candidates. If we do not adequately protect our intellectual property rights, competitors may
be able to erode, negate or preempt any competitive advantage we may have, which could harm our business and ability to achieve profitability. To protect our proprietary position, we have filed patent applications and may file other patent
applications in the United States or abroad related to AMX0035 or any future product candidates that are important to our business; we may also license or purchase patents or patent applications filed by others. The patent application process is
expensive and time-consuming. We may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the scope of the patent protection we obtain is not sufficiently broad, we may not be able to prevent others from developing and commercializing
technology and products similar or identical to ours. The degree of patent protection we require to successfully compete in the marketplace may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us
to gain or keep any competitive advantage. We cannot provide any assurances that any of our patents have, or that any of our pending owned patent applications that mature into issued patents will include claims with a scope sufficient to protect our
proprietary therapeutics or otherwise provide any competitive advantage. Other parties have developed or may develop technologies that may be related or competitive with our approach, and may have filed or may file patent applications and may have
been issued or may be issued patents with claims that overlap or conflict with our patent applications, either by claiming the same compounds, formulations or methods or by claiming subject matter that could dominate our patent position. In
addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Furthermore, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally twenty years
after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents
protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing
products similar to AMX0035 or any future product candidates. In the event that an alternative combination, or TURSO as a single drug product, is developed and approved for use in indications for which we may seek approval and falls outside the
scope of our patent claims, the marketability and commercial success of AMX0035 could be materially harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if they are unchallenged, our
owned patents and pending patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our patents by developing similar or alternative therapeutics in
a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. For example, a third party may develop a competitive therapy that provides benefits similar to our product candidate but falls outside the scope of our patent protection or license
rights. If the patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
protection provided by the patent and patent applications we hold or pursue with respect to AMX0035 or any future product candidates is not sufficiently broad to impede such competition, our
ability to successfully commercialize our product candidate could be negatively affected, which would harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We, or any future partners,
collaborators, or licensees, may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential
opportunities to strengthen our patent position. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">It is possible that defects of form in the preparation or filing of our patent or patent
applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our partners, collaborators, or licensees whether current or future,
fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, or licensees are not fully cooperative or disagree with us as to the prosecution,
maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our patents or patent applications, such patents may be invalid and/or
unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The patent position of biotechnology and pharmaceutical companies carries uncertainty. In addition, the determination of patent rights with respect to
pharmaceutical compounds commonly involves complex legal and factual questions, which are dependent upon the current legal and intellectual property context, extant legal precedent and interpretations of the law by individuals. As a result, the
issuance, scope, validity, enforceability and commercial value of our patent rights are characterized by uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pending patent applications
cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Assuming the other requirements for patentability are met, currently, the first to file a patent
application is generally entitled to the patent. However, prior to March&nbsp;16, 2013, in the United States, the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual
discoveries, and patent applications in the United States and other jurisdictions are not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in
our patent or pending patent applications, or that we were the first to file for patent protection of such inventions. If third parties have filed prior patent applications on inventions claimed in our patents or applications that were filed on or
before March&nbsp;15, 2013, an interference proceeding in the United States can be initiated by such third parties to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. If third parties
have filed such prior applications after March&nbsp;15, 2013, a derivation proceeding in the United States can be initiated by such third parties to determine whether our invention was derived from theirs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, our patents may be challenged in
the courts or patent offices in the United&nbsp;States and abroad. Also, while we believe that we have disclosed all potentially relevant prior art relating to our patents and patent applications, there is no assurance that we have found all such
prior art or disclosed it in every relevant jurisdiction. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not
published until 18 months after filing or, in some cases, not at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent
protection of such inventions. If such prior art exists, it may be used to invalidate a patent, or may prevent a patent from issuing from a pending patent application. For example, such patent filings may be subject to a third-party submission of
prior art to the U.S. Patent and Trademark Office, or USPTO, or to other patent offices around the world. Alternately or additionally, we may become involved in post-grant review procedures, oppositions, derivation proceedings, ex parte
reexaminations, inter partes review, supplemental examinations, or interference proceedings or challenges in district court, in the United States or in various foreign patent offices, including both national and regional, challenging patents or
patent applications in which we have rights, including patents on which we rely to protect our business. An adverse determination in any such challenges may result in loss of the patent or in patent or patent application claims being narrowed,
invalidated or held unenforceable, in whole or in part, or in denial of the patent application or loss or reduction in the scope of one or more claims of the patent or patent application, any of which could limit our ability to stop others from
using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pending and future patent applications may not result in patents being issued that protect our business, in whole or in part, or which effectively
prevent others from commercializing competitive products. Competitors may also be able to design around our patents. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the
value of our patents or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our rights to the same extent or in the same manner as the laws of the United States. For example, patent laws in various
jurisdictions, including jurisdictions covering significant commercial markets, such as the European Patent Office, or EPO, China and Japan, restrict the patentability of methods of treatment of the human body more than United States law does. If
these developments were to occur, they could have a material adverse effect on our ability to generate revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The patent application process is
subject to numerous risks and uncertainties, and there can be no assurance that we or any of our future development partners will be successful in protecting AMX0035 or any future product candidates by obtaining and defending patents. These risks
and uncertainties include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee
payment and other provisions during the patent process. There are situations in which noncompliance, whether intentional or not, can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent
rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">patent applications may not result in any patents being issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">patents that may be issued or <FONT STYLE="white-space:nowrap">in-licensed</FONT> may be challenged, invalidated, modified,
revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our competitors, many of whom have substantially greater resources and many of whom have made significant investments in
competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use, and sell AMX0035; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent
protection both inside and outside the United States for </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts,
allowing foreign competitors a better opportunity to create, develop and market competing product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">countries other than the United States may, under certain circumstances, force us to grant a license under our patents to a
competitor, thus allowing the competitor to compete with us in that jurisdiction or forcing us to lower the price of our drug in that jurisdiction. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Issued patents that we have or may obtain or license may not provide us with any meaningful protection, prevent competitors from competing with us or
otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. Our
competitors may also seek approval to market their own products similar to or otherwise competitive with our products. Alternatively, our competitors may seek to market generic versions of any approved products by submitting ANDAs to the FDA in
which they claim that patents owned or licensed by us are invalid, unenforceable or not infringed. In these circumstances, we may need to defend or assert our patents, or both, including by filing lawsuits alleging patent infringement. In any of
these types of proceedings, a court or other agency with jurisdiction may find our patents invalid or unenforceable, or that our competitors do not infringe our patents. Thus, even if we have valid and enforceable patents, these patents still may
not provide protection against competing products or processes sufficient to achieve our business objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, we rely on the
protection of our trade secrets and proprietary, unpatented <FONT STYLE="white-space:nowrap">know-how.</FONT> Although we have taken steps to protect our trade secrets and unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> including
entering into confidentiality agreements with third parties, and confidential information and invention assignment agreements with employees, consultants, collaborators, vendors, and advisors, we cannot provide any assurances that all such
agreements have been duly executed, and third parties may still obtain this information or may come upon this or similar information independently. It is possible that technology relevant to our business will be independently developed by a person
who is not a party to such a confidentiality or invention assignment agreement. We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or trade secrets by consultants, collaborators, vendors, advisors, former
employees and current employees. Furthermore, if the parties to our confidentiality agreements breach or violate the terms of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets
as a consequence of such breaches or violations. Our trade secrets could otherwise become known or be independently discovered by our competitors. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have
insufficient recourse against third parties for misappropriating our trade secrets. If any of these events occurs or if we otherwise lose protection for our trade secrets or proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> our business
may be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>It is difficult and costly to protect our intellectual property and our proprietary technologies, and we may not be able to ensure their
protection. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection for our
proprietary product candidate, AMX0035, as well as on successfully defending these patents against potential third-party challenges. Our ability to protect our product candidate from unauthorized making, using, selling, offering to sell or importing
by third parties is dependent on the extent to which we have rights under valid and enforceable patents that cover these activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The patent positions of pharmaceutical, biotechnology and other life sciences companies can be highly
uncertain and involve complex legal and factual questions for which important legal principles remain unresolved and have in recent years been the subject of much litigation. Changes in either the patent laws or in interpretations of patent laws in
the United States and other countries may diminish the value of our intellectual property. Over the past decade, U.S. federal courts have increasingly invalidated pharmaceutical and biotechnology patents during litigation often based on changing
interpretations of patent law. Further, the determination that a patent application or patent claim meets all of the requirements for patentability is a subjective determination based on the application of law and jurisprudence. The ultimate
determination by the U.S. Patent and Trademark Office, or USPTO, or by a court or other trier of fact in the United States, or corresponding foreign national patent offices or courts, on whether a claim meets all requirements of patentability cannot
be assured. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our owned patents or patent applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We
cannot provide assurances that any of our patent applications will be found to be patentable, including over our own prior art publications or patent literature, or will issue as patents. Neither can we make assurances as to the scope of any claims
that may issue from our pending and future patent applications nor to the outcome of any proceedings by any potential third parties that could challenge the patentability, validity or enforceability of our patents and patent applications in the
United States or foreign jurisdictions. Any such challenge, if successful, could limit patent protection for our products and current or future product candidates and/or materially harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to challenges during litigation, third parties can challenge the validity of our patents in the United States using post-grant review and
inter partes review proceedings, which some third parties have been using to cause the cancellation of selected or all claims of issued patents of competitors. For a patent filed March&nbsp;16, 2013 or later, a petition for post-grant review can be
filed by a third party in a nine-month window from issuance of the patent. A petition for inter partes review can be filed immediately following the issuance of a patent if the patent has an effective filing date prior to March&nbsp;16, 2013. A
petition for inter partes review can be filed after the nine-month period for filing a post-grant review petition has expired for a patent with an effective filing date of March&nbsp;16, 2013 or later. Post-grant review proceedings can be brought on
any ground of invalidity, whereas inter partes review proceedings can only raise an invalidity challenge based on published prior art and patents. These adversarial actions at the USPTO review patent claims without the presumption of validity
afforded to U.S. patents in lawsuits in U.S. federal courts, and use a lower burden of proof than used in litigation in U.S. federal courts. Therefore, it is generally considered easier for a competitor or third party to have a U.S. patent
invalidated in a USPTO post-grant review or inter partes review proceeding than invalidated in a litigation in a U.S. federal court. If any of our patents are challenged by a third party in such a USPTO proceeding, there is no guarantee that we will
be successful in defending the patent, which may result in a loss of the challenged patent right to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the EU, third parties can challenge the
validity of our patents by filing an Opposition before the EPO. An adverse determination by the Opposition Board can result in the narrowing or invalidation of a European patent. If any of our European patents are challenged by a third party in such
an opposition proceeding, there is no guarantee that we will be successful in defending the patent, which may result in a loss of the challenged patent right to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately
protect our rights or permit us to gain or keep our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may not be able to generate sufficient data to support full patent applications that protect the entire breadth of
developments in one or more of our programs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">it is possible that one or more of our pending patent applications will not become an issued patent or, if issued, that the
patent(s) claims will have sufficient scope to protect our technology, provide us with commercially viable patent protection or provide us with any competitive advantages; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">if our pending applications issue as patents, they may be challenged by third parties as invalid or unenforceable under
United States or foreign laws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may not successfully commercialize AMX0035 before our relevant patents expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may not be the first to make the inventions covered by each of our patents and pending patent applications; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may not develop additional proprietary technologies or product candidates that are separately patentable.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, to the extent that we are unable to obtain and maintain patent protection for AMX0035 or any future product
candidates or in the event that such patent protection expires, it may no longer be cost-effective to extend our portfolio by pursuing additional development of a product or product candidate for <FONT STYLE="white-space:nowrap">follow-on</FONT>
indications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our
business would be harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to patents, we also may rely on trade secrets to protect our proprietary product candidate,
especially where we do not believe patent protection is appropriate or obtainable. Trade secrets are difficult to protect. We seek to protect our confidential proprietary information, in part, by confidentiality agreements and invention assignment
agreements with our employees, consultants, scientific advisors, contractors and collaborators. These agreements are designed to protect our proprietary information. However, we cannot be certain that such agreements have been entered into with all
relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially
equivalent information and techniques. For example, our employees, consultants, contractors, outside scientific collaborators and other advisers may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a
third-party entity illegally obtained and is using any of our trade secrets is expensive and time-consuming, and the outcome is unpredictable, and we may not be able to obtain adequate remedies for such breaches. We also seek to preserve the
integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures
could be breached. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and
<FONT STYLE="white-space:nowrap">know-how.</FONT> Notably, proprietary technology protected by a trade secret does not preempt the patenting of independently developed equivalent technology, even if such equivalent technology is invented subsequent
to the technology protected by a trade secret. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology
or information to compete with us, which could harm our competitive position. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Patent terms may be inadequate to protect our competitive position on our
products for an adequate amount of time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the
natural expiration of a patent is generally 20 years from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
patent term of a U.S. patent may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and Trademark Office in granting a
patent, or may be shortened if a patent is terminally disclaimed over an earlier-filed patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Various extensions may be available, but the life of
a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such
candidates are commercialized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a Patent Term
Extension, or PTE, of up to five years beyond the normal expiration of the patent to compensate patent owners for loss of enforceable patent term due to the lengthy regulatory approval process. PTE is limited to the approved indication (or any
additional indications approved during the period of extension). We anticipate applying for PTE in the United States. Similar extensions may be available in other countries where we are prosecuting patents and we likewise anticipate applying for
such extensions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The granting of such patent term extensions is not guaranteed and is subject to numerous requirements. We might not be granted an
extension because of, for example, failure to apply within applicable periods, failure to apply prior to the expiration of relevant patents or failure to otherwise satisfy any of the numerous applicable requirements. Moreover, the applicable
authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our
patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to obtain approval of competing products following our patent expiration by referencing our clinical and preclinical data and launch their
product earlier than might otherwise be the case. If this were to occur, it could have a material adverse effect on our ability to generate revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes
in the interpretation of patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The United States Congress is responsible for passing laws establishing patentability standards. As with any laws, implementation is left to federal
agencies and the federal courts based on their interpretations of the laws. Interpretation of patent standards can vary significantly within the U.S. Patent and Trademark Office, and across the various federal courts, including the Supreme Court.
Recently, the Supreme Court has ruled on several patent cases, generally limiting the types of inventions that can be patented. Further, there are open questions regarding interpretation of patentability standards that the Supreme Court has yet to
decisively address. Absent clear guidance from the Supreme Court, the USPTO has become increasingly conservative in its interpretation of patent laws and standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to increasing uncertainty with regard to our ability to obtain patents in the future, the legal landscape in the United States has created
uncertainty with respect to the value of patents. Depending on any actions by Congress, and future decisions by the lower federal courts and the Supreme Court, along with interpretations by the USPTO, the laws and regulations governing patents could
change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be able to enforce our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Filing, prosecuting, enforcing and defending patents on our product candidate in all countries throughout the world would be prohibitively expensive, and
our intellectual property rights in some </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
countries outside the United States can be less extensive than those in the United States. The requirements for patentability may differ in certain countries, particularly in developing
countries; thus, even in countries where we do pursue patent protection, there can be no assurance that any patents will issue with claims that cover our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual
property laws. Additionally, laws of some countries outside of the United States and the EU do not afford intellectual property protection to the same extent as the laws of the United States and the EU. Many companies have encountered significant
problems in protecting and defending intellectual property rights in certain foreign jurisdictions. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For
example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. Consequently, we may not be able to prevent third parties from practicing our inventions in certain countries outside the
United States and the EU or from selling or importing products made from our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to
develop and market their own products and, further, may export otherwise infringing products to territories where we have patent protection if our ability to enforce our patents to stop infringing activities is inadequate. These products may compete
with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Proceedings to enforce our patent rights, whether or not successful, could result in substantial costs and divert our efforts and resources from other
aspects of our business. Moreover, such proceedings could put our patents at risk of being invalidated or held unenforceable, or interpreted narrowly, and our pending patent applications at risk of not issuing, and could provoke third parties to
assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Furthermore, while we intend to protect our intellectual property rights in major
markets for our products, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products, if approved. Accordingly, our efforts to protect our intellectual property
rights in such countries may be inadequate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Others may challenge inventorship or claim an ownership interest in our intellectual property which could expose
it to litigation and have a significant adverse effect on its prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A third party or former employee or collaborator may claim an
inventorship or ownership interest in one or more of our or our licensors&#146; patents or other proprietary or intellectual property rights. A third party could bring legal actions against us and seek monetary damages and/or enjoin clinical
testing, manufacturing and marketing of the affected product or products. While we are presently unaware of any claims or assertions by third-parties with respect to inventorship or ownership of our patents or other intellectual property, we cannot
guarantee that a third party will not assert a claim or an interest in any of such patents or intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights,
such as exclusive ownership of, or right to use, intellectual property that is important to AMX0035 or any future product candidates. Further, regardless of the outcome, if we become involved in any litigation, it could consume a substantial portion
of our resources, and cause a significant diversion of effort by our technical and management personnel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and
time consuming and could prevent or delay us from developing or commercializing AMX0035 or any future product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our commercial
success depends, in part, on our ability to develop, manufacture, market and sell our product candidate without infringing the intellectual property and other proprietary rights of third parties. However, our research, development and
commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Third parties may have U.S. and
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> issued patents and pending patent applications relating to compounds, methods of manufacturing compounds and/or methods of use for the treatment of the disease indications for which we are developing
AMX0035 or any future product candidates. If any third-party patents or patent applications are found to cover AMX0035 or any future product candidates or their methods of use or manufacture, we may not be free to manufacture or market such product
candidates as planned without obtaining a license, which may not be available on commercially reasonable terms, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There is a substantial
amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our
products candidates, including patent infringement lawsuits in the United States or abroad. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to
the composition, use or manufacture of AMX0035 or any future product candidates. While we perform periodic searches for relevant patents and patent applications with respect to our proprietary drug candidate, AMX0035, we cannot guarantee that any of
our patent searches or analyses including, but not limited to, the identification of relevant patents, the scope of patent claims or the expiration of relevant patents are complete or thorough, nor can we be certain that we have identified each and
every patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of AMX0035 or any future product candidates in any jurisdiction. Because patent applications can take many years to
issue, there may be currently pending patent applications which may later result in issued patents that AMX0035 or any future product candidates may be accused of infringing. In addition, third parties may obtain patents in the future and claim that
use of our technologies infringes upon these patents. Accordingly, third parties may assert infringement claims against us based on intellectual property rights that exist now or arise in the future. The outcome of intellectual property litigation
is subject to uncertainties that cannot be adequately quantified in advance. The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which
patents cover various types of products or methods of use or manufacture. The scope of protection afforded by a patent is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement,
we would need to demonstrate that our product candidate, product or method either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity
is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur
substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could significantly harm our business and operating results. In addition, parties making claims against us
may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources, and we may not have sufficient resources to bring these actions to a successful conclusion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are found to infringe a third party&#146;s intellectual property rights, we could be forced, including by court order, to cease developing,
manufacturing or commercializing the infringing product candidate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the
infringing product candidate or product. If we were required to obtain a license to continue to manufacture or market the affected product, we may be required to pay substantial royalties or grant cross-licenses to our patents. We cannot, however,
assure you that any such license will be available on acceptable terms, if at all. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations as a result of claims of patent
infringement or violation of other intellectual property rights. Further, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of
witnesses and the identity of any adverse party. This is especially true in intellectual property cases that may turn on the testimony of experts as to technical facts upon which experts may reasonably disagree. Furthermore, we may not be able to
obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies
licensed to us; alternatively or additionally it could include terms that impede or destroy our ability to compete successfully in the commercial marketplace. In addition, we could be found liable for significant monetary damages, including treble
damages and attorneys&#146; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing AMX0035 or any future product candidates or force us to cease some of our business operations,
which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. Furthermore, because of the substantial amount of discovery
required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation
and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we
regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many of our current and former employees and our licensors&#146; current and former employees,
including our senior management, were previously employed at universities or at other biotechnology or pharmaceutical companies, including some which may be competitors or potential competitors. Some of these employees, including members of our
senior management, may have executed proprietary rights, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT STYLE="white-space:nowrap">non-competition</FONT> agreements, or similar agreements, in connection with such previous
employment. Although we try to ensure that our employees do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that we or these employees have used or
disclosed intellectual property, including trade secrets or other proprietary information, of any such third party. Litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary
damages, we may sustain damages or lose key personnel, valuable intellectual property rights or the personnel&#146;s work product, which could hamper or prevent commercialization of our technology, which in turn could materially affect our
commercial development efforts. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available
on commercially reasonable terms or at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual property to
execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
develops intellectual property that we regard as our own, which may result in claims by or against us related to the ownership of such intellectual property. If we fail in prosecuting or
defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a
distraction to our senior management and scientific personnel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to
build name recognition in our trademarks and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our trademarks or trade names may be challenged,
infringed, circumvented or declared generic or determined to be infringing on other marks. We rely on both registration and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may
be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to
respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to
seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Moreover, any name we propose to use for our products in the United States must be
approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names.
If the FDA objects to any of our proposed product names, we may be required to expend significant additional resources in an effort to identify a usable substitute name that would qualify under applicable trademark laws, not infringe the existing
rights of third parties and be acceptable to the FDA. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Intellectual property rights do not necessarily address all potential threats to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may
not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">others may be able to make products that are competitive to AMX0035, for example a TURSO monotherapy, or any of our future
product candidates but that are not covered by the claims of the patents that we own; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">others may independently develop similar or alternative technologies or otherwise circumvent any of our technologies
without infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we or any of our collaborators might not have been the first to invent the inventions covered by the patents or patent
applications that we own; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we or any of our collaborators might not have been the first to file patent applications covering certain of the patents or
patent applications that we or they own or have obtained a license, or will own or will have obtained a license; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">it is possible that our pending patent applications will not lead to issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">issued patents that we own may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a
result of legal challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights, or in
countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">ownership of our patents or patent applications may be challenged by third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on
our business; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">patent enforcement is expensive and time-consuming and difficult to predict; thus we may not be able to enforce any of our
patents against a competitor. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our reliance on third parties for research and development and manufacturing requires us to share our trade
secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets and protect other
proprietary information. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We consider proprietary trade secrets or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> and
unpatented <FONT STYLE="white-space:nowrap">know-how</FONT> to be important to our business. We may rely on trade secrets or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> to protect our technology, especially where patent protection
is believed by us to be of limited value. We rely on third parties for research and development work, and expect to rely on third parties for future manufacturing of our proprietary product candidate, AMX0035, and any future product candidates. We
also expect to collaborate with third parties on the development of AMX0035 and any future product candidates. As a result of the aforementioned collaborations, we must, at times, share trade secrets with our collaborators. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Trade secrets or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to maintain as confidential. To protect this type of
information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements and, if applicable, material transfer agreements, consulting
agreements or other similar agreements with us prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade
secrets. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the
event of unauthorized disclosure of confidential information. The need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the
technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets, a competitor&#146;s discovery of our
trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations. Enforcing a claim that a third party obtained illegally and is using trade secrets
or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> is expensive, time consuming and unpredictable. Moreover, the enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data
potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our
agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#146;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our
business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may need to acquire or license intellectual property from third parties, and such licenses may not be available or may not be available on
commercially reasonable terms. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A third party may hold intellectual property, including patent rights that are important or necessary to the
development of additional future product candidates. It may be necessary for us to use the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
patented or proprietary technology of one or more third parties to commercialize our current and future product candidates. If we are unable to acquire such intellectual property outright, or
obtain licenses to such intellectual property from such third parties when needed or on commercially reasonable terms, our ability to commercialize additional future product candidates, if approved, would likely be delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The risks described elsewhere pertaining to our intellectual property rights also apply to the intellectual property rights that we may <FONT
STYLE="white-space:nowrap">in-license,</FONT> and any failure by us or our licensors to obtain, maintain, defend and enforce these rights could have an adverse effect on our business. In some cases we may not have control over the prosecution,
maintenance or enforcement of the patents that we license, and may not have sufficient ability to provide input into the patent prosecution, maintenance and defense process with respect to such patents, and potential future licensors may fail to
take the steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Risks Related to
Our Business Operations, Employee Matters and Managing Growth </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>A pandemic, epidemic, or outbreak of an infectious disease, such as the ongoing and
evolving <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, may materially and adversely affect our business, including our preclinical studies, clinical trials, third parties on whom we rely, our supply chain, our ability to raise capital,
our ability to conduct regular business and our financial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are subject to risks related to public health crises such as the
ongoing and evolving <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The pandemic and policies and regulations implemented by governments in response to the pandemic, often directing businesses and governmental agencies to cease <FONT
STYLE="white-space:nowrap">non-essential</FONT> operations at physical locations, prohibiting certain nonessential gatherings and ceasing <FONT STYLE="white-space:nowrap">non-essential</FONT> travel have also had a significant impact, both direct
and indirect, on businesses and commerce, as worker shortages have occurred, supply chains have been disrupted, facilities and production have been suspended, and demand for certain goods and services, such as medical service and supplies, has
spiked. We have experienced certain impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic to date, including having to make certain alterations to our preclinical and clinical trial activities, such as scheduling certain work <FONT
STYLE="white-space:nowrap">off-site</FONT> and performing <FONT STYLE="white-space:nowrap">off-site</FONT> assessments. For example, we had to amend our CENTAUR trial protocol to allow for remote visits by patients, instead of patients making site
visits. In addition, in some cases we were forced to delay enrollment at certain sites in our recently completed Phase 2 clinical trial for AMX0035 in AD. There can be no guarantee we will not experience other impacts, such as being forced to
further delay or pause enrollment, experiencing potential interruptions to our supply chain, facing difficulties or additional costs in enrolling patients in future clinical trials or being able to achieve full enrollment of our studies within the
timeframes we anticipate, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has been and may continue to be
extensive in many aspects of society and could continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world. Although many of the government imposed
<FONT STYLE="white-space:nowrap">COVID-19</FONT> restrictions have eased, the full extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic could ultimately impact our business, preclinical studies, clinical trials and financial
results will depend on future developments, which are highly uncertain and cannot be accurately predicted, including the emergence of new variants and subvariants of the virus that causes <FONT STYLE="white-space:nowrap">COVID-19,</FONT> such as the
Omicron variants and subvariants, for which current vaccinations may be less effective or ineffective, among others. Other global health concerns could also result in social, economic, and labor instability in the countries in which we or the third
parties with whom we engage operate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we have continued to take
precautionary measures intended to help minimize the risk of the virus to our employees, including closing or reducing access to our executive offices and temporarily requiring employees to work remotely, suspending all
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
<FONT STYLE="white-space:nowrap">non-essential</FONT> travel for our employees and discouraging employee attendance at industry events and <FONT STYLE="white-space:nowrap">in-person</FONT>
work-related meetings, all of which could negatively affect our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While we have been working closely with our third-party manufacturers,
distributors and other partners to manage our supply chain activities and mitigate potential disruptions to the production of AMX0035 as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, if, despite vaccination efforts, the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to cause societal and commercial disruption for an extended period of time, there could be significant and material disruptions to our supply chain and operations, and associated delays
in the manufacturing and supply of AMX0035 and any future product candidates. Any such supply disruptions, including disruptions in procuring items that are essential for our research and development activities and securing manufacturing slots for
the products needed for such activities, could adversely impact our ability to initiate and complete preclinical studies or clinical trials and generate sales of and revenue from our product candidates, if approved, which could have a material
adverse effect on our business, financial condition, results of operations and growth prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has affected and may in the future affect employees of third-party CROs located in affected geographies that we rely upon to carry out our clinical trials. If current efforts to control the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic are not successful, if the spread of the virus or any variant of the virus increases, or if a new variant, virus or pandemic emerges, we may experience additional disruptions that could severely
impact our business and clinical trials, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays or difficulties in our commercialization efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays or difficulties in enrolling patients in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and
clinical site staff; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of sites or facilities
serving as our clinical trial sites and staff supporting the conduct of our clinical trials, including our trained therapists, or absenteeism that reduces site resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed
or recommended by federal, state or national governments, employers and others or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">risk that participants enrolled in our clinical trials will acquire <FONT STYLE="white-space:nowrap">COVID-19</FONT> or
another virus or illness while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events or patient withdrawals from our trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">limitations in employee resources that would otherwise be focused on conducting our clinical trials, including because of
sickness of employees or their families or the desire of employees to avoid contact with large groups of people; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays in receiving authorizations from regulatory authorities to initiate our future clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">interruption in global shipping that may affect the transport of clinical trial materials, such as the AMX0035 used in our
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in local regulations as part of a response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or
other pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or the discontinuation of the clinical trials altogether; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">interruptions or delays in preclinical studies due to restricted or limited operations at research and development
laboratory facilities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due
to limitations in employee resources or forced furlough of government employees; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal of the FDA, Health Canada, the EMA or the other regulatory bodies to accept data from clinical trials in affected
geographies outside the United States, Canada or the EU or other relevant local geographies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any negative impact the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic or any future pandemic or similar disruption has on patient enrollment or treatment, or the development of AMX0035 and any future product candidates, could cause costly delays to clinical trial
activities, which could adversely affect our ability to obtain regulatory approval for and to commercialize AMX0035 and any future product candidates, if approved, increase our operating expenses, which could have a material adverse effect on our
financial results. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has also in the past caused significant volatility in public equity markets and disruptions to the United States and global economies and any future pandemic or similar
disruption could lead to further market dislocation. Any such increased volatility and economic dislocation may make it more difficult for us to raise capital on favorable terms, or at all. If we or any of the third parties with whom we engage were
to experience renewed shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on our
business and our results of operations and financial conditions. To the extent the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or any future pandemic or similar disruption adversely affects our business and financial results, it may
also heighten many of the other risks described in this &#145;&#145;Risk Factors&#146;&#146; section, such as those relating to the timing and completion of our clinical trials and our ability to obtain future financing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability,
an ongoing military conflict between Russia and Ukraine, and record inflation, any of which could have a material adverse effect on our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the military conflict between
Russia and Ukraine. In February 2022, a full-scale military invasion of Ukraine by Russian troops began. Although the length and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine has led to market disruptions,
including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions, which has contributed to record inflation globally. We are continuing to monitor inflation, the situation in Ukraine and global
capital markets and assessing its potential impact on our business, including the impact on the supply chains we rely on for the manufacture of AMX0035 or other future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although, to date, our business has not been materially impacted by the ongoing military conflict between Russian and Ukraine, geopolitical tensions, or
record inflation, it is impossible to predict the extent to which our operations will be impacted in the short and long term, or the ways in which such matters may impact our business. The extent and duration of the conflict in Ukraine, geopolitical
tensions, record inflation and resulting market disruptions are impossible to predict but could be substantial. Any such disruptions may also magnify the impact of other risks we face. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Inadequate funding for the FDA, the SEC and other government agencies, including from government shutdowns, or other disruptions to these agencies&#146;
operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent
</I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>
those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, the
ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC
and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary
government agencies, which would adversely affect our business. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material
adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We depend heavily on our executive officers, principal consultants and others, and the loss of their services would materially harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our success depends, and will likely continue to depend, upon our ability to hire and retain the services of our current executive officers, principal
consultants and others, including Josh Cohen and Justin Klee, our <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officers, James Frates, our Chief Financial Officer, Margaret Olinger, our Global Head of Commercial and Chief Commercial
Officer, and Patrick Yeramian, our Global Head of Clinical Research&nbsp;&amp; Development and Chief Medical Officer. We have entered into employment agreements with Mr.&nbsp;Cohen, Mr.&nbsp;Klee, Mr.&nbsp;Frates, Ms.&nbsp;Olinger and
Dr.&nbsp;Yeramian, but they may terminate their employment with us at any time. The loss of their services might impede the achievement of our research, development and commercialization objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ability to compete in the biotechnology and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial,
scientific and medical personnel. Our industry has experienced a high rate of turnover of management personnel in recent years. Replacing executive officers or other key employees may be difficult and may take an extended period of time because of
the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize products successfully. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key employees on
acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and
commercialization strategy. Our consultants and advisors may be employed by other entities and may have commitments under consulting or advisory contracts with those entities that may limit their availability to us. If we are unable to continue to
attract and retain highly qualified personnel, our ability to develop and commercialize AMX0035 or any future product candidates will be limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We only
have a limited number of employees to manage and operate our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2022, we had 226 full-time employees. Our focus
on the development of AMX0035 requires us to optimize cash utilization and to manage and operate our business in a highly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
efficient manner. We cannot assure you that we will be able to hire and/or retain adequate staffing levels to develop AMX0035 or to run our operations and/or to accomplish all of the objectives
that we otherwise would seek to accomplish. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our employees, independent contractors, consultants, collaborators and CROs may engage in misconduct or other
improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements, which could cause significant liability for us and harm our reputation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are exposed to the risk that our employees, independent contractors, consultants, collaborators and CROs may engage in fraudulent conduct or other
illegal activity. Misconduct by those parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">FDA regulations or similar regulations of comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory
authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">manufacturing standards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced
by comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">laws that require the reporting of financial information or data accurately. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Activities subject to these laws also involve the improper marketing, use or misrepresentation of information obtained in the course of clinical trials,
creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of product materials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter
misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a
failure to be in compliance with such laws, standards or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against
us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of civil, criminal and administrative penalties, damages,
monetary fines, disgorgement, integrity oversight and reporting obligations, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future
earnings, and curtailment of our operations, any of which could have a material adverse effect on our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently expect to continue to significantly increase the number of our employees and the scope of our operations, particularly in the areas of
regulatory affairs and sales, marketing and distribution, as well as to support our public company operations. To manage these growth activities, we must continue to implement and improve our managerial, operational and financial systems, expand our
facilities and continue to recruit and train additional qualified personnel. Our management may need to devote a significant amount of its attention to managing these growth activities. Moreover, our expected growth could require us to relocate to a
different geographic area of the country. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion or
relocation of our operations, retain key employees, or identify, recruit and train additional qualified </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
personnel. Our inability to manage the expansion or relocation of our operations effectively may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business
opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could also require significant capital expenditures and may divert financial resources from other projects, such as the development of
additional product candidates. If we are unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to generate revenues could be reduced and we may not be able to implement our business strategy,
including the successful commercialization of AMX0035 or any future product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Risks Related to Our Common Stock and This Offering
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If you purchase shares of our common stock in this offering, you will incur immediate and substantial dilution. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The offering price of our common stock is substantially higher than the net tangible book value per share of our common stock, which on a pro forma basis
was $3.29 per share as of June&nbsp;30, 2022. Based on an assumed public offering price of $29.75 per share, which is the last reported trading price of our common stock on the Nasdaq Global Select Market on&nbsp;October&nbsp;3, 2022, you will
experience immediate dilution of $<U>24.17</U> per share, representing the difference between our pro forma net tangible book value per share after giving effect to this offering and the assumed public offering price per share of common stock. This
means that you will pay a higher price per share than the amount of our total tangible assets, less our total liabilities, divided by the number of shares of common stock outstanding. Furthermore, if the underwriters exercise their option to
purchase additional shares or our previously issued options and other rights to acquire common stock at prices below the public offering price are exercised, you will experience further dilution. In addition, you may also experience additional
dilution if options or other rights to purchase our common stock that we may issue in the future are exercised or converted or we issue additional shares of our common stock at prices lower than our net tangible book value at such time. For more
information, see &#147;Dilution.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The price of our stock may be volatile, and you could lose all or part of your investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The trading price of our common stock may be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are
beyond our control, including limited trading volume. In addition to the factors discussed in this &#147;Risk Factors&#148; section and elsewhere in this prospectus, these factors include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the commencement, enrollment or results of our ongoing and future preclinical studies and clinical trials, or any future
preclinical studies or clinical trials, we may conduct of AMX0035 and any future product candidates, or changes in the development status of our current and any future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any additional regulatory submissions for AMX0035 or any future product candidates and any adverse development or perceived
adverse development with respect to the applicable regulatory authority&#146;s review of such submissions, including without limitation the FDA&#146;s issuance of a &#147;refusal to file&#148; letter or a request for additional information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">adverse results or delays in our preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing clinical trial;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">adverse regulatory decisions, including failure to receive regulatory approvals for AMX0035 and any future product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in laws or regulations applicable to AMX0035 and any future product candidates, including but not limited to
clinical trial requirements for approvals; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the failure to obtain coverage and adequate reimbursement of AMX0035 and any future product candidates, if approved;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes on the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any changes to our relationship with any manufacturers, suppliers, licensors, future collaborators or other strategic
partners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to obtain adequate product supply for any approved drug product or inability to do so at acceptable prices;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to establish collaborations, if needed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our failure to successfully commercialize AMX0035 and any future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">additions or departures of key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unanticipated serious safety concerns related to the use of AMX0035 and any future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">introduction of new products or services offered by us or our competitors, or the release or publication of clinical trial
results from competing product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">announcements of significant acquisitions, strategic partnerships, joint ventures, or capital commitments by us or our
competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to effectively manage our growth; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">actual or anticipated variations in quarterly operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our cash position and rate of expenditures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the
public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research
coverage by securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in the market valuations of similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">overall performance of the equity markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">issuances of debt or equity securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">sales of our common stock by us or our stockholders in the future or the perception that such sales may occur;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in accounting practices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">ineffectiveness of our internal controls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to
obtain patent protection for our technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">significant lawsuits, including patent or stockholder litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">general political, geographical, and economic conditions, including the impact of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, historically high inflation, rising interest rates and the evolving conflict in Ukraine; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">other events or factors, many of which are beyond our control. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the stock market in general, and pharmaceutical companies in particular, have experienced
extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our
actual operating performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Unstable market, economic, political and geographical conditions may have serious adverse consequences on our business,
financial condition and stock price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As widely reported, global credit and financial markets have experienced extreme volatility and
disruptions in the past several years, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in the rate of inflation, increases in unemployment rates and uncertainty
about economic stability, including most recently in connection with the ongoing and evolving <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and the conflict in Ukraine. There can be no assurance that further deterioration in credit and
financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions.
Our business could also be impacted by volatility caused by geopolitical events such as the situation in the Ukraine. If the current equity and credit markets deteriorate, or do not improve, it may make any necessary debt or equity financing more
difficult, more costly, and more dilutive. Furthermore, our stock price may decline due in part to the volatility of the stock market and the general economic downturn. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy,
financial performance and stock price and could require us to delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential
<FONT STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive these difficult economic times, which could
directly affect our ability to attain our operating goals on schedule and on budget. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are an emerging growth company and a smaller reporting company, and
the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an emerging growth company, as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of
exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the
Sarbanes-Oxley Act of 2022, or the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory votes on
executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an emerging growth company until December&nbsp;31, 2027, although circumstances could cause us to lose that status earlier,
including if we become a &#147;large accelerated filer&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Securities Exchange Act of 1934, as amended, or the Exchange Act, or if we have total annual gross revenue of
$1.235&nbsp;billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following December&nbsp;31 or, if we issue more than $1.0&nbsp;billion in
<FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during any three year period before that time, in which case we would cease to be an emerging growth company immediately. Even after we no longer qualify as an emerging growth company, we
may still qualify as a &#147;smaller reporting company&#148;, which would allow us to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of
Section&nbsp;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
statements. Investors may find our common stock less attractive because we may rely on these exemptions. We may take advantage of certain of the scaled disclosures available to smaller reporting
companies and will be able to take advantage of these scaled disclosures for so long as our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and our voting and
<FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. If some investors find
our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised
accounting standards. This provision allows an emerging growth company to delay the adoption of accounting standards that have different effective dates for public and private companies until those standards would otherwise apply to private
companies. We have elected to avail ourselves of this exemption from new or revised accounting standards, and therefore we will not be subject to the same requirements to adopt new or revised accounting standards as other public companies that are
not emerging growth companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have broad discretion in the use of the net proceeds from this offering and may invest or spend the proceeds in ways with
which you do not agree and in ways that may not yield a return on your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although we currently intend to use the net proceeds from
this offering in the manner described in the section titled &#147;Use of Proceeds&#148; in this prospectus, our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that
do not improve our results of operations or enhance the value of our common stock. You will not have the opportunity to influence our decisions on how to use the net proceeds from this offering. The failure by our management to apply these funds
effectively could result in financial losses that could harm our business, cause the price of our common stock to decline and delay the development of AMX0035 or any future product candidates. Pending their use, we may invest the net proceeds from
this offering in a manner that does not produce income or that loses value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>A significant portion of our total outstanding shares may be sold into the
market, which could cause the market price of our common stock to decline significantly, even if our business is doing well. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sales of a
substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our
common stock. As of June&nbsp;30, 2022, we had outstanding 58,533,226 shares of common stock, which may be resold in the public market immediately without restriction, unless held by our affiliates or existing stockholders subject to a <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement. Moreover, holders of an aggregate of approximately 17.3 million shares of our common stock have rights, subject to specified conditions, to require us to file registration statements covering
their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We do not anticipate paying any cash
dividends on our capital stock in the foreseeable future. Accordingly, stockholders must rely on capital appreciation, if any, for any return on their investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have never declared nor paid cash dividends on our capital stock. We currently plan to retain all of our future earnings, if any, to finance the
operation, development and growth of our business. In addition, the terms of any future debt or credit agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain
for the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Concentration of ownership of our common stock among our existing executive officers, directors and principal
stockholders may prevent new investors from influencing significant corporate decisions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our executive officers and directors, combined with
our stockholders who own more than 5% of our outstanding common stock, own a significant portion of our common stock. As a result, these stockholders acting together, would be able to significantly influence all matters submitted to our stockholders
for approval, as well as our management and affairs. For example, these stockholders, if they choose to act together, would significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially
all of our assets. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that our stockholders may feel are in their best interest. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Delaware law and provisions in our amended and restated certificate of incorporation, or our certificate of incorporation, and amended and restated bylaws, or our
bylaws, could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Provisions
of our certificate of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium
for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our certificate of incorporation and
bylaws: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and
privileges as they may designate (including the right to approve an acquisition or other change in our control); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that the authorized number of directors may be changed only by resolution of the board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that our board of directors or any individual director may only be removed with cause and the affirmative vote of
the holders of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the voting power of all of our then-outstanding common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by
the affirmative vote of a majority of directors then in office, even if less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">divide our board of directors into three classes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of
stockholders and not be taken by written consent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for
election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#146;s notice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock
entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that special meetings of our stockholders may be called only by the board of directors pursuant to a resolution
adopted by a majority of the total number of authorized directors; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for the following types of
actions or proceedings under state, statutory and common law: (i)&nbsp;any derivative action or proceeding brought on our behalf; (ii)&nbsp;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former
directors, officers or other employees to us or our stockholders; (iii)&nbsp;any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of
the Delaware General Corporation Law, our certificate of incorporation or our bylaws; (iv)&nbsp;any action or proceeding to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws; (v)&nbsp;any action or
proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi)&nbsp;any action asserting a claim against us or any of our directors, officers or other employees governed
by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#146;s having personal jurisdiction over the indispensable parties named as defendants; provided these provisions of our certificate of
incorporation and bylaws will not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction; and provided that, unless we consent in writing to the
selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the
Securities Act of 1933, as amended, or the Securities Act. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The amendment of any of these provisions, with the exception of the
ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto, would require approval by the holders of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of our
then-outstanding common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, as a Delaware corporation, we are subject to Section&nbsp;203 of the Delaware General Corporation Law.
These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A Delaware corporation may opt out of this provision by express
provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These and other provisions in our certificate of incorporation, bylaws and Delaware law could make it more difficult for stockholders or potential
acquirors to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer or proxy contest involving our company. The existence of these
provisions could negatively affect the price of our common stock and limit opportunities for you to realize value in a corporate transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For
information regarding these and other provisions, see &#147;Description of Capital Stock.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are obligated to develop and maintain proper and effective
internal controls over financial reporting and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will be required, pursuant to Section&nbsp;404 of the Sarbanes Oxley Act, or Section&nbsp;404, to furnish a report by management on, among other
things, the effectiveness of our internal controls over financial reporting for the fiscal year ending December&nbsp;31, 2023. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal
controls over financial reporting. Our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting until our first annual report required to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
be filed with the SEC following the date we are no longer an emerging growth company, as defined in the JOBS Act, and are not a smaller reporting company with less than $100&nbsp;million in
annual revenue. At such time as we are required to obtain auditor attestation, if we then have a material weakness, we would receive an adverse opinion regarding our internal control over financial reporting from our independent registered public
accounting firm. We are required to disclose significant changes made in our internal controls procedures on a quarterly basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We continue the
costly and challenging process of enhancing our financial reporting systems and processes as necessary to allow for the operation of effective internal controls over financial reporting to comply with the requirements of Section&nbsp;404. We may not
be able to complete our assessment, testing and any required remediation of internal controls over financial reporting in a timely fashion. Our compliance with Section&nbsp;404 will require that we incur substantial legal, accounting and other
compliance expense and expend significant management efforts. We currently do not have an internal audit group. We will need to hire additional accounting and finance personnel and consultants with appropriate public company experience and technical
accounting knowledge to develop and maintain the internal controls over financial reporting necessary to comply with Section&nbsp;404. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have
identified past material weaknesses in our internal controls over financial reporting. If during the evaluation and testing of our internal controls over financial reporting, we identify one or more additional material weaknesses in future periods,
we will be unable to assert that our internal controls over financial reporting are effective. We cannot assure you that there will not be additional material weaknesses in our internal controls over financial reporting in the future. Any failure to
maintain effective internal controls over financial reporting could severely inhibit our ability to accurately report our financial condition or results of operations. If we are unable to conclude that our internal controls over financial reporting
are effective, we could lose investor confidence in the accuracy and completeness of our financial reports,&nbsp;the market price of our common shares could decline, and we could be subject to sanctions or investigations by the SEC or other
regulatory authorities. Failure to remedy any material weakness in our internal controls over financial reporting, or to implement or maintain other effective control systems required of public companies, could also negatively impact our ability to
access to the capital markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, effective disclosure controls and procedures enable us to make timely and accurate disclosure of
financial and <FONT STYLE="white-space:nowrap">non-financial</FONT> information that we are required to disclose. As a public company, if our disclosure controls and procedures are ineffective, we may be unable to report our financial results or
make other disclosures accurately and on a timely basis, which could cause our reported financial results or other disclosures to be materially misstated and result in the loss of investor confidence and cause the market price of our common shares
to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be
the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our bylaws provide that, to the fullest extent permitted by law and subject to the court&#146;s having personal jurisdiction over the indispensable
parties named as defendants, the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any derivative action or proceeding brought on our behalf; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any action or proceeding asserting a breach of fiduciary duty owed by any of our current or former directors, officers or
other employees to us or our stockholders; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any action or proceeding asserting a claim against us or any of our current or former directors, officers or other
employees arising out of or pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or bylaws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any action or proceeding to interpret, apply, enforce or determine the validity of our certificate of incorporation or our
bylaws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of
the State of Delaware; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any action asserting a claim against us or any of our directors, officers or other employees that is governed by the
internal affairs doctrine. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange
Act. Furthermore, Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To
prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our certificate of incorporation further provides that the federal district courts of the
United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a
stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of
our certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These exclusive forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes
with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive forum provision in our certificate of incorporation to be
inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional
dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect that we will need significant
additional capital in the future to continue our planned operations, including conducting clinical trials, commercialization efforts if we are able to obtain marketing approval of any of AMX0035 or any future product candidates, research and
development activities, and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time
to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain
rights, preferences and privileges senior to the holders of our common stock, including shares of common stock sold in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to
our 2022 Plan, our management is authorized to grant stock options to our employees, directors and consultants. Additionally, the number of shares of our common stock reserved for issuance under our 2022 Plan will automatically increase on
January&nbsp;1 of each year, beginning on January&nbsp;1, 2023 and continuing through and including January&nbsp;1, 2032, by 5.0% of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
total number of shares of our capital stock outstanding on December&nbsp;31 of the preceding calendar year, or a lesser number of shares determined by our board of directors. In addition,
pursuant to our ESPP, the number of shares of our common stock reserved for issuance will automatically increase on January&nbsp;1 of each calendar year, beginning on January&nbsp;1, 2023 (through January&nbsp;1, 2032), by the lesser of (i) 1.0% of
the total number of shares of our common stock outstanding on the last day of the calendar month before the date of the automatic increase, and (ii) 1,210,000 shares; provided that before the date of any such increase, our board of directors may
determine that such increase will be less than the amount set forth in clauses (i)&nbsp;and (ii). Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience
additional dilution, which could cause our stock price to fall. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>General Risk Factors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a public company, we incur significant and ongoing legal, accounting, and other expenses that we did not incur as a private company. We
are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC annual, quarterly, and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley
Act, as well as rules subsequently adopted by the SEC and the Nasdaq Global Select Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of
effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate
governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#147;say on pay&#148; and proxy access. Emerging growth companies and smaller
reporting companies are exempted from certain of these requirements, but we may be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political
environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our
business in ways we cannot currently anticipate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect the rules and regulations applicable to public companies to substantially increase our
legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on
our business, financial condition, and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or
services. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to
serve on our board of directors, our board committees or as executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Cyber-attacks or other failures in our telecommunications or information
technology systems, or those of our collaborators, CROs, third-party logistics providers, distributors or other contractors or consultants, could result in information theft, data corruption and significant disruption of our business operations.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We, our collaborators, our CROs, third-party logistics providers, distributors and other contractors and consultants utilize information
technology, or IT, systems and networks to process, transmit and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
store electronic information in connection with our business activities. As use of digital technologies has increased, cyber incidents, including third parties gaining access to employee accounts
using stolen or inferred credentials, computer malware, viruses, spamming or other means, and deliberate attacks and attempts to gain unauthorized access to computer systems and networks, have increased in frequency and sophistication. Cyber-attacks
also could include phishing attempts or <FONT STYLE="white-space:nowrap">e-mail</FONT> fraud to cause payments or information to be transmitted to an unintended recipient. These threats pose a risk to the security of our, our collaborators&#146;,
our CROs&#146;, third-party logistics providers&#146;, distributors&#146; and other contractors&#146; and consultants&#146; systems and networks, and the confidentiality, availability and integrity of our data. There can be no assurance that we will
be successful in preventing cyber-attacks or successfully mitigating their effects. Similarly, there can be no assurance that our collaborators, CROs, third-party logistics providers, distributors and other contractors and consultants will be
successful in protecting our clinical and other data that is stored on their systems. Any cyber-attack, data breach or destruction or loss of data could result in a violation of applicable U.S. and international privacy, data protection and other
laws, and subject us to litigation and governmental investigations and proceedings by federal, state and local regulatory entities in the United States and by international regulatory entities, resulting in exposure to material civil and/or criminal
liability. Further, our general liability insurance and corporate risk program may not cover all potential claims to which we are exposed and may not be adequate to indemnify us for all liability that maybe imposed; and could have a material adverse
effect on our business and prospects. For example, the loss of clinical trial data from completed, ongoing or future clinical trials for AMX0035 or any of our future product candidates could result in delays in our development and regulatory
approval efforts and significantly increase our costs to recover or reproduce the data. In addition, we may suffer reputational harm or face litigation or adverse regulatory action as a result of cyber-attacks or other data security breaches and may
incur significant additional expense to implement further data protection measures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our ability to use net operating losses and research and development
credits to offset future taxable income may be subject to certain limitations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2021, we had U.S. federal and state
net operating loss carryforwards of $115.7&nbsp;million and $102.9&nbsp;million, respectively, some of which begin to expire in 2034. As of December&nbsp;31, 2021 and 2020, we also had U.S. federal research and development tax credit carryforwards
of $2.7&nbsp;million and $1.6&nbsp;million, respectively, which begin to expire in 2029. These net operating loss and tax credit carryforwards could expire unused and be unavailable to offset future taxable income or tax liabilities, respectively.
U.S. federal and certain state net operating losses generated in taxable years beginning after December&nbsp;31, 2017 are not subject to expiration. Federal net operating losses generally may not be carried back to prior taxable years except that,
under the Coronavirus Aid, Relief and Economic Security Act, federal net operating losses generated in 2018, 2019 and 2020 may be carried back to each of the five taxable years preceding the taxable year in which the loss arises. Additionally, for
taxable years beginning after December&nbsp;31, 2020, the deductibility of federal net operating losses generated in taxable years beginning after December&nbsp;31, 2017 is limited to 80% of our taxable income in such taxable year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, and corresponding provisions of state law, a
corporation that undergoes an &#147;ownership change&#148; is subject to limitations on its ability to utilize its <FONT STYLE="white-space:nowrap">pre-change</FONT> net operating loss carryforwards or tax credits, or NOLs or credits, to offset
future taxable income. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least five percent of a corporation&#146;s stock increases its
ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. Our existing federal and state NOLs and our existing research and development credits may be subject to limitations arising from
previous ownership changes and, if we undergo an ownership change, our ability to utilize NOLs or credits could be further limited by Sections 382 and 383 of the Code. We have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
not yet completed a Section&nbsp;382 analysis. In addition, this offering or future changes in our stock ownership, many of which are outside of our control, could result in an ownership change
under Sections 382 and 383 of the Code. Our NOLs or credits may also be impaired under state law. Accordingly, we may not be able to utilize a material portion of our NOLs or credits. Furthermore, our ability to utilize our NOLs or credits is
conditioned upon our attaining profitability and generating U.S. federal and state taxable income. As described above, we have incurred significant net losses since our inception and anticipate that we will continue to incur significant losses for
the foreseeable future; and therefore, we do not know whether or when we will generate the U.S. federal or state taxable income necessary to utilize our NOLs or credits that are subject to limitation by Sections 382 and 383 of the Code. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We could be subject to securities class action litigation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This
risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#146;s attention
and resources, which could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our failure to meet Nasdaq&#146;s continued listing requirements could result in a delisting of our common
stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we fail to satisfy the continued listing requirements of the Nasdaq Global Select Market, such as the corporate governance
requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our
common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price
or improve the liquidity of our common stock, prevent our common stock from dropping below the minimum bid price requirement or prevent future <FONT STYLE="white-space:nowrap">non-compliance</FONT> with the listing requirements of the Nasdaq Global
Select Market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If securities analysts publish negative evaluations of our stock, the price of our stock could decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The trading market for our common stock depends in part on the research and reports that industry or securities analysts publish about us or our
business. If one or more of the analysts who may cover us issues an adverse opinion about our company, our stock price would likely decline. If one or more of these analysts ceases research coverage of us or fails to regularly publish reports on us,
we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc383770_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus and the documents incorporated by reference into this prospectus contain forward-looking statements that involve substantial risks and
uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements, other than statements of historical facts,
contained in this prospectus and the documents incorporated by reference into this prospectus, are forward-looking statements. These include statements regarding our strategy, future operations, future financial position, future revenue, projected
costs, prospects, plans and objectives of management and expected market growth are forward-looking statements. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148;
&#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;target,&#148; &#147;would&#148; and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these identifying words. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These forward-looking statements include, among other
things, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our use of the net proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to obtain and maintain regulatory approval of AMX0035 and any future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to successfully commercialize and market AMX0035 and any future product candidates, if approved, and the timing
of any commercialization and marketing efforts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to contract with third-party suppliers, manufacturers and other service providers and their ability to perform
adequately and to produce sufficient quantities of clinical and commercial supplies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential market size, opportunity and growth potential for AMX0035 and any future product candidates, if approved;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to build our own sales and marketing capabilities, or seek collaborative partners, to commercialize AMX0035 and
any future product candidates, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to obtain funding for our operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the initiation, timing, progress and results of our preclinical studies and clinical trials, including our Phase 3 clinical
trial of AMX0035 for the treatment of ALS, known as the PHOENIX trial, and our research and development activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified
professionals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to advance AMX0035 and any future product candidates into, and successfully complete, clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to successfully recruit and enroll suitable patients in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing or likelihood of the accomplishment of various scientific, clinical, regulatory filings and approvals and other
product development objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the pricing and reimbursement of AMX0035 in the United States and Canada and in any other jurisdictions in which AMX0035 is
approved, if any, and of any other product candidates, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the rate and degree of market acceptance AMX0035 and any future product candidates by physicians, patients, third-party
payors and others in the medical community; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the implementation of our business model, strategic plans for our business, product candidates and technology;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our product
candidates and technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developments relating to our competitors and our industry, including any regulatory developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our estimates regarding expenses, capital requirements, cash runway and future and needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our financial performance; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">other risks and uncertainties, including those listed under the section titled &#147;Risk Factors&#148; and those listed in
the documents incorporated by reference in this prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may not actually achieve the plans, intentions or expectations
disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking
statements we make. We have included important factors in the cautionary statements included in this prospectus and the documents incorporated by reference in this prospectus, particularly in the &#147;Risk Factors&#148; section in this prospectus,
that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations,
joint ventures or investments that we may make or enter into. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">You should read this prospectus, the documents incorporated by reference into this
prospectus and the documents that we have filed as exhibits to the registration statement of which this prospectus is a part completely and with the understanding that our actual future results may be materially different from what we expect. We do
not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc383770_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We estimate that the net proceeds to us from our issuance and sale of&nbsp;6,000,000&nbsp;shares of our common stock in this offering will be
approximately $167.0 million, assuming a public offering price of $29.75 per share, which is the last reported trading price of our common stock on the Nasdaq Global Select Market on&nbsp;October 3, 2022, after deducting estimated underwriting
discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise in full their option to purchase additional shares, we estimate that the net proceeds from this offering will be approximately $192.2 million,
after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A $1.00 increase or decrease in the
assumed public offering price of $29.75 per share, which is the last reported trading price of our common stock on the Nasdaq Global Select Market on October&nbsp;3, 2022, would increase or decrease our net proceeds from this offering by
approximately $5.6&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions. An increase or decrease of
1.0 million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase or decrease our net proceeds from this offering by approximately $28.0&nbsp;million, assuming no change in the assumed public
offering price per share and after deducting estimated underwriting discounts and commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently estimate that we will use the net
proceeds from this offering, together with our existing cash, cash equivalents, and short-term investments, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $100.0 million to fund production and commercialization activities &#150; for AMX0035 for the treatment of
ALS in the United States and Canada and the regulatory approval process and market preparation in Europe for AMX0035 for the treatment of ALS; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $30.0 million to fund the completion of our ongoing Phase 3 PHOENIX clinical trial for the treatment of ALS,
including the open label extension phase, and the completion of post-marketing requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $20.0 million to fund the development and expansion of our pipeline to address other neurodegenerative
indications, and for formulations and derivatives of AMX0035; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the remainder for working capital and other general corporate activities, which may include funding for the costs of
operating as a public company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This expected use of the net proceeds from this offering along with our existing cash, cash
equivalents, and short-term investments represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. For example, we may use a portion of the net
proceeds for the acquisition of businesses, products or technologies to continue to build our pipeline, our research and development capabilities and our intellectual property position, although we currently have no agreements, commitments or
understandings with respect to any such transaction. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development and our sales and marketing and commercialization
efforts, demand for AMX0035 in the United States and Canada or any future products, if approved, our operating costs, the status of and results from clinical trials, any collaborations that we may enter into with third parties for AMX0035 or any
future product candidates and any unforeseen cash needs. Moreover, our estimates of the costs to fund our current and future trials are based on the designs of the trials. If we were to modify the design of any of these trials, for instance, to
increase the number of patients in the trials, our costs to fund the trials could increase. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on our current plans, we believe that our existing cash, cash equivalents and short-term
investments, together with the net proceeds from this offering, will be sufficient to meet our anticipated operating and capital expenditure requirements for at least the next twelve months. We have based this estimate on assumptions that may prove
to be wrong, and we could use our available capital resources sooner than we currently expect. We do not have any committed external source of funds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including
short-term, investment-grade, interest-bearing instruments and U.S. government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc383770_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have never declared nor paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance the
growth and development of our business. We do not intend to pay cash dividends in respect of our common stock in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc383770_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth our cash, cash equivalents, and short-term investments and our capitalization as of June&nbsp;30, 2022: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on an actual basis; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on an as adjusted basis to give effect to our issuance and sale of&nbsp;6,000,000 shares of our common stock in this
offering at an assumed public offering price of $29.75 per share, which is the last reported trading price of our common stock on the Nasdaq Global Select Market on&nbsp;October&nbsp;3, 2022, after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us as of June&nbsp;30, 2022. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our capitalization following the closing of
this offering will depend on the actual public offering price and other terms of this offering determined at pricing. Cash, cash equivalents, and short-term investments are not components of our total capitalization. You should read this table
together with the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our consolidated financial statements and related notes included in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021 and our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2022, each of which is incorporated by reference in
this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands, except<BR>share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash, cash equivalents, and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">206,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">373,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock, $0.0001 par value; 300,000,000 shares authorized, 58,533,226 shares issued and outstanding,
actual; 300,000,000 shares authorized,&nbsp;64,533,226 shares issued and outstanding, as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">617,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(257,760</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(257,760</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">192,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">359,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A $1.00 increase (decrease) in the assumed public offering price of $29.75 per share, which is the last reported trading
price of our common stock on the Nasdaq Global Select Market on October&nbsp;3, 2022, would increase (decrease) the as adjusted amount of each of cash, cash equivalents, and short-term investments, additional
<FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity (deficit) and total capitalization by 5.6&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus,
remains the same and after deducting estimated underwriting discounts and commissions. An increase (decrease) of 1.0 million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease)
the as adjusted amount of each of cash, cash equivalents, and short-term investments, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity (deficit) and total capitalization by $28.0 million, assuming
no change in the assumed public offering price per share and after deducting estimated underwriting discounts and commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The table above
excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">8,528,039 shares of our common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30, 2022, at a
weighted average exercise price of $12.08 per share; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">670,013 shares of our common stock issuable upon vesting of restricted stock units outstanding as of June 30, 2022 under
our 2022 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">3,121,919 shares of our common stock that are available for future issuance as of June&nbsp;30, 2022 under our 2022 Plan,
as well as any future increases, including annual automatic evergreen increases, in the number of shares of common stock reserved for issuance thereunder in accordance with the terms of such plan; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">605,000 shares of our common stock that are available for future issuance under our 2022 ESPP. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc383770_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the
public offering price per share of our common stock and the as adjusted net tangible book value per share of our common stock after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our historical net tangible book value as of June&nbsp;30, 2022 was $192.8&nbsp;million, or $3.29 per share of our common stock. Our historical net
tangible book value is the amount of our total tangible assets less our total liabilities, which is not included within stockholders&#146; equity. Historical net tangible book value per share represents our historical net tangible book value divided
by the 58,533,226 shares of our common stock outstanding as of June&nbsp;30, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After giving effect to our issuance and sale
of&nbsp;6,000,000&nbsp;shares of our common stock in this offering at an assumed public offering price of $29.75 per share, which is the last reported trading price of our common stock on the Nasdaq Global Select Market on&nbsp;October&nbsp;3, 2022,
and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of June&nbsp;30, 2022 would have been $359.8&nbsp;million, or $5.58 per share. This
represents an immediate increase in as adjusted net tangible book value per share of $2.29 to existing stockholders and immediate dilution of $24.17 in as adjusted net tangible book value per share to new investors purchasing common stock in this
offering. Dilution per share to new investors is determined by subtracting as adjusted net tangible book value per share after this offering from the assumed public offering price per share paid by new investors. The following table illustrates this
dilution on a per share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assumed public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Historical net tangible book value per share as of June&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase in as adjusted net tangible book value per share attributable to new investors purchasing shares in
this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">As adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dilution per share to new investors purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A $1.00 increase or decrease in the assumed public offering price of $29.75 per share, which is the last reported
trading price of our common stock on the Nasdaq Global Select Market on October&nbsp;3, 2022, would increase or decrease our as adjusted net tangible book value by $5.6 million, our as adjusted net tangible book value per share after this offering
by $0.09 and dilution per share to new investors purchasing shares in this offering by $0.91, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated
underwriting discounts and commissions. An increase of 1.0 million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase the as adjusted net tangible book value per share after this offering
by $0.34 and decrease the dilution per share to new investors participating in this offering by $0.34, assuming no change in the assumed public offering price and after deducting estimated underwriting discounts and commissions. A decrease of
1.0&nbsp;million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would decrease the as adjusted net tangible book value per share after this offering by $0.36 and increase the dilution per share to
new investors participating in this offering by $0.36<U>, assuming no change in the assumed public offering price and after deducting estimated underwriting discounts and commissions. </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the underwriters exercise their option to purchase additional shares in full, our as adjusted net tangible book value per share after this offering
would be $5.88 per share, representing an immediate increase in as adjusted net tangible book value per share of $2.59 to existing stockholders and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
immediate dilution in as adjusted net tangible book value per share of $23.87 to new investors purchasing common stock in this offering, assuming a public offering price of $29.75 per share,
which is the last reported trading price of our common stock on the Nasdaq Global Select Market on October&nbsp;3, 2022, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. If any
shares are issued upon exercise of outstanding options, you will experience further dilution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The discussion and table (other than the historical
net tangible book value calculation) above are based on 58,533,226 shares of our common stock outstanding as of June&nbsp;30, 2022, and exclude: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">8,528,039 shares of our common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30, 2022, at a
weighted average exercise price of $12.08 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">670,013 shares of our common stock issuable upon vesting of restricted stock units outstanding as of June 30, 2022 under
our 2022 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">3,121,919 shares of our common stock that are available for future issuance as of June, 2022 under our 2022 Plan, as well
as any future increases, including annual automatic evergreen increases, in the number of shares of common stock reserved for issuance thereunder in accordance with the terms of such plan; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">605,000 shares of our common stock that are available for future issuance under our 2022 ESPP. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc383770_9"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Introduction </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our mission is to one day end the suffering
caused by neurodegenerative diseases. Unlike most other cells in the body that regularly die and are replaced as part of healthy function, mature neurons are normally resistant to cell death and generally cannot regenerate. We believe AMX0035 is the
first drug candidate to show both a functional and survival benefit in a large-scale clinical trial of patients with ALS. On September 29, 2022, the U.S. Food and Drug Administration, or FDA, approved AMX0035, known as RELYVRIO in the United States,
for the treatment of ALS in adults, and we are preparing for commercial launch of this product. AMX0035 received marketing authorization with conditions as ALBRIOZA by Health Canada for the treatment of ALS in June 2022, and we commenced Canadian
commercial sales of ALBRIOZA in the third quarter of 2022. We submitted a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA in Europe in the first quarter of 2022, which was validated in the same quarter. The
results of our Phase 2 clinical trial of AMX0035, known as the CENTAUR trial, were published in September 2020 in the <I>New England Journal of Medicine</I> and in October 2020 in the <I>Journal of Muscle and Nerve</I> and demonstrated functional
and survival benefits for ALS patients. We believe AMX0035 has the potential to be a foundational therapy, meaning that it could be used alone or in conjunction with other therapies to change the treatment paradigm across a broad range of
neurodegenerative diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">AMX0035 is a dual <FONT STYLE="white-space:nowrap">UPR-Bax</FONT> apoptosis inhibitor composed of PB and TURSO (also
known as TUDCA). Through the resolution of the UPR and by inhibiting translocation of the Bax to the outer mitochondrial membrane, we have shown in multiple models that AMX0035 can keep neurons alive under a variety of different conditions and
stresses, including in in vitro models of neurodegeneration, endoplasmic reticulum stress, mitochondrial dysfunction, oxidative stress and disease-specific models of a variety of other conditions, as well as in vivo models of ALS, AD and multiple
sclerosis. We are pursuing ALS as our first indication as it is a disease of rapid and profound neurodegeneration, and we are focused on the development and potential commercialization of AMX0035 for ALS globally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have received marketing authorization with conditions by Health Canada for ALBRIOZA for the treatment of ALS. We announced commercial availability of
the product in July 2022. We have submitted to the national reimbursement authorities, CADTH and INESSS, to seek recommendation of reimbursement for ALBRIOZA by the Canadian provincial governments, and are actively working with private payers in
Canada to obtain reimbursement coverage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are also actively pursuing regulatory approvals of AMX0035 for the treatment of ALS Europe. Our MAA
also remains under review by the Committee for Medicinal Products for Human Use, or CHMP, of the EMA. The review process is proceeding as expected, with receipt of the Day 120 List of Questions following the CHMP meeting in June 2022. We intend to
continue to work with the EMA through its review process, and we expect a decision in the first half of 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2021, we initiated a
Phase 3 clinical trial of AMX0035 for the treatment of ALS, known as PHOENIX trial, at clinical trial sites in the United States and Europe. Enrollment in the PHOENIX trial was completed in March 2022 in the United States and remains ongoing in
Europe. We anticipate topline results from the PHOENIX trial in 2024. This trial is designed to provide further data evaluating the safety and efficacy of AMX0035 for the treatment of ALS to further support our global regulatory efforts. In July
2022, we announced a planned OLE for the PHOENIX trial. In March 2022, we announced the launch of an EAP in the United States that the FDA has authorized for people with ALS who meet eligibility criteria for participation. The United States EAP for
AMX0035 is running parallel with the PHOENIX trial. People living with ALS who are eligible for PHOENIX are not eligible for the United States EAP as the criteria for entry do not overlap. However, the EAP will be wound down alongside the commercial
launch of RELYVRIO in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA approval on September 29, 2022 of AMX0035 as RELYVRIO for the treatment of ALS in adults was
granted following the second virtual meeting of the FDA&#146;s Peripheral and Central Nervous System Drugs Advisory Committee, or the Advisory Committee, held on September 7, 2022. The Advisory Committee initially met on March 30, 2022 and voted 4
(yes) and 6 (no) on the question of whether the data from our randomized, controlled Phase 2 CENTAUR trial and OLE established a conclusion that AMX0035 is effective in the treatment of patients with ALS. At the second meeting of the Advisory
Committee, the Advisory Committee voted 7 (yes) to 2 (no) in response to the question of whether available evidence of effectiveness is sufficient to support approval of AMX0035 for the treatment of ALS, taking into account the unmet need in ALS,
the status of the ongoing PHOENIX trial and the seriousness of ALS. At this meeting and the previous Advisory Committee meeting, the FDA presented concerns regarding choices of statistical models for the prespecified primarily analysis and the
interpretability of the survival results. In both Advisory Committee meetings, we presented scientific arguments and analyses, together with experts in the field, which we believe sufficiently addressed these concerns. At the second meeting of the
Advisory Committee, we stated that if our PHOENIX trial is not successful then we will do what is right for patients, which includes voluntarily removing the product from the market. We will work in consultation with regulatory authorities when the
PHOENIX data are available. We could also be required by regulatory authorities to withdraw AMX0035 from the marketplace. As a result of the FDA&#146;s approval of AMX0035, we are preparing for a commercial launch of RELYVRIO in the United States.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are also developing AMX0035 for other neurodegenerative diseases by leveraging our deep knowledge of and relationships in the neurodegenerative
space. We believe the approach of a dual <FONT STYLE="white-space:nowrap">UPR-Bax</FONT> apoptosis inhibitor designed to help keep neurons alive could be clinically meaningful for the treatment of other neurodegenerative disease indications in
addition to ALS. Many common and rare neurodegenerative diseases are characterized by substantial neuronal cellular loss, including AD and Wolfram syndrome, as well as Parkinson&#146;s Disease, Huntington&#146;s Disease, Progressive Supranuclear
Palsy, Multi-System Atrophy, and others. We conducted a Phase 2 clinical trial in AD, known as the PEGASUS trial, to obtain safety data along with initial efficacy and biomarker data which could help us prioritize additional indications to pursue
with AMX0035. We believe the topline results from the PEGASUS trial, reported in November 2021, provide further biological knowledge about AMX0035 which will help inform future clinical development of AMX0035 for the treatment of AD and in other
potential indications. Based on these topline results, AMX0035 met the PEGASUS trial&#146;s primary endpoint of safety and tolerability. The <FONT STYLE="white-space:nowrap">6-month</FONT> trial was not powered to evaluate differences between groups
in efficacy outcomes and no differences were seen in a newly developed composite outcome of cognitive, functional, and imaging measures, or secondary efficacy endpoints of cognition, function, and imaging. In this trial, AMX0035 showed significant
effects on biomarkers including neurogranin, YKL-40 or Chitinase 3-like 1 (CHI3L1), and fatty acid binding protein 3 (FABP3). These results build on previously reported findings that AMX0035 exhibited significant effects on the tau protein, tau
phosphorylated at threonine 181, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">8-hydroxy-2&#146;&#151;deoxyguanosine,</FONT></FONT> or <FONT STYLE="white-space:nowrap">8-OHdG,</FONT> and the amyloid beta 42 to 40 <FONT
STYLE="white-space:nowrap">(amyloid-&szlig;1-42,</FONT> <FONT STYLE="white-space:nowrap">amyloid-&szlig;1-40)</FONT> ratio in cerebrospinal fluid. We will continue to evaluate these data and discuss the results of the PEGASUS trial with scientific
advisors as we consider potential next steps for the development of AMX0035 for the treatment of AD within our clinical development strategy. Based on preclinical evidence, we are continuing to evaluate plans to explore the use of AMX0035 in
patients with Wolfram syndrome. We intend to prioritize our development efforts around neurodegenerative diseases that result in substantial disability, and ultimately death, and where unmet medical needs are greatest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since our founding in 2013, our goal has been to improve the quality of, and extend, life for patients suffering from neurodegenerative diseases. One of
our key strategies towards achieving this goal has been to form direct relationships with patients, their families, advocacy groups, and healthcare professionals to bring much needed innovation to patients. Throughout the development of AMX0035, we
have partnered with members of the disease communities we serve, including the ALS Association, the Northeast ALS Consortium, or NEALS, ALS Finding a Cure, the Healey Center at Massachusetts General Hospital, the Cure Alzheimer&#146;s Fund, the
Alzheimer&#146;s Association and the Alzheimer&#146;s Drug </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Discovery Foundation, to ensure our goals are aligned with patient needs. In addition, many of the key opinion leaders in the ALS community were and are investigators in our recent and ongoing
trials. These relationships are a cornerstone of our culture and corporate strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our current pipeline, including the stage of development and
approvals of AMX0035 in our target indications, is represented in the table below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383770g05v33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">AMX0035 is a proprietary oral fixed-dose combination of two small molecules: PB, which is a small molecular chaperone
that reduces the UPR, preventing cell death resulting from the UPR, and TURSO, (also known as TUDCA), which is a Bax inhibitor that reduces cell death through apoptosis. While the PB and TURSO molecules individually are not proprietary to us, we own
patents and patent applications covering AMX0035, including the fixed-dose combination of AMX0035 itself. We believe that our proprietary combination of these two molecules will allow us to target abnormal cell death to better prevent
neurodegeneration than treatment with either mechanism of action alone. In <I>in vitro </I>studies, PB and TURSO were observed in combination to prevent nearly 100% of neuron death. However, PB and TURSO alone only prevented a moderate percentage of
neuron death in <I>in vitro</I> studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The results of our CENTAUR trial were published in September 2020 in the <I>New England Journal of
Medicine</I> and in October 2020 in the <I>Journal of Muscle and Nerve.</I> Trial results showed that patients receiving AMX0035 experienced statistically significant benefit in function, as measured by the
<FONT STYLE="white-space:nowrap">ALSFRS-R,</FONT> as well as nominally significant improvement in overall survival, or OS, when analyzing the full randomized population through the OLE trial in a post hoc analysis (July 20, 2020 and March 1, 2021
data cutoffs). The data were further evaluated in the following post hoc analyses providing consistent support for an observed survival benefit: a new analysis utilizing a statistical method to adjust for the effect of treatment crossover; a new
analysis comparing observed survival in the CENTAUR trial to predicted survival using the European Network for the Cure of ALS survival prediction model derived from an ALS natural history database; and a new analysis comparing observed survival
from the CENTAUR treatment group to survival of matched treatment nalve participants from historical clinical trials of ALS. AMX0035 was shown to be generally well-tolerated with the prevalence of adverse events comparable across placebo and
treatment groups. We believe AMX0035 is the first drug candidate in ALS to demonstrate a statistically significant benefit in function as measured by a prespecified mean rate change in <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> and a nominally
significant benefit in a longer-term post hoc analysis of OS, which are both important outcomes for people with ALS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Company and Team </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Amylyx was founded with the ambitious goal of improving the quality and length of life for patients suffering from neurodegenerative diseases. From a
dorm room at Brown University in 2013, our <FONT STYLE="white-space:nowrap">Co-CEOs</FONT> and <FONT STYLE="white-space:nowrap">Co-Founders,</FONT> Josh Cohen and Justin Klee set out to determine why neurons die, and have ever since been working to
develop AMX0035, which we believe is the first drug candidate to show function and survival benefits in patients with ALS, and other novel therapies. To help realize our goal, we have assembled a team with deep scientific, clinical, business and
leadership experience, bolstered by expertise in biotechnology. Our Chief Financial Officer, James Frates, brings over 20 years of experience as the Chief Financial Officer of Alkermes. Our Chief Commercial Officer, Margaret Olinger, brings three
decades of expertise in commercial launches and operations, most recently at Alexion. Our Chief Technical Operations Officer, Tom Holmes, brings more than 25 years of leadership experience at Biogen in supply chain, pharmaceutical manufacturing and
program management. Our Global Head of Clinical Research&nbsp;&amp; Development and Chief Medical Officer, Patrick D. Yeramian, brings over 30 years of medical and pharmaceutical industry experience. Our Head of Regulatory Affairs, Tammy Sarnelli,
brings more than 30 years of experience from Biogen and other companies in early and late-stage neurology and rare disease development. Our Global Head of Human Resources, Debra Canner, brings over 20 years of experience, having served as the Chief
of Human Resources Officer at Akamai and as part of Genzyme. Our Chief Legal Officer and General Counsel, Gina M. Mazzariello, brings more than 20 years of corporate and commercial legal experience in the healthcare industry, including holding
leadership positions at Boehringer Ingelheim USA, Inc. This team brings a diverse set of skills uniquely suited to drive successful commercialization of AMX0035 in ALS while continuing to advance AMX0035 in other indications. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our mission is to one day end the suffering
caused by neurodegenerative diseases. Key elements of our strategy to achieve this mission include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Effectively and efficiently commercializing RELYVRIO for ALS in adults in the United States and ALBRIOZA for ALS in
Canada.</I></B> We received FDA approval in the United States for AMX0035 as RELYVRIO for the treatment of ALS in adults in September 2022. We received marketing authorization with conditions in Canada for ALBRIOZA for the treatment of ALS in June
2022 and launched ALBRIOZA commercially in Canada in July 2022. We believe our commercial capabilities, coupled with our understanding of the ALS patient and medical community, will enable us to successfully commercialize RELYVRIO for ALS in the
United States and ALBRIOZA for ALS in Canada and to launch AMX0035 for the treatment of ALS successfully in other key territories, if approved. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Obtaining additional regulatory approvals of AMX0035 for ALS, with an initial focus on Europe.</I></B> In June 2022,
AMX0035 received marketing authorization with conditions as ALBRIOZA in Canada for the treatment of ALS and in September 2022, AMX0035 received approval in the United States as RELYVRIO for the treatment of ALS in adults. Based on the results from
our CENTAUR trial, we have been exploring pathways towards regulatory approval in several additional territories, including Europe. We believe that the CENTAUR trial may be also able to support marketing authorization in Europe and other
jurisdictions. We submitted an MAA in Europe in the first quarter of 2022, and we expect a decision by in the first half of 2023. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Effectively and efficiently commercializing AMX0035 in other key territories, if approved</I></B>. We are continuing
to build our sales team, internal capabilities and outside vendor network to support commercialization in the United States and Canada. We will continue to build our capabilities in Europe and other jurisdictions to support commercialization, if
approved. We </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
anticipate that our commercial infrastructure will be scalable for subsequent launches in other key markets if we receive marketing approval in these territories as well. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Maximizing the therapeutic potential of AMX0035 by expanding into additional neurodegenerative diseases.</I></B> We
believe the data from the CENTAUR trial showing a functional and survival benefit for ALS patients treated with AMX0035 support its potential mechanism of targeting endoplasmic reticulum, or ER, stress and mitochondrial dysfunction. Based on our
extensive understanding of disease pathways, we believe AMX0035 may provide benefit across multiple diseases characterized by neurodegeneration. As we select the next indications for AMX0035 we will prioritize those indications which we believe, if
successful, will most rapidly lead to marketed products and to patient benefit. We conducted our Phase 2 PEGASUS clinical trial in AD to obtain safety data along with initial efficacy and biomarker data which will help us evaluate the development of
AMX0035 for the treatment of AD within our clinical development strategy. We are also continuing to evaluate plans to explore the use of AMX0035 in patients with Wolfram syndrome. We are also planning to submit an IND for two additional indications
in 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Continuing to cultivate a network of patient advocacy groups, key opinion leaders, research institutions, and
healthcare professionals to inform our patient-centric approach.</I></B> We have cultivated a network of key constituents, which we believe will continue to help us to develop therapies in an efficient and impactful manner. Integrating the
experiences and insights from these parties, which include patients, their families, and organizations such as the ALS Association, NEALS, ALS Finding a Cure, the Healey Center at Massachusetts General Hospital, the Cure Alzheimer&#146;s Fund, the
Alzheimer&#146;s Association and the Alzheimer&#146;s Drug Discovery Foundation, continues to inform our approach to developing therapies that can potentially transform the lives of patients and their families. We intend to continue to engage with
each of these constituents through conferences, clinical trials and informal communications as we further develop and pursue commercialization of AMX0035. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Deploying a strategic approach to design, acquire and develop new therapies. </I></B>We follow a scientifically
rigorous approach to evaluating new opportunities to broaden our portfolio. We plan to target assets that allow us to leverage our experience with neurodegenerative pathways and AMX0035&#146;s mechanism of action, focusing primarily on preventing
neuron death. When evaluating assets, we consider not only our ability to apply our experience with AMX0035 but also a variety of factors, including unmet medical need, biological rationale, feasibility of clinical development, potential for
regulatory approval, costs of development, competitive landscape and commercial potential. For example, in July 2022, we announced that we entered into a <FONT STYLE="white-space:nowrap">two-year</FONT> sponsored research agreement with Sunnybrook
Research Institute to expedite the identification of novel drug candidates that inhibit Bax and Bak for the development of therapeutics for neurodegenerative diseases, specifically ALS. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Neurodegenerative Disease </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The prevention of
neurodegeneration represents one of today&#146;s most significant unmet medical needs. The development of therapies that preserve neuron health has historically presented unique challenges, including an imperfect understanding of underlying biology
and a lack of translation of activity observed in preclinical studies to results in clinical trials. Currently approved therapies for many neurodegenerative diseases are generally only symptom modifying and have demonstrated limited efficacy. There
remains an urgent need for novel approaches to address most neurodegenerative diseases, especially for progressive and severe conditions such as ALS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The Role of the Endoplasmic Reticulum and Mitochondria in Neurodegenerative Disease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unlike most other cells in the body that regularly die and are replaced as part of healthy function, mature neurons are normally resistant to cell death
and generally cannot regenerate. Neuron death is only triggered when multiple stress factors are activated beyond the neuron&#146;s recovery capacity, a circumstance commonly seen in neurodegenerative disorders. Most neurodegenerative disorders have
complex pathophysiology, with multiple pathways contributing and converging to eventually cause neuron death. A large fraction of these pathological changes in neurons can be linked to dysfunction in the ER and mitochondria that affect metabolism
and secretion of lipids and proteins, calcium homeostasis, and energy production. Dysfunction in these two essential cellular structures is implicated across many neurodegenerative disorders, highlighting the central role they play in maintaining
neuron health and survival and providing the rationale for our focus, which is to rescue ER and mitochondrial function, and to protect and preserve neurons. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>ER Stress </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The ER is responsible for protein and lipid
synthesis, folding and quality control of proteins, and storing calcium for cellular energy production by the mitochondria. The ER is also a primary sensor of stressful intracellular conditions, activating a wide number of molecular pathways that
belong to a specific process, referred to as the ER stress response, that controls protein homeostasis. ER stress, or dysfunction associated with protein misfolding and aggregation, has been implicated in the pathogenesis of neurodegenerative
disease. In neurodegenerative disorders, misfolded proteins and accumulations of protein aggregates can cause oxidative stress and a feedback loop resulting in ER stress. When the ER stress response is activated due to misfolded and aggregated
proteins, the UPR, is engaged as a regulatory mechanism to reduce the load of misfolded proteins and restore a healthy cellular state. Molecular chaperones are the critical regulators of protein homeostasis under ER stress. Pathological conditions
such as neurodegenerative diseases that disturb protein folding and maturation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
can trigger ER stress and engage the UPR. When the natural protein homeostasis in the cell cannot be achieved, the UPR triggers cellular death, or apoptosis, as illustrated in the graphic below.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>The Role of the ER in Neurodegenerative Disease </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383770g22z92.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Mitochondrial Dysfunction </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The mitochondria are a central regulatory point for the control of cell death. When mitochondria detect sufficient cell damage, they signal for the cell
to initiate a cell death cascade. Among other steps, this cascade includes the recruitment of a series of apoptotic proteins including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Bcl-2-associated</FONT></FONT> X protein, or
BAX, the release of cytochrome c from a pore in the mitochondrial membrane called the mitochondrial permeability transition pore, and finally the activation of caspase 3, an executioner protein for apoptosis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In neurodegenerative diseases, triggers such as altered calcium homeostasis, glutamate excitation of the cell, damage to the mitochondria or
mitochondrial DNA and detection of aberrant double-stranded DNA and accumulation of unfolded proteins at the mitochondria all lead to mitochondrially mediated cell death. Inhibition of proteins such as BAX could result in a greater threshold for
cell death and longer survival of key neurons implicated in the progression of neurodegenerative disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Linkage Between Mitochondria and ER </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The mitochondria and the ER are often physically linked by a membrane called the mitochondrial associated ER membrane, or MAM. Through this linkage,
calcium and molecules are shuttled between the two organelles. It is our belief that this connection, or crosstalk, allows the cell to integrate responses between the two organelles and that activation of mitochondrial damage pathways will activate
the UPR and <I>vice versa</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Both the mitochondria and the UPR in the ER can trigger cell death. As such, we believe both pathways
are crucial to the pathogenesis of neurodegenerative diseases and both need to be addressed simultaneously to effect a substantial change in survival of neurons undergoing neurodegenerative processes. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>The Role of the ER and Mitochondria in Neuron Death </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383770g36n42.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The figure above depicts events of ER stress and mitochondrial dysfunction associated with eventual cell injury and
death. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Background and Rationale for AMX0035 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We
have designed AMX0035 to reduce neuron death through simultaneous mitigation of ER stress and mitochondrial dysfunction. AMX0035 is a coformulation of two small molecules, PB and TURSO. PB has been shown to reduce ER stress through upregulation of a
protein known as <FONT STYLE="white-space:nowrap">DJ-1</FONT> that is a master chaperone regulator, recruitment of other chaperone proteins, and as a small molecular chaperone. TURSO is a bile acid that has been shown to recover mitochondrial
bioenergetic deficits through incorporation into the mitochondrial membrane, reducing BAX translocation to the mitochondrial membrane, reducing mitochondrial permeability, and increasing the apoptotic threshold of the cell. Through our research, we
identified the specific ratios at which the combination of PB and TURSO target these critical, connected pathways and show synergistic activity in improving neuronal cell viability <I>in</I> <I>vitro</I>. We then developed AMX0035 as an optimized
oral formulation to be tested <I>in vivo</I> and clinically. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our preclinical studies have shown that PB and TURSO, in combination, can inhibit a
number of pathological pathways associated with neurodegenerative diseases in cell culture and animal models. For example, in an <I>in vitro </I>model of neurodegeneration, we tested the potential abilities of PB and TURSO individually and in
combination to prevent oxidative-induced neuronal death, or cell viability, which was measured using a PrestoBlue reagent. In this experiment, hydrogen peroxide was applied to rat primary cortical neurons in a concentration sufficient to kill
approximately 40% of the neurons. Particular doses of PB and TURSO individually protected against some of the neuron death, and cell viability reached approximately 80%. However, when these rat primary cortical neurons were dosed
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
with particular ratios of PB and TURSO in combination, nearly 100% of oxidative-induced neuron death was prevented. The results of this <I>in vitro</I> model are shown in the graphic below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383770g80r72.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, we have observed benefit from the administration of particular ratios of PB and TURSO across <I>in
vitro </I>models of ER stress, mitochondrial dysfunction, oxidative stress, and disease specific models of ALS, AD, Parkinson&#146;s disease, multiple sclerosis, or MS, Friedreich&#146;s Ataxia, primary mitochondrial myopathies and a variety of
other conditions. We have also conducted <I>in vivo </I>models of PB and TURSO, in combination, including models of ALS, AD and MS. Additionally, academic groups have conducted studies with monotherapy treatment with TURSO and/or PB in models of
ALS, AD, MS, Parkinson&#146;s Disease, Huntington&#146;s Disease, Progressive Supranuclear Palsy, Multi-System Atrophy, <FONT STYLE="white-space:nowrap">X-linked</FONT> adrenoleukodystrophy, and a variety of other models. We believe this body of
evidence collectively supports the use of this combination to treat neurodegenerative indications and led us to pursue the development of our proprietary drug candidate, AMX0035. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>AMX0035 for the Treatment of ALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Overview of ALS </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are initially developing AMX0035 for the treatment of ALS, an adult-onset, progressive, and fatal neurodegenerative disorder of the neuromuscular
system resulting in muscle weakness and paralysis leading to death. ALS involves the progressive degeneration of motor neurons in the spinal cord and brain that are responsible for controlling voluntary muscle movement. This progressive loss of
motor neurons leads to muscle weakness, loss of muscle mass, and inability to control movement. ALS remains universally fatal with a median survival of less than three years from symptom onset and less than two years from diagnosis. Despite being
classified as a rare disease by the FDA and the EMA, ALS is considered one of the more common adult-onset neuromuscular diseases worldwide. We estimate based on public sources that there are approximately 29,000 ALS patients in the United States.
More than 30,000 ALS patients are estimated to be located in the EU and the United Kingdom and about 3,000 ALS patients are located in Canada. Over 90% of patients have no family history of ALS, known as &#147;sporadic&#148; ALS. While other
development approaches seek to address genetic instances of ALS, AMX0035 is designed to target all instances of ALS, regardless of whether it is sporadic or genetic. Due to the <FONT STYLE="white-space:nowrap">two-year</FONT> median survival of
patients diagnosed with ALS, a high proportion of the patient population has been recently diagnosed and a therapy that is able to improve the survival of patients with ALS has the potential to increase the number of patients who are able to
continue living with their disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Medical costs for patients newly diagnosed with ALS in the United States are substantial and increase
rapidly with each disability milestone. Care of patients with ALS is intensive and requires a team of medical professionals, special equipment, and assistance with daily activities. Caregivers are often forced to miss work or give up employment
opportunities to provide care, leading to increased financial strain. The disease also impacts the patient&#146;s family, who generally provide the bulk of caregiving, which often entails the provision of
<FONT STYLE="white-space:nowrap">24-hour</FONT> care. The constant adaptation of caregivers to the demands of the ALS disease progression requires significant physical effort and mental exhaustion particularly during the advanced stages of the
disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Significant Unmet Need in ALS </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">ALS is a
heterogeneous disease that arises from multiple mechanistic underpinnings, leading patients to experience variable onset and delayed diagnosis, persistent progression and loss of muscle function, and shortened survival. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There is a significant unmet need for ALS therapies that target multiple pathogenic pathways, are disease-modifying, and can provide both functional and
survival benefit to patients. Only two <FONT STYLE="white-space:nowrap">FDA-approved</FONT> therapeutic agents for ALS, riluzole, an anti-glutamatergic agent, and edaravone, a free-radical scavenger, have been shown to modulate the course of ALS. In
pivotal clinical trials, riluzole demonstrated longer time to tracheostomy or death compared to placebo and edaravone demonstrated longer retention of function compared to placebo. However, a need remains for ALS therapies that demonstrate both
retention of function and longer survival, allowing patients to maintain greater independence for longer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Due to the multi-pathway pathophysiology
of ALS, experts agree that successful treatment will likely require concurrent targeting of multiple key neuronal death pathways. There is a strong rationale for treatments that target identified convergence points of these critical pathways,
including in the ER and mitochondria, and we believe that a therapy that targets multiple pathways at once, like AMX0035, aligns with the emerging ALS treatment paradigm. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Clinical Development of AMX0035 for ALS </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We designed
our Phase 2 CENTAUR trial with input from leading ALS experts from NEALS to detect a significant difference between AMX0035 and placebo. The study also provided the option for participants to continue with available approved therapies, riluzole and
edaravone, for the duration of the trial. The FDA granted Orphan Drug Designation for AMX0035 for the treatment of patients with ALS in September 2017. The EMA granted orphan designation to AMX0035 for the treatment of patients with ALS in April
2020. In December 2019, we announced positive topline results from our CENTAUR trial. The trial met its primary endpoint, and we published detailed trial data in the <I>New England Journal of</I> <I>Medicine </I>in September 2020 and in the
<I>Journal of Muscle and Nerve</I> in October 2020. We submitted an NDS in Canada in the second quarter of 2021, an NDA in the United States in the fourth quarter of 2021 and an MAA in Europe in the first quarter of 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In June 2022, AMX0035 received marketing authorization with conditions as ALBRIOZA by Health Canada for the treatment of ALS. In September 2022, AMX0035
received approval by the FDA for the treatment of ALS in adults following the second virtual meeting of the FDA&#146;s Advisory Committee held on September 7, 2022. The Advisory Committee initially met on March 30, 2022 and voted 4 (yes) and 6 (no)
on the question of whether the data from our randomized, controlled Phase 2 CENTAUR trial and OLE established a conclusion that AMX0035 is effective in the treatment of patients with ALS. At the second meeting of the Advisory Committee, the Advisory
Committee voted 7 (yes) to 2 (no) in response to the question of whether available evidence of effectiveness is sufficient to support approval of AMX0035 for the treatment of ALS, taking into account the unmet need in ALS, the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
status of the ongoing PHOENIX trial and the seriousness of ALS. At this meeting and the previous Advisory Committee meeting, the FDA presented concerns regarding choices of statistical models for
the prespecified primarily analysis and the interpretability of the survival results. In both Advisory Committee meetings, we presented scientific arguments and analyses, together with experts in the field, which we believe sufficiently addressed
these concerns. In describing its basis for approval, the FDA acknowledged this scientific debate but concluded that the data met the substantial evidence standard, noting the limitations of exploratory and post hoc analyses. As a result of the
FDA&#146;s approval of AMX0035, we are preparing for a commercial launch of RELYVRIO in the United States. In Europe, our MAA also remains under review by CHMP. The review process is proceeding as expected, and we have received and responded to the
Day 120 List of Questions following the June CHMP meeting. We intend to continue to work with EMA through its review process, and we expect a decision in the first half of 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>CENTAUR, Our Phase 2 Trial of AMX0035 in ALS </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In September
2020, we published detailed results from the Phase 2, randomized, double-blind, placebo-controlled CENTAUR trial. The CENTAUR trial was conducted at 25 centers of the NEALS, and evaluated adult patients with ALS. Key inclusion criteria were definite
ALS defined by the revised El Escorial criteria, which entails having various clinical signs and symptoms, defined as upper and lower motor neuron signs, in at least three defined body regions, less than 18 months from symptom onset and slow vital
capacity, or SVC, greater than 60%. These criteria were chosen to select a homogenous, rapidly progressing patient population to potentially increase the likelihood of observing a treatment effect. Participants were allowed to continue on their
selected standard of care, including treatment with riluzole and/or edaravone. Eligible participants (n=137) were randomized <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">two-to-one</FONT></FONT> to treatment with AMX0035, one
sachet (each containing one gram of TURSO and three grams of PB) given once daily for the first three weeks, and if tolerated, the dose was then increased to twice-daily for the remainder of a 24 week treatment period, or matching placebo. Two
participants did not have <FONT STYLE="white-space:nowrap">follow-up</FONT> efficacy assessments and were not included in the efficacy population (modified intention to treat, or mITT, n=135). These two participants were included in the safety
population (intention to treat, or ITT, n=137). Upon completion of the <FONT STYLE="white-space:nowrap">24-week,</FONT> parallel group phase of the trial, participants were eligible to enroll in the OLE trial in which all participants were followed
up to 35 months while participants and physicians remained blinded to the original treatment group. Of participants completing the CENTAUR trial randomization phase, 92% elected to enroll in the OLE. The first
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
protocol of the OLE was completed in March 2021. Actual duration of patient treatments across the randomization phase and the OLE, both with the <FONT STYLE="white-space:nowrap">PB-TURSO</FONT>
combination and via placebo, are shown in the graphic below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383770g23s23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The primary efficacy outcome measure for the CENTAUR trial was the rate of decline in the <FONT
STYLE="white-space:nowrap">ALSFRS-R</FONT> total score. The <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> scale is the most widely used ALS rating scale in ALS clinical practice and in ALS clinical trials. It measures patient&#146;s functional
ability and is broken down into four domains: bulbar (which includes speech, salivation and swallowing), fine motor (which includes handwriting, cutting food/handling utensils, dressing and hygiene), gross motor (which includes turning in bed,
walking, and climbing stairs) and breathing (which includes dyspnea, orthopnea and respiratory insufficiency). A decrease of one point on the <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> scale can reflect severe limitations in a patient&#146;s
independence, and a <FONT STYLE="white-space:nowrap">two-point</FONT> increase on the <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> scale would be associated with: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">eating successfully with some difficulty instead of needing a feeding tube; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">being short of breath only while walking instead of having difficulty breathing while sitting or lying down; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">being able to dress independently instead of needing assistance. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The CENTAUR trial met its primary endpoint with a statistically significant reduction in clinical decline among participants randomized to AMX0035
(n=87) compared to placebo (n=48) <FONT STYLE="white-space:nowrap">(p-value</FONT> of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
0.03) over 24 weeks. These results showed that patients receiving AMX0035 scored an average of 2.32 points higher on the <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> as compared to patients
receiving placebo after 24 weeks, a difference of 25%, as shown in the graph below. In a survey of ALS clinicians and researchers conducted and sponsored by NEALS, with the objective of determining what percentage reduction in <FONT
STYLE="white-space:nowrap">ALSFRS-R</FONT> would be considered clinically meaningful, a difference of greater than or equal to 20% in <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> total score was considered clinically meaningful by a majority of
clinicians and researchers surveyed. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383770g13a00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Secondary efficacy outcomes measuring disease free progression were the decline in muscle strength as measured by
Accurate Test of Limb Isometric Strength, or ATLIS, testing and lung function measured by SVC, both expressed as percent of predicted values and key study events including death, permanent ventilation and hospitalization. Neurofilament was also
measured as a biologic measure. The analysis also indicated statistically significant preservation of upper limb strength with AMX0035 treatment measured on ATLIS (p=0.042), while the lower limb measure did not reach statistical significance
(p=0.34). An average of these two, referred to as the total ATLIS score, trended in favor of AMX0035 (p=0.11). There was also a trend in favor of AMX0035 therapy preserving lung function as measured by SVC, with a numerical difference of 5.11%
although this was not statistically significant (p=0.076). These efficacy data are summarized in the table below. In addition, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-event</FONT></FONT> analysis was conducted on
key study events including death, permanent ventilation and hospitalization events over the <FONT STYLE="white-space:nowrap">24-week</FONT> randomized phase of the trial. Because enrollment of patients in the CENTAUR trial was limited to patients
who, in the investigator&#146;s opinion, would be able to complete <FONT STYLE="white-space:nowrap">6-month</FONT> follow up, few events of this nature were expected during the initial, <FONT STYLE="white-space:nowrap">24-week</FONT> randomized
phase of the trial. As a result, we observed a positive, but not statistically significant, difference between the trial&#146;s treatment and control groups during the <FONT STYLE="white-space:nowrap">24-week</FONT> randomized phase of the study.
There was no statistically significant difference between the rate of decline in plasma levels </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
of the neurofilament observed in the trial&#146;s treatment and control groups during the <FONT STYLE="white-space:nowrap">24-week</FONT> randomized phase of the study. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383770g96o04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Phosphorylated neurofilament heavy chain was measured in plasma in the CENTAUR trial. There were no statistically
significant differences between groups in this outcome. A limitation of this outcome is that it was measured in plasma rather than cerebrospinal fluid and the ultimate relevance of this outcome in ALS is still under investigation by the field. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">It is important to note that most (77%) participants were receiving riluzole or edaravone at or before study entry, with a greater proportion receiving
edaravone in the placebo group (50%) compared with the AMX0035 group (25%). <FONT STYLE="white-space:nowrap">Pre-specified</FONT> analyses were conducted to determine if the use of concomitant medications impacted results. These analyses found that
AMX0035&#146;s effect on the primary outcome was consistent regardless of baseline use of concomitant medications (riluzole and/or edaravone). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">OS
was analyzed for all subjects randomized in the CENTAUR trial (ITT analysis) and compared patients originally randomized to AMX0035 (n=89) with those randomized to placebo (n=48). In this post hoc analysis, the vital status of each participant was
measured by a participant locating service which used sources such as the U.S. social security death index up to July&nbsp;20, 2020 even if he or she did not continue into the OLE, stopped study drug, dropped out of the study or was lost to <FONT
STYLE="white-space:nowrap">follow-up.</FONT> Over the duration of follow up, the risk of death was 44% lower among those originally randomized to AMX0035 compared with those originally randomized to placebo (hazard ratio, or HR, of 0.56; a 95%
confidence interval, or CI, ranging from 0.34 to 0.92; and a <FONT STYLE="white-space:nowrap">p-value</FONT> of 0.023). Median survival duration was 25.0 months (95% CI of 19.0 to 33.6 months) in the group previously randomized to AMX0035 and 18.5
months (95% CI of 13.5 to 23.2 months) in the group previously randomized to placebo as seen in the graph below. As reflected in the data tables below, participants originally randomized to AMX0035 showed a longer median survival of 6.5 months (data
cutoff July 20, 2020) and 4.8 months (data cutoff March 1, 2021) than those originally randomized to placebo. The FDA considers that the survival data available for RELYVRIO are exploratory and should be interpreted cautiously given the limitations
of data collected outside of a controlled study. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Post Hoc Survival Analysis (July 20, 2020 Data Cutoff) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383770g11d11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Post Hoc Survival Analysis (March 1, 2021 Data Cutoff) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383770g39d73.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We also conducted three additional post hoc analyses of AMX0035 survival data which we provided as
confirmatory evidence of our findings in the CENTAUR trial and which were provided to the FDA in support of our marketing application for AMX0035. These analyses consisted of the following: a new analysis utilizing a statistical method to adjust for
the effect of treatment crossover; a new analysis comparing observed survival in the CENTAUR trial to predicted survival using the European Network for the Cure of ALS survival prediction model derived from an ALS natural history database; and a new
analysis comparing observed survival from the CENTAUR treatment group to survival of matched treatment nalve participants from historical clinical trials of ALS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We also performed sensitivity analyses on the CENTAUR trial data, including a joint rank test, which showed no bias in the estimate of the primary
functional outcome by loss of data due to participant death. Sensitivity analyses were also performed to account for missing data and death or death-equivalent events. These sensitivity analyses yielded results similar to the primary analysis. In
sensitivity analyses designed to account for concomitant medication use, the treatment effect size was consistent between primary analysis and analyses corrected for concomitant medication use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">AMX0035 was generally well-tolerated with an adverse event rate substantially similar to placebo. Adverse events, or AEs, were reported in 97% (86 out
of 89) of participants receiving AMX0035 and 96% (46 out of 48) of participants receiving placebo, with the nature of the AEs being substantially similar in both groups. The most commonly occurring (greater than or equal to 5%) AEs in either
treatment group are shown in the table below. Because of the progressive neurodegenerative nature of ALS, many of these AEs (<I>e.g.</I>, muscle weakness, falls, dyspnea, fatigue) were likely attributable to the underlying ALS disease. Events
occurring in greater than or equal to 5% of patients in either treatment group and more frequently (greater than or equal to 2% of patients) in patients who received AMX0035 compared with those who received placebo were predominantly
gastrointestinal events, which were <FONT STYLE="white-space:nowrap">non-serious</FONT> and mostly mild in intensity and declined considerably in occurrence after three weeks on treatment. A total of 19% of the patients in the AMX0035 treatment
group and 8% of the patients in the placebo group discontinued their participation in the trial due to AEs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The most commonly occurring AEs were
diarrhea, abdominal pain, nausea, upper respiratory tract infection, constipation, muscular weakness, fall, headache, dizziness and viral upper respiratory tract infection. Health Canada also noted the occurrence of hypersalivation. Consistent with
the known safety profile of TURSO, diarrhea and nausea occurred more frequently in patients who received AMX0035 compared with those who received placebo. In contrast, muscular weakness, fall, constipation and headache occurred more frequently in
patients who received placebo. The observed AEs from the CENTAUR trial are summarized in the chart below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="12" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Adverse Events (AEs)<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP> Occurring in </B><FONT STYLE="font-family:Times New Roman">&#8805;</FONT><B></B><B>5% of Patients in either Treatment Group<BR>(Safety Population, n=137)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>MedDRA System Organ Class</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Preferred Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Placebo&nbsp;+&nbsp;SOC<BR>(n=48)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AMX0035&nbsp;+&nbsp;SOC<BR>(n=89)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Overall<BR>(n=137)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gastrointestinal disorders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29&nbsp;(60.4%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60&nbsp;(67.4%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89&nbsp;(65.0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Musculoskeletal and connective tissue disorders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21 (43.8%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38 (42.7%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59 (43.1%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Injury, poisoning and procedural complications</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23 (47.9%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35 (39.3%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58 (42.3%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Nervous system disorders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19 (39.6%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33 (37.1%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52 (38.0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Infections and infestations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21 (43.8%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28 (31.5%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49 (35.8%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Respiratory, thoracic and mediastinal disorders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10 (20.8%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29 (32.6%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39 (28.5%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Investigations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10 (20.8%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26 (29.2%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36 (26.3%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General disorders and administration site conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13 (27.1%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20 (22.5%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33 (24.1%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Skin and subcutaneous tissue disorders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8 (16.7%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16 (18.0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24 (17.5%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Psychiatric disorders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9 (18.8%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14 (15.7%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23 (16.8%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Renal and urinary disorders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8 (16.7%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10 (11.2%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18 (13.1%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Metabolism and nutrition disorders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4 (8.3%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10 (11.2%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14 (10.2%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cardiac disorders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0 (0.0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7 (7.9%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7 (5.1%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Eye disorders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 (2.1%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5 (5.6%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6 (4.4%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Includes serious adverse events. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">SAEs occurred less frequently in the AMX0035 treatment group (12.4% of patients) compared with the
placebo treatment group (18.8% of patients). This difference was largely driven by a higher incidence of respiratory events, including respiratory failure in the placebo treatment group (8.3% of patients), compared with the AMX0035 treatment group
(3.4% of patients). ALS disease progression often leads to respiratory failure, and it is the most common cause of death in patients with ALS. The observed SAEs from the CENTAUR trial are summarized in the chart below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Serious Adverse Events (SAEs) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383770g31v63.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Overall, a total of seven patients (two (4% of patients) who received placebo and five (6% of total patients) who
received AMX0035) died during the conduct of the <FONT STYLE="white-space:nowrap">24-week,</FONT> double-blind study. None of the deaths was considered by the investigator to be related to AMX0035. Consistent with the most common cause of death in
patients with ALS, the majority (four of seven patients) of deaths during the study were from respiratory failure (two patients in each group). Other causes of death (in the AMX0035 group) included post-extubational supraglottic and infraglottic
aspiration (attributed to aspiration pneumonia), diverticulitis, and subdural hematoma secondary to a fall. Death equivalent was defined as either tracheostomy or permanent assisted ventilation, or PAV. PAV was defined as more than 22 hours daily of
<FONT STYLE="white-space:nowrap">non-invasive</FONT> mechanical ventilation for more than one week (seven days). One patient in the placebo group (2% of patients) and none in the AMX0035 group experienced a death equivalent event (i.e.,
tracheostomy) during the <FONT STYLE="white-space:nowrap">24-week</FONT> study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe AMX0035 is the first drug candidate in ALS to
demonstrate a statistically significant benefit both in function as measured by a prespecified mean rate change in <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> and in a longer-term analysis of OS, both important outcomes for people with ALS. In
summary, patients in our CENTAUR trial showed a statistically significant improvement in function and a statistically significant improvement in overall survival and AMX0035 was shown to be generally well-tolerated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Clinical Development Plan of AMX0035 in ALS </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We submitted an
NDA to the FDA in the fourth quarter of 2021 and, on September 29, 2022, the FDA approved AMX0035 as RELYVRIO for the treatment of ALS in adults. We submitted an NDS for AMX0035 for the treatment of ALS to Health Canada in the second quarter of
2021, and in June 2022, AMX0035 received marketing authorization with conditions as ALBRIOZA in Canada. We also submitted an MAA for approval of AMX0035 for the treatment of ALS to the EMA CHMP in the first quarter of 2022, and we expect a decision
in the first half of 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2021, we initiated our global <FONT STYLE="white-space:nowrap">48-week</FONT> PHOENIX, randomized,
double-blind, placebo-controlled trial at clinical sites in the United States and Europe. Enrollment in this trial was </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
completed in March 2022 in the United States and remains ongoing in Europe. We anticipate topline results from the PHOENIX trial in 2024. The primary endpoints in our PHOENIX trial will be a
composite measure of survival and <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> total score progression over 48 weeks and safety and tolerability over 48 weeks. The secondary endpoints of our PHOENIX trial will be SVC, <FONT
STYLE="white-space:nowrap">ALSAQ-40</FONT> (a questionnaire which provides a subjective health measure to specifically assess quality of life for patients with ALS), <FONT STYLE="white-space:nowrap">EQ5D-5L</FONT> (a standard qualify of life
measure), decline in King&#146;s (a staging measurement in ALS based on the number of central nervous system (CNS) regions involved and requirement for gastrostomy or noninvasive ventilation) and MiToS stages (a functional staging measure that can
be derived prospectively from the <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> subscore using standard methods), ventilation free survival, and long-term survival. Key inclusion criteria for the PHOENIX trial include ALS patients with clinically
definite or clinically probable ALS by El Escorial criteria <FONT STYLE="white-space:nowrap">(2-4</FONT> body areas with clinical signs consistent with ALS), &lt;24 months from symptom onset, SVC &gt;55%, and riluzole/edaravone use permitted. In
July 2022, we announced a planned OLE for the PHOENIX trial and in March 2022, we announced the launch of a United States EAP that the FDA authorized for people with ALS who meet certain eligibility criteria for participation. The EAP will be wound
down alongside the commercial launch of RELYVRIO in the United States. The PHOENIX trial is designed to provide further data evaluating the safety and efficacy of AMX0035 for the treatment of ALS to further support our global regulatory efforts.
Because marketing approvals we have obtained may be limited, subject to restrictions or post-approval requirements, we may need to provide post-marketing support in those jurisdictions. For example, as part of our approval for RELYVRIO in the United
States, we have post-marketing requirements to conduct carcinogenicity studies in mice and rats, drug-drug interaction studies, and studies in patients with kidney or liver impairment. In addition, one of the conditions of the marketing
authorization in Canada for AMX0035 (ALBRIOZA) for the treatment of ALS is the provision of data from our ongoing PHOENIX trial and other additional planned or ongoing studies. The outcomes of the PHOENIX trial and any potential withdrawal could
have a material effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any additional regulatory approvals we may receive may be limited or subject to restrictions or
postapproval commitments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>AMX0035 for the Treatment of Other Potential Indications </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on our extensive understanding of disease pathways, we believe AMX0035 may provide benefit across multiple diseases, including AD, Wolfram
syndrome, Parkinson&#146;s Disease, Huntington&#146;s Disease, Progressive Supranuclear Palsy, Multi-System Atrophy, primary lateral sclerosis, ischemic stroke, MS, Friedreich&#146;s ataxia, Leigh&#146;s syndrome and Leber&#146;s hereditary optic
neuropathy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are prioritizing these conditions on an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">indication-by-indication</FONT></FONT> basis, based on the strength of the data supporting AMX0035&#146;s potential, including the data from our recently completed PEGASUS trial; the
urgency of the unmet need; the practicality of conducting clinical trials in these conditions; the efficiency of clinical development activities; and the commercial potential. For some of these indications, given the data already produced by the
company on AMX0035, we believe it may be possible to move directly into Phase 3 evaluations of safety and efficacy which could allow for a rapid development pathway. We will prioritize those indications which we believe have the greatest chance of
providing patients with benefit and the most rapid pathway to market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We continue to evaluate plans to explore the use of AMX0035 in patients with
Wolfram syndrome. Additionally, we are also evaluating plans to submit potential additional INDs for AMX0035 in other indications in the 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Clinical Development of AMX0035 for AD </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We designed our multicenter, randomized, double-blind, placebo-controlled Phase 2 PEGASUS trial with AD experts to evaluate the safety, tolerability and
activity of AMX0035 in patients with late mild cognitive impairment, or MCI, or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">early-to-moderate</FONT></FONT> dementia. The PEGASUS trial was designed to have broad entry criteria
to include participants at different stages of AD to allow us to assess the biological effect of AMX0035 across the spectrum of disease and determine if there are any patients who might see a greater benefit from therapy. Eligible participants
(n=95), adults ages 55 to 89 years old, were randomized <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">three-to-two</FONT></FONT> to treatment with AMX0035, one sachet (each containing one gram of TURSO and three grams of PB)
given twice-daily over 24 weeks, or matching placebo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The primary investigator for the PEGASUS trial, Dr.&nbsp;Steven Arnold, presented topline
results from the PEGASUS trial at the Clinical Trials on Alzheimer&#146;s Disease conference, or CTAD, which was held during the fourth quarter of 2021. Based on these topline results, AMX0035 was generally well-tolerated with approximately 80% of
patients completing dosing in the trial in the AMX0035 arm. Safety results are depicted in the figure below. As in the CENTAUR trial, a higher percentage of patients in the AMX0035 arm had gastrointestinal adverse events. However, no SAEs were
attributed to AMX0035 in the PEGASUS trial. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383770g22b30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">6-month</FONT> trial was not powered to evaluate differences between the AMX0035
and placebo arms in cognition, function or imaging. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The primary endpoint of the trial was to compare the safety and tolerability of a fixed-dose
combination of AMX0035 versus placebo in subjects with MCI (high or intermediate likelihood due to AD) or dementia due to AD over a <FONT STYLE="white-space:nowrap">24-week</FONT> treatment period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The secondary endpoints of the trial were to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">determine the effects of AMX0035 treatment on whole brain and regional brain atrophy, as assessed by volumetric MRI;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">assess the impact of AMX0035 treatment on clinical symptoms as measured by the Alzheimer&#146;s Disease Assessment
Scale-Cognitive Subscale, or <FONT STYLE="white-space:nowrap">ADAS-Cog,</FONT> the Dementia Severity Rating Scale, or DSRS, and the FAQ; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">assess the effect of AMX0035 treatment on measures of neuropsychiatric symptoms, as assessed by the Neuropsychiatric
Inventory Questionnaire; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">measure the effects of AMX0035 treatment on functional MRI measures including connectivity with resting state Blood
Oxygenation Level Dependent imaging. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, the trial evaluated differences between the AMX0035 and placebo arms as
measured by GST, a newly developed composite outcome of cognitive, functional, and imaging </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
measures named the Global Statistical Test, or GST, over the <FONT STYLE="white-space:nowrap">24-week</FONT> treatment period. The GST is a combination of three change-from-baseline to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-study</FONT></FONT> endpoints: Cognition (Modified Alzheimer&#146;s Disease Composite Score, or MADCOMS), Function (Functional Activities Questionnaire, or FAQ) and Total Hippocampal
Brain Volume (Magnetic Resonance Imaging, or MRI). The GST is calculated for each subject as a mean score across the above three component endpoints for each subject in the trial. This mean score was then analyzed as an efficacy variable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Finally, the exploratory objectives of the trial were to measure the effect of AMX0035 treatment on biochemical markers of <FONT
STYLE="white-space:nowrap">amyloid-&szlig;1-42,</FONT> <FONT STYLE="white-space:nowrap">amyloid-&szlig;1-40,</FONT> total tau <FONT STYLE="white-space:nowrap">(t-tau),</FONT> tau phosphorylated at threonine 181 (ptau 181), neuronal injury markers,
mitochondrial redox and function markers, and neuroinflammation, as assessed in cerebrospinal fluid (CSF) from all volunteers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While functional MRI
analyses remain ongoing, no significant differences between dosing groups were observed for any efficacy endpoints in this trial (p&gt;0.05). Key efficacy results are included in the figure below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383770g23a23.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">a</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Hippocampal volume component is based on standard ADNI MRI algorithm but was also assessed via additional MRI algorithms
included in the Statistical Analysis Plan and yielded similar findings. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383770g24x25.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Significant impacts on multiple biomarkers of interest in AD were observed in the trial. In CSF, the AMX0035-group
showed significant reductions of tau protein 181 (p&lt;0.001) and phosphorylated tau protein (p&lt;0.001) compared with the placebo group, modulation of the amyloid beta 42/40 ratio (p&lt;0.05) and increase of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">8-hydroxy-2&#146;</FONT></FONT> -deoxyguanosine, (p&lt;0.01). These topline results from the PEGASUS trial are still subject to further audit and verification procedures and additional biomarker results are not yet
available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe the biomarker and imaging outcomes from the trial have substantially improved and will continue to inform our knowledge of
the impact of AMX0035 on the neurodegenerative pathways </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
relevant to the progression of AD, which have been and will be informative as we continue clinical development of AMX0035 in AD and other potential indications. We believe these insights will
help us to examine any effects of AMX0035 on AD&#146;s progression, which could inform future work in AD as well as clinical trial design for other indications. We will continue to evaluate these data and discuss the results of the PEGASUS trial
with scientific advisors as we consider potential next steps for the development of AMX0035 for the treatment of AD within our clinical development strategy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Clinical Development of AMX0035 for Wolfram Syndrome </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Wolfram syndrome is a rare, pediatric, life-threatening disease thought to be caused by variants in the Wolfram syndrome WFS1 gene, or WFS1, and, in a
small fraction of patients, pathogenic variants in the CDGSH iron sulfur domain protein 2 CISD2 gene, or CISD2. Wolfram syndrome results in deafness, blindness, ataxia, neurodegeneration and ultimately death. There are currently no drugs approved
for Wolfram syndrome. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Wolfram syndrome appears to be a disease of ER stress. WFS1 encodes and produces the vital wolframin protein, which appears
to be involved in ER regulatory processes. WFS1 deficiency leads to chronic ER stress and the UPR. WFS1 also negatively regulates activating transcription factor 6 (ATF6), a UPR molecule, resulting in cell death. Furthermore, a recent study
suggested that WFS1 impacts mitochondrial function by transporting Ca2+ from the ER to the mitochondria through the MAM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">AMX0035 targets pathways
central to Wolfram syndrome, including the UPR, and has shown beneficial effects in a variety of models of Wolfram syndrome, including cellular models and patient-derived cell line models. For example, to test the potential effects of AMX0035 in the
modulation of ER stress in the context of Wolfram syndrome, the effects of PB, TURSO and AMX0035 were tested in an <I>in vitro</I> model of wild-type and WFS1-deficient pancreatic beta cell lines. In these cells, when compared with the control
group, only AMX0035, but not PB or TURSO alone, was able to significantly prevent tunicamycin-induced cell death in WFS1-deficient pancreatic beta cell lines as measured by caspase 3 / 7 activity (p equal to 0.017). Additionally, a combination of PB
and TURSO was studied <I>in vitro</I> in human patient-derived neural progenitor cells harboring mutations in WFS1, which cause Wolfram Syndrome. Both PB and TURSO, when applied alone, were observed to inhibit cell death in each of three different
human cell lines as compared to control conditions, and the application of PB and TURSO in combination was observed to result in significantly lower levels of cell death in three separate patient-derived Wolfram syndrome cell lines differentiated to
produce patient-derived neural progenitor cells, as compared to either the control or treatment with PB or TURSO alone. In each of these models of Wolfram syndrome, use of AMX0035 was observed to have significant synergistic effects lowering cell
death as compared to either the control group or treatment with PB or TURSO alone. For these reasons, we believe AMX0035 is a promising clinical candidate for Wolfram syndrome and we are continuing to evaluate plans to explore the use of AMX0035 in
patients with this disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Patient Advocacy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
patient advocacy landscapes for ALS, AD and other neurodegenerative diseases are large, and encompass groups at the international, multiregional and country-specific level. We have built strong medical and commercial relationships at the
international level, with our current emphasis being on ALS advocacy groups in the United States, Canada and Europe. We plan to engage country-specific groups in Europe based on clinical trial results, as well as our medical and commercial
priorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Working with key advocacy groups is critical to our mission, as patients are at the center of everything we do. This starts with
transparent communication and awareness about our science, data </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and development plans. We seek ensure that these advocacy groups are informed and able to answer questions from their members about PB, TURSO and AMX0035. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We engaged with patient advocacy groups in the United States and Europe for feedback on the design of our ongoing global Phase 3 PHOENIX trial of
AMX0035 for the treatment of ALS, which is emblematic of the partnerships we are building with the community. In addition, we treat patient advocacy groups as important stakeholders as we address access to AMX0035 outside ongoing clinical trials,
such as expanded access and compassionate use programs. We have sought and will continue to seek guidance and insights from as many patient advocacy groups as possible and have plans in place to engage groups on an ongoing basis. These groups have
also reviewed messaging and press releases from the company to ensure they take into account the patient voice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Commercialization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe the global commercial opportunity for AMX0035 in ALS is driven by its being the first and only treatment for ALS of which we are aware that
potentially provides a combination of longer retention of function, improved survival, a generally well-tolerated side effect profile and convenient oral administration. AMX0035 has been shown to have a significant impact on clinically meaningful
endpoints, including reducing time to first hospitalization and permanent ventilation in ALS patients. AMX0035 is also being considered for other neurodegenerative disorders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">ALS is a rare disease, but public sources estimate that ALS affects at least 200,000 people worldwide, and we estimate that there are approximately
29,000 ALS patients in the United States. More than 30,000 ALS patients are estimated to be living with ALS in the EU and the United Kingdom and about 3,000 ALS patients are estimated to be living with ALS in Canada. In the United States, ALS is
treated by neurologists at certified ALS Centers or by other neurologists. In Canada and in Europe, most ALS patients are treated at ALS Centers. The vast majority of people with ALS (over 90%) have sporadic disease, showing no clear family history.
Most people who develop ALS are between the ages of 40 and 70, with a median age of 55 at the time of diagnosis. However, cases of the disease do occur in people in their twenties and thirties. People with ALS spend approximately <FONT
STYLE="white-space:nowrap">one-third</FONT> of their disease course searching for a diagnosis and, once diagnosed, there are few approved therapies available. ALS is a relentlessly progressive and highly heterogenous disease that arises from
multiple mechanistic underpinnings, leading patients to experience variable onset, persistent progression, and shortened survival. The disease remains universally fatal with median survival of less than three years from symptom onset and less than
two years from diagnosis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have conducted market research with physicians, patients, caregivers, nurses, and payors in the United States, Western
Europe and Canada to understand the unmet need and potential of AMX0035 in ALS. Clinicians universally report dissatisfaction with currently approved therapies and state the need for additional options for their ALS patients. When shown a target
product profile for AMX0035, the majority of ALS specialists and neurologists with whom we spoke are open to utilizing it in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">early-to-mid-stage</FONT></FONT></FONT> patients, with some also stating the potential for use in late-stage patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We submitted an NDA to the FDA in the fourth quarter of 2021 and, on September 29, 2022, the FDA approved AMX0035 as RELYVRIO for the treatment of ALS
in adults. We submitted an NDS for AMX0035 in ALS with Health Canada in the second quarter of 2021, which received marketing authorization with conditions as ALBRIOZA by Health Canada in June 2022. We also submitted an MAA in Europe in the first
quarter of 2022, and we expect a decision in the first half of 2023. We also plan to discuss AMX0035 with other health authorities around the world to determine the most appropriate path forward in their respective territories. We also initiated our
ongoing Phase 3 PHOENIX trial in the fourth quarter of 2021 to further support the safety and efficacy of AMX0035 for the treatment of ALS and our global regulatory efforts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our <FONT STYLE="white-space:nowrap">pre-launch</FONT> activities in other key jurisdictions include
building awareness of and education regarding the disease severity and pathophysiology of ALS, increasing understanding of the clinical impact of a change in a patient&#146;s <FONT STYLE="white-space:nowrap">ALSFRS-R</FONT> score, and building
general awareness of our company through active participation in key neurology conferences, patient meetings, partnerships with patient advocacy groups, targeted omnichannel initiatives and payor education in each of the key territories. In
addition, we intend to continue to pursue an active public relations strategy. For example, the double-blind results of our CENTAUR trial have already been published in the <I>New England Journal of Medicine, while the long-term survival study
results appeared in the Journal of Muscle&nbsp;&amp; Nerve. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our initial plans are to continue to build out our commercial operations in the
United States and Canada and to build commercial operations in Europe to be prepared for potential approval of AMX0035 in the EU. There are approximately 186 ALS Association certified, recognized, or affiliated centers in the United States, 17
Canadian ALS Research Network Clinics in Canada, and less than 11 ALS Centers of Excellence per country in the major EU countries, which we plan to target with a specialty key account management team. We will continue to evaluate market entry
opportunities beyond these geographies either on our own or with a partner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Competition </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The biotechnology and pharmaceutical
industries are characterized by rapid technological advancement, significant competition and an emphasis on proprietary products. We face potential competition from many different sources, including major and specialty pharmaceutical and
biotechnology companies, academic research institutions, governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize, including AMX0035, may compete with current therapies
and new therapies that may become available in the future. We believe that the key competitive factors affecting the success of any of our product candidates will include efficacy, safety profile, dosing, cost, effectiveness of promotional support
and intellectual property protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many of our competitors, either alone or with their collaboration partners, have significantly greater
financial resources and expertise in research and development, preclinical testing, clinical trials, manufacturing, and marketing than we do. Future collaborations and mergers and acquisitions may result in further resource concentration among a
smaller number of competitors. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before
we are able to enter the market or make our development more complicated. These competitors may also vie for a similar pool of qualified scientific and management talent, sites and patient populations for clinical trials, as well as for technologies
complementary to, or necessary for, our programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>AMX0035 for the Treatment of ALS </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to AMX0035, in the past 30 years, only two product candidates had been approved for the treatment of ALS in the United States and Canada, and only
one product candidate had been approved for the treatment of ALS in Europe. These two previously approved drugs, riluzole (marketed under the name Rilutek) and edaravone (marketed under name Radicava in the United States and Radicut in Japan), are
often used in combination. We expect that further therapies and drugs which may be approved in the future will also be used in combination with existing drugs, absent incompatibility or other barriers to combination. For example, in May 2022,
Mitsubishi Tanabe Pharma America, Inc. announced that the FDA has approved an oral alternative to Radicava for the treatment of ALS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe there are currently no other approved treatments for ALS which show both a functional and
survival benefit for ALS patients. Patients with ALS are commonly treated with riluzole and edaravone, which are palliative in nature. We believe that these two drugs will not directly compete with AMX0035, as we believe that successful treatment
will likely require concurrent targeting of multiple key neuron death pathways. However, we are aware of several product candidates in clinical development that may compete with AMX0035 for the treatment of ALS, including product candidates being
developed by Biogen, Biohaven and UCB. To date, we believe none of the above product candidates has shown statistically significant clinical results on prespecified outcomes in any prior trials. We anticipate that ALS will continue to be an area of
research in the healthcare sector and that drug candidates will continue to be developed and studied for treatment of the disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While we
anticipate the general practice in ALS will continue to be the combination of approved agents, our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer
or less severe side effects, are more convenient or are less expensive than products that we may develop. In addition, we are aware of one ongoing clinical study in Europe which is evaluating the effects on ALS of TURSO, one of the two components in
AMX0035. The outcome of this study could have an impact on the commercial potential of AMX0035. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A large number of trials and studies are ongoing in
the many additional neurodegenerative diseases which we are evaluating for future clinical work for AMX0035 including AD, Wolfram syndrome, Parkinson&#146;s Disease, Huntington&#146;s Disease, Progressive Supranuclear Palsy, Multi-System Atrophy,
primary lateral sclerosis, ischemic stroke, MS, Friedreich&#146;s ataxia, Leigh&#146;s syndrome and Leber&#146;s hereditary optic neuropathy. Some of these diseases also have therapies approved which impact disease progression. The competitive
landscape in these diseases will affect the potential opportunity for AMX0035. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Supply and Manufacturing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We rely, and expect to continue to rely for the foreseeable future, on third-party contract manufacturing organizations, or CMOs, for the production of
AMX0035 in compliance with current Good Manufacturing Process, or cGMP, requirements, for commercial supply as well as for use in clinical trials under the guidance of members of our organization. For AMX0035, we utilize two active pharmaceutical
ingredients, or APIs, PB and TURSO, which are manufactured and released to us from third-party manufacturers. We have long term, single-source supply agreements in place for these APIs, including authorization to reference the relevant drug master
files with these vendors. We have single-source arrangements for the manufacturing and packaging of bulk drug at established CMOs for commercial supply and for our clinical trials. We manufacture AMX0035 bulk drug at Patheon Inc., or Patheon, a
subsidiary of Thermo Fisher Scientific Inc., located in Whitby, Canada. We have <FONT STYLE="white-space:nowrap">scaled-up</FONT> our third-party manufacturing capabilities in a manner that we believe will support commercial demand and have entered
into agreements covering the manufacture of AMX0035 through 2025. Following manufacturing, bulk drug is then sent to PCI Pharma Services in Rockford, IL, for primary and secondary packaging. As we look to markets outside of the United States, we
plan to add additional manufacturing and distribution sites to support local market demand. In addition, we utilize a risk-based approach to bring on additional manufacturing sites as needed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have built a team of pharmaceutical industry technical operations leaders. This team has significant technical, manufacturing, analytical, quality,
regulatory, including cGMP, and project management experience to oversee our third-party manufacturers and maintain quality and regulatory compliance. In addition, members of this team have been involved in commercializing and launching rare disease
products across the globe. We plan to continue to build our technical operations team as we move towards commercialization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Manufacturing Agreement with Patheon </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2019, we entered into a master manufacturing services agreement, or the Manufacturing Agreement, with Patheon, pursuant to which Patheon
provides cGMP manufacturing, quality control, quality assurance, stability testing, packaging and related services to us. We have executed an initial product agreement under the Manufacturing Agreement, which covers AMX0035. The Manufacturing
Agreement has an initial term ending in December 2025, and will automatically renew if there is a product agreement in effect, with the renewal period ending upon the termination of the last product agreement in effect. The product agreement
covering AMX0035 has an initial term ending in December 2025 and automatically renews for successive terms of two years, unless either party gives prior notice of its intent not to review. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may terminate the Manufacturing Agreement or any product agreement: upon 30 days&#146; prior written notice if any government or regulatory authority
permanently prevents us from selling AMX0035 in Canada, the EU or the United States, if approved, or upon 90 days&#146; prior written notice, if we no longer intend to order manufacturing services due to AMX035&#146;s discontinuance in the market.
Patheon may terminate any product agreement under the Manufacturing Agreement upon 30 days&#146; prior written notice, if we project zero volume for twelve successive months during the term of such product agreement. Additionally, Patheon may
terminate the Manufacturing Agreement or any product agreement if payment in full of any overdue, undisputed invoice is not received within 30 days of Patheon&#146;s suspension of manufacturing services for nonpayment or, in certain circumstances,
upon nine months&#146; prior written notice if we assign any rights under the Manufacturing Agreement or a product agreement. In addition, either party may terminate the Manufacturing Agreement or any product agreement for cause, including the other
party&#146;s uncured material breach and upon written notice, in the case of the other party&#146;s insolvency or bankruptcy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Supply Agreement with CU Chemie
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In October 2019, we entered into a supply agreement with CU Chemie Uetikon, GmbH, or CU Chemie, a division of the SEQENS group, pursuant to
which CU Chemie agreed to supply to us, on a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis, bulk drug substance of PB, for use in the manufacture of AMX0035. The agreement has an initial term of five years and will automatically renew
for successive terms of two years, unless earlier terminated. After the expiration of the initial term, either party may terminate the agreement for convenience upon three months&#146; prior written notice. Additionally, either party may terminate
the agreement in the case of the other party&#146;s uncured material breach or upon the insolvency or bankruptcy of the other party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Supply Agreement with
ICE </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In December 2019, we entered into a supply agreement with Prodotti Chimici e Alimentari S.p.A. (now ICE S.p.A., or ICE), as amended in
July 2021, pursuant to which ICE agreed to supply to us, on a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis, bulk drug substance of TURSO, which we use in the manufacture of AMX0035. The agreement has an initial term of five years and
will automatically renew for successive terms of five years, unless earlier terminated. ICE may terminate the agreement upon three months written notice. Additionally, either party may terminate the agreement in the case of the other party&#146;s
insolvency or bankruptcy, or in case of the other party&#146;s uncured breach. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Intellectual property is of vital importance in our field and to pharmaceuticals generally. Our commercial success depends in part on our ability to
obtain intellectual property that protects AMX0035 and its uses, and any future product candidates. We seek to protect and enhance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
proprietary technology, inventions and improvements that are commercially important to the development of our business and AMX0035, in particular, by seeking, maintaining and defending U.S. and
foreign patent rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are actively building our intellectual property portfolio in our therapeutic area, including around AMX0035. Our current
patent portfolio as of the date of this prospectus includes three patent families. In those three families, we currently own a total of 99 issued patents and pending patent applications directed to our technologies, including AMX0035. Currently, our
patent portfolio includes four issued U.S. patents, 50 issued foreign patents, 13 pending U.S. patent applications and 32 pending foreign patent applications. Our issued patents and pending applications cover the relative amounts of a phenylbutyrate
compound and a bile acid (such as TUDCA) and some of our issued and pending claims cover the specific ratio of those two drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our earliest in
time patent family relates to compositions of a bile acid and a phenylbutyrate compound (including TURSO and <FONT STYLE="white-space:nowrap">4-PBA)</FONT> and methods of treating neurodegenerative disease, and its associated causes at a cellular
level, using those compositions. This family includes four issued U.S. patents and 50 issued foreign patents (including rights in countries in which our issued European patent was validated). The foreign jurisdictions in which we have been issued
patents include Albania, Austria, Australia, Bosnia and Herzegovina, Belgium, Bulgaria, China, Croatia, Cyprus, Czech Republic, Denmark, Estonia, the EU, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Iceland, Italy, Japan,
Lithuania, Latvia, Macao, Macedonia, Malta, Monaco, Montenegro, Netherlands, Norway, Poland, Portugal, Romania, San Marino, Serbia, Slovenia, Slovakia, South Korea, Spain, Sweden, Switzerland, Turkey, and United Kingdom. We also have patent
applications pending in Australia, China, the EU, Hong Kong, Japan, South Korea, the United States and other jurisdictions. In this family, we have composition of matter claims issued in the United States (U.S. Patent No.&nbsp;11,071,742, which was
issued on July&nbsp;27, 2021) and Australia, and pending in applications filed in China and Hong Kong. These issued patents and others that issue from this family may first begin to expire as early as December 2033. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our second patent family is directed to specific compositions of a phenylbutyrate compound and a bile acid (including TURSO and <FONT
STYLE="white-space:nowrap">4-PBA)</FONT> and methods of manufacturing those compositions. We have patent applications pending in this family in the United States, EU, and other jurisdictions, as well as a Patent Cooperation Treaty, or PCT,
application. In this family, we have composition of matter claims pending in applications filed in the United States, Argentina, Australia, Brazil, Canada, China, the EU, Israel, Japan, South Korea, Mexico, and Taiwan, as well as in the PCT
application. Although no patents have yet issued from this family, we expect the term on patents issuing from this family to extend until at least July 2040. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our third patent family is directed to methods of treating particular symptoms of ALS and/or reducing the associated adverse events with combinations of
a phenylbutyrate compound and a bile acid (including TURSO and <FONT STYLE="white-space:nowrap">4-PBA).</FONT> We have patent applications pending in this family in the United States, EU, and other jurisdictions, as well as a PCT application.
Currently, we do not have any composition of matter claims pending in this family. Although no patents have yet issued from this family, we expect the term on patents issuing from this family to extend until at least August 2040. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot be sure that patents will be granted with respect to any of our pending patent applications nor with respect to any patent applications that
may be filed by us in the future. Further, we cannot be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our commercial products. Finally, we cannot be sure that
our granted patents, and any future patents granted to us, will be found valid and/or enforceable following a litigation or administrative procedure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In January 2021, Bruschettini S.r.l. and Lederer&nbsp;&amp; Keller Patentanw&auml;lte Partnerschaft
mbB each filed oppositions at the European Patent Office to our issued European Patent, EP2978419. At a high level, this patent claims various methods of treating neurodegenerative disease (and or the causes or conditions thereof) with a bile acid
and a phenylbutyrate compound. The opponents contended that the patent should be revoked in its entirety on various grounds, including for allegedly having an insufficient disclosure and for lack of inventive step. The EPO issued a preliminary
opinion dated October&nbsp;13, 2021, and a summons to attend oral proceedings (also dated October&nbsp;13, 2021) that set a date of June&nbsp;2, 2022 for the oral proceedings. At the oral proceedings on June&nbsp;2, 2022, the Opposition Division
maintained European Patent, EP2978419 as granted. The scope of the issued claims was not limited. On June&nbsp;17, 2022, the Opposition Division handed down the written decision providing detailed legal reasoning for the outcome of the oral
proceedings. On August&nbsp;4, 2022, Bruschettini S.r.l. filed a notice of appeal. The other opponent did not file a notice of appeal. On September&nbsp;29, 2022, Bruschettini S.r.l filed a request to withdraw the appeal. As the sole appellant has
withdrawn their appeal, the Board of Appeal may now close the appeal proceedings. The decision of the Opposition Division would as a result become final and EP2978419 would be maintained as granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we
file, the patent term is 20 years from the date of filing of the first <FONT STYLE="white-space:nowrap">non-provisional</FONT> application to which priority is claimed. In the United States, patent term may be lengthened by patent term adjustment,
which compensates a patentee for administrative delays by the United States Patent and Trademark Office in granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier-filed patent. In the United States, the term of a
patent that covers an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug may also be eligible for a patent term extension of up to five years under the Hatch-Waxman Act, which is designed to compensate for the patent term lost during the FDA
regulatory review process. The length of the patent term extension is calculated based on the length of time it takes for regulatory review. A patent term extension under the Hatch-Waxman Act cannot extend the remaining term of a patent beyond a
total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Moreover, a patent can only be extended once, and thus, if a single patent is applicable to multiple products, it can only be
extended based on one product. Similar provisions are available in Europe and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug. When possible, depending upon the length of clinical trials and other
factors involved in the submission of an NDA, we expect to apply for patent term extensions for patents covering our product candidates and/or their methods of use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We also rely on trademarks, trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> continuing technological innovation, confidentiality
agreements, and invention assignment agreements to develop and maintain our proprietary position. The confidentiality agreements are designed to protect our proprietary information and the invention assignment agreements are designed to grant us
ownership of technologies that are developed for us by our employees, consultants, or other third parties. We seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and
physical and electronic security of our information technology systems. While we have confidence in our agreements and security measures, either may be breached, and we may not have adequate remedies. In addition, our trade secrets may otherwise
become known or independently discovered by competitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our commercial success also depends in part on our ability to operate without infringing
on the proprietary rights of others and to prevent others from infringing our proprietary rights. A comprehensive discussion on risks relating to intellectual property is provided under the section of this prospectus entitled &#147;Risk
Factors&#151;Risks Related to Our Intellectual Property.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have conducted searches of the patent landscape at certain points and in certain
jurisdictions with respect to AMX0035, and based on these searches and our analyses, we have not identified any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
issued patents that we believe are valid and could be successfully asserted to block our ability to commercialize AMX0035. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">European Patent EP3016654, entitled &#147;Tauroursodeoxycholic acid (TUDCA) for Use in the Treatment of Neurodegenerative Disorders,&#148; is owned by
Bruschettini S.r.l. The patent relates to use of TURSO in the treatment of ALS in a mammal. An opposition has been filed to the grant of EP3016654 at the European Patent Office (EPO), asking the EPO to revoke EP3016654. The EPO issued a preliminary
opinion on November&nbsp;18, 2019 finding that at least the main claim of EP3016654 lacked novelty. Oral proceedings were held before an Opposition Division of the EPO on June&nbsp;11, 2021. At the end of the oral proceedings, the Opposition
Division announced the decision revoking all claims of EP3016654. A written decision has been issued; however Bruschettini has appealed the decision of the Opposition Division to the Board of Appeal. A response to Bruschettini&#146;s appeal has been
filed on June&nbsp;7, 2022 requesting that the appeal should be dismissed and that the decision of the Opposition Division to revoke all claims of EP3016654 be upheld. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA and comparable regulatory
authorities in state and local jurisdictions and in other countries, including Canada and member states of the EU impose requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs, such as
those we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping,
approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>U.S.
Government Regulation of Drug Products </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or
FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial
resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the
FDA&#146;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines,
refusals of government contracts, restitution, disgorgement or civil or criminal penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The process required by the FDA before a drug may be
marketed in the United States generally involves the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#146;s good
laboratory practice, or GLP, regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Submission to the FDA of an investigational new drug, or IND, application, which must become effective before human
clinical trials may begin; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Approval by an independent IRB at each clinical site before each trial may be initiated; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Performance of adequate and well-controlled human clinical trials in accordance with current Good Clinical Practices, or
cGCP, requirements to establish the safety and efficacy of the proposed drug product for each indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Submission to the FDA of an NDA, including payment of application user fees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">A determination by the FDA within 60 days of its receipt of an NDA to accept the marketing application for review;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Satisfactory completion of an FDA advisory committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced
to assess compliance with current good manufacturing practice, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#146;s identity, strength, quality and purity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Satisfactory completion of FDA audits of clinical trial sites to assure compliance with cGCPs and the integrity of the
clinical data; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">FDA review and approval of the NDA. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Preclinical Studies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Preclinical studies include laboratory
evaluation of product chemistry, toxicity and formulation, as well as <I>in vitro</I> and animal studies to assess potential safety and efficacy. The conduct of preclinical studies is subject to federal regulations and requirements, including good
laboratory practice regulations for safety/toxicology studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">An IND sponsor must submit the results of the preclinical tests, together with
manufacturing information, analytical data and any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an
investigational product to humans and must become effective before human clinical trials may begin. Some preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue even after the IND is submitted. An
IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the
IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to initiate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Clinical Trials </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Clinical trials involve the administration
of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with cGCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their
participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol
for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical
trial before it is initiated at that institution. The IRB also must review and approve the informed consent form that must be provided to each clinical trial subject or his or her legal representative, and must monitor the clinical trial until
completion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH,
for public dissemination on their www.clinicaltrials.gov website. Information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the
registration of the clinical trial. Although sponsors are obligated to disclose the results of their clinical trials after completion, disclosure of the results can be delayed in some cases for up to two years after the date of completion of the
trial. Failure to timely register a covered clinical study or to submit study results as provided for in the law can give rise to civil monetary penalties and also prevent the <FONT STYLE="white-space:nowrap">non-compliant</FONT> party from
receiving future grant funds from the federal government. The NIH&#146;s Final Rule on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
ClinicalTrials.gov registration and reporting requirements became effective in 2017, and both the NIH and FDA recently signaled the government&#146;s willingness to begin enforcing those
requirements against <FONT STYLE="white-space:nowrap">non-compliant</FONT> clinical trial sponsors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Human clinical trials are typically conducted
in three sequential phases, which may overlap or be combined: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and
tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to
preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial
sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for
the labeling of the product. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after
initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a
condition of approval on an NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and
more frequently if SAEs occur. Written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies or animal or in vitro testing that suggest a significant risk
for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the
sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#146;s initial receipt of the
information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Phase 1, Phase 2 and Phase 3 trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or
the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical
trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an
independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated check points based on access
to certain data from the trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop
additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable
of consistently producing quality batches of product and, among other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested
and stability studies must be conducted to demonstrate that the drug does not undergo unacceptable deterioration over its shelf life. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Expanded Access to an Investigational Drug for Treatment Use </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Expanded access, sometimes called &#147;compassionate use,&#148; is the use of investigational products outside of clinical trials to treat patients with
serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational
products for patients who may benefit from investigational therapies. FDA regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis for: individual patients (single-patient IND applications for treatment in emergency settings and <FONT STYLE="white-space:nowrap">non-emergency</FONT> settings); <FONT
STYLE="white-space:nowrap">intermediate-size</FONT> patient populations; and larger populations for use of the investigational product under a treatment protocol or treatment IND application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the
sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory
alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the
expanded use of the investigational drug for the requested treatment will not interfere with initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential
development of the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There is no obligation for a sponsor to make its drug products available for expanded access; however, as required by
the 21st Century Cures Act, or Cures Act, passed in 2016, if a sponsor has a policy regarding how it responds to expanded access requests, it must make that policy publicly available. Sponsors are required to make such policies publicly available
upon the earlier of initiation of a Phase 2 or Phase 3 trial; or 15 days after the investigational drug or biologic receives designation as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, on May&nbsp;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain
patients to access certain investigational products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical
trials and without obtaining FDA permission under FDA expanded access program. There is no obligation for a manufacturer to make its investigational products available to eligible patients as a result of the Right to Try Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Combination Rule for Fixed-Dose Combination Products </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under
the combination rule, the FDA may not file or approve an NDA for a fixed-dose combination product unless each component of a proposed drug product is shown to make a contribution to the claimed effects and the dosage of each component (amount,
frequency, duration) is safe and effective for the intended population. To satisfy these requirements, the FDA typically requires a clinical factorial study, designed to assess the effects attributable to each drug in the combination product. This
is particularly true when the ingredients are directed at the same sign or symptom of the disease or condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA has accepted a variety of
approaches to satisfy the combination rule. In December 2015, the FDA proposed regulations that would allow the agency to waive the requirements of the combination rule for certain drug products under particular circumstances. The FDA has not, to
date, finalized these regulations, but the FDA has stated that factorial studies may be unethical (e.g., omitting a drug known to improve survival) or impractical (there may be too many components to conduct a factorial study, meaning the trial
cannot be conducted). The FDA has also stated that it may be possible to use other types of clinical and nonclinical data and mechanistic information available to demonstrate the contributions of the individual active ingredients to the effect of
the combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Similar requirements may be imposed on us by the EMA in the EU and comparable regulatory authorities
in other jurisdictions. While no similar combination rule formally exists in Canada, Health Canada may consider the contributions of each component in a combination product in connection with review of the NDS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>NDA Submission and Marketing Approval </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Assuming successful
completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#146;s chemistry, manufacture, controls and proposed labeling, among other things, are
submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. The FDA will initially review an NDA for
completeness before it accepts it for &#147;filing.&#148; Under the FDA&#146;s procedures, the agency has 60 days from its receipt of the NDA to determine whether the application will be accepted for filing based on the agency&#146;s threshold
determination that the application is sufficiently complete to permit substantive review. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of
&#147;filing&#148; of a standard NDA, for a new molecular entity to review and act on the submission, and six months from the filing date of a new molecular entity NDA with priority review. Accordingly, this review process typically takes 12 months
and eight months, respectively from the date the NDA is submitted to the FDA. The FDA does not always meet its PDUFA goal dates for standard or priority NDAs, and the review process is often extended by FDA requests for additional information or
clarification. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective for its intended use(s), with the latter determination being made on the basis of substantial evidence. This finding can be substantiated
based on two adequate and well-controlled studies, or in certain circumstances on a single, large, multicenter, adequate and well-controlled study that is very persuasive or from a single adequate and well-controlled study together with confirmatory
evidence. FDA regulations and guidance also allow for greater flexibility and tolerance for uncertainty in the context of rare and fatal diseases. The FDA also assesses whether the facility in which the product is manufactured, processed, packaged
or held meets standards designed to assure the product&#146;s continued safety, quality and purity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, under the Pediatric Research
Equity Act of 2003, or PREA, as amended, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to
support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until
after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new
dosage form, new dosing regimen or new route of administration must submit an initial Pediatric Study Plan, or PSP, within 60 days of an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 meeting or, if
there is no such meeting, as early as practicable before initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and
design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data
from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered
based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs. PREA does not apply to a drug for an indication for which orphan drug designation has been granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they
are sufficiently complete to permit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The
resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive review. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA may refer an application for a novel drug or a drug that presents difficult questions of safety or efficacy to an advisory committee. An
advisory committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is
not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA also may
require the submission of an REMS if it determines that a REMS is necessary to ensure that the benefits of the drug outweigh its risks and to assure the safe use of the drug. A REMS may include one or more elements, including medication guides,
physician communication plans, patient package insert and/or elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the
specific REMS provisions, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve
the NDA without a REMS, if required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is
manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with cGCP requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the
manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a Complete Response Letter. A Complete Response Letter generally contains a statement of specific conditions that must be met in order to
secure final approval of the NDA and may require additional clinical or preclinical testing in order for FDA to reconsider the application. If a Complete Response Letter is issued, the applicant may either resubmit the NDA, addressing all of the
deficiencies identified in the letter, or withdraw the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those
conditions have been met to the FDA&#146;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or
precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#146;s safety after approval, require testing and surveillance programs to monitor the
product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may
prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and
additional labeling claims, are subject to further testing requirements and FDA review and approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Orphan Drug Designation and Exclusivity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug product intended to treat a rare disease or condition, which is generally a
disease or condition that affects either (i)&nbsp;fewer than 200,000 individuals in the United States, or (ii)&nbsp;more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and
making the product available in the United States for this type of disease or condition will be recovered from sales of the product. A company must request orphan drug designation before submitting an NDA. If the request is granted, the FDA will
disclose the identity of the therapeutic agent and its potential use. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation or for a select
indication or use within the rare disease or condition for which it was designated, the product is entitled to orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications to market the same
product for the same indication for seven years, except in certain limited circumstances. If a drug designated as an orphan drug ultimately receives marketing approval for an indication broader than what it was designated for, it may not be entitled
to exclusivity. Orphan exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the same indication is shown to be clinically superior to the approved
product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Further, the FDA may approve more than one product for the same
orphan indication or disease as long as the products contain different active ingredients. Moreover, competitors may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the
same product but for a different indication for which the orphan drug has exclusivity. U.S. lawmakers have also recently raised the possibility that regulatory or legislative changes might need to be made to the Orphan Drug Act to foster
competition. This includes the introduction of legislation that, if adopted into law, would require us to demonstrate to the FDA that AMX0035 would be economically unviable when facing competition to maintain our exclusivity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Expedited Development and Priority Review Programs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA
maintains several programs intended to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening diseases or conditions. These programs include Fast Track designation,
Breakthrough Therapy designation, Priority Review and Accelerated Approval, and the purpose of these programs is to either expedite the development or review of important new drugs to get them to patients earlier than under standard FDA development
and review procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA has a FastTrack program that is intended to expedite or facilitate the process for reviewing new drugs that meet
certain criteria. Specifically, new drugs are eligible for Fast Track designation if they are intended to treat a serious or life threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the
condition. Fast Track designation applies to both the product and the specific indication for which it is being studied. The sponsor can request the FDA to designate the product for Fast Track status any time before receiving NDA approval, but
ideally no later than the <FONT STYLE="white-space:nowrap">pre-NDA</FONT> meeting. Fast Track designation provides increased opportunities for sponsor interactions with the FDA during preclinical and clinical development, in addition to the
potential for rolling review once a marketing application is filed, meaning that the agency may review portions of the marketing application before the sponsor submits the complete application, as well as priority review, discussed below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, a drug may be eligible for designation as a breakthrough therapy if the product is
intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently
approved therapies on one or more clinically significant endpoints. The benefits of Breakthrough Therapy designation include the same benefits as Fast Track designation, plus intensive guidance from the FDA to ensure an efficient drug development
program. A product may also be eligible for priority review if it treats a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA
determines at the time that the marketing application is submitted, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis, whether the proposed drug represents a significant improvement in treatment,
prevention or diagnosis of disease when compared with other available therapies. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the
review and to shorten the FDA&#146;s goal for taking action on an NDA for a new molecular entity from ten months to six months from the date of filing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A product may also be eligible for accelerated approval if it treats a serious or life-threatening disease or condition, generally provides a meaningful
advantage over available therapies and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM,
that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of accelerated approval, the FDA requires that a sponsor perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a
drug shown to be effective can be safely used only if distribution or use is restricted, it will require such post-marketing restrictions, as it deems necessary to assure safe use of the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for
qualification or decide that the time period for FDA review or approval will not be shortened. Fast Track designation, Breakthrough Therapy designation and Priority Review designation do not change the standards for approval, but may expedite the
development or review process. Drugs granted accelerated approval also must meet the same statutory standards for safety and effectiveness as those granted traditional approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>U.S. <FONT STYLE="white-space:nowrap">Non-Patent</FONT> Exclusivity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Data exclusivity provisions under the FDCA can delay the submission or the approval of certain <FONT STYLE="white-space:nowrap">follow-on</FONT>
applications. The FDCA provides a five-year period of data exclusivity within the United States to the first applicant to gain approval of an NDA for an NCE. A drug is an NCE if the FDA has not previously approved any other new drug containing the
same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an ANDA for a generic version of the drug or a 505(b)(2) NDA for another version of
such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, such a <FONT STYLE="white-space:nowrap">follow-on</FONT> application may be submitted after four years if it contains a
certification of patent invalidity or <FONT STYLE="white-space:nowrap">non-infringement.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA has previously taken the position that NCE
exclusivity is not available for fixed-dose combination products if one of the active moieties in the combination product had been previously approved in a drug product. In October 2014, however, the FDA reversed that position when it issued final
guidance stating that an application for a fixed-dose combination product will be eligible for <FONT STYLE="white-space:nowrap">5-year</FONT> NCE exclusivity if it contains a drug substance with a single, new active moiety, even if the
fixed-combination also contains a drug substance with a previously approved active moiety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDCA also provides three years of market exclusivity
for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This
three-year exclusivity period covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving <FONT STYLE="white-space:nowrap">follow-on</FONT> applications that do not reference the
protected clinical data. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical
studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pediatric exclusivity is another type
of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing regulatory exclusivity periods or listed patents. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity may be granted
based on the voluntary completion of a pediatric trial in accordance with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148; for such a trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Post-approval Requirements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Drugs manufactured or distributed
pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and
reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There are continuing, annual user fee
requirements for any marketed products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For
example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">FDA regulations require that products be manufactured in specific facilities and in accordance with cGMP regulations which require, among other things,
quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. In addition, drug manufacturers and other entities involved in the manufacture and
distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements.
Manufacturers and other parties involved in the drug supply chain for prescription drug products must also comply with product tracking and tracing requirements and for notifying FDA of counterfeit, diverted, stolen and intentionally adulterated
products or products that are otherwise unfit for distribution in the United States. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require
investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue
to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Once an approval of a drug is granted,
the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market, such as if, based on new evidence of clinical experience not contained in the
application or not available to the FDA until after the application was approved, there is a lack of substantial evidence that the approved product will have the effect it is purported or represented to have under the conditions of use prescribed,
recommended, or suggested in its labeling. Sponsors may also voluntarily withdrawal their approved products from the market for similar reasons. Later discovery of previously unknown problems with a product, including adverse events of unanticipated
severity or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition
of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution,
prescription or dispensing of products. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or
product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Fines, warning letters or holds on post-approval clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or withdrawal of product
approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Product seizure or detention, or refusal to permit the import or export of products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted by a
manufacturer and any third parties acting on behalf of a manufacturer only for the approved indications and in a manner consistent with the approved label for the product. The FDA and other agencies actively enforce the laws and regulations
prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Other U.S. Healthcare Laws </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Healthcare providers,
physicians, and third-party payors will play a primary role in the recommendation and prescription of drug products for which we obtain marketing approval. Arrangements with third-party payors, healthcare providers and physicians, as well as
patients and other third-parties, in connection with the clinical research, sales, marketing and promotion of products, once approved, and related activities, may expose a pharmaceutical manufacturer to broadly applicable fraud and abuse and other
healthcare laws and regulations. In the United States, these laws include, without limitation, state and federal anti-kickback, false claims, physician transparency, and patient data privacy and security laws and regulations, including but not
limited to those described below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the Anti-Kickback Statute, or AKS, which makes it illegal for any person or entity, including a prescription drug
manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer or pay any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, that is intended
to induce or reward, referrals including the purchase, recommendation, order or prescription of a particular drug for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. The AKS has been
interpreted to apply to arrangements between therapeutic product manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. A person or entity does not need to have actual knowledge of the statute or specific intent
to violate it in order to have committed a violation. Further, courts have found that if &#147;one purpose&#148; of remuneration is to induce referrals, the AKS is violated. In addition, the government may assert that a claim including items or
services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal civil and criminal false claims laws, including the FCA, which can be enforced by private citizens through
&#147;qui tam&#148; or &#147;whistleblower&#148; actions, and civil monetary penalty laws, which impose criminal and civil penalties against individuals or entities for, among other things,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal health care programs that are false or fraudulent; knowingly making or
causing a false statement material to a false or fraudulent claim or an obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation.
Pharmaceutical and other healthcare companies have been, and continue to be, prosecuted under these laws, among other things, for allegedly providing free product to customers with the expectation that the customers would bill federal programs for
the product and for causing false claims to be submitted because of the companies&#146; marketing of the product for unapproved, <FONT STYLE="white-space:nowrap">off-label,</FONT> and thus generally
<FONT STYLE="white-space:nowrap">non-reimbursable,</FONT> uses. Similar to the AKS, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal
criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or
property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or
making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Like the AKS, the Patient Protection and Affordable Care Act, or the ACA, amended the
intent standard for certain healthcare fraud statutes under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their
respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the
creation, use, receipt, maintenance or disclosure of individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information. HITECH also created four new tiers of civil
monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and
seek attorneys&#146; fees and costs associated with pursuing federal civil actions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal Physician Payments Sunshine Act, created under the ACA, and its implementing regulations, which require
manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program to report annually to CMS under the Open Payments Program, information related to
payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate
family members. Effective January&nbsp;1, 2022, these reporting obligations extend to include transfers of value made during the previous year to certain <FONT STYLE="white-space:nowrap">non-physician</FONT> providers such as physician assistants
and nurse practitioners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer
protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services
reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts
payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts,
compensations and other remuneration and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and
security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of a
pharmaceutical manufacturer&#146;s business activities could be subject to challenge under one or more of such laws. Efforts to ensure that business arrangements comply with applicable healthcare laws involve substantial costs. It is possible that
governmental and enforcement authorities will conclude that a pharmaceutical manufacturer&#146;s business practices do not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare
laws and regulations. If any such actions are instituted against a pharmaceutical manufacturer, and it is not successful in defending itself or asserting its rights, those actions could have a significant impact on its business, including the
imposition of significant civil, criminal and administrative penalties, damages, disgorgement, imprisonment, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, reporting obligations and
oversight if we become subject to integrity and oversight agreements to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance,</FONT> contractual damages, reputational harm, diminished profits and future earnings, and curtailment of
operations, any of which could adversely affect a pharmaceutical manufacturer&#146;s ability to operate its business and the results of operations. In addition, commercialization of any drug product outside the United States will also likely be
subject to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States, numerous federal and state
laws and regulations, including state data breach notification laws, state and federal health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of health-related and
other personal information. For example California recently enacted the California Consumer Privacy Act, or CCPA, which creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security
obligations on entities handling personal data of consumers or households. The CCPA will require covered companies to provide certain disclosures to consumers about its data collection, use and sharing practices, and to provide affected California
residents with ways to <FONT STYLE="white-space:nowrap">opt-out</FONT> of certain sales or transfers of personal information. The CCPA went into effect on January&nbsp;1, 2020, and the California State Attorney General has submitted various versions
of final regulations. The California State Attorney General also now has the authority to commence enforcement actions against violators as of July&nbsp;1, 2020. Further, a new California privacy law, the California Privacy Rights Act, or CPRA, was
passed by California voters on November&nbsp;3, 2020. The CPRA will create additional obligations with respect to processing and storing personal information that are scheduled to take effect on January&nbsp;1, 2023 (with certain provisions having
retroactive effect to January&nbsp;1, 2022). We will continue to monitor developments related to the CPRA and anticipate additional costs and expenses associated with CPRA compliance. Other U.S. states also are considering omnibus privacy
legislation (with one additional law already passed in Colorado and Virginia) and industry organizations regularly adopt and advocate for new standards in these areas. While the CCPA and CPRA contain an exception for certain activities involving PHI
under HIPAA, we cannot yet determine the impact the CCPA, CPRA or other such future laws, regulations and standards may have on our business, as these laws either do not yet apply to us or are not yet in effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event we decide to conduct clinical trials or continue to enroll subjects in our ongoing or
future clinical trials, we may be subject to additional privacy restrictions, under state and federal law or other obligations. We also may become subject to laws in other countries, including the General Data Protection Regulation in Europe. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Current and Future U.S. Healthcare Reform Legislation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Payors, whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare costs and
those methods are not always specifically adapted for new technologies such as gene therapy and therapies addressing rare diseases such as those we are developing. In both the United States and certain foreign jurisdictions, there have been a number
of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. In particular, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education
Reconciliation Act of 2010, or collectively, the ACA, was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars; addressed a new methodology by which rebates owed by manufacturers under
the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid
Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; created a new Medicare Part D coverage
gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of January&nbsp;1, 2019)
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the
manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; and provided incentives to programs that increase the federal government&#146;s comparative effectiveness research. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA. On
June&nbsp;17, 2021, the Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#146;s decision, President Biden
issued an Executive Order to initiate a special enrollment period from February&nbsp;15, 2021 through August&nbsp;15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain
governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies
that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administrations or other efforts, if any, to challenge repeal or replace
the ACA, will impact our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was
enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2
trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2%
per fiscal year. These reductions went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension that lasted from May&nbsp;1, 2020
through March&nbsp;31, 2022 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Following the suspension, a 1% payment reduction began April&nbsp;1, 2022, lasting through June&nbsp;30, 2022. The 2% payment reduction resumed on
July&nbsp;1, 2022. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several providers, including hospitals and cancer treatment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. The Bipartisan Budget Act of 2018, also amended the ACA,
effective January&nbsp;1, 2019, by increasing the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and closing the
coverage gap in most Medicare drug plans, commonly referred to as the &#147;donut hole.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Canadian Review and Approval Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In Canada, our small molecule product candidates and our research and development activities are primarily regulated by the Food and Drugs Act and the
rules and regulations thereunder, which are enforced by Health Canada. Health Canada regulates, among other things, the research, development, testing, approval, manufacture, packaging, labeling, storage, recordkeeping, advertising, promotion,
distribution, marketing, post-approval monitoring and import and export of pharmaceutical products. The drug approval process under Canadian laws requires licensing of manufacturing facilities, carefully controlled research and testing of products,
government review and approval of experimental results prior to granting approval for commercial sale of drug products. Regulators also typically require that rigorous and specific standards such Continuing Good Manufacturing Practices, or cGMP, GLP
and cGCP are followed in the manufacture, nonclinical development and clinical development, respectively, of any drug product. The processes for obtaining regulatory approvals in Canada, along with subsequent compliance with applicable statutes and
regulations, require the expenditure of substantial time and financial resources. For further information, see &#147;Risk Factors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
principal steps required for drug approval in Canada are as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Nonclinical Safety Pharmacology and Toxicology Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-clinical</FONT> studies are conducted in vitro and in animals to evaluate pharmacokinetics, metabolism and possible
toxic effects to provide evidence of the safety of the drug candidate prior to its administration to humans in clinical studies and throughout development. Such studies are conducted in accordance with applicable laws and GLP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Clinical Trials </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Similar regulations apply in Canada
regarding clinical trials as in the United States. In Canada, Research Ethics Boards, or REBs, are used to review and approve clinical trial plans when trials are performed in Canada. For clinical trials that involve the administration of an
investigational new drug to human subjects, an application must be made to Health Canada and approved before the trial can commence at a Canadian site. Trials are performed under the supervision of qualified investigators, in most cases a physician,
in accordance with cGCP requirements. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the trial procedures, the parameters to be used in monitoring safety and the efficacy criteria to be
evaluated and a statistical analysis plan. The protocol and the informed consent forms that are signed by subjects, are reviewed and approved by the REB affiliated with the site where the trial will be conducted. Human clinical trials for new drugs
are typically conducted in three sequential phases, Phase 1, Phase 2 and Phase 3, as discussed above in the context of government regulation in the United States. Similar to the FDA, Health Canada also accepts foreign clinical trial data in support
of marketing applications. Additionally, the manufacture of investigational drugs for the conduct of human clinical trials is subject to cGMP requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>New
Drug Submission </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In Canada, upon successful completion of Phase 3 clinical trials or earlier stage trials if agreeable to Health Canada, the
company sponsoring a new drug then assembles all the nonclinical and clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
data and other testing relating to the product&#146;s pharmacology, chemistry, manufacture, and controls, and submits it to Health Canada as part of an NDS The NDS is then reviewed by Health
Canada. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Health Canada will not approve the new drug unless compliance with cGMP&#151;a quality system regulating manufacturing&#151;is
satisfactory, and the NDS contains data that provide substantial evidence that the drug is safe and effective in the indication and at the dosage studied. If Health Canada is satisfied that the NDS contains sufficient information, then marketing
authorization for the new drug may be granted. In Canada, the marketing authorization for a new drug is called a Notice of Compliance, or NOC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
testing required to generate data for inclusion in an NDS, and approval process for an NDS, requires substantial time, effort and financial resources, and may take several years to complete. This is necessary to help ensure the efficacy, safety and
quality of the product. Data obtained from nonclinical and clinical testing are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. Health Canada may not grant approval of
an NDS on a timely basis, or at all. In Canada, NDSs are subject to user fees and these fees are typically increased annually to reflect inflation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Health Canada has authority to grant conditional marketing approval following the review of an NDS for a new drug that would treat a serious,
life-threatening or severely debilitating disease or condition. A Notice of Compliance with conditions (NOC/c) can be granted when there is promising evidence of clinical effectiveness based on the available data that the drug has the potential to
provide (i)&nbsp;effective treatment, prevention or diagnosis of a disease or condition for which no drug is presently marketed in Canada or (ii)&nbsp;a significant increase in efficacy and/or significant decrease in risk such that the overall
benefit/risk profile is improved over existing therapies, preventatives or diagnostic agents for a disease or condition that is not adequately managed by a drug marketed in Canada. When a NOC/c is granted, the company to which the NOC/c is issued
must make certain commitments to Health Canada, which typically include a requirement to provide confirmatory data to Health Canada to support the safe use and efficacy of the new drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if Health Canada approves a product candidate, it may limit the approved indications for use of the product candidate, require that
contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#146;s safety after approval, require testing and
surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Health Canada may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After
approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements, notification, and review and approval before the change can
be implemented. Further, should new safety information arise, additional testing and/or regulatory notification may be required, or Health Canada may require an update to the product label that impacts the scope of the approved indications or other
conditions for clinical use. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>European Union Approval Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The process governing approval of medicinal products in the EU generally follows the same lines as in the United States. It entails satisfactory
completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires the submission to the relevant competent authorities of an MAA and
granting of a marketing authorization by these authorities before the product can be marketed and sold in the EU </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Following the UK&#146;s departure from the EU, a separate marketing authorization will be required in order to place medicinal products on the market in Great Britain (under the Northern Irish
Protocol, the EU regulatory framework will continue to apply in Northern Ireland and centralized EU authorizations will continue to be recognized). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Clinical
Trial Approval </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Clinical Trials Directive 2001/20/EC, the Directive 2005/28/EC on GCP and the related national implementing provisions of the
individual Member States of the European Union, or EU Member States, govern the system for the approval of clinical trials in the EU. Under this system, an applicant must obtain prior approval from the national competent authority, or NCA, of the EU
Member States in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site after an independent ethics committee, or EC, has issued a favorable opinion. The clinical trial
application must be accompanied by, among other documents, an investigational medicinal product dossier (the Common Technical Document) with supporting information prescribed by Directive 2001/20/EC, Directive 2005/28/EC, and corresponding national
laws of the EU Member States and further detailed in applicable guidance documents. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the
NCA and ECs of the EU Member State where they occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In April 2014, the new Clinical Trials Regulation, (EU) No 536/2014, was adopted, which is
set to replace the current Clinical Trials Directive. The Clinical Trials Regulation will be directly applicable in all EU Member States without the need for any national implementing legislation. It will overhaul the current system of approvals for
clinical trials in the EU. The new Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the EU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the
new coordinated procedure for the approval of clinical trials, the sponsor of a clinical trial will be required to submit a single application for approval of a clinical trial to a reporting EU Member State through a centralized EU Portal. The
submission procedure will be the same irrespective of whether the clinical trial is to be conducted in a single EU Member State or in more than one EU Member State. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Clinical Trials Regulation has not yet become effective. It is expected that the new Clinical Trials Regulation will come into effect following
confirmation of the full functionality of the Clinical Trials Information System, the centralized EU portal and database for clinical trials foreseen by the new Clinical Trials Regulation, through an independent audit. This is currently expected to
occur in December 2021. When the Clinical Trials Regulation becomes applicable, the existing Clinical Trial Directive and national legislation put in place to implement the Directive will be repealed. Following implementation of the Clinical Trials
Regulation, a transitional period will be in effect for one year where new clinical trial applications can be submitted either under the existing Clinical Trials Directive or under the new Clinical Trials Regulation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>PRIME Designation in the EU </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In March 2016, the EMA launched
an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical
need and provides accelerated assessment of products representing substantial innovation where the marketing authorization application will be made through the centralized procedure. Eligible products must target conditions for which where is an
unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EEA or, if there is, the new medicine will bring a major therapeutic </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
advantage) and they must demonstrate the potential to address the unmet medical need by introducing new methods of therapy or improving existing ones. Products from small- and <FONT
STYLE="white-space:nowrap">medium-sized</FONT> enterprises, or SMEs, may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited
to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated contact and
rapporteur from the EMA&#146;s CHMP or Committee for Advanced Therapies, are appointed early in PRIME scheme facilitating increased understanding of the product at EMA&#146;s Committee level. A <FONT STYLE="white-space:nowrap">kick-off</FONT>
meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Fixed-Dose Combination Guideline </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As with the FDA, the EMA
has also issued regulations to address review and approval of fixed-dose combination products. This EMA&#146;s Guideline on clinical development of fixed combination medicinal products came into force on October&nbsp;1, 2017. The basic scientific
requirements for any fixed combination medicinal product are justification of the pharmacological and medical rationale for the combination, and establishment of the evidence base for the relevant contribution of all active substances to the desired
therapeutic effect (efficacy and/or safety) and a positive benefit-risk for the combination in the targeted indication. For products that involve initial combination of two active ingredients, the EMA has indicated that the design of clinical
efficacy/safety studies to support a fixed combination medicinal product application for initial treatment will depend on its rationale, specifically to achieve superior efficacy or improved safety compared to use of the single active substances. In
situations when it has been established that monotherapy will not be adequate, appropriate or ethical to reach the desired therapeutic effect, initial use of combination therapy should be easily justified (<I>e.g. </I>HIV). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Marketing Authorization </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To obtain a marketing authorization
for a product European Economic Area (<I>i.e.</I>, the EU as well as Iceland, Liechtenstein and Norway), or EEA, an applicant must submit an MAA either under a centralized procedure administered by the EMA, or one of the procedures administered by
competent authorities in the EU Member States (decentralized procedure, national procedure or mutual recognition procedure). A marketing authorization may be granted only to an applicant established in the EEA. Regulation (EC) No 1901/2006 provides
that prior to obtaining a marketing authorization in the EU, applicants have to demonstrate compliance with all measures included in an <FONT STYLE="white-space:nowrap">EMA-approved</FONT> Paediatric Investigation Plan, or PIP, covering all subsets
of the pediatric population, unless the EMA has granted (1)&nbsp;a product-specific waiver, (2)&nbsp;a class waiver or (3)&nbsp;a deferral for one or more of the measures included in the PIP (for example, when this data is not needed or appropriate
because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over
existing treatments for pediatric patients). Products that are granted a marketing authorization with the results of the pediatric clinical trials conducted in accordance with the PIP (even where such results are negative) are eligible for six
months&#146; supplementary protection certificate extension (if any is in effect at the time of approval). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The centralized procedure provides for
the grant of a single marketing authorization by the European Commission that is valid across the EEA. Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by
certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (<I>i.e.</I> gene therapy, somatic-cell therapy and tissue-engineered medicinal products)
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and products with a new active substance indicated for the treatment of certain diseases, including HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune
dysfunctions and viral diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of public health, the centralized
procedure may be optional. The centralized procedure may at the request of the applicant also be used in certain other cases. We anticipate that the centralized procedure will be mandatory for the product candidates we are developing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the centralized procedure, the CHMP is responsible for conducting the initial assessment of a product and for several post-authorization and
maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops, when
additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210 days. Accelerated evaluation might be
granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. If the CHMP accepts such request, the time limit of 210
days will be reduced to 150 days (excluding clock stops) but it is possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. At
the end of this period, the CHMP provides a scientific opinion on whether or not a marketing authorization should be granted in relation to a medicinal product. Where the CHMP gives a positive opinion, the EMA provides the opinion together with
supporting documentation to the European Commission, who make the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#146;s recommendation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The European Commission may grant a <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;marketing authorization under exceptional
circumstances&#148;. Such authorization is intended for products for which the applicant can demonstrate that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use, because either (i)&nbsp;the
indications for which the product in question is intended are encountered so rarely that the applicant cannot reasonably be expected to provide comprehensive evidence; (ii)&nbsp;in the present state of scientific knowledge, comprehensive information
cannot be provided; or (iii)&nbsp;it would be contrary to generally accepted principles of medical ethics to collect such information. Consequently, marketing authorization under exceptional circumstances may be granted subject to certain specific
obligations, which may include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the applicant must complete an identified program of studies within a time period specified by the competent authority, the
results of which form the basis of a reassessment of the benefit/risk profile; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the medicinal product in question may be supplied on medical prescription only and may in certain cases be administered
only under strict medical supervision, possibly in a hospital and in the case of a radiopharmaceutical, by an authorized person; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the package leaflet and any medical information must draw the attention of the medical practitioner to the fact that the
particulars available concerning the medicinal product in question are as yet inadequate in certain specified respects. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A
marketing authorization under exceptional circumstances is subject to annual review to reassess the risk-benefit balance in an annual reassessment procedure. Continuation of the authorization is linked to the annual reassessment and a negative
assessment could potentially result in the marketing authorization being suspended or revoked. The renewal of a marketing authorization of a medicinal product under exceptional circumstances, however, follows the same rules as a &#147;normal&#148;
marketing authorization. Thus, a marketing authorization under exceptional circumstances is granted </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
for an initial five years, after which the authorization will become valid indefinitely, unless the EMA decides that safety grounds merit one additional five-year renewal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The EU medicines rules expressly permit the EU Member States to adopt national legislation prohibiting or restricting the sale, supply or use of any
medicinal product containing, consisting of or derived from a specific type of human or animal cell, such as embryonic stem cells. While the products we have in development do not make use of embryonic stem cells, it is possible that the national
laws in certain EU Member States may prohibit or restrict us from commercializing our products, even if they have been granted an EU marketing authorization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unlike the centralized authorization procedure, the decentralized marketing authorization procedure requires a separate application to, and leads to
separate approval by, the competent authorities of each EU Member State in which the product is to be marketed. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure.
The reference EU Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EU Member States who, within 90 days of
receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health,
disputed elements may be referred to the European Commission, whose decision is binding on all EU Member States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The mutual recognition procedure
similarly is based on the acceptance by the competent authorities of the EU Member States of the marketing authorization of a medicinal product by the competent authorities of other EU Member States. The holder of a national marketing authorization
may submit an application to the competent authority of an EU Member State requesting that this authority recognize the marketing authorization delivered by the competent authority of another EU Member State. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Conditional Marketing Authorization </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The European Commission
may also grant a <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;conditional marketing authorization&#148; prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional
marketing authorizations may be granted for product candidates (including medicines designated as orphan medicinal products), if (i)&nbsp;the risk-benefit balance of the product candidate is positive, (ii)&nbsp;it is likely that the applicant will
be in a position to provide the required comprehensive clinical trial data post-authorization, (iii)&nbsp;the product fulfills an unmet medical need and (iv)&nbsp;the benefit to public health of the immediate availability on the market of the
medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including
obligations with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance
remains positive, and after an assessment of the need for additional or modified conditions and/or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications
for a conditional marketing authorization. A conditional marketing authorization can be converted into a standard centralized marketing authorization (no longer subject to specific obligations) once the marketing authorization holder fulfils the
obligations imposed and the complete data confirm that the medicine&#146;s benefits continue to outweigh its risks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Regulatory Data Protection in the EU </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the EEA, innovative medicinal products approved on the basis of a complete independent data package qualify for eight years of data exclusivity upon
marketing authorization and an additional two years of market exclusivity. Data exclusivity, if granted, prevents applicants for authorization of generics or biosimilars of these innovative products from referencing the innovator&#146;s preclinical
and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization, for a period of eight years from the date on which the reference product was first authorized in the EEA.
During an additional <FONT STYLE="white-space:nowrap">two-year</FONT> period of market exclusivity, a generic or biosimilar MAA can be submitted and authorized, and the innovator&#146;s data may be referenced, but no generic or biosimilar medicinal
product can be placed on the EEA market until the expiration of the market exclusivity. The overall <FONT STYLE="white-space:nowrap">ten-year</FONT> period will be extended to a maximum of 11 years if, during the first eight years of those ten
years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with
existing therapies. Even if a compound is considered to be an innovative medical product so that the innovator gains the prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such
company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Periods of Authorization and Renewals </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A marketing
authorization has an initial validity for five years in principle. The marketing authorization may be renewed after five years on the basis of a <FONT STYLE="white-space:nowrap">re-evaluation</FONT> of the risk-benefit balance by the EMA (for a
centrally authorized product) or by the competent authority of the relevant EU Member State(for a centrally authorized product). To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated
version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. The European Commission or
the competent authorities of the EU Member States may decide, on justified grounds relating to pharmacovigilance, to proceed with one further five-year period of marketing authorization. Once subsequently definitively renewed, the marketing
authorization shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the EEA market (in case of centralized procedure) or on the market of the authorizing EU Member State
within three years after authorization, or if the product is removed from the market for three consecutive years, ceases to be valid (the <FONT STYLE="white-space:nowrap">so-called</FONT> sunset clause). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Orphan Drug Designation and Exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Regulation (EC)
No.&nbsp;141/2000, as implemented by Regulation (EC) No.&nbsp;847/2000 provides that a drug can be designated as an orphan drug by the European Commission if its sponsor can establish: that the product is intended for the diagnosis, prevention or
treatment of a life-threatening or chronically debilitating condition and either (i)&nbsp;the prevalence of the condition is affecting not more than five in ten thousand persons in the EU when the application is made, or (ii)&nbsp;that without
incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify the necessary investment in its development. In each case, the applicant must demonstrate that there exists no satisfactory method of
diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the drug will be of significant benefit to those affected by that condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Once authorized, orphan medicinal products are entitled to ten years of market exclusivity in all EU Member States and in addition a range of other
benefits during the development and regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
review process including scientific assistance for study protocols, authorization through the centralized marketing authorization procedure and a reduction or elimination of registration and
marketing authorization fees. During the period of market exclusivity, marketing authorization may only be granted for a &#147;similar medicinal product&#148; with the same orphan indication if: (i)&nbsp;the marketing authorization holder for the
original orphan medicinal product consents to the authorization of the second orphan product; or (ii)&nbsp;the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities. Marketing authorization may also be
granted to a similar medicinal product with the same orphan indication if it is established that this product is safer, more effective or otherwise clinically superior to the original orphan medicinal product. A &#147;similar medicinal product&#148;
is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The period of market exclusivity may, in
addition, be reduced to six years if at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation because, for example, the original orphan medicinal product is sufficiently profitable not
to justify maintenance of market exclusivity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Regulatory Requirements After a Marketing Authorization has been Obtained </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Where an authorization for a medicinal product in the EU is obtained, the holder of the marketing authorization is required to comply with a range of
requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Compliance with the EU&#146;s stringent pharmacovigilance or safety reporting rules must be ensured. These rules can impose
post-authorization studies and additional monitoring obligations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The manufacturing of authorized medicinal products, for which a separate manufacturer&#146;s license is mandatory, must
also be conducted in strict compliance with the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice.
These requirements include compliance with EU cGMP standards when manufacturing medicinal products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import
the active pharmaceutical ingredients into the EU. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and advertising
directed toward the prescribers of drugs and/or the general public, are strictly regulated in the EU notably under Directive 2001/83EC, as amended, and are also subject to EU Member State national laws. <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Direct-to-consumer</FONT></FONT> advertising of prescription medicines is prohibited across the EU. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>General Data
Protection Regulation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the EU, including
personal health data, is subject to the EU General Data Protection Regulation, or GDPR, which became effective on May&nbsp;25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data,
including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards
to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries
outside the EU, including the United States, and permits data protection authorities to impose large penalties </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
for violations of the GDPR, including potential fines of up to <FONT STYLE="font-family:Times New Roman">&#128;</FONT>20&nbsp;million or 4% of annual global revenues, whichever is greater. The
GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance
with the GDPR will be a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Brexit and the Regulatory Framework in the United Kingdom </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On
June&nbsp;23, 2016, the electorate in the United Kingdom voted in favor of leaving the EU, commonly referred to as Brexit. Following protracted negotiations, the United Kingdom left the EU on January&nbsp;31, 2020. A transition period began on
February&nbsp;1, 2020, during which EU pharmaceutical law remained applicable to the United Kingdom, however this ended on December&nbsp;31, 2020. Since the regulatory framework in the United Kingdom covering quality, safety and efficacy of
pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from EU Directives and Regulations, Brexit could materially impact the future regulatory regime that applies
to products and the approval of product candidates in the United Kingdom, as the United Kingdom legislation now has the potential to diverge from EU legislation. It remains to be seen how Brexit will impact regulatory requirements for product
candidates and products in the United Kingdom in the long-term. The MHRA has recently published detailed guidance for industry and organizations to follow from January&nbsp;1, 2021 now that the transition period is over, which will be updated as the
United Kingdom&#146;s regulatory position on medical products evolves over time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore, while the Data Protection Act of 2018 in the United
Kingdom that &#147;implements&#148; and complements the EU&#146;s GDPR, is now effective in the United Kingdom, it is still unclear whether transfer of data from the European Economic Area, or EEA, to the United Kingdom will remain lawful under
GDPR. The Trade and Cooperation Agreement provides for a transitional period during which the United Kingdom will be treated like an EU Member State in relation to processing and transfers of personal data for four months from January&nbsp;1, 2021.
This may be extended by two further months. After such period, the United Kingdom will be a &#147;third country&#148; under the GDPR unless the European Commission adopts an adequacy decision in respect of transfers of personal data to the United
Kingdom. The United Kingdom has already determined that it considers all of the EU and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom to the EU and EEA remain unaffected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Pricing Decisions for Approved Products </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the EU, pricing
and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the
cost-effectiveness of a particular product candidate to currently available therapies or <FONT STYLE="white-space:nowrap">so-called</FONT> health technology assessments, in order to obtain reimbursement or pricing approval. For example, EU Member
States have the option to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a
product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products, but monitor and control
prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage
health care expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on health care costs in general, particularly prescription products, has become intense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a result, increasingly high barriers are being erected to the entry of new products. Political,
economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States, and parallel trade, i.e., arbitrage
between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced EU Member States, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will
allow favorable reimbursement and pricing arrangements for any products, if approved in those countries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Rest of the World Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For other countries outside of Canada, the EU and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements
governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. Additionally, the clinical trials must be conducted in accordance with GCP requirements and the applicable regulatory requirements
and the ethical principles that have their origin in the Declaration of Helsinki. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we fail to comply with applicable foreign regulatory
requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Coverage and Reimbursement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Successful
commercialization of new drug products depends in part on the extent to which reimbursement for those drug products will be available from government health administration authorities, private health insurers, and other organizations. In the United
States, government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drug products they will pay for and establish reimbursement levels. The availability and extent of
reimbursement by governmental and private payors is essential for most patients to be able to afford a drug product. Sales of drug products depend substantially, both domestically and abroad, on the extent to which the costs of drugs products are
paid for by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to
control costs by limiting coverage and the amount of reimbursement for particular drug products. Third-party payors are increasingly challenging the price, examining the medical necessity, and reviewing the cost-effectiveness of medical products,
therapies and services, in addition to questioning their safety and efficacy. Obtaining reimbursement for our products may be particularly difficult because of the higher prices often associated with branded drugs and drugs administered under the
supervision of a physician. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA and foreign approvals. These
studies could result in delays or disadvantageous coverage for products we develop. Our product candidates may not be considered medically necessary or cost-effective. Obtaining coverage and reimbursement approval of a product from a government or
other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our product on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis, with no assurance that coverage and adequate reimbursement will be obtained. A payor&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate
will be approved. Further, one payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
us to maintain price levels sufficient to realize an appropriate return on its investment in product development. If reimbursement is not available or is available only at limited levels, we may
not be able to successfully commercialize any product candidate that we successfully develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In many countries, the prices of drug products are
subject to varying price control mechanisms as part of national health systems. In general, the prices of drug products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for
drug products, but monitor and control company profits. Accordingly, in markets outside the United States, the reimbursement for drug products may be reduced compared with the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States, the principal decisions about reimbursement for new drug products are typically made by CMS, an agency within the HHS. CMS decides
whether and to what extent a new drug product will be covered and reimbursed under Medicare, and private payors tend to follow CMS to a substantial degree. However, no uniform policy of coverage and reimbursement for drug products exists among
third-party payors and coverage and reimbursement levels for drug products can differ significantly from payor to payor. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#146;s
determination that use of a drug product is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot be sure that coverage or reimbursement will be available for any product that we commercialize and, if coverage and reimbursement are
available, what the level of reimbursement will be. Coverage may also be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Future coverage and reimbursement may be subject to
increased restrictions, such as prior authorization requirements, and to changes in the rates of reimbursement for orphan drug products both in the United States and in international markets. Reimbursement may impact the demand for, or the price of,
any product for which we obtain regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The MMA established the Medicare Part D program to provide a voluntary prescription drug
benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. While all Medicare drug plans must give at least a
standard level of coverage set by Medicare, Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each Part D prescription drug plan can develop its own drug formulary that identifies which drugs it will
cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used
by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for drugs for which we obtain marketing approval. Any
negotiated prices for any of our products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors
often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from
<FONT STYLE="white-space:nowrap">non-governmental</FONT> payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For a drug product to receive federal reimbursement under the Medicaid or Medicare
Part B programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based on the average manufacturer price, or AMP, and Medicaid
rebate amounts reported by the manufacturer. As of 2010, the ACA expanded the types of entities eligible to receive discounted 340B pricing, although under the current state of the law these newly eligible entities (with the exception of
children&#146;s hospitals) will not be eligible to receive discounted 340B pricing on orphan drugs. As the required 340B discount is determined based on average manufacturer price, or AMP, and Medicaid rebate data, the revisions to the Medicaid
rebate formula and AMP definition described above could cause the required 340B discount to increase. The American Recovery and Reinvestment Act of 2009 provides funding for the federal government to compare the effectiveness of different treatments
for the same illness. The plan for the research was published in 2012 by HHS, the Agency for Healthcare Research and Quality and the NIH, and periodic reports on the status of the research and related expenditures are made to Congress. Although the
results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of our product candidates, if any such drug or the
condition that they are intended to treat are the subject of a trial. It is also possible that comparative effectiveness research demonstrating benefits in a competitor&#146;s drug could adversely affect the sales of our product candidate. If
third-party payors do not consider our drugs to be cost-effective compared to other available therapies, they may not cover our drugs after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow
us to sell our drugs on a profitable basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These laws and future state and federal healthcare reform measures may be adopted in the future, any of
which may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any product candidates for which we may obtain regulatory approval or the frequency with which any such product
candidate is prescribed or used. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Outside of the United States, the pricing of pharmaceutical products and medical devices is subject to
governmental control in many countries. For example, in the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some
countries may require the completion of additional studies that compare the cost effectiveness of a particular therapy to currently available therapies or <FONT STYLE="white-space:nowrap">so-called</FONT> health technology assessments, in order to
obtain reimbursement or pricing approval. Other countries may allow companies to fix their own prices for products, but monitor and control product volumes and issue guidance to physicians to limit prescriptions. Efforts to control prices and
utilization of pharmaceutical products and medical devices will likely continue as countries attempt to manage healthcare expenditures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal Proceedings
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are not currently subject to any material legal proceedings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Facilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our offices are located in Cambridge,
Massachusetts and consist of approximately 8,850 square feet of leased office space. The lease expires in October 2026. In January 2022, we entered into an operating lease for additional office space in Cambridge, Massachusetts. The lease includes
an option to extend the lease term for one period of three years at the then prevailing market rate. The lease called for a security deposit of $0.5&nbsp;million. The lease was amended in March 2022 to increase the monthly minimum rent payment
amount. Total minimum rental payments over the initial three year lease term are expected to be $5.7&nbsp;million. We believe that our facilities are adequate for our current needs and that suitable additional or substitute space would be available
if needed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employees and Human Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2022, we had 226 full-time employees. Of our workforce, 47 employees are directly engaged in research and development with the rest
providing administrative, business and operations support. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider the relationship with our employees to be good. We also use outside
consultants and contractors with unique expertise and skills for limited engagements. As of June&nbsp;30, 2022, we utilized multiple outside consultants or contractors that represented approximately 6 full-time equivalents to supplement our
full-time workforce. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our human capital is integral to helping us achieve our goal to end the suffering caused by neurodegenerative diseases. Our
human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and
motivate selected employees, consultants and directors through the granting of stock-based compensation awards and cash-based performance bonus awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc383770_10"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth information with respect to the beneficial ownership of our common stock as of September 15, 2022 by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">all of our directors and executive officers as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The column entitled &#147;Percentage of Shares Beneficially Owned&#151;Before Offering&#148; is based on a total of 58,533,226
shares of our common stock outstanding as of September 15, 2022. The column entitled &#147;Percentage of Shares Beneficially Owned&#151;After Offering&#148; is based on&nbsp;64,533,226&nbsp;shares of our common stock to be outstanding after this
offering, including the&nbsp;6,000,000&nbsp;shares of our common stock that we are selling in this offering, but not including any additional shares issuable upon exercise of outstanding options or any exercise by the underwriters of their option to
purchase additional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Beneficial ownership is determined in accordance with the rules and regulations of the SEC and includes voting or
investment power with respect to our common stock. Shares of our common stock subject to options that are currently exercisable or exercisable within 60 days after September 15, 2022 are considered outstanding and beneficially owned by the person
holding the options for the purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Except as otherwise noted, the persons and entities in this table have
sole voting and investment power with respect to all of the shares of our common stock beneficially owned by them, subject to community property laws, where applicable. Except as otherwise set forth below, the address of the beneficial owner is c/o
Amylyx Pharmaceuticals, Inc., 43 Thorndike St., Cambridge, MA 02141. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Shares&nbsp;Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B><I>5% Stockholders</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Morningside Venture Investments Limited<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,302,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Viking Global Opportunities Illiquid Investments <FONT STYLE="white-space:nowrap">Sub-Master</FONT> LP<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,770,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">ALS Invest 1 B.V.<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,795,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Perceptive Advisors LLC<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,971,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B><I>Named Executive Officers and Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Joshua Cohen<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,973,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Justin Klee<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,973,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">James Frates<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Margaret Olinger<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Patrick D. Yeramian, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">George Mclean Milne Jr, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Isaac Cheng, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Paul Fonteyne<SUP STYLE="font-size:75%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Daphne Quimi<SUP STYLE="font-size:75%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>All Current Executive Officers and Directors as a Group (ten persons)</I><SUP
STYLE="font-size:75%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,692,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Represents beneficial ownership of less than 1% of our outstanding stock. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i) 9,057,264 shares of common stock held by Morningside Venture Investments Limited, or Morningside, and
(ii) 244,878 shares of common stock held by MVIL, LLC, or MVIL, a wholly-owned subsidiary of Morningside. Frances Anne Elizabeth Richard, Jill Marie&nbsp;Franklin, Peter Stuart Allenby&nbsp;Edwards, and Cheung Ka Ho are the directors of Morningside
and share voting and dispositive power with respect to the securities held by Morningside, including by MVIL, its wholly owned subsidiary. Ms.&nbsp;Richard, Ms.&nbsp;Franklin, Mr.&nbsp;Edwards and Mr.&nbsp;Cheung each disclaim beneficial ownership
of the securities held by Morningside and MVIL. Cheng Yee Wing and Wong See Wai are the managers of MVIL and share voting and dispositive power with respect to the securities held by MVIL. Ms. Cheng and Mr. Wong each disclaim ownership of the
securities owned by MVIL. Morningside is ultimately wholly beneficially owned by a family trust established by Madam Chan Tan Ching Fen. The address of Morningside is 2nd Floor, Le Prince de Galles, <FONT STYLE="white-space:nowrap">3-5</FONT> Avenue
Citronniers, MC 98000, Monaco. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Based on a Schedule 13G/A filed with the SEC on September 12, 2022 by Viking Global Investors LP, or VGI, Viking Global
Opportunities Parent GP LLC, or Opportunities Parent, Viking Global Opportunities GP LLC, or Opportunities GP, Viking Global Opportunities Portfolio GP LLC, or Opportunities Portfolio GP, Viking Global Opportunities Illiquid Investments Sub-Master
LP, or Viking, DRAGSA 96 LLC, or DRAGSA 96, O. Andreas Halvorsen, David C. Ott and Rose S. Shabet. Consists of (i) 3,919,596 shares of common stock held by Viking and (ii) 1,850,940 shares of common stock held by DRAGSA 96. VGI provides managerial
services to Viking and DRAGSA 96. VGI has the authority to dispose of and vote the shares of common stock directly owned by Viking and DRAGSA 96. Opportunities Parent is the general partner of Opportunities GP, which has the authority to dispose of
and vote the shares of common stock controlled by Opportunities Portfolio GP (which consists of the shares of common stock directly held by Viking) and the shares of common stock directly held by DRAGSA 96. Opportunities GP serves as the sole member
of Opportunities Portfolio GP and has the authority to dispose of and vote the shares of common stock controlled by Opportunities Portfolio GP, which consists of the shares of common stock directly held by Viking. In addition, Opportunities GP is
the general partner of each of Viking Global Opportunities Intermediate LP and Viking Global Opportunities LP. The membership interests of DRAGSA 96 are held by Viking Global Opportunities Intermediate LP and Viking Global Opportunities LP.
Accordingly, Opportunities GP has the authority to dispose of and vote the shares of common stock directly held by DRAGSA 96. Opportunities Portfolio GP serves as the general partner of Viking and has the authority to dispose of and vote the shares
of common stock directly owned by Viking. Viking has the authority to dispose of and vote the shares of common stock directly owned by it, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of
Opportunities Portfolio GP, which provides managerial services to Viking. Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment
in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests
through Viking. DRAGSA 96 has the authority to dispose of and vote the shares of common stock directly owned by it, which power may be exercised by Opportunities GP and its general partner, Opportunities Parent, and by VGI, an affiliate of
Opportunities GP, which provides managerial services to DRAGSA 96. The membership interests of DRAGSA 96 are held by Viking Global Opportunities Intermediate LP and Viking Global Opportunities LP. Opportunities GP is the general partner of Viking
Global Opportunities LP and Viking Global Opportunities Intermediate LP. Mr.&nbsp;Halvorsen, Mr.&nbsp;Ott and Ms.&nbsp;Shabet, as Executive Committee Members of Viking Global Partners LLC (general partner of VGI) and Opportunities Parent, have
shared authority to dispose of and vote the shares of common stock beneficially owned by VGI and Opportunities Parent. The address of each of the entities is c/o Viking Global Investors LP, 55 Railroad Avenue, Greenwich, CT 06830.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 5,795,280 shares of common stock held by ALS Invest. ALS Invest is managed by SUNU Ventures BV.
Felix-Andr&eacute; von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the shares held by ALS Invest. The address for ALS Invest and SUNU Ventures BV is Eerste Weteringdwarsstraat 54E,
1017 TP Amsterdam, The Netherlands. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Based on a Schedule 13G filed with the SEC on June&nbsp;21, 2022 by Perceptive Advisors LLC, or Perceptive Advisors,
Perceptive Life Sciences Master Fund, Ltd., or Perceptive Master Fund, and Joseph Edelman. Consists of 2,971,413 shares of common stock directly held by Perceptive Master Fund. Perceptive Advisors serves as the investment manager to Perceptive
Master Fund and may be deemed to beneficially own such shares. Mr.&nbsp;Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i) 2,823,585 shares of common stock and (ii) 150,024 shares of common stock underlying stock options
exercisable within 60 days of September 15, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i) 2,823,585 shares of common stock and (ii) 150,024 shares of common stock underlying stock options
exercisable within 60 days of September 15, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 197,768 shares of common stock underlying stock options exercisable within 60 days of September 15, 2022.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i) 188,425 shares of common stock and (ii) 80,350 shares of common stock underlying stock options
exercisable within 60 days of September 15, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i) 178,000 shares of common stock and (ii) 82,771 shares of common stock underlying stock options
exercisable within 60 days of September 15, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i) 910,821 shares of common stock and (ii) 10,400 shares of common stock underlying stock options
exercisable within 60 days of September 15, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i) 6,578 shares of common stock and (ii) 8,400 shares of common stock underlying stock options exercisable
within 60 days of September 15, 2022. Dr.&nbsp;Cheng, a member of our board of directors, is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside Venture Investments Limited and MVIL, LLC.
Dr.&nbsp;Cheng has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of all shares referred to in Footnote 1 above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i) 3,947 shares of common stock and (ii) 42,208 shares of common stock underlying stock options exercisable
within 60 days of September 15, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 35,452 shares of common stock underlying stock options exercisable within 60 days of September 15, 2022.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Includes options to purchase 757,397 shares of common stock exercisable within 60 days of September 15, 2022 held by
executive officers and directors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc383770_11"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>The following summary description of our common stock and preferred stock summarizes the material terms and provisions of our capital stock. The
following description of our capital stock does not purport to be complete and is subject to, and qualified in its entirety by, our certificate of incorporation and bylaws, which are exhibits to the registration statement of which this prospectus
forms a part, and by applicable law. The terms of our common stock and preferred stock may also be affected by Delaware law.</I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our authorized capital stock consists of 300,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par
value $0.0001 per share, all of which shares of preferred stock are undesignated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2022, we had 58,533,226 shares of our common
stock outstanding, held by 134&nbsp;stockholders of record, and no shares of our preferred stock outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our
common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend
rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after
payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more
series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund
terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common
stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company
or other corporate action. No shares of preferred stock are outstanding, and we have no present plan to issue any shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Certain holders of our common stock are entitled to rights with respect to the registration of these securities under the Securities Act. These
rights are provided under the terms of an amended and restated investors&#146; rights agreement, or the investors&#146; rights agreement, between us and certain holders of our common stock. The investors&#146; rights agreement includes demand
registration rights, short-form registration rights and piggyback registration rights. All fees, costs and expenses of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
underwritten registrations under the investors&#146; rights agreement will be borne by us and all selling expenses, including underwriting discounts and selling commissions, will be borne by the
holders of the shares being registered. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Certain holders of our common stock are entitled to demand registration rights. Under the terms of the investors&#146; rights agreement, we will be
required, upon the written request of the holders of at least 25% of our outstanding registrable securities, as defined in the investors&#146; rights agreement, or a lesser percent if the total amount of registrable shares requested to be registered
has an anticipated aggregate offering price to the public, net of selling expenses, of least $15.0&nbsp;million, to file a registration statement and use commercially reasonable efforts to effect the registration of all or a portion of their
registrable securities for public resale. We are required to effect only two registrations pursuant to this provision of the investors&#146; rights agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Short-Form Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the
investors&#146; rights agreement, if we are eligible to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> upon the written request of the holders of at least 10% of our outstanding registrable securities, as defined
in the investors&#146; rights agreement, may demand in writing that we register their registrable securities under the Securities Act so long as the total amount of registrable shares requested to be registered has an anticipated aggregate offering
price to the public, net of selling expenses, of least $3.0&nbsp;million. We are required to effect only two registrations in any twelve month period pursuant to this provision of the investors&#146; rights agreement. The right to have such shares
registered on Form <FONT STYLE="white-space:nowrap">S-3</FONT> is further subject to other specified conditions and limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Piggyback Registration
Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the investors&#146; rights agreement, if we register any of our securities either for our own account or for the account
of other security holders, the holders of registrable securities are entitled to include their shares in the registration. Subject to certain exceptions contained in the investors&#146; rights agreement, we and the underwriters may limit the number
of shares included in the underwritten offering to the number of shares which we and the underwriters determine in our sole discretion will not jeopardize the success of the offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Indemnification </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our investors&#146; rights agreement
contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are
obligated to indemnify us for material misstatements or omissions attributable to them. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Expiration of Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The demand registration rights and short form registration rights granted under the investors&#146; rights agreement will terminate no later than
January&nbsp;11, 2027, the fifth anniversary of the completion of our IPO. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Anti-Takeover Effects of our Certificate of Incorporation and Bylaws and Delaware Law
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our certificate of incorporation and bylaws include a number of provisions that may have the effect of delaying, deferring or preventing another
party from acquiring control of us and encouraging </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue
<FONT STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. These provisions include the items described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Board Composition and Filling
Vacancies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our certificate of incorporation provides for the division of our board of directors into three classes serving staggered
three-year terms, with one class being elected each year. Our certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of
<FONT STYLE="white-space:nowrap">66-2/3%</FONT> or more of the shares then entitled to vote at an election of directors. Further, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of
our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has
the effect of making it more difficult for stockholders to change the composition of our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>No Written Consent of Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special
meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our bylaws or removal of directors by
our stockholders without holding a meeting of stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Meetings of Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our certificate of incorporation and bylaws provide that only a majority of the members of our board of directors then in office may call special
meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws limit the business that may be conducted at an annual meeting of
stockholders to those matters properly brought before the meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Advance Notice Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or
new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken.
Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our bylaws specify the requirements as
to form and content of all stockholders&#146; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Amendment to Certificate of Incorporation and Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any amendment of our certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our
certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment
of the provisions relating to stockholder action, board composition, limitation of liability and the amendment of our bylaws and certificate of incorporation must be approved by not less than <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
outstanding shares entitled to vote on the amendment, and not less than <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the outstanding shares of each class entitled to vote thereon as a
class. Our bylaws may be amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of at least
<FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the outstanding shares entitled to vote on the amendment, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the
outstanding shares entitled to vote on the amendment, in each case voting together as a single class. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Undesignated Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our certificate of incorporation provides for 10,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares of
preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of
directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other
transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our certificate of incorporation grants our board of directors broad power to establish the rights and
preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also
adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Exclusive Jurisdiction for Certain Actions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our bylaws
provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action
asserting a claim of breach of a fiduciary duty owed by any of our directors, officers and employees to us or our stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our
certificate of incorporation or our bylaws, or (iv)&nbsp;any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named
as defendants therein. Although we believe this provision benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits
against our directors and officers. The enforceability of similar exclusive forum provisions in other companies&#146; bylaws has been challenged in legal proceedings, and it is possible that a court could rule that this provision in our bylaws is
inapplicable or unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our bylaws also provide that the United States Federal District Courts will be the exclusive forum for resolving any
complaint asserting a cause of action arising under the Securities Act or the Exchange Act, unless we consent in writing to an alternative forum, is intended to allow for the consolidation of multi-jurisdiction litigation, avoid state court forum
shopping, provide efficiencies in managing the procedural aspects of securities litigation and reduce the risk that the outcome of cases in multiple jurisdictions could be inconsistent. Although our bylaws contain the choice of forum provisions
described above, it is possible that a court could rule that such provisions are inapplicable for a particular claim or action or that such provisions are unenforceable. For example, under the Securities Act, federal courts have concurrent
jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act, and investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Section&nbsp;203 of the Delaware General Corporation Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law. In general, Section&nbsp;203 prohibits a publicly held
Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination
is approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">before the stockholder became interested, our board of directors approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested
stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers,
and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or at or after the time the stockholder became interested, the business combination was approved by our board of directors and
authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our board of directors and
authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Section&nbsp;203 defines a business combination to include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; any sale, transfer, lease, pledge or
other disposition involving the interested stockholder of 10% or more of the assets of the corporation; subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the
interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share
of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial
benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, Section&nbsp;203 defines an interested stockholder as any entity or
person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Exchange Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our common stock is listed on the Nasdaq
Global Select Market under the trading symbol &#147;AMLX.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc383770_12"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Future sales of our common stock, including shares issued upon the exercise of outstanding options or warrants, in the public market after this
offering, or the perception that those sales may occur, could cause the prevailing market price for our common stock to fall or impair our ability to raise equity capital in the future. As described below, only a limited number of shares of our
common stock will be restricted from sale in the public market after consummation of this offering due to the contractual and legal restrictions on resale described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Sale of Restricted Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on the number of shares of
our common stock outstanding as of June 30, 2022 and assuming (1) no exercise of the underwriters&#146; option to purchase additional shares of common stock and (2) no exercise of any of our other outstanding options, we will have outstanding an
aggregate of approximately 64,533,226 shares of common stock following this offering. All of the shares sold in this offering will be freely tradable in the public market without restriction or further registration under the Securities Act, unless
held by our affiliates, as that term is defined under Rule 144 under the Securities Act, or subject to lock-up agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Of the shares that were
originally issued and sold by us prior to our initial public offering in transactions that were exempt from registration under the Securities Act, approximately 16.1 million of those shares are deemed &#147;restricted securities&#148; as that term
is defined under Rule 144 under the Securities Act. Restricted securities may be sold in the public market only if their offer and sale is registered under the Securities Act or if the offer and sale of those securities qualify for an exemption from
registration, including exemptions provided by Rules 144 and 701 under the Securities Act, which are summarized below. Any shares held by our affiliates may only be sold in compliance with the limitations described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, under Rule 144, any person who is not
our affiliate and has not been our affiliate at any time during the preceding three months and has held their shares for at least six months, including the holding period of any prior owner other than one of our affiliates, may sell shares without
restriction, subject to the availability of current public information about us. In addition, under Rule 144, any person who is not our affiliate and has not been our affiliate at any time during the preceding three months and has held their shares
for at least one year, including the holding period of any prior owner other than one of our affiliates, would be entitled to sell an unlimited number of shares immediately without regard to whether current public information about us is available.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A person who is our affiliate or who was our affiliate at any time during the preceding three months may sell any unrestricted securities, as well
as restricted securities that the person has beneficially owned for at least six months, including the holding period of any prior owner other than one of our affiliates, under Rule 144. Affiliates selling restricted or unrestricted securities may
sell a number of shares within any three-month period that does not exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1% of the number of shares then outstanding, which will equal approximately&nbsp;645,332&nbsp;shares immediately after this
offering, assuming no exercise of the underwriters&#146; option to purchase additional shares; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the average weekly trading volume of our common stock on the Nasdaq Global Select Market during the four calendar weeks
preceding the filing of a notice on Form 144 with respect to the sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sales under Rule 144 by our affiliates are also subject to
manner of sale provisions and notice requirements and to the availability of current public information about us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, under Rule 701 of the Securities Act, any of our employees, consultants or advisors, other than our affiliates, who purchased shares from us
in connection with a qualified compensatory stock plan or other written agreement is eligible to resell these shares in reliance on Rule 144, but without compliance with the holding period requirements of Rule 144 and without regard to the volume of
such sales or the availability of public information about us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All of our directors and officers and certain stockholders have signed a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement which prevents them
from selling any of our common stock or any securities convertible into or exercisable or exchangeable for common stock for a period of not less than 90 days from the date of this prospectus without the prior written consent of Goldman Sachs &amp;
Co. LLC, BofA Securities, Inc., SVB Securities LLC and Evercore Group L.L.C., subject to certain exceptions. See the section entitled &#147;Underwriting&#148; appearing elsewhere in this prospectus for more information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Certain holders of our securities are
entitled to various rights with respect to registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act
immediately upon the effectiveness of the registration. See &#147;&#151;Registration Rights&#148; appearing elsewhere in this prospectus for more information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity Incentive Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have filed one or more
registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register our shares issued or reserved for issuance under our equity incentive plans. Accordingly, shares registered under such registration
statements are available for sale in the open market, unless such shares are subject to vesting restrictions with us or the <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc383770_13"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>FOR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following discussion is a summary of certain U.S. federal income tax considerations applicable to <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holders (as defined below) with respect to their ownership and disposition of shares of our common stock issued pursuant to this offering. For purposes of this discussion, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder means a beneficial
owner of our common stock that is for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a corporation or any other organization taxable as a corporation for U.S. federal income tax purposes that is created or
organized in or under laws other than the laws of the United States, any state thereof, or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an estate, the income of which is not subject to U.S. federal income tax on a net income basis; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a trust that (1)&nbsp;has not made an election to be treated as a U.S. person under applicable U.S. Treasury Regulations
and (2)&nbsp;either (i) is not subject to the primary supervision of a court within the United States or (ii)&nbsp;is not subject to the substantial control of one or more U.S. persons. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This discussion does not address the tax treatment of partnerships or other entities that are pass-through entities for U.S. federal income tax purposes
or persons that hold their common stock through partnerships or other pass-through entities. A partner in a partnership or other pass-through entity that will hold our common stock should consult his, her or its tax advisor regarding the tax
consequences of holding and disposing of our common stock through a partnership or other pass-through entity, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This discussion is
based on current provisions of the U.S. Internal Revenue Code of 1986, as amended, or the Code, existing and proposed U.S. Treasury Regulations promulgated thereunder, current administrative rulings and judicial decisions, all as in effect as of the
date of this prospectus and, all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any such change or differing interpretation could alter the tax consequences to
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders described in this prospectus. There can be no assurance that the Internal Revenue Service, which we refer to as the IRS, will not challenge one or more of the tax consequences described
herein. We assume in this discussion that a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds shares of our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code, which is generally property held for
investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of that <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s individual circumstances including the alternative minimum tax, or the Medicare tax on net investment income, the
timing of income accruals required under Section&nbsp;451(b) of the Code, the rules regarding qualified small business stock within the meaning of Section&nbsp;1202 of the Code and any election to apply
<FONT STYLE="white-space:nowrap">Section&nbsp;1400Z-2</FONT> of the Code to gains recognized with respect to shares of our common stock. This discussion also does not address any U.S. state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
taxes or any other aspect of any U.S. federal tax other than the income tax. This discussion also does not consider any specific facts or circumstances that may apply to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and does not address
the special tax rules applicable to particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">financial institutions; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulated investment companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">pension plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations that
accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;qualified foreign pension funds,&#148; or entities wholly owned by a &#147;qualified foreign pension fund&#148;;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or other
integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons who have elected to mark securities to market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons who have a functional currency other than the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as
compensation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">certain U.S. expatriates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This discussion is for general information only and is not tax advice. Accordingly, all prospective <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holders of our common stock should consult their tax advisors with respect to the U.S. federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of the purchase, ownership and disposition of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Distributions on Our Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Distributions, if any, on
our common stock will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current
and accumulated earnings and profits, the excess will be treated as a <FONT STYLE="white-space:nowrap">tax-free</FONT> return of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s investment, up to such holder&#146;s tax basis in the
common stock. Any remaining excess will be treated as capital gain, subject to the tax treatment described below in &#147;Gain on sale or other taxable disposition of our common stock.&#148; Any such distributions will also be subject to the
discussions below under the sections titled &#147;Backup withholding and information reporting&#148; and &#147;Withholding and information reporting requirements&#151;FATCA.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Subject to the discussion in the following two paragraphs in this section, dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder
generally will be subject to withholding of U.S. federal income tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. If we or another
withholding agent apply over-withholding or if a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder does not timely provide us with the required certification, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be entitled to a
refund or credit of any excess tax withheld by timely filing an appropriate claim with the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Dividends that are treated as effectively connected
with a trade or business conducted by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base
maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States, are generally exempt from the 30% withholding tax if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder satisfies applicable certification
and disclosure requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same U.S. federal income tax rates applicable to United States persons (as defined in the Code). Any U.S.
effectively connected income received by a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a corporation may also, under certain circumstances, be subject to an additional &#147;branch profits tax&#148; at a 30% rate or
such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder&#146;s country of residence generally will be required to provide a properly
executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or successor form) to the applicable withholding agent and satisfy applicable certification
and other requirements. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders are urged to consult their tax advisors regarding their entitlement to benefits under a relevant income tax treaty. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing a U.S. tax return with the IRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Gain on Sale or Other Taxable Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Subject to the discussions below under &#147;Backup withholding and information reporting&#148; and &#147;Withholding and information reporting
requirements&#151;FATCA,&#148; a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to any U.S. federal income tax on any gain realized upon such holder&#146;s sale or other taxable disposition of shares of our
common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a U.S.
trade or business and, if an applicable income tax treaty so provides, is attributable to a permanent establishment or a fixed-base maintained by such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, in which case the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed on a net income basis at the U.S. federal income tax rates applicable to United States persons (as defined in the Code) and, if the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a foreign corporation, the branch profits tax described above in &#147;Distributions on our common stock&#148; also may apply; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present in the United
States for a period or periods aggregating 183 days or more in the taxable year of the disposition and certain other conditions are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30% tax (or such
lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence) on the net gain derived from the disposition, which may be offset by certain U.S. source capital losses of the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder, if any (even though the individual is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S. federal income
tax returns with respect to such losses; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we are, or have been, at any time during the five-year period preceding such sale or other taxable disposition (or the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period, if shorter) a &#147;U.S. real property holding corporation,&#148; unless our common stock is regularly traded on an established securities market and the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder holds no more than 5% of our outstanding common stock, directly or indirectly, actually or constructively, during the shorter of the <FONT STYLE="white-space:nowrap">5-year</FONT> period ending on
the date of the disposition or the period that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder held our common stock. Generally, a corporation is a U.S. real property holding corporation only if the fair market value of its U.S. real
property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we do not believe that we
are, or have been, a U.S. real property holding corporation, or that we are likely to become one in the future. No assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rules
described above </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Backup Withholding and Information Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We must report annually to the IRS and to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder the gross amount of the distributions on our
common stock paid to such holder and the tax withheld, if any, with respect to such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
distributions. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders may have to comply with specific certification procedures to establish that the holder is not a United States person (as
defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock. Dividends paid to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to withholding of U.S. federal income
tax, as described above in &#147;Distributions on our common stock,&#148; generally will be exempt from U.S. backup withholding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Information
reporting and backup withholding will generally apply to the proceeds of a disposition of our common stock by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the
holder certifies its status as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a
payment of disposition proceeds to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder where the transaction is effected outside the United States through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker. However, for
information reporting purposes, dispositions effected through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected
through a U.S. office of a broker. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the application of the information reporting and backup withholding rules to them. Copies of information returns
may be made available to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is incorporated under the provisions of a specific treaty or agreement. Backup withholding is not an
additional tax. Any amounts withheld under the backup withholding rules from a payment to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder can be refunded or credited against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder&#146;s U.S. federal income tax liability, if any, provided that an appropriate claim is filed with the IRS in a timely manner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Withholding and
Information Reporting Requirements&#151;FATCA </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Provisions of the Code commonly referred to as the Foreign Account Tax Compliance Act, or FATCA,
generally impose a U.S. federal withholding tax at a rate of 30% on payments of dividends on our common stock paid to a foreign entity unless (i)&nbsp;if the foreign entity is a &#147;foreign financial institution,&#148; such foreign entity
undertakes certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a &#147;foreign financial institution,&#148; such foreign entity identifies certain of its U.S. investors, if any, or
(iii)&nbsp;the foreign entity is otherwise exempt under FATCA. Under applicable U.S. Treasury regulations, withholding under FATCA currently applies to payments of dividends on our common stock. Although the FATCA provisions of the Code would
require FATCA withholding on gross proceeds, currently proposed U.S. Treasury Regulations provide that FATCA withholding does not apply to gross proceeds from the disposition of property of a type that can produce U.S. source dividends or interest.
Taxpayers (including withholding agents) can generally rely on the proposed Treasury Regulations until final Treasury Regulations are issued. Under certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be eligible for
refunds or credits of this withholding tax. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders
should consult their tax advisors regarding the possible implications of this legislation on their investment in our common stock and the entities through which they hold our common stock, including, without limitation, the process and deadlines for
meeting the applicable requirements to prevent the imposition of the 30% withholding tax under FATCA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc383770_14"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and the underwriters named below have entered into an underwriting agreement with respect to the shares being offered. Subject to certain conditions,
each underwriter has severally agreed to purchase the number of shares indicated in the following table. Goldman Sachs&nbsp;&amp; Co. LLC, BofA Securities, Inc., SVB Securities LLC and Evercore Group L.L.C. are acting as joint book-running managers
of this offering and as representatives of the underwriters. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Number&nbsp;of&nbsp;Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">BofA Securities, Inc. </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">SVB Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">H.C. Wainwright &amp; Co., LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters are committed to take and pay for all of the shares being offered, if any are taken, other than the
shares covered by the option described below unless and until this option is exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters have an option to buy up to an
additional&nbsp;900,000&nbsp;shares from us at the price to the public less the underwriting discount. They may exercise that option for 30 days. If any shares are purchased pursuant to this option, the underwriters will severally purchase shares in
approximately the same proportion as set forth in the table above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table shows the per share and total underwriting discounts and
commissions to be paid to the underwriters by us. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase&nbsp;900,000&nbsp;additional shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full&nbsp;Exercise</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Shares sold by the underwriters to the public will initially be offered at the public offering price set forth on the
cover of this prospectus. Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share from the public offering price. After the
initial offering of the shares, the representatives may change the offering price and the other selling terms. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters&#146; right to reject
any order in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and our officers and our directors and certain shareholders have agreed with the underwriters, subject to certain
exceptions, not to dispose of or hedge any of their common stock or securities convertible into or exchangeable for shares of common stock during the period from the date of this prospectus continuing through the date 90 days after the date of this
prospectus, except with the prior written consent of the representatives. See &#147;Shares Eligible for Future Sale&#148; for a discussion of certain transfer restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;AMLX.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the offering, the underwriters may purchase and sell shares of common stock in the open market. These transactions may include short
sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
number of shares than they are required to purchase in the offering, and a short position represents the amount of such sales that have not been covered by subsequent purchases. A &#147;covered
short position&#148; is a short position that is not greater than the amount of additional shares for which the underwriters&#146; option described above may be exercised. The underwriters may cover any covered short position by either exercising
their option to purchase additional shares or purchasing shares in the open market. In determining the source of shares to cover the covered short position, the underwriters will consider, among other things, the price of shares available for
purchase in the open market as compared to the price at which they may purchase additional shares pursuant to the option described above. &#147;Naked&#148; short sales are any short sales that create a short position greater than the amount of
additional shares for which the option described above may be exercised. The underwriters must cover any such naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are
concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of
common stock made by the underwriters in the open market prior to the completion of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters may also impose a penalty bid.
This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short
covering transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their
own accounts, may have the effect of preventing or retarding a decline in the market price of our stock, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of the common stock. As a
result, the price of the common stock may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these activities at any time. These transactions may
be effected on the Nasdaq Global Select Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We estimate that the total expenses for the offering, excluding underwriting discounts and commissions, will be approximately $0.8&nbsp;million. We have
agreed to reimburse the underwriters for certain of their expenses in an amount up to $25,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have agreed to indemnify the several underwriters
against certain liabilities, including liabilities under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters and their respective affiliates are full service
financial institutions engaged in various activities, which may include sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other
financial and <FONT STYLE="white-space:nowrap">non-financial</FONT> activities and services. Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to the issuer and to
persons and entities with relationships with the issuer, for which they received or will receive customary fees and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the ordinary
course of their various business activities, the underwriters and their respective affiliates, officers, directors and employees may purchase, sell or hold a broad array of investments and actively traded securities, derivatives, loans, commodities,
currencies, credit default swaps and other financial instruments for their own account and for the accounts of their customers, and such investment and trading activities may involve or relate to assets, securities or instruments of the issuer
(directly, as collateral securing other obligations or otherwise) or persons and entities with relationships with the issuer. The underwriters and their respective affiliates may also communicate independent
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
investment recommendations, market color or trading ideas or publish or express independent research views in respect of such assets, securities or instruments and may at any time hold, or
recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>European Economic Area </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In relation to each Member
State of the European Economic Area, each being a Relevant State, no shares have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which
has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except
that the shares may be offered to the public in that Relevant State at any time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus
Regulation), subject to obtaining the prior consent of representatives of any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">provided that no such offer of the shares shall require us or any of the representatives to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or
supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For the purposes of this provision, the expression an &#147;offer to
the public&#148; in relation to the shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase
or subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No shares have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in
relation to the shares which has been approved by the Financial Conduct Authority, except that the shares may be offered to the public in the United Kingdom at any time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK
Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">in any other circumstances falling within Section&nbsp;86 of the Financial Services and Markets Act 2000, or FSMA.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>provided</I> that no such offer of the shares shall require the Issuer or any Manager to publish a prospectus pursuant to
Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#147;offer to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
public&#148; in relation to the shares in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered
so as to enable an investor to decide to purchase or subscribe for any shares and the expression &#147;UK Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act
2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Canada </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares may be sold only to
purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act
(Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with
an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Securities legislation in certain
provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised
by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or
territory for particulars of these rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to section 3A.3 of National Instrument <FONT
STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT>
regarding underwriter conflicts of interest in connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), or the SFO, of Hong Kong and any rules made thereunder; or (b)&nbsp;in other circumstances which do not result in the document
being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, or the CO or which do not constitute an offer to the public within the meaning of the CO. No advertisement,
invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to
be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to
&#147;professional investors&#148; as defined in the SFO and any rules made thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Singapore </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each joint book-running manager has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of Singapore.
Accordingly, each joint book-running manager has represented and agreed that it has not offered or sold any shares or caused the shares to be made the subject of an invitation for subscription or purchase and will not offer or sell any shares or
cause the shares to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus or any other document or material in connection with the offer or
sale, or invitation for subscription or purchase, of the shares, whether directly or indirectly, to any person in Singapore other than: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore,
as modified or amended from time to time, or the SFA, pursuant to Section&nbsp;274 of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any
person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which
is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor, securities or securities- based derivatives contracts (each term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest
(howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">(i) to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section&nbsp;275(1A) or
Section&nbsp;276(4)(i)(B) of the SFA; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">where no consideration is or will be given for the transfer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">where the transfer is by operation of law; as specified in Section&nbsp;276(7) of the SFA; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations
2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Singapore SFA Product Classification&#151;In connection with Section&nbsp;309B of the SFA and the CMP Regulations 2018, unless otherwise
specified before an offer of Notes, we have determined, and hereby notify all relevant persons (as defined in Section&nbsp;309A(1) of the SFA), that the shares are &#147;prescribed capital markets products&#148; (as defined in the CMP Regulations
2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations
on Investment Products). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Japan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares have
not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none of the shares nor any interest therein may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any &#147;resident&#148; of Japan (which term as used herein means any person resident in Japan, including any
corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an
exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Switzerland </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares may not be publicly offered in
Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been prepared without
regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any
other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in
Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Neither this document nor any other offering or marketing material relating to the offering, us or the shares have been or will be
filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of shares has not
been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Dubai International Financial Centre </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This
document relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services Authority, or DFSA. This document is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA.
It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify
the information set forth herein and has no responsibility for this document. The securities to which this document relates may be illiquid and/or subject to restrictions on their resale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this
document you should consult an authorized financial advisor. In relation to its use in the Dubai International Financial Centre, or DIFC, this document is strictly private and confidential and is being distributed to a limited number of investors
and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be offered or sold directly or indirectly to the public in the DIFC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>United Arab Emirates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares have not been, and
are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the DIFC) other than in compliance with the laws of the United Arab Emirates (and the DIFC) governing the issue, offering and sale of securities.
Further, this prospectus does not constitute a public offer of securities in the United Arab Emirates (including the DIFC) and is not intended to be a public offer. This prospectus has not been approved by or filed with the Central Bank of the
United Arab Emirates, the Securities and Commodities Authority or the DFSA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Australia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001, or the
Corporations Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">has not been, and will not be, lodged with the Australian Securities and Investments Commission, or ASIC, as a disclosure
document for the purposes of the Corporations Act and does not purport to include the information required of a disclosure document for the purposes of the Corporations Act; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the
categories of investors, available under section 708 of the Corporations Act, or Exempt Investors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares may not be directly
or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for or buy the shares may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any shares may be
distributed in Australia, except where disclosure to investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares,
you represent and warrant to us that you are an Exempt Investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As any offer of shares under this document will be made without disclosure in
Australia under Chapter 6D.2 of the Corporations Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions
in section 708 applies to that resale. By applying for the shares you undertake to us that you will not, for a period of 12 months from the date of issue of the shares, offer, transfer, assign or otherwise alienate those shares to investors in
Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Bermuda </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Shares may be offered or sold in Bermuda only
in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, <FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons (including companies) may not carry on
or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable Bermuda legislation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Saudi Arabia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities Regulations as
issued by the board of the Saudi Arabian Capital Market Authority, or CMA pursuant to resolution number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-11-2004</FONT></FONT> dated 4&nbsp;October 2004 as amended by resolution
number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-28-2008,</FONT></FONT> as amended. The CMA does not make any representation as to the accuracy or completeness of this document and expressly disclaims any liability
whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the information relating to the
securities. If you do not understand the contents of this document, you should consult an authorized financial adviser. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>British Virgin Islands </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription by or on our
behalf. The shares may be offered to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands), or BVI Companies, but only where the offer will be made to, and received by, the relevant BVI Company
entirely outside of the British Virgin Islands. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>China </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus will not be circulated or distributed in the People&#146;s Republic of China, or PRC, and the shares will not be offered or sold, and
will not be offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale directly or indirectly to any residents of the PRC except pursuant to any applicable laws and regulations of the PRC. Neither this prospectus
nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with applicable laws and regulations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Korea </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares have not been and will not be
registered under the Financial Investments Services and Capital Markets Act of Korea and the decrees and regulations thereunder, or the FSCMA, and the shares have been and will be offered in Korea as a private placement under the FSCMA. None of the
shares may be offered, sold or delivered directly or indirectly, or offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the
applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of Korea and the decrees and regulations thereunder, or the FETL. The shares have not been listed on any of securities exchanges in the world
including, without limitation, the Korea Exchange in Korea. Furthermore, the purchaser of the shares shall comply with all applicable regulatory requirements (including but not limited to requirements under the FETL) in connection with the purchase
of the shares. By the purchase of the shares, the relevant holder thereof will be deemed to represent and warrant that if it is in Korea or is a resident of Korea, it purchased the shares pursuant to the applicable laws and regulations of Korea.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Malaysia </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No prospectus or other offering
material or document in connection with the offer and sale of the shares has been or will be registered with the Securities Commission of Malaysia, or Commission, for the Commission&#146;s approval pursuant to the Capital Markets and Services Act
2007. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be
made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Malaysia other than (i)&nbsp;a closed end fund approved by the Commission; (ii)&nbsp;a holder of a Capital Markets Services License;
(iii)&nbsp;a person who acquires the shares, as principal, if the offer is on terms that the shares may only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each transaction; (iv)&nbsp;an
individual whose total net personal assets or total net joint assets with his or her spouse exceeds RM3&nbsp;million (or its equivalent in foreign currencies), excluding the value of the primary residence of the individual; (v)&nbsp;an individual
who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies) per annum in the preceding twelve months; (vi)&nbsp;an individual who, jointly with his or her spouse, has a gross annual income of RM400,000 (or its
equivalent in foreign currencies), per annum in the preceding twelve months; (vii)&nbsp;a corporation with total net assets exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii)&nbsp;a
partnership with total net assets exceeding RM10&nbsp;million (or its equivalent in foreign currencies); (ix) a bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x) an Islamic bank licensee or
takaful licensee as defined in the Labuan Financial Services and Securities Act 2010; and (xi)&nbsp;any other person as may be specified by the Commission; provided that, in the each of the preceding
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
categories (i)&nbsp;to (xi), the distribution of the shares is made by a holder of a Capital Markets Services License who carries on the business of dealing in securities. The distribution in
Malaysia of this prospectus is subject to Malaysian laws. This prospectus does not constitute and may not be used for the purpose of public offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any
securities requiring the registration of a prospectus with the Commission under the Capital Markets and Services Act 2007. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Taiwan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and
regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the
Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the shares in Taiwan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>South Africa </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Due to restrictions under the securities
laws of South Africa, no &#147;<I>offer to the public</I>&#148; (as such term is defined in the South African Companies Act, No.&nbsp;71 of 2008 (as amended or <FONT STYLE="white-space:nowrap">re-enacted),</FONT> or the South African Companies Act)
is being made in connection with the issue of the shares in South Africa. Accordingly, this document does not, nor is it intended to, constitute a &#147;<I>registered prospectus</I>&#148; (as that term is defined in the South African Companies Act)
prepared and registered under the South African Companies Act and has not been approved by, and/or filed with, the South African Companies and Intellectual Property Commission or any other regulatory authority in South Africa. The shares are not
offered, and the offer shall not be transferred, sold, renounced or delivered, in South Africa or to a person with an address in South Africa, unless one or other of the following exemptions stipulated in section 96(1) applies: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Section&nbsp;96(1)(a) the offer, transfer, sale, renunciation or delivery is to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">persons whose ordinary business, or part of whose ordinary business, is to deal in securities, as principal or agent;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">the South African Public Investment Corporation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">persons or entities regulated by the Reserve Bank of South Africa; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">authorized financial service providers under South African law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">financial institutions recognized as such under South African law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">a wholly owned subsidiary of any person or entity contemplated in (c), (d) or (e), acting as agent in the capacity of an
authorized portfolio manager for a pension fund, or as manager for a collective investment scheme (in each case duly registered as such under South African law); or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">any combination of the person in (i)&nbsp;to (vi); or </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Section&nbsp;96(1) (b) the total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater
than ZAR1,000,000 or such higher amount as may be promulgated by notice in the Government Gazette of South Africa pursuant to section 96(2)(a) of the South African Companies Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc383770_15"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The validity of the shares of our common stock offered hereby is being passed upon for us by Goodwin Procter LLP, Boston, Massachusetts. Certain legal
matters relating to this offering will be passed upon for the underwriters by Wilmer Cutler Pickering Hale and Dorr LLP, New York, New York. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc383770_16">
</A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The financial statements of Amylyx Pharmaceuticals, Inc., incorporated by reference in this prospectus by reference to Amylyx
Pharmaceutical&#146;s annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, have been audited by Deloitte&nbsp;&amp; Touche LLP, an independent registered public accounting firm, as stated in
their report. Such financial statements are incorporated by reference in reliance upon the report of such firm given their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc383770_17"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act with respect to the
common stock we are offering by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information pertaining to us and our common stock, you should refer to the registration
statement and to its exhibits. Whenever we make reference in this prospectus to any of our contracts, agreements or other documents, the references are not necessarily complete, and you should refer to the exhibits attached to the registration
statement for copies of the actual contract, agreement or other document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">You may access, free of charge, our Annual Reports on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and amendments to those reports filed or furnished pursuant to
Section&nbsp;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are subject to the informational requirements of the Exchange Act and will file annual, quarterly and current reports, proxy statements and other
information with the SEC. You can read our SEC filings, including the registration statement, at the SEC&#146;s website at www.sec.gov. We also maintain a website at www.amylyx.com. Information contained on or accessed through our website is not a
part of this prospectus (other than those filings with the SEC that we specifically incorporate by reference into this prospectus or any supplement to this prospectus) and the inclusion of our website address in this prospectus is an inactive
textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc383770_18"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The SEC allows us to incorporate by reference in this prospectus much of the information we file with the SEC, which means that we can disclose
important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus and information that we file later with the SEC will
supersede information contained in this prospectus. This prospectus incorporates by reference the documents listed below and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other
than those documents or the portions of those documents not deemed to be filed) until the offering of the securities under the registration statement is terminated or completed: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000095017022005157/almx-10-2021.htm">Form <FONT
STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2021, filed with the SEC on March&nbsp;31, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the periods ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1658551/000095017022009695/amlx-20220331.htm">March&nbsp;31,
 2022</A>, filed with the SEC on May&nbsp;12, 2022 and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1658551/000095017022016883/amlx-20220630.htm">June&nbsp;30, 2022</A>, filed with the SEC on August&nbsp;11,
2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/0001658551/000119312522006731/d273128d8k.htm">January&nbsp;11,
 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001658551/000119312522166699/d327621d8k.htm">June&nbsp;
3, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001658551/000119312522171014/d362452d8k.htm">June&nbsp;
9, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001658551/000119312522172425/d358853d8k.htm">June&nbsp;
13, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001658551/000119312522188015/d379654d8k.htm">July&nbsp;
5, 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1658551/000119312522254838/d379888d8k.htm">September 30, 2022</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The information included in our <A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312522130050/d235425ddef14a.htm">Definitive
 Proxy Statement</A> on Schedule 14A, filed with the SEC on April&nbsp;
29, 2022, to the extent incorporated by reference into Part III of the Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000095017022005157/almx-10-2021.htm">Form <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal
year ended December&nbsp;31, 2021. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will furnish at no cost to you, on written or oral request, a copy of any or all of the
reports or documents incorporated by reference in this prospectus, including exhibits to these documents. You should direct any requests for documents to Amylyx Pharmaceuticals, Inc., 43 Thorndike Street, Cambridge, Massachusetts 02141, or by
telephone at (617) <FONT STYLE="white-space:nowrap">682-0917.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">You also may access these filings on our website at www.amylyx.com. The
information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus will be deemed modified, superseded or
replaced for purposes of this prospectus to the extent that a statement contained in this prospectus modifies, supersedes or replaces such statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B><U>6,000,000</U>&nbsp;Shares </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383770g92x08.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">Common Stock </P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">Preliminary Prospectus </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:14pt">
<TD VALIGN="top" ALIGN="center"><B>Goldman&nbsp;Sachs&nbsp;&amp; Co.&nbsp;LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>BofA&nbsp;Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>SVB&nbsp;Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Evercore&nbsp;ISI</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>H.C. Wainwright&nbsp;&amp; Co. </B></P> <P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022 </P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;13.
Other Expenses of Issuance and Distribution. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth the expenses to be incurred in connection with the offering
described in this Registration Statement, other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimates except the Securities and Exchange Commission&#146;s registration fee and the Financial Industry
Regulatory Authority, Inc. filing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Securities and Exchange Commission registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Financial Industry Regulatory Authority, Inc. filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accountants&#146; fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Miscellaneous fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">756,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Section&nbsp;145 of the Delaware General Corporation Law, or the DGCL, authorizes a corporation to indemnify its directors and officers against
liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover
expenses (including attorneys&#146; fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding if the director or officer acted in good
faith and in a manner the director or officer reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the director or
officer&#146;s conduct was unlawful. Section&nbsp;145 permits corporations to pay expenses (including attorneys&#146; fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding upon receipt of an
undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that such director or officer is not entitled to be indemnified by the corporation as authorized in Section&nbsp;145. In addition,
Section&nbsp;145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or
arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section&nbsp;145. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have adopted provisions in both our certificate of incorporation and bylaws that limit or eliminate the personal liability of our directors to the
fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director, except for
liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable
remedies such as an injunction or rescission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, our bylaws provide that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to the
fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we will advance reasonable expenses, including attorneys&#146; fees, to our directors and, in the discretion of our board
of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have entered into indemnification agreements with each of our directors and intend to enter into such agreements with certain of our executive
officers. These agreements provide that we will indemnify each of our directors, certain of our executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys&#146;
fees (but excluding judgments, fines and settlement amounts), to each indemnified director, executive officer or affiliate in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for
any action or proceeding arising out of that person&#146;s services as a director or officer brought on behalf of us or in furtherance of our rights. Additionally, certain of our directors or officers may have certain rights to indemnification,
advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#146;s or officer&#146;s services as a director
referenced herein. Nonetheless, we have agreed in the indemnification agreements that our obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide
indemnification for the expenses or liabilities incurred by those directors are secondary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We also maintain general liability insurance which
covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriting agreement filed as Exhibit 1.1 to this registration statement provides for indemnification of us and our directors and officers by the
underwriters against certain liabilities under the Securities Act and the Exchange Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;15. Recent Sales of Unregistered Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Set forth below is information regarding shares of our common stock and shares of our preferred stock issued, and stock options granted, by us within the
past three years that were not registered under the Securities Act. Included is the consideration, if any, we received for such shares and options and information relating to the section of the Securities Act, or rule of the Securities and Exchange
Commission, under which exemption from registration was claimed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>(a) Issuances of Convertible Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From December&nbsp;17, 2019 to April&nbsp;22, 2020, we issued convertible promissory notes to various investors in the principal amount of
$16,042,503.77. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From January&nbsp;27, 2021 to February&nbsp;9, 2021, we issued convertible promissory notes to various investors in the principal
amount of $27,320,508.40. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No underwriters were involved in the foregoing issuances of securities. The securities described in
this section (a)&nbsp;of Item 15 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section&nbsp;4(a)(2) under the Securities Act and Regulation D promulgated thereunder
relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. The recipients of securities in the transactions described above represented that they were accredited investors
and were acquiring the securities for their own account for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks of the investment and could hold the securities
for an indefinite period of time and appropriate legends were affixed to the instruments representing such securities issued in such transactions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>(b)
Issuances of Capital Stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In June 2020, we issued and sold an aggregate of 14,496,835 shares of Series B preferred stock at a price per
share of $16.974077, for an aggregate purchase price of approximately $64.4&nbsp;million. Included in this amount was approximately $34.4&nbsp;million of outstanding principal and interest on the convertible promissory notes issued between July 2017
and April 2020, all of which converted into Series B preferred stock in this financing in accordance with their terms. In July 2021, we issued and sold an aggregate of 13,150,430 shares of Series <FONT STYLE="white-space:nowrap">C-1</FONT> preferred
stock at a price per share of $10.265809 and 3,170,585 shares of Series <FONT STYLE="white-space:nowrap">C-2</FONT> preferred stock at a price per share of $8.725938, for an aggregate purchase price of approximately $162.7&nbsp;million. Included in
this amount was approximately $27.7&nbsp;million of outstanding principal and interest on the convertible promissory notes issued between January 2021 and February 2021, all of which converted into Series <FONT STYLE="white-space:nowrap">C-2</FONT>
preferred stock in this financing in accordance with their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No underwriters were involved in the foregoing issuance of securities. The
securities described in this section (b)&nbsp;of Item 15 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section&nbsp;4(a)(2) under the Securities Act and Regulation D
promulgated thereunder relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. The recipients of securities in the transactions described above represented that they
were accredited investors and were acquiring the securities for their own account for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks of the investment and
could hold the securities for an indefinite period of time and appropriate legends were affixed to the instruments representing such securities issued in such transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On January&nbsp;11, 2022, upon the closing of our initial public offering, all 37,107,459 shares of our then-outstanding redeemable convertible
preferred stock automatically converted into 39,474,330 shares of common stock. The issuance of such common stock was exempt from the registration requirements of the Securities Act, pursuant to Section&nbsp;3(a)(9) of the Securities Act, involving
an exchange of securities exchanged by the issuer with its existing security holders exclusively where no commission or other remuneration is paid or given directly or indirectly for soliciting such exchange. No underwriters were involved in this
issuance of shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>(c) Stock Option Grants and Option Exercises. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Before the filing of our registration statement on Form <FONT STYLE="white-space:nowrap">S-8,</FONT> we granted options to purchase an aggregate of
7,196,882 shares of common stock, with exercise prices ranging from $0.001 to $8.47 per share, to employees, directors, and consultants pursuant to our 2015 Plan. Of these, options for 232,588 shares have been terminated, options for 2,298,375
shares have been exercised, and options for 4,665,919 shares remain outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No underwriters were involved in the foregoing issuances of securities. The issuances of stock options
described in this paragraph (c)&nbsp;of Item 15 were issued pursuant to written compensatory plans or arrangements with our employees, directors, consultants and advisors, in reliance on the exemption provided by Rule 701 promulgated under the
Securities Act, or pursuant to Section&nbsp;4(a)(2) under the Securities Act, relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. All recipients either received
adequate information about us or had access, through employment or other relationships, to such information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;16. Exhibits and Financial Statement
Schedules. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>(a) Exhibits. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The exhibits to the
registration statement are listed in the Exhibit Index attached hereto and incorporated by reference herein. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>(b) Financial Statement Schedules. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or the
related notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d383770dex11.htm">Form of Underwriting Agreement </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312522006731/d273128dex31.htm">Fourth Amended and Restated Certificate of Incorporation of Amylyx Pharmaceuticals, Inc. (Incorporated by reference to Exhibit 3.1 to the Registrant&#146;s
 Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the Securities and Exchange Commission on January&nbsp;11, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312522006731/d273128dex32.htm">Second Amended and Restated Bylaws of Amylyx Pharmaceuticals, Inc. (Incorporated by reference to Exhibit 3.2 to the Registrant&#146;s Current
 Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the Securities and Exchange Commission on January&nbsp;11, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312522000260/d155225dex41.htm">Specimen Common Stock Certificate (Incorporated by reference to Exhibit 4.1 to the Registrant&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-1/A</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-261703)</FONT> filed with the Securities and Exchange Commission on January&nbsp;3, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312521359405/d155225dex42.htm">Second Amended and Restated Investors&#146; Rights Agreement, dated as of July&nbsp;
1, 2021, among the Registrant and the parties thereto (Incorporated by reference to Exhibit 4.2 to the Registrant&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
333-261703)</FONT> filed with the Securities and Exchange Commission on December&nbsp;16, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d383770dex51.htm">Opinion of Goodwin Procter LLP. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312522000260/d155225dex101.htm">2015 Stock Option and Incentive Plan, and form of award agreements thereunder (Incorporated by reference to Exhibit 10.1 to the Registrant&#146;s
 Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1/A</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-261703)</FONT> filed with the Securities and Exchange Commission on January&nbsp;3, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312522000260/d155225dex102.htm">2022 Stock Option and Incentive Plan, and form of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to the Registrant&#146;s
 Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1/A</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-261703)</FONT> filed with the Securities and Exchange Commission on January&nbsp;3, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312522000260/d155225dex103.htm">2022 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.3 to the Registrant&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-1/A</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-261703)</FONT> filed with the Securities and Exchange Commission on January&nbsp;3, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312522000260/d155225dex104.htm">Executive Cash Incentive Bonus Plan (Incorporated by reference to Exhibit 10.4 to the Registrant&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-1/A</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-261703)</FONT> filed with the Securities and Exchange Commission on January&nbsp;3, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312522000260/d155225dex105.htm"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy (Incorporated by reference to Exhibit 10.5 to the Registrant&#146;s
 Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1/A</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-261703)</FONT> filed with the Securities and Exchange Commission on January&nbsp;3, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312521359405/d155225dex106.htm">Lease Agreement, dated as of October&nbsp;
23, 2018, as amended, by and between the Registrant and Bullfinch Square Limited Partnership (Incorporated by reference to Exhibit 10.6 to the Registrant&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-261703)</FONT> filed with the Securities and Exchange Commission on December&nbsp;16, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312522000260/d155225dex107.htm">Form of Employment Agreement, between the Registrant and Josh Cohen (Incorporated by reference to Exhibit 10.7 to the Registrant&#146;s Registration
 Statement on Form <FONT STYLE="white-space:nowrap">S-1/A</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-261703)</FONT> filed with the Securities and Exchange Commission on January&nbsp;3, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312522000260/d155225dex108.htm">Form of Employment Agreement, between the Registrant and Justin Klee (Incorporated by reference to Exhibit 10.8 to the Registrant&#146;s Registration
 Statement on Form <FONT STYLE="white-space:nowrap">S-1/A</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-261703)</FONT> filed with the Securities and Exchange Commission on January&nbsp;3, 2022).
</A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312522000260/d155225dex109.htm">Form of Employment Agreement, between the Registrant and James Frates (Incorporated by reference to Exhibit 10.9 to the Registrant&#146;s Registration
 Statement on Form <FONT STYLE="white-space:nowrap">S-1/A</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-261703)</FONT> filed with the Securities and Exchange Commission on January&nbsp;3, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312522000260/d155225dex1010.htm">Form of Employment Agreement, between the Registrant and Margaret Olinger (Incorporated by reference to Exhibit 10.10 to the Registrant&#146;s
 Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1/A</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-261703)</FONT> filed with the Securities and Exchange Commission on January&nbsp;3, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312522000260/d155225dex1011.htm">Form of Employment Agreement, between the Registrant and Patrick D. Yeramian, M.D. (Incorporated by reference to Exhibit 10.11 to the Registrant&#146;s
 Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1/A</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-261703)</FONT> filed with the Securities and Exchange Commission on January&nbsp;3, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312521359405/d155225dex1012.htm">Form of Director Indemnification Agreement (Incorporated by reference to Exhibit 10.12 to the Registrant&#146;s Registration Statement on Form
<FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-261703)</FONT> filed with the Securities and Exchange Commission on December&nbsp;16, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312521359405/d155225dex1013.htm">Form of Officer Indemnification Agreement (Incorporated by reference to Exhibit 10.13 to the Registrant&#146;s Registration Statement on Form
 <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-261703)</FONT> filed with the Securities and Exchange Commission on December&nbsp;16, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312521359405/d155225dex1014.htm">Master Manufacturing Services Agreement, dated as of November&nbsp;
12, 2019, by and between the Registrant and Patheon Inc. (Incorporated by reference to Exhibit 10.14 to the Registrant&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
333-261703)</FONT> filed with the Securities and Exchange Commission on December&nbsp;16, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312521359405/d155225dex1015.htm">Supply Agreement, dated as of October&nbsp;
29, 2019, by and between the Registrant and CU Chemie Uetikon GmbH (Incorporated by reference to Exhibit 10.15 to the Registrant&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-261703)
</FONT> filed with the Securities and Exchange Commission on December&nbsp;16, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000119312521359405/d155225dex1016.htm">Research, Development and Supply Agreement, dated as of December&nbsp;9, 2019, and Deed of Amendment, dated as of July&nbsp;
26, 2021, by and between the Registrant and ICE S.p.A. (formerly Prodotti Chimici e Alimentari S.p.A.), as amended (Incorporated by reference to Exhibit 10.16 to the Registrant&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1
</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-261703)</FONT> filed with the Securities and Exchange Commission on December&nbsp;16, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1658551/000095017022005157/amlx-ex21_1.htm">Subsidiaries of the Registrant (Incorporated by reference to Exhibit 21.1 to the Registrant&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> filed with the Securities and Exchange Commission on March&nbsp;31, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d383770dex231.htm">Consent of Deloitte&nbsp;&amp; Touche LLP, independent registered public accounting firm. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d383770dex51.htm">Consent of Goodwin Procter LLP (included in Exhibit 5.1). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#sig">Power of Attorney (included on signature page). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>107</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d383770dexfilingfees.htm">Filing Fee Table. </A></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Portions of this exhibit (indicated by asterisks) have been omitted in accordance with Item 601(b)(10) of Regulation <FONT
STYLE="white-space:nowrap">S-K.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Indicates a management contract or any compensatory plan, contract or arrangement. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;17. Undertakings. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">(a) The undersigned registrant
hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant&#146;s annual report pursuant to section 13(a) or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by
reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">(b) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">(c) The undersigned registrant hereby undertakes that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus
filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)&nbsp;(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this
registration statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form
of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 4th day of&nbsp;October, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AMYLYX PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Joshua Cohen</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Joshua Cohen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I><FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Joshua
Cohen and Justin Klee and each of them, his true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power of substitution and resubstitution for him and in his name,
place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and any subsequent registration statements pursuant to Rule 462 of the Securities Act and to file the
same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and
agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying
and confirming all that each of said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and
on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Joshua Cohen</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Joshua
Cohen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer and Director (Principal Executive Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>October&nbsp;4, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Justin Klee</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Justin
Klee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer and Director (Principal Executive Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>October 4, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ James M. Frates, MBA</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">James M.
Frates, MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>October 4, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ George Mclean Milne Jr, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">George Mclean Milne Jr, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>October 4, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Paul Fonteyne, MS, MBS</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Paul
Fonteyne, MS, MBS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>October 4, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Isaac Cheng, M.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Isaac Cheng,
M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>October 4, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Daphne Quimi, MBA</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Daphne
Quimi, MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>October 4, 2022</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-8 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d383770dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amylyx Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I><U>Underwriting Agreement </U></I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">October [&#9679;], 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp;
Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SVB Securities LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">As representatives (the
&#147;Representatives&#148;) of the several Underwriters </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">named in Schedule I hereto, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Goldman Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West Street, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10282-2198 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o BofA Securities, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Bryant Park </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10036 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o SVB Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">53 State Street, 40<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02109 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Evercore Group L.L.C. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">55 E. 52nd St. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10055 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amylyx Pharmaceuticals, Inc., a Delaware corporation (the &#147;Company&#148;), proposes, subject to the terms and conditions stated in this
agreement (this &#147;Agreement&#148;), to issue and sell to the Underwriters named in Schedule I hereto (the &#147;Underwriters&#148;) an aggregate of [&#9679;] shares<B> </B>(the &#147;Firm Shares&#148;)<B> </B>and, at the election of the
Underwriters, up to [&#9679;] additional shares (the &#147;Optional Shares&#148;) of common stock, par value $0.0001 per share (&#147;Stock&#148;) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase
pursuant to Section&nbsp;2 hereof being collectively called the &#147;Shares&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The Company represents and warrants to, and
agrees with, each of the Underwriters that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) A registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-[</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]) (the &#147;Initial Registration Statement&#148;) in respect of the Shares has been filed with the Securities and
Exchange Commission (the &#147;Commission&#148;); the Initial Registration Statement and any <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment thereto, each in the form heretofore delivered to you, have been declared effective by the
Commission in such form; other than a registration statement, if any, increasing the size of the offering (a &#147;Rule 462(b) Registration Statement&#148;), filed </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the &#147;Act&#148;), which became effective upon filing, no other document with respect to the Initial Registration
Statement or document incorporated by reference therein has been filed with the Commission; and no stop order suspending the effectiveness of the Initial Registration Statement, any post-effective amendment thereto or the Rule 462(b) Registration
Statement, if any, has been issued and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Act has been initiated or threatened by the Commission (any preliminary prospectus included in the Initial Registration Statement or filed
with the Commission pursuant to Rule 424(a) of the rules and regulations of the Commission under the Act is hereinafter called a &#147;Preliminary Prospectus&#148;; the various parts of the Initial Registration Statement and the Rule 462(b)
Registration Statement, if any, including all exhibits thereto and including the information contained in the form of final prospectus filed with the Commission pursuant to Rule 424(b) under the Act in accordance with Section&nbsp;5(a) hereof and
deemed by virtue of Rule 430A under the Act to be part of the Initial Registration Statement at the time it was declared effective, each as amended at the time such part of the Initial Registration Statement became effective or such part of the Rule
462(b) Registration Statement, if any, became or hereafter becomes effective, are hereinafter collectively called the &#147;Registration Statement&#148;; the Preliminary Prospectus relating to the Shares that was included in the Registration
Statement immediately prior to the Applicable Time (as defined in Section&nbsp;1(c) hereof) is hereinafter called the &#147;Pricing Prospectus&#148;;<B> </B>such final prospectus, in the form first filed pursuant to Rule 424(b) under the Act, is
hereinafter called the &#147;Prospectus&#148;; any reference herein to any Preliminary Prospectus, the Pricing Prospectus, the Pricing Disclosure Package or the Prospectus shall be deemed to refer to and include the documents incorporated by
reference therein pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Act, as of the date of such prospectus or the Applicable Time in the case of the Pricing Disclosure Package; any oral or written communication with
potential investors undertaken in reliance on Section&nbsp;5(d)<B> </B>of the Act or Rule 163B under the Act is hereinafter called a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Testing-the-Waters</FONT></FONT>
Communication&#148;; and any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the Act is hereinafter called a
&#147;Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication&#148;;<B> </B>and any &#147;issuer free writing prospectus&#148; as defined in Rule 433 under the Act relating to the
Shares is hereinafter called an &#147;Issuer Free Writing Prospectus&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) (A) No order preventing or suspending the use of any
Preliminary Prospectus or any Issuer Free Writing Prospectus has been issued by the Commission, and (B)&nbsp;each Preliminary Prospectus, at the time of filing thereof, conformed in all material respects to the requirements of the Act and the rules
and regulations of the Commission thereunder, and did not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading; <I>provided</I>, <I>however</I>, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with the Underwriter Information (as defined in
Section&nbsp;9(b) of this Agreement); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) For the purposes of this Agreement, the &#147;Applicable Time&#148; is [&#149;] [a.m.][p.m.]
(Eastern time) on the date of this Agreement. The Pricing Prospectus, as supplemented by the information listed on Schedule II(c) hereto, taken together (collectively, the &#147;Pricing Disclosure Package&#148;), as of the Applicable Time, did not,
and as of each Time of Delivery (as defined in Section&nbsp;4(a) of this Agreement) (as supplemented by any post-effective </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amendment thereto) will not, include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; and each Issuer Free Writing Prospectus and each Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication does not conflict
with the information contained in the Registration Statement, the Pricing Prospectus or the Prospectus and each Issuer Free Writing Prospectus and each Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, as supplemented by and taken together with the Pricing Disclosure Package, as of the Applicable Time, did not, and as of each<B>
</B>Time of Delivery (as supplemented by any post-effective amendment thereto) will not, include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall not apply to statements or omissions made in reliance upon and in conformity with the Underwriter Information; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The documents incorporated by reference in the Pricing Disclosure Package and the Prospectus, when they became effective or were filed
with the Commission, as the case may be, conformed in all material respects to the requirements of the Act or the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), as applicable, and the rules and regulations of the
Commission thereunder, and none of such documents contained untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein not misleading; and no documents were filed
with the Commission since the Commission&#146;s close of business on the business day immediately prior to the date of this Agreement and prior to the execution of this Agreement, except as set forth on Schedule II(b) hereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Registration Statement conforms, and the Prospectus and any further amendments or supplements to the Registration Statement and the
Prospectus will conform, in all material respects to the requirements of the Act and the rules and regulations of the Commission thereunder and do not and will not, as of the applicable effective date as to each part of the Registration Statement,
as of the applicable filing date as to the Prospectus and any amendment or supplement thereto, and as of each<B> </B>Time of Delivery, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein not misleading; provided, however, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with the Underwriter Information; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Neither the Company nor any of its subsidiaries has, since the date of the latest audited financial statements included in the Pricing
Prospectus, (i)&nbsp;sustained any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree or
(ii)&nbsp;entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is
material to the Company and its subsidiaries taken as a whole, in each case otherwise than as set forth or contemplated in the Pricing Prospectus; and, since the respective dates as of which information is given in the Registration Statement and the
Pricing Prospectus, there has not been (x)&nbsp;any change in the capital stock (other than as a result of (i)&nbsp;the exercise, if any, of stock options or the award, if any, of stock options or restricted stock in the ordinary
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
course of business pursuant to the Company&#146;s equity plans that are described in the Pricing Prospectus and the Prospectus or (ii)&nbsp;the issuance, if any, of stock upon conversion of
Company securities as described in the Pricing Prospectus and the Prospectus) or <FONT STYLE="white-space:nowrap">long-term</FONT> debt of the Company or any of its subsidiaries or (y)&nbsp;any Material Adverse Effect (as defined below); as used in
this Agreement, &#147;Material Adverse Effect&#148; shall mean any material adverse change or effect, or any development involving a prospective material adverse change or effect, in or affecting (i)&nbsp;the business, properties, general affairs,
management, financial position, stockholders&#146; equity, results of operations or prospects of the Company and its subsidiaries, taken as a whole, except as set forth or contemplated in the Pricing Prospectus, or (ii)&nbsp;the ability of the
Company to perform its obligations under this Agreement, including the issuance and sale of the Shares, or to consummate the transactions contemplated in the Pricing Prospectus and the Prospectus; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Company and its subsidiaries do not own any real property and have good and marketable title to all personal property owned by them,
in each case free and clear of all liens, encumbrances and defects except such as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and its
subsidiaries; and any real property and buildings held under lease by the Company and its subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as are not material and do not materially interfere with the
use made and proposed to be made of such property and buildings by the Company and its subsidiaries; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Each of the Company and its
subsidiaries has been (i)&nbsp;duly organized and is validly existing and in good standing under the laws of its jurisdiction of organization, with power and authority (corporate and other) to own and/or lease its properties and conduct its business
as described in the Pricing Prospectus, and (ii)&nbsp;duly qualified as a foreign corporation or other form of entity for the transaction of business and is in good standing under the laws of each other jurisdiction in which it owns or leases
properties or conducts any business so as to require such qualification, except, in the case of this clause (ii), where the failure to be so qualified or in good standing would not, individually or in the aggregate, have a Material Adverse Effect,
and each subsidiary of the Company has been listed in the Registration Statement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company has an authorized capitalization as set
forth in the Pricing Prospectus and all of the issued shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and conform, in all material
respects, to the description of the Stock contained in the Pricing Disclosure Package and Prospectus; and all of the issued shares of capital stock of the Company&#146;s subsidiaries have been duly and validly authorized and issued, are fully paid
and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and (except, in the case of any foreign subsidiary, for directors&#146; qualifying shares) are owned directly or indirectly by the Company, free and clear of all liens, encumbrances,
equities or claims; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The unissued Shares to be issued and sold by the Company to the Underwriters hereunder have been duly and validly
authorized and, when issued and delivered against payment therefor as provided herein, will be duly and validly issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and will conform in all material respects to the
description of the Stock contained in the Pricing Disclosure Package and the Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) The issue and sale of the Shares and the compliance by the Company with this Agreement
and the consummation of the transactions contemplated in this Agreement and the Pricing Prospectus will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, (A)&nbsp;any indenture,
mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company
or any of its subsidiaries is subject, (B)&nbsp;the certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> (or other applicable organizational document) of the Company or any of its subsidiaries, or (C)&nbsp;any statute or
any judgment, order, rule or regulation of any court or governmental agency or body having jurisdiction over the Company or any of its subsidiaries or any of their properties (except in the case of clauses (A)&nbsp;and (C), for such defaults,
breaches, or violations as would not, individually or in the aggregate, have a Material Adverse Effect); and no consent, approval, authorization, order, registration or qualification of or with any such court or governmental agency or body is
required for the issue and sale of the Shares or the consummation by the Company of the transactions contemplated by this Agreement, except such as have been obtained under the Act<B>, </B>the approval by the Financial Industry Regulatory Authority
(&#147;FINRA&#148;) of the underwriting terms and arrangements and such consents, approvals, authorizations, registrations or qualifications as may be required under state securities or Blue Sky laws in connection with the purchase and distribution
of the Shares by the Underwriters; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) Neither the Company nor any of its subsidiaries is (i)&nbsp;in violation of its certificate of
incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> (or other applicable organizational document), (ii) in violation of any statute or any judgment, order, rule or regulation of any court or governmental agency or body having
jurisdiction over the Company or any of its subsidiaries or any of their properties, or (iii)&nbsp;in default in the performance or observance of any obligation, agreement, covenant or condition contained in any indenture, mortgage, deed of trust,
loan agreement, lease or other agreement or instrument to which it is a party or by which it or any of its properties may be bound, except, in the case of the foregoing clauses (ii)&nbsp;and (iii), for such violations or defaults as would not,
individually or in the aggregate, have a Material Adverse Effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) The statements set forth in the Pricing Prospectus and Prospectus
under the caption &#147;Description of Capital Stock&#148;, insofar as they purport to constitute a summary of the terms of the Stock, under the caption &#147;Material U.S. Federal Income Tax Consequences for
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders&#148;, and under the caption &#147;Underwriting&#148;, insofar as they purport to describe the provisions of the laws and documents referred to therein, are accurate, complete and fair in all
material respects; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) Other than as set forth in the Pricing Prospectus, there are no legal, governmental or regulatory investigations,
actions, demands, claims, suits, arbitrations, inquiries or proceedings (&#147;Actions&#148;) pending to which the Company or any of its subsidiaries or, to the Company&#146;s knowledge, any officer or director of the Company, is a party or of which
any property of the Company or any of its subsidiaries is the subject which, if determined adversely to the Company or any of its subsidiaries (or such officer or director), would individually or in the aggregate have a Material Adverse Effect; and,
to the Company&#146;s knowledge, no such proceedings are threatened or contemplated by governmental authorities or others; there are no current or pending Actions that are required under the Act to be described in the Registration Statement or the
Pricing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Prospectus that are not so described therein; and there are no statutes, regulations or contracts or other documents that are required under the Act to be filed as exhibits to the Registration
Statement or described in the Registration Statement, the Pricing Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement and the Pricing Prospectus; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) The Company is not and, after giving effect to the offering and sale of the Shares and the application of the proceeds thereof, will not
be an &#147;investment company&#148;, as such term is defined in the Investment Company Act of 1940, as amended (the &#147;Investment Company Act&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) At the time of filing the Initial Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that
the Company or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the Act) of the Shares, and at the date hereof, the Company was not and is not an &#147;ineligible issuer,&#148; as defined under Rule 405
under the Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) There are (and prior to the Time of Delivery, will be) no debt securities or preferred stock issued or guaranteed by
the Company that are rated by a &#147;nationally recognized statistical rating organization&#148;, as such term is defined in Section&nbsp;3(a)(62) under the Exchange Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) Deloitte&nbsp;&amp; Touche LLP, which has certified certain financial statements of the Company and its subsidiaries, is an independent
public accounting firm as required by the Act and the rules and regulations of the Commission thereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) The Company maintains a
system of internal control over financial reporting (as such term is defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> under the Exchange Act) that (i)&nbsp;complies with the requirements of the Exchange Act, (ii)&nbsp;has been
designed by the Company&#146;s principal executive officer and principal financial officer, or under their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles and (iii)&nbsp;is sufficient to provide reasonable assurance that (A)&nbsp;transactions are executed in accordance with management&#146;s general or specific
authorization, (B)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain accountability for assets, (C)&nbsp;access to assets is
permitted only in accordance with management&#146;s general or specific authorization, (D)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any
differences and (E)&nbsp;the interactive data in eXtensible Business Reporting Language included in the Registration Statement, the Pricing Prospectus and the Prospectus fairly presents the information called for in all material respects and is
prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto; and the Company&#146;s internal control over financial reporting is effective and the Company is not aware of any material weaknesses in its internal control
over financial reporting (it being understood that this subsection shall not require the Company to comply with Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended (the &#147;Sarbanes-Oxley Act&#148;) as of an earlier date than it would
otherwise be required to so comply under applicable law); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) Since the date of the latest audited financial statements included in the
Pricing Prospectus and the Prospectus, there has been no change in the Company&#146;s internal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
control over financial reporting that has materially and adversely affected, or is reasonably likely to materially and adversely affect, the Company&#146;s internal control over financial
reporting; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) The Company maintains disclosure controls and procedures (as such term is defined in Rule
<FONT STYLE="white-space:nowrap">13a-15(e)</FONT> under the Exchange Act) that comply with the requirements of the Exchange Act; such disclosure controls and procedures have been designed to ensure that material information relating to the Company
and its subsidiaries is made known to the Company&#146;s principal executive officer and principal financial officer by others within those entities; and such disclosure controls and procedures are effective; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) This Agreement has been duly authorized, executed and delivered by the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) Neither the Company nor any of its subsidiaries, nor any director or officer of the Company nor, to the Company&#146;s knowledge, any
other employee of the Company or any of its subsidiaries, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i)&nbsp;made, offered, promised or authorized any unlawful
contribution, gift, entertainment or other unlawful expense (or taken any act in furtherance thereof); (ii) made, offered, promised or authorized any direct or indirect unlawful payment; or (iii)&nbsp;violated or is in violation of any provision of
the Foreign Corrupt Practices Act of 1977, as amended, or the rules and regulations thereunder, the Bribery Act 2010 of the United Kingdom or any other applicable anti-corruption, anti-bribery or related law, statute or regulation (collectively,
&#147;Anti-Corruption Laws&#148;); the Company and its subsidiaries have conducted their businesses in compliance with Anti-Corruption Laws and have instituted and maintained and will continue to maintain policies and procedures reasonably designed
to promote and achieve compliance with such laws and with the representations and warranties contained herein; neither the Company nor any of its subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance of an offer,
payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of Anti-Corruption Laws; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with the requirements of
applicable anti-money laundering laws, including, but not limited to, the Bank Secrecy Act of 1970, as amended by the USA PATRIOT ACT of 2001, and the rules and regulations promulgated thereunder, and the anti-money laundering laws of the various
jurisdictions in which the Company and its subsidiaries conduct business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency (collectively, the
&#147;Money Laundering Laws&#148;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is
pending or, to the knowledge of the Company, threatened; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) Neither the Company nor any of its subsidiaries, nor any director or officer
of the Company nor, to the Company&#146;s knowledge, any other employee of the Company or its subsidiary or any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries is (i)&nbsp;currently the
subject or the target of any sanctions administered or enforced by the U.S. Government, including, without limitation, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#147;OFAC&#148;), or the U.S. Department of State and including, without limitation, the designation as a
&#147;specially designated national&#148; or &#147;blocked person,&#148; the European Union, Her Majesty&#146;s Treasury, the United Nations Security Council, or other relevant sanctions authority (collectively, &#147;Sanctions&#148;), (ii) located,
organized, or resident in a country or territory that is the subject or target of Sanctions (a &#147;Sanctioned Jurisdiction&#148;), and the Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend,
contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities of or business with any person, or in any country or territory, that, at the time
of such funding, is the subject or the target of Sanctions or (ii)&nbsp;in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise)
of Sanctions; neither the Company nor any of its subsidiaries is engaged in, or has, at any time in the past five years, engaged in, any dealings or transactions with or involving any individual or entity that was or is, as applicable, at the time
of such dealing or transaction, the subject or target of Sanctions or with any Sanctioned Jurisdiction; the Company and its subsidiaries have instituted, and maintain, policies and procedures designed to promote and achieve continued compliance with
Sanctions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) The financial statements included in the Registration Statement, the Pricing Prospectus and the Prospectus, together with
the related schedules and notes, present fairly in all material respects the financial position of the Company and its subsidiaries at the dates indicated and the statement of operations, stockholders&#146; equity and cash flows of the Company and
its subsidiaries for the periods specified; said financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#147;GAAP&#148;) applied on a consistent basis throughout the periods involved. The
supporting schedules, if any, present fairly in accordance with GAAP, in all material respects, the information required to be stated therein. The interactive data in eXtensible Business Reporting Language included in the Registration Statement
fairly presents the information called for in all material respects and has been reported in accordance with the Commission&#146;s rules and guidelines. The selected financial data and the summary financial information included in the Registration
Statement, the Pricing Prospectus and the Prospectus present fairly, in all material respects, the information shown therein and, other than <FONT STYLE="white-space:nowrap">non-GAAP</FONT> measures, have been compiled on a basis consistent with
that of the audited financial statements included therein. Except as included therein, no historical or pro forma financial statements or supporting schedules are required to be included in the Registration Statement, the Pricing Prospectus or the
Prospectus under the Act or the rules and regulations promulgated thereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) From the time of confidential submission of a
registration statement relating to the Shares with the Commission (or, if earlier, the first date on which a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication was made) through the date
hereof, the Company has been and is an &#147;emerging growth company&#148; as defined in Section&nbsp;2(a)(19) of the Act (an &#147;Emerging Growth Company&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) There are no persons with registration rights or other similar rights to have any securities registered pursuant to the Registration
Statement or otherwise registered by the Company under the Act except as have been validly waived or complied with in connection with the offering of the Shares; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) No labor disturbance by or dispute with current or former employees or officers of the
Company or any if its subsidiaries exists or, to the Company&#146;s knowledge, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of the Company&#146;s
or any of its subsidiaries&#146; principal suppliers, manufacturers or contractors. Neither the Company nor any of its subsidiaries is a party to any collective bargaining agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) The Company and its subsidiaries have insurance covering their respective properties, operations, personnel and business, including
business interruption insurance, which insurance is in amounts and insures against such losses and risks as are reasonable and is ordinary and customary for comparable companies in the same or similar businesses; and neither the Company nor any of
its subsidiaries has (i)&nbsp;not received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance nor (ii)&nbsp;any reason to believe
that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be reasonably necessary to continue its business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) The Company&#146;s board of directors meets the independence requirements of, and has established an audit committee, a compensation
committee and a nominating and corporate governance committee, in each case, that meets the independence requirements of, the rules and regulations of the Commission and the Nasdaq Global Select Market (the &#147;Exchange&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) The Company and its subsidiaries, and to the Company&#146;s knowledge, their respective directors, officers and employees, are, and at
all times have been, in compliance with applicable Health Care Laws (defined herein) including, but not limited to, the rules and regulations of the Food and Drug Administration (&#147;FDA&#148;), the U.S. Department of Health and Human Services
Office of Inspector General, the Centers for Medicare&nbsp;&amp; Medicaid Services, the Office for Civil Rights, and any other governmental agency or body having jurisdiction over the Company or any of its properties, and has not engaged in any
activities which are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or any other local, state or federal healthcare program, except for such noncompliance that would
not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. For purposes of this Agreement, &#147;Health Care Laws&#148; shall mean, as applicable, the federal Anti-kickback Statute (42 U.S.C. &#167; <FONT
STYLE="white-space:nowrap">1320a-7b(b)),</FONT> the Physician Payments Sunshine Act (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7h),</FONT> the civil False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the criminal False Claims Act
(42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(a)),</FONT> applicable criminal laws relating to health care fraud and abuse, the exclusion laws (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7),</FONT> the civil monetary
penalties law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a),</FONT> the health care fraud criminal provisions under the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &#167;&#167; 1320d et seq.)
(&#147;HIPAA&#148;), the exclusion laws (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7),</FONT> the civil monetary penalties law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a),</FONT> HIPAA, as amended by the Health
Information Technology for Economic and Clinical Health Act (42 U.S.C. &#167;&#167; 17921 et seq.), the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.), the Patient Protection and Affordable Care Act of 2010 (Pub. Law <FONT
STYLE="white-space:nowrap">111-148),</FONT> as amended by the Health Care and Education Reconciliation Act of 2010 (Pub. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Law <FONT STYLE="white-space:nowrap">111-152),</FONT> and the regulations promulgated pursuant to the aforementioned statutes. Neither the Company nor any of its subsidiaries is a party to or has
any ongoing reporting obligations pursuant to any corporate integrity agreement, deferred prosecution agreement, monitoring agreement, consent decree, settlement order, plan of correction or similar agreement imposed by any governmental authority.
Neither the Company nor any of its subsidiaries has received any written notification, correspondence or any other written communication, including, without limitation, any Form FDA 483, notice of adverse finding, warning letter, untitled letter or
other correspondence or notice from the FDA or any similar regulatory authority, or any notification of any pending or, to the Company&#146;s knowledge, threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration or other
action, from any governmental authority of alleging material <FONT STYLE="white-space:nowrap">non-compliance</FONT> by, or material liability of, the Company or its subsidiaries under any Health Care Laws; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) Each of the Company and its subsidiaries possesses, and is in material compliance with the terms of, all applications, certificates,
approvals, clearances, registrations, exemptions, franchises, licenses, permits, consents and other authorizations issued by the appropriate Governmental Authorities and necessary to conduct their respective businesses (collectively,
&#147;Licenses&#148;), including, without limitation, all Licenses required by the FDA, or any component thereof, and/or by any other U.S., state, local or foreign government or drug regulatory agency (collectively, the &#147;Regulatory
Agencies&#148;), except where a failure to so possess or noncompliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. All such Licenses are in full force and effect and neither the Company nor
any of its subsidiaries is in violation of any term or conditions of any such License, except where a failure to be in full force or effect or such violation would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect. Each of the Company and its subsidiaries has fulfilled and performed all of its respective obligations with respect to such Licenses and, no event has occurred which allows, or after notice or lapse of time would allow, revocation or
termination thereof or results in any other impairment of the rights of the holder of any such License, except for such failure or occurrence that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
Neither the Company nor any of its subsidiaries has received any notice of proceedings from the applicable Regulatory Agency proposing to revoke or materially adversely modify any such Licenses and, to the Company&#146;s knowledge, no Regulatory
Agency has taken any action to limit, suspend or revoke any such License possessed by the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) To the Company&#146;s knowledge,
the manufacturing facilities and operations of its suppliers are operated in compliance in all material respects with all applicable statutes, rules, regulations and policies of the Regulatory Agencies; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Other than as disclosed in the Registration Statement, the Pricing Prospectus and the Prospectus, none of the Company&#146;s product
candidates has received marketing approval from any Regulatory Agencies. The <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials that are described in the Registration Statement, the Pricing Prospectus and the Prospectus
were and, if still pending, are being, conducted in all material respects in accordance with the protocols submitted to the FDA or any foreign governmental body exercising comparable authority, and all applicable laws and regulations; the
descriptions of the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials conducted by or, to the Company&#146;s knowledge, on behalf of the Company or by a licensor, and the results thereof, contained in the Registration
Statement, the Pricing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Prospectus and the Prospectus are accurate and complete in all material respects; the Company is not aware of any other <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical
trials, the results of which call into question the results described in the Registration Statement, the Pricing Prospectus and the Prospectus; and the Company has not received any notices or correspondence from the FDA, any foreign, state or local
governmental body exercising comparable authority or any Institutional Review Board or ethics committee or similar body requiring the termination, suspension, material modification or clinical hold of any
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials conducted by or, to the Company&#146;s knowledge, on behalf of the Company or by a licensor; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) Neither the Company nor its subsidiaries, nor any of their respective officers, employees or directors, nor, to the Company&#146;s
knowledge, any of its or their respective agents or clinical investigators, or licensors, has, for the past three (3)&nbsp;years, been excluded, suspended or debarred from participation in any U.S. federal or foreign health care program or human
clinical research or, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion, or convicted of any crime or engaged in any conduct
that would reasonably be expected to result in debarment under 21 U.S.C. &#167; 335a or comparable foreign law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) The Company and each
subsidiary owns or has valid and enforceable licenses or other rights to all patents and patent applications, copyrights, all material trademarks, trademark registrations, service marks, service mark registrations, trade names, service names and <FONT
STYLE="white-space:nowrap">know-how</FONT> (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures) and all other technology and intellectual property rights necessary for the
conduct, or the proposed conduct, of the business of the Company in the manner described in the Pricing Prospectus and the Prospectus (collectively, the &#147;Company Intellectual Property&#148;); to the Company&#146;s knowledge, there are no rights
of third parties to any of the patents, trademarks (other than which would, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole) and copyrights within the Company
Intellectual Property disclosed in the Registration Statement and the Prospectus as being owned by the Company and its subsidiaries and such patents, trademark and copyrights are owned by the Company and its subsidiaries free and clear of all
material liens, security interests, or encumbrances; to the Company&#146;s knowledge, the patents, material trademarks and copyrights held or licensed by the Company and its subsidiaries included within the Company Intellectual Property are valid,
enforceable and subsisting; and other than as disclosed in the Pricing Prospectus and the Prospectus, (i)&nbsp;neither the Company nor its subsidiaries is obligated to pay a material royalty, grant a license, or provide other material consideration
to any third party in connection with the Company Intellectual Property, (ii)&nbsp;no action, suit, claim or other proceeding is pending or, to the knowledge of the Company, is threatened, alleging that the conduct of the business of the Company in
the manner described in the Pricing Prospectus and the Prospectus is infringing, misappropriating, diluting or otherwise violating any intellectual property rights of others, (iii)&nbsp;no action, suit, claim or other proceeding is pending or, to
the knowledge of the Company, is threatened, challenging the validity, enforceability, scope, registration, ownership or use of any of the Company Intellectual Property, (iv)&nbsp;no action, suit, claim or other proceeding is pending or, to the
knowledge of the Company, is threatened, challenging the Company&#146;s and its subsidiaries&#146; rights in or to any Company Intellectual Property, and the Company is unaware of any material facts which could form a reasonable basis for any such
action, suit, proceeding or claim, (v)&nbsp;the Company has not received written </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
notice of any claim of infringement, misappropriation or conflict with any asserted rights of others with respect to any of the Company&#146;s or its subsidiaries&#146; products, proposed
products, processes or Company Intellectual Property, (vi)&nbsp;to the knowledge of the Company, the development, manufacture, sale, and any currently proposed use of any of the products, proposed products or processes of the Company and its
subsidiaries referred to in the Pricing Prospectus and the Prospectus, in the current or proposed conduct of the business of the Company, do not currently, and will not upon commercialization, to the knowledge of the Company, infringe any right or
valid patent claim of any third party, (vii)&nbsp;to the Company&#146;s knowledge, no third party has any ownership right in or to any Company Intellectual Property in any field of use that is exclusively licensed to the Company or its subsidiaries,
other than any licensor to the Company or its subsidiaries of such Company Intellectual Property, (viii)&nbsp;no employee, consultant or independent contractor of the Company or any of its subsidiaries is, to the Company&#146;s knowledge, in
violation in any material respect of any term of any employment contract, patent disclosure agreement, invention assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement,
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement, or any restrictive covenant to or with a former employer or independent contractor where the basis of such violation relates to such employee&#146;s
employment or independent contractor&#146;s engagement with the Company or actions undertaken while employed or engaged with the Company, (ix)&nbsp;the Company has taken reasonable measures to protect its material confidential information and
material trade secrets and to maintain and safeguard the material Company Intellectual Property, including the execution of appropriate nondisclosure and confidentiality agreements and (x)&nbsp;the Company has complied with the material terms of
each agreement pursuant to which the Company Intellectual Property has been licensed to the Company, and any such agreements are in full force and effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) All patents and patent applications owned by or licensed to the Company and its subsidiaries or under which the Company and its
subsidiaries have rights have, to the knowledge of the Company, been duly and properly filed and maintained; to the knowledge of the Company, there are no material defects in any of the patents or patent applications disclosed in the Registration
Statement and the Prospectus as being owned by the Company or its subsidiaries; to the knowledge of the Company, the parties prosecuting such applications have complied with their duty of candor and disclosure to the United States Patent and
Trademark Office (the &#147;USPTO&#148;) in connection with such applications; and the Company is not aware of any facts required to be disclosed to the USPTO that were not disclosed to the USPTO and which would preclude the grant of a patent in
connection with any such application or could form the basis of a finding of invalidity with respect to any patents that have issued with respect to such applications; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) Any statistical, industry-related and market-related data included in each of the Registration Statement, the Pricing Prospectus and the
Prospectus are based on or derived from sources that the Company reasonably believes to be reliable and accurate in all material respects; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) The Company and its subsidiaries possess all licenses, certificates, permits and other authorizations issued by, and have made all
declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities having jurisdiction over the Company and its subsidiaries that are necessary for the ownership or lease of their respective
properties or the conduct of their respective businesses as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, except where the failure to possess or make the same would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect; and except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor any of its subsidiaries has received notice of any revocation
or modification of any such license, certificate, permit or authorization, except where such revocation or modification would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) All United States federal income tax returns of the Company and its subsidiaries required by law to be filed have been filed and all
taxes shown as due on such returns or that otherwise have been assessed, which are due and payable, have been paid, except assessments against which appeals have been or will be promptly taken and as to which adequate reserves have been provided.
The Company and its subsidiaries have filed all other tax returns that are required to have been filed by them pursuant to applicable foreign, state, local or other law except insofar as the failure to file such returns would not, individually or in
the aggregate, reasonably be expected to have a Material Adverse Effect, and has paid all taxes due pursuant to such returns or pursuant to any assessment received by the Company and its subsidiaries, except for such taxes, if any, as are being
contested in good faith and as to which adequate reserves have been provided and except insofar as the failure to pay such taxes would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) The Company has not taken and will not take, directly or indirectly, any action that is designed to or that has constituted or might
reasonably be expected to cause or result in stabilization or manipulation of the price of the Shares; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) Neither the Company nor any
of its subsidiaries is a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company or any of its subsidiaries or any Underwriter for a brokerage
commission, finder&#146;s fee or like payment in connection with the offering and sale of the Shares; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) No relationship, direct or
indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company or any of its subsidiaries, on the other, that is required by the Act to be
described in the Registration Statement and the Prospectus and that is not so described in such documents and in the Registration Statement, the Pricing Disclosure Package and the Prospectus; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) There are no contracts, arrangements or documents which are required to be described in the Registration Statement or to be filed as
exhibits thereto which have not been so described and filed as required; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) Except as would not reasonably be expected to have a
Material Adverse Effect, (i)&nbsp;The Company&#146;s and its subsidiaries&#146; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;IT
Systems&#148;) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, and are, to the knowledge of the Company, free
and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other corruptants; (ii)&nbsp;the Company and its subsidiaries have implemented and maintained reasonable controls, policies, procedures, and safeguards to maintain and protect their material
confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data (including all personal or personally identifiable data (&#147;Personal Data&#148;)) used in connection with their businesses; to
the knowledge of the Company, there have been no breaches, violations, outages or unauthorized uses of or accesses to any Personal Data, except for those that have been remedied without material cost or liability or the duty to notify any other
person, nor any incidents under internal review or investigations relating to the same; the Company and its subsidiaries are presently in compliance in all material respects with all applicable laws or statutes and all judgments, orders, rules and
regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal
Data from unauthorized use, access, misappropriation or modification; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) The Company and each director and officer of the Company, in
their capacities as such, are in compliance, to the extent required, with all provisions of the Sarbanes-Oxley Act, and all rules and regulations promulgated thereunder applicable to, and the Company at such time, and is taking steps designed to
ensure that it will be in compliance, at all times, with the other provisions of the Sarbanes-Oxley Act when they become applicable to the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) None of the subsidiaries of the Company is a &#147;significant subsidiary&#148; of the Company as such term is defined in Rule <FONT
STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Exchange Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) No
forward-looking statement (within the meaning of Section&nbsp;27A of the Act and Section&nbsp;21E of the Exchange Act) included in any of the Registration Statement, the Pricing Prospectus or the Prospectus has been made or reaffirmed without a
reasonable basis or has been disclosed other than in good faith; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) The Stock is registered pursuant to Section&nbsp;12(b) of the
Exchange Act and is listed for trading on the Exchange and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Stock under the Exchange Act or the delisting of the Stock from the
Exchange, nor has the Company received any notification that the Commission or the Exchange is contemplating terminating such registration or listing. To the Company&#146;s knowledge, the Company is in compliance with all material applicable listing
requirements of the Exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Subject to the terms and conditions herein set forth, the Company agrees to issue and sell to each of
the Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from the Company, at a purchase price per share of $[&#9679;], the number of Firm Shares set forth opposite the name of such Underwriter in Schedule I
hereto and (b)&nbsp;in the event and to the extent that the Underwriters shall exercise the election to purchase Optional Shares as provided below, the Company agrees to issue and sell to each of the Underwriters, and each of the Underwriters
agrees, severally and not jointly, to purchase from the Company, at the purchase price per share set forth in clause (a)&nbsp;of this Section&nbsp;2 (provided that the purchase price per Optional Share shall be reduced by an amount per share equal
to any dividends or distributions declared by the Company and payable on the Firm Shares but not payable on the Optional Shares), that portion of the number of Optional Shares as to which such election shall have been exercised (to be adjusted by
you so as to eliminate fractional shares) determined by multiplying such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
number of Optional Shares by a fraction, the numerator of which is the maximum number of Optional Shares which such Underwriter is entitled to purchase as set forth opposite the name of such
Underwriter in Schedule I hereto and the denominator of which is the maximum number of Optional Shares that all of the Underwriters are entitled to purchase hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby grants to the Underwriters the right to purchase at their election up to [&#9679;] Optional Shares, at the purchase price
per share set forth in the paragraph above, provided that the purchase price per Optional Share shall be reduced by an amount per share equal to any dividends or distributions declared by the Company and payable on the Firm Shares but not payable on
the Optional Shares. Any such election to purchase Optional Shares may be exercised only by written notice from you to the Company, given within a period of 30 calendar days after the date of this Agreement, setting forth the aggregate number of
Optional Shares to be purchased and the date on which such Optional Shares are to be delivered, as determined by you but in no event earlier than the First Time of Delivery (as defined in Section&nbsp;4 hereof) or, unless you and the Company
otherwise agree in writing, earlier than two or later than ten business days after the date of such notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Upon the authorization by
you of the release of the Shares, the several Underwriters propose to offer the Shares for sale upon the terms and conditions set forth in the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. (a) The Shares to be purchased by each Underwriter hereunder, in definitive or book-entry form, and in such authorized denominations and
registered in such names as the Representatives may request upon at least forty-eight hours&#146; prior notice to the Company shall be delivered by or on behalf of the Company to the Representatives, through the facilities of the Depository Trust
Company (&#147;DTC&#148;), for the account of such Underwriter, against payment by or on behalf of such Underwriter of the purchase price therefor by wire transfer of Federal <FONT STYLE="white-space:nowrap">(same-day)</FONT> funds to the account
specified by the Company to the Representatives at least forty-eight hours in advance. The Company will cause the certificates, if any, representing the Shares to be made available for checking and packaging at least twenty-four hours prior to the
Time of Delivery (as defined below) with respect thereto at the office of DTC or its designated custodian<B> </B>(the &#147;Designated Office&#148;). The time and date of such delivery and payment shall be, with respect to the Firm Shares, 9:30
a.m., New York City time, on [&#9679;], 2022 or such other time and date as the Representatives and the Company may agree upon in writing, and, with respect to the Optional Shares, 9:30a.m., New York time, on the date specified by the
Representatives in the written notice given by the Representatives of the Underwriters&#146; election to purchase such Optional Shares, or such other time and date as the Representatives and the Company may agree upon in writing. Such time and date
for delivery of the Firm Shares is herein called the &#147;First Time of Delivery&#148;, such time and date for delivery of the Optional Shares, if not the First Time of Delivery, is herein called the &#147;Second Time of Delivery&#148;, and each
such time and date for delivery is herein called a &#147;Time of Delivery&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The documents to be delivered at each<B> </B>Time of
Delivery by or on behalf of the parties hereto pursuant to Section&nbsp;8 hereof, including the cross receipt for the Shares and any additional documents requested by the Underwriters pursuant to Section&nbsp;8(j) hereof, will be delivered at the
offices of Wilmer Cutler Hale Pickering and Dorr LLP, 7 World Trade Center 250 Greenwich Street New York, NY 10007 (the &#147;Closing Location&#148;), and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shares will be delivered at the Designated Office, all at such Time of Delivery. A meeting will be held at the Closing Location at 5:00 p.m., New York City time, on the New York Business Day next
preceding such Time of Delivery, at which meeting the final drafts of the documents to be delivered pursuant to the preceding sentence will be available for review by the parties hereto. For the purposes of this Section&nbsp;4, &#147;New York
Business Day&#148; shall mean each Monday, Tuesday, Wednesday, Thursday and Friday which is not a day on which banking institutions in New York City are generally authorized or obligated by law or executive order to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The Company agrees with each of the Underwriters: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) To prepare the Prospectus in a form approved by you and to file such Prospectus pursuant to Rule 424(b) under the Act not later than the
Commission&#146;s close of business on the second business day following the execution and delivery of this Agreement, or, if applicable, such earlier time as may be required by Rule 430A(a)(3) under the Act; to make no further amendment or any
supplement to the Registration Statement or the Prospectus prior to the last Time of Delivery which shall be disapproved by you promptly after reasonable notice thereof; to advise you, promptly after it receives notice thereof, of the time when any
amendment to the Registration Statement has been filed or becomes effective or any amendment or supplement to the Prospectus has been filed and to furnish you with copies thereof; to file promptly all material required to be filed by the Company
with the Commission pursuant to Rule 433(d) under the Act; to advise you, promptly after it receives notice thereof, of the issuance by the Commission of any stop order or of any order preventing or suspending the use of any Preliminary Prospectus
or other prospectus in respect of the Shares, of the suspension of the qualification of the Shares for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding for any such purpose, or of any request by the Commission
for the amending or supplementing of the Registration Statement or the Prospectus or for additional information; and, in the event of the issuance of any stop order or of any order preventing or suspending the use of any Preliminary Prospectus or
other prospectus or suspending any such qualification, to promptly use its best efforts to obtain the withdrawal of such order; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
Promptly from time to time to take such action as you may reasonably request to qualify the Shares for offering and sale under the securities laws of such jurisdictions as you may reasonably request and to comply with such laws so as to permit the
continuance of sales and dealings therein in such jurisdictions for as long as may be necessary to complete the distribution of the Shares, provided that in connection therewith the Company shall not be required to qualify as a foreign corporation
(where not otherwise required) or to file a general consent to service of process in any jurisdiction (where not otherwise required); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
Prior to 10:00 a.m., New York City time, on the New York Business Day next succeeding the date of this Agreement (or such other time as may be agreed to by you and the Company) and from time to time, to furnish the Underwriters with written and
electronic copies of the Prospectus in New York City in such quantities as you may reasonably request, and, if the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) is required at any time prior to
the expiration of nine months after the time of issue of the Prospectus in connection with the offering or sale of the Shares and if at such time any event shall have occurred as a result of which the Prospectus as then amended or supplemented would
include an untrue statement of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Prospectus (or in lieu
thereof, the notice referred to in Rule 173(a) under the Act)<B> </B>is delivered, not misleading, or, if for any other reason it shall be necessary during such same period to amend or supplement the Prospectus in order to comply with the Act, to
notify you and upon your request to prepare and furnish without charge to each Underwriter and to any dealer (whose name and address the Underwriters shall furnish to the Company in connection with such request) in securities as many written and
electronic copies as you may from time to time reasonably request of an amended Prospectus or a supplement to the Prospectus which will correct such statement or omission or effect such compliance; and in case any Underwriter is required to deliver
a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act)<B> </B>in connection with sales of any of the Shares at any time nine months or more after the time of issue of the Prospectus, upon your request but at the
expense of such Underwriter, to prepare and deliver to such Underwriter as many written and electronic copies as you may request of an amended or supplemented Prospectus complying with Section&nbsp;10(a)(3) of the Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) To make generally available to its securityholders as soon as practicable (which may be satisfied by filing with the Commission&#146;s
Electronic Data Gathering, Analysis and Retrieval System (&#147;EDGAR&#148;) or any successor thereto), but in any event not later than sixteen months after the effective date of the Registration Statement (as defined in Rule 158(c) under the Act),
an earnings statement of the Company and its subsidiaries (which need not be audited) complying with Section&nbsp;11(a) of the Act and the rules and regulations of the Commission thereunder (including, at the option of the Company, Rule 158); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) During the period beginning from the date hereof and continuing to and including the date 90<B> </B>days after the date of the Prospectus
(the <FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Period&#148;), not to (i)&nbsp;offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise transfer or dispose of, directly or indirectly, or file
with or confidentially submit to the Commission a registration statement under the Act relating to, any securities of the Company that are substantially similar to the Shares, including but not limited to any options or warrants to purchase shares
of Stock or any securities that are convertible into or exchangeable for, or that represent the right to receive, Stock or any such substantially similar securities, or publicly disclose the intention to make any offer, sale, pledge, disposition or
filing or (ii)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or any such other securities, whether any such transaction described in clause (i)&nbsp;or
(ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise (other than the Shares to be sold hereunder or pursuant to employee stock option plans existing on, or upon the conversion or exchange of convertible or
exchangeable securities outstanding as of, the date of this Agreement), without the prior written consent of the Representatives; <I>provided</I>, that the restrictions contained in this paragraph shall not apply to (a)&nbsp;the Shares to be sold by
the Company hereunder, (b)&nbsp;the issuance by the Company of shares of Stock or any other security pursuant to the exercise of an option or warrant or the conversion and/or exchange of a security in each case outstanding on the date hereof and
described in the Registration Statement and the Prospectus, (c)&nbsp;grants of options, restricted shares or restricted share units to officers, directors, employees and consultants of the Company in accordance with the terms of an incentive
compensation plan described in the Registration Statement and the Prospectus, or the issuance by the Company of shares of Common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock upon the exercise thereof, (d)&nbsp;the filing by the Company of a registration statement with the Commission on Form <FONT STYLE="white-space:nowrap">S-8</FONT> in connection with such
aforesaid plan, or (e)&nbsp;the issuance of shares of Stock, or any securities convertible into or exercisable or exchangeable for shares of Stock, or the entry into an agreement to issue shares of Stock, in each case in connection with any bona
fide merger, joint venture, strategic alliance, commercial or other collaborative transaction, or the acquisition or license by the Company of the business, property, technology or other assets of another individual or entity that is an unaffiliated
third party of the Company, or the assumption of an employee benefit plan in connection with such a merger or acquisition, provided, that the aggregate number of shares of Stock or securities convertible into or exercisable for Stock (on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> or as exercised basis, as the case may be) that the Company may sell or issue or agree to sell or issue pursuant to clause (e)&nbsp;above shall not exceed 5% of the total number of shares of the
Company&#146;s Stock issued and outstanding immediately following the completion of the transactions contemplated by this Agreement and with respect to any transaction described in clauses (b)-(e) of this Section&nbsp;5(e) occurring during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period, any transferee or other recipient of Stock or other Company securities agrees to be bound in writing, until the end of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, by the restrictions
set forth in a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form described in Section&nbsp;8(h) hereof; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) During a
period of three (3)&nbsp;years from the effective date of the Registration Statement, so long as the Company is subject to the reporting requirements of either Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act, to furnish to its stockholders
as soon as practicable after the end of each fiscal year an annual report (including a balance sheet and statements of income, stockholders&#146; equity and cash flows of the Company and its consolidated subsidiaries certified by independent public
accountants) and, as soon as practicable after the end of each of the first three quarters of each fiscal year (beginning with the fiscal quarter ending after the effective date of the Registration Statement), to make available to its stockholders
consolidated summary financial information of the Company and its subsidiaries for such quarter in reasonable detail, provided, that no reports, documents or other information needs to be furnished pursuant to this Section&nbsp;5(f) to the extent
they are available on EDGAR; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) During a period of three (3)&nbsp;years from the effective date of the Registration Statement, so long
as the Company is subject to the reporting requirements of either Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act, to furnish to you copies of all reports or other communications (financial or other) furnished to stockholders, and to
deliver to you (i)&nbsp;as soon as they are available, copies of any reports and financial statements furnished to or filed with the Commission or any national securities exchange on which any class of securities of the Company is listed; and
(ii)&nbsp;such additional information concerning the business and financial condition of the Company as you may from time to time reasonably request (such financial statements to be on a consolidated basis to the extent the accounts of the Company
and its subsidiaries are consolidated in reports furnished to its stockholders generally or to the Commission), provided, that no reports, documents or other information needs to be furnished pursuant to this Section&nbsp;5(g) to the extent they are
available on EDGAR; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) To use the net proceeds received by it from the sale of the Shares pursuant to this Agreement in the manner
specified in the Pricing Prospectus under the caption &#147;Use of Proceeds&#148;; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) To use its best efforts to<B> </B>list, subject to notice of issuance, the Shares on the
Exchange; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) If the Company elects to rely upon Rule 462(b), the Company shall file a Rule 462(b) Registration Statement with the
Commission in compliance with Rule 462(b) by 10:00 p.m., Washington, D.C. time, on the date of this Agreement, and the Company shall at the time of filing either pay to the Commission the filing fee for the Rule 462(b) Registration Statement or give
irrevocable instructions for the payment of such fee pursuant to Rule 111(b) under the Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Upon request of any Underwriter, to
furnish, or cause to be furnished, to such Underwriter an electronic version of the Company&#146;s trademarks, servicemarks and corporate logo for use on the website, if any, operated by such Underwriter for the purpose of facilitating the <FONT
STYLE="white-space:nowrap">on-line</FONT> offering of the Shares (the &#147;License&#148;); provided, however, that the License shall be used solely for the purpose described above, is granted without any fee and may not be assigned or transferred;
and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) To promptly notify you if the Company ceases to be an Emerging Growth Company at any time prior to the later of
(i)&nbsp;completion of the distribution of the Shares within the meaning of the Act and (ii)&nbsp;the last Time of Delivery. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. (a) The
Company represents and agrees that, without the prior consent of the Representatives, it has not made and will not make any offer relating to the Shares that would constitute a &#147;free writing prospectus&#148; as defined in Rule 405 under the
Act; each Underwriter represents and agrees that, without the prior consent of the Company and the Representatives, it has not made and will not make any offer relating to the Shares that would constitute a free writing prospectus required to be
filed with the Commission; any such free writing prospectus the use of which has been consented to by the Company and the Representatives is listed on Schedule II(a) hereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company has complied and will comply with the requirements of Rule 433 under the Act applicable to any Issuer Free Writing Prospectus,
including timely filing with the Commission or retention where required and legending;<B> </B>and the Company represents that it has satisfied and agrees that it will satisfy the conditions under Rule 433 under the Act to avoid a requirement to file
with the Commission any electronic road show; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company agrees that if at any time following issuance of an Issuer Free Writing
Prospectus or Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication any event occurred or occurs as a result of which such Issuer Free Writing Prospectus or Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication would conflict with the information in the Registration Statement, the Pricing Prospectus or the Prospectus or would include an untrue
statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances then prevailing, not misleading, the Company will give prompt notice thereof to the Representatives
and, if requested by the Representatives, will prepare and furnish without charge to each Underwriter an Issuer Free Writing Prospectus, Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication or other document which will correct such conflict, statement or omission<B>;</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company represents and agrees that (i)&nbsp;it has not engaged in, or authorized any
other person to engage in, any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications, other than
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications with the prior consent of the Representatives with entities that the Company reasonably believes are qualified institutional buyers as
defined in Rule 144A under the Act or institutions that are accredited investors as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Act; and (ii)&nbsp;it has not distributed, or authorized any other person to distribute, any
Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications, other than those distributed with the prior consent of the Representatives that are listed on Schedule II(c) hereto; and the
Company reconfirms that the Underwriters have been authorized to act on its behalf in engaging in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Each Underwriter represents and agrees that any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications undertaken by it were with entities that such Underwriter reasonably believes are qualified institutional buyers as defined in Rule
144A under the Act or institutions that are accredited investors as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. The Company covenants and agrees with the several Underwriters that the Company will pay or cause to be paid the following: (i)&nbsp;the
fees, disbursements and expenses of the Company&#146;s counsel and accountants in connection with the registration of the Shares under the Act and all other expenses in connection with the preparation, printing, reproduction and filing of the
Registration Statement, any Preliminary Prospectus, any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any Issuer Free Writing Prospectus and the Prospectus and amendments
and supplements thereto and the mailing and delivering of copies thereof to the Underwriters and dealers; (ii)&nbsp;the cost of printing or producing any Agreement among Underwriters, this Agreement, the Blue Sky Memorandum, closing documents
(including any compilations thereof) and any other documents in connection with the offering, purchase, sale and delivery of the Shares; (iii)&nbsp;all expenses in connection with the qualification of the Shares for offering and sale under state
securities laws as provided in Section&nbsp;5(b) hereof, including the reasonable fees and disbursements of counsel for the Underwriters in connection with such qualification and in connection with the Blue Sky survey (iv)&nbsp;the costs and
expenses of the Company relating to investor presentations on any &#147;road show&#148; undertaken in connection with the marketing of the offering of the Shares, including, without limitation, expenses associated with the preparation or
dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations (with the prior approval of the
Company), travel and lodging expenses of the representatives and officers of the Company and any such consultants, and 50% of the cost of any aircraft chartered in connection with the road show; (v)&nbsp;all fees and expenses in connection with
listing the Shares on the Exchange; (vi)&nbsp;the filing fees incident to, and the reasonable fees and disbursements of counsel for the Underwriters in connection with, any required review by FINRA of the terms of the sale of the Shares;
(vii)&nbsp;the cost of preparing stock certificates; (viii)&nbsp;the cost and charges of any transfer agent or registrar; and (ix)&nbsp;all other costs and expenses incident to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the performance of its obligations hereunder which are not otherwise specifically provided for in this Section; provided that the aggregate amount of fees of counsel payable by the Company
pursuant to subsections (iii)&nbsp;and, solely with respect to fees and disbursements for underwriters&#146; counsel, subsection (vi), shall not exceed $25,000 in the aggregate. It is understood, however, that, except as provided in this Section,
and Sections 9 and 12 hereof, the Underwriters will pay all of their own costs and expenses, including the fees of their counsel, stock transfer taxes on resale of any of the Shares by them, and any advertising expenses connected with any offers
they may make and the travel and lodging expenses incurred by representatives of the Underwriters in connection with any road show. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.
The obligations of the Underwriters hereunder<B>, </B>as to the Shares to be delivered at each Time of Delivery,<B> </B>shall be subject, in their discretion, to the condition that all representations and warranties and other statements of the
Company herein are, at and as of the Applicable Time and such Time of Delivery, true and correct, the condition that the Company shall have performed all of its obligations hereunder theretofore to be performed, and the following additional
conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Prospectus shall have been filed with the Commission pursuant to Rule 424(b) under the Act within the
applicable time period prescribed for such filing by the rules and regulations under the Act and in accordance with Section&nbsp;5(a) hereof; all material required to be filed by the Company pursuant to Rule 433(d) under the Act shall have been
filed with the Commission within the applicable time period prescribed for such filing by Rule 433; if the Company has elected to rely upon Rule 462(b) under the Act, the Rule 462(b) Registration Statement shall have become effective by 10:00 p.m.,
Washington, D.C. time, on the date of this Agreement; no stop order suspending the effectiveness of the Registration Statement or any part thereof shall have been issued and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Act
shall have been initiated or threatened by the Commission; no stop order suspending or preventing the use of the Pricing Prospectus, Prospectus or any Issuer Free Writing Prospectus shall have been initiated or threatened by the Commission; and all
requests for additional information on the part of the Commission shall have been complied with to your reasonable satisfaction; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Wilmer Cutler Pickering Hale and Dorr LLP, counsel for the Underwriters, shall have furnished to you their written opinion
and negative assurance letter, each dated such Time of Delivery, in form and substance satisfactory to the Representatives, and such counsel shall have received such papers and information as they may reasonably request to enable them to pass upon
such matters; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)<B></B>&nbsp;(i) Goodwin Procter LLP, counsel for the Company, shall have furnished to you their written
opinion and negative assurance letter, each dated such Time of Delivery, in form and substance satisfactory to the Representatives, and (ii)&nbsp;Fish&nbsp;&amp; Richardson, intellectual property counsel for the Company, shall have furnished to you
their written opinion and negative assurance letter, each dated such Time of Delivery, in form and substance satisfactory to the Representatives; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) On the date of the Prospectus at a time prior to the execution of this
Agreement, at 9:30 a.m., New York City time, on the effective date of any <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment to the Registration Statement filed subsequent to the date of this Agreement and also at each Time of
Delivery, Deloitte&nbsp;&amp; Touche LLP shall have furnished to you a letter or letters, dated the respective dates of delivery thereof, in form and substance satisfactory to the Representatives; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) (i) Neither the Company nor any of its subsidiaries shall have sustained since the date of the latest audited financial
statements included in the Pricing Prospectus any loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree,
otherwise than as set forth or contemplated in the Pricing Prospectus, and (ii)&nbsp;since the respective dates as of which information is given in the Pricing Prospectus there shall not have been any change in the capital stock or <FONT
STYLE="white-space:nowrap">long-term</FONT> debt of the Company or any of its subsidiaries or any change or effect, or any development involving a prospective change or effect, in or affecting (x)&nbsp;the business, properties, general affairs,
management, financial position, stockholders&#146; equity or results of operations of the Company and its subsidiaries, taken as a whole, except as set forth or contemplated in the Pricing Prospectus, or (y)&nbsp;the ability of the Company to
perform its obligations under this Agreement, including the issuance and sale of the Shares, or to consummate the transactions contemplated in the Pricing Prospectus and the Prospectus, the effect of which, in any such case described in clause
(i)&nbsp;or (ii), is in your judgment so material and adverse as to make it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares being delivered at such Time of Delivery on the terms and in the manner
contemplated in the Pricing Prospectus and the Prospectus; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) On or after the Applicable Time there shall not have
occurred any of the following: (i)&nbsp;a suspension or material limitation in trading in securities generally on the Exchange; (ii)&nbsp;a suspension or material limitation in trading in the Company&#146;s securities on the<B> </B>Exchange;
(iii)&nbsp;a general moratorium on commercial banking activities declared by either Federal or New York State authorities or a material disruption in commercial banking or securities settlement or clearance services in the United States;
(iv)&nbsp;the outbreak or escalation of hostilities involving the United States or the declaration by the United States of a national emergency or war or (v)&nbsp;the occurrence of any other calamity or crisis or any change in financial, political
or economic conditions in the United States or elsewhere, if the effect of any such event specified in clause (iv)&nbsp;or (v) in your judgment makes it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares
being delivered at such Time of Delivery on the terms and in the manner contemplated in the Pricing Prospectus and the Prospectus; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Shares to be sold at such Time of Delivery shall have been duly listed, subject to notice of issuance, for quotation on
the Exchange; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The Company shall have obtained and delivered to the Underwriters executed copies of an agreement from
officers, directors, and certain stockholders of the Company, substantially in the form attached as Annex I hereto; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company shall have complied with the provisions of Section&nbsp;5(c)
hereof with respect to the furnishing of prospectuses on the New York Business Day next succeeding the date of this Agreement (or such other time as may be agreed to by you and the Company); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The Company shall have furnished or caused to be furnished to you at such Time of Delivery certificates of officers of the
Company satisfactory to you as to the accuracy of the representations and warranties of the Company herein at and as of such Time of Delivery, as to the performance by the Company of all of its obligations hereunder to be performed at or prior to
such Time of Delivery, as to the matters set forth in subsections (a)&nbsp;and (e) of this Section and as to such other matters as you may reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. (a) The Company will indemnify and hold harmless each Underwriter against any losses, claims, damages or liabilities, joint or several, to
which such Underwriter may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a
material fact contained in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, any Issuer Free Writing Prospectus, any &#147;roadshow&#148; as defined in Rule
433(h) under the Act (a &#147;roadshow&#148;), any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) under the Act or any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, and will reimburse each Underwriter for any documented legal or other expenses reasonably incurred by such Underwriter in connection with investigating or defending any such action or claim as
such expenses are incurred; <I>provided</I>, <I>however</I>, that the Company shall not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue
statement or omission or alleged omission made in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus or any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, in reliance upon and in conformity with the Underwriter Information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each Underwriter, severally and not jointly, will indemnify and hold harmless the Company against any losses, claims, damages or
liabilities to which the Company may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of
a material fact contained in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, or any roadshow or any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, any
Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, or any roadshow or any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, in reliance upon and in conformity with the Underwriter Information; and will reimburse the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company for any legal or other expenses reasonably incurred by the Company in connection with investigating or defending any such action or claim as such expenses are incurred. As used in this
Agreement with respect to an Underwriter and an applicable document, &#147;Underwriter Information&#148; shall mean the written information furnished to the Company by such Underwriter through the Representatives expressly for use therein; it being
understood and agreed upon that the only such information furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter: the concession and reallowance figures appearing in the second
sentence of the fifth paragraph under the caption &#147;Underwriting&#148;, and the information contained in the first two sentences of the eighth paragraph and the first sentence of the ninth paragraph under the caption &#147;Underwriting&#148;.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an indemnified party under subsection (a)&nbsp;or (b) above of notice of the commencement of any action,
such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in writing of the commencement thereof; provided that the failure to notify the
indemnifying party shall not relieve it from any liability that it may have under the preceding paragraphs of this Section&nbsp;9 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses)
by such failure; and provided further that the failure to notify the indemnifying party shall not relieve it from any liability that it may have to an indemnified party otherwise than under the preceding paragraphs of this Section&nbsp;9. In case
any such action shall be brought against any indemnified party and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it shall wish, jointly
with any other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party (who shall not, except with the consent of the indemnified party, be counsel to the indemnifying
party), and, after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party shall not be liable to such indemnified party under such subsection for any legal expenses of
other counsel or any other expenses, in each case subsequently incurred by such indemnified party, in connection with the defense thereof other than reasonable costs of investigation. No indemnifying party shall, without the written consent of the
indemnified party, effect the settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or threatened action or claim in respect of which indemnification or contribution may be sought hereunder (whether or not
the indemnified party is an actual or potential party to such action or claim) unless such settlement, compromise or judgment (i)&nbsp;includes an unconditional release of the indemnified party from all liability arising out of such action or claim
and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any indemnified party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) If the indemnification provided for in this Section&nbsp;9 is unavailable to or insufficient to hold harmless an indemnified party under
subsection (a)&nbsp;or (b) above in respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as a
result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other from the offering
of the Shares. If, however, the allocation provided by the immediately preceding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sentence is not permitted by applicable law, then each indemnifying party shall contribute to such amount paid or payable by such indemnified party in such proportion as is appropriate to reflect
not only such relative benefits but also the relative fault of the Company on the one hand and the Underwriters on the other in connection with the statements or omissions which resulted in such losses, claims, damages or liabilities (or actions in
respect thereof), as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other shall be deemed to be in the same proportion as the total net proceeds from the
offering (before deducting expenses) received by the Company bear to the total underwriting discounts and commissions received by the Underwriters, in each case as set forth in the table on the cover page of the Prospectus. The relative fault shall
be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company on the one hand or the
Underwriters on the other and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the Underwriters agree that it would not be just and equitable if
contribution pursuant to this subsection (d)&nbsp;were determined by <I>pro rata</I> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable
considerations referred to above in this subsection (d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to above in this subsection (d)&nbsp;shall
be deemed to include any documented legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this subsection (d), no Underwriter
shall be required to contribute any amount in excess of the amount by which the total price at which the Shares underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages which such Underwriter has
otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations in this subsection (d)&nbsp;to contribute are several in proportion to their respective underwriting obligations and not joint.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The obligations of the Company under this Section&nbsp;9 shall be in addition to any liability which the Company may otherwise have
and shall extend, upon the same terms and conditions, to each employee, officer and director of each Underwriter and each person, if any, who controls any Underwriter within the meaning of the Act and each broker-dealer or other affiliate of any
Underwriter; and the obligations of the Underwriters under this Section&nbsp;9 shall be in addition to any liability which the respective Underwriters may otherwise have and shall extend, upon the same terms and conditions, to each officer and
director of the Company (including any person who, with his or her consent, is named in the Registration Statement as about to become a director of the Company) and to each person, if any, who controls the Company within the meaning of the Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. (a) If any Underwriter shall default in its obligation to purchase the Shares which it has agreed to purchase hereunder at a Time of
Delivery, you may in your discretion arrange for you or another party or other parties to purchase such Shares on the terms contained herein. If within <FONT STYLE="white-space:nowrap">thirty-six</FONT> hours after such default by any Underwriter
you do not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
arrange for the purchase of such Shares, then the Company shall be entitled to a further period of <FONT STYLE="white-space:nowrap">thirty-six</FONT> hours within which to procure another party
or other parties satisfactory to you to purchase such Shares on such terms. In the event that, within the respective prescribed periods, you notify the Company that you have so arranged for the purchase of such Shares, or the Company notifies you
that it has so arranged for the purchase of such Shares, you or the Company shall have the right to postpone such Time of Delivery for a period of not more than seven days, in order to effect whatever changes may thereby be made necessary in the
Registration Statement or the Prospectus, or in any other documents or arrangements, and the Company agrees to file promptly any amendments or supplements to the Registration Statement or the Prospectus which in your opinion may thereby be made
necessary. The term &#147;Underwriter&#148; as used in this Agreement shall include any person substituted under this Section with like effect as if such person had originally been a party to this Agreement with respect to such Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by you and the
Company as provided in subsection (a)&nbsp;above, the aggregate number of such Shares which remains unpurchased does not exceed <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of all the Shares to be purchased at such
Time of Delivery, then the Company shall have the right to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter to purchase the number of shares which such Underwriter agreed to purchase hereunder at such Time of Delivery
and, in addition, to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter to purchase its pro rata share (based on the number of Shares which such Underwriter agreed to purchase hereunder) of the Shares of such defaulting
Underwriter or Underwriters for which such arrangements have not been made; but nothing herein shall relieve a defaulting Underwriter from liability for its default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by you and the
Company as provided in subsection (a)&nbsp;above, the aggregate number of such Shares which remains unpurchased exceeds <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of all the Shares to be purchased at such Time of
Delivery, or if the Company shall not exercise the right described in subsection (b)&nbsp;above to require <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase Shares of a defaulting Underwriter or Underwriters, then this
Agreement (or, with respect to the Second Time of Delivery, the obligations of the Underwriters to purchase and of the Company to sell the Optional Shares) shall thereupon terminate, without liability on the part of any <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter or the Company, except for the expenses to be borne by the Company and the Underwriters as provided in Section&nbsp;7 hereof and the indemnity and contribution agreements in Section&nbsp;9
hereof; but nothing herein shall relieve a defaulting Underwriter from liability for its default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. The respective indemnities, rights
of contribution, agreements, representations, warranties and other statements of the Company and the several Underwriters, as set forth in this Agreement or made by or on behalf of them, respectively, pursuant to this Agreement, shall remain in full
force and effect, regardless of any investigation (or any statement as to the results thereof) made by or on behalf of any Underwriter or any director, officer, employee, affiliate or controlling person of any Underwriter, or the Company, or any
officer or director or controlling person of the Company, and shall survive delivery of and payment for the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. If this Agreement
shall be terminated pursuant to Section&nbsp;10 hereof, the Company shall not then be under any liability to any Underwriter except as provided in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Sections&nbsp;7 and 9 hereof; but, if for any other reason, any Shares are not delivered by or on behalf of the Company as provided herein or the Underwriters decline to purchase the Shares for
any reason permitted under this Agreement, the Company will reimburse the Underwriters through you for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses approved in writing by you, including
fees and disbursements of counsel, reasonably incurred and documented by the Underwriters in making preparations for the purchase, sale and delivery of the Shares not so delivered, but the Company shall then be under no further liability to any
Underwriter except as provided in Sections 7 and 9 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. In all dealings hereunder, the Representatives shall act on behalf of each
of the Underwriters, and the parties hereto shall be entitled to act and rely upon any statement, request, notice or agreement on behalf of any Underwriter made or given by you jointly or by Goldman Sachs&nbsp;&amp; Co. LLC on behalf of you as the
Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All statements, requests, notices and agreements hereunder shall be in writing, and if to the Underwriters shall be delivered or sent by
mail, telex or facsimile transmission to you as the Representatives in care of Goldman Sachs&nbsp;&amp; Co. LLC, 200 West Street, New York, New York <FONT STYLE="white-space:nowrap">10282-2198,</FONT> Attention: Registration Department; in care of
BofA Securities, Inc., One Bryant Park, New York, New York 10036; in care of SVB Securities LLC, 1301 Avenue of the Americas, 12th Floor New York, New York 10019, Attention: Stuart R. Nayman; and in care of Evercore Group L.L.C., 55 E. 52nd St. New
York, NY 10055; and if to the Company shall be delivered or sent by mail, telex or facsimile transmission to the address of the Company set forth in the Registration Statement, Attention: <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive
Officers, with a copy (which shall not constitute notice) to Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210, Attention: Mitchell S. Bloom&nbsp;&amp; Benjamin K. Marsh; provided, however, that any notice to an Underwriter pursuant to
Section&nbsp;9(c) hereof shall be delivered or sent by mail, telex or facsimile transmission to such Underwriter at its address set forth in its Underwriters&#146; Questionnaire, or telex constituting such Questionnaire, which address will be
supplied to the Company by you upon request; provided, however, that notices under subsection 5(e) shall be in writing, and if to the Underwriters shall be delivered or sent by mail, telex or facsimile transmission to you as the Representatives at
Goldman Sachs&nbsp;&amp; Co. LLC, 200 West Street, New York, New York 10282-2198, Attention: Control Room; in care of BofA Securities, Inc., One Bryant Park, New York, New York 10036; in care of SVB Securities LLC, 1301 Avenue of the Americas, 12th
Floor New York, New York 10019, Attention: Stuart R. Nayman; and in care of Evercore Group L.L.C., 55 E. 52nd St. New York, NY 10055. Any such statements, requests, notices or agreements shall take effect upon receipt thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into
law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include the name and address of their respective clients, as
well as other information that will allow the Underwriters to properly identify their respective clients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. This Agreement shall be
binding upon, and inure solely to the benefit of, the Underwriters, the Company and, to the extent provided in Sections 9 and 11 hereof, the officers and directors of the Company and each person who controls the Company or any Underwriter, or any
director, officer, employee, or affiliate of any Underwriter, and their respective heirs, executors, administrators, successors and assigns, and no other person shall acquire or have any right under or by virtue of this Agreement. No purchaser of
any of the Shares from any Underwriter shall be deemed a successor or assign by reason merely of such purchase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. Time shall be of the essence of this Agreement. As used herein, the term &#147;business
day&#148; shall mean any day when the Commission&#146;s office in Washington, D.C. is open for business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. The Company acknowledges and
agrees that (i)&nbsp;the purchase and sale of the Shares pursuant to this Agreement is an <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction between the Company, on the one hand, and the several Underwriters, on the
other, (ii)&nbsp;in connection therewith and with the process leading to such transaction each Underwriter is acting solely as a principal and not the agent or fiduciary of the Company, (iii)&nbsp;no Underwriter has assumed an advisory or fiduciary
responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on other matters) or any other
obligation to the Company except the obligations expressly set forth in this Agreement, (iv)&nbsp;the Company has consulted its own legal and financial advisors to the extent it deemed appropriate, and (v)&nbsp;none of the activities of the
Underwriters in connection with the transactions contemplated herein constitutes a recommendation, investment advice, or solicitation of any action by the Underwriters with respect to any entity or natural person. The Company agrees that it will not
claim that the Underwriters, or any of them, has rendered advisory services of any nature or respect, or owes a fiduciary or similar duty to the Company, in connection with such transaction or the process leading thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company and the Underwriters, or
any of them, with respect to the subject matter hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. This Agreement and any transaction contemplated by this Agreement and any
claim, controversy or dispute arising under or related thereto shall be governed by and construed in accordance with the laws of the State of New York without regard to principles of conflict of laws that would results in the application of any
other law than the laws of the State of New York. The Company agrees that any suit or proceeding arising in respect of this Agreement or any transaction contemplated by this Agreement will be tried exclusively in the U.S. District Court for the
Southern District of New York or, if that court does not have subject matter jurisdiction, in any state court located in The City and County of New York and the Company agrees to submit to the jurisdiction of, and to venue in, such courts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. The Company and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right
to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. This
Agreement may be executed by any one or more of the parties hereto in any number of counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same instrument. Counterparts may be
delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g.,
www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. Notwithstanding anything herein to the contrary, the Company is authorized to disclose
to any persons the U.S. federal and state income tax treatment and tax structure of the potential transaction and all materials of any kind (including tax opinions and other tax analyses) provided to the Company relating to that treatment and
structure, without the Underwriters imposing any limitation of any kind. However, any information relating to the tax treatment and tax structure shall remain confidential (and the foregoing sentence shall not apply) to the extent necessary to
enable any person to comply with securities laws. For this purpose, &#147;tax structure&#148; is limited to any facts that may be relevant to that treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. Recognition of the U.S. Special Resolution Regimes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the
transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any
such interest and obligation, were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event that any
Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted
to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) As used in this section: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;BHC Act Affiliate&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in accordance with, 12
U.S.C. &#167; 1841(k). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Covered Entity&#148; means any of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167;
252.81, 47.2 or 382.1, as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;U.S. Special Resolution Regime&#148; means each of (i)&nbsp;the Federal Deposit
Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please sign and return to us counterparts hereof, and upon the acceptance hereof by
you, on behalf of each of the Underwriters, this letter and such acceptance hereof shall constitute a binding agreement between each of the Underwriters and the Company. It is understood that your acceptance of this letter on behalf of each of the
Underwriters is pursuant to the authority set forth in a form of Agreement among Underwriters, the form of which shall be submitted to the Company for examination upon request, but without warranty on your part as to the authority of the signers
thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Amylyx&nbsp;Pharmaceuticals,&nbsp;Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title:</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted&nbsp;as&nbsp;of&nbsp;the&nbsp;date&nbsp;hereof:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Goldman Sachs &amp; Co. LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>By:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Name:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Title:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BofA Securities, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>By:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Name:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Title:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SVB Securities LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>By:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Name:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Title:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Evercore Group L.L.C.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>By:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Name:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Title:</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of each of the Underwriters </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to
Underwriting Agreement] </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE I </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Number&nbsp;of<BR>Firm Shares to<BR>be Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Optional&nbsp;Shares&nbsp;to<BR>be&nbsp;Purchased&nbsp;if<BR>Maximum Option<BR>Exercised</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#9679;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#9679;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#9679;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#9679;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVB Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#9679;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#9679;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#9679;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#9679;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">H.C. Wainwright&nbsp;&amp; Co., LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#9679;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#9679;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#9679;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#9679;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE II </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Issuer Free Writing Prospectuses not included in the Pricing Disclosure Package: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">[None] </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Information other than the Pricing
Prospectus that comprise the Pricing Disclosure Package: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The public offering price per share for the Shares is $[&#9679;]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The number of Firm Shares purchased by the Underwriters is [&#9679;]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The number of Optional Shares that may be purchased by the Underwriters is [&#9679;]. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communications: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">[Testing-the-Waters</FONT></FONT>
presentation dated [&#9679;], 2022] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEX I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amylyx Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[</B>&#9679;<B></B><B>], 2022 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman
Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SVB
Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Goldman
Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York
10282-2198 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o BofA Securities, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Bryant Park </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10036 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o SVB Securities LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">53 State Street, 40<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02109 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Evercore Group L.L.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">55 East 52nd Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10055 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Re: <U>Amylyx Pharmaceuticals, Inc. - <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The undersigned
understands that Goldman Sachs&nbsp;&amp; Co. LLC, BofA Securities, Inc., SVB Securities LLC and Evercore Group L.L.C., as representatives (the &#147;Representatives&#148;), propose to enter into an underwriting agreement (the &#147;Underwriting
Agreement&#148;) on behalf of the several Underwriters named in Schedule I to such agreement (collectively, the &#147;Underwriters&#148;), with Amylyx Pharmaceuticals, Inc., a Delaware corporation (the &#147;Company&#148;), providing for a public
offering (the &#147;Public Offering&#148;) of the Common Stock of the Company (the &#147;Shares&#148;) pursuant to a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> to be filed with the Securities and Exchange Commission
(the &#147;SEC&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In consideration of the agreement by the Underwriters to offer and sell the Shares, and of other good and valuable
consideration the receipt and sufficiency of which is hereby acknowledged, the undersigned agrees that, during the period beginning from the date of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and continuing to and including the
date 90 days after the date set forth on the final prospectus (the &#147;Prospectus&#148;) used to sell the Shares (the <FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Period&#148;), the undersigned shall not, and shall not cause or direct any
of its affiliates to, (i) </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offer, sell, contract to sell, pledge, grant any option to purchase, lend or otherwise dispose of any shares of Common Stock of the Company, or any options or warrants to purchase any shares of
Common Stock of the Company, or any securities convertible into, exchangeable for or that represent the right to receive shares of Common Stock of the Company (such options, warrants or other securities, collectively, &#147;Derivative
Instruments&#148;), including without limitation any such shares or Derivative Instruments now owned or hereafter acquired by the undersigned (such Common Stock and Derivative Instruments, collectively, the &#147;Undersigned&#146;s Shares&#148;),
(ii) engage in any hedging or other transaction or arrangement (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative
transaction or instrument, however described or defined) which is designed to or which reasonably could be expected to lead to or result in a sale, loan, pledge or other disposition (whether by the undersigned or someone other than the undersigned),
or transfer of any of the economic consequences of ownership, in whole or in part, directly or indirectly, of any of the Undersigned&#146;s Shares, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled
by delivery of Common Stock or other securities, in cash or otherwise (any such sale, loan, pledge or other disposition, or transfer of economic consequences, a &#147;Transfer&#148;) or (iii)&nbsp;otherwise publicly announce any intention to engage
in or cause any action or activity described in clause (i)&nbsp;above or transaction or arrangement described in clause (ii)&nbsp;above. The undersigned represents and warrants that the undersigned is not, and has not caused or directed any of its
affiliates to be or become, currently a party to any agreement or arrangement that provides for, is designed to or which reasonably could be expected to lead to or result in any Transfer during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Period. For the avoidance of doubt, the undersigned agrees that the foregoing provisions shall be equally applicable to any issuer-directed or other Shares the undersigned may purchase in the Public Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If the undersigned is not a natural person, the undersigned represents and warrants that no single natural person, entity or &#147;group&#148;
(within the meaning of Section&nbsp;13(d)(3) of the Securities Exchange Act of 1934, as amended), other than a natural person, entity or &#147;group&#148; (as described above) that has executed a <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreement in substantially the same form as this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, beneficially owns, directly or indirectly, 50% or more of the common equity interests, or 50% or more of the voting power, in the
undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the undersigned may transfer or otherwise dispose of the Undersigned&#146;s Shares: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as a bona fide gift or gifts or to a charitable organization or educational institution for no value, provided
that the donee or donees thereof agree to be bound in writing by the restrictions set forth herein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any member of the undersigned&#146;s immediate family or any trust for the direct or indirect benefit of the
undersigned or the immediate family of the undersigned, provided that the member of the undersigned&#146;s immediate family or trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any
such transfer shall not involve a disposition for value; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by will or other testamentary document or by intestacy, provided that any filing made under Section&nbsp;16 of
the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), shall include a footnote noting the circumstances described in this clause; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pursuant to a court order or settlement or other domestic order related to the distribution of assets in
connection with the dissolution of a marriage or civil union, provided that any filing made under Section&nbsp;16 of the Exchange Act shall include a footnote noting the circumstances described in this clause; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to general or limited partners, members, stockholders, other equity holders or trust beneficiaries of the
undersigned or to any investment fund or other entity that controls or manages, or is under common control with, the undersigned, provided that any such transferee agrees to be bound in writing by the restrictions set forth herein;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">acquired in the Public Offering (other than any issuer-directed shares of Common Stock purchased in the Public
Offering by an officer or director of the Company) or acquired in open market transactions after the completion of the Public Offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">prior to the first public filing of a prospectus for the Public Offering, provided that the transferee agrees
to be bound in writing by the restrictions set forth herein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by surrender or forfeiture of shares of Common Stock or other securities of the Company to the Company to
satisfy tax withholding obligations upon exercise or vesting or the exercise price upon a cashless net exercise, in each case, of share options, equity awards, warrants or other rights to acquire shares of Common Stock, provided that any filing made
under Section&nbsp;16 of the Exchange Act shall include a footnote noting the circumstances described in this clause; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pursuant to a bona fide third-party tender offer, merger, consolidation, business combination, stock purchase
or other similar transaction or series of related transactions approved by the Board of Directors of the Company and made to all holders of the Company&#146;s capital stock involving a Change in Control, provided that in the event that such tender
offer, merger, consolidation, business combination, stock purchase or transaction or series of related transactions is not completed, the Undersigned&#146;s Shares shall remain subject to the restrictions set forth herein; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with the prior written consent of the Representatives on behalf of the Underwriters </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In addition, with respect to clauses (i), (ii), (iii), (iv), (v), (vi) and (viii)&nbsp;above, it shall be a condition to such transfer that no
filing under the Exchange Act or other disclosure of such transfer shall be required or voluntarily made during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, except (a)&nbsp;as contemplated by clauses (iii), (iv) and (viii)&nbsp;above
and (b)&nbsp;any required filings on Form 5 the filing deadline for which falls during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For purposes of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, &#147;immediate family&#148; shall mean any relationship by
blood, marriage or adoption, not more remote than first cousin and &#147;Change in Control&#148; shall mean the transfer (whether by tender offer, merger, consolidation or other </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
similar transaction), in one transaction or a series of related transactions, in each case occurring subsequent to the Public Offering, to a person or group of affiliated persons (other than an
Underwriter pursuant to the Public Offering), of the Company&#146;s voting securities if, after such transfer, such person or group of affiliated persons would hold more than 50% of the outstanding voting securities of the Company (or the surviving
entity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In addition, notwithstanding the foregoing, (1)&nbsp;if the undersigned is a corporation, the corporation may transfer the
capital stock of the Company to any wholly-owned subsidiary of such corporation; <U>provided</U>, <U>however</U>, that in any such case, it shall be a condition to the transfer that the transferee execute an agreement stating that the transferee is
receiving and holding such capital stock subject to the provisions of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and there shall be no further transfer of such capital stock except in accordance with this <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, and provided further that any such transfer shall not involve a disposition for value; provided, further that no filing under the Exchange Act or other public disclosure reporting a reduction in
beneficial ownership of Common Stock shall be required or shall be voluntarily made during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and (2)&nbsp;the restrictions on transfer and disposition of the Undersigned&#146;s Shares during
the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period shall not apply to the repurchase of the Undersigned&#146;s Shares by the Company pursuant to any contractual arrangement in effect on the date of this agreement and disclosed in the
Prospectus that provides for the repurchase of the undersigned&#146;s Common Stock or in connection with the termination of the undersigned&#146;s employment or other service with the Company; <U>provided</U> that no filing under the Exchange Act or
other public disclosure of such repurchase shall be voluntarily made during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and any filing under the Exchange Act or other public disclosure required to be made during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period shall include a statement to the effect that such repurchase related to the circumstances described in this clause (2). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The undersigned now has, and, except as contemplated by the terms hereof, for the duration of this
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement will have, good and marketable title to the Undersigned&#146;s Shares, free and clear of all liens, encumbrances, and claims whatsoever. The undersigned also agrees and consents to the entry
of stop transfer instructions with the Company&#146;s transfer agent and registrar against the transfer of the Undersigned&#146;s Shares except in compliance with the foregoing restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In addition, the undersigned may enter into any plan designed to satisfy the requirements of Rule
<FONT STYLE="white-space:nowrap">10b5-1</FONT> (a <FONT STYLE="white-space:nowrap">&#147;10b5-1</FONT> Plan&#148;) under the Exchange Act (other than the entry into such a plan in such a manner as to allow the sale of shares of Common Stock, in each
case, within the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period); provided, however that, no sale of shares of Common Stock may be made under such <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan during the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; provided further that no filing under the Exchange Act or public disclosure regarding the establishment of such plan shall be voluntarily made during the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and any such filing or public disclosure that is required to be made during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period shall include a statement to the effect that no disposition
of the Undersigned&#146;s Shares may be made under such plan during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary contained herein, this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement will automatically
terminate and the undersigned will be released from all of his, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
her or its obligations hereunder upon the earliest to occur, if any, of (i)&nbsp;prior to the execution of the Underwriting Agreement, the Company advises the Representatives in writing that it
has determined not to proceed with the Public Offering of the Shares, (ii)&nbsp;prior to the execution of the Underwriting Agreement, the date on which the Company files an application to withdraw the registration statement related to the Public
Offering of the Shares, (iii)&nbsp;the Underwriting Agreement is executed but is terminated (other than the provisions thereof which survive termination) prior to payment for and delivery of the Shares to be sold thereunder or (iv)&nbsp;the Public
Offering has not been consummated on or prior to October&nbsp;31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that none of the
Underwriters has made any recommendation or provided any investment or other advice to the undersigned with respect to this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement or the subject matter hereof, and the undersigned has consulted its
own legal, accounting, financial, regulatory, tax and other advisors with respect to this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and the subject matter hereof to the extent the undersigned has deemed appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The undersigned understands that the Company and the Underwriters are relying upon this <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreement in proceeding toward consummation of the Public Offering and that the Company shall be deemed a third-party beneficiary hereto. The undersigned further understands that this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement is
irrevocable and shall be binding upon the undersigned&#146;s heirs, legal representatives, successors, and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of page
intentionally blank] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Exact Name of Shareholder</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Authorized Signature</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d383770dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g383770ex5_1.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwin Procter <SMALL>LLP</SMALL></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New York
Times Building</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">620 Eighth Avenue</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10018</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">goodwinlaw.com</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+1 212 813 8800</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:56%; font-size:10pt; font-family:Times New Roman" ALIGN="center">October&nbsp;4, 2022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amylyx Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">43 Thorndike St. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, Massachusetts 02141 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Securities Registered under Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT></U>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel to you in connection with your filing of a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT>
(as amended or supplemented, the &#147;Registration Statement&#148;) pursuant to the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), relating to the registration of the offering by Amylyx Pharmaceuticals, Inc., a Delaware
corporation (the &#147;Company&#148;) of up to 6,900,000 shares (the &#147;Shares&#148;) of the Company&#146;s Common Stock, $0.0001 par value per share, including Shares purchasable by the underwriters upon their exercise of an <FONT
STYLE="white-space:nowrap">over-allotment</FONT> option granted to the underwriters by the Company. The Shares are being sold to the several underwriters named in, and pursuant to, an underwriting agreement among the Company and such underwriters
(the &#147;Underwriting Agreement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have reviewed such documents and made such examination of law as we have deemed appropriate
to give the opinions set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinions set forth below, on certificates of officers of the Company.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opinion set forth below is limited to the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon issuance and delivery against payment
therefor in accordance with the terms of the Underwriting Agreement, the Shares will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement and to the references to our firm under the
caption &#147;Legal Matters&#148; in the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations
thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">/s/ Goodwin Procter LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">GOODWIN PROCTER LLP</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>d383770dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> of our report dated
March&nbsp;31, 2022 relating to the financial statements of Amylyx Pharmaceuticals, Inc., appearing in the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Amylyx Pharmaceuticals, Inc. for the year ended December&nbsp;31, 2021.
We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&nbsp;&amp; Touche LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;4, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>d383770dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">S-1</FONT></B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amylyx
Pharmaceuticals, Inc.</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table 1: Newly Registered Securities and Carry Forward Securities </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="8%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Security<BR>type</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Security<BR>class<BR>title</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Fee<BR>calculation<BR>or carry<BR>forward<BR>rule</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Amount<BR>registered</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Proposed<BR>maximum<BR>offering<BR>price<BR>per share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Proposed<BR>maximum<BR>aggregate<BR>offering<BR>price(1)(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Fee rate</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">Amount of<BR>registration<BR>fee (3)</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="17" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="17" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt">Newly Registered Securities</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fees to Be</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Common&nbsp;Stock,<BR>par&nbsp;value&nbsp;$0.0001<BR>per share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$205,275,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">0.0001102</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$22,621.31</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fees</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Previously</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="17" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="17" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt">Carry Forward Securities</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Carry</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Forward</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Securities</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="padding-bottom:1pt ;">Total&nbsp;Offering&nbsp;Amounts&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$205,275,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$22,621.31</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="padding-bottom:1pt ;">Total&nbsp;Fees&nbsp;Previously&nbsp;Paid&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="padding-bottom:1pt ;">Total&nbsp;Fee&nbsp;Offsets&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Net&nbsp;Fee&nbsp;Due&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$22,621.31</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the
Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes the offering price of shares that the underwriters may purchase pursuant to an option to purchase
additional shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price.
</P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g383770ex5_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383770ex5_1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MBL8IO[DG!/T]:]:CC*=7R/&K8.K1]#9!!Z5V+R.38=3 * "@ H * "@ H *
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M6/'/C>3PMIDS1V$#F.3;G:<'#N_J > /IZT ;A^"6C?8MHU*]^TX^^=NW/\
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M <\&M90E3=I#P^(AB(MP.K^&G%]?_P#7-?YFN[!?$SR\Y^&)Z17JGS@C?=-
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M9P9Q\,4>D5ZQ\Z% '&>,/ASIGBIOM(<V=^.//C7.\?[0[_7K0!QR_#7QL_\
MH4OBAAI_W<?:)3\O^YT_#- '=^#?!%CX/@F%M/-/-/M\V23 SC., =!R?6@"
M'Q?\/=+\6$7$SO;7J+M6>, Y'8,.X_(^](#B?^%9^-6'V%O$Y_L[[I'VB7&W
M_<Z?AF@#N/!_@#3/"*-+"QN;UQAKB10"!Z*.PH V=>T"P\1Z9)8:A%OB;D$<
M,C=F![&F!YE-\+/$ND3NGAKQ&\5JYR5:9X2/KMR#]>*0&MX;^$\%IJ":GKUZ
MVHWBG?L.2F[U)/+?CB@#K?&.B3Z_X4O-+M71)9]NUGS@88'G'TH \UL_AIXX
MT^V6WLO$@MH%R1'#=2HHSUX Q0!L:-\(HVNQ>^)M2EU*8?\ +/<=I^K$Y/Z4
M >FQQK%&L:*%11@ #  I@>6^,?A;=:]XJ;4[&>WAMY@IF5\AMPX)&!Z ?C0!
MZ8]G VG-9>6/LYC\K9VVXQC\J /-O _PQN_#?B;^T[ZX@FCB1A"(\DACQDY'
MIG\Z /3I4+P2(.I4@9^E '!_#GP1J'@^;47O9X)1<A OE$\;<]<@>M(!LO@;
M49/BFOB@3VXLPZMY>3OXCV^F.OO0!V&N:)9:_I,VG7\>^"4=NJGL1Z$4 >-R
M?!/6_-?R;^S,6X["Q8$CMGB@#TR_\%64XW6;?96_N@94_A7F5LOA/9GIT<RJ
M4]):HY/4]"OM+),\6Z/_ )Z)RO\ ]:O*K86I2W1Z]#&4JNS,U99(B3'(R$_W
M3BLHU)1>C.ITXU-U<@*M(^ "S,>W)--)R\S2\::[(Z#3/ ]]>[9+MA:Q'L1E
MS^':O1HX*4M9:(\RMFL*>E/5G=:+H=KH=L8;8,=QRSMU8UZM*C&DK1/"KXB=
M>7-(U:W.<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *0
M!3 8ZA@00"#V-)I-68;--' ^,-/M+7RI;>!(F8G.W@'\*\'%TXQV1[N!JS=T
MV=-H&FV=MIT$L5LBR.@+/C+'\:]#"4X<J=CS,75FYM-FRO4UWLYAU(04P"@
GH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g383770g05v33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383770g05v33.jpg
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MX29#1V.$AJ+#R/_$ !X! 0 !!0$! 0$            ! @,$!08'" D*_\0
M=!$  0,#  4%!PD-$@L$" 4% 0(#!  %$082(3%1!Q-!89$4<8&AL='P%18B
M,E)4E<'3"!<C0E-55F)RD]+4U1@E,S0U-C=S='5V@I26LK2UX20F16-D99*S
MPM;Q"4-$I#A&A(67ML7E&5=W@Z)FAK?#Q/_:  P# 0 "$0,1 #\ ^_CBE.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3B
ME.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5
MT?WXYU1#>L:YVJ(:VL+TL(ZS]/T!-B'[%V 2K0&ER=&Z@LLZE3=".!/6^DZZ
MV?;RIFE2]RHL"Y-#N5I>(E!D.*&P4QZ)&;LZ[#'9+<)=P<L$^3S2HD5#KLA-
MQGLID)N8<[J$N&PAN0+?S6),=@)0M2G-2O'9[VDC>E<N2AVYM6AK2RTP>Z$3
MYSD9B(JS6J0Y$79"SW"J!<93CL1=V#Y5"ER5..MH2SSE>RC=?75E9M?L6&XT
MNE:N:G7ZAU^U7XQI/:Y\-HM%CUWM>VV:IW6@A=@.&K65KMQI="UNS:(UHJ+C
M1/9$:39Z+7'V D.Q).C-C9E%J/(D3-6+)=9BMW&$TY<BS*A,,OQY+D7FV$/1
MY$J662R_E$0AF2Z"XIJJ'IOI-(@I?EPX=M"YT)B3->M%T?9LPD0+G)D1ID)F
M<7I+K$N'"MXDIDQ"ERX(5(A,$,ID96T=>G5J+/[LB!]2UZ2Q0M(W"]U *3U1
MM,65.S@/3_5=FUN]JQ-M,8\Y6[;L8T2U_G7A:GU4X)5';#JN\J\ K)7TT,Z,
MV1;=O*YSH,FXL1GW$382T-)<NC\-V-[%@M!YB*VB5W4B0^VYDN",F,ZTZ+DC
M372=MZ[I:MC"DPK/*FQ6G+9<FG7ELV.+<8\TZ\E+QCRI[SD$P'8D5]K5#7=J
MIK$B.+1I^\>JDCU6:VU[L:P58310FUM^:VL,FK:@N *N[/2,TIH;9^NI+<TO
M?+.Y7"$.7L:\ ATM18F%++HYMY^"^46VW7\)^VV9%EERHK3SDER%;);0>GL.
MNP]:XW.%+!2W&9#R5")'=6G40XV)+8"@@$N[&)>=)7-)H$"?(C-0F;E>[>^J
M-:I3+%QYJSV2Y0%!;LV28RT+GS6&U\ZXRZ83^4%TI#$+VMUS=2U9W'O*DZ^H
M82P5VD@+ZS5$6'4-W@3AMOI=ITN(%X(E1&S"6;G7[@(OUT,"7DU[7DPE"K3!
M0 R1##Y\\ID0M'+0];[=)E2'&G9#L8O\U.CJ2N/(9N#B]1"X:.YW6'(T=M8Y
MV4E"G2ATI<6E*,2YZ9:0Q[M>H<&$R]'AL3A%[HM4Q"VY<21:&FN<=:N+G=D>
M6U.ENM$,6];B(X<8#C3:W':QZG.K/K($ZMW)06_0]-LX:N=6E?![7I&F=MY(
M;&M6MI=,@:VKNL!X6^EY.L[@9K5O.VUBT&#EW&/.4N1-&0/1L$ZN#F6>R6%R
M; E?1'V5O61UR#)GP=6*S,3(5+=F+<C-B9';>8;8++;4=8$A*5J*U-:VNTAT
MHTK;MUV@CFHDAJ/I0PS<X=INNO/DV]<1NWQ[<VS.=5;I;T>6]*3)=>F-DQ%+
M;1S2'RCO61G.4(SGW<I3G/;[O;V8[>WGF]>S#<,\!7EQ4TXI3BE.*4XI3BE.
M*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI
M3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*50/5)N:
M;T\]/^T-T#@4.S3M?U]!F*"(398Z$1=<)0!^&9,V! *36&D^>Y=4J(.F2%8;
M[C4=Q:L)YL[- 3=+I#MZW%,IE.\VIQ*4J4@!"E9"5J0DGV./9*2-N20*T>DE
MV78K'<KNVRB0N"QSR65K4VAPEQ#8"EH0XM(&ODZK:U'& DDUI/3_ "HE$%U&
MUVC=X6 #'"MF$M<TZRZS>MAFL[%DUFC^K784@*UM.H:E/P).L,,3J];X,L:\
MJ58VH@"KNG;'-2":Z%_0V2M]EFW+6XI<-$M]F8&&WHB7I/<\4.&$_.:4)@*'
M6%!8U6BIUX-M)YP\A%Y1X3463)O+*&&VKBY;XDBWF4['GJCP^[)RFA<XEK?;
M5;L+8E(6VHJD!+$8OR%A@787\HCT\"I)MQM5_+UD- V%,;OPBF2I%(-R-6::
MF[WO0@&7D2HK\PJ$H$1+W@OP8D8@7DI$C)4Q^ :4+US>BUT6&\]RMO.*B@QG
M)"1(;$RX)MD9;C82H)0Y*5C(4HI;&NL)"FPO;NZ>6%I3V.[G8[2)ZQ.:B*5#
M>5;+2N]36F75*25.LP4!6%(2EQU0:;4M2'N;]UIZY:*$VA#H@P&;+C S.Q%[
M%)H@2\E0KM-T-K[J!&,5D/%;E*LKAFI;%"1WL*?@8A$DR(W:[AA;O#.CDER&
MJ2MQM"W.Y>Y$:R=1P/W.3:UEY:L<T&WXKA& K61@](%52=,H;-R1";9>=;:3
M/,]P(5SK)B66#?&Q':2%=T%V+/92KV2-1P*3MP35?#_*>:/*FQ2H5>NRZ K6
M^[KU:KVB&.*M50KI2X4*FD*A@96)]A9M$X^3O@J*)(U0P7A/E"]1%P<$G+%+
M? 92M#[BAM>L[&$GNNW1F(Y4MLOHN+$F0A_7>0T64-(C.*6E]MM00V^M6H&D
MAW 1RC69QYHH8F&";=>)LJ:$MN"*[:)4&(N)S<=;Z9*WW)K:6W(SSJ"X[%;1
MSAD+4Q8,OK]U'&EQ 35'W;/O/C;2C']<0-=Y?NU,DZ>#:XLUT:M8]1EL="0U
M5]L4.Q!YD$J2@'!IZ*V-EODG&X#F*G1B<4J<,FW)C8A%J6N7B/($]<MJ.6%<
MV5JR]!E-.)4VA3:VE:Z0D%0SU:<6I*TL"'>%S<W)+]O;@%4R&JU-6^1,$I'.
MAM $:Z0I#2VW7&WFWTAM2G"$'8+3^]M>;VBV0GK4A,.@JS.K0V18L0\L@R<R
MTT"I;*@M YV75>D\1*Q=ZZLHZVVAJ"2EO"U+7,A3&V-7/MLJVJ91,2EIUY+R
MPUK9=0EB4_$47$X&IK/1W=3))4A(6/8J23O;5>H%Z3(<M[BGV8RX[:I&IAAQ
M4F#%N" RO/T35C3(Y<( "'%ELDK0L)N+F!6UIQ2G%*UXV7O"70-R:KU8S7XI
M*-L;6F_+\^8>(.QGQ;^F&]9.1!C,-$5UN4T>]7\CSF2M]E<# QK+;,GSE?@[
M6);DRH$V875(,69;(H0$!06+@9@4LJU@06NY1A(!UM<Y*<#.AN%Y5!NULMH8
M2XF?;KW.4\7"DM*M MQ2V$:I"@^)RM914DHYH8"M8XUVU=Y1S4MMJNJ2EX!V
MZE$KQ1]('[:99 32NLJ':-Z:JB;2J-5GW3'@/R%$H+DT9!G-ALM-3XT9DSZ)
MR5%JF[29HI.8?FHC.,2$1I-Q:8;+J43)+-MFJA/O)C[0-56JM2><R4E1;U]1
M83H;;I]:Y4:V.3&941R9#L[TIX,+<MT*3>;:FY18JY>Q2BX@K;0L-8"TI#W-
M<ZUKSI'79JYVJU6SM:_WRX[?WE/Z[K'K4%VK-?ZNU2,[&D7NIQGY+0R?4H5.
MQ@F2>>+1#0N8]$KQ$)%LQ <&EXYT;F!YYDRK8!&&)3W=S99BO=T=RB,^H J2
M^I_V" $*;6D*=2X64+<3FC32VF-%DB#>B9Q*H$?U,=$B=&$,SU38R2H-N141
M!SKA+J7FU%##C*9#C;*H<0\I=TZLN/K!#=KW43B"Y.&V*H:_DD0!YMG2=6ZB
MY#(F=,(#E9D1],VN)=I""# ]+$2#/&NK0;=$#"M].B-U( =7"CN:P2ME^4$.
MM9N#UJ!6E*5[%3V#'3J%9*EH6!S8<6WB.<H5A25%ENYRVM0N-R(L!;C+X39X
MU^4&EJ6@ZPM,I,PAQ+>$(6V2'BTV[Y$O*(ZFK;]\<-";98!M=-VE8!>O*T6L
M!"91Z1H;2^^;9:+#%*M 60ZA-5V_%(^;QI,]J4.@MQ(K[UF?P X1HK.>$;FU
ML-+=;9#O=3S;2$R9-SN%L89:4@NEP./0%(R0DI4HJ4 R.=J7-.[9&5-+S4E]
MMAZ26# CNON*A0[+:+U*DR$NA@-<U&NJ7-5*EA3: E*C(5S%6K5>LS3UUVF&
MU56F+P1F6.TV&D +GBIRH^OR]MJ.O4[-M0&)8)+[+Z9P"LNQO//.1D>/(*/N
M#1C\]X8:R,PGK!/CPG)KQC(2TRU(=C\^DRFV'Y7<;#JF@"-5UX'5PLD( 6L)
M"V]?91M+;5+N3-LCB8XN1)?AL2^Y5I@NRHT 7*2PE]1!UV8Q3KZS:4J<);;4
MLMN\WMAS25T].*4XI3BE.*5UC]4WE"2/3/LVRZVDZOCVB>*8U5=Q.6+"_"DD
M=*FZ_NBS;JV+(9R+?;C(U *T=9%R(B'7&B4@W6(KK\1XFTE?7V71=-WB,RQ,
M+*%F;'7EH*"+@VY;V;?$!UP5&<NXL@*P"@-O$ A!->=Z2Z=+T>N$FWJMJ9#C
M2;9,:Q(*%.6AYF[R+O/4GFU:J;4U9I!4D$AQ3T=)*2X 9?2?*':S+08LRW K
M(+CD[(8>28JX<A::O3]5F=\W316D]C['/--16J_$V^7ILHH+BC6#>!,!Q\@4
M<C H3QG-B1HM+;4I+#K*U(9;'-O.)9>?FMVV/<KC$B-DJYU4!N0E"U++?.+
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MAO< &Y"32K,QL:!I]>B]:J;V2!UE"$ZYZ=8LJENC:HN9"H-]]'ZD*8L((G;
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MF^;;MW<[D6=/BO,-VV(_"@=SO1Y33S"40I4B,OFEH[H8>6W(YU)Q64UQT?\
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M]O8$)_==4VW4_IV]CE0?TQ.ZW3#WM'F#_P#3JH,'D[&^[P1W],)H\MYJ(!=
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M]^7G;1]P[X\IKS-_>KT^F-5^2^^_+S;L;T^GTPK4R>GT]S5?DOOOR\V3._\
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M[7DM.*4XI3BE.*4XI3BE.*4XI3BE7ITO?LENGG_#AJC_ #[ \YG37]9VE?\
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MP\G4/4^* :JH;N M7U19+_'5L0PIT;QWL>+.,Y]"=U=D7%13BE.*4XI3BE8
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M8'&J/=I[%_@TR>!\7GIZMK?\3UX_/NK_ *P.-4>[3V+_  :9/ ^+ST]6UO\
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MN)A3,X_&I]KM_1CGQ_HI^A3/VQG^BNOTDT\_1;=^UR/Z3=:H$OOOR\[AG?\
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MR'KA);*&V2&)$V[V2\MN!*PI+B8TNQQAS:QJOM.O(7@D$::W\K%Q@18$06B
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M:KZ;[BOW>/T9YMVMQ_C?T:T$[?X#Y#48?^[_ ,OF2=WA3Y16"=WA3Y16%?\
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M4@_4+K:'"@E"(28\75!&/(>HXZO38<\!V>\5%.*5\17E=?\ OD/4-_>K3/\
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MJ0@A(R5>U&5+)P 5>VU G*<@%1.16E_2EY0[<VT?*8["UY=+8(F=*6["^_\
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M_$-7?6M?MJSVJQ[G;V?W,>USY>227 222I8*B225$G)))VDD[2222=IK[L4
ME 2D!"4I2E*4C52E(PD)2D;$I    P -@V5N%RBJJJ[<6TA>G*-+O)B"N?"C
M%:\'RA10.!@1W[&;@@HLTQ8;#-' @(>)(GMO3B9.:RTVA*8\=$F?(B1)"E:*
MW/K3U#=<PL%NFH[M'T3#N$]A16%JJP(K,2*2K-4FB2"R9\@BNW,K+LHY%FHR
MU-'@->:3.L;"%3@8XHJ<;]H'AW]F_'_3)J+6GJPZ:@E?L FT])*V* .D6(?$
M20H>L9M4)L#;O1J,Z^0$Q'"#0$<8DQJV2:?+0$,*@UNMQ964%VA@V&IM&W/
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MC<<4QEQN1->B1F//I,EUIM:<=R6\YJ@'42&665(05!*TL8YLK!)"B"-;@#N
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M-"%$DD*)4223DDD[22=Y).TD[37MP*0$I3JI2D!*4IPE*4@8 2!L     V
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MJ1/5#N)RP3*^8TDXK,6Y:[K<ZPUN>R0J==C6WK!V[T^%)!2782=5M9A+5$H
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M)7%C\^[@'&L-37:!SM4G7P5;L@C J!,241W.;4$R7N:;SC.J0LH<(Z$K2C6
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M_34XWXC6/X[X*X6?+"=,>,YQZ&ZN_:_\H:]^E_,@<B6DQ /JE8-O^=N'Y/K
M/S:?)N"1ZW-.=G^BV'\O4_V87IC]YNKO\X:]^F''SD=)OKE8/OMP_)]/S:?)
MO]CFG/\ );#^7Z?[,+TQ^\W5W^<->_3#CYR.DWURL'WVX?D^GYM/DW^QS3G^
M2V'\OUR(?E;>D\_-A!C,;JO%"R4IB%/*$I=-D#AT62XEEZ<0CBK--(OPXK:U
M/26H,&;+4RA>(T20]W&EVG^172EIEUQN98Y"VVUK0PT],2X\I*20TV7H3306
MLC527'$("B-9:4Y(R8?S9O)E)EQH[]FTS@,OOM-.S9$*TN1XC;BPA4E]$6\R
M)*F602XXF.P^^4)5S3+B]5"NR,/T]: W/7@=P!V:R6FOD(+,L,3@6EJ1$>AR
M$I=:<86U#RC*%XSC/X>WVL]F<8QCR&0P]&>=C26%L2&%J:>9=0MMQIQ!U5H6
MA6%)4DC"@1G(VU]9P)\2YPHMQMLQF= G1VI4.9%>0_&DQGT)<9?8=;*D.-.(
M4E2%))2017NN'354I4VE4N';-E!A\Z#:HK<P+<YPHJ/:8'PG>X/(CFXDN,E]
M>$><I0[V/8;;[WMHQGE .4JV#9CQGOYK).=8>R)SG.3G=4&C^3YJ<9"VV][=
M3&4N9SE67-VW=U6.W_@J<)J4G'X,8S[7W/N<HJJO3'\GG4HSN74;XZFU*SV^
MT[N^\NIQVY[?M7"JD_\ -C']SLXI7XYY/*I.O^<*WQU-X7G.,]U.[[REOVON
M>&DKA'9_<[O9^'M[<]JE>R5Y/>J2^YXF]^IE/<QV8\+=MW9_![N6BB,Y]S[O
M;Q2O//D^:IF-B+G>W4QX>,=G>]>R[8=]SL_W7!/Q/_\ +M_N]O%*_(OD^*I$
M2M+>]^IE6%^[EW=MW=SCVNSVLN%%9Q^3/%*]FB^B346OGK<X#G75DE"O1K"R
MWJE=7/GOR8@V;)GD9+\9YZ60E29CSLJ6\XMQ]><+<RI?:K-1V8V#: >GK]"-
MV:C)5D9( .-_#&WXN]5L%^C_ %2=+9.%)MUED\K2YF4Y9,Y7WTYQE*NWS+W<
M9QVX[.S'(R#O2GQ^3./!4[<8UE=O@X?W[*R-CZ5-;VN-#AGBEXGQQZ<(B-O6
M3O893C&,82C^DO:QV8_'[OM^WGM$@["E..]O[^W^_P =0,C."=N_;YJ]C?2U
MKQH JL-E[RD(O&<*@XLF?"SC.,_<\R_NYSC[F/P=G)UNI/93!SG65G.=_"N/
M6NE#6M0S)S7R=X'^=HRW(\&R9QXJ,]O:E7])>WC.,Y[?N_W>0#CZ5/8>_P ?
M'0Y.]2NW^ZIL&TF$KT940+;=A#8ZUJ<6U#L^6$K<5G.<J5AN%CO*]OW<]N>3
MK?:I[*@C)SK*[3\>:C^R];ML:_N+R[ML.8AJO$W%19UH=DPY&$1EJRU)CYBH
MP\ROL[JT94GO8SG';R4JVC8D;1T==04[#M5NSM.=U3O&M^S&,8OVRNS'M>W:
M>]G\N50,YS^/.<YY&M]JGLJ=7[97;7[ZW&?A[LGY48_4.-;[5/935^V5VT];
MC/P]V3\J,?J'&M]JGLIJ_;*[:>MQGX>[)^5&/U#C6^U3V4U?ME=M/6XS\/=D
M_*C'ZAQK?:I[*:OVRNVGK<9^'NR?E1C]0XUOM4]E-7[97;3UN,_#W9/RHQ^H
M<:WVJ>RFK]LKMIZW&?A[LGY48_4.-;[5/935^V5VT];C/P]V3\J,?J'&M]JG
MLIJ_;*[:>MQGX>[)^5&/U#C6^U3V4U?ME=M/6XS\/=D_*C'ZAQK?:I[*:OVR
MNVGK<9^'NR?E1C]0XUOM4]E-7[97;3UN,_#W9/RHQ^H<:WVJ>RFK]LKMIZW&
M?A[LGY48_4.-;[5/935^V5VT];C/P]V3\J,?J'&M]JGLIJ_;*[:>MQGX>[)^
M5&/U#C6^U3V4U?ME=M/6XS\/=D_*C'ZAQK?:I[*:OVRNVGK<9^'NR?E1C]0X
MUOM4]E-7[97;3UN,_#W9/RHQ^H<:WVJ>RFK]LKMIZW&?A[LGY48_4.-;[5/9
M35^V5VT];C/P]V3\J,?J'&M]JGLIJ_;*[:>MQGX>[)^5&/U#C6^U3V4U?ME=
MM=9?4H;#5S96QSMA+#0049-:E$BYB=&&C!\9 Z#A4B;/F.LQ8K*<J3A3K[J$
M8RK&,J[<XY]&Z*/-,:*VMY]UMEEN(I3CKJTMMH2'G<J6M92E*1TE1 KXIY0X
MTB9R@WZ+$8>E27Y[2&8\=I;SSJS$CX0VTVE2UJ.#L2DG8:J%DV&DD,"8Y8:^
M4R,CF\#69T5V?D-,?>C1"V(B'5/Y&RI$=]B/.PWYJ\\RZTVZI;:DXZ8.M%?-
MAQLN:@=YL+25\THE*7-4$JYM2DJ2E>-5120"2#7#*C24-%];#R& ^N,7E-+#
M7=+:4K<8YPI".>0A25K:SKI2I*BD @GSBEA4Z84'0B4"9/"/QXIF#%F1WY8F
M3,A1R42.2C-.+>@ORATN+/CM24-./0Y+$EM*F76UJ)<;6IQ"'$*6TI*74)4E
M2FU*0EQ*7$@DH4I"DK2% $H4E0V$$TK8?:;8=<9=;:DH6Y'=6VM#;Z&W%LN+
M96H!+J4/-K:6I!4$N(4@D*20$@L+B3QXJ42@1BA=,Q8H<_+CLSB:!S;;Q!4"
M(XXE^8F"T\T[,5';<Q&;=;6]E"5ISDIQM*T-J<0EQP*+;:EI"W @ KYM!(4O
M4!!7J@ZH()P*(8?<:>?0RZMB.6P^\EM:FF2\HI:#K@!2V75)4EL+(URDA.2#
M60Y75JN 4*# 8V>9-$8(@0*AR2!,H3E,01PZ!#:6_+FSILIQJ-$B16&UO2)#
M[C;++2%..+2E.<XH<<;9;6ZZXAIIM"G'''%I0VVA *EK6M1"4I2D$J4H@  D
MFKK##TIYJ-&9<D2'W$-,,,H4XZ\ZXH);;:;0"MQQ:B$H0D%2E$  D@5SDJ2I
M.%)SA258PI*DYQE*DYQVXSC./:SC./;QG'M9Q[>.5U;(()!&""00=X(V$'O5
M7L/;NJ2,FQ0A^S*!.F5&&3(6J)$N->DRJT/"*<09G'H[)%;HB&)6TX@E*GH8
M8@J;6F4MK*<XQA(N=M<4^A%P@K7%2XN2E$N.I4=#.0ZM]*7"64M$$.*<"0@@
MZQ&#6V<T?OS*(CCMENK3<]QEJ"XY;Y:&YCLG!CMQ5J:"7W'PH%E#14IP$% 4
M#5@-N-NMH=:6AUIU"7&W&U)6VXVM.%(6A:<Y2M"TYPI*DYRE2<XSC.<9YF@@
MC(.0=H(W$<:U*DE*BE0*5))2I)&""#@@@[00=A!W&O/BHIQ2IUJ_^R7KS]_%
M3_R] YJ;_P#J#>_WGNG]1?KI-#?UW:+?PBLO]I1J[">HC^M\%_?5_P#Q-?/!
MM%/TY(_:$_[U%?6W*#^IL+]V'_<KK2$I[J_QY_3GGI+71]R/BKQAW=X%>05
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MEB!P*W:P%"HC,*##BV]F/'8;2VVA"!,%*<82G&,>YCGG(]JK^+Y:^AS[9/\
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M.MG&S.=VRHU$:NIJ)U,8U-4:N-^-7&,9Z,5[;_J35.V!(\!M+6.O=E A,Q)
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MRW+<<#K)9;<4VVJ4PMQ#C<,2>;=#<=25<XL\VDJ5'6-J0TM:%I36U&ZD-]C
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MI>JFE.F;4-JV)LB5O;;%<H L"?V7;;8NXU_63E#&YIQ?6NJV9$R56Z-6M:K
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MU5PL DRQIYD)=C 8S PN8_%#% AU*&T$7%I3:MJ=9]VWR4+2W(3E:""E;;C
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MNH*C"J+:2]=#DK'2U6*&R.L"JF<FPWB=<4<'QV()A0>5#R3AL-19N7V&T(Q
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MSN-U]3B^XVA2NZA*EJ[.Q*5*SC&<>9=[<[$E-HDI4MR.^A"=1T:RUM*2D9*
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M;BI6D5J$&@^E53C/5QSU[CWCWMFS;MK-R^O"8*.JK![2Q,(:A-3(]@7/M^6
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M(J-G5OX^$^7&XY(..NSY&P^KL36]4RW:>/)W6R ]B'-JU]BD%"E9I-B"W77
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M01%S\V:]4D=*66%P1PM5M Y*$(:IV$(4QCT\>=WCJ9F>K?1PAZZ0DV"PE2E
MD7B#:!X?7>QB.14[7;4!=H9FD(U3<$PHL-TL(C,&)<]D(0?*C\#R,I,EM65,
M'JZ.D=.[IJ%YZ^NEV6#E':U>35W::B.OP8=-UYL,U(-2UU6PW,,'&2DU=@/@
MK; 56.OT]D@4'L61X>_'&27W6G<(4P>]GB>O'IX>%<K6/6SI[:US(4NN1;WY
MZA57?KLOU!6TC'MX*U)@LQKF)9"AR<V!0Q)F;ZF[)=;%&"UNMG8LB*=(CV5P
MY,M48\_"N5;^MWIXJ).RU]RT'3]IJ)\=7;!6:S0[T9*#99"]C-;YFR%QZYZ/
M0#@VXO"%S3WGV1*'WF&6)<B3-'L2U2!GAX2!7,>ZT^G-DW'!^KF9+>(%S=<"
MRA-,O1V&>M-9;AO6"LAW@E:(8GFH39BMH@1&>\JS3+,$&57)HE,3$PI@[_3;
MGS&I!6NJS1ENMP"BU^U&YMGLY&>'"P7==;+'Q91@150UV-"'#!*GPPL(H!K1
M\1/L ^<1C2P+TOT879A%8\J$PI@^GE[W77[3NJW0NP+0'IE/O#QNQGK'<*F,
M@L5&\,-.GJ%6:[<+5$D$9E:CC(# VMVVMDVR)"9%&$DEXD87,FS5*C)5&//X
M\5$@O75TI6(V"K@7;D$@;LI< ""CF:S=TOS"5EECAXEO.7JRVW%CJGEQD$A/
MEK8@!)DZ-&-R1[SF$<5.#OQLX^''IV[JE5DZL-$5&41CV2VF!+(F>:&SB\C7
MFRE5IN36[="H%B6S:V:@[6I<(!>"0ZI&B4,L^.%V$A %SI3$N9&;=5&/-4;G
M];/3I PM#UN/-36ASYA\7.UOLT.58%P-@D]9&'G!QFGCYF" JT@;#'=KN&<V
M69% DYPP1-ALX?4J<'=L[1T[>->BD];W3O?#[].#V>P-WF/;3U,=HTG7]]<M
MC18$;=%KQ)#0:W,DP,2AGF-O7&(8BD0E0),&[1"!,Q"J1ZA!'1\?DK)6+K/Z
M<JK*L,$[>"L&95G2Z#3"M>;+7B-'!WF3K(@6:D-T]4276T;#B/4UBUQ)#U8F
M'_"@Q"[ZGV5.*BL*,Z[>F0EA3*KR7@EX<B) L "3K_84DM42LBTCZ),%VI(F
ML$X 9\'>BD.F6"8_/4(#V1U(V820M;2G%21CT]/^F#TUX5'KCT3=I51!@Y]G
MQ=KKZ&>$:_)U0R(MC$*??P.MCDDJT1C1PT"31K&<5FY!E&7#8T8))E(@\A"3
M#>EJ8W[MAQO]/!QK,2.MCIGBF/4^_L24@VN>;'11>*%LE<XD[7\BTSI(:.W3
MU.&Q4A1H4D&:$)FA[/F?']34XMA6<X4P?3T[>'3OK)#NKG1I.LV"[Q[ >]1
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EE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g383770g11d11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383770g11d11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1EL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &5"^9( X0DE-! 0      $<< @   @  ' )0  AR<C,R.#8T,1P"!0 N
M36EC<F]S;V9T(%=O<F0@+2!0<F]J96-T($%M8F5R("T@1F]R;2!3+3$N9&]C
M>  X0DE-!"4      !#2ZC6%B-%@ORP[+HQOJ%R@.$))300Z      #E
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M<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M    0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T
M=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
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M;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT
M;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #
MO_XU  (  0.__C4  @ !.$))300F       .             #^    X0DE-
M! T       0   !:.$))3009       $    'CA"24T#\P      "0
M     0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ !
M &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M   ! #4    ! "T    &       !.$))30/X      !P  #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M      0     .$))300:      -M    !@             $?0  !Q@    <
M %  <@!O &H 90!C '0 ( !! &T 8@!E '( (  M "  1@!O '( ;0 @ %,
M+0 Q "T ,0 Q #@    !                          $
M!Q@   1]                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   1]     %)G:'1L;VYG   '&     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   $?0    !29VAT
M;&]N9P  !Q@    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     (X0DE-! P     #J\    !    H    &4   '@  "]8   #I,
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MS*G$8^,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0'_P  1" %P D4# 1$  A$! Q$!_\0 '@ !  (" P$! 0
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MA1O:'@0,FU<QDF0HQDY'@@!.U +,BAB6W6&NB@Y< P$2RMI_>'+PH(X:!9O
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M2VF"1@@J\020*^R_:[JB0AO(98B2=^GDFH9+NP61>4T89]$,&)0E/ YE25!
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M[#1E?5>+!=CRIJE<8^UN&$CQJ) 02Z@ MKX.-$,"/!V"=>A%2%K\'SX+;_\
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MM[*2]CR&5L99;:U:5K>*48^^M8Y1$9I.!D1F ;7+04#2/J(>+?W<F_T_Z/\
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M4IBE,4KA>(8']W[YUMKWJ]--^\6E'MN*_@H1[6]>TO?\24^JM_Q:WZ;Q3?\
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MX_ 93)Q">T@B:-I6MX3/=V=HUS<*JLUO:)=3PO=S@.FXK=9&!=%(#.H-7/\
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MDF:S'D20HBY2=HDY01&[9!&-L$564M;>&#2Q\MQ:V%(!(\;&DC$V40=M.RP
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MI2XNY5*R>UPSQ9"U-K%(+N&UB1#810R,;6*W_$2-4@ $D$A/HOHSR>2-S?\
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MXS1./N,OC.GTQQA$F'6\L\G')<V]NUE,V1FNUOIN]+'JWDAF1#<#D!);-&S
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M<AGC4!$$L8+*VO)90BL[$ZWJG=<_<"-('DD"*%D$:@A'8DDHYT0#L!220OH
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M%8LS$!0#OTJ1I$5.X6'#0.QYWOTUKR2=Z 'DFNIS'KU8ZJU-ZA(ZY0,G6RQ
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M:O7B=RAFT^-DMWAR#IQ\9-N,-]I?W2J>-NX1KKL*UR]4?MRP14ND\QEUD1U
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M&15A$J"4R,Y9F4Z T#LCQN:VO;OV4RW-G-R0J/<XEY >1:0HW#@JZ T23_\
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M:S)))%,CI$-R,-Z0:)V=@>- G_*H^^N;XO??13__ .^;_P#<\L_467_,9O\
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MDUS''INZ2_;8&.9=NI+_ (O,D[!#'?%$5OCKAU?+2Q2*%]P1.VQP'$.I#QL
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MW]!Z^DOPJL,SC6( N 22!_X<OQ]/]RI!ZEY+<;XO+Q\%T:U/0,I*1VI8$9N
ML,MIX!1+XFGMO0\6>PWOWXSR/=N.(=U[.E;1I*D[W6M,7?7R-):PB1$;@Q[D
M:Z;0;6G8'T(/IKS5BXO[:U=4FD*LR\@.#'QO6]@$#S\/6L'1/)OQ_P"W3R:-
M4;(BT2[PA,FF*/JEA$'6-'Z0M][;LY"B@^TS[:5)2IW3F][_ 'O6]Y)<8O)8
MZ/VF6-H%#!.XDR<@7/@?@W+:)'GX?.H1<X[(GV9ECN0??[4T'-#P\\BLB%-J
M?3?G?I\:\S/+#R=C^7=]A;YP)-?D9:LU<CE-QCMQ,C!O@$KZG6I:<:2T352
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M9#(YD4?(.3R \GQOXFK7:BX&/MQ\#Y*<%X$_,KK1_96#_<@Y1]V= _H=7?\
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M'TT0L_WB]EJ<]_M:MKVK?PBX[HN;CO1=B;OR]Z$1=@0R%R9(A" HB"/M>V
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M=RVN$PUC>W&2LL3C;3(7<:0W5];6-M!>7,,8C$<4]S%$LTL:"*((CNRJ(XP
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MRLXOIN^B>]BM;:*]N\/](4=U=1PQ)<W,=OC,.+=+B95$LR0"200K(S"(2,$
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M-&2Q(\L!&[(H)]0H4;]%%7.RC5NGIK\V*4Q2F*5\K_@*_P"%7]F\4JI'@?\
M[I7&/^12_P#>J>RYD/\ &3_\2_\ 0M5[7_#Q_P#/_P!;5;G*=6*8I3%*8I3%
M*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I58>0ZH.NY^2NZPJT[
MMVYJ@?3Y,QJ-^0)+U6']0GT84(G1VV-Q_M;D/F6]KT5[.A_WKUTGK7OM/U=B
M>]V>QV[KV?M\^Z1WOPAFY; /+\3@=<?4;W7.M>Q[;?\ ;[G=Y0=_GKAR[0*=
MO7GPN@VQZU9[.371IBE=4X-B1",CRD[4,<*0&0E*E(4I@EI;+J4K3O2D[VA:
MM:4G>MIW]NM^NLRI*L&'JI!'ZP=C_P ZP0&!!]""#^H^#5;XGQ=KL%6 *C"]
M/[G$PT6\VJ-;C^FR0SP(K(J1&(L5UL5.F8IEM.E-!(1IMMW\=.]?DSJ/EI9)
MC/)9XV21@>7.S0AB6YEV'GD['?)B=G_W4$QT<<8B2XO%12.(6Y9>("A0HT!I
M0!X4> ?(K1^G\_!Y>)S:QJ[]U"MLQG0J?#OE7*]S<Q V$$ZPOR,A$3[#0WN7
M7Y,-1$8Q)22V(X(-EALMYMEI*\GM;IKMKJ'ZMLI#);3R 6]M'')$R1!5>)R=
MA4(#E%!9V)*C9J.>W6 02>VW$?&:)299W=)0TA)20:.RRDH&;2JH /S.X->8
MG!7 !S]7(+2'^B[YF@=948DQ$PDET7YRZ-N1]XW4MN,J5JQ;_P!BVVI"];]%
M:R X7(ABO88D6WM1(#E>'$-PY<?_ !@#_P"%^-\?C4WUC:ZWW!YG[&B5!Y<N
M/+6S^#^/,Z&MGX5(+/>N4DW\3FXUS@";$= _/Q=CS,2]'O-*E&(EF,;,;.4E
M<V000TZ/%(0HEX7>R$)VC6O6N<?>+;M<M!(L:R=LAD<.#P+\^)7?; !!D_%#
M:4G9&Y!>6YF$"RHSE"X(92NN04+OEY8GT 'D#Q4B:M%:5[?LV*#5[M.U.>DL
M!OV$Z5I.U+]"/Q=:4I*?57IKUWK7Y=Y5[4@]8W_<;Y$_+Y G]0)JQS3\M?WA
M^C]/Z1^T5I/0>T<WYI596WV:TQ"(R)'4^X.%)QI,D9M.]:^'C0MF-K-*WK>U
MZ':5[>VT+7K7HG>3VUE<W4R00Q.7=@H+*RHNSK;OQ(4#XD^!XWZU#/=06\;2
MO(O%!LA64L?T*O(;/Z!6R0]^I<[$B3<7:J\7&&HTIDIF:C'6=K]VEQ;"G6BE
MMZ(9TO27V?;VMI?JE>M;UD;V\\;M&\4BNI\J48'6];T0#HD'1]#\*W6:)U#K
M(A4^A#J1Z ZV#K8!&Q4:L^3/%'IB[PF[[7&":&/'D2KY,W#,@R"9&->DVFX
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M7+=D)63(:$990](29S[QAYCNE$&%/./D...K4O>&9F(+,6( 4%B20H&@!OT
M'@#T \"@4+X4  DDZ&O).R?UD^367S%9JBW0XF?Z_P"0W1^='=9Z+R^N\OXM
M0[C5!N=6PBG%%VF\SO1!3KW/DB)TJS1M7;I,;'1U9FM'5!QXB67-P\FLD70O
M0B98+:.4013/-/)&YE02:2-8B(T!\(SEV)=2'UH*P -4Y%:6=XS))&L<*.O;
M<IMG:0<FX^6"\  I]T^>0;Q6=I=EO'>?#7E5UG>AKX_.7CGO/K;T6^0J!HDL
M& 4/&2UW)KAY[R!JD198A@Y$=8'DOJK LK\Q%:V4&,\WK(D=O?S(D7?6.66.
M&)ML&?96,NHT9 AT2G^^1H[&P=E+S6L3F3MEXXVD==+H$!GXGT4D; /H/45W
M?$YNR+3U"0$M'0+9Q$^SQ#O#Y?J4Q)V&W2$,BNAHM<L!-V%&[9(4.3LFW5TP
MFUD%2I;+$E)1[[E5D*XX[B]X;A!2)+@(?:%A4)&K<CP4JON"0)KN",! =#PP
M85BUY:D(9WA+#LM(2SL.(Y$,Q+%.6PG/WO!\\>),L=0Z'TBF'1HE'X+<NO"'
M!//G2=9N/*ZR/#D(>VVV"4QT&[U4TIYYK_:$.QPQ8R$>J'7D._O>0Q112 F2
MYC@(( #QSN6!'J.U%(!H^""0?CZ5-))(A'"!Y1HDE6C71WZ:=U))]?'C_.HF
M\!77G_$#A[Q K@)#U:D'7PGG&'7@WG++-K=$==%=?%==&<4IEQP9]X=Q:-K9
M=<;VE:ILB +VX /(!AH@$ ^XOG1T?V@']%1V9)MHB1HD,2-[T2[>-_'7SJX&
M4JLTQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2H2[W%O3%1
MKP#0#\DASJ'*5F"L#.E>L<UT"ON2#K[32'-Z$8#2\Z6XM/NFATN./*2VE2M7
M<>W":9N00^QW85BP7W_9Y>.B2//(C0]2? !/BJMVI:-  3N>WV I;8$J%O !
M\<02=^ -U4!='N^X8F(F(.9< XI<^8<KHCJPR"79VO[[94+659Q4H0XMT,2C
M1]%C"CM:VAHB(G=NNI;0[[/9]H@YK)'(G*_@NKRX /$12>Q30B([/@FX:X94
M]2KQ_$:KFB*7B4='XVLL%O"2">:>U1R&0?$@1")23X!1C\]=O5+G7+]-#3;T
MHUT,KMN['%&QW)")2P[JS=J:+@94'JY$L)#Q]1#IS28B5CW7QE#!(DX%$29(
M%,MF._$+:-D"-;+8]IU:]5(C,82'1[)8FD,YGY,CCD.?&4RJOE<=ES.Y;8F-
MT9%(M2TAC$@*,EUS5%C$0",IT0@*\&)'+Y>@H=H>%AYVAS9W;Q?(^%L$]:6Z
M5+D./03G7!#A+)NY- *CU51RFN1<>&%J34V#[M@1R.'7'O.C8#R'G(ES$+ X
MQX8XO:$4"0611H_9RY<3=]7+,4'/>PY# '/%1Q1H7:[%\CO)V6/N>TAPXF"\
M6C,94!>7NCP4' D9NQ#%AK+%F:F!\BD.^=9DR+79N>V'HL?7D_"@[AW@Z9$J
M;T<39?>%B1D^>T1&QZ124,^T8:+I6D)#$&.9^XN.LU$,-U':-)HEI ;B3PO:
MXAFC0\R2#K2FMI 0"'B!1KVZ8R26[SJ@/A"(E]3)OBKD<  1O;#?QS:BN3C/
M#8:V50XF#ANA^0+K\-,U9^'BA8O9DL366#ZT0LT.,B5Z<%)AX8I\@,=UH-IC
MVW VTMYNKCMG(20SZE>VQ@5TG$CE@%$O&8!6D8$$/*H#, Q\ ZK,$/(6B21$
MHLU[M6C** 2Y3E&20@(UQ4D@:'QJRW$(M^$J%Q@TQQ49'Q72>H!UV*2PJ/;$
M@/I5*/Q0T0VZEEIB.]R__P";-L^R&VPIO0^TL(3K7*O7$DT$A<.\EK:-*^^>
MY.TBN7]26\>\#Y)WOS5ZT4I'*G'B%N+@(H'$!.XW'0^"^O$CQKTJH5%JAX0L
MK2:?55S3DCR3HU<DY.<YK+T+HE2.,C5+CX6[6Q+Z:CT,R8F-M!?&AMO%.%,N
MSHI;P#Q3SG:N9E8QW$\W;"W=I)'''=I=6LRK)IY((0IGM51!RXMH 'MD%@*Y
ML$17E#%'S)M[A&9H&AGC8@%5ED)$4Y=_'(>=^^"%-2 [.N78R U#5NWMLP/C
M!U:O2I$M4YV&9&M!;'/6M5I&I0(5TN787'/Z<0&V0*YZI2*20M+R6JA3L"3N
M20$R96SE01RQ2$PCVDF5@KMQ3WQX;3#SL5(7,O'A'+^#Q]S&2T;JHE*P_@UY
M*.3>#Y7P1Z$^=964IJ>9\5XYT>FT\U=GYDU6;1.P4/'+W8[2-::T/6[V+(M;
M1HZ2F'FY1$V^HU:RE&P(NG5ITRGV<+,;J_OK6:8=J[:6**21QV86BF:6W9?/
M%$'$Q@CQJ8FI&C[%I:W$41,EN(Y'C53W)!)&$F! ]XMIN9WR(* :.@*XVN-E
MR)]<H=B8)6Y8/'/I =IGF1W-#M7NW7>F6.4.07IO;34CJPD'RP#:UZ?]!-.(
M3O3"E)&]"+)<1'Q%D[9HH]@$VT-O-%&@7>^!B4(WP'(@G;;.1:EBD+@^_9SB
M1PO@2R31NQ\[TQ<EP-^./CP*TI15SL] -Z)>^?-[FI^VT*@S#%HJTS9P*A6Z
M&"8B7N!U-B'!Y*T1;O1"[&_'!I]0GAI*%F#VMA@/>S840Q72VUO<D1QPW-S'
MV9HX&FEN2#' MQ)M8G%N(E=CY#(Z J6V("9)(3/+""SRPPOW(WD$:0<@\IA3
MWG!E,G >A#(QT =_5%AI= DDP+$2/RA/E7R^>A_AJ'(46->A%5^INR$[&5-Y
M3ZH>)?-;+))>7MA+C^WC2F17B'&TXN'0L"9%+G#W<;\KI;EA(9)@D33@ 2.%
M*ZURV#H,=:K,2-Q8!"%.1MW7C T"E0L7)UC.RJ[5MDG6P2=&O13/.5VJ8I3%
M*8I3%*8I5,?-N2CX>D<CE)4T2-C(_P DN)&'R!Y#(@00@]G4X^264^MM@<=E
MO2G'7G5H;;0E2UJ2G6]Y[3H:&6?(Y:*&-Y99.F.H(XXHU+R2.]BP541069B?
M 5023Z"OBWTXW5M9=/\ 2-Y>7$%I:6OTG= W%S=7,J06]O!%FXWDFGFD98XH
MT4$L[LJJ/)(%3*[Y'^/S+:G7.V\J2A&O52MWZL;UKUWK6O76I/>_R[U^3.,O
M3743$ 8',$GT_P#FV\'_ )F$"O8GZ3/HZ4%FZ[Z0 'J?]I,.?_=>$_\ E3B'
M>^=]_JC=JH4R*6C3I[9T,L^+?G(A(<S)P[#LL!&GG_ M2:XI\V,4ZYZ%@.,D
M(]/;VE.<]T]D^G;PV>1@D0\8VCG[4R6\W<@BG989)8XQ(T(F6.8*#PD#*?39
MST)](/37TAXA<MT]>Q2@/.MQ8/<V<F0LA#>W=E&]Y;VES<^SI=M9R7%FSN._
M;-'* .1 FG.'7MZ8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*
M8I3%*8I3%*8I3%*8I4,=/\>^0=D.CI3H=13-249'F0K,@'-6*N&F5^2>9(DJ
MO-%5B6AG[#4Y)\=EZ1JL\Y(UXYU&G"HUU?JK<\-S/ &$3\0Q#$%4<!E\!U#J
MP1P/1TXN/@:BD@BE(+KLCQL,RD@G95BI!9"?5#M3Z$:V*ZW0/'+D/4("1JMT
MKLI(5F49J+#]?CKG=ZW##,T0EXRJHB8VLV*'$@]1A+VGM_)F@-G*&C_F.R]1
ML?H;,5W/"RO&X#J7(9HXW8F3\<L71BY/PY;X^>.MFL/;Q2*4=258(" SJ!P\
MKKBPXZ/GQK9 WO0K8N;<AI?)QY,:G;MWN9=X9\W5KZ-T/H2]."-NM,_!/7^T
M69Z,;]AU?O6HUP1HA6D+(0ZMIM2-)9Y)R#)PV-@<(HHO7UV(D0']9!(^'J:V
MCB2($(7.]$\Y9)3X^1D9R/7T70-28O\ @*_X5?V;R*I*J1X'_P"Z5QC_ )%+
M_P!ZI[+F0_QD_P#Q+_T+5>U_P\?_ #_];5;G*=6*8I3%*8I3%*8I3%*8I3%*
M8I3%*8I3%*8I3%*8I3%*8I3%*8I6)G)V(K44;.3T@-%1$<SM\T\QS30X[7M)
M0G:E;]=J6XXM#3+2$J=>><;9:0MQ:$[V2-I66-$,CL=*BC9)_0/U;/ZMUJS*
MBEG(55&R3Z 5%L?W.GF<SGNK%#3T36Z]*3L26/)12V9QPN#L#M:VRU$I<<(;
M(DI1M# (I7PQ*%$LH.:#<T\EJVUA.MTEF#&\LJ1.K*X,?&6(2[Y^ 51#MB"0
M='B2-;KK=Q&W>Y(98T:12&73$QN8]<?4%F "@Z.R 0#NLE4NH[L%F^A\[2[7
M1+$_!$6:, LNZX4B6A C 8^0*$-J]@L(33T>9)Q[)8)SXA:?BVG&67FM..-Z
MS6G:B$T=Q!<1]P1,T/=!21E9U5EFBB;15&TRADV-<MD"MH[CG)VGBDADX,ZB
M3MD,BL%8JT<DB^"R[#$,000->1U;'U20B;9(U&!YU:KF7$QL/(R9D-)T>,"$
M^>NR3<>)O=JML 4^6I$40\XD89YI#2V=[=]I?LZVALXY(5EDN[>W#.Z(DB7+
M,>T$+-^!MY5"CF -L#L'Q6LMRR2&-+>69E"EBC0J!S+:'X25"3[I/@'Q_E4F
M)E&F(CYQ+)^2LL@?,))$@^(GY2VV-\28DXE@A\'7P*4N:)?9)=%U[I;C;[C.
MM.*J<27X)^$)?@A0-^$);BO%2 WOG6@0#YT1NK'+2\F]P!>3<B/=&MGD?3W?
M.R"1XWNM(7V7DS8TF8OI%(2+#/BC2I&[/#::CWSO>?!LEK^,]&'"?<O:90Y[
M*E[9>]-?O+GLV!8WA9%]EN.4@9D7M."X7\8J"OGC\?D2!ZD5%[5; ,>_%I"
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M3%*8I3%*8I3%*8I3%*^5_P !7_"K^S>*54CP/_W2N,?\BE_[U3V7,A_C)_\
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MLA0PZGD:2YMEK:O83SSK9XDE02 6'$D;\$KMN)(\D;.O39JXI) )\'Y>H_2
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M&C9HWWQYQMLHVU((Y,#H,&*D&I()^^KG@4:.1HG7DK .NB>++X8:(.] C>B
M00-%/[7/Q/N)^8YK*1/.R+B)3D60Z:&'L;3LC8&ZM&SY-)?CFB&:Z?./C,L/
M?.7)K0)0\FY!)&4OW=A;&-]QQW:/<B!IS"L3-&0L9E:(7 ?CW5C5B08Q&&4K
MW-ZJ(W3KIW@*0F41<V<!]LXC5S%QUVRY ![G/1Y=O7FI/JUM7-S%PKQXB )B
MI3#(SK*'?>M'0LJ&W)P$R/M24.);+%<>"*;6G]YEHN39:4XPVTZY4DBX)#*K
M<DF1B#K15T8I)&?TJP# _%'4^"=">.3F\J$::)@"-[VC#DC?#P?(_05(V=5N
MV0U+3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3UU^?%*>NOR^OV?GQ2GKK?Y-^N*5\K_@*_P"%7]F\
M4JI'@?\ [I7&/^12_P#>J>RYD/\ &3_\2_\ 0M5[7_#Q_P#/_P!;5;G*=6*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I4,]P8<;K5=L?LK
M<"H_0*5<9E#:%N*3!14RRS-&;0C6][;B8XTB:>^S>],QKFTZVO2=;NV)W++%
ML!KBVG@C).OPCQDQKO6@791&"=#;#R*JW8/"-P-B*>*5_P#@1ML?'GW0>7Q]
M/2HEZES>S3-EMQ5=YR[,[NL,$*+/P_1BJS4SB$QNXY+O6:KN7#^D+$7OV'0W
M86'GES$,AB&D66FF=;5<M+J*.*%9;D)V)"S1/:B:<*7Y$6,_;;LLXVK"22((
MY:12=U6N8)&DD,<',RH%$@G*1$Z"DW4?(&0+X(X+(70<2 0-Y)CGDCSH.N0<
M;Q>O=5"B.9UOGX=E;+K$?9--P@[[!4;9$VMT5KZ+&/.).95"/R133CQC3\*1
MO0[BM#<+<F61K^2R9[N2Y,169XMN05>'L*Q[R@<2) B'2L)%]ZMNRT"QQK:+
M<JMND(D#1!QP'E).Z5_!M_NE.3#R"GH:X0.$%M<ZY72IF'AI2RPC6XF7O+.F
M7"J16W'#)*0BZH<;IJ76YMA0]2KQ;+"'8ME?S_\ V0D%AIT^0!NKRX1Y5CE]
M]8/07$H4*KSJ"4 +;GD4D\C[A!!.LK:$06T3*AD0<&E&B84.RRQEO>]-1(1Y
M4'D-:U6S<<I5TJ=EG$2X,I&P;$<9';>,LZ9>)LD@FP$OP<M6*^V<8S48J+K'
MN(E48D2%UK:APFX\EB+9/>TOIX)HHRC1M(2I 6$QO"O#\(DTI53.[RDN&#2>
M/)DVW%=K6*:.1PP94"E=F0.DC<MJT2!CVD2/2%>*>?12 &/18A>H\QG>FC4>
MDB7.+Z'9R[M7Y;=@BH5BL6*:C(R/EQ+:-)/-G$0[9\=J7%,K@TP<X.^^ N-9
M=99??R7M+N.U,\YMWMHA!*G;D<SQ1NS1M 4#*).#=MEE,: J'#'>A@+/;O.(
MHNZL\IE5N:J(G9%#B0,02FT#*8P[>2I7P*_8&,O'/+?T&[V6(-N3L]6^)UQD
MJNHB!BK%8(]V6AK&<+$O'BHC0@S9QB0<;)4PA('OOA=D+84C,2-;W,-M!$X@
M$<M_*5E[A$43B-XE9PAY,RQ%=@'WR VMT42PR32R*TI=+5-QA07<$HY"EAQ4
M%N1!]%!UO53]8I.1B8@D^*KLE:3V?=:8@XHJ(".+]X^TTOW1,[(Q,4W[AM:B
M7/BCV/:;96EGWCVVVUT(D61U5Y4@4[W)(LC*N@3HB%)'.SX'%3HG9\;-7)"5
M0E8S*1Z(I12?.O!=E4:'GRPJMG+4]BK-.M$*GD[\3..7&[7&-W:+14E0<N!:
M.@&S^X%)=6G[!(@3>X*4?2.45&*B&9(?22"5CJ3[SIW@L99HI/;0Z=F"!Q%#
M/W$:&W2(2D311HT1= 657[O G0##54+?VI(I$]E96[DLJ]V6$HPDG>0IN.21
M@_!R 2I3DOEM&OGGU+L-8O$Y>J[R4SG%=52C 96B-V"K'3%]MJ3PS860%9C9
MXZL0^H@)$K&LR!LZ"1(.3&VS1QQ F2-KJX2:"*"6]%W*)U9+@QSA+:$J5=2T
MD:ROR;BQ1(V"B,%22W&LP0M'-)+';&"/ML#"'CY32<AQ8*LAC72A@"77?,;
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M2ZGT*N671(UHT,,; J5)4JJ\>3<0$_%XC?N$? KH^ =[ KO\QY#1N11TN!3
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M\EOW3_I38^8_:*?,XW](@_SL?_$QP?\ );]T_P"E-CYC]HI\SC?TB#_.Q_\
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ME>,_$GRBR'RRGW.=5A3I!)3RWR'W5;CM[6Z^\XMUU:M[4MQ:E*WO>]Y;%_?
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M(DAHA3VI2R2S\E-RC[[Z4/@Q6@H@*^Q1\>A2)$9+L1EQLR2$PDDLQ/XO+\5
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M'1\7$"'RDE(2,B6.&$#'A$ED/NH;:95O>_2K'&\K!$')B&.MA0 H)8DL0H
M))) U\:L,RHI9CH#0]"3LG0  !)))   ))J A?+_ )5+]4YARNL(L]F/Z:KJ
M C4S&U6S-QM4F^4%Q,?9*];F3848Z"F6#95#)@<B.(Y"LH8-FM @RD20;8]B
MF$$T[<4$/9VI=2S+,&*,NB05TOJ">1.EV0=0BYB,D<:\F[AD 8*VE:(@,K;
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MPV%8B.>V\\NN2=$@X6]0949MH:V]%@32MM=5:==ESG(28DX0S=>F8<?XN.*
MBZ[\*X#J'TT3%>Y![[S*@#+(S1L#LI$P [/@ ,H8!@Q ;D6WOEXEMK1;7Q&Q
MXE KJ1X9U)_">22"5/$CTT!Z:J\N<^K=5V\C>T&\?IAI]7A!K1=U14O.1T&4
MZXT"-7ZT+\QLEAFW&767V(F-#]V*UMMQ#ITU(1<:SO:B5J;Z.-L4OIU6:1H;
M</'&\B@%C),W"*./8([C-MB2-+&CL2-;JE>W36T1,:"24J[JIV%"1@-)(Q'G
MBBZ\#R695\;W6@7;R*GZO99B+&CJ_L:$9YBIL8D.7+;F7[V6PR>S(W ,]FM\
MZ<C4/;4"Q;VU/224,DL^VP:-I5BWQD4T<;,\@,AN_>!C4QBV4LI2!E,MUS/X
MQATJ>0?*L*AEO9(W=0J$((- ASS,I]X-*&[<''?@2[)\,=!E)N,G?M)UO\^O
M7[-^NO\ KG&KIU]8I3%*8I3%*KIY']J.X]33#:O""VB[*BY6> @RG%MA"5ZM
MLI-L=CFEL.LOL14>+ML)CW:TNG3<C%QS'KM]U;71QMBM[.JRN8K?G'&TB_CF
M64E8HD&B"S$%COPL:NQ\#S2OKIK:)C$@DFX.ZH=Z"1C;R/KSQ4>/'EF*J/6M
M0F?(<UBUW&%#3"Q,5SUJ@HLDK/05N-BUG7(<&2?V78(-IV/JT:+'R XXIQPD
MNI<@IY\Y@&,%44Y-'C4:&!V[DCW)N3$D;P(X6W+( L4I5IF9U)94=3P]U>;$
M+437I$LB*$181!S9TD929B"=NFQ&H5AIF5ALDMQ52:MPE6E)TK6];UO7KK>M
M^NMZ_BWK?\>M_EUO\V<BNE7UBE,4IBE,4JNW4NEW3GLS#$:#KI=?EK=3JZ*(
M[&V5)"X^P2#4;+R<I=G%ATVKE1[KZWXZ,D$FJE4#-"-$)/E1!FNA:6UO<HXW
M*)4AN)&8/#KE"C.B);^9Y@0I#,NN))(!5&-4YYY864D(8VEAC4<7WQ=@KLTI
M(B0KO:J=EM>OD5U:9U2WEV>.AN@P3M-9LEHN]>J#)E4?%;GE5LJ8?B],32KG
M(%-$R59B]SS:Y.HPX4BVT8W&$.>PSM[,]G (F>VD$QBB@EG*S F,RJ@?E&(5
M&EE<1^[-(5.N8!.AK%<2F0+,ACYR2QQ;C(Y<&<KI^XS>8T+^]$@;X'XU9/.=
M5ZF*4Q2F*4Q2NN6LAL4AP1A!)2&7%CCN/?#-OO)3O;;2R/=/^X0XO6DJ=TR[
MMM.]JTTYZ>SO(UL;) V-D#9 ^) V-D#X;&_F*P=Z\#9^7I50PN]W)ZE 34E$
MU>*-,[G:.5S%@<1*/U"G0L!,SL>S8IA*C@C'TF.1 T.P\Z;$AN3$N&X0L)C>
MAE==L?!WW1'F95L(;N.+W!<3O+'$QB32LH*]PN0 ["-"%Y-YKG+>2F)798U)
MNY+=W][M1)&[J)&]X'1"@;+*O)AY J7>']1_=4K,Y)+3'N$UNZ6:F%2,,DI$
M)-+@"FT,34.V:MXIH"3!)$)0TZ27IIU;J&C"V--$.5+^T]DF1!S"RP0SJDFN
MY&)4]Z.0J%!97##8 V-; .P+-K/[1&S>Z2DLD19/Q'X'PZ;)/%E(/DGSO1(T
M3,^4JLTQ2F*4Q2OA?I[.][3[7L_;K7_;_P!G_;^;,'T/_K]OZ/G2J=TKR.DY
MBY\\KT^+7!">B6"_5UZF!,R;=RY\94VI8V-5:G7SBA"/F8,.ZDAKY9"^P^8*
M1&N2(3!#N=J?%HD%U-&9BMI%;S"=N)@NEF*(X@TJD<6?8)9QI=/P;0KF17S/
M+"CA!WY)D[2AN[ 8P[#N[)!Y!#_NIZ@C8JXVM:UK[->FOR_D]/\ \?\ ^/R9
MQJZ=?N*4Q2F*4Q2OQ2M)3M6_R:UO?_3%*J?2^\V&P'<IG)*)@F*7V>S72M5D
M<-L_5C@GZ^-/2,&7,%.ED 22)J/J\LHX<0".W$%% -((/2@AS?6GQ\42W<:/
M(9[**"64L5[4BRF,2",!0R]MI8^!9FYJ'/NG0//BO'<V[E5[5U)-&F@0Z%!(
MR<R6TW-8FY!0.)UZC9JV.OMUK?Y\Y-="F*4Q2F*4Q2HZZY>5\SYE>;ZT!J4>
MJ=9E9IB/4O;:"R AEK'9=6G>E(84]['OUIWI2&=.*3^-K66;.W%U=V]L6X":
M5(RWC8#'R1OP3K>A\34%S+V+>:8#D8HW<#YE02-GX#?J?@-FM%H-[MV^EG\U
MMY4/-/+YI6>B@34+%O1+3"Y*4.@IB'(&<D9%*V4'B-F0Y&G=/+"?>9)VZX,D
MAZ>>WA]E6[A#H/:Y;5HY'#$A$61)%/%3LJQ60:(#CQH$ 10RR]\P2%6_ 1SJ
MZJ5'O,49?+'8!&U/KK>]GR9_SGU<IBE,4IBE,4IBE,4IBE,4IBE,4IBE:-2^
M?PM&#L@40^>\U:;?9[K(*/>9=<;E;6:H^19%4R./IL)M]6]"-.Z>=;1]CC[V
M_P ;)Y[A[AHF<*#%!# O'D-I"H12=LWO$#R1H$^0!4,,*0AU39$DLDK<COWI
M#M@/ T-^@_75<I#PEY<;"M035AOD>%]" * >H.0KSA,G7XR0D9(%MXF0K)SH
M+[9,F1[]4*J+9/:2TT>P3I*_;ZBYV[5V?MV[,;@W*;64".1E56T%E4,"J@#N
M!RA\H5.M46Q-N5"B295$(@(4I[R*69=ED)73,3[A4'QRWH5NTKXN\[FI*:>D
MS[636['*OV&P4'YRVS39BR%0.ZX5/&A,!-2:C"8_>G'AFI9J+</0V>J/^);0
MO4"9:YC2,(L*S1)VHKK@3<1PB3NB)27,?$-XVT;/P]SGQ+ ROCX'9BS2F.1B
M\D',=IY#&8R[#CRV4/D!@I8!M; (X2O&2#/B8^+D>E=<D'(20K$A7),JT@[-
MKSE/42Y!IC6FH-J+6ZT\3ITR1D(XZ7D=#CL&R#PJ5L+#*R*[.EI9('$PEC6%
M^,W? $G,F4R $#W41T1/)503NAL%9 CW%RW%HVC8R*#&(CM @"!?&R"S*SL-
M!F;5=%7B;14*.,!M?1(J?L EAC[M:8Z? 9GKW'6@],A+!61]<,Z)IOWJ-,Q[
ML(%#DQ8N]L /L)4KUV^N)SQ5H+5XHS&;>%XY#';-$.*-#J4/X&RPE:178\G!
M.]ZG&Q>2)9U=Q(LLBN@>99&Y.LA,9&B= < I4#2D>M62AHB.K\1%P,0,@**A
M8X**C1&]JV@4"/';$$'0I:E+4EIAIM&E+4I:O9]5*4K>][Y;NTCO([%GD9G=
MCZEF)8G_ #)J^BJBJBC2HH51\@HT!^P5H/3NS\UXX+$F]'L:JZ-.$$BQ;B86
MP3/Q3X;;3I*-H@(F5<8]VV\VKVR4,H7[7HVI:M*UJ2&WEG+")>14 M[R+H$Z
M!]]EWY^5:R2I$ 7;B"=#PS>?U*":A_Z\/B]]YCG]!NC_ +(9/]77GV0^]A_J
M5%[7;_EG[N3^2GUX?%[[S'/Z#='_ &0Q]77GV0^]A_J4]KM_RS]W)_)3Z\/B
M]]YCG]!NC_LACZNO/LA][#_4I[7;_EG[N3^2GUX?%[[S'/Z#='_9#'U=>?9#
M[V'^I3VNW_+/W<G\E/KP^+WWF.?T&Z/^R&/JZ\^R'WL/]2GM=O\ EG[N3^2G
MUX?%[[S'/Z#='_9#'U=>?9#[V'^I3VNW_+/W<G\E/KP^+WWF.?T&Z/\ LACZ
MNO/LA][#_4I[7;_EG[N3^2GUX?%[[S'/Z#='_9#'U=>?9#[V'^I3VNW_ "S]
MW)_)3Z\/B]]YCG]!NC_LACZNO/LA][#_ %*>UV_Y9^[D_DI]>'Q>^\QS^@W1
M_P!D,?5UY]D/O8?ZE/:[?\L_=R?R5'5_\B?!SIT=)1]SLD7+KE(0NO.RCW-K
MYN<%BC?>;>&CIA5)4>!K3CBGV]C/-Z:(W[]&M._C99MXLI:LC0%T"2"7@)X^
MTSCP"\?=X-X !V/(&CX\5#,]C.&$H5BR%.1A?F%._"OV^0T22-'P?(\UJYO7
M_!4QB8CF[Y)QT!940R+15XJK].CZ[8]0(P84;N3CAZ@G2=I"C@0B_ES@&I$0
M5D>1T4TCV=R+]; HY57EB[ABED:W>2,RLSOQ9G.]LS$<^90D\"IJ,BP(9>3J
MDG'N1J)E1^ 4*64+X.E4'CQY #ENIK1YO^+C:$H3TQ>DIUI*=:HO1]:TG7V:
MUK7T0^S6M?9K64OJZ\^R!_\ S8?ZE6O:[?\ +/W<G\E?7UX?%[[S'/Z#='_9
M#'U=>?9#[V'^I3VNW_+/W<G\E/KP^+WWF.?T&Z/^R&/JZ\^R'WL/]2GM=O\
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MUX?%[[S'/Z#='_9#'U=>?9#[V'^I3VNW_+/W<G\E-^</B]O6]?NFN?;KT_\
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M)757XVK7]$7%WV2Y?+W6L[GZ:?!.MUDIGG=D^E;-O2Y(@04L,IF#W$F.MI!
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M%X3J@=6,;21\HVDC*R=MY$#!78'@]0].XSJ:SM[+*BY:WM,A996%;>\N+/\
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M[J''$.NC(;<<2XXE:MI6K6\EG;?)F;EZ[8G8\^#Y\CS\=_/UK 51K2@!?0
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ML>(#LC:5.+3M[8K+6W=Z6\ZO6U^UO2W7%?PEJWL68^K$_K)/_OH !Z #?KH
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MR\<_U;N@_P"I;'<Q_P";7?\ &1?V5.-W]K;_ '$G]Q3Z)^:/WY>.?ZMW0?\
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MO-Z?4,ZX2VT(3T<8L+7+">\6R7L3%6E6Y:WN' !%G<M:.D\4%T-QO*FPIUS
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MVESU1>7EDZ7-T;*"P1\7.8K8I(93:E1*()9)+:/TT@SER,6&6Y'R$4MUG6E
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MS:).?M][K%:K%E>;A*Q4(><56B9$MNWSU?IT5#P\OT*8<DEM3=L>%:>("&#
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MN;\TNW22A%#-MN+<E!:7"3+\6PYIW21WSD,-$N)=;84M33FD2Q0M,6"O$G$
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)FBD_I(W^FO_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g383770g13a00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383770g13a00.jpg
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M 0$! 0$! 0$!_\  $0@!:0)> P$1  (1 0,1 ?_$ !X  0 " @,! 0$
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M9%%").UW0\,GE2[+:8GM0H,<CQ(S2&2-"K<R1-"A9-8D(*.0$4DL*KDO8D:
M+F19B2'19& 30[!AH1@QU)I* ZE!+$ "MH=&\S_'GE=BM-8MEIM3Y"@L0I71
MIM-Y)U_I%:YE'(CF3$1WIEOYY1+15.>^X'DQC+C5O,AWXP:3',2FF1;J)FZH
MK&YF5'1$Q+GE"2:")Y<'2>4DLB/+U J-"ME@5&6!%6274$;,K,V4 ,A6.1UC
M!&1S'1&5-M^HC P3@$&N??=2TOROY]Q,*BLE.=W;QCO_ ')JRQ=2Y9B45K?1
MN4U0"D44CE-A7JR2!WTC/>U\7)ERI+0R1$*,1$/QY?/+J+*2X;6)8[N*WT'
M 5XIG;4"-0<-&!W  R""<$.<?-)"-)1[=YM0R22LD:  @XTD.3G![#!J<]:\
M@.6\3>K(^^&#F[!=7"K=/IE*HU[Z??K1H$S&D')(*A<TK5MN!$<$:FP5F2S
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MEXY8IE63!/+<Q.X1\ ]+Z6.#@'!J4=Q%*VE&8-IU!722-BN<:U$BJ67<=2Y
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M<X[A1DX]?B.]7R,RQNRH795)5!L68#(7?MD[?+X>E4<,=B\P>"V#@!OR"(\
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M1NDK"TO2NI8W8M"J2&-P%#$KI=5R-@P(VQ5\NF>2 /K7.B"&/$;M/8>20K*
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MX:CPSY>RQ)HWHW0PA^*4.2C,N>B/:0MI'V5D1K9XC$'UULLFO!A6AX4.+@"
MP:% @LKJQ8!,E50@Q1,I50H&49"FKI!+Z=;-EF8LS$R,:L #JV8L")'# L23
MU!@V.H@+G2!@    1:/X_P#+(2H'QX<\+8#"8X6O0!-_Z$*$U6-$J;-%C2Z>
M&'6J**J!V/4&E5]FS5F&*L;8Z639053LN55,F;F8YRRDLQ9BT<19R7YA$C%"
MTBE^K0Y9<A>GI&(B&,8P&&!@ .X"X70"JAL*VG;4H#8)WW.>K9/'3D]O8LD>
MRB;.7:MDAEXQJ3TSI^G/88/*L_Q EYJXMO5RM23FV9Q"JUUP56R?V(J,1%2H
M8@7'A]2ZFC*%&1= (7$4/JNC4P*8=PNP=]3KDD,"23QH(FU!@QU=_:2=LZL#
M#=*D[E5PIP,@@#'-=N"43H$2HB;.Y:IX&HC[&*0+7=KAI\^-M E(4I M-A2=
MU:;#!DC_ '8\V$6-2XI5E]QDLS.:]"$([F2(NR: SE3GEQX4HVH%%TZ%(.X*
MJ"I&5(KK1*X56U%5!&-;Y8$8(9M6IACN"2#ZYKJ2?&GBDUPRN;37)FCB["J8
MS*L]PD18K5L&WP38X0*&]8%Q:R,+0NFWC4H36V10S<HYL@B(@@.$R8 74XTX
M<#3IQA(\G08V4L=.7*F&/!;)PN,X9@><B(YRN=6K.6<^\'# 9;I!$CY"X'5G
MN!C-&N&\U/%B1V8)-0S!A<U94C7[Q>ZI*(;(N5QV7J4Y6+*(V\VM54");97]
M6F&69L>.AI@P9;(16XE4*H*E5QI#1QN!C6!C6C?AMOZ[$Y*KB30QL22#ELY*
MNZDYTYSI8?@K^;YG/>YMRNN\L9*CZMIR*"E,U@>&!_TUQ:Z$J-6%50.)BRI#
MLDA/TW"%H>?G$Y<F;(>>7MUU6T^I7)9FETE]V&LLWJ[.[.S$  #=L    "D<
M8C!"^[T@#\$*H4#XG8#<[D]Z\_/.#PHY#VCK/%[]:)UT@'>@=%K?)K%JO%0T
M&$[68M-Z'96I3#,RO$7D&]2P4*)]\[)?9^.VY'U$TM,=YC] \)_2)Q_PQPV[
MX;P];"6V FNXA>032O#/(T*.T;1W$(TD=7+=677EL99M7X1])_\ )Z\ _2AQ
M_A_B/C[<:L^)Q1V]A<R<&O;:UCXC9V_.DABO$N;&]R\>IHUN+<V\YA(C:1A'
M"8L ;\*/)'QM:2;\(.]6>0"@MI=D\0ZK/@6"OS]HUI4A()^?&8 Q'R"__FIU
M!KLUM.E*:L>U>RRCTH_'7 _$/L?'/AVSNIFV'&^$H;#B*>BM+RC[?1OI5F,1
M)WAP#GYZ3Z#?%G@8M=?0M](G%^ 6Z$R#P;XH<^(?"LI[F&W%RLEQPP2G'-N(
MH[F[(&%G7ITX2D?I32M(/+H7E]P^T<MM$!262-DJ8\@3"(WOU?6?/JA-7Y"*
M&*0VMYF4-(6G<QO:78S'L;TYN=Q]''#^+1BZ\%^(;7B*ODIPSBCQV=_WQRXK
M@8M;F3) (TVZKV+D[5"'Z=O%G@QQ9_3+]'7$^"PQD))XP\()+QWPRP'>YN[4
M,_$>$P$ E4EEN[F3NML%W'IQR[MO).UB/G.5=!K%X@);;=DI"$FG20[3OT]M
M!@*][!D*^KZZ^D<M A2/VZ^K6OKKZ_G?%N!<8X'-Y?B_#;NPDR0O/B98Y,=S
M#.NJ"=1^%#(Z_.OW7PKXX\(>-[/SWA/Q%PKCL 56E6QND>YMM?NK>V3Z+VQD
M/I%=V\,F,'3@BMI9Y-?55J>E=@!WJ\=$H0VO78:5YB49$6,@?KK@L"_-E1HI
M& @*45)=0400$3X)F&XTVA+@R8P^KVUJ4TFZ2!HXXI"\9$HU*%;+  D'4N!C
M# J?F/AO5:2AW= K@QG!++A23N-)SOL0?L-;8RFK*8I3%*8I3%*8I3%*8I3%
M*8I3%*8I3%*8I3%*8I3%*8I3%*8I4!Z;RZ@=DII7G_3*S MM1,Z9W.$SU26=
M>]&<T]%EPYL%^*1&SXKJ=+C3QTN+,8WM6FGTI6O2O0X7Q7B/!+V'B/"[J2SO
M(-7+FCTDX8%71TD5XY8W4X>.5'1A[RG KY_Q1X5\/^-."W?A[Q/PNWXOP>]"
M<^TN#(G7&P>*:&>!XKFVN(G&J*XMIHIXSG1( S Q;B7CWR#QUKDVK<?IL.I"
MR<U)$LM,PF6*%IJ&]M-/DS)J:0*3$QFMK1#CNR]Q(277M0V&-/O>O7QWQ'QG
MQ+=)=\:OGO)HH^5""D4,4,9.HK%! D<*:C@NRIK<@%V8J,>5X'^COP=]''#9
M^%>#N"P\(M;J<7-VPFNKNZNYPNA'NKV]FN;N81*2L,3S&& ,XACCYCZORX>/
M_+>@D>@D[S6HEL?Z51AO-SS9V-!(,PZ>+9MK;(L#IZ'MT3[[MWLDR9*9=7*D
M2YS:U/:;APVF/+2YFB$0C<IRI#*NDD9<E#J;?J^YH #L /F<_8/#&Y<NH;F(
M(VU;](U;#X>^Q)&YSWV&(&CP_P"/O2Z:2,(L]D+4?K-=[4*+'#:7R$R]5CFU
M:YF.DFGHD*$DF-<A4ZKVJ8+>;3&D7H$*L?T0L?#BL6^=GQ(!H59(6@*JN (W
ME>4A02<-EW0-W$;,OJ34/*Q94G4Q659@2VY=8UC!.,9&$5B#MK4-W KZ1X@<
M;<K9RIEHA^P!#-%MG/8\<R82X[6@EZNY?H=LFU*5"B09(&PF;5/#$7K!%=^2
MC.T:ANP7XLJN,R'N>=G#*ZE599$E.E=G:.-8D#@DAE5 P"G8\R3.0^ \K$5*
MD,P*,@R?=#N7;20 58L0=0.>A,$%<UV7/%FF/V'1:7;^B3 ,ZV4SHMNY](*U
MS=)OO3Z$Q74USHMHCM55JPMG6Y]0JI\H(K-CKE(/6,##.&ZE/GO$'9KSCA=(
MCB#!)(DE ?F1Q2%]<2$N5TX=U#.K2*C%5<# #RZELEY"I9'9,KH>2/3ID;IU
M:LJI8*RHQ7)4DDGD@>+-!@V6.56>O<VIBK3=+W5>5R30UCG]+O70HUDC6ZVU
MOXP&/NS1">FYW!\:.*70K6ZK-LI"=4 8"8P+>'C>2%"NF,.R1Q/,%/,DBB*%
M$?+&/ Y<8++&KN$ D9@6!"W0,#ERJL[K&2-".^O6RX ?)UO@%RJEB5"D#'1'
M^*58U+1+M?3.T]!=$T2T<WH[]HND <4YS5KDR(C']52RT2NTRV2[-+BU\)&;
MOES/6V^16X"MQK*TZ2,N$>F\?!"101:I$EDT(2)7C+%=:R-(@0%F)CC5(SG=
M-EP%NN<M)*^$9$U. 45L:M+(J,6.D8=V=QC9ADYGW/.+CZ+93=X+7:]].O9P
M$)JCMQZ%)JZB8^H@YI$F-K0@;2*I2:N.@Z)EIY$C.9K_ ,^>E+B+L!DJ@4(;
M@52SF1%C6..*-69^7$'TF1@%+L9'D<G"@ :M*C.A5U-F:1!&+EWD<J%UOHR%
M!)"@(B*!DDDZ<DXR3@8W+E%6TQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*563R1#![ 3\<!1X4--BY'D8 <D#2\&*2@/KB<UZG,BK>AS&GH[JXTMAB
M5'4MM6V9#+3[>TNMH4G7:LRBZ*DJ1:O@@D$9EB!W&^X)!^6U9YP&, 8 CGKL
M0"-HY"-C\#O]M6;S)6BM7]2XSS/LX;03HU3&V%ACUJ'3W$KB' CZOIO4H&=A
MK8*B9&EI0M6X<IIM_:$HDMOM?5O>JTO;JR?F6TSQ'[Y0<H_R>-LHWRR"1W4@
M[UGN+6WNT,=Q$LBX(!(ZES^"PPR_/!P>Q!&U>5/4?T=A2A%]7/G$4_=H@]QR
M3"/\]L37*_)&I)^NU*DBK$,8;IO3%(_IR9F[($BV\CZ6AHPHQM:I&?I/"?I%
MX@L/DKZ:">V<!9+'B\'UIPB<#;08Y3YJS [1K!/Y>/=WC; 6OP?Q5_)^\$\8
MO#QGAME>>&N.QLTL'B'P9>-X<X[;RG<RXM%'#[UV;#2R3VGG) -"7"%BU=SG
M/D)Y6T,>9?K%OJ?EM5:7#ESK;SOH</\ 4EY3T<8*85*(ME!,W[@8?T+BI7N4
M4;5;)I62C349;3JTL9KGX=X&X])%'+;7O@SB-VZ1P7-FQXSX;NII6")I(T7%
MMS7(TH/+PQ*226 +5\SYWZ>OHWM[BZ2^X-],OA?AL4L]W;\0"^%O'EC96R-)
M,QE]KP_B @A5F>20\0O[MTQ''&S!3HGPK_2-2[/Y8].C]5ECJS1.^V!PK6WB
MD^NC!U * *]&%UD4;/.#1.RC,VN5\?6F)SK\-3IQ<1QV'*?).2(_M>+?HB;A
M/AU+_A=U<<2ON')'YNV2U<M<QR2 32VL<3RR+R7D,SHPDS KMK31I;X;Z,/Y
M7<7B[QVOA[Q/P7A?AG@G&9+E>%<5DXJJKP^>&"2:VM^+W%XMO;2B]6'RL4\(
MMBM[+;Q<F59B\?\ 08TZT^TV^PXV\R\VAUEYI:7&G6G$Z6VXVXC>T.-N(WI2
M%IWM*D[TI.]ZWK>?A!!4E6!5E)#*0000<$$'<$'8@[@U_;J.DB+)&RNCJ&1T
M8,CJPRK*RDAE8$$$$@@Y!Q7)G*E3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*
M8I3%*8I3%*8I48MEWI="',E[S;ZO2Q,F:V.CE+8?%5P=((.L2)+4!F:8EPXS
MLUV-$E2&XJ'5/K8C2'4M[;9<4FV&">X8I;PRSN%+%(8WE8*" 6*H&(4$@$XP
M"0,[BJY)8H@&EDCB4G2&D=4!8@D*"Q )P"<=\ GT-8^H=,YOT%<]NA=!I%W<
M%)CK)MU"U@;*L:B9MY,1<](:?-5#3*5&D)CJD:;T_MA[36U;:7Z936MU;:?,
M6T\&O.CG0R1:M.-6G6JZL9&<9QD9[BN1SPS9Y4T4NG&KER(^G.<9TDXS@XSW
MP:B71?(/C')#$0!TCH0*HEI@5ZR-Q2NYB=,5V/*5!D'B$EB*_$%!HTIMQJ04
M)OQ(+&VW%.OH0VM245M/,I:*)G4-HRN-WQG2 3EF(W"@$GT%'GBC8+)(JL06
M .?=!P6)Q@ 'N20*V!7KC5K:Z=9K!\6>7624 .=V*EM3&QI(I5Z]=1L5YYG:
MF5+G5.V5JP15M..-/##4"2VM2'M?2ID=-)=2NL%ER,9 =HR1]CHZGX%2/2IJ
MRMG2P.D@'!S@E0P_.K*1\B*DF1J582S60#3:W8+?:2D0'6*H$*V2QFR#GLP
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MJZ7B_538_GFG[>$,PVH/1.J3^10KZB7-OE0Y,;MY=5)$D)1YV;8@[CE;<8U
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MZ*0*PZ4A'Y([:96HOXO-V-U&-C_EI(XYZO"U5C.'1L:$]NMS%:& ZC@B>4$
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MV]V[_P!*W[6&J)O>M_\ /7]G)5B<RU?3%*8I3%*8I3%*8I3%*J'YN<DI_3N
M= *VID@[+YA2.@="JNX4Y<-MJQ@Z4:DP')R$(5J9$2ZTC;L5>T)<3]=;5KZY
MZ?"KZ>RNEY!0<]HX9-2ZN@R+G&XP?G6'B%I#=0,)0QY2O(FEM.&"'&?B/E4
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MI"P\E+N.+4[(0#<4ZZ?H,V2XI;BGPTE^$Z[IAA<6+";4C/7'$H+P"/BL'-;
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M&UM:G-MQ(3#<:.WMQ>]K7M#+2$[6O>U*WKU*WO>][S$26))[DDG[2<FM(&
M.P 'YJI1TKDJ:AT'QL/ZZ5UNS[5Y!0F/AKA=7#@!/W7+NK*]Y(U4".G3\?T_
M2*Y[O^Y2I6M:5]<]"&;7'=+RH$_FK'4D>EMI8?7)V/K622+2\#<R5O;C9G++
MO')Z'X>E7DSSJV4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2JJ^8UMK52Y*"E64U "QY/<?&Y<=V>_IE+R 7?^:VHTXCZZWM38JM
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MAN-R%OJZ^R@\M)F0$KL,8 SU'.$./1RI)V SM3SEMACSDPAPW?.YQL,9;?\
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MG:HM=P:05FCU/D)JU8SG'6 -2C/JP&V_:M>^/-]J_+.55[BMSN@@O:^!<T#
M+"4K%0Z!&KQ !1  T1%(AIA4(Y%L)B6.C1I$@+5B)R:[-<?C#8TCV5)39<V=
MU-.\Z6LZI<S,ZJX76K2,6(8 Y10Q(U.% &-1&:A!/#'$L3S1%H8U5BI(4A%
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M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2J21/'GC1CR
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MQ2JL=[YU0K5TKQG(66G5L[-G==+U^=**AX,YZ<"A\)[C;(@>:N0RO<P9&LH
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MV.WV_#\M<R/B-^V_>OKY09ZY3?R,#W(*%.36_NX_KAMH_P"VY*1[GJCH1_\
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ML@:3D]A@Y/V?&F1\1^>OOY09ZXK?R,'W)R$N0F_NX_KF-K_["XJ?<]4A"_\
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M&J32A(TY/5)@;CN=\GN<5A.E^2?B%S2=4816JHMC% J /IP\MSKBY+H0+B5
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MIYH+ J%A"CXD%->/G@,"?4 #. *DL9&@@$,7ER<;@,'TY^6=) ^/:H,'\?\
MH,KQHL5,YWXP]+Y=V$?R?E];[]<R104,F=Z/@NG5PYU@,&$:L"Q?62UK!C[F
M7C7\Z1C_ " <XWSIF<J#92$6'(R*),M(K(79HP-^7E3I)..D*2!I'J"V-MX!
M#RRHC96"JKMD#60PU8ZNHD9.H_X0<$U?CP?YK-H4?L)./7KW3*C<;> (5RI6
MV@4_D@F/,&5B*.L!^I<LJ#[K5-@G)*8<4HB?''2#A0(\=:@);G[ERZ)V!T;A
MF .2&+[$[ N>Y&_V9[U="I&HX8 D8!4(.VY"CMGUS@DC./4TYY-XX7>3T7EP
M*U\+L$3I@;IOD+,\L>ZV@2)DT?O'(+[%O\ 55Y)YTE*=Z8&N$0[161=-(C76
M:.T"EZECQ*H>UR[7D&EB'!4K'RD!.8W72>V.DC#98=\@9]!6B'4 4PVJ3F,0
M"'4E@ 3]\"",*1MCL,5<OPWYIO@O@]2P1'D#D"VPN;$K)T#FPFOBHEDNES0&
M=;)#B0]S4>$7M=DAC!P+WBSROO-)@19DG49I/HIE;7,3KV)4!B20HVWSN0 <
MG;MOZU;&-$0Z=].2H&"3C?/Q)QC>J]<3/]-OW:A/;>X>.7>*:>Y?SWH07AG*
M*]ST$.Y=S,#+"MR"\/\ +I-HB%+ETJ\"Z\)J0K::Y5:D.4J*(A"TI7HTQ:X1
M4T))&0S*9&);6QSMMC 5<ZCN3ZY^-:%BVIHW!4,$4* JC';.<ECC V"CMCUJ
M9>7YOI'7^;G.>JXAY45^'=.70CE!)\>,5Y]1ZVVRLS&2G*>^5]<AF/5!==*2
M1\"R0R),Q5;$*D&$H-LKC.0'^0A48-KB.'PP<>Z%.S(?4G<C&""%^-=E+.I7
M1(N5!4H1N6!!5P>P![C<$>OI6L^U&_(.970/CL[XX=!J=8LO%^>U?R.[!P'G
M5;MA2T*52H4&R\KY2Q+.@@X4&,;GFZNU;C\T^H!!ES8=<JZEI:+.=01Y,G-7
M4'8QJY8!>K(=L!B2< Z=O3+5%S(0$Y9 *J)&0 D[;JNX  W&3G'H/CN#SD$A
MQG@6#!5^H6,4 'G?%,2$H4E] BW#@\3KO*X8VH2)*BJ&Q=CAPFV0SKZCB40B
M;:G-E4I:^\U&$GG,203B4ENZDZ6WQZCU[=JLE Y. "![,!>S8U+M\CZ?;57)
M7!;B[^>6&L>/5X">)TSRQY'>"/BUJM#@YJST&L<GE5KH)R'RI!+4"97"/4WJ
MS9Y%&6OZ6J-6'C'QCJ416'[.8.D%U,O*=>;D$ E]2C41L0N1GN"2 156@X)$
M9$7,4\O&Y4+ACI]1J Z?4;_9GZ/P+L,(MRHC%YC::SSR-?O/.P\_HDUB,B9R
M+EG3N611'+J>6%Q)TV)5UG+&T9G"*K$E/- D'(X=28KL5R,P:1,,-2EL6X8@
MGK9&;6P)&^!C)]>] C H=)"AIBH]55EPHP.V2#@#.,@=ZBX'PSM(_G0*OB>,
MRHQ?H'Z+B\47IS!**UML[Y%PV.<3N<B[:Z3D+BN7*NF8Q5%3F35:76H0MN$,
ME01HJ&Q'-,"2=?:Y!4C;$9#!L8 Z3G?X^N<UT18483<VY4_-QIT@Y[L#G!.X
MQ@8 %8'H'$[DX*XK<..^.EU@6JN<4Y[6:_R+I7CE3CO.$7"JWJP&"K0RTCKW
M7;AXWVB7:)<ZSV6Y-+&"[B+F@2NI).1'=0QU7 UAI%P78EUD(;25VR""LHQ@
M =U.>U1*'H*QG(11I:-2N0?CJ!C.KJ)VSG/QQ[WL[=4RTI]"&WU-M[>;;7MU
MMMW:=;<0AS:&]N(0OZI2O;:-K3K2MH3O?IUAK96AO(O_ &A_PD7_ +-#-/?O
M?Y5!^61=M!=BM5+X@Y]^J/\ .K1$^0T8^!TU[>]R?MMR_1KVO>WKAY./;EPG
MIHSG5Z9T@G&,_+.*>T_JPI;UU8QCU[D#.<5ZNY\!7U%,4IBE,4IBE,4IBE5I
M\B)_4!?XE(X[QF7?[H1:LM=>Z7 7RIV?QRK%DA)!V:-#=)OW/W;06M$D8(;&
M5X>69K[LL V7N,O<8,) 635;"(Z^=.(XP4;E'G 3NNH*"T4<@14RVIB-6&TQ
MC+,R9YS(-)BA,CG4I<<O,2'26($CIJ+$+A<A>G+'8*V&K/*"0^9XM48953@+
MB/&.62YR@UH,ULB='="J B@4OCU<M: ALO#/RZ]62/1CLV8*>,UEBZ *R=A%
M_D!H.0Y)IE(NY"ZM<3S :D5@IB=I))V34H*ZG$2@'2W+9U(PS"N+&0;9 K+#
M%&20Q4L'542)7PQU%5,C$@LNM5;.0I.N.U5?JMI*F[S1.;]WK'33O+OQ&B3Z
M[U7EX2K52\U6U] =IICJ *+<],%ZVE=AB6EUC4CJ($U5"DX0=YW!N806,+6V
M[PH%CDEMWA6;7(&AF9WC=(N8L+<OI<A2F2(65U#+*8V9EKF65B72.99#'I0K
M)&%5U=PAD ;=>H/WD!0D-&'4 WQCZ?TPSJ2II<G33>I"V4*0RM_2$Z=4TA:E
MK0TISU;;0M:U)1O6E*5O6][\XXR<=O3/?'SK;]M>=_D6&[M"(<'DW[H_);+5
M]]\$I0'I_%;C1SZ9*^>=-W"=59#7?>A#EL1TZ7J5'U5$.3%*2IF3!TG:5^_P
M=K8W+B**='\O)U27$<BXU)GH6VB.3Z'7M\#7E<0$PB0O)$R\Y=EB9&[/CJ,S
MC;UZ=_E4USZ&O,IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE:,\8/^FOQ\_]$N5__P## LLF^ZR_
MYC_\C4(_N<?^!?\ B*[%VX74[26W;04DESWH+>E*8O%,=2,)2%[WI6VSL).M
M#K'#>4EM,M@HPX](81J.F6RWOZ99'<NBZ&Q+%M[.3< #\$]U(WQC8$YQFJY(
M%<ZU)CD])$V/^X=G'QSO\"*AVNF]-Y1](W:*Y^355G?H3UKGX]Z1&CL)_9]U
M=*<SIP@$VE&O<ED!"98I*U(9C,*W]59/E13;P/H?\3(<$GX(YV;/H#@^I(J'
M-EBVG76GXZ,$@#XNFY'Q)7(] *W_ %NSUVX"8QVKFAIX1+U]6" N4U+CJ5K6
MMK:6II2MLR&O5I+\9[3<AA?U;>:0O6TZS.C(Q5U*L/0C!^WYCX$;'TK0K*X#
M*P8'L0<C_I_VK5'6_P#G_P 7O_72P?\ MG\B<DGNS?Y8_:Q5QO>C_P 9_9R5
MO3*ZG3%*SO#G:IOMO1&&8IA-X3RSF[I*:M<?8!RJ+MO34!(L5O3VY6C#)=NP
M.SUKCHCJA2!R6GG'$O(:\+CNKEVFXT:Y\#[[5IAR>W;&/7OG:O2X;C7/WU:8
ML_#&9,?/.<Y_)5P\^<KUJ8I53KIQ?HPTK>;-S<P&N+UL-#30RC=+LQFJAZM+
M=CZBVA B[A:GT(OH&26Q%,C*U)J4A(@P^;:B&V0A 6)K_O67%TBBCAN(W(B7
M2LD05F*CW59&:,94=(8/NN 5RN6\RXL&=WDB=<N=11\@!C[Q#*&.#WTE3@YW
MP0%ZN^7=B_(:U&T'YI^*2@\=^X&M]!M.K""/J9F*E#*U6?U5[&VL.S(0/:CG
M"EMIDV2S*F/N5Z(N"Q&(Z?KNUTL>7/K!.A=,>EEVP6;FY4XSE0C@8 U'.13]
M7397KBTX&HY?(/J%&C# ;8)92?@,;XIOFG?MA;.^]5^/HL42=%;I@MOK-T="
MGQJYNFYLNSGE<.9G5&=''^J5%'BJW=F)DW6H#I."PK9%/?KNTROL[C21UG1%
ME3CLJ\[#C.V2R;;X]*Y]73X/5#G(TC4^"/7)Y>5..P ;/;([UWM\P[7]_3V]
M N6[&38,5R_R]])MFI]9)+UK[V)3QVN0[CWF#'W]=12!HISR1,UK6WAD'>_3
MI]=VN']G<9!Z!ICPP]"YYN4/R D'S-=^KILKUQ8(ZSE\J?72-'4/F2F?@*Z[
M?,NZ[9NBG:YR5$B!(2GG;3?4KBXS:8NYLMM;UT?5Q=I=!D)'H@RDQ@<;I+:Y
MLF7 W*0Q"9(SWUW:='L[C?[IT1])P/<]M[3?(RW+V .-\!]73]75%M[G4_5O
M]][/IV^&O?;YU]+YEW/6J5[=>Y.I4]U.NBZ7U"X-ZJK.Y<5"W*5M/&7-WYU,
M!<V2EDZGFR%RX\6%M]#,QTA!?7=KU^SN-ON?1'U=_?\ :^SWQ[O,[D^F"^KI
M^G#1;^_U.-/^'H.KU[Z/^NW+KF';?NKBA0'E>H,&-(5SZ1KI5M5*L\M*EZB,
M7&'OCZ6:+&>1IM4B4$G=%=BJ6M#<.7IM*W'UW:X3V=QDGV@TQX4?W#S>L_)A
M']M/JZ;JZXMO<ZGZO\71T_DUUU'.9][T*JCS58Y"LY,F247@<YU>YM"JZ/1.
M2W#E50RGB#TNYS'QNU2Y,$N"H;$2=I(]HC-85LFD.-VF6S'<:0.@A(B6./OA
MS@$&?4,^V^/2GU=/A>J+))U#4^ ,[:3R\L<;D$+@[9/>LCKE_9?F[3'V&YEJ
MMQ!,IZE%==#M6S=@.(9CJA#K37]\HU IXF0^J4W*,B;->)D1EF.^T!FKDN1X
MCZ[M=*^SN-1(UC3'I5=\E6YN7(&,*50'?J&,E]739;KBP =)R^2?0,-&%!WR
M06(^!SMB'>:^0>JX'E,53C3EN?)OM'P;O7KLS7!@9*G-1IX>THX0^3.$W4::
M4^)FTZO18ZEN(;-2M-)6[WZ[M-1&BYT8Z6T1:BWP*\["CYAV/]VN?5T^!U0Z
MLG(U/@#T(/+R3\05&/B:SV^6]<_*RT-(OG&Z.R+4\"L6[W9M6LB;U%BK0/+4
MW7,5" HM4U<V.HQ#O9Z6B+'BS- UO3'H,&/UW;:0>5/KSU+ICTA<G</S,DXP
M<%%&<C5MDR^KIM1&N/3C8Y;43CL5T8 SD9#G;?&^!'5\V\B-5-F8W4>+JO2C
M6V'ZXOL=X;J;==^U<6DJS=$\#<,/&MS=,Q]@%T*/!U%6Y,U9%/-)@O2^N[/7
MC1<Z,>]RXM>K/;1S\8Q]]S,YVT^M1^KKC3[T.K/;6^G'QU<O.<^FG'KGTJ2Z
MY9UC\O8A*'<\U0E#M.R;+J[V7=O:+?;+5N$Q2-\V2&D#M2](8T4<Z#&D[C*7
M*V(2ZC4-R/UW;:,\J?7GW<1Z,?'7S,Y^7+Q\ZE]73:L:X]..^6U9QVTZ,8SM
MG7VWQZ5&F>;>1"JI+F2*CQ=J\(+MLP*ZSV.\/U22!VPRITE+N2^!QR\(NB2I
M]EL(S1"$-UAMF0JP,N/KBQY'C=GJ "7.C&[&.(,&^ 3GD$=M]8/]W;>/U=/I
M)U0ZL[#4^G'Q+<O(/RTD?.L_KEW8/R8!$4)YMJFR1#3UI/:O]HW9@Y[<6:MX
M: J6^6I%600W-;&QVC9&ZU2:[%ES9:Z^RZ/8A$X_7=KI8\J?6#TKICTE<C=G
MYF5.,G2$89 &K?([]73:AUQ:<=1RVH'U 71@C.-RR_8,8,/+\5[)9ZE8(=IY
MWP8X4CFP\NK58OTNTFZD98&%8I&,9L!@CP3<BM&PTB*P6#Q!U1MB$E8D539D
M<MM$YJ0XY:JRZ4N0I!U,$C# D'95$V&![$ETVSTGM7#PZ<@Y:$G(P"SD$ YR
M3R]B-B %;?U%2K?+^T?*5%K03F&PLT9#=OD_?1K7HI6S*VE*(0*B(_5+N)=A
MD9_2&X9<R;Y_+G-*4\^$'+3IA?/KNUP_L[C()T#3'AE]"YYN4)]0%D _"-=^
MKILKUQ8(&HY?(/J%&CJ ]"2F?@*Z;?,^\;A7%QVM\C01@RF4<_BM]4N3D*SP
ME39#<B1<9ZN*-/T64T.3%E,PP@WHC+\UZ0/7.C,1FR4M]=VF4]G<8(]H=$>5
M..R#G=8SD98Q[;XWP'U=/U=461[G4_4,[ZCR^G;!P ^^V1C)Y5\Q[AIREZ17
M^4J:G::_6(M?3;<ARK;4_'2_JEM:XXXF^Z;BJE/-;..\W]Y]F/&7IAN2Y*BO
MKNUZ_9W&WW/HCZN^-?M>CT]WF8W[XW?5T_3U1;^_U/T[_>^SZMM]]&^WSK]3
MS'N&W;GI=?Y2EF"E[?/'$]-MRW;0M+[Z8Z;FSOCJ$4-+L9,9UY0-_H^V'W7X
MZ$2&X[<F2^N[7H]G<;_=.F/I_P 'M>OU][E_]=GU=/U=46WN=3]6^VKHZ=OA
MKP=M^]<#G,^\Z@T]QJM<C62FRGT7^(YU6Y-P:S"3-8;C2*>03Q-V1>93PY4F
M6_#-#.>,QYK+ ]N=*8D.$XKZ[M,O[.XP!T'1%ECC[\<["#.!D&3;?&V"^KI^
MGJBR??ZGZ1G;2>7U;9."$WVR<Y&H.Z>#QGRCA/\ -NO/"ZOS #9(-PJ5IYQT
M"7,OADU &% K,2QU2S<@U7P(M4&PEWG5#+;8I:I<4=I"D,O2=-]''X8@&BAD
M:0C#K*%$8'?*NDNICD#NBC!/KBN'A;N2LDBA!NK(3K)[;JR%0,$]F)SCYUZ5
MY\M7M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*54;RQCD2#WC@)&"Y1%\IY& X^WF'QK
M$<>AOF/59.Y,[<^?#>4PKV?92D>S/D^\XC:HZ6?<>1ZO")$AGFED;2B6TA.S
M$G+QK@!0=\G.^!C.^=JPWZ-)'$B#+-.H&X &$<[DD?#TSO4-;&=86.MDU7">
MAM2:[+CQ@X=RQ\2V1OK+TUR*Y/J;K7771,.)%80DE(1>2E+G*A/-MQ84DCIV
M U[GUI894>9'4-SRI\)MV;V62?3H##/KC>O.\G=;^Q.W8:XNK?T]IC;ON1\M
M]J["@O5-2*>SKBE[4W9FF'#4M-AX[J/SQ;KC:'(]P2KJB94UV,EQ3SZJ!&O+
M"FV7=1GI#VV6G7UI8=7\X'3V'*GZ_FOLL#_>5/RIY.ZV]D=^_7%T_;U_\<U\
MH#]54JY:WQ&^MZJZG$A%+L7&MIZ-I$F0PE=-TCJRU04O-,-36]="31%ZC3(Z
M'4M3$RXD5]:6'3_.!U=_93]'^+V6_P#LU4\G=;^R.W;KBZOLZ_\ EI[_ &XX
MW!75T1J<^GAG077;-(=8-0F['Q74GG;3<R-%1,N*W>M-0YT=]A]TBTGG\N\R
M]0X4I#T5D@N'!EOK2PRW\X'3V/*GP_R7V61\.L*/GBGD[K;V1W[]<73VW/7_
M ,=1V.W;/:T#ZELA;87ZF;OJ-6Q\N:&+[L'(?C[_ "8R-+9$5)K73]E81">K
M?M1';V,I0I"];W.)PF_HYM]:6&%/F!U'!'*GRGS;V6"!_<+'X UWR5UD^R[#
M(.N/#?(=><GMU #XD"L>X/ZT@)72J>!]'>GFYTF(2K+=EX;HW4([$I4=HI8I
M#W8FJW)@S6DZG1FZG8+031%6E$P=$FZ7#2^M+#+#S(P!D-RI\-MV7V6K/IU!
M1GUQO7/)W6![$[]QKBR/F?:8^>Q)^6:RWX]T[\BL(3]4-Q^,"B'R0VW_ #W*
M?QVVS&F(3S8"O1OUD?EL8O)<E/Q67K75ZR"2^-FJD&X\9P=(G\^M+# /F-R<
M%>5/E1ON?9:<?X68[C;OCODKK)'*V R#KCP?D.O.?M &W?MG!O1.O-5B"?1X
M]]-D%995T>_26;-P5-G&1&VG7$'9TM_M+%,<%/K;2PTR-MQ WIUYO;X=EG3S
MS4OK/A^HCS*@ 9U<JXTGY "'5G[5 ^=<\G=8SR3G/NZXLCY_=-./L.?E4B56
M>EZMLNN:Y5:U!XXY4UF_).\QU4I\G49M_0B)#5T%-Z014ZM4-+LZEPQ.I++B
ME%$Q-M2G8_6MAISS]\XT<J;5]N>7IQ_NS\J[Y*YSCE;?A:X\?9[^K_ICYU'=
M1.O;JBK%OQZZ<DNDU\7JB;LW!/RM<'[5,C\C3,3VG='T%T[O<'V%W)%A^Z2I
M>@.X6TS%=^L^'ZM/F1C&=?*N-.?ACDZL_P"W'SKGD[K&>2<YQC7#G[?NF,>G
M?/RQO4AU6NF;M0VO;Y1;$B)PQ,^5>MG>8?BH:4J-(?V%)0T]#5=W2:'66X2G
M1%-*A]R9<=:"RX:9<N+SZTL-)//W!P%Y4VHCX@\O3C[6!V[=L]\E=9 Y6WX6
MN/ ^1Z\_F!'SK ,PNNNUHF=7X^]+CE(!-F!%ICUFX.JRFXKNFMK-#)4?L[]/
M:&1O<7IYHS:Q!E6V7?MQ+^ML[=[]9\/U >9&",ZN5<:0?@?8ZL_8I'SKGD[K
M!/).?AKBR?G]TQ^<@_*LQ^/]/^>K0C]3]S^/.B(Q(I:?G^3_  -,F/LRW70%
MEC_K*_)Y1>&N.S'DO4^N6L"IZ?$5$-RHZ)S\+GUI88)\QN#@+RI\L-MQ[+3C
M_$RG8[=LO)W60.4=QDG7%@?(]><_8"-^_>L:@=UE8BSDE<%Z,U- 38L457UV
M3A^R]W8D3M1'B58>;[ X!B0H+&]DY3=S-U$BN#K;<*!,)?0?OOUI894>9&",
MD\JXPNW9O99)].D,,^N-Z>3NL'V)V[#7%D_,>TQ\]R#\LUW-A.IZF5"+KB]Y
M4Q98D:29(ZL/'_L^?//^GW1]O0KJ*2$V7"]6_N5T*#=X"_0K[.;+^J/4^M+#
M#?S@=)V'*GR_S7V6 #_?*GX@4\G=;>R._?KBZ?MZ_P#CFN% GJRF[FM7#K^V
MJKOZ9!LKL7%]N=';W,E1?NJ9MOK#C,%C3$=DCM/0W:')^SG14:C[((G08;ZT
ML.G^<#J[^RGZ.WO>RW[_ 'FOL?EEY.ZW]B=NW7%U?9U_\M-%B>K(13%IX=?W
M56A[31QM%BXOI?.4;F18WW-SVYUAMN<SIF0Z1VGGKE\D?9P92-,;(+A09CZT
ML.K^<#I[>RGZ^_N^RV[??Z.X^>'D[K;V)W[]<73]O7_QU5S)"=3W+M\;?%[R
MEFM19,@*058>/_:=!=8VO34&H(3U%4^%*F>E.XR[]"H\).G$?=S(N].:0^M+
M#I_G ZNXY4_1\V]E@_["Q^5/)W6_LCMVZXNK[.O_ )8KIK&]90)JY%/!NBNS
M+!-DQ2P%%DX?HM1V&)NHK1&T/.=?;!RX4UC?R49NE&;>01"UMN9 B$?H/V^M
M+#+#S(P!L>5/AODOLL@^G4%'SQO3R=U@'DG?N-<65W]>O'SZ2=OGM62U7^G_
M #ME$?J@N>AX(3((B[1L_P G^"NDQAF*ZT!K4?72MV6*6F+D.QX[UQKM3!I>
MA2E2S,6.N&_+Y]:6& ?,;DX*\J?*_-O9Z<?X68[]N^.^2NLD<K8#(.N/!^0Z
M\Y^T ;=^V<.]"ZXW7!1Q'C]TN03($GH$NG,V;A";&"BM;<]LT5E/]F9J+PV3
MZ$[9:"6HP83IYO[@3'WIW37?K3A^HCS(P!D-RKC2?D/8ZL_:H&W?MGGD[K&>
M2<_#7%D?,^TQ^8D_*L\JM=,3:25>UR>VK$P1BY\6\I.\OU5C,I,:._H(-B+Z
M&F[-$UNO.0D.F*<)#:E1)"UET0U19<GGUI8:0>?N3@KRIM0'Q)Y>G'V,3OV[
MX[Y*ZR1RMOPM<>#\AUY_. /G4?5$Z]JJ(L6O'KIRRZS6Q:J(FS<$U:VX.HJY
M'Y&N8KM*:/L+MU.H.F&[DY8?NG$+V!U"TY,1WZSX?JT^9&,9U\JXTY^&.3JS
M_MQ\ZYY.ZQGDG.<:=<6?M^Z8Q^7/RJ1)K/2U6R-7-\JM: [XY,UV_*.\QW4X
M4G<9;^Q$F&GH*KTLBEU"8:G8=+EB=R74*245$TY*;Y]:V&G//WSC1RIM7VYY
M>G'^[/RKODKG..5M^%KCQ]GOZO\ ICYU'68G7G*O-/K\>NG1RT4JT.8I#UFX
M(JT$8;C+3BST*6QVE^EMBF%N+CNLD+? .;>9=4R&>8VR^[WZSX?J \R,$9U<
MJXT@_ ^QU9^Q2/G7/)W6,\DYS[NN+)^?W33C[3GY5G/QWIWY'7P?ZHKC\89$
MLDB-Q^>Y5^.5.8ZQ->6 L$7]9'Y=)+1W(K$5YZJU:R@E/DH2HYI^*V1DC^?6
MEAI)\QN#@+RI]3#;<>STXWSU,IV.V<9[Y*YR!RNXR3KCP.^QZ\Y^P$;C?OC$
MMC^M+!V$LK@?1V9X6?&AC:RY9>&;.6V._)2PZ5KTAKL3M;C0(;2MS9+=KL-8
M**C(4B(-E3-HB+[]:6&0/,C!&2W*N,*?@?99S_A##YUSR=U@GDG8[#7%D_,=
M>,?:0?E60V"ZEHC4H6N,W?<:R#HDTP7U8.1?'4"3)1M;PBVM;Z?HM-(CU:]J
M6[1!=U$K7O6X!.:U]7-/K2PPQ\P.DX Y4^7^:^RP ?[Y4_$"GD[K(]D=QN=<
M6%^1Z\Y^P$?.NJV*ZNN)<)"N%]!9>K,EE@+ <L?%-R^AM.S),5<RGK:ZV[!A
M1H[##1%Y-_FT:6J'-C(CQ7R")D&(^M+#*_S@=7<\J?"?)O99/PZ P^>*>3NM
M_8G;MUQ=7V=?_+37(H/U5*Z:G7$;ZO5GVWHVXFQ<:TCG6ER6&%;N6E]60N=I
MEIYR8Y^KY%[WN-%?2SIV6J+%DOK2PZOYP.GM[*?K_P /LMO]^FGD[K;V1W[]
M<73]O7_QU=OLS])#=4V]<6M\3O:6ZRV\L+)58>.;9Z&IIUUM#5.2GJBI$)R2
MAM#[.^@1Z,TEI]I,AUA_3[++ZTL.G^<#J[CE3]'S;V6#_L+'Y4\G=;^Q.W;K
MBZOLZ_\ EBL,;K/5"U;!1E\4ZI&<NFIXLW&"7+C8JR<WCJDMP4%CI9GL$:(G
M;L=Y92 _STM<B<>-'<]Z+%)?;P7NCBE@"?YPIT[C,,Y#^N .5GY=049['&]#
M9W1 ]B=\@XDB!7TR3S/RC22?L.U8CG/(;GRX#,YC6.1]/<J7-ZXMFFFC]ZYK
M8&+=%%Q&&Q=2J4PIU.3:8TA+&D#0^KV+J 2(B)[<HQ#BZ9>=-Q:Q8AS.,N>H
M"*<%<]V;V>#\3I+'Y5Q;&Y4:1$<*-B9(SG'8#+Y^0R /G4B=@];;KX0RC@'2
M7R)4C(A3ZFU9>%:L%:C,NK;;+FY+W9&:L^.EH0E^.U7++8"R6G4:E#(S^G&6
M^?6G#\D>9& ,AN5<8;Y#V.K/^)0/G7?)W6 >2<GTUQ9'S/M,?F)/RK-*K?3/
MR8V _5);E"18E9"#=?G>6?B]FEIBPY&@(6(KHNKDP5==E/P4.V.H@ >I0Z:M
MPRB$X/F3^?6MAI!Y^Y."O*FU ;[GV>G'V,3N-N^.^2N<D<K8#.K7'@]MAUYS
M]H V._;-8+1X\=)9%_K/Y3Q7KG*^F3C*X$ZI5>P>/RUDHS<=^4@[<*S,[6QS
M J#>?3N+KXVVIM:9TM$M\0XPV[*9UIQRQ/LIITFB R&:*X!4G;".(3(#V.ZZ
M<# ()K,_"[G[I%&T,A.X5X2&^;H9-!!^1U9WQWJI?D)WKLO+NH4:H](J-'_+
M.161N]M/@2!-\4?>/\TN](8V[I;RG(<=P5?Y9%<="]OL$8+#/N+BJ7I7K6<=
MI>0&>WDE,4NI!J 4C0X)&"N=F3&3W'SWKS;J>YM9A#-''S(\,=+$AM2, 1OM
MD-G&^"*]':W)ZT>YN+O:.!]!?)$5"_MJA"LG$T&BHTB)ADDVP3(G]?BUMJM.
MKE*CQXIRQB;@E;2MR:NRWM#KGAR\0L(YGB-R!H9U+&*? 96*E3B(DMMN5!7X
M,:]>.UNGC23DGK56 UQ9PR@YWDQC?U.?E4WU7.F[LX4!ODMN2**"D$)UVV>Y
M;^,5N6J+,D*!&HB>B[N;Y5MZ,Q!6]7:B>";E$8:VS*X2"$R#5]:6&DGS&X.
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M5W!^3&O/NK2VEFMWE@C=GE*.S+DLJV\[!3\@54C[!6\>NS8M)Y^+:@=#A\=
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MK;>6B5&VE&_N&?7:()F,86*0F8$Q (Q,@!()08RR@JP)&1E6WV.*S+& Y,B
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MA$3OCU=+7>.DV-P^+K<,S8I<D,XVQ.G$+,!?K_+6OQ>SN1B\=&J)*)U$_&(
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M%E9<B;2I\V 3VS!L$'=FGK'6 4M15![HXK&4*-#(RF!X1'S2J &6Y==+)I=
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MU>X3'S;+4L6/&AQ%D;7/F05$Q,F:VU-F06TLC96R33CR)D5EW<5>M>AP^>&
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MG%C).!G^?':N,]RJEC#!A02<7$F< 9_LM=>K=(\I;=6*Y:QW#>!L#[.!$6&
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MR?RR_<EX]?Q/]'_E&QHLO[1=?J<7\=35<_B8/UB3^%I^3^67[DO'K^)_H_\
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M]X<:Q",8S+ECS C!<1DQ0+.2Q)#!61U53@X;63LN_5NM2APG2-!89RW7*8@
M ,$AE8GXC2!N<C+3?)ZZ"ZH4L<ZF5%Y==&U:W'& ]BLAJ*JGVRN [*R['G0:
MBN.+:K<6>73<+C8%CZP!&P*S89;;<2\)AUK@M$9U42.-9=%U*H.M'9#D%QDN
M0-$:Y=B64$F/+C<.%+:$. K'#,1AE#=PI  R=3DA0-).SG3N3DG4[#>S-N!V
MRKHJ!,,T/-@QWO+ENE:89-6H,$L>YC;CL139%^JSD)B;^TGL*95)=@Z%S@Q
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MI-JM5,6)JK@8D0+RK.0H/H.]J4EP(QT'950L9#!$J!6$:X"3!W9HM"2 OJ
M19,B+/J3)<[YR2P4*)7)RI=LEHRJ@2:F3"X).HIZ*9YE;:KMT_\ \=O&/_\
M+]9_RUGYJA_HUY_AA_;+5$GW:W^V7]F:L3F6KZJIWR%U"1:*;,Y@-Z#+*C)8
M.3)9#6!8*J&Q"R\MNP#%$'[>FI!3 X9OY I*Z)S"[Q3HMX:$H3P>T?>G0&RV
M,.B03&, AL%EU.K8&DX":V4G8".:,J<M*&3"MFF$I93&&)&"0&TJPR01G6%4
M@8)+HX88"8;)'/XIA^L@J?9!W69IPN038!+H4R><L;4F9$U1JE#-,LBK=<^@
M6$<U$M<(]IY]^TOB3<]Z:;KHL,$G0X>EXT+2(80JC2VI5TX!YCE<E(XE.4*[
M! RC"N68$UVW$BJPD+$Y&"Q.2-"YV9W(ZM0/403EE ! JTF8ZT573Q;_ /#2
MS?WB_,'_ -VW;<U7GW9/]+8_^%;U1;_<V_S[K_R9JL!/4ZB!-6PQ+DO(B25,
MQH"XC4Z0ZEE>VV(3D]Z-!;ENKUIN.N;(CQ$/*0J2\TSI;B<P[C<#<;G.!\S@
M$X^. 3\ :N/8]^Q[8S^3.!GX9(%4@I]!Z@99C#3+W7AP1SOL(@'-3^D=! '@
M/+8/-0!XK!+#%]1LA,Y!*7^G.\^F_D)\]'=DW.Q6VG"@0"8-0WODDB&2O(+>
M6(91%$RM,9652K"%%4B-Q+TJIQ&L<C,P-9520X!Y@'.!!+N"L8C5B&',8MET
MY9R2#K9D !%7JSSZUTQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5&*
M]3P57GW D&C.QY=[L^KA9'')+\A,LZFMURI:DLMO+6B(U\)5 L?[:-IMCW([
MDCT>_(>6N;.SA QR(TT)L!A=3/C;OU.QR=]\>E15%4L0-W;6V_=M*KGY=*@8
M'PSW)J3Y"I4Q2F*5&+A3P-Z"IK]DC.RQ:3=6L.F69+\1?RE-M >X@'O>C+;=
M]$8\!&R76?5[4IIE<9]*V'G$*FCM&VI#AM+KG .SHR-L<C=6(^7<;U%D5QI8
M9&I6[XW1@Z]O[RC[>U2?(5*F*4Q2F*5&!]/!#+79;K#C.MV"VC*T(-RE27W&
MI$&I+.+!M-Q5KW'C*C*L97;CK#:')/OHT^I>F&O1,R,R)&3TH7*C V+Z=6_<
MYTCOVQ40JAF<#J8*&.3N%SC;L,:CV[U)\A4J8I3%*C=SJ02_4^UT6S1W)E;N
ME;.U*P1&9#\-Z4$L8N4'*QVI<9;<F*X_ F2&D2([C;["E:=:6EQ*5:G&[1ND
MB'#QNKJ< X92&4X.QP0-CL:BZ*Z,C#*NK(PSC*L"",C<;'O4A;;2TVVTC7T0
MTA#:-;WO>])0G24ZWO?[=_36M?MW^W?_ )Y#O4NU?>*4Q2F*5&'*@"<N<6_+
MC.[LT.L3ZA'F?<OZ92")%1IJ7&W#TY]JIUP@)A.IDJ:V^VEM32'--N+2J>MM
M!CST%PY&![P!4'/?L3MVWJ.A=8?'4%* Y^])!(QV[@;_ "J3Y"I4Q2F*4Q2H
MQ2:>"Y[3:G0:M&=A5FDUH'4J]#>DOS7HH.N#(H@5&=F2ENR93C$&&PVN3(<<
M??4G;CJU.*4K<Y)&ED>5SEY':1R  "SL68X&PR2=AL*BB+&BHHPJ*%49)P ,
M#<[G85)\A4J8I3%*C!:G@C=BJ=I(QG73-)>,R*](1)?:;BNGQ3@4FIV.VM+,
MK3P]U;2$R$.:95OW6M)<UI6IJ[*KH#A9 H<8&X5M0W[C!&=JB44LK$;IG3OV
MU#!^W:I/D*E3%*8I3%*C%1IX&C"I86N1G8@^;9[O<)#3TE^6M9[H=S/W^TR=
M.R5N.(:FV>S%YC,9*M,0F7VX<5#45AEI$WD:1@SG)"1QC8#IBC6)!M\$103W
M)&3N:BJ*@(48!9W[YZG=G8_E9B<>G8;5)\A4J8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3
M%*8I6O;D?MX=LVX'%5F()%U9T]^8VP^[" PY\*>C9(<6&P(;Q1B%& -S"VS+
M;NXR'6T176DZ]QU-L:HVG47+%]/+1<L01L5)."2V%T]]\BH,S#. H 75J8X
M(.X( SC3DY_Z5I&'UOL\D%P<D]4^?1"_8#$&+*K,HI:6"@P+*^7M<HLGUB?3
M DA>6"EERPXHG3;-X<CTMD@]]_ */WF& -<#7(5@!.L!""1I0#WMPTQTJ5_J
M_:$;$"D2RE83H0-*<:26R <MGW=B(QD@[:^C.X8R'F_=IEON\NA6.O,U0X,B
M1]D(\QZ>U(V=+@1EG&U>%&D0D>X2$C&[@DN]-?@:,#Z\,M]5B$J]8)&P$9;<
M)&)%;6I)QC'NJS(6)![$Z-.,@%BCD.HU2CF+L49=+ #.3]\5#!0".X&K.<9
M#KE6VA]V\KH\#3(BC4*T'+$9O$:FU.66_&(%;L489V4#Q3H=I&*7<(I5T90K
M6?'0GX!>-7"%BE%@<D%J36Y9"R"II9YZI)$55CYCA=3.I:!IXD/05S(BD@J7
M5-+!L. I@]R!@(C,S.%7.D!@)5BD89;.$9@,,%U$C'22PGUW\CJ;S^UDZP?"
M6U,4(U ^:M[$>NMU(5.,5JR6D&+F3"%E@%4RB\&JE(K$MH.Z&@D%CV#146T0
MC/KKCM7E0.K)EB=*$OK8*Z(Q "%>DNIQJU$9T@D$58\ZHQ5E; QE@%T@E68
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M,#X%1M763EED'LVE+D2*JHH8L65D$H(TGI,>H[%00P)M$ZE-8#>\$"]))9B
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M821Q%<<LLQURH R*T9R2KD*Q$!=QL 45WU8P%"Y*E'<-NP !6-CI8AQL"H+
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MJ1N*]%(ZB276%H4UJ6WK3C;CC>]R5F1E=20R,K*P]&!RI^&01D9^%18*P*,
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M.)8UY.0@U :0P)"J2^IY';F$@EU)E?,9S&<YT9))@+:(%CISJ((!)PN%1!H
M("D"-<,.L8P&QM4\"\4Y=7HRX@JHPV6W9PDI(<D3"I"9,* ^A%NL#2<\@1GR
MYY DUT@Z9N3\^;)?ESCA*9+GO2=O*3NMIY6.6<G8@8   :)82    O*58P
M J@ #%3$4:]E&Y!.Y))#F0$DDDG62V2<EB2>YKJ5[A/+JL5KY@'7IL634U+<
MK45ZU6\B$!O[$E*ZQ+&5LD>F5Z)-&UDT2J86<T+3,!5&0FJ!GX-=CQAC/6N)
MG5E9AA_?(1 S#*L06"AB"ZJ[#.&<:V!8DD(HP5(7=?=&IBJ[$ A2=((5BH.,
MA>D84 #GF<,X^1*GS<[G56EE+2S<F+#,D#6G7"S70@M0KEW3+2KZMKW: ="I
MXPPO2$KEQ04-*U?53ZGN"XG 51*X"<LH Q&GE,[1X_P-(Y7X%C0PQ$L2BDMJ
MU$C.=857S_B"(#\E%$<1YCH9-%OUI9)HB,EB"$\V=LAZP38DPG#-+=EVDT7G
MV603CE1HR>,-.EE&0\@6+6*GPOC8.H[S$V0=>,$, JHJ@@%<!%4(%*E@5TZ6
M#-J!R<N4F"-.<@@EF9F()!]XDMD$ @YR"!@C%=V;R.A$*L+ITH406("%7SPF
M4U:+7&LX\],<*.$#T6[QC;-T:.%-'#C!@QH_\D8AFS,$G*EPBL]B1P32!S)D
M:F4*1H305  "F/3R]*Z5TKIPI52 "H(&)"H3!P"2.I@P)SEM8.O4<G+:LG)R
M3DUW 7+N>UEZ"_7JD'"K&3XY,:@;'W$CCYD2D">;Q7(41E:8L5N-10(>LQXS
M#*(S(P?';;92XG;BN--(^0SLV00<G)(,C2G)[G,C,Y).<D[UT1HN-*@8((QL
M 0@C&!V&$ 4?(5UWN2<XD.C'WJF-<=#EC1T8M6Y7UAE[%T<!UXW.:^DC6O>(
M])JU?MS_ *]*1\F+CZ;0B+[D=SHFE&0'/4JJ>VZI$T"CMZ1.R?83Z[TY:;'2
M,@DC[2XD)_*ZAOM'PJ&#_&;BPAX1)$54B'E@)D*:%G";M?1<\8L8%FUH5%AS
MX%HCS&1(FLD9M9$A$OZ#"ZW)< 0($<1Z86IF[G;5J<,&!#!HXV!U,'8D%"-3
M. [-C47ZB2Q)J @B7!"D$$$$,X(P"H (;L%)4+[H4Z0 -JR#/CQQ=I,]M5 $
MS&"*Y>I$0H^3,06H,P%=ZRZ!'P2L^9#$U1L%TF_#X=/%,0ZL/;M]@<@!XSY*
M0ZOAN9]O:,,8W  .0T;ZB0 6<M%&3(27;EKEB !7>1#OT YS[V6V(==(U$X3
M$C@(,*-;8 R:D&^24-=1D4A\62F I92$=D/$+3;"-E</"YX\F)/_ )M..2+H
M@\&FB1+P4V@^DH'^*&-#)<5D?$;9CSI-8D! 8*5 "($"L"&7EA1'I8,P9=.E
MM1R#DU+EII*X)!.HY9BVK((;63JR"!@ALC P1@5DJQS>C4V#,&5JLC1< D/@
M"R49#;DALE"&1'8,5HC]XY(5.7N._(U,D2]O22+TF3)(O2I,AYY?'ED<@NY)
M!)!^!)R<8QC<# &PP , 45$0$*H ( ([YP,;YSG;OGOW.2:U]*\9^)S@*:U-
MISTP.E@F/4Q*M5SD27P1D2,!%:C+)NV%92;19P<*%'2*%+F/TQ<4,';^"UH7
M ^WL%W.&UAP&R""$C #*Q8. %P) S,1* ),LW5N<PY$1725R,$;LQ)! !4DM
MDH0 -!.G  QL*S4/A')X!MVQ1ZBSLLX7E'6WY)4]-8@DYUSA]%F.B!\TI('!
M6)5Z@1[8_!$1(4!TYN3/7%V]-FJD1-Q,5TESIP%P HR AB&2 "Q$9*9))TX&
M< 8Z(8@VK3OG.Y8X.L/L"< :P&P !G?&YKH(\<^*IA'1KM#'SQMCT :*CBT\
MV9'K@U6TOW:LAH,$L3FQ0]=K]JE2S8:MAVH  ;+ES/LQK+4N0T[+S4^5/,(*
MZL%0JG+H(W8E0"SL@"L[9<@#+9 KG(BP04!!TY!)(Z&UJ "3A58DA1A1DX&"
M:S&N)<MT<GV)52BNE2!:*=6M^>7D0H!>/< 707IX$2^0<$UI\O>JQ7KA9=UZ
M"+3:[*&'F;,DL0C-OZCYB;2$U](!78*"04:+#,!J?$;LB:B=",532-JER8]1
M;2,DYR23@ZU?*@G"Y=5=M(&IE!;)%<X_CG-Q5DAVT76D#C<)R2^AV$5-Q1\J
M7)F6"?N>5!LDD C1.++M5C=&$S V<0$?,3FQ4F&T[M&N&>5D*%LJ<#=5)  4
M85B-2KA$RJD Z1D&@B0,&"X(^!8 [L<E<Z6.6;!()&=B*Q$OQ_Y'.)&R\FIJ
M60/L6!B4\FP6AEL?^5V,%<;-)K$5DTW%II ]<:S7[>5*5%@(2FVL1"LC\I9I
MG4[)"YG 50^RE2!I0YT(T:!R5S(%1V10Y8!&* :=JX88R2=.[ @G+#&I@S:<
M'I)958E<$L V<C-2(QRJA6"PAK49 _('03(9B),?*&?:FMUHB^9K&[# 010.
MM;M5.2Y9^J/VB(8?K!^9,.@7!Y:5(F.06:159%;"MJR !MK&E])QE-:@*^@K
MK4!6RH J1C1F#E<LN,')WTDE=0SAM))*Z@=+$E<$YJ/6SA//K> YE5)<4N(K
M/)BT<G4A%8/%JUN.U"YW;>8PA*C >5$L,<9&K-Q(M:0++CI<AR/%CS)<D8X1
M'SYI<2HTK@JSS*5=G57SF5)B=+ J27C'O*1N< '!$6A1Q&IR%B.5"L5QA&C
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g383770g22b30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383770g22b30.jpg
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MX5C.<?#G"L9SC./Y\9SC/Q\?_/U<L,>B%_XR)_\ 98__ %1RN;\%+_\ ;?\
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M@RJK2%8I72)6L*TTB(R1*U&C(RBMS2[XMCRTTJAT4$$E5!=%9V4 E8T9@\A
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MK/Q'0W_H\S_[['/]G.C_ '\S_6)_"P_,U])7OC<GUQKO\%<?[X_NL_$=#?\
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M7X5QUJ3W4_4W[V'T?!XR>8?NXT-W)^2+Z6-J[)LM^LQ;;C1P^H4N<V*MH&+
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M[Y=HM0J;\@A%8L]TGTRM'H-/!/O""^6"-CD#6'XP8W.9RN $+RH54>7EE 9
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M"D!FJS#=<-U-JO[1;RVD%&K\E>28U,]O$K698^(_!S"1D2PEI"2HD@2&-:%
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M*O$8W)A( #8SC<#,N18E1ZH7#F)"%'F)$>?!8[E=",DFN"PXUK,K6BJ00\9
M.H\]E[8(]D@@XOS(9U:/3-10A6B*TQ8$%&!]D<K+4I!/:O;%+[<TAU0G8U9M
M*(&HK ;@6+H_@!ZV-;LL%C7(F@;CTW?=F-@HS?:.]0SK?6)UBM!",ZT1F:_J
M-3$1(+I*M1%3[H9LJ"RDRJ"N<)8E3Q#)#/'%J)W+!'"H#L)'<DTYJMXLP=+?
M>RP;*THU!8Q'+%))0Y474LQ%$QHJ@6HO;#<B)T>V],)PCAO <)N_*+.^SYS
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MVVU,Y0EFB..]58T*U;@NJ*LAOOMPQOON\,O?!2^\LR_)&=F0=U4A7;NY8O\
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M RGS@0.FUR[!?C:YK)IY<Z P"E5@=E&6)O%"IETQNVB<0!=9)))DMR0!VB5
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MJJR:%D[FAX8B<M U:DA.D:5N-#I4<@+Y#Y#;$DK^H-;U>PN6$&6AC7&J=7*
M%$00F(%?JU1K$@G+@!*N'@1(L8-#??)^5/;8\I,EH:$B]C<,,.CQXMF<PRZ6
MA)[;2$E[9W< %G)!U';:^5L>;&Y+"BMJ# =E4   "JMT% JAOO\ 4!R J=Y$
M NS/_>=CXL_^F3?\^5\27\0?./3$](]X?_/TX@%CU[K:X!9];MI2N6FNE&DL
MDP-CJ#AL*190ZAY#4\638E09C2'FFW4MR&'$I=;0YC&%(3G&99)$8.FI'7=6
M5]+ \K#"B-MMCC,T<; JS*RGF&0D'ZP00<<U[7^MZB%@5RIE:[6*\*9S'%@:
M]4' H4:PIQ;JF( L:S&@PV<NN..Y;CL-HRXM:\I\I2LY/)([%WU.[;LSOJ8G
ME98V3MMN< D:@!650.0", /J %#%98Z7>G.57@%7LPVBWP14O6S%29O^N1=N
M75PY0FZ1;KH%PN(?R.!"&<PQ B&SCSC <2*BRI$QV'B2N[KF:#NZ/)$TFDR&
M*5H];*M:VTL+9C;,3S9F( NL0X$!"JVAPMA=<9;2">0M30 H >  [L90ETW]
M-IF!7!1>HZD*BZ<EQ-1&DM2!)T"K)=D8ENIKD.4)=C@TN2L8DN8&-Q<+D8P\
MK&7,>5R(S6:4N5EF!DKB$3N#)0H:R&MJ&PU70P,$!"@B,A/9!CV7O[(T[;[[
M=]'F,39S76LW9Q4FZ1K3A(Z'BUTV0<IRESC-?@J(*A RLM3&7R >&HL55%&2
MW'H4=1,AEIA&9DGSE?$E  !:E8NHUFE<U; <@QTK;#<T-]AB?#CLG4MD43H-
MD;[$UN-SL=MSXX@N.G31,.JHH];S5:/3UV8':R-;HE&AU,,:) # T[&:+P!
MR/'E0YA 0-];M(0RZ6A1?5<U]T;(EQ)%O6<P7,CEI)-#QAY)&=E#J5)4L200
MK-I.^DG4 & (AP(0NA2J*6#$(A4$@AMZ7D2!?B-KK;%K^HJS\LX_@I+_ #Y1
M;>[^T,6:5_&#RMZ8>HJS\LX_@I+_ #XMO=_:&&E?Q@\K>F(#:J#K>R,EPUCM
MX,J(+Q%P"P,Q4)I480@28J69$(A!EH>ASHDIG.4OQI#+C+K:\MN(4G.<9]/+
M33I%'H@8Z22KK*JF]9-CO!!VOQ%XS210LS:IUWYJ48_H/CBNJKTZ=-U%D3Y=
M(B:LITLI <%DY-5U)!KT@B,=6AUT=/>$#8;DR XXVVXY#D*<CK6VA:F\J0G.
M-+9O./6N&9Z-C5F U'Q%DT?F,5C+Y=>4T8L4:B(V\-N[&:J&F-(:^@R1E"*4
M:D#9LM4^8/J&N.[4*7.6A+:YLF(&B0F'Y:D(0A4AUM;V4)2G*_)3C&(MF<TY
M!?+R.0*!:=6('@";VQT00**6=%'.EC8"_&A6_B>_$6G]-'3P;P=8M)*G746<
MM<BZ^HKIKMFT! UCG"H(HH0 0# V4@8X6Q"41)9;4M<@J0*S<+0LC)2N0SF<
M6M.7D0A=&I)E4E020&(JZNA\@!W#'.KY<V#.A!.JC&Q -5L#R\?K)/?B1!M'
M:'K@)NK5Z7K\#662T(^S70VLVQ8)HZ-(PBXXTV(@PF![9: 6&CBD(DF/B9%(
MCX4UAYN3%8=;X<UFV;4T$K,05+&=2Q4@J19WH@D$71!(Y''1! !0G0"P:$;
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M[31E_EJKNQKC8DRJVY20J#RM659%\H?3XG39YXMWE.+,.,,.,,<*^+/]F?\
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ML]KC7.?2-CV/><FT%J?WPK8C< SI\C0IU>$%!XFP%J[)T56Q+D<@*)'Z_#L
M:VSG9$)HR%=',/>>GOM;IE4H'C6'2&T,8C/88@E0PF8BB%8@H*V-]PQ4AHZ6
M,FHBQQ.'5 T=/#4#F188D[BN_'@V)>]IFQ6Z4ZV=MJ)M0VIJ'5X.'0@M)+VQ
M$%V9KBS[0M C%]'3JL@C*K-^)5UI5M;<K0)%60?=]%3)ER\=C2(&'B:::.61
MN(7"W4BQJ>&=9&I%;L4S:](NA@S-3A;V:-1H +42C.1J[-Z7([0T@+?B<8@+
MM*T5>F6)XU9-FD;AK/:6O8^PP>W!NGDG$TF_3J^"\@;/TS70M1G5]H0;FW.O
MD1_E6)RR@I=>.RV8") =H8U9UI8PLD;E#$9=.M S;B5F?464(P/9TL&471QP
M-0-ER5900_#+4U#_ .F%6J;4*[6I:) L8W1YEQ;AQAAQAAQAAQACP;9Z496X
M0]?&'2! !-J5L&WBJ66GW(0%L==LPN"4%,$ALQ[$^)G+H@X8%RH\V!,C/0R,
MC&64O89>:HBZ2BB+%06#*497B9E920:(V.S*I%$;@=UC%SY*1P 2HI@P*N 0
M0"+&Q[B1RY$XKRM] %9J]_B7V X=DMB+;:=@5BB$MC,S=;U"_79HDS:KE6JF
MM]+$$T7P;/NX2])E"Q4D^9E APN1.<<Y8W2R,F@[6JHSB$B1T2M*,W>!I7D
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MVFD<G;OD=R/!2!W8FD1762Z$O(7-&NY44?H1%!\6L@"ZQ8_=0O\ T8?B$/\
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M:-)L\33NO8B9YG8-CU1:=)VT[.Q#=DV"\1-<VBM2KN60*AYDR"%C(@(9ZP#
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MG/+<]_<-SAUN?WQY5[^7=B2U_95RFEHT:249<9<2_P"6G H.WG/D,.+3^DW
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MAAQAC67J9HQG9FH]PZ_KKD9L];Z#80(9,YW+ ^22( G&84 D]A*\LC",C+<
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g383770g22z92.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383770g22z92.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X6.2:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(Q+3 T+3(V5#$Q.C4P.C4U*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3 T+3(V5#$Q.C4P.C4V*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,2TP-"TR-E0Q,3HU,#HU-BLP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$U-CPO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%N045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y54]I3VA2,41)=V]Y:U9"
M2'5$:28C>$$[<4@O4FUM+SAS:U O04-,6"MM2W4O4FUM+W=$3$I$+WE,6"MM
M2W4O4FUM+SAS:U O04-,6"MM2W4O4FUM+W=$3$I$+WE,6"MM2W4O4B8C>$$[
M;6TO.'-K4"]!0TQ8*VU+=2]2;6TO=T1,2D0O>4Q8*VU+=2]2;6TO.'-K4"]!
M0TQ8*VU+=2]2;6TO=T1,2D0O>4Q8*VU+=2]2;6TO."8C>$$[<VM0+T%#3%@K
M;4MU+U)M;2]W1$Q*1"]Y3%@K;4MU+U)M;2\X<VM0+T%#3%@K;4MU+U)M;2]W
M1$Q*1"]Y3%@K;4MU+U)M;2\X<VM0+R8C>$$[04-,6"MM2W4O4FUM+W=$3$I$
M+WE,6"MM2W4O4FUM+SAS:U O04-,6"MM2W4O4FUM+W=$3$I$+WE,6"MM2W4O
M4FUM+SAS:U O04-,6"8C>$$[*VU+=2]2;6TO=T1,2D0O>4Q8*VU+=2]2;6TO
M.'-K4"]!0TQ8*VU+=2]2;6TO=T1,2D0O>4Q8*VU+=2]2;6TO.'-K4"]!0TQ8
M*VU+=28C>$$[+U)M;2]W1$Q*1"]Y3%@K;4MU+U)M;2\X<VM0+T%#3%@K;4MU
M+U)M;2]W1$Q*1"]Y3%@K;4MU+U)M;2\X<VM0+T%#3%@K;4MU+U)M;28C>$$[
M+W=$3$I$+WE,6"MM2W4O4FUM+SAS:U O04-,6"MM2W4O4FUM+W=$3$I$+WE,
M6"MM2W4O4FUM+SAS:U O04-,6"MM2W4O4FUM+W=$3"8C>$$[2D0O>4Q8*VU+
M=4=M86-$55=S3F8K36$O,'A6131Q-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-R8C>$$[1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1B8C>$$[6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$P-V]I33=S1E)14WI%,$%!,TI*
M3TMS228C>$$[,4@X-'9*,$4X='9P<'5V349Z065--F%203%Z2$<R=V\Y>%9,
M9&1Z,VMX5E1(;GIZ,TMO:V<X:%A9:&)D1VYV8E9764AV>&E-.5!P3R8C>$$[
M2W)*9GI/,3-4;WI.<G9K<E9B3S%5,$YX879B6&DO.$%!3$EK<"MH2RLR2W U
M-5DO35!Y9C5L;&$S,')51F$O:D9:=$]N5G)E-U1A<"8C>$$[-5%40DI.=D5#
M;4MS:EIG<6QJ,$%Q8U9E939X*V5N:U14;F5+3V%A.6YJ67$X8TU40VA862]%
M+T)4.2M:361*375(:S$K2T\Q-W!&4"8C>$$[+W=!-4IE6'=W.4133'52935D
M-#!0,T%V;&\P374X3D(W56@S1E5T+RMC:B]!0W<T2'(V6F5X365V2#!N5694
M>54O:&=/:&PS:$DW5"8C>$$[>#EX6F(U0B]-0W<X,U!Q:'1!5FIS-6Q%2W5#
M2$U4;T-'659)2'AH9U!L;$]B0UE68FQA9E5$2F1D1UA:435$<U9D:7)S5F1I
M<50K628C>$$[=DXR9RM856AB5F)J,&98-65I;U)N6G5&2S=+1#1J2G=G6F-M
M17!I4$YH='@K93-L<$-W:'-R=5EI=D9Q4G%P.$]R5D@S6F%.35=O-B8C>$$[
M;4M(:B]0=E-#-$5M;#-#<#-+=6I(-VIX+UAH+TQ(=E(K6DAC:30O>G$P0S=U
M3$]',V=N:65A-6IJ:SEB:6=#4%93>%E&:%%';40X=28C>$$[47E';T)E:F=G
M9T5';U!1-6IT-W-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5E-J>E0U<#!J
M>7IP16UQ87!)5FE5:4]'1TUC-7 U;B8C>$$[,FIH:&I'-WE/9&="*W)&5T17
M=FQ8>DXU.31A;C5X:V%Y,%)Z>7,O2S!$;C!V5"]:839D0W!N8SED+S-9<#EL
M9V$T<3E",')29$DP:28C>$$[,6ET-T,R:71O;U5%86-&5E-%1SE+9T1B,GA6
M2&AL4%%G+TQ&6%EQ>'9Z6"M8=FQ8>E!'<#%'>E588V)C-$PK1#EZ8WAU2V9%
M:W%5628C>$$[2&)X>%9I.7(U:3AZ*U%B=414=D]6>3)R95=,:5%1,EAM=&="
M3&)U>&]K5V]"97IB0515-B]A.&-65G!0>4TX;#-M<UA7<3-C;'AC:28C>$$[
M.6QE9&]054-29WE(:V5*44LS52]Z6FQ$5GI!;T]%9$)J36I).55C=C5,9FQY
M<6A2<&5W.%I:4V9V3$4U2#@Q:S<R63!7261%3G%F-28C>$$[2BM16',U=G$R
M;&XV>G=)9W!02V=$;F]446YO9EDT639Q9#@R371$:5!2369Y."],<E,O2FUN
M=C9B;6953&A6*W588F9#1'AQ94MR5R8C>$$[:7%+-4A.;D]1*U105&%A3TEB
M8S)4+W!05&8X06QR:"\U1TPO049Y;FA,:U=(9G!05&8X06QR:"\U1TPO049X
M-%-T:#,V5# S+VQR:"8C>$$[+W=#4FDO,7@T4W1H,S94,#,O;')H+S5'3"]8
M2&A+,D8P9"]9>4]%:G5);F1U:7$V:VXV06-A2S)%;3@T95,Y3C@P,C%V0F5Y
M4$-,928C>$$[47E,2D9X-6UO230Q64YT:SAE47@U35HT>$QM;%9R*U0S:V%'
M3E9E,&MN8T1E4U-6-FXV05%V-%I)-35-0F=I<D@X<"]):$)(-D\V+R8C>$$[
M.%=39C@Q65!';#-P.$=08VQ3+VLQ-6)/=DQC<$<P96QW271,5&TW1U-7<$Q&
M:35*-&=5-DAF-DXU*T]A.#)09U)T;3DU<D]J-F4V=R8C>$$[6%8S1D)+5G%K
M3$U/9DAP6&HY<6YV;$%I4S-%9TEF.$%X5C5E+W=#5S90.$%(*VU(9TM/24\O
M>%8U92\U8F\O>"]P:G=&94E/+W=!5B8C>$$[95AV*U<V4#AF-EDX0EAI1'8X
M5BM84G5B*TE$=5-305!M4TUE07)X0DUO6F]:-&MM9VM75TM18VMK46AL64AU
M0TYJ:U=3+T9867$W1B8C>$$[6%EQ-T97;5I557-X0W%O<7I(64%$<5-C5F59
M959,4G90=FUE5'IP<4I:=$1S1V5$>7):,6]O4W!74S=C03$U>C!Q3F@K-S0Y
M47AX5B8C>$$[-D9Q.30Q:G!S<SA904U9;W9G3S-48D1%5U9E96%R<D=P1TXU
M-7)I-&8W2$=)2#!Z2UAC2G=J5E17=2MX>DIJ14MM1VUA=F0R53AB;R8C>$$[
M:W-V<6YI,&-B4$M!95 W93=)4'9'0U5147%A;GI*<45C-W$U5D="2'=Z54-5
M24)(1V=7<#,S,WE(:&A65V9Z4D)F851+='!)0F1S2R8C>$$[3'=98D97*TQV
M=#!/1'<Y,5EP<48U4&4V6DYB-FER>6%F9$E9-6MB-#1:1D]X0E8V:C=J;&Y!
M1E4O=T%O4$Y$5VPO8V528C(T965/,28C>$$[:DYZ-61U6F0S97E5:%AT,EEK
M.&YT,DE!.%5).$UP>5$T5%-V5G-G<G-64T<Y<UE.5SAY3F%8>4-E=W-,4TMD
M8E(O:6EK;75:2E9$>28C>$$[269H9C Q="]H<4YU4E!7;5=!,4=X>F%Y3&Q2
M-4)697@X;E)Z3D,Y=' V4V]32&IA3T5-0W%Q-U9"1S%&9%0X:4UJ>'DW,EA!
M3S5:-B8C>$$[2&MJ8CDQ<'9X3UDQ*T-$9#%C27DY3V]D9TME2G@T-60V.$DW
M;%$R2&LX3WE',C X36=5<W9#1V]$9W-P3S-D5DI(=&IX>3<Q-$(S3"8C>$$[
M4EHK5$-30F(V8U-+5D%31&)K4T(R-VM(2&IL,W)W:G564#A!1"]L4S=I6E)P
M,6I01V%C=4U-5$1C0FAU0C1%15EE3UAE<&A(=5<K5B8C>$$[5VQ';E17>GE0
M2W1L9%A&=$1*25-Z;4M+56E-37@S67%T1G%D>E1F9DA*>E)J-4IX:T=B<U9D
M:7%384TY<F%A9G%/<%0O0WAU8C)3-R8C>$$[;F]3>%,S;FMJ5W1.>45I:D-G
M93)3:WAI,TPU>3AT>%-Y>%-8<7$X1'9(3T-R,%)O>5$S23!O04MD8VI42G!F
M3W9L:&UK45@V97)'428C>$$[1VEO,U!C03=,4W K,3(Y+T$T,'$K8GIF-6)I
M859(=FLU=SAJ2VEH;4LX83%Q040T63!Q<G S;5A19%-U1&(R1C=(8U1"969&
M1%@T9"8C>$$[=#8Y3RM+<65K4G!B-GAQ,7)#06QV>6AU1FE!;W%V37!%;D5D
M=5)4;#AY5#-Y8W5166IM9V1/1W%8*VM1-C%E83%.65)855,S46=G4R8C>$$[
M,45-355I.#%5=$Y$2S=&5E!X35<S4%%!6DM204Y5=VE#4F1R-%9J;FI-:UAM
M=31D0EAK=T]N8E5R5W8K:F)D1&ME261W*S,Y8DQH4"8C>$$[969S+U5U.45E
M<3!0*TMB;C%62W%Y9C=J*U%A4FEI0VXQ8G%Z2U%09DAI2&-0="]7=D-E."]:
M*W!55G16,'I6<DM#93EF54Q(54=E128C>$$[1V195FQI;E-.<&Q+;4));%I'
M4TYW459Q1%1F=&@R24\Q56IC16(S865:5S)-1R]/6%4W:3$X:WDV9F%U,&0S
M<C%X1'!-56E%0FQ7-28C>$$[2CED;'%2=71U:VAX0W!F3#5R:3!45&)B4W1'
M06ES<E)&:&E:>%9U2V=!05905'<K-%IK4GAD-G1195IT8VQS<#,Q2U-L;%!'
M5FAA4B8C>$$[5E=R35!H24\Q0E1F.5=%=T%/>7%D=3!T=D9&8U1-6EIR;6E1
M4G X1%142&--<3!8-$M6<7HY=#A*5EIF874V=W@R.&-G2V]I:55X:R8C>$$[
M:%=F.7)I5#A82'=R:4EQ:U1A:E5K:T562C,Y:#0U84EQ9V1"='11=DY!16QT
M13AJ4VU1*W P46-N2BLP>#1J<C0T>6]+>7DR=$Y3:"8C>$$[<T-R.' R:FIF
M,%E9-DE!-T1P-C!N<&EH+W=!;&IL4D\V<V8X,#)C=6@V6'!N;3%!<V0O-6-U
M66(R-$%-4FME0C(Y2SEJ<D5$5E=G:R8C>$$[4&9T:TUM-G9B,5I854UP1$MW
M<7)$8T5(;U%C;U9V1E5P='8K57(Q2"]M07-F*U0Q,VMZ.4DY-2]1=T@Q2#-$
M.4Q%-S5.23%7+T4Y>B8C>$$[-5IU>DQQ539W4S-$*V]N1E)):TIK8TM$=S1O
M:4U0.$%6-FEL8VEY43AT<#58=59K96)Y>F9Q;G%.>49*9U-#>DU347 V354U
M9DUM=B8C>$$[=7%T*W$V2$Q:9W0U83%#3TIM:5-+,W),*SA)<D=O8U5Q<7%(
M36A0,#1Q:&])=$,Q0S1K:VLX;S9G<E!)0D5885IA;'=!4S-:93-4.28C>$$[
M:U8Y<U9:9F]%:T5'<S-&;EDV5E!A=U1Q3&TU=7!I-%1L=U%+:4$X;#5F1G5+
M.79U56\S>7@O8S9J+S(P8G8X035/;DI4-F4U:$1R-R8C>$$[,#5Y1$XR2W5X
M5DMT0VEJ;#!U-&EL55!(2F0S-G5J0V]:5&5406=G.6IK<&,R36532#%J4F)3
M1%0U1S W4G)7.'54>$AO3W%+2$%)<B8C>$$[>5DK4$5D9G!Y3$IJ87)Q2U--
M6#AO,F%81&M(<D=O2DE1+S-H,DQC<6IJ,2MG8FQ#23!U,#%+4S1J4S0X<C)A
M=WIY2V)I-E-22$E3528C>$$[4V5Q>$I,35-P4%-P2#,O0W%Y,GHP6%-,2B]5
M<S=+0S-K<%1N1D=Q;6YZ07=*43%H+W=!<$1Q=B]!0FIT9C%36DDX9WA(3DDT
M9%-L="8C>$$[=DIE:5=Q-F10<45D-7!A0U51.&=&0U<V16AM545J:T-A66-N
M,4@S;W@O4U!C>"LT5%%:13182&Q454AA,V=":EI$2WDX6D4K>7)F1"8C>$$[
M=4%1,U1B-'4T;UES;%%T<$YN2D9E1'EV<4)U3%=D-3%J4G R;U9L<D4Q1#A*
M2EIJ461.:C%X5D]F3R]M1S@P+WDY<&UV2F)#3S9G:R8C>$$[;'5K=%IQ;6A'
M;C-40EAP>$YF15IB:&IX1W9X>D14<4HX365,=2]56&HR<B]!2BME8V(K3S-%
M359V67E7,#9Z<DI!2DMT>$)":F---R8C>$$[0FM93G5->C0V3TDX,U5Z-U-M
M95%P;%AN2'I(8V5:8F9Y0G%-=&LQ;C9T>&0S:W1T3%5":D1B;4U&1#EO;S-R
M8VQ0:&U"3$AW>G$S8R8C>$$[66-N2$53<7)196]A:F)7-V-O-TI'3E%A4TUZ
M3"]W04156FMX:F)A:CE0.$%-13!T;7,X=C=W>D1N-F=9<$EP4%5)=S-P6'-D
M<VE9-R8C>$$[<6IV.%<R04-V3F%"<FE%1EDU,C1M5&ED,DA)2W8R=#8W8C10
M1%9$>FU78E,U-4AM839D,6IU-V52>#A3971+63)H<4]Q:6]+-'%Q,B8C>$$[
M;6LR,#DW8S)4=W(V1F]Q3&0S5&-J25HS4EA+4CA3;S)$8C$V9E1G<VID5B]L
M2FIB859(87=Z3UE,6#DS15-D*TE*.$MD92M-*V1Q;28C>$$[:G9Z-3AG0RLS
M3&5U,61Q.3AJ4W!4-7)G4S8X<V%T84=H5V5Z=4EZ6&(W8U1$05)S<C!$>4QE
M3F4K4U!,,39X2F$U,'EZ;5ET4W!-;"8C>$$[=6IB,"ME639P-6EQ53)X2"M,
M3E)(8S)&:E%F2V$W<BMV2FXV4C=Z*VAG4'%0=4@V54)C*UAV361X9#-%=C9A
M94,S:VM*:'1556M#328C>$$[;G4Y5F%T2V)$654Y>FM787DP.',K84EB:WI3
M95EP2D8T=4DT;6E"5E-W25-T5RM,:EAV:7%%6'DS-39A-6E75%A13$Y39VQD
M4S-Q<R8C>$$[<4M!5S0X5D%::E55-54O83-/2W(Q.'(K8VUM0WHK64=.<V=J
M-&Q62W4W2VA"-6-E4$5".3EM4$QV:7%C*UAT2S%J5#%M1W!A;S)P="8C>$$[
M2G<Y3FY12G<T9SAQ06)B,4="5G9L:BLU,4@O=&\S9B]!0V1/5&XP.7I#2%@S
M<'IK1V)S5F1I<5=E6&8K3V9,+T%->'0Y+S%'5%I+6"8C>$$[3FI(:VUE4EI-
M6"\U5B]P8V])=35P6C%$=$EI:6M91'-#<%DX44-X,T).5'5F;FAT57HP5'DW
M839/,&=T6%EW=D=K86\K-4%34U=3=B8C>$$[3'8X03,Q4&]W2VUU2W!6645(
M>D1Q,4XV2F%Q9EDX6$Y0=4EY4C5":4]A1#!3,G4W<GE6;VE79#$Y5FM&<%IS
M6E%O87%R1716-FHO4"8C>$$[8G!H>6959F5J2#E).7E"=69+4&UM93)E2G9-
M:V],.&1W:%1I5G)3:DLT8EE52%AF-U(S>4Q.5VXX<V5:,F-'2'I&3$=I.&5-
M9G Q1R8C>$$[>3!A<$Q6*TMG*S=X2GA634YF4T-B54Y#=#565U):3'E5=$4T
M1$)K1FIC:'%G.79I1U-H>5 T-FAH4&U09BMG<5=R95)F2W5Q>#(X9"8C>$$[
M,7 P26ET-3%U3T5C84E(6D%11FLT<E9K*TMP6'9H:FQK3U)9>G=X;'I$169Z
M;71L:&TX;V%K94M7,71Q=C%/97)E;7%P93(X:U,Q628C>$$[03!8,494-F%:
M1THS8E=+875B4S%F:F5A87I7<E5%3C=B6$):2#EG-TLV,4=:9W169E$Y4'-,
M*S)7,C X6&Y'3FE!>&I%>4M34V5,4R8C>$$[4CA+9&8U8T4U16,Q5#5F>3!L
M:V\Y>&1';F5+3D%P4"MZ63=F.$1K1&U+<&HO:&4K:U,R:E!#,VA75T9::S-0
M*VDR:&%21DI.2W9)-R8C>$$[9D4S5&)P:V5.57=S.4%N.4%U1U@Q2C5P<F@S
M<#$Y4U$X4$@W35E69F]Y4$=Q0C S>7!06G<S2U)-<&HY6C)H5&9:3UAW:F8R
M>5)N828C>$$[;U=:>DA73G%#4F9T5C(S>5-P0C4U=3-S+THR=%A1545R6GEP
M14M%,6QK6# T,7 S<3=J0DDW2SE8.'5A8RMM95AT3# Q+W0R5G!"8B8C>$$[
M3C,S:6E61# O=T)835I5>'A63$Y5,&%3-G598C9Z=6I:86I!<E)R3T5%:5!'
M>$)-8W-:<'E7;W%+34-$,%!7<S1Y<EDX;45O,W5/828C>$$[>C9T-7(O-G5.
M:"\P9WIF.6QE3G@W:C@O,DQ5=3AF3#ER=G$S;78X039U3F@O=T))33,O6EAJ
M8V4T+U Y:3%,=DAY+V%P:V59=S-%-B8C>$$[='!W66)%9E4U83$O-E1-9E0S
M2#AF0DAQ-W@X=C)Q;C%B>E@O04Y81W<O-E%:=CA!<W)X=5!C9FXK>$Y3-W@X
M=C)T4%HK86Y5;V15="8C>$$[27<R>&5+>&-/4&142F-Y3%@U<6-B:C-F8BMX
M86PS+UHK,65',&IY,V]Z3E!0-E9P04AL;75*;7$W=3=&,V1J='ED,V%U=S9N
M8D)V228C>$$[<$920VQO2&UV4V1:<U5U;UHT:TUL4TE426Y-2T1S5U5(8F%M
M,D=50T-S6F=H3D=U<E925G!K541Q4W=(.&-J5$I+8C=Z=C54<W%I9B8C>$$[
M5F)C3T-"-F%Y2WIK;B]*56LU25DU2&]W3U-)-G%Z84LT;FMU9$]V<&)*8FLK
M<%!#:7AV1WIN<DE&:U9I<DXS;V%(<E-U*T1I-S P:R8C>$$[=7$V;G)7;C-%
M<V9Q86IC=W=&03@Q=F%W4%5Y2U=(049">4,X9FE.9'-.:G57:6<R.#%A9W!)
M6DYC0D<O+TA/9S-(='0W63)/-6%+,B8C>$$[>C@Q-FIC>7!(>#%Q4&M#5V0Y
M4&A#9VA73E!S-R]927)J63=L;W!T;S%Z<3)Q*W1X=3<K>E=)3'9D,G1V17I&
M=5%)5F5,9EHT-#)/-28C>$$[85!E;FUM-F)"65%U:V)V3$I+-6QU3&E5:'!*
M2D-!3U1%041O04%!04%"46):16TP9U5G1CAQ,CA,3TQ+.79,1T(R3"]!1E<S
M;$%I5B8C>$$[;4Y7-$LV=G="2G)X6&(R>69I9#19.$AC,R]H>6(O<3@V:B]Y
M36DO-G T3U!Y0SA(;5AF-&-M+S9V3V\O.&I)=BMQ95!(-4)E1'I+=B8C>$$[
M66%$8E=L,F)X-34W>3<T1TI*-VU4;552:4-Y;V]#;W9)<4MK0W!P=F=--T9*
M14M.<&QK5U1(9GI#.')N>E U3S%04C1Y175P;R]5<R8C>$$[6E14-$QM1FA,
M03(O+T9I0W9T:7)W;GEL-6AS<C-4=%(P>E5H3F%,8WAL6DEL54Y,8GIX4T1M
M<%=1:F1(57%A-S5N1&5):W).9$(Q=B8C>$$[4G)'.7,Y3VAD:W,T25%K8GDP
M1%!+>E9A4G%%:7)(27II5'5Q3C@X95=0>D,Q5'I08GEE6$Y61FIO+S%)4D@O
M4TI)-EA(2U%T2G=21"8C>$$[-FQ66D%0:EAP;4UQ6#8O-60O3F57>3!&-T17
M631P-T,R1G9R6F56=C-K;C=42W9O2&M86%E-*S0K9%=*5D@R3VMF;F%S9&PO
M=6,P*R8C>$$[85 X03!2<$$P4V<X4%-0,6Q15F=(*S=33T\S,E%.=V$U1E=9
M*U5B4'I(1&]&<$0U9VM7-#%L5DEV6F]H4D=F:U-#2TQ'4',P-D1#4R8C>$$[
M<2LY.'-4,U8P6F5A26AP55903#E634EN4W-1.'AA6$AQ9FY0469*<TQ#84LS
M;%183F1+,&]L=&%V5S)I8V8X048Q>'@R.$9*>4IL828C>$$[=E5S:7)S5F1I
M<G-69&ER-7%"8E=F>C1Q:$HU86U26&%O5S-&1"]W26IZ82]4:"M$;S<T=%8X
M9C!0<%A.53=X,DMS5"]!1$PX<U,K628C>$$[9DQY,C!"<&-1>GAY4D@Y:U9B
M9WAB,D-/5&QU1V9#5W),1&E&4$]B<CAJ.5I$13)/<#)L,4='2T(S3%(O1414
M:5%056]A.7-V1W!$428C>$$[9$UE:%50.$%L4B]M-69I:VYS;%%B<S-Q=G-"
M,S-J1T@X>$9(-6%36C9D*U)B<S!:=CE9:E=P;SA-0U9B8EIG1UDY4B]Q-44V
M;G5$228C>$$[86)V3#$K=V<K<C)C3G8V>EA(;W%)+U=C9W,S1&%R53)R='9M
M2U1B;$)8=TIE5V59.5$P,C Q92]T3&Y69&)--&Q:9S!-,&%P2#9L2"8C>$$[
M0WA$86ER=%1#:$Y023)O869F-B])64PW5F)H-#=C<W-.+TUS:TMH94-&;%9F
M,GIY>$MS+W=*9&ER<U9D:7)S5F1I<G-69&ER=VXX-28C>$$[=DE&>&\K<7DK
M94Y'9V%7=W546'I"85%G<S!B,#0O6$5297$P03E59&8R=DA,<U=8:#EY<TEV
M<&I01D)C44U*25I50FIK53AL24EQ0R8C>$$[0U!N;69#:7)0=$,X,S9N0F))
M2$Q81G$V1#%):5=R=4]Q;G-2,GEI54%3<6-1-FYQ*W(V:6LQ;F53,F1J85=Y
M9EAP-40X6DEC,"M&5"8C>$$[=7I:07A!5FY79U<P.'-C3C Q>3@X0E%-:E!5
M37A0.$%-1&U023E&5#-)2WAN>G@U-7,O3$9N1$A(0S)O83=Q1&5J;RMJ=R\S
M,7A-9B8C>$$[*TEX<C%D>G-"-S!'2W%0-64K57(O43=+-W8X05=P:W4O32MT
M4VDV,7$W4W9!=4)X:FAJ<C!J:%0T54=+<W-X5C)+=7A6,DMO5%8Y4B8C>$$[
M:# S4W)V54HR2W<R<TQZ4TU"5V=24V$P>559,F%9>6M!0U,K9E!Y3W-:.5HO
M34\T,6TT570Y5U-7-6QL2%%4>G-12VXS1%!M>3%:-"8C>$$[654V6',X8V55
M>5 T=#E(6G$S94]X5C)+=DY.5CAT=TIE,TUM;BM56F)V,%I65EIH9FU(,4]"
M<5=#1G518C1I86YQ2TAE=$U+2%-E6"8C>$$[-51:36DK5D=-:5-#4S)F.4I(
M:3-Q8TEY5FLU0F@K-VI8-W4R2W%%,VQP14U54V53<&A)-7%L3#EV5$1*=CAB
M2G-+.$YY971C5F5K-B8C>$$[8EE7,6A945=D=$@V545+.%5J2DQ%9'IU974K
M0DM*>%8T:#4X+W=#570Q2"]!1C$O-4YR:V=H3B]Y;2\U4T\U+S5G,R]!3U1S
M94%Q2"8C>$$[<D="3'-69&ER<U9D:7)S5F1I<G-68U%#2TAC2$98:VYM>CAK
M;5,T;#%(>5DX3G0V<D=3-3!#-7%T;DEX,TQ7-W%'83-C*T%"43$V1"8C>$$[
M3$E:1$AK<D@Y33%F461'9&)(>EI:,VYL=353=3DW0WHR>F(P<6PQ0TI):71E
M:$I83$1M=%=D*UAT5B],<$E*,F@X=S983F(S4VA(-"8C>$$[,V-&3G0Y+VDR
M27)L8W R<5E4+VU8*U=M:5%2,C!V;4]W2E=I>'=15$IC4RMW155(<5!5,3(R
M,WE"3G%L16XU:"MB4$UJ1S X:C9$3B8C>$$[1D9)5$=F34=S>'1B,C!D4'1-
M;'8O9E-%03%(24HY3T)5-3AO+VPQ6F%(9GIA,W%.-4QR9FUI-EAH9&%Z9$)1
M=U=P4'!W4FHT65EX,"8C>$$[0W)I<DQS5F1I<G-69&ER<U9E4&9N-7)U=F%B
M<%DP=4Y68E-T5W!7-'$S<5)V1S-*-#8Y3TQI;%!K9DAB3S!C26LS,41R93!C
M:V]X<B8C>$$[<$I-9BMC9CE&=$Q0>6DK;TQ*2$ID-FI+>E1C1T):16HK1D5A
M:%!4-UA3=2M1,6MY6E8S32MZ<UEJ:G9V96]::4]E-T952'$R:U='<B8C>$$[
M5UIS-RM->3)Z34=A4&MY,4LW:79%9S1Q:W$O;'8U4E9N6F)7448Q5D@O9GIB
M:$]N-V98,W<R<6]0>2\X<D,Q4S%&<2]O;U=:4C8P="8C>$$[951C86MT>7)8
M.3)T4&QJ87%-6#5A9559=V8X05)P1UEQ1F1M;FQQ=U9I=W%!=TA5*T=.<6UE
M:2M73D8P5C58,#9%>$Y/07-T6&0V:"8C>$$[5UIX.6]N;UI$9U98,6TK=F)'
M>F$U=&)),WI*=3A+4'AF:C1Q2TYY*U=+=D5034=Q1%9.6G5R.%)'151S1#92
M3E-T1D,Y841W>5-%9B8C>$$[-4HQ,3E',6AP;S=6-WE394DR-E%2;6I&;617
M,C)A=C)-5F4P5U5T>DYA>'E834@Q85IX5F]/669J-T9G04LU1DMT:7)S5F1I
M<G-69"8C>$$[:7)S5F1I<G-69&EQ:F5.06QP33EW1F%"55IP5FMP>$MG5E!+
M=3%-24-K=FYR42]Z1C!F5U!-,$9P<4=J84IP*VY4>6Q4951736-J0B8C>$$[
M2VYG<DYS1DQB1&MD:#%P;7=N<$%),DYY-G)&,FAX5&\P03DT<V9,6&QY,$-.
M86%:6GA-3GA*1&)X2G8T:FEO>EA/,5101E5N.'A#5R8C>$$[539B64Q+.$U.
M+V0K:F1.17A347A*8GI4;$9D4T=8;5E1<$DS<%=L36Y$<64U:%!O3SET9DM(
M;%%!1#E$5U15+V%A,VE::C@R6E-39B8C>$$[;FHT:W4X<C1C931.+W=#169+
M;B]!1EIB1"]P1V@O-7!X.%-8958X3U!C2&8T4CAQ9CE75W<O-E)O9CA!;6Y(
M>$ID-5AW-#EW9"]H2"8C>$$[>7 O,5IB1"]!2U)O9BMA8V9%;#-L9D1J,T)P
M=DHO;%)L2R]O87E7=C=35SA335!C37%G9RLT>#A36&56.$]08T5*<&UL5U8U
M2&8V6"8C>$$[<4U9,4,R,'DY.4]Z3C$K*V1583-I;E5&;7%72V5U5D)/.4%+
M;753;$EI:4YR1$=-46)",V]P-6)73FQA<'=T8F5/0DLQ-'A)<4-V:B8C>$$[
M4E%-<DI*8D%!1F)!;#)+=7A6,DMU>%8R2W5X5G!M5E9,35%Q:F-K-T%9<4%W
M2'IN-64X=39M>EAD;&12,BMO9G1L47I24VLO>F-!,28C>$$[1SDX2$5',SAV
M4'52+VLW4W9,1VIX2S!D,4A0<45I+TAC>4%P<V8R62M91D(K=DAI0VY"361'
M64%G:6\S0C9(0S%/>%8R2W5X5C)+=28C>$$[>%8R2W5X5C)+=7A64W4W5S-U
M-V%7,G5%17-%>6Q*63)&47EN66=G-%%A45)B>D@X>F9Y871.8VEB571#4DQB
M5F\P04U(,EDU;%%50R8C>$$[+W=#4S%"4E0Y0C(V6F5$5D=/>#5/0G$Y14UM
M.&1P344X:R]M>C5H.&TS2C!4>D9B>3-&;$%1:&EK,G5)05 U959/4S V06YP
M,$Y.<R8C>$$[>4UU;6I094QI64Y:3$5E1UEE-V589DXO;#-Z1&)#-#!M.6IU
M0E%C-&=A4TI5:T%/:&]Y.4\T>EA4>'EJ>D1T.&5737AC5&$W5W8X028C>$$[
M:G!A0B]W07@W+SA!541D67@U2#-F<$-:.'@W+T%.0E8Y83%#-7-,4517.7-B
M;'DO16]/5W<T:S%00EAB8V=+3G5P2&))33!G=E!09"8C>$$[.6)O2D(U9G9P
M1C5L5U)58FY11'%O-#!.5SA33FE$-UEA5D5A5C5W=G)Z-F]S,FA8='4Q>3-&
M;DLO06@T<S-6=4)P<T]O1TMO84AZ,R8C>$$[9G9',&IE6#=X54%9:C17<CA%
M4FMO,TI&.$M#;%%E,DY+>4A2.55F56)E4UIR5U<P36-Z>&5N3W!6:45/>D0R
M3T)54&]V+TA3,2\X028C>$$[-6HP+S9G8EA*>35$,V9P3$-(32LO=T1113)Y
M1$XR2W5X5C)+=7A6,DMU>%9#-FQQ3G9P.7$P.'@Y:U=T0W@K;CA49TI:-#A:
M:U5G328C>$$[<F%N0SEW;#%B6'0P3TIG<W950G0Q0DEQ5S1K;'%#=4AG-S)W
M-5)(84<S;C%33'IJ-6MG,#!345=D>&%P8FE&5FAT:3A#2C8T8VMV5B8C>$$[
M>40X04%)2#1::UDT5S!K:S@R0UA6*S9347IA:7A-5&AE1GI&2SAN33%!5FQ9
M4GA+0S,R84LU<#)R;#%D1D))-4MM:V9N6DAO;FU3,B8C>$$[,%-C4$YB>78V
M8S-*9V916G5)5D<X5%=V26<O9C!Y=5=K3F-59FLS:DE*-U0K8C-7=W9R82MT
M575B9'5C56=Q1#1E>'I&0F%P=TU44B8C>$$[4D=,0C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMS8S@S95%03%AM<41H<61S4%A556EU-"]H;50U3CE043=:8FIZ
M4VAY86,R;FAK2'%$>"8C>$$[<E=V>4LX-F%,9&DW.'0S9C%W2V8S8GA0.5=U
M17(Q-V=B94EB-DUZ;S9U16A5;E9Z-U!Y44YW4#9#.6YE,FUT13AQ5W,X>E1Z
M43-0<"8C>$$[=DY*.70R6%1R:T9M.7I434<W-'9X,41T87)H2#0U1FM/5DYR
M<U9D:7)S5F1I<54V3"]X,'1F.$$K63E0*V]#,7EC=5$Y,S93=VAZ4"8C>$$[
M=B]113)Y1$XR2W5X5C)+=7A6,DMU>%9I;7-46$8Q3F94;4-35WIG43(P1%%3
M;4]B,5-E3&-!0G15.5AR,#=(1$%75RM:-%EI4&9U9B8C>$$[,$UB,4=B4V1)
M,#59-U,P:V=7-E):0D1C8FE);%)Y*TYI5W T1'AQ8WE)9WE/-U$X-#@S4UA4
M-G1B:5<W:F=!+V514FUR5DI0,E-!<"8C>$$[<%552&AM5&HU2VIO<FI5-VY2
M5%!Q=#$V1VUX<%99+U15:W@P04)2:4AB<7EM=DAW3F5L0G1A<$AA,DUU;U12
M96QC:5=294UY4W1$1B8C>$$[25DT-4-W259Y=7I+<6=D1V]E-7EF1E-V469Y
M5S%V56)$5DPW>79Q9'<Q=WES8FDQ;5E5<6MN>&-4+VQ)5V]2,C5$35!644%)
M:T]V,R8C>$$[=5(Y55!/4#-063AX,TAD:7)S5F1I<G-69&ER<U9D:7)S5F1I
M<G-69&EQ1#%84S1D4G0P:652-%I9<$9M=#=M16=34E-R5VIR54UV428C>$$[
M:T5%145%9S=(2E)L5$=58E%1,#-Z3T%"*VUO>E1U8DYA+VA)35!&2'52574Y
M,S9/.'HO.5AM3"]!2U%X+W="5DUE2U!C=%,W,V9O-R8C>$$[>E X03E8;4PO
M<$1(+U942&EJ,TQ5=3DS-D\X>B]W1%8U:2\V47@O,55X-&\Y>3%,=F-D3CAZ
M;F(Y3E)J,T9M=&9O<DEC94M08W13-R8C>$$[,&)P3VQ1-F)B3D1(23@P:W-J
M5%A&>$M16DI:6"LP-SA1<2M!04%!04%!,G=3;&%9>&])>DES;EEQ-T9867$W
M1EA9<3=&6&Y(;'E4>B8C>$$[="]I33--.7=I*U=9=S=08CA5<C!9,7)4;7I&
M.3EJ;&=%94%F>FTW569756\X*S-S='9C4W9D.'!96&M9>%-!,$9A9D%I;F]#
M<%!4328C>$$[:D5';#5T<3EV<#1S;G9*-4-L-TE63G-'9FLS3&PX5$5/=FAT
M-$@S24=:04HU9$9A5'I.9% U94=J=F)R3U%R05A4<T<Y3F963$UV0R8C>$$[
M;E%51S%2<T%/,D5W04YQ9UET9FYJ=&IP-C-*=45I:31W5$MR:51I3C-#*VY8
M;W125FI3;2]B2D5+>4PX<C=J54EV3CEL2#9B>%=X9B8C>$$[:S-R351)>$Y$
M43AH>G X3F9I4&9-8E8Q=TXK;C5K9C!3*VQ-=U=H,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2R8C>$$[=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W9..50Q4UA2.5=L<S4T-7!,5DA,3#958D]O43%)3$915#<U8FE&
M:74U=7HW:U,W=VQN;B8C>$$[2#9N<#%J1').-T1.9#)5.&A23%)35F\S;WE3
M8VER8FEG:3,O04M:9FI(16%$:5IS;V=,63-C>&9L56PK.&ML;G%5<S1U1V=%
M2CE.5B8C>$$[85)+9S U1E<T:6Q/;S=:8BLX<F\Q;E92."LU<S8Q*UAK2T]L
M=%I89'9':3="630R*S!'6E9"9#)A<D--;F8U1V@R>$5*;R].>#@P;28C>$$[
M,4\R=6]T3F@Q5%1P6E8P*S1A45$Y1F179VQ:0G-T04LX2S5+3EA28CAC*TE7
M1U8O;%HU6G4U9%AS=%=U54A&,4US8VQA<V5,535%9"8C>$$[9U-T37AD5&M"
M<4DW,TMX8E)L3#1F3C=:;4TP3WA6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,B8C>$$[2W5X5C)+=7A6,DMU>%9J=FY$
M47)M*W148S)$8TPK2F%+859Q0G8P-VM967DT5&)D:FM#3T4O0DLO2V5Q4G!P
M.%=N86A-6F)Q1V\Y4R8C>$$[86Y*:%4K4%A9,'DR5RLT835W35124T17.5HX
M*VI8-VA,5%1,5V)4;$Q,6G-Z>&AI44A)64@Q07A,+T)8;T(P<#-Y-DU98T\U
M,V-/528C>$$[<W9&<TYK4&]T.34U3W$Q,794-V4R,#4K26M+.$(V6CE/4FU:
M5T5J1G%V44=O+V%W>6I#=&IU;DA,2UIE;V))9GIB9$A76&@P9E-12B8C>$$[
M;356:TM#<7)5,#9G6D=-:$1C=5IJ>&U2,F5K95503'@P8E,T67!4>75"1W%-
M9C5656)+4#%N355K:S)795=9,FI(-E%N=4)P9&ER<R8C>$$[5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5E-J5B]+*VYA:51)4C9.=R8C>$$[9CDR<#-0:5)T:4YT=S-2>D=Q
M3S19,4XK6%8R<R]R4EA#>6Q45D=K6G51*U%O44]N:FQG>7E8.3)E.$EY2'E:
M<4QJ:F,S2T)$,4%Q+R8C>$$[-$AI4'AW2$I)<BLW2&5F<U1R4E!,1VMA3W8X
M06]S23E5,4Q3:T-T5#%P-%I$;G555'EK:6AS13)X86QK,W)E:R]O.&96;V5(
M3W9'=B8C>$$[871..%912"]!1'-N+TQN+T%-;&-69"]Z<VXO3&XO>59X5C,O
M041S;B],;B]!36QC5F0O>G-N+TQN+WE6>%8S+T%$<VXO3&XO04UL8R8C>$$[
M5F0O>G-N+TQN+WE6>%8S+T%$<VXO3&XO04UL8U9D+WIS;B],;B]Y5GA6,R]!
M1'-N+TQN+T%-;&-69"]Z<VXO3&XO>59X5C,O041S;B8C>$$[+TQN+T%-;&-6
M9"]Z<VXO3&XO>59X5C,O041S;B],;B]!36QC5F0O>G-N+TQN+WE6>%8S+T%$
M<VXO3&XO04UL8U9D+WIS;B],;B]Y5B8C>$$[>%8S+T%$<VXO3&XO04UL8U9D
M+WIS;B],;B]Y5GA6,R]!1'-N+TQN+T%-;&-69"]Z<VXO3&XO>59X5C,O041S
M;B],;B]!36QC5F0O>B8C>$$[<VXO3&XO>59X5C,O041S;B],;B]!36QC5F0O
M>G-N+TQN+WE6>%8S+T%$<VXO3&XO04UL8U9D+WIS;B],;B]Y5GA6,R]!1'-N
M+TQN+R8C>$$[04UL8U9D+WIS;B],;B]Y5GA6,R]!1'-N+TQN+T%-;&-69"]Z
M<VXO3&XO>59X5G-F-&IQ2R]5-F0V97)I<B\O6CPO>&UP1TEM9SII;6%G93X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L
M=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P
M9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI
M8G)A<GD@,3 N,#$\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N
M=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC871I;VXO<&]S
M='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^375N
M=7-A;7DL($1U<F=A(%M#5U-=/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/F<R,GHY,CPO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE
M($YA;64Z(" @(" @(" @(" @(" @-RYA:28C>$$[57-E<FYA;64Z(" @(" @
M(" @(" @("!R<C(S,#<R."8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @
M,3<M07!R+3(P,C$@,3 Z,CDZ,34F(WA!.T535"!4:6UE.B @(" @(" @(" @
M(" @,3<M07!R+3(P,C$@,# Z-3DZ,34F(WA!.U-C<FEP="!697)S:6]N.B @
M(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP
M)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[
MXH"B(#(@8FQA8VL@<G5L97,@8VAA;F=E9"!T;R!O=F5R<')I;G0N)B-X03LF
M(WA!.^* HB Q,"!B;&%C:R!T97AT(&-H87)A8W1E<G,@8VAA;F=E9"!T;R!O
M=F5R<')I;G0N)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R
M97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($%R:6%L+4)O
M;&1-5"8C>$$[(" @(" @(" @($%R:6%L+4ET86QI8TU4)B-X03L@(" @(" @
M(" @07)I86Q-5"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@
M<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0TU92R8C
M>$$[(" @(" @(" @($)L86-K)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE
M.B @(" @(" @(" @(" @(&<R,GHY,BYA:28C>$$[57-E<FYA;64Z(" @(" @
M(" @(" @("!R<C,U-S0Y-R8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @
M,C4M07!R+3(P,C$@,#DZ,#8Z,#(F(WA!.T535"!4:6UE.B @(" @(" @(" @
M(" @,C0M07!R+3(P,C$@,C,Z,S8Z,#(F(WA!.U-C<FEP="!697)S:6]N.B @
M(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP
M)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[
M*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N
M<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N
M*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@
M:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($%R:6%L+4)O;&1-5"8C
M>$$[(" @(" @(" @($%R:6%L+4ET86QI8TU4)B-X03L@(" @(" @(" @07)I
M86Q-5"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N
M="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0TU92R8C>$$[(" @
M(" @(" @($)L86-K)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @
M(" @(" @(" @(&<R,GHY,BYA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @
M("!R<C(Y,S<T."8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,C8M07!R
M+3(P,C$@,3$Z-3 Z-3$F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C8M
M07!R+3(P,C$@,#(Z,C Z-3$F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @
M(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'
M<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE
M('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M
M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X
M03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE
M(&1O8W5M96YT.B8C>$$[(" @(" @(" @($%R:6%L+4)O;&1-5"8C>$$[(" @
M(" @(" @($%R:6%L+4ET86QI8TU4)B-X03L@(" @(" @(" @07)I86Q-5"8C
M>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T
M:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0TU92R8C>$$[(" @(" @(" @
M($)L86-K)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP=&EO;CX*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS
M=$1I;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N
M<VEO;G,C(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN
M<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B/@H@(" @
M(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @(" @
M(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^5')U93PO>&UP5%!G
M.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z2&%S
M5FES:6)L94]V97)P<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P
M<FEN=#X*(" @(" @(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=$1I;3IW/C<Y,BXP,# P
M,# \+W-T1&EM.G<^"B @(" @(" @(" @(#QS=$1I;3IH/C8Q,BXP,# P,# \
M+W-T1&EM.F@^"B @(" @(" @(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$
M:6TZ=6YI=#X*(" @(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @
M(" @(#QX;7!44&<Z1F]N=',^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/D%R:6%L+4)O;&1-
M5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&;G0Z9F]N=$9A8V4^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\
M+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R
M<VEO;E-T<FEN9SY697)S:6]N(#<N,# \+W-T1FYT.G9E<G-I;VY3=')I;F<^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T
M1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&
M:6QE3F%M93YA<FEA;&)D+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IF;VYT3F%M93Y!<FEA;"U)=&%L:6--5#PO<W1&;G0Z9F]N=$YA;64^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L/"]S
M=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=$9A8V4^271A;&EC/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I
M;VX@-RXP,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F%R:6%L:2YT
M=&8\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^07)I
M86Q-5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^4F5G=6QA<CPO<W1&;G0Z9F]N
M=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y/<&5N
M(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#<N,# \+W-T1FYT.G9E<G-I;VY3
M=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L
M<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F9O;G1&:6QE3F%M93YA<FEA;"YT=&8\+W-T1FYT.F9O;G1&:6QE3F%M93X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D)A
M9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @(" @(#QX;7!44&<Z
M4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y9
M96QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y";&%C:SPO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP
M5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z4W=A=&-H1W)O=7!S
M/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'<F]U<#PO>&UP1SIG
M<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XP
M/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4W=A=&-H
M1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP
M34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @
M(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E
M;G0C(CX*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HR0C5!
M1#(R-S1#039%0C$Q0CDS03DX.3-&0T-#,#@S-SPO>&UP34TZ1&]C=6UE;G1)
M1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HR0C5!1#(R
M-S1#039%0C$Q0CDS03DX.3-&0T-#,#@S-SPO>&UP34TZ26YS=&%N8V5)1#X*
M(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.CDY
M.$,U-#@W,S$Y1D5",3%",34S13 R1#1",S0X,3)#/"]X;7!-33I/<FEG:6YA
M;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD
M969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-
M.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HR035!1#(R-S1#039%
M0C$Q0CDS03DX.3-&0T-#,#@S-SPO<W12968Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HR035!1#(R-S1#039%
M0C$Q0CDS03DX.3-&0T-#,#@S-SPO<W12968Z9&]C=6UE;G1)1#X*(" @(" @
M(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.CDY.$,U
M-#@W,S$Y1D5",3%",34S13 R1#1",S0X,3)#/"]S=%)E9CIO<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD
M969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-
M33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @
M(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.CDY.$,U-#@W,S$Y1D5",3%"
M,34S13 R1#1",S0X,3)#/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 T+3$W5#$P.C(P.C4V*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V
M=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA
M;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A
M;F-E240^>&UP+FEI9#HR0C5!1#(R-S1#039%0C$Q0CDS03DX.3-&0T-#,#@S
M-SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.G=H96X^,C R,2TP-"TR-E0Q,3HU,#HU-BLP-3HS,#PO<W1%=G0Z=VAE;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@
M26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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MP#W5LA\2VHCOY@OS9_E)?4V0X#(:"T2Z)R'<5FML!@<0^T .O:9$ $?L$4S
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M_'>0QB"*8E.)3& !X$0&G==G=VO(]1^W12"1HO)UXD7Y-U#/I9;J<\-BP/-
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M]QL; V*FCG/KKDPB81,(F$3")A%]%$DEB@15--4@*)*@50A3E!5!4BR*@%,
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MQ[?_ !99V4N*?4*U0*M7Z3389C7JK5HEE"0$)&H@@RC8R/1*@V;(D#DQNTA
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M5FKES@8FU5"?A;36)YDC)0=BKLHRFH.8CW!>Y!]%RL:NY8OVBQ?5)PU752.
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MZO'-F3ITX0*!%&Z1$DDQ%D!_+,43<\!V\"//QQ7ODSW7N!!O>Y]F8&8N=25
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MUW#*6>I%*!5P(B8 $G(G[R&+Z@/(\_'.;>P,>0+$7(:>E\A?T9'2W>JB;Z7
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MIUO745&"A'*-'Y%9-PB0R8D62; (^2N"?F <P<&*8>WXCQEJG86'> R+2.
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M/EIEY\K<=58%"5V8KM)F&%+90C=[%ME0II$S LT<-3H"1JY<F3$4O:UQ,)E
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M.*0QQ;V;6GC8[N7*UP>-^29<=;Z'A;/SZ]UE<R@M"L6PMFT_ P3$" 1DW@&
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M6>NH=!6MUJ,;,(@L;+A4RP35*8@X1%U&''\S9E["LG<O&PY)!N_FJ]%/3H,
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MW4H_J/?;:;:5CY"Q:^GHU]3WM!E@J1&KZO.Z:BYAB5EW5E:0X0*C.\.9X_\
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MHBV#T0=.:E1V??I:Q7.]RK>Y3=$1DR/Z+JUZNT%-2OU3@% 7EG15"*W.8:.
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M&_A?E8^FUNI4>_K]^>G"RQF1;/GQ3(Q\<O(N"EY(5JBHX%50/@0Q42"< 'U
M1+R8/3U]>,O#$>O/+.^FNH%QX<="%'G]&?7W\R[:G]..\MG/4O8:*O%LG!P(
MF]?IN6+%JF42]SE51Z!%1 HF#DA2B4P"/'PS$JL8$,8.\ =X--C<YWY'+3PY
M64V(_;[^_%3CU]6:WT65>:FK+*-+SL^?3!C"0%9 5P(Y==J2#$@AR("JX\LJ
MX@(B*/F<?$,U\DSZX7:XM:#O.<?X5M  +Y:FYT(T"K&Z!?4GT7OKF->.E\^%
MUBF[WDWTN]#UM0GWCA]M/<$C,V"30;$.X62D;M(@]<M4P*'>4L7'KIM3"//
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M8@(622F'-!DE)*G2X+V2-6CVT_$HM))--\BD]3?-DVKFK?)-BPMN-^UP00"
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M+4QH5KMK1>A[;2-Q6"7.RKK2+E]@VL7R@6"$DEX=6=MK0S,[N2L(,9) J2B
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M/@(_H'D,ALL<+B6@$YBS1[C+DBUJ/2S .W!W+^>?'564\TY42@0O=SSP!A*
M@ <_Z<N#$'"]FGIF,K>!M?CKT19JPZ>*4R(!3'>+F$G88Q_+[C!Z!ZFX$W \
M!SZ^OVY;EKII&[MRT7!R(.GA[E%I#JROFG>B/IDW'U*WQ=PG5-04>7L2<09X
MDT/8[ J0L?4Z?'K'3,"<I<;4]AJS%F-_%DD)5NHL)42*&#%,KSJXY];:Z>_F
M4 .) !%R;#+VD^HKSV_DNW35=;Z\ZI_%1W@@H_V)U+7:UTJ@3#QN=([Z'7M@
MW#<EKC 5%4H1%@V E#5.*\A0AHU37U@C0 S59,,H5^4@68-&@>>WLX\RO7YA
M64PB81,(F$3")A$PB81,(F$3"+^?EXTEH):O$HZCUD% 4:PCO7E7;\#R"9Z_
MJNDL)%/D/M),$DN0^P1$!]0'/I[X/X>QV2PD$6=(VJF/7M:VH<P_[LL]:^'O
MA;J!4_"!M YINV)]!3MZ&##*..0>$PD76>#=6SVCQ)NF-F5/O3C9ZZV1<PE$
M2I$K.L;K.I*'$ $"\NV#9(AAX#SE4PYY$,KV]F['9+&'7L7Q4\(YGMJRGB('
M/R7$GH#P5OX*:<U/P@;.LM<1SU=03P IL.K)P3_XHV@=2%_0@SY>7W*F$3")
MA$PB814U^-EHS^Z+TPQ6UHQGY]@T;:$)-TJF3O7&D7)1G7K&B0I0\PP(3):G
M++'Y$C9C&OUCE G>H3KMCJWXOB3Z5SK,K8BT"^7;0WDC)X9L[5HTNYS0#?(\
MCMC1?&,-;5-;>2BE#B;9]C,1'(.>3^R<> #25"ZH^!8]NNI==W)+?#BH7FS4
MFNV2Q52=U^26BXJ7G(MO*.(5*396>+>M_HHSHK!PLK'/S*N&ZRI"$(<A";>7
M;40U51$:$2P1S21QRLGW'N8QQ:'EKHW []MX .;8$#,A:B+8LS4E/,*TPSR0
MQR2120![&O>P.W YLC7-W+[I):^Y!('!:@L_@5]5<6=0]:OND[2U*(^60\];
MH*24 !]!,U>TQ>/3Y#CD/I@_ ^GJ'ULRX]M<,=_A(*R(_P!'$]OG$P=_Z%B2
M;%8FV_9ST<HX7?*QQ\#"6C_;6G)+P<.NYB<Q6VO:E,  B *1VR::D0W'P$H2
M\I%' !^SN(4?7U /7C+;M;@AUJ)6?SJ>8V_V6N]%UB.V2QMM[01/_FU$(OW;
M[F^FRZ=/P@^OLY^TVG(I$O\ RBFT-6B0/]"-P54_U$'*SM7@?XVX]!35/TQ
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M3")A$PB81,(F$3")A$PB81,(F$6C^I/IXU;U8:,V7T\;G@26+6^TZR[K=@9
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M\;R"*R;Q&1;+)%4;K-G#<YT#-UD5"*I*)G.FX3,55)0Q! 1]$I*YA#2T[S2
M018@@YAVEL[Y$$@BW"ZL=.^X/JS_ &:<E'16JO693I?6,H*H'*)2<"CY9^\0
M .! >0*(<CR(<AFV?4B6+<N- XWUY7.G#B/1FH\_H_;[5-O6GMDS!-'9'3@Z
M"R2;<S3_ !$#MP\L> XY 3\"(^OZ?7.1KP!(?&W'6QUMW&]N%N*E;L)5)%RB
MB5HHX;+E Q&[A,/K("H0Q#& 1 Q1^H8Q1[@'X_IRW3U;*0]J_P"2X;AUROIE
M>_#2_>"BX=>ILC!2J"AUG2ZS7O("X@/<H  <W')0X-_C?$H_'] 9F/KH967
MS-SKGEH/#2UN%B-"BM \._4\(S8['V(I$I+6F<LTDD1ZY1(=RU:H(I*BBF<Q
M1%,%5C";TX$1'X_#CCL9K'OW8FDAF\"[.W<,K9#/097(.62FPM?B3Z.OOI9<
M^QW:]VC?%)9F]IBXJNV,Z"[! 5$BJ%$5$P64*';W@<HCR)A,  /IZ!F$87/@
M+];MSMS[^'$GU7"99\];^L<;]/2K<ZQ%-B+&66;-U50(!DECID.JF4X%, $.
M)1.7[?7GN#GX^F<D]SOC+VF]MWU'('+4#AP]"IUYZ]>'T>OSK/   ^'_ /./
M3*U*^<(F$7T/SVCP(@/_ )/'</\ , C\/T\_8 >OISA/?W_:J*O&&\;/4/AM
M4UWKFCJ0NU^L:V1)/S(U*V<"_BZ(632XC+QMI2-7(ZCHE/S$GL%3T5FUDNRO
MLZ+,8J#7=V6/*N.,ON=&WS)MEEH/IU S[E ;P6_!^VY8ML./%4\3LTQ=NJ'8
M<N%_U5KJ_H$5E:(^?IIGC=F7^&513:1%S9,"M&NM-?(,VC#4\.VCW!HZ/LS2
M%BZ05;WBVXS)O$CCIX]YX]VOK1PK*81,(F$3")A$PB81,(F$3")A$PB\YWY1
MAU!IT_IZUCTZQ3T"36Y;F-LLK9)3DP476_D.4&[Q(H@*:<K=)2OO6"AP$JIZ
MM(%(43(F,3U;X*L+,^*5F*O;>.@I^PA<?QFKN"6GB64[)6N T$S;ZY^"_#SC
M@I,"P[ 8GVFQ:K^-5#0?_P"BP_=<&O%\A+62P/C)N"::2V;;CQL9[TOE%?T6
M/"XT4IT\="73W17[,65CE:<GL6W)*)^4\)8]E.5[FX8R!> _W;!,9B/K2H<?
M5)"II]Q^SO-\K;98D,4VDQ2I8[>B94&D@(-VF*D:*<.;_HRNC=,/Z0K[P^#C
M!C@6QF!43V;E1+2"OJ@19XGQ!SJMS'C+RX62QTYY"(#.UU8!G,+N$PB81,(F
M$3"+C.WK-@F"SYVV9(F.5(JKM=)NF90X")$P46.0HG,!3"4@#W& !X >!PBU
M1MQO 6FDJ-75\:U.,C)2"OLC8(]6->OVL1JVT1=UD74<B[2D6*I6;ZNMT)([
MR+EV*3<735['.?-\D9&NE]1;O%E!S&MNO<?V+!/=_P!5A$R;)O:)]C],3LR6
MSRA)V$++34A>*Q$5BV0<JN]AU@CW=P1;)2KX(MO#V-C.S$F[K;^#3DSM!7/+
M33I:Y]'FMJHW1SYC49DBQX:FWGNL;E>G/1#*9*O/3;H[VT-+8V[9 U155=(R
MY]@SLX\":+50F8EFWB+?<(LQDIF/A%FBP+R"#ZTJ#+NESPZ<^%@,M.')-T<>
MOFS)SUXD$_38K+%.GK6;QQ7UT+'/I.:HPIQDUFDQ *.EV-3<RTM%R#QRM"N'
M4<]DWEBLCV2LT$K"3KM&SV)DUEVL1-R#%PN<],[^G]W&Z;HYG0#AH/"_._>N
M1(:\U+;KK<)-S:W<A+2D2G*3T2G+Q8Q+> FV&O6SI1L?Z-%0T7*P^L89M(!]
M)NDVL;/3YR"P+:$5A7(RT]!RO[?0GDDDW[]-,O1[3Q75RO3UJF>B"5\]KG4X
M9?7\?!.8YE/5TR<K&0L!8X*/N;]9>%=.WDBT:7:4D%' N/S6=R[MK,R,&[>@
M18Z_0:W]^6G?U3=%K7R MPX7URX'POP6$3?396)6R O);0.I0K$PE)*V1#QS
M"C.7U[9%-I(IOI*:!)%DE'-9/=$BXK_T%'1L<R4:0$:E&N5&T:^9SO=!Z>%O
M8HW0>.N?"YUSTZ^;+.^4I*^SJU092S%E+-BIJ6*>L4LK(2;,[A"3N=FE)95)
MTKRCY* 23U>(AD%R@=)DQ:QI%%U&@F&GW\RJR''KGU*RE%XS<+.FS=TV7<,3
MII/4$5TE5F:BJ15DDW21#F.W.HB<BJ9%2D,=(Q5"@)# (E*Y.$3")A%67XK?
M][?6?ZX*U_9.]Y=A^6.XJA^@[_H*\\>9:M)A%(OI%_OG-%_UDUG_ .>)E$GR
M'=RENH[QZUZQ<PE?3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB@1X@WAP]-7B2:>5U7OVM&++Q!7SO6VU*\FU:;#U=/O$B$/)5J6616(XBWQ
MD&Q;#591-U7["@V;"\:$DF$1)QI5-<6&X\1P(7AFV_I/KV\"N^HU'>M1>=17
M11+S1F%.V?6RO@K";9XNH=NA%R:X/U]774Z9CN76MK>HK 3#U*3-49601%W:
MLW&&8S58>YK"YTM.#G$7?)!.9C)ON\]P^23>VZ3O*]9DHR\E^IZ^T=V8X]9]
MZ%MNA.KN'<VK1=XCY\Z:95YBF/3I15\J@K]I3$L=9<*&>I)%6-[,C+LP>03Q
M8BA8V4?$**F>B4>.TM5#>"3R[#?8[R9 .(<TYVS !:2TZ E67-<TYCI?AE?,
M&V=_5Z9QZ<T<Z@?-BU6R@E45,ND53ZR8CW ';P  /KW?I^(<?IS#JZL/<2YV
M>NOTCEEI;F>(5)]^/O[YJ8M8TX\6,8KQJ1,.0(5,B7(=H_;Z\\#SQZ9K&U#9
MW%DUI(QY0:[Y(<"+$6SR%P,\KZ!2/'I;UK+?[A92N0%)J82]Y1X!,/3DQ2B/
M(\\^@B''(_'**BJ$32(G!@&5@0>_AEUOUSXI?6U_/Z_0IB]-E(&C(RC'R%44
MG\HX<J#Z]AU3@D!CB'J "8"E >. X#X"/KG/5,SI+DF]LQIR.O'/U<LE"V7<
M=.LC7)K;&;1$%3K)JKF*D &,</4JAN/\8/4.0X 0'D>?3BU'73F,,$S@T9;I
MM8=Q(OZ44DX5,002.(?RD@ 3?I[0 H<_]N:Z4-[0D#/0GUJ.7#Z=?WKO<H4I
MA%A]]OU(U=49N_;(N-8U_1ZPS4D[)<+E.1E;K,%'(A_&/)>;F'3..CVP&$I/
M.<.4RBH<A"]QSE*),SIKYUY(NN?\HDV+O^]CT:>#'KFV;EV]<5W-?-OQO4G+
MTK,.1;OWNHZ;,M2$%K'E4\Z0VILIM%5.O-4'<@E!/HX[*U,RO-BL-Z0[HY7%
M^'?XV4I?"8\ 2&Z;+>WZP^O.P-NHSK2GI0;HU;STDZNE1U3:9!7V]>P.)B;,
MX<;(VRB[4%=>[28*1->DP%6I(.Y!BSN+HH?)O#=:-UOI/L[LUZ:,*TF$3")A
M$PB81,(F$3")A$PB81,(M+5#J%U%==G7_2L3<(]MMW6;I%.VZXF3?1%M;QKU
MBSE8JS1<6]%,]@JDM$R,<_:V&"-(QK<'J3"36CYA-S&M]A/A==3T=-B#Z=YH
M:QI,%7']\@+VN<Q\+WMN(IV/8]KHI=QYW2Y@=&6O.HI<=PNLQ&NPB*J8W%,/
M<!58?+]ZJFQO8R6.HBC?8STLL4D;V3PF2,;X9(62AT;?!=XK?5*GU8]:FS[I
M"R(2.OZ0NGJC6:R2OG-'%3I+IZW7F62@#V*-+39W5AM#)4"$/]'S#-%4!,AS
MGTKL5@QP39^CIY&;E54@UM8"+.$]0UI$;A:X=#"V*%PS\N-Q!L5\5_"7M(-I
M]KL1K(9.TH:,C#,.(-VNI:-SVF5A!L65-2^HJ6&P.Y,QIS:M9>'KTWK]5O6!
MI33RK([RL/[4VLFP1[!%!'7E/_\ ZBMJ;A4 $K?Z6C6!J\R64 2?2LS'I=IS
M*E(;+VHQ88+@6(5X=NS,A,5+GF:J?[U 0./9O>)7 9[D;C<6NM?L-@#MIMJ<
M(PHL+Z>2I;45V1+104O_ $BJ#CHWM8V&!A.7:RQMS) /](4A")D*FF4I"$*4
MA"$*!2$(4 *4I2E  *4H  %*       <!GR?KJOOL  6 L!D - .2^V$3")A
M$PB81,(M0[>T]![DBFL'9'/;%-65I0(T,P:/B _M%:D:<K+I>U]Q47T=6YZS
M,6"A""9)6:,[ P':)D4D&WH]=_6 H(OK[^^:U YZ1*VX=2R9+$+:$F9VT3SI
MBWK<:E)HDM2VQFKVKQTT1P7Z.I*,!M"SL4(%K')N2RRQ9D)8&SB0A7J_&V?/
MZ>^_$GP4;O7S>:PY"V5N[/)?G6^D2"K:[-T2SC,JI*'82)+/ FMK*7KZGF^<
MNZC+7.3D:2^.PD+&5Y;T6I8=1.X6E-M2FB<DD5I.]X>]N%C;3(WT&93=Z^CS
M:W XZ :G(+BH](J?L<05_L)S)R4+7H*I-5UZX#:/7KE:7UX[AF;IO'6!G-%>
MMI*CR-B-,1UDCI UFN4Z^250BNR#4;VN6M_.;Y\CKRTL%&YUY ]0+9=-!GWK
M.*KTUUVI:KE=;L)8SIY--:<VEK1(Q#5PXG$:+!5&MPL;8F!'")IBOO82F1T5
M884\BV++QS^<;D=,E9-1R2+YW[_"]].Z^7)3NY$7.?$Z\.5LLA?FL<>])T$[
M++.R3[)O-S3Y25D7C6FQ$7'N'SA+7#=ZW"/K[J$>-(9XWI5C3491LPQD$E]C
M666;3"-@(A,'G>TZ:9Y\?#T<!E;)"V_CGIQM;V^?6^:P.)Z*4@BYF&G;FDX:
M!88R>KSQI%.R3SAQ%P-7AU4+;8VLO%3LE59]Q%VE_,T>,D8P@+W>=61M!W7T
M8O%MX^_??*^G#GH/&-P9Y]V7O]&N=\EF:G2#5BQ"K%M.E-)/%9%![-3%>:V)
MR6'GJ:_J\TQCBR[]PLW=I24_;[56GLF[F6L'*VN6;O8N=9*G25B_/AI;+U?1
M8Y#,)N#GWD@&]_2.8^E<.Q]&=1GR@);)(LU%7K]]('(U<IB_<S\EMM]9'SA6
M*FH=Z[DGJ6V'+:,6E7DI'1Y:Y#D?Q4VP4>QRTAQ'A^SGW>NULK-SKW]=<^_/
M(Y];K=&LM0,];3U[G&TL$B-T>M5RM@C?9!CF[23L<F0JCM9_(KNG;A2QJD?"
MR&'A'"[/Z;)7T+--VR<L,$WMT]_?S7L !4!8DY9]+>_#S7UNMQY"E,(F$59?
MBM_WM]9_K@K7]D[WEV'Y8[BJ'Z#O^@KSQYEJTF$4B^D7^^<T7_636?\ YXF4
M2?(=W*6ZCO'K7K%S"5],(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A%CEOIU2V#6)RDWRKUZZTVSQSB'LE3M<-'6&MS\2[+V.HV9A)9N[C9-
M@X)]59H\;+(*!QW$'@,)IHO*7UM?DOE*DK8XWQX9>X)7I4VY'NEYJ.UM,3UF
M+K<90_>H?\Q[W"G>W_6)G!SJ]S)5*ZP @JG'1S*LQ*?82IKG,<',<YK@;AS2
M00>A&85YLIM9XWAUU_;Z^JK>1\0/Q5?"\F&M/\2GHXF-F4%BZ2C&.[(EFTA%
M7B)E ;MU8_;%)96#3]Q< W!%PA!2;*OV]P90OYP2C9VX,*6:,1J+6D=OCF;!
MUNI L>>8N3>YS4]FQ]]QUB?X)X?2!W=.BN0Z8_'7\+/>J4:TE=TNM!VEZFV(
MXK6_:Z[IJ*#@ [%5C7J+-8=:-FP*"  +RY-ECI"5<[9$"JE3?'7-\IM[Z6M;
M+F+$YCA;._G5#HY&WLTNZCC]/33T9J[36LYI?<,8E.ZGV?K7:L,HD1=.8UG=
MJS>(LR1NT2*FDJW*R3;@PB':/?VFY]!$/C0:M[_E$B_4Z9<A>^MN[-627BWD
M\P<^(X=+<?:M^0U1:QW\@AR<B)Q[OAY@\<F]1$>?3^C^G++Y2=#?SV]I\?I0
M$GA;3KEE?A;33]BS S9)1/RUB@L'' ]X?$/] ^G'V>O(?8.6@2,PIMX::</?
MS=-;\1\_B:_'.)"4?L(>*8IF6=/Y-XW8,&B)?4RCAXZ42002+_C'54*4/B(Y
M!-\REA>_&W?X]3Z57+O[QAO#.Z:TGO\ =.ZR=,J2L?W@O5-=V+^Z[<".2 8"
ML7-:U6A<):.<K'X(4)EM&MT^XJKAP@W RP%6&.=HTGKH/.<E0WO+\J=E]H60
M=0>&+T9[-WQLN7,LU@;%L6OR\@*ZY/XKVR%TOJQU.6VQ1YC*$73=2ESIZS4I
M2B_B>U0Z:17!"1F]P:._T< /"_GS6GZIX-'BZ^*];83:?BU=2T[IG5"#Y*8A
MM&P3R"DK,P:*AW$0K6LJFH74>LGB\<L#(;39#VG8"(I@WM%<?N$U#X4E[&91
M@$Z;Q]/4WZ6'ADO5!T7>'UTF] %"_,+IDU1#4SVYNW3M5W?!].;*OCAOP8KN
MYWA^0TQ+%!<57+2'159UJ'5<+D@(2*;*"AA6G.<XW<;\N0[@IHX5*81,(F$3
M")A$PB81,(F$3")A$PB81>8K\H9Z:)=I%ZMZV]<'D8:PTQ1+5&S9> <NHV20
M@)I5ZM1+&=ZP4;+-B,)9_-U*1>"J9P\+:*Y'<@U:]F>P?!;B\9?6[/5>[)%4
M7K:-DH#V&6,-%3#NN!!+HV1SL;8-;V,S_E.S^=_ATV>E9'ANV&']I#/2$89B
M,L#G1R-@F+S15!?&6EH9*^:DD>3O/^,T\?R6V7D<SW!?+Z]?OY.ATNLZUJW9
M/5G.),U[!LJ3<ZPHHD417<Q-)JCYN[M;DXIF,=JI9[:DR:JLW $<$;TUD\(7
MV:32.IX7\*N,NFK:3!(RX14C!65.1 DJ)VEL(SR<(8"XAPN+U#FG-AM]2_ -
MLXRGP[$-IY@TSXA([#:,W:714=,]KZEV1)::BJ#&ECK.#:1CP-V0$^EO/(U]
M!IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*L'K!E.M_3PR>P]2;*6M
M>KR>:\DX?\PJ ^LM%0]3JF<@6J&6FJVW+R8LN0IGT:W 0FDSHMU)AQ=C$;LG
M9'G>P/[5;=O#.]QW#V*GO;?5GOG>=9:T_9US0L-?93+6P-F*58JD,9.69LY!
M@W<BZA(6.=G!-K)O4Q0.N9N<5@.=(RB:1B9#8VM-Q>_>J"XG4^I1QRM0F$62
MTZW3]!M,#=*J]+'6.LR;68A7YVK1Z5I(,U 5;+F:/T'+-P"9P WE.6ZR)_@=
M,P>F00' @Z%-%8-J;JYZ_=VW!E2==W,DU,.N%72WYA:]1BX:/ Y2+RTY(FJ@
MH1L:W[@[UE1%1=4R;1DBZ?+MVRMET<;1<W'+/55ASSD#Z KXM7U^^5NHL&&R
M[\IL:XG#VB8GBP4%7(Y-PH0@&CX:,@HR-*6-:B42I.)'VJ0=*&5<*J-TE$6#
M3'-KY"PX<?.K@O;,W*V'D*4PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$7"D8V.F&#R*EV#*4BY%LLSD(V1:H/F#YHX(*2[5XS<IJMW39=,
MQDUD%TSI*D,)#E,41#"*HOJ+\!KPK^I9=_*VCI7J>O+2_%50UKT8\D]./TW*
MXB9=ZI 4MS'T23>K*"*JSJ<J,JJJL)E3F,H=0QRK$CVZ./CGZU4)L3\D-T!]
M)C+]/G6=O?4SY%4R\<K>*E4=F.(]4>1*5O(5)]IA\0A!$"$4\PS@I  3JK'Y
M,8J^V=Q#3X?MMZ%@0?DYWBE44/9=2>,=L-A'HAVM2!;>HG78%(4."!['6=F6
M5!    #M364 H>@"/&%/:L.L8OX'Z.:^?X 3QGYSEK:_&<V(O'G^HH3^[;U6
M6'E,>>X!9R5IC4#\@/\ (,N!1Y$!,'Q$H[1G&)OH_P#Q"^[+\DUNVP7[63ZE
M?$QV/LGL6*JY8,M92\H_]?\ ?#-;5?MP6;RUC (E*JI5S]OQ,4X#VX3MK?)8
MUOM\ %87HK\EX\+/42[60NM6VWU$2C<4EBFV]LIVRAB.TQ PJ)P&JH[6S)TU
M$P<!'SIIQL9/ZCD'/J82I,KSE>W<+>G7Z5>1ICIZT/TYUK\S]":<UGINL&\D
MR\-K6DUZFLWRR!!33=R98*/9'E7XE$PJ2$D=T]7.=159PHHH<YBH))S)OQ6X
ML*$PB815X7#K5OEYV%;-1]%>C3=0]BU]+K5O9FUK-<&^M^GS75H;@'ME56NQ
MHR=EK_<(<QDBV"KT:%>J0OM*)7THBY([:MNI@V>IJ:E@KMH,1^Q454P34=%%
M3FKQ2KA-]V84^_$RF@DL>RFJ9&B2QW6%I:X\)5;7UM;75.%[(X,<>GH974^(
M8G45;</P*@J6_+IC6&*:6NJH3NB>FHHGF'?:'RAP>UO%^F?%I'U#7_A[D ?7
ML-M#J(,8G/KVF,75P%,8OP$Q0 HB B <95V>Q'XUM3^9X5]=5';?"?\ B.PH
MZ'$<>)'?_P#RY/ICQ:?\@?#V^\_J)_==CL]B/QG:G\SPKZZG:_"A^(["_../
M?JY/ICQ:?\@?#V^\_J)_==CL]B/QG:G\SPKZZG:_"A^(["_../?JY/ICQ:?\
M@?#V^\_J)_==CL]B/QG:G\SPKZZG:_"A^(["_../?JY/ICQ:?\@?#V^\_J)_
M==CL]B/QG:G\SPKZZG:_"A^(["_../?JY/ICQ:?\@?#V^\_J)_==CL]B/QG:
MG\SPKZZG:_"A^(["_../?JY/ICQ:?\@?#V^\_J)_==CL]B/QG:G\SPKZZG:_
M"A^(["_../?JY/ICQ:?\@?#V^\_J)_==CL]B/QG:G\SPKZZG:_"A^(["_../
M?JY/ICQ:?\@?#V^\_J)_==CL]B/QG:G\SPKZZG:_"A^(["_../?JY/ICQ:?\
M@?#V^\_J)_==CL]B/QG:G\SPKZZG:_"A^(["_../?JY/ICQ:?\@?#V^\_J)_
M==CL]B/QG:G\SPKZZG:_"A^(["_../?JY=6MUI;QZ?Y2);==73[#:RUY,2;&
M$1ZE-*7AWL[2D#,2;A-I'I;)C9> K5\UC"NGBK=BA:YF+DJ\+YZV0>.X](KA
MRC6-G\.Q-DCMG,4DJZJ-CI#A&(TS:/$98V N>:1\<LU-62!H<XP1O9*&-<6M
M>; T':[&,#DB;MG@46'4$LC(1M#A%8[$<(AED=NQC$(Y8*>MPZ%SRU@J9HY(
M-][6O?&+N$S-YZBIW4?I'8NG+8*+VH[4I4G75WS8$7@-0E6GF0UBC# 84%7L
M))%CY^'7 XI@^8M%RF$I0$=!AM=/A.(TE?!=L]%4,E#3=N]N.M)$_B&R,WHI
M!KNN<-5UF-872X_@^(834V?2XE1RP%[;/W.T9>&HCU:7PR=G/$[,;[&.S"\Q
MM>_)G[HX$@VOJXK$2'H*A*]J"5L(_P Y2*26P*Q_H,9+T_\ $'/7Y?A=IQ_@
M,#F?R,M>R+T,I9N/"_BOG>#_ .GNK=;XSM131<Q!A4L_F,E=3>>W@58ST<>#
MK9.BZXIV_6O6YMQ CE=NI9Z?&TBL1M"NB*'!?9K+59J6MK%T84>]NVE6XMK!
M%I*JC$3#!50R@\IC^WD6T%.:>KV>H38$0SOJ)GU-.3_"AGC9 YHO8NC-XGD#
MM&.&2[W93X*:C9*K%7A^V&*#><TU%+'1T\=%5M;;R:BFFEJF/-KM;*W=GB#C
MV4L9))NZ#GCU^/V\!P'/]'(\?T<C_3GGB]@3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$7P( 8!*8 $H@(" @ @("' @(#Z" AZ" ^@AA%4/UA>'*PM
M/TILOI^CFD39!\Y]/ZW0\IG$3Q_559Y4^X4VT/+G'N,K"F%&)D!'N8FC79!0
MD;\<I&3LQP/$?L]^:MN9J1YO9[/W*C21CI"(?O(J68NXR3CG*[*0CI!LLS?,
M7C90R3AJ[:N")KMW""I#)K(K)D43.4Q#E P"&9(((N,P5;7#PBE=TP](VQ>I
M>=#Z(2/7:#&NB(V.^2#50\>U$O:=6-A4!,D,Y.F2,4P,D%4V[,JB2TF[9)K-
MO:+;Y SJ2,A[>BEK2[Z5Z0]*Z,UUH*H-Z=KN%(P;?Q2LM+N>QQ/6.0(02&DI
MV2!-,[MP;N/Y*!"(L6":AF\<T:-^$@Q7.+C<FZO  :+;^4J4PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB\NGBY>+;U(]-'50YT/
MTVVRLUR)IE#JJ]Y<25/KUIDC7FS)O+'Y**\ZT?H-6K6HR534(V*WY]J<NSJB
M8#)E)['L/L/A.+X*W$L6@FE?45,PI@R>6!GQ:$MBN1&YI<73LG!=?0 "UB5\
MY?"A\)^T&S^TKL%V?JJ>GBI**E-8Z2D@J9#65 ?46#IFO:UC:66E(;NWWG/)
M)! %5E;\8+Q.-I76IT9OU5PE/5N=G@ZNVF9>@Z3J=6@EI^3:Q24K8;"&MU7$
M1 QQW17<K)**+ R8I+N3$4\KM'M)=A-CZ.GGJ3@LDXIX99C&RIQ&>:01,+RR
M*+XV!)*X-W8V #><0+B]UYK!\*?PB8C5TM&W:6*E-7404S99:+!Z6FA=/*V,
M2U$XP\NBAC+@^60D[D8<ZQM8^TSI?U#L_4>NVK#<^^[AU#;-ER-GUHN=@2C(
MFOMG0)"(1-(K$*Q8,8F!;&5/VNWA7DU+JB+M\[0; QB8SY^QBNHZZJ+L/PR#
M"J..[8:>(ODE<+_+J9I'.<^5UAY+=V.,>2UI=O2/^M]G,*Q'"Z!K,6QNKQW$
M90U]35SB..!KK914=/$QC(H&W/EO#YI3=[WANY%%)+-2N@3")A$PB810X\0;
M;-ET?T6]1>RZ8Z486^$UV^C:O)H'%-Q#V&W/F%,AYMJH'\AU"R%@;RK4Q@,0
M'#-,3E.3N*.^V7H8<1V@PJCJ&AT$E6UTS"+MDB@:Z=\;AQ;(V(L<.3BN3VZQ
M.HP?9''L0I'%E5#0/CII&Y.BGJGLI(IFG@Z%\[9&G0.8+@C);AZ>M)5#IRTM
MKK2U'8H,X*A5J/AS+I)@1>:F 2!>PV:2. =SF8LTXM(3LLZ4$3N'[]=0>THE
M*7!Q3$9\5Q"KQ"H<725,SY+$W$<=[10L&@CAB#(F-&0:T!;; L'I< PB@PBC
M8UL%%3LBW@ '32VWIZB0@#>EJ)C)-*XYND>X]%N;->MLF$3")A$PB81,(F$3
M")A$PBZ"U5:NWBLV"F6^&C[%5;5#2-?L4#*MR.HV8A9=HJQDHY\W4 2JMG;1
M=5!4@\")3B)1*8 $+L,TM/-%402.BFAD9+%*P[KXY&.#F/:1H6N (5BIIJ>M
MIYZ2JA944U3%)!402M#HY896EDD;VG5KVD@]^6:@AX9TI,L]!W33<S*O9\.E
MOJ&WATRP,])KF<R,I2]6V]5&BB\6, =RD73I6$@4@  [&T2@0W<<ISFZ3:]D
M;L3IZ^.-L7V9PO#L8EB8+,945L =4[HSR?.R24\W/)T7%_!Y+*W!*S"997S_
M &MX[C&SL,\AWI)*3#:HMHM\\XZ26&$9"S8FC4$FP[.67=IA$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(H/=671)1>HY@XL,3['3MLM6W;'
MVM%N)6,\""8%;Q=P;-R"H];]A2-VTPB0\M%I@EV>WLD BU;C)"S+5M\Q[.2I
M<T'/0^^JKKZ;O#.O-DMCV1W\T6J-,K4NLR& 9/D59F[KLE  18OV2BJ<=5W
M@ FER*!(OT>Y&,2:BI]*-;KY@!Y.9/'@/#GPLJ PG7(>_O=7LUJLU^FP496*
MK#1]?K\*U(RBXB*;)M&+)LGR($112*4O<<YC*K*F[E5USJ+KJ*+**'-CDDFY
MS)5T"V07>9")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A%Q7SYG&,GDE(.46;"/:N'SYXX.5)NU9M$3KN7*ZAA J:*"*9U53F$"D
M(0QA'@,J:USW-8T%SG.#6M N7.<;  #,DD@ <2J7O9&Q\DC@QD;7/>]QLUK&
M@N<YQX!H!)/ !?SO-_ZBZHNK"1ZE/$&B]1W.3T;+[2L\^ZNZC5))NQK3V;=M
M88(N.=+I3<[7Z;"MXN$G9V&CY")KP- ),OF@MW1D/J7"Z[!\$9A&R[ZZG9B4
M=%#$*<.)+IFQM=)ON:#'%+42.?+%%(]CY=[[VUUVW^$L;PO:/::3:#;F+"ZR
M3!IL2J9W5A: V.G?,]L79L<X2S04D38X9IH6210;EI7LW7;M>F=2N&7I4\)?
MQFE-4(UKIEZM[ X=ZR1!K":RW%**JNGFND0[6["J7EP;S'#VB)!V-X:PG%5W
M3$P382/M%4*@XJWDFV^P K3-B^!Q!M8=Z2KH& !M4=734PR#:DYF2(>34'RF
M6FN)OH'X,?A9.&"GV>VHG<[#AN0X=BLA+GX>T6:REK'9N?1#)L,^;Z069)O4
MNZZE]?+!^QE6+*4BWK22C))HW?QTBP<HO&+]B\1(X:/63MN=1NZ:.D%$UV[A
M!11%=$Y%4CF(8IA\,<US'.8]KF/8XM>QP+7-<TD.:YI +7-((((!!!!%U]2L
M>R5C)(WMDCD:U\<C'!['L> YCV.:2US7-(<US20X$$$@KEY2JDPB81,(JY?%
ML_P>/4A_YGHG_P!UJ)G5[#_A5A']+4?\'4+@OA/_  %Q_P#HJ+^\Z)6-9RB[
MU,(F$3")A$PB81,(F$3")A$PB815R^'/_P &ZXO^D:ZJO_JM8SJ]J_E;._V4
MP3]',N V ^3MG_;_ &F_24RL:SE%WZ81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81?155)!-1991-%%(AE%553E3333( F.=0YQ I"%* B8QA I0 1
M$0 ,::J0"XAK07.<0&M )))-@ !F23D ,R5&N]]4FOJFHLQA!6N<JD)B&)$J
MD1B4U Y#L4F%"*I*^H '='MWY/40$Y3 (!@38A!%=K+ROTLP^3?J_,?[(<N[
MP?X/<;Q(-FJPW"J9UCO532ZI<T\64@+7MMRJ'P'B 0M)([GZA-EKK)4N*CJZ
MR XH&5;M68*)?:8%'U@.N*RQ0'@QF#-(Y/003*8!-E ^RU0W?BIS#&='N:&"
MW/>F/E7T!8WTKH3@GP>X(=S$L2=B=2WY43)Y) 'MU;V6' =D<LV5$YX@FQ 7
M4W*F=0\56I2RS>Q9AW[!'OY \+#6*P"X5!BW%P= 4&J#)@DHH(>20>3I@IR'
M=VASE4>'8A.ZSZL,O;1\EL],@&-/ ZZ$%6SM9L-2^31[+B;=R#YJ&@!-M"))
M9*B6QYN /1:14D]H1K)E+O;G8XEJ^AAFFIG-LE4'JJ8% PMTFR;L3"N'/P.J
MF//^+\>-G%LO7S7[+$03>QOVPSM?^.2<CK:US93]O6S+CNR;*0;IX=AA[R1>
MV;3 !SROPZK7;3K4LE5>&;?W2;,JJV-PNA)MALW8D4>!.HFZ1F%#D$/B#?S'
M)0'D"E'U"_\ :EM0T;T!BJ+ D-%0S>(__N QN8S!+^XW4_9KX-\2\FKP9^'D
MV!>RD-.QI_C X7.YU@><6?%I!(4E-5>(/$6HPMG2M6N16PB5Z>KR)(ZPLBD,
M!5%9"!>**G!0!$"@FHC$)CR40-]IM34_93#'AF*8=/3W-@]T;F-=SW'G>BE/
M\QX"/V%P#&&.FV:QUCG@;WQ>:1E2UN637A@BJJ9I-O*EBF=KY)N+3OHFVJ)L
M9(/S:FDCORD\Q:%? #&90  Y.)F2IA%PFF AYCABH[:E$0**_=Z9=AJ89_\
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M"D3<6!B(NXV0;^8F5RH\:M'[3O15DVATES2!>,J&XAA%6_#<:II*6ICMG(T
M%IONR!S;LEB=:S9HBYAL;DD.(S<:V,H,4I#C>R$C)X7[SI</8XGRA8O;3!_W
MR*9E[OHIK.SM#N_>X768IJ)K)IJI*$525(51)5,Q3IJ)G*!B*)G*(E.0Y1 Q
M3%$2F*(" B @.9.NB\K<US7.:YI:YI+7-<"'-<#8M<#8@@@@@BX.17WPH3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(O@Q2F*)3 !BF
M2F*8 $IBB' @(#Z" AZ" ^@AZ#C31-=5YK/$O\#*%V<O8-Y]&4;$U38+@74M
M;-'@=K#U"YNC=R[F1U^X5,A'4^R.3B<5J^Z.UJ<LH<JK-Q6W22Y9?UO9'X1I
M*,18;C[Y)Z4;K(,1L9)Z=N0#*H"[YX6C24!T[!DX2M([/Y^^$+X&XL1=/C.R
M4<5-7.WI:G!KLAI:MV;G/H7'=CI*AQU@>64LA-V.IW B7R.VVHVFA66:IMVK
MLU4K97'ZT7/5NQ1KN'FX>1;CPLSD8U^D@[:+DY WEK)%$Q#$4+R0Y3#[A!/#
M4PQU%/+'/!*T/BFB>V2.1AT<Q[26N!Y@GDOE^II:FBJ):6L@FI:F!YCFIZB-
M\4T4C=621O#7L<.3@#8@Z$+/]']0&Y.FV\L=CZ0V%8=>6YCVIF?P;H :RC,J
MA5315@AW1'$/8X990A#KP\XPD(Y4Y"*';"JFF<N-B.&4&+4SJ3$:6*J@=GN2
MMS8ZUM^*06DBD R$D3F/ N ZQ(6=@^-XM@%:S$,'KIZ"J9EVD+O)D9<$Q3Q.
M#H:B$D NAG9)&2 2VX!'JAZ,_P H6UO<DHJE=9%8#6%G$$6@;9I+"1F->2JO
MU4RN;%6$?I"SU!=4>WS5XK\Z(A18RSE4M?8D*BGXQC_P75=.7U& S?'(<W?$
M:AS(ZI@UM%,=R&<#@']C):P':N-S]([)_#I058BI-K*?['5&3?LG1QR2T,AT
M#JBF':5-*XY7=%\9B+B7$4[!8>B2A;%H.U*Q'776ETJ]^J,L3S(ZR4^=C;#"
MNP[2F.1*1BW+IMYZ7>4KAN90J[=0127334 2AY94TM313/IZNGFIIXS9\,\;
MXI&\B6/#76/ VL1F"0O=Z*OHL2IHZS#ZNFKJ647CJ*6:.>%VEP)(W.;O"]G-
M)WFG)P!R699CK+5<OBV?X/'J0_\ ,]$_^ZU$SJ]A_P *L(_I:C_@ZA<%\)_X
M"X__ $5%_>=$K&LY1=ZF$41+5 7&KWG>STFFY/<D5NF!K3.%<1TG16T>Q;1%
M/4J;O7-X)<;+ O8^I_2(R5M0D(AC8VBA;A:4S1R<LBU9SE666=K=_GR&O#P"
MI.1.5[\<N5K&_=Z=%H%74'5/7(Z9KT5,;"G(.(T"YUW6%6.T6S!R_P![Q.G:
M_ &VVBW=2[!ZPHMD7C'%=KE=<S:1ZYL8)/8;NH(_G,E::]-V\K9\N%[VXY^;
M++O@AW,Z<^(M?EK8VUSY77Z676N_!MTQ9&%-VA,V]E$=040]M:NV4$*M*Q-]
MVU0GU 3UO!I[.C9.L.H75<2\*=A!M-7NU7<'] .[<C,OH^W-XRRN1PT'('7+
MVZG)20<[ \<R>9&F>65^1TSNL<8Z>ZD0E(Z?=PVR59F,C][U>IRA=C+,5:_"
MV^Q].%JJ_MS*5W=>Y%*(DT*IM)DDQ?6NXOHQ^C"-'_L3%E6#14W;?46RN+:G
M/H-,N OUXQ9UCD;\#?09<"3KGQ^BVQ[?KCJF7:W!C'3EH6@:=;X2!IY6EO?.
MYW8>LIJ\R5[M$NX*QV/KZ67F*W!/:#KAL>7O=3M3]C0MA&C)-9C>T6TQ +>/
M$'AH;6ZY'7(9&W)"'<.!\XUZ=!KG8^.P'U,W4MTPQ%;<R&P%-BI6?V]<T?)(
MIVY"JAL60E8B%F3I[B9R4W'1E./$Q4[&--\$MLM#M'#9:]3\X=V$RRWN%O1I
MW<^G@F>[QO>_6U]-;Z=0>"T[7M)[JEKI5WUJA-G5YO98+1[#8LS ;NLC+N@Z
M,WWNQG8&1D66TWEM2DU_IK6LI(IQLC8%#.9*3*C=;%))3LT_7%N'&V0XEO2W
M/V#118WXYD7-\\@1GG?/I<#GDN VUGU8';WI.;F=G>VN6TD63<5Z>$C2QR8[
MGJ$[!R%5^E.H]0PP[:@1UF92,'4XWIY=.Z9-NJH=X-F)"%@I);PMX\K9\.[^
M-GGS3RNN0'6^?.]SE?2QT"R>JT[J8:W33DU*PU[]FC4H")LL2^V%+.JFS@FF
MP[VG(S[QR.]I*1;65:@2,#,S-9N==WX267)7*A&7UF_K\C:VT96.8UOIGIII
MSRU'')39P/3(:Y6OGQ'#F''K=6-Y2JTPBKE\.?\ X-UQ?](UU5?_ %6L9U>U
M?RMG?[*8)^CF7 ; ?)VS_M_M-^DIE8UG*+OTPB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3"+%[G;X:BUR1LTZOY+&/1$P)E[1</')_JMF+1,QB^:Z=*]J:1
M>0*7DRBIB(IJ*%MRRLAC=(\V:T>)/ #F2=/8MAA>&56+UT&'T;-^>=UKFX9$
MP9R32N .['&V[GFQ)MNM#GN:TU%[&WE RMJ5NVWW,G]#HI"M 5:,:R*Z;EL9
MX#9K$LW#9N9-% 5P 95\8R+AT*:A2*(F\L6V-AV'3XQ,9Y@6T[#9K02 XC^"
MTY6:+??'C,G(9WW?5\6Q.AV$PUF"8*&2XQ/&U]55.#7/B<]O^,3-\H&5P)^*
M4QNR&.TD@<'#XQ(2B=7FC8B,!?Z9]E3D7+- S5M$ Q3@451(W:MTU4 40[$Q
M.0@I)F+Y9>.\"@.=/+AKXFM8&M8R-OD@6+2!D&EEP !;AIRS7CDLLL\CYII'
MS32N<^225Q?(][B2YSGN)+G$YDDWN5MZ82TCL69C]@N%HRSV*K,2OXU^U(U%
MTA&^85S["<'#@&HG!4 X,8>X1#GCUS#9VC1N-  SRWCD3:Y!M?,<#8]=%;]_
M?W[[+2&[NHS73^KSU-D%'X+2S9-)&(8D[W+1LT3%0';M=OWH*%<)CW&13.8Y
M0#U)R'KE14LAW3:Y!))_G.!L ;D#3(WTM=%2MN+J@Z2&<:M7EKK;(H)IY)00
M1,8R%15=Q$F[)%=FY>1Y3KHMS>AET6YT@'CZXA\?0Z&F>T,!M;=:;B[<[9$-
M))M;7ER4\]?$WZ=/4M-:5GNE.^13^C:OH4UMB?39%=2<=8!%\#UO*6 YB.IU
MC,^QP*R*3D$'R:B;)0/9P/V\@F?C*J3NW) S!MPSXWL+VUOX:#4-=;<;^'OI
MFL^W32+?7*\SBC:PUU$4A05?(KL3).0GS2*3!^#-:OC'1D0@F(@HJ!4_.]!<
MI]O\GTQ!*'97L;@<\ASN+G*QL.!S4VUL?:?#/B--=+@<-$0,_L60M<[IRNST
M[1ZE&K4R,NS:91EU9V-DYUN[E_(*\GF<J1J!DT8I%J9JL";CZY$3&$#!EV.(
M/ )(==PM8V:"3J=.'+T647(OZ01]!58_7)U+75K(W[ILJ,!,2=9ADV,98[3*
M-%$WLL=B?VL"F69D$21RYQ%N9,QB^G F "9UF&T4,-7$XD D@V!.MKC1QS(U
M.8/+0J'97 S-R!GU(SM^S+SJ-7AZ=2-[Z=MV1DA 2LK^;-LD&T-:Z0W;F<Q%
MF3.J9!J5XU345]F<QAU3GBYQNB#J..=5(RBC!V]9.\C;_9K#<<PU@F8&SQ[Q
MIJIK1VT#R /))/E1O.[VD1.Z\#@]K',W6SNT-?L_6"II"3$\@5=(\_>:F-I&
M3F@G<E9<]E,T;T9-COM<]C_Z W2%U11,J@UJ$G,%=P"C[Z&8.'2P>V4ZP 1%
M0];F2'-YC5LJ#EN=N5;@K0'+5RB)HI\FNA\O.BJL(K'X;7MW2T_>I,]QS22&
M/8XVO$^QL=6.!8X AP;Z)M/@E%M)AOVTX T&<,<[$*5C0))>S ,I=&V]JRG'
ME2 ?XS#:1A<[LS-9OF<O(4PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB@=UI^'-TU]<D *6T:P,)L)@Q,TK&WJ@1K&WR# @',U9O
M'9D%&MH@$E3F$U?L2#UHB19TI$*Q#]P,@3I=G]J\7V<EO13=I2N<'34,Y<^F
MDTWG-;<&&4@?X6(M<;-$@D8-P\5M=L%L_ME!;$J?L:]C-VGQ6E#8ZV&U]UCW
MEI;4P D_>)VO: 7&(Q2.[0>.?K6\(GJKZ-UI:RG@%-PZ99&672VMKV->.THJ
M.3$1!:^50AG<U2E$T^TSI\L:3JJ1U$T$+0Y<&%$GO&SVW."X^&0B7XAB#K T
M54]K2]YRM33^3'47/R6@,F.9,(&:^5-KO@NVEV3,M08#BN$L)(Q.AC>YL48O
M9U;3#?EHR!\I[C)3 D-%2YQLJL,[->;K<NENH?>73I8PM>C]J7364V8Z1G:M
M6FG+)A+$0$3)-Y^$.96$L3(AA$P,)V.D60FX,9N(@ A@8AA6'8K%V&(T5/61
MY[HFC#G,)U,4F4D3C_&B>QW5;;",=QC :CXU@^)5>'3$C>--,YC)0W,-GA-X
M:A@.>Y-'(R_\%>N?P:O$KZJ.MFZ7S6^ZJ[0YR!UK0VUAD-K0,2ZK-B=3LG-,
MHN!A)J&8+JU5RXF6R=BD2.8>+K:3=*!6(#-P97N)X=M]LC@NSU/35>'RU,<M
M74F)M#*\31")D;GRR1R/ G C<86$2/F),@\H+Z@^"?X0=I=KZNLP_%Z>BG@P
M^B;/)B<,3J>=TTDK(X(9HF.-,YTS142!T,4 :('#<<3=3R\6S_!X]2'_ )GH
MG_W6HF<UL/\ A5A']+4?\'4+M?A/_ 7'_P"BHO[SHE8UG*+O4PB81,(F$3")
MA$PB81,(F$3")A%7+X<__!NN+_I&NJK_ .JUC.KVK^5L[_93!/T<RX#8#Y.V
M?]O]IOTE,K&LY1=^F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB815^[1F7>
M\MO,==Q;M5*FU1X<DH[;CWIG<(*E;2\ER &3,H550D'%'4*=(BZIW'=Y#I7M
MU,H?7U8IX\XH;ND(( \GY;KG*XON,'.Y%P5['@<,.QFR\V/U,;78KB<;&TD3
MQY09*-ZD@YM:X UE58M)C:R,CM(FWA]U&=-?4MO#926NZ].0%8TO&/$VS%LK
M&LBJC"H( =B+:729G?.#F<DX."9SK"<145$3"8P]W@]704M.7'>+&, ,;&OS
MME9H<6M%N)NT$BY)NO(ZBHGK)YJFIE,L]1*Z665^;GO>27$D#(7.30 &BP:
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M=0P;P9G;(&[G$@@D/&8LNC^$3&#6XR,/B=_T;"H^QW6FS352!KZAP XQCLX
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MZ< -;GS<LSEGTYE8G?M4SFQ*NV]NNI8ENYB%D5H8$4/.3E42#RJ*JO:[,0.
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M)!8^?M2QP)#V;KP;.7.[!T-928$^LQ&%U-7X]B>);15=*Z^]2OQ:I=/%3N!
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M;T@<=/9;GEYK*]V;K<1.P,"A0YIM'O*U,0TU9CNFZ3G\X8X"G,+5_)M_,=H
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M-F(4\D<U)7,8+ &>!TNZ&M$H:U@;KP>D+J]#T3\3?>($#T("FD>F]50"AZ%
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M$IE+$DSL:54=NF-@;:H41@GC+CVMC+RDE.-T7S3D0 '+<3MUD3<@(*(E$!Y
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M87CN+=V*/<04G%QL,D($AFRKAT51(YTVI_XT3)@(]P ;CU[A*(\#F#"Q!8N
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MWIGR/':SRR2;@<(V7W8V,8&M%$75K/Q+S8$LFU IS'4$BH)]I@ W)A]1*/\
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M=UU3)8DLE+?)HX+_ 'MI[=Y.7;W'E*4A2D(4"E* %*4H 4I2E#@"E .
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M<V$&.8_1 -?N5<;>+V![K<]^,LE)ZR!Q6P-%\'&.G?@K'8-4/\IT;I31-#N
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=9IR/C'AO+;OVBGG$;F;F\WL(J8Z:A2%!!!L5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g383770g23a23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383770g23a23.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #! =8# 1$
M A$! Q$!_\0 'P !  $$ P$! 0            <$!08( @,) 0L*_\0 3A
M 00" @ !"04& P4$!@L !0,$!@<! @ (F D1$A,4%1886!=7UM?8&B%6E=35
M&2(C"C$T4;,D)2AT,C4V<W:U,S<X06)Q=X&(L;;_Q  < 0$  P$! 0$!
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MFS'.BF<.]=$<95WV0]9C5+&5-LXTQG/&UN>#Y?>X/'PY].>.<BQQR.>W/?\
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MH:U<$5C&SK00BQ07<IJNU2N[)[H-3;ZJ;OMFCK5KA7+=7&D!'()",0+)(4D
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M88Z^UCX;76U',):NH?O;ZPYVL"$ --&Q (CJZH(3[2]CP]=9?3A)ZM-Y!]V
M8C7F!\Q(%.HL'9WMK('$MM7R9APE<N_7A>;JV^^)6.'^"D7P9604(@2<AH^\
MLH1)H>,?'EU,@6#TX%+J):O/5CF^QE5@LGR:)0D/BJB#VKIB +$W4IMNIH,P
MA9)&"CS$*RW7/EO-]2VZ30,9>AOZMR#8"NZ&Z!D#*"QI02">:'FHC2R:=Z>Q
MABIHNZ87P: RV'4)>%I/Y< 0Z\U?$K)$P&\;'JRK;@*&[6C4\4FS:>AX"U)Y
MIRHH'&]22QE,OI,F8^3Q 2U[X_#M*LS Z=6C?4Z>$(YU4KQ&33Q330!87CZ9
MC,E>T3R-6W;TR4D)Y7UDYC4B8AE@ED+*((T<+-)%'*3*K[]^P$11(MD^^-Z
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M4$DT4]?-HDGIIKKKCJ    [  #X\#YGG.<FR3Z\Y3\G&.,8XQE[ _P#&*_\
MEM_^JCRC]A^W_P"CC/TZ;R 695G;F ]JXG4TRO&%..O\NZ_S>)ULK%5+"AKQ
MY/H_8<8F ,+,)+%!T@"&70Y['90U8F4"0[9$"6R@\9-'6J'PFG:*;12:-YH]
M/)[2FIC>4/TI (VB=&9$=D900Z$J5;S+P2,^KF62/4IJ5B>9.@\+K'LWH=ZR
M*X#LH8-15@&L4IHB\TBA-%]F*-G^O81]U^EL\/WU'>\FT@JFO)%7[TC3DS[)
MVO5=@UE'I:9.RR/ 5P:8*!+M)U+8VZ,L TJ<D5DV[]FNR=/?0DU&EU$7LRZE
M(UT[>'[9I5D GCTL,T<K1JJ,P;=(#&CA2R =C8'(D,\+B<PN[2C6%HXV0F)]
M1)$Z*Q9E7;MC.YE) 8D\CDP@\Z3W2'K@)&1?6=X^G=@>3WZ<UJ_/"&M?#\#9
M_19T\=["53.I:N>'E8X7MZK4AM0M#[?4B%DN2@\ :,-@@MRNPW&OT[2LS:JH
MHO$M=*%)D-QZA0NFFBCVE7$,Q,Y4T5VE@I9A>3:64($$!+R:/31EE""GA8F:
M-WW J98P(@PL-84L%%B=2M$NW%HP"[A_D\Y**ZUAK$LUY*.L2>M8%9-)Y+)J
M;KR#PZ]5^NSR8Z4S&,QXI')7"?=X61K2)\P/ZV*3&I.%EE=><:D=&33GQ)&U
M9CA":O[Y414GEDD@]J"==]P='MD" KTPQH9J829$F&B80!Y"VG\A9V:)$28P
M%NDNTJR$66IA)7>H4:^3XN5>G+O93NCV4CL-KY/YI!Z%0=N8S)R5=V ZO_LW
M943JR&2)P063&2BK(;**ECB9\2\;C6NPIFV!'7 ]#T\[GQ* 3Z<QZ@K$?$C)
MJ:#H)8QIM)$\TB@>9)I$F<JPL[B64$UF:Z*3HRAX0S^QA(;*L4;K3NL:L3PT
M:-$M@T*%,0+R1^PO1NS&DNLM"E*G?QRCV4VZ+STS7U7@:HWS8XNKHI?,?LA.
M-P&P=5*UF,HBIDU4LH+ 9Z/U'S/2,#D]5R)=B.UUSTWB$12+KSAIS'XA&LLS
M3?=&9].T6^2*I8UD59D#1FX]Y-!2;O-I)-TG2C*P[]&Y2,1C>(Q*)*1_(S*Q
MC8K(*?:.20,VQZ8[R?KCK *1,U7;#!/LC;O8JS J<S?T^S>5-#HS'(H6V+2"
M T^$ PJN@4[D[O"K&$1'0TTBTGF2?OHRB0D&H=CQ:[9JNKJ!-"?98=+"W3$Q
M$\CNZTLL[-)*T:"C(^TND?E6EW'HTI:#IPF.0">2>1=QC!B154VT<2JD:NQX
M1;"LXW-N:AZG<\C/1QQC'&,<8QQC'&,<8SQ.MSRUG3V&SJ7U78U(=BS)RL9^
M3!$VZ]85H<$M)? 9"X9:%A"KZT?-E4<8&Y>A2NC=L\0WT0=HX;+XQC3[;1?R
M>?IKK-+I]=HO!-1)IM9IX]1IYDU6A03:?41K)&^UM6CA9(W!VNJFC3*#8SS9
M?%?"T=XI=5$'C<JZ-'*VUT:B.(B+5AW!/(L','3\O!T92>'"*5%]D4B$G2:(
M25^G4E8:/)"@P:*,&*)QUK:F%RR3)BJJS:)O]W&C9HHHW1UT1WVTST_YL_T^
MI1]@ZFDLH/;/#Z4DV2H]LI;/)JK/.4^V?"+)]LBMJW'IS6U"A9Z7-#@7\,QA
MCY:KR<HR(D8 -ZNW4/@9A5=8M"6-"TVTB)19SNDJX6(QM"RDPSU5PH@@HNHY
M9*[J[HI;J9VV3TSBQ_DV_E!+B0^":LR+PLAUV@+@<\!CK=P[GL?B?7*CQ;P4
M*4&I@"-9*"&7:2>22O1HV>]CG+T+\N;T'!Z@M O7OL('TBXMZ#C.@NFJI'ZQ
MT(2W9J$0X+5I:*.! L@H.'J/1X_#=HZW8,]ET5-FJ&=(;^33]/VW;O =4V\A
MGW:WP\[F%TS7K?,19HFR+/KDCQCP=:K5PC:-JU%,-JFK J'@&AP..!Z99RWE
MK/)SGH^'B9WJ_=AJ*Q[;78!&2U#TX1CX/;1)1#78.&>64L.&;:HJJHZY9-D,
MZI**)XSC3?;&9'\FW\H"LSKX'JU=O><:[0!F_P!YAK;/]IR#XMX,0%.J@*K[
MJF&4@?L!AH?V9=HCY<KH) !ZXB"=>.P4)%.GNY%T,B-,51&Q[D@J@W;*/UV0
M:T&399ZHV:-6^[I1+9?=!LW2V4RFBGKK#_R:?I_(09/ M5(0*!?6Z!B!WH%M
M:35DFOGDKXQX.@I-7"@)LA8IE!/K0A'.7(9Y>3HX%#HQX/1W903'VZ"S5 &,
MJ:LF =!LXV5W<-T1C6U4F2:"^ZRVZR.B&J:NRJNV^NV5-LY@_P F7Z>LQ9O
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M]9*XTWAND>9BD".55%D0DM0-T+.?F>LT[SZ_Q)E:-5BU<V]I)%C4%YI HMB
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M3ICMZM3?3TODJO#'G]#;.OG\WS_Y\WG\WG\WGSYO^>>? C0V >KW /N>HO\
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MZ@^F/@KO#]?_ ![!_M?^C_WQU!^J?[P_PX];Y0WZ@^F/@KO#]?\ Q[!_M?\
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M\)OWV/LO3?K3_P!^/]UCY .VGU7]=?!S9?ZV.*E_7C_";]]C[+TWZT_]^/\
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MD'9+ U!WLKMV,7IV2ZS4N9NI8-M"'B3.MGF]7%!!%[$49@T4=N['50CLP9Q
M^,U""GB;4JU>)=*Z:'JS*8RKA(FAT^HE$6[>+D'5! 8J>$Y7<#9['.=M1,8H
M660%"TBS3P1-+6RNF>FP.P,"3(:8*P 4T<H']P]EY<$ZGRFO^X4#,@[\N-W2
MA(S7U+QYX"T1"Q:U9%K,<#IXUTE$?FCU*!"F4P@97&C*-GWAIJ.7V9-V6NTB
M+3HVI5](X:&+K 22L&.YHQLM"5*#>=KBRR@$\WD&34,-.R:I2)I.D3'$I7@2
M'?3C<&(4!D/ -T:K/7H(T(L PAB8*['BS,8P:%#FS)L-V,D6[5)%Z5V',_\
ML8_8BYT5>99-?^S-<K900_TD].>6Q!8D#:"20MD[03P+/)H<6>3GI@$  FR
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M!8#:$L<2UP-D@TU-!4(D#I]&HCI%B \\"AT=LB&FI [?2T"\<(.) U#L'I$
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M&;F0KJ1OX8_KF1DPCR)%-S,.>OMR371)(UATD,DD:?N2KF)GD]7#4<H>-:E
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M%W2-(Y%42*QXDC*<$6"&613\QO10?D2>X&6>-F,9 -I(&H@T059&^BNS#U8
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MBR;/([G.H*0  #P*[>F5/QE$/XJC?\\%_P!5R+'J/J,FCZ'Z''QE$/XJC?\
M/!?]5Q8]1]1BCZ'Z''QE$/XJC?\ /!?]5Q8]1]1BCZ'Z'((;P.J"4HM%2=)U
M/.XI-9@!L8*UE6(O(=PTEQ 8Y7A]DD-,(/&K=#5A!@I=H505]J=N)&88*H-T
M!S=1[N9R$BV2%&1&C;:Q7<N]I%-@CXN5(_U0>Y.8] ,TG4C5U9E=0R!J;8J-
MP01V0&^YW$?#*.05A7.K\25JJQXY23X?$CT!<:01K TQ+B)2(NG('";,&Y;Y
M%BI"&/9?&8R<;MU&[$B;.JEPY](CE!*5U- B2IAO60;W:PZBN2#;*RTK+8L
M45(O!T]48KAI63R( -K'<:6J#!K937!+6#><'M80/$>BD9CULL8T+JMS 7M(
M-FB\.=)5<Y@<2(0;"#?9QI[9)Q<HBA<O'I&S//%G/N<L0;@R 5XHV?M0U(W,
MS*K&7J=8EB.H)'#^M*58 J5'< D'MD>SG:JJ641E#"-H/3V*4^(M@RDJVXDT
M31!HC$#=#00P&',MKD *FMI/+IK))(=C-12UZ2F<Q<,%%YG'$9&%?IPF51-D
M-9@H"_$J.!X4"@@U/"94];MR*5AJP"3L&W:B*HED4!$ND8JPWJQ)+@T2?=*B
MP:MI2P W->YF9FC1B68@[EW*=C+0"$<  6&(O)HKQK':]]='!M@QC%9@8M H
MA6D*U(@<YB N'A%0[S;<QKA H2R72U%HZMB;LG[#J&PY;.T_>B[-KC)*LGF-
M=1F=I'OWR[6.+(%<]@+OFZO-4C9/*+Z:JBQK7*A5HV:LWQW)[=^:R,P50PJ/
MO@F&%U)8CD >SPW3\<46A2J-;R2?#I$(6,)/E4E%I(G$0TMDT?@PPLEAD,CY
MM\/.ZR5=,>^8:'4A@;5-SA%E;<?O%C*D+0(V[BBER#98 KMY&4&G((IGI-YB
M7:/(S@B[JVVAF"@\ $AMQHCB6K;8S9D<L@AV18%5(H-"LH_'C@6!$@P-^V':
ML)/)0C5%PP9CI7,M52&C^1^PN"P8:1= (ZZ%@7#T<\E=3$L;1])1N+%F$C D
M$VJD\DJG%+=,1N8$T1!T\AD60R,=H 53&" : 9@!0#/S;42H)52%L'O>P1#$
MF 3=[=[.?/JN=SF35+&Y(_AH;U$FED7DD91'R^:AV6QHW'!XF2O@X]MHR:[)
MH8&F)!K*CX0:03@3IM*!4C$@1965B055@UJA)"M:@D\\V!M!(R>@^Y7+.YC+
MM&K #S,I6F<+N*@,0!Q\"VXJ");K!.%UK6T KQ"<1XFG!H9&8E@FH7%(*D]H
M\&9"MR2J.KS?5%5_NUV=JIZ[[:Z*+;:XVSC&,\REE$DDDG WNS58XW$FK^-7
M5YI'&8XTCHG8BI==]H O^VKS.?C*(?Q5&_YX+_JN4L>H^HR]'T/T./C*(?Q5
M&_YX+_JN+'J/J,4?0_0Y]Q,8CG_=*HYG_P#(X,S_ /TZXL>H^HQ1]#]#G#Y&
M>DWT>=6?#[4OX1YX&=%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/
MM2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U.
M/D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/
MM2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U.
M/D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/
MM2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U.
M/D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/
MM2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U.
M/D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/
MM2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U.
M/D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/
MM2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U.
M/D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/
MM2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U.
M/D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/
MM2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U.
M/D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/
MM2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U.
M/D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/
MM2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U.
M/D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/
MM2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U.
M/D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/M2_A'C%GU/U./D9Z3?1YU9\/
MM2_A'C%GU/U.<M>C?2C7/GUZ?=6M<^;S>?7K]4V,^;_EY\1+'[OW8XQ9]3]3
MFTG&1CC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8X
MQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&
M.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&8J_G4(%RP% B<RBHZ=2E
MB2)QF%OY"(:2R1#0VGK3! %''#Q,P78B4\X4).Q[-PW8Z9]-THEK^_EQ'(4:
M0(YC0@/(%8HI;W0S ;5+? $@GX94N@8(64.P)5"P#,!W(6[('Q(''QSJ:V#
MGTBE<093>(/)9!&0PE.(NUDH9Q(H:.-,U"(9_*PJ3W<E'F18>DJ^&.B[9F@_
M9IJ.6JBJ&FV^!BD"HYC<)(2(W*,%D*FF"-5,5/!"DT>#S@.A9E#J60 NH8%D
M#"P6%VH(Y%@6.1F(F^P-#1F#1^SI'=M11^M98Y191:PS=DPT5!I*\<(/G*#2
M/RQ^:;@#+E=L+)N$4!Q!RJH@.?*Z:;)M'&R=UTVH>1HET\S2H+>)8I&D0 @$
ML@4LHL@60.2/490S0JBR--$L;<*YD0(QY-*Q.T\ G@GL?3+MBXZBS7JMMZVG
M7.U5(-=WRUF:S>,[5^DRT<89[NU)EJ3S'=&VKO.&NR^Q'">'.<(9V];G&G(Z
M$_5Z/1EZQ-"+IOU;[UTZWW7-5ENK'LZG43I]^IO797KNO;_SRT[]@:'3K;2Y
M%+JJ?2HE=\)IVCO8D1UKQ17+C9GA'29Y+XCNZ^7FNS3"&I'*OM6NS;T/7:YT
MQ;V;4=7H=";K_P!3TGZO:_<V[JKFZJN>V5Z\/3ZO5CZ7]9O79_>O;WX[]^,N
M@ZYJ?+XK_(JUJV)_:QH54JSW?.8P\^TI,$VP\-[P##<HIF8ZAFFV'17:.^\<
M#F^<+//4IY]+E3!.O4N&4=';UKC<=+<:7J6/N]QX7=5G@9(EB.RI(SU+Z=.I
MZFWEME'ST.3MNOCEP?6?6HPZ?BQ*PX,/DT4B_P ;RB.OI: :'8W"_3W2^+SX
MAP03(!XOZQ-1/W^1;MA/II[Z>U^EKMC$"&4JKB*0H[]-&",5>3]16 IG_P!4
M$M\LDR1AF4N@95W,I90RK^LPNPOS/'SRCK:WZFN02\/5%9]?6D#'O=AK\Q7<
MRCLT&,2.NF%-F+Q_'"))JV>83SA3V9=71;*6VJF-,Z;:[9F6":!@L\,L+$6%
MEC:,D>H#@$C(CEBE7=%(DBW19&5@#Z$J31^62+S+-,<8QQC'&,<8QQC'&,<8
MQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'
M&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC/$+RB
MPB1BNV=37[#&9!_+NI?6J==C!PT=ZS58_&(A=U2 [>BWG3VURIF04G*+&8MV
M^,;[+/\ 9EC73SXQOK[_ (8R'13Z9R FLU<>E)/]%I-/.T#_ /XZA(B3Z7GD
MZT$:J.902VF@:< &K5)D$J^AN%G%'XD9IH#=6@--=Q"C$:4QV$\H9275W ,"
MY?X%/0I;M+:/8@<%CVA-TF[2C[BHNMS1FV=/%$G7NMS G+Y5+;?TM<=S"$KH
ME++[-X9J-7N:K##1PZ8LQ447Z^J)-"K$@&<H,@]I(!Z^NB@VJ314ZF28*M_T
M>E!0)YHH3EX'2H'UW4ICKYV"CL=IF$]:_*2#IX&C<ADS.9PR&4!V H/L?.8(
M.Q*UA[-L<$Q^;K3F+:/%AZ7LRHUFQ7URX2RJI5D;4B?4Z9VGDU7A9C9D4QR/
MJ=-J=+'(=EDJ6CZ;U?()/8Y*L(.E#.JQ+!K@X!;<B0S0S.@W$ $*V];KDCL#
MF12#:"$;R)=D8['M]?)LL^Y]+3"3+-(B2'U>3F8;KY8D2DM\-8ON);-UJO$V
MV6JIG))@D(S&R,K NI-NX>:,'!5*J]40#2NW_P"JG0SH@+J9EC;4Q.FGWV3U
M6@6<I'NWA'"T-P&6;89C.J__  ?:HF;RD1LXA=6FVU1C$AC#-MV[EW'W2V2K
M()OU65[+4_V1C4/6!]-1][76K9=P%63K?KK*.Q!BD:WCM<W0"$N';V/BXP.3
M&SBNU[.1C8&-/;,76+>^RCQSJ;3Q5-7[)/I'?=KCI]/TH%KVI=,NHE>6!R '
M+&XY1"69A%0V@#;FA;3^T1SJA&E$LW4E(/0:<QHJ2J+*[>'3J;0IDLV2=V:E
M3NOS\YM-2Y.O8AVPB$6MWN1VSZ<#F8]Z'#RIU3X'I>9F#Z*#/9VVF8+=DMC=
MH @C=)JB+,ZR0B<:H*-2J;MQVQRK'#T-2P+O#H='KFL,R"<Z]4#GG[S3H\+-
M9)!4*>1G,Z%Y1+ I"K)JM3I@ 0K&(:1G*KQY)F60 =FW$@=CF29#A[FL+LG>
MUR"[9$1ON)TN;6\]1@\;0ETZKBH]NS<5B-)D]X@JJLQ-AXE5L(A=D60!8-B.
M2 E]-=$F!CUWH.,]S01:73P&$MHM>8+D<I'+/[(SZ@=0BU9YI)(HF-;6$9M:
MXG:)99YI1*$U6DZIV+N=(SJ$6([0>0L2)(X%VN[@CC/0SH'9FLQ[&7")%R6@
M^Q(E"FZZ<ONV= UN1JYN3=#9)(F(&HK1",STC@9":B1CXA(1*\8>M'P@)LX&
MF!S1%08U:^;XE#LTL#%-1I6,\H&CU,HF(!5"T\+%4D$;$*K;P0S45)Y)[M')
MOGE :&<=*,G4PQF.Z9ML<@LH7 )(VU2BF XSU^YXN>GCC&.,8XQCC&.,9IWV
M'(!%+>I&+V=*WL-I(W#[M)FR:<Z,UJ**6K']ZOVKJ/F):"-QQYC7X()W-*AH
M54LFU=D(FD>]3L_C ]9#NTH;H:AX4#SJ^G51TUE(A?K=5@C*X_G%@0M5@.4[
M.0>68CJPK(VV(K*2=YC!E7I]-2P93[AE8+?)7=5J#D0;V&=D'36'M35HCV4^
M8AZ?ETOT/62G6\\E])%;>0!@R)R5INV!J"D[Q@\??A&,Q>[ &9"5O2XW<]'M
M]"1<+MTU772%828RTZ)MBZL:3K"68*A!61=/(P)C&XA IVMY5;/>S:5 9//M
MB9KDZ<CQ&0!2S<,AE0$;CM\Q(W*;98(/3V0:]<>S1A"UI!4\#B-P[)TRR9VZ
MPDY8P('5]5KH_!4+6?D#I(T% V4^E[PR,@,P?-@IU$S6*4G?0Z-OP3OH6-?:
MM(IA69Y( 9R82@#&68))T0%",T2H%,B#<I6;8'<-F)<F#4'J-&BRGI5*&+ 1
MH2@DLEE$A:PC&B#'N**0?1F\)AA2L@#Z('DEA4WM"EH.YDT=*:*I8C$\MZ'0
MZ2>[#0M?.S=P6$E"$<8E!CM)Z,)E&[UDX1>-4]]?,TZ?>L'7F.*>38XKS1P2
M2+:GN%90Q4BF4$'@G.Z9ONP584\D*;@?Z+RHK40>[ E00;!((Y&:>Q66O=K#
MA!C$Z.K7\1[B7;!;$KYS.SB[5O1@,O;J4?9DZT6,* (]#@=1":NL*-2A"/"]
MWYMZ!,X*J/;&*-Y!W.@Z4B]-1IET,$L4O34$ZAA#N*S!0[NTS31,A8TH9=H$
M2[.1&.]&WMUCJIDD3>U=(&3:#'N*JJQ"-U:AS1NY"&N7:.PJAECT:S@O8%3%
MO675P,C2A('>B42JJIP))\8<B^R9!<%(0L>D@TBL^:*L!QUQ,E;38Q%"(1$%
MI&%['):1HXYT!,FF!@BF8:@-IC)-,P"AM* RLR$ $6HC$+.7=BXB&6U+Q,0%
MF/4DC!B*S;(XU))$Y(8*P)[ [S(%VH-O4.8@YDDN&]B(\ %R)26607[3R$3(
M3 V]'Q02]HP@RDA1Q7KNB&QU7:*/*TKMR&V(.R<-"Q[WV"'3\5-"<IGB(LC8
M(C:9F*;(ET:,H.G56&H!4"4:@KYQ-*&H*[/M8QE%2,D5W,)@H;<[:A@Q$I(,
M1#'88;\O3CKDHJVH<.6>COEUT/%I%4,<<FWKHJ]$%)O#$CC]91R_D@NOY[)X
M("E3YTKMMN\>RH)'!TB=O<[9P\<$U'.GFT5UQCS]4JI.P4!05C<J.R-)&DC(
M!\ C,5 ^ %?#.R!BT8W$D@NEGDL$=D#$_$L%#$_$GX=LF[G/FN.,8XQFEW<&
M3(1/2ES2]QO*^T9WM1B+F)-9.%B[.8BC%T0 0?=R)9;"$@*@!,==&&SP.V)-
MHRLD5</9*Q)J,!"@WOT*%^NO0$MZ;4D.49RA73R,H2O*K%@IW%2XH!"H+7R:
MIMO2;JE*FA\@8*'!FC#%OZ14*6L A:)+ T*J>Q-A14NXJ"-HV&,;5X\N^, K
M^(1F=:A5X]#9)4-E2VMF4HD,=+L2D3!V!9K.IA:"RC\>C*QDA: L[.PLE<ZJ
MQI8G43OTB91IW;3!XMP=TGB24HKJ5=HHC,W .QD+<,@R9W4F)0XV&95F*O6U
M6BD:,,RD%0\G2 Y&\,!RK$'4"4R<84IR;CVULL%2T9.=@D:"(67V:LBH0;^I
M1<C?L&-DBII'M7S^UC]9R9DG$X8Y,G\;Z1)$866EXC61(GC_ '(A6>,]%@'7
M3>TB+213L)V4'I&-J$*S*0[A5Y>U",5*KRLP,3@2"U:?HF7421 QAB-X<69#
M&P*H2?=VDL-P9MV'LU-&H=TWT2?2MHTMV8P/$J?'FF(S--QXNC;!NAJUDK(>
MKA$(4-2ROHZ&F 1%3=DNW)&HSOA9H^W34\\1JLFNL)<"2;%4[X[;410'83[P
M5)79&[^57[BQUEV9=+[P$KINW#:X B>4!@.%)=%5AVY*_'-7:9GZ(X_0,N?V
M604LF0YO-]W% 2*Q2KX+!@43CTL*RDK)(H:-KQ^NAM5VP-A4$BY!$8 ;BHF<
M=CFZRHM\OOOUSQ6NI00KTE]G&A9(E#2,[H$5)%7=,TT)DD=2SDNH- J*YXI
M# _4.\]8ZH-(2$50Q<LI.U!%*$12 H56('E/%[[)3N+-YY&99 ;,;OI(-MGK
MVA)&XV]Y>/FPF,'997[ME&J@H5D@T@5H@K7C!QRC(C! QZ! :9/.V.TM*P\-
M&14:6-S&Z21$*T.I*;M,AC9U24%Y]22986A=;50M@JH/35RYM.ZAU9)+;J0
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M]ZV[FV]JW&J]*NLG:EW7/KM%_6\Z=["[.[R;689Z,)ZR'W K&%7Z?9BO$O;
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MUU?2423=R(F9<#F; 4/&O%GS@N+;,\N';KV?1!IS/PLD2MYO*[,#M1=[/PC
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MY(E:8F6-5:%TBZ8EW(3*)PXDVADWK'T@!81G8 LV;12-*CD1@1N6$BL^\I3
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MR@%)VNZ&:@]EFKC1@53T40UOIY8EDEDG>7=)'J$\D:2$G40R1EV+2QT5+[J
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MI7DXALM(LKF85T8F)"M-=SDFI^)2F5$=CU9"["?V]!P)D7$C!>(EIU!HVVE
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M(L;RNTNG,9V(RK]VG4/48NX6MR!2;<JH)&"ZG<MJ(W9G5%$<H<;F5F\[;5V
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MDW%56-2+\J.S,6 55^+%5:\TZQ%5.W<X8C>XC0*FW<6<W7+*  "23V !(S:
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MV8@E4(!S,Z@[!(L9:/IF4L6"CIBR-I(HNR#?M)4 $!F%YE1WLA'1=L4S5(P
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M"3D@MV,</DXX=0*0XXLVU=[+I,Y1'C8Q??3"+QDX:[JH;Z1RM&0*#)O5F0V
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g383770g23s23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383770g23s23.jpg
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M 0 # 0$!          <("08% P0* @$+_\0 5Q    4# 0$*"0@) 08$! <
M  0%!@<" P@!"1,4%1955IB9U-81$A@X4U>7T]49(51867>:UR(C47B5EK>X
MTA<D,3,T4I0E,D*3"C=VM29!9'%TD;/_Q  = 0$  04! 0$
M 0(#! 4&!P@)_\0 8A$  0(# P,." L&!0,!! @'  $" P0%!@<1$A,A%3%1
M4E-45966F-'2T]04(D%QD927U0@75F%BDJ&BL<'6)#*!D^'P(R9"97(E,_$6
M&#=78S4V0V1S=8*T=G>RM;;B\O_:  P# 0 "$0,1 #\ _?P
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M8N%:!"HB(F&"^,Y,4\J(C</Q4V' I
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M=)0D!"2"%JP02D=&2RA5.3$TE8LE")(M8*EK5NS:HHI$'O
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MI! I7;:3-X:5]&NW:-:4E"T4S^B84+:&[^E8C%5UU5=*K_%==?.OE)( @
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M>V9L*KA2V8B24_4]GEW#HWB;F-%2%DL4%#E15T;&&.G3Z=*_Q3$T, I
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M3!2Y454PPT)ABF.G2NG3@J_Q3$TQ I
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MZM<K>AOE'^4P:J0-[U+BNH=W'Q8USAV[KVHW>?J4>6%'?JURMZ&^4?Y3!JI
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ME&1&0DH=EK,678YL56.>LQ#LS1Z1#G'(K&YM\VR.^"BN;"<QKWHZ4!D'/@
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M)@GH0QHD2)%>L2+$?%B.PRGQ'.>]V"(U,7.57+@U$1,5T(B(FA#[ DH
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MU[9E?%@R9_8KWK-G^L/"+ [ZN)Y-W]]V'!^2_)6TD]KVS*^+!DS^Q7O6;/\
M6'A%@=]7$\F[^^[#@_)?DK:2>U[9E?%@R9_8KWK-G^L/"+ [ZN)Y-W]]V'!^
M2_)6TD]KVS*^+!DS^Q7O6;/]8>$6!WU<3R;O[[L.#\E^2MI)[7MF5\6#)G]B
MO>LV?ZP\(L#OJXGDW?WW8<'Y+\E;23VO;,KXL&3/[%>]9L_UAX18'?5Q/)N_
MONPX/R7Y*VDGM>V97Q8,F?V*]ZS9_K#PBP.^KB>3=_?=AP?DOR5M)/:]LROB
MP9,_L5[UFS_6'A%@=]7$\F[^^[#@_)?DK:2>U[9E?%@R9_8KWK-G^L/"+ [Z
MN)Y-W]]V'!^2_)6TD]KVS*^+!DS^Q7O6;/\ 6'A%@=]7$\F[^^[#@_)?DK:2
M>U[9E?%@R9_8KWK-G^L/"+ [ZN)Y-W]]V'!^2_)6TD]KVS*^+!DS^Q7O6;/]
M8>$6!WU<3R;O[[L.#\E^2MI)[7MF5\6#)G]BO>LV?ZP\(L#OJXGDW?WW8<'Y
M+\E;23VO;,KXL&3/[%>]9L_UAX18'?5Q/)N_ONPX/R7Y*VDGM>V97Q8,F?V*
M]ZS9_K#PBP.^KB>3=_?=AP?DOR5M)/:]LROBP9,_L5[UFS_6'A%@=]7$\F[^
M^[#@_)?DK:2>U[9E?%@R9_8KWK-G^L/"+ [ZN)Y-W]]V'!^2_)6TD]KVS*^+
M!DS^Q7O6;/\ 6'A%@=]7$\F[^^['KHC:R3555*(G+6T=0TX^I$B1U?/RELWS
MB:BE#)JU8,JQ\NB7E57,$TVS76<-V$E,45.[8LW+9$@;-56B]RID.?<YJ*M>
M8USD17NF*"K6(JX*Y49E.5&II5&M<Y43!$5<$,>;G["2\M,1H3[C9R-!@18L
M*2@6>OSAQYN)#AN?#EH+YMDM*LBQW-2%#?,S$"7:]Z.C1H4-'/;9[R9WE]<3
M*W^)P+^00V&I\7A6I?6DNY' ?^O:7_\ #&[KU>V'ZR'DSO+ZXF5O\3@7\@@U
M/B\*U+ZTEW(?^O:7_P##&[KU>V'ZR'DSO+ZXF5O\3@7\@@U/B\*U+ZTEW(?^
MO:7_ /#&[KU>V'ZR/02<=G<EJJ8IW\L<G5FRG*!(]>1U91A&M*5;10S;,7$U
M3I3X.3S]2>>HMZE3M)(^1-ZEKMW0L<+7M:+U%39&*US7+4Z@]&N1RL>Z3R7(
MBHJM=DR;79+M9<ES5P5<%1=)8F;;TV8EIB79=Q8&5='@18+9J6@6L29EG18;
MF)'EUC6MC04CP5<D2$L6#%AI$:U8D*(W%BV=&P.!
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M9Y<?NQSW_2IU@2W73SI^)9P"  ,T<1?/QVLWWR8H_P!E\/@2NLWS?FII<!
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MC3TM3X+'JYT. R)#EIB+&63=%C0VO57/<Z<!EG)
M                                    5CS9\S/+C]V.>_Z5.L"6ZZ>=
M/Q+. 0 !FCB+Y^.UF^^3%'^R^'P)76;YOS4TN @ #)N8"*S<E!]5V$EZWK-3
MC4-;=TALW;4G$[E.MWYJRT@ZW--7?:U_WTKFNFFIW3]9X!S<TC_"(V#(RIEK
M@K:%X0B^:/C_ (J?3\I]&69BRK:!2$?,TEKDD8&4V-?DZ@147)UHE&1,*8Y-
M993_ .Q_=(WX.7N1) ZJ*S[P6,'[G'Y.?U-YGY/?5%YQ+^@<'+W(D@=5%9]X
M&#]SC\G/ZC/R>^J+SB7] X.7N1) ZJ*S[P,'[G'Y.?U&?D]]47G$OZ!P<O<B
M2!U45GW@8/W./R<_J,_)[ZHO.)?T#@Y>Y$D#JHK/O P?N<?DY_49^3WU1><2
M_H'!R]R)('516?>!@_<X_)S^HS\GOJB\XE_0.#E[D20.JBL^\#!^YQ^3G]1G
MY/?5%YQ+^@<'+W(D@=5%9]X&#]SC\G/ZC/R>^J+SB7]!R[L:*<X"285>;5<R
MBGD7*VEM)M+FR@(U%K#K1%HFIM0\3T,WJ:-%<@O%B)I'JM^$Q2HVB^I?36]I
M1H)18K<5:V8:JHK55+.JF+7(J.:N"Z4<BJBIK*BJBZ"U&U-F&M;'B4",UD6%
M'8V-\(7.-9&@/;%@QFH]KD;%@Q&MB0HB(CX;VM>Q4<B*G4<'+W(D@=5%9]X(
MP?N<?DY_4NY^3WU1><2_H'!R]R)('516?>!@_<X_)S^HS\GOJB\XE_0.#E[D
M20.JBL^\#!^YQ^3G]1GY/?5%YQ+^@<'+W(D@=5%9]X&#]SC\G/ZC/R>^J+SB
M7] X.7N1) ZJ*S[P,'[G'Y.?U&?D]]47G$OZ!P<O<B2!U45GW@8/W./R<_J,
M_)[ZHO.)?T#@Y>Y$D#JHK/O P?N<?DY_49^3WU1><2_H'!R]R)('516?>!@_
M<X_)S^HS\GOJB\XE_0.#E[D20.JBL^\#!^YQ^3G]1GY/?5%YQ+^@<'+W(D@=
M5%9]X&#]SC\G/ZC/R>^J+SB7] X.7N1) ZJ*S[P,'[G'Y.?U&?D]]47G$OZ!
MP<O<B2!U45GW@8/W./R<_J,_)[ZHO.)?T#@Y>Y$D#JHK/O P?N<?DY_49^3W
MU1><2_H'!R]R)('516?>!@_<X_)S^HS\GOJB\XE_0.#E[D20.JBL^\#!^YQ^
M3G]1GY/?5%YQ+^@<'+W(D@=5%9]X&#]SC\G/ZC/R>^J+SB7] X.7N1) ZJ*S
M[P,'[G'Y.?U&?D]]47G$OZ!P<O<B2!U45GW@8/W./R<_J,_)[ZHO.)?T%K8F
MQL6%GBF]G&MQRHM8YKO]28KFPS8,;.@R4TUOV-4]3I-'[ZPVS>MVFB_^M3[E
M_<M*-=S\2]I5ILI:1<_-18CX#H:^,Z#$I<&!$5-*9+L7*Z&N.G2W'TGG=H[=
M2TKJC2I&4K<"H0O\&!5Y"]"LUVGPXOB.S\!8<)LK/0\E59XL9&92KXV+<"_E
MNW;M6Z+5JBBU:M44V[=NW331;MVZ*=*:****=-*:***=-*:::=-*::=-----
M--!N=;6/''.<YRN<JN<Y5<YSE57.<JXJJJNE55=*JNE5TJ?V!
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M))3L),MC<M(4PQ(C,J'$1\-[V.GX9IQH
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M_>=PW*#X07>APKD_RUM+_9;LO_A(9=0V]>]6H/4&8N_WG<-R@^$%WH<*Y/\
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M5LL_2^'?[2FFG3P4Z:4Z?[_!IIIIIX?V_,-R>-'^@
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MA0HTO%9#BRZT6 S)F'(_#%\5[4A*]%8CE:IH -T>,@
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M*-;K':BZ:H
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M=W <4F%S!@[\/CF1WA#-R^Y2G(NJ=8:IU?AFUW/1NN[@>\U8\82^YVXA:1_
M->JTO(Z3I0I;!;*MEIU6JBH%R>E*@\70YK#9:9*K=O :<KBOV4)"L:W%17NV
MT\J8KIKAP9=\2&S,R:Y;VMP=8^HPFKE.1/&BQ')#AIITQ'JC&)XSE1J*8=1K
M=7DZ?/3>K5LT\%DYF9Q@?#"NZJL=,Q ?%Q@TNGTY\_4HJ9/^'(2+'SDX_"7E
MFNC1&(NI!'$W%=+/$U-,QHQ^3E).-%SR>H$8:CDH>(GBEZ@P4.$S9=MV[Y4T
M5OV[=\N8L7*+UF]11<MUTUTTU:="E-IS51S9"2:YJHK7)*P$5%1<45%2'BBH
MNE%32BGS]&O'O#F(467F+>6SCP(\-\&-!C6HKD6%&A16JR)"BPWSSF1(<1CG
M,>Q[5:]JJUR*BJA8$9IQ@
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M/+
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M/(B'"O>^(]T2(YSWO<Y[WO<KGO>Y5<YSG.55<YRJJN<JJJJJJJXJ?*)*0
M
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M/!EHT!*&D6-%E7P8D9/\:.QCHFG-/6&Q[;YC<'CX
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MPL(/@T=L=LU&5DSC+RV6F?@7Y&X/'0
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M,)$9E0Y>!#1$1&0F)H)/&0<^
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M>L2$F.4UBHB(_!Q,(RCF
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M3,S,QHDQ,S,Q$?&CS$>,]T2-'CQHCG1(L:+$<Z)$B1'.>][G.<Y7*JGWA)9
M
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MR#;GDH
M                      &"NT/=,L7IZ8TGX[L/,!GS3'S:FO'A0<+7PD8>
M5T>O6)'7=AMX.!PI#8<\UQD<3"MQP6T4FT'N24:B"Z?0GLU76V3Z:4(7*G]_
MWZ"MN&E%PPU]*X:=*;"X[/\ Y4U$P?934CC#S&5A,<F_"#2:,(QR@(!24$]-
M2)%M)Z:V4\O;XZHZ,<4$9&<ERJBNZJHZ,<,)"4:KN)Z77O L7II%*ZZ^==;6
MURTP$%"Y+V>\927(KJDF[+>2#)4G?)S8F9108\E;5MM,K)[18#5C-%>26BU(
M!_>2M::+,0"-ZO0U<L7KI:LQ59TKNU 3BOS>A//L;)<ID-;5DM-":FKC=3NU
M0R-!'C*]U:E==BQXE==>_%U7I+$Z3YZKQ_$KOZ%;.FM%%%/B:>+X=1!!N;/F
M9Y<?NQSW_2IU@2W73SI^)9P"  ,T<1?/QVLWWR8H_P!E\/@2NLWS?FII<!
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MXCW/>[2Y[W*YRKAABKG*JKH1$TKK'S"2D
M                                                 #\P.V*94>QW
MEU&DLIK8?!Y^OV'E6A\NQV;0N></H6:#&UF7':':%)-_TR35LX2I2G$^&6XI
M4N)"DTV*@- F<D=]H3C5RY5P(0N,THJ:-?1XB.55P71I\RX?QUO+MGL[5%GK
M&"6(RM'[11V"RU+'Z,#[;92 ON)V(K53#;63K]E"378[/_Q&["J;K746MNE6
MKO&7'N>JUH9-6CULQ=%"XXKCKXJGH+E@0   %8\V?,SRX_=CGO\ I4ZP);KI
MYT_$LX!  &:.(OGX[6;[Y,4?[+X? E=9OF_-32X"  ,4IT,PY1,,C4K9S#>A
M6I=2IHH4/9YY#D7;2:W;];HX";;M:H)=4\/_ #-I)UU)4U_-9U\4<K-K*>$Q
M\M:;EYQV5G8TZV)CC_K2&F0CMG)T;!]5V0AVG6S%#65A7H+++3H"P5I-+L3&
MIJP\GQ? HL^[PQ\OA^XZ9_Q53][211OR"/IV!_\ /V47NACXR6S2?Y]0Z#H\
MU:_<;X.)[ONL-^01].P/_G[*+W08R6S2?Y]0Z!FK7[C?!Q/=]UAOR"/IV!_\
M_91>Z#&2V:3_ #ZAT#-6OW&^#B>[[K#?D$?3L#_Y^RB]T&,ELTG^?4.@9JU^
MXWP<3W?=8;\@CZ=@?_/V47N@QDMFD_SZAT#-6OW&^#B>[[K#?D$?3L#_ .?L
MHO=!C);-)_GU#H&:M?N-\'$]WW6&_((^G8'_ ,_91>Z#&2V:3_/J'0,U:_<;
MX.)[ONL-^01].P/_ )^RB]T&,ELTG^?4.@9JU^XWP<3W?=8\=;<N-2&7*&7"
MX-GXF%3BND)!&\J2-DT6LF%M84"Z<AIY:LS131<45%4,%B:<7MZZWS!R[9M6
M*:KM5.FM;&2L17(Q*4Y6L?$<B1ZAH9#:KWNT^1K45R_,AB3DU:.GPX46<=>[
M+PX\U*R,)\2CW?HD2;GH[)64@-P5?'CQXK(3$7!%<]$5432;7P?"S-A]NZ<7
MFFWVLXG(FH-U[TM94<RH@G%E-*F/#JD7'2>-J-*87,J*CH0JO6RQJZ7O4:G*
M-;M-.E'22DK"EF?X<-D-\1K%BYMT1S%<U%_=SBJ[)17.PQP5472F)\SVLM55
M+33W[;49VH2,C'G&TE:A+R$O.0I6/$9AX2VGP84!9A\.! SR-6)#;$8J0E1J
MKC-HRSE
M                           # _:33^ZFWD.PEZ*LQL,64RHTB"=&I*$
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MC:_[]?!IIIX=?FTTT^8;T\+7771A\R8X)\VE57TJJ_.?Z
M
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M:'%6 W1P9IQ@
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MFEM0)TWBERNBB[K5H)1</0J>E%1?L4EX"
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MVZWSE^@*0
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M.*'+MLTXG4M):.5OW[=HB7OFZ+IXT5*T7;] ?WZ-<D$
M
M     !^9'::SQAC)61BXGR*>R(CU[8_IAZ F5,Q'%MJ3Y![MR7LN: ,I6C"3
M!1E4VHNEYS-I9;*"DJT?ED-N-21F2\W:T5MU6R]FP;+"XUKL-9-.G#'!<-*8
MKY,G%?+IQ1,-?%=QL'&>>C[#C&!CJ28_D4\U(,C5!,(TI):*A2(D5)K532U*
M4\6\W#1Y!;2ZG46Z"9ULI!\^GMNNSHAECYVV0I-710NNNMKKK:W\/F+4 0
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MRW($
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M44!/=)A632UWP%C)PK9L&M=+%=>H$HF*_P '+Z$5?R+5 0
M
M       !^<':XXSE/]6VL_(OPYQ?/I2^U%F2L@I_=.SF0<S'ZMFTV4H6CU5+
M'2J94E+>BFR8M>;MEVA.,W55SR(AQTM-QHT[_2;UO47&*N&&4[R(B(_)]&/F
MPUL$QQ-C,#JG!7A;BQ6[&.6C1RUP1&=2ZP"+ )12GM%4J:J;J<0DV,T\L1+,
M%,(7M:K*:T=X$#" 1T+IIT@1.ES!2R*':ZZ<=*Z<<<?X^7S^4MD!    5CS9
M\S/+C]V.>_Z5.L"6ZZ>=/Q+. 0 !FCB+Y^.UF^^3%'^R^'P)76;YOS4TN @
M#,:7J)6_U+>7 M&4NJ5PS>WCJSLGL9&@U]PW.UXO K9=YBARHQ+P^'Q"2S3H
M<HJ\>JO3Q:J!H)GPC/Q<G5#)RUPS50D(4/#1^Y#BN2(Q/F>F)[[9E;/:@TOP
MI;O?"/!6YW52P%OJG4,O*=CX7/TR&LA-1=F+*JL)4P1-**1QXDT_]&973"Q
M[4+'[3_NG&=,ZQO,;+;-UWLRO-[(>)-/_1F5TPL0.U!^T_[IQG3.L,;+;-UW
MLRO-[(T;@(LY2L7(%#L+OXLLW+JH8N428\F:_G=65,J1F^0OG'0P=:FNH%#!
M.NQ>2]$^K6HNG5EBYK74S;NZZ[R31Z2[,XD9'*KE_:(L*-%5%<JM58D%5AN1
M4P5N3K-P1=.)X=;*)(Q+03JTY]&?*M;+L:M!I=4H]-2)#EX;(S(5/K*)4($5
MD5'LF,\B(^.D1\-,VYI,HRCEP      (OEB&H\FY$;3>DI$NKR2T)*C27$ M
M:55='J)/Z(7JC2$P%FJ^C'B%\U;178@)2E<2S=R^E*E!>HBJDCI"_?+7!**J
M:VPJ?P5,%^Q24 (
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M7#^..&'SE^@*0
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M5^Q"3P(
M                             _/-M)XQC5GY.1-JMXW2%D,Q);2):=KK
M;3!SL<6.,D$)Q7E&'FZUU-K)[MS(A1'7V@N-!F*J498K8:=]-1EXB5744VFJ
M"TYR:["ICL^E4_ N-7%%TX*F'DQ3#3KX-73\ZK_3;C'Q&*MV#8D0B4?NZ*"B
M1'S63BT9OYW5/Y[,.R52"MFVU'6]JW4^:G6OH=-.A!47ZGDY]50W8NF]5Q2U
MN[ZN24+KKIQTZ^S\_D_ F$"    K'FSYF>7'[L<]_P!*G6!+==/.GXEG (
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MI<Z:LWC7@L45Z@2BX+_!R>E%3\RU8$
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M\'+Z$5?R+<@0
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M)B953O<V4UN'"OB J8?^47\"QP$&:.(OGX[6;[Y,4?[+X? E=9OF_-32X"
M.*4'XD)ITR0OI;UO7BMS6U<NI\?/E4)5U::::ZU%E!.;YHB;M_/\UTL8NVM=
M?#II7KKIKX)P\WI3I(Q3Y_0O0?3_ -2D+D:0?9?(O=@,%^;TITC%/G]"] _U
M*0N1I!]E\B]V P7YO2G2,4^?T+T#_4I"Y&D'V7R+W8#!?F]*=(Q3Y_0O0/\
M4I"Y&D'V7R+W8#!?F]*=(Q3Y_0O0/]2D+D:0?9?(O=@,%^;TITC%/G]"] _U
M*0N1I!]E\B]V P7YO2G2,4^?T+T#_4I"Y&D'V7R+W8#!?F]*=(Q3Y_0O0/\
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M2@:J2^X5+BFI=U'Q7U_AJ[GVKW9_JLL@UW$2=K>2'*FE%X@06R-E0*$W0VG
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MK-9^.D&!+H_,0(<O"_P9:%!@,R8,&&SQ(;<K)RG93W.<O5BZ:X
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M;"(>5Q'(^(]Z,9"1[W.2'#R\B&CE548S+<]^0Q%R6Y;WOP1,ISEQ5?G$E
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M# 8YV"-APF,8QC&M8WLA=-6
M                  8X[0>27W',ML!>;K3>\IPJJQ//T;O9EX[//&EKRRWY
M_>5J.R+$?[BKG1?;5>B>TFA=<!E%5F\J&KC0==]"6W@W%Q*NHI<"IJ)Y<$7%
M%178X8:<=9%\NOCH^=,--_\ #VQ+!;%7'8O.RJ@K<RV8;CZU)JLV32$>1#[T
MH;2?2O&29]K6K#6/U5G]+N^S[8LV6X=.Z&32#:M)5TI12(7#%<-;'1YBQX$
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ML1ZQ(CXBM8U7O<]6PVHQC5<JNR6,;@UC$QP:U-#41$30A\PDH
M                                                 /S3;0.+3]>?
MK<8JU&NQ[MQA*,22I,[0.YOP154<<<DIBQ ;*?ZHNR!=OE]7#*9HC:1J$XLW
MUI,I4XZ2;.KG;JH;:".N$8\NOYD_O7^PN-7Q57%^**B>*ODTKK:^'V>DW1Q(
M9AR.L88#8B@Z(V>IUI12RD$RZX=;#>9D4+MU.0RA>H_'+5:5DLV4-F7?$TT;
MQ!#*E$VTF4EM2I0K;JT+VI*%TJJZ4T^5<5_BI8@""/9(ER*8;1"SEEZ3H]BI
MN'%&PD%%^2'HVV,B&E8S1<N%DPLJN=22R%]1,6[-ZY8)6K]1F[1:N56[55-%
M6N@8*NLF)VZ>H$%8@25$LZ44DQ2*%E!.44\S9.$% @<LT&29TD<+5W"YHH:+
MW+=\L9L7+EF_9N47;5==%5-6H%;LV?,SRX_=CGO^E3K ENNGG3\2S@$  9HX
MB^?CM9OODQ1_LOA\"5UF^;\U-+@(  KPZ"]RIP*U6A0W<TU-UZZ5T068<=%6
MGBT_/2N4UZ4J>G_ZK33P5?[O_2)T;"^G^A2JKC__ *JOVHIX.]KOT$[T<#7^
M8:-A?2G0,5V?N.Z1O:[]!.]' U_F&C87TIT#%=G[CND;VN_03O1P-?YAHV%]
M*= Q79^X[I&]KOT$[T<#7^8:-A?2G0,5V?N.Z1O:[]!.]' U_F&C87TIT#%=
MG[CND;VN_03O1P-?YAHV%]*= Q79^X[I&]KOT$[T<#7^8:-A?2G0,5V?N.Z1
MO:[]!.]' U_F&C87TIT#%=G[CNDKQDQ)R?$;%;*DK'E1 H?<N1'"Z:=M8F)[
MKM5N":'XBQHVRI](77*V2=:5?77*GZ*M^R>-*%E/I,:IZ0K&ZK1&]8F&1(D)
M608C83E7!7/A)':K=*.:L-7,1<I-&*NUO(N)NJ!/4VG5*'-U6F3-6EH+'OAR
MTG5(U%F&3+%:^!,0Y^%+3<1CH#FJYK6PD5SE14>Q6HJUVU25#3773B^Y?F_9
MLA%WP?\ ^XYG!VYQ.3,3I/I7PF!OR2YR\EV8X)/\WG+U0B[[\,';G$Y,Q.D>
M$P-^27.7D>S'!)_F\Y>J$7??A@[<XG)F)TCPF!OR2YR\CV8X)/\ -YR]4(N^
M_#!VYQ.3,3I'A,#?DESEY'LQP2?YO.7JA%WWX8.W.)R9B=(\)@;\DN<O(]F.
M"3_-YR]4(N^_#!VYQ.3,3I'A,#?DESEY'LS7B+"^I6-&#9UM:V*J6>W:J[-;
M*JC>Y:KNI16[<HO1]7K5<9)BFNNK0PU;NNMU!O[HF7==T+5#II=,)>#HP_PH
M>C-9A4Q:BX+ UX*[,-=+%\5=*'S5:%^<KU9?E9:+4YY$<E52NHYK9F(UJMK3
M<&U9BHB9%1:B-G&9,PU,F(AWHO&G
M                                      ,&=L1%\[R,](>.Q]#3/>D<
ML=@.=T/1ZF<'8HS:?A76Y+T*MES-9KMN2$]9/HIU(BYR/:5T1KM1-T6)4/L$
M^V21FE1)DJ *VX8Z?+]+)36777S^;#Y\=&G>#%EZ%L-<7[$C,^Y'[\M0;&U#
MN95UCMR,:VROZ-=.X32-(W:*4AMR/Z"IG=*;3*2T9*M->UXB)=3RADC>L4$U
MDQU_*4KKKYU+5@09CYUG7BWY>Q]=L+MJB39Y36#/**AQ4H0H5F%%/1<X%:%:
MY&?MTVIS)!*4P59IKB1'B,1/WWT9-N],>"ZUB+36;]S18:XJ3#!<=;1IQPTZ
M</(N..G63Y_)ILMA:F-9&Q?B)-9J\8<:*61%/=3YEFF8XJ)N"\Y5N^[VW8C8
MX8.FHU(,]VW5QIID;WSZC<8"<B%6AJI*/ V_;XA5Q5?_ #K:-?R^<^;-GS,\
MN/W8Y[_I4ZP#==/.GXEG (  S1Q%\_':S??)BC_9?#X$KK-\WYJ:7 0 !6)W
MJ3?M.59MFEF/+!B@[73=LJF2+X:BA;KTII\-)MN)R==))%[P>#6HF6N5VJ-/
M!5I5KK5J*D3';?P;C^92JX;'\7:?P4YSA9L<O1;TLI$^%!D_\OJ_U&5_Q^M_
M0<+-CEZ+>EE(GPH,G_E]7^HRO^/UOZ#A9L<O1;TLI$^%!D_\OJ_U&5_Q^M_0
M<+-CEZ+>EE(GPH,G_E]7^HRO^/UOZ#A9L<O1;TLI$^%!D_\ +ZO]1E?\?K?T
M'"S8Y>BWI92)\*#)_P"7U?ZC*_X_6_H.%FQR]%O2RD3X4&3_ ,OJ_P!1E?\
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M?9S=VGX65+6#8GG8
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M;"5[VQ5?!EX<PCX3&I&2&L1CYO&6<F
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MC3$5[YB)$:K7T:&L#P960H#F-5Z1DBLBY7B*Q#0,;H\8
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M2:A0LED?_$1QV0NFL
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MSG.<JJYSE55<Y5555555Q4^424@
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MQ3%<%PPQ3R+AIPQV,5P/G @
M                *IY@Q-C-,D8H[7RL:7'*.B3W2UU*2^$7FF;@\2J&XR":
M?WPQE9&5ZMR1E-?+[E?-5I]6^O'O6*S%LK<M8D[3Y2I0FP)R"D>$R(D5K%?$
M9A$:US$=C#>QVAL1R88X:=*:$PZ^Q=OK67<U6/7+&U=U%JDS(1:7&FF2=/GE
MB2,>8E9J++K!J4I.2[4?'DI:)G&PFQ6K"1K8B-<]KLV/(.V+_J&T_F[(OOV-
M9_Z3H7!S?6)KO!Z?_P"U3?Q\O8W)VR7N$V4BEOL=IQA';6C)/X)CEN,EKH;#
M2]V4S'!S/2D4D1;9'?"T8-J]_>B18*6-U5#1E0N>)XYR_=,:W*ZMU!@PY>%#
M@0FY$*##9"ALQ5V0R&U&,;BY5<N2U$3%555PTJJGB57JU0K]5J5<JTPLW5*S
M/S=4J,TL*#!69GI^/$FIN.L&7API>$L6/%?$6' A0X3,K)APV,1&IU=*(BT(
MW%VA(2Z&_P '5)' 5) I2C<$U%]2E27P9I:T)<'5%-=2M1+<-[:E]=;.MK<]
M=:1<-<>>VF8SV87,E&>U&TU"IR[3?-EFTA):$7-7Z*-SHO&;*65*V[]VBC]"
MFY=IJKIH_1TJTT^8 >S40(UGK*I62*5*1<H8(6%&HM9J/6")N\5,&R5DWK1J
M8ME#1@B2OF"U%RFS?O%"MV[1567M54 >&39+,3W*I/0@T6P1>*R6MDE=V$T!
M*+.55)VMRW(HI+MDI0J'BUO<+&YV#1J[:HW&UXM&FYT>*!]_1O(%)%+3*4-'
MT34.\1,(B?HF$M"*.83-/ FWTLII8WNGWD_3330C=*6[-9333]15; 'GHC(9
M;94UQ:;;0:[?6',9T..161$!)25-PFZ:KE=)I</D"A<TK&::[UVO2^?NF+NE
M5VY5I5X:ZM=0/[;[+9S3OK!IK--M-HTXCVJFX#+?0DM&OKJE5K7K4HK%Y.*E
MKBF>UUNW-=39VJ^8UUN5^&Y^G5X0.E                  5CS9\S/+C]V.
M>_Z5.L"6ZZ>=/Q+. 0 !FCB+Y^.UF^^3%'^R^'P)76;YOS4TN @ " 7-0IZK
MRIK9M.36UJ:K\34I$Z.MEM=/%I^>RJW_ -<>H_9?N?I5:^'37_<)P\WI3I*5
M1%7R_5Q^W)7\3P_$5_0NSV)H08+\WI3I(P3Y_J)U1XBOZ%V>Q-"#!?F]*=(P
M3Y_J)U1XBOZ%V>Q-"#!?F]*=(P3Y_J)U1XBOZ%V>Q-"#!?F]*=(P3Y_J)U1X
MBOZ%V>Q-"#!?F]*=(P3Y_J)U1XBOZ%V>Q-"#!?F]*=(P3Y_J)U1XBOZ%V>Q-
M"#!?F]*=(P3Y_J)U1XBOZ%V>Q-"#!?F]*=(P3Y_J)U2EN<\DRA%T<P\?8"TK
M-M3>F8&'D3K1]:@=AG2%]G2MD3'S$=Z=K:<:4KD;9A00%LZ7*&2Q<NK%35=J
M^D*28H4%SMFB(S+8YOBZ45$54:]$7_2JM7%%R5P<B+Y40S)".DI-P9A$BKFG
M93FPHT25B/AX+G839B"C8L)(T++@N<Q<49$<J(NL:V"HQ@
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M#161:C=_EB["O)SOT5K3D*"%30NOH5$Q\BXHJ_EHU\4TZ-9='@(
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MIUJ/K*-JX*J2M3QO.ZI)MLVV2UU6[CCJ3J$2FI3U+::B?[Z3M0
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M:ABNRI)8$                    %8\V?,SRX_=CGO^E3K ENNGG3\2S@$
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M7I(I90V>OV"]P2U<%T[#D]+51/M4NX!
M
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MP(
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M?\&FNGB&2^I>C2[;U\/AUHUJT\.NFGS_ # 3@NROV=!VH$@       !!D_0
MT,BVRRFJ]%1R))!B35"DZI-]L&DPH<,NN"9+;DIM--4:U5)6;-UO*2^V"!)P
MEBU@HI&DB\;L)JJE':[)^P)1</0J>E%1?Q)S @
M
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MZ[,*W3KKIIKKIY:\):^#7P?/IX=&WX-?!K\WAT_W@,&[;[JFDH%(
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MTN@PCN<@X$FR<5R!(DLJ A4UOG3'8\JI\^P6* @
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M36TY?KM-Q(2;6AEKHB!5I<:FAY&-B<I<%3R+Y-C3C_>./I+Q 4@
M   !GJX=GZE/TR9-2C/DR2$<;S =$=0RMK.K*MNJ)DURRC%LR67)6Y:&M=.R
M0^6R_(0B,VVU^0J%HI0G,<I97$==55MTK:Z)Q^9$TX^7S;..&E?+Y?-A9F#X
M5HAXM(BBIO%8D-^R](5R3I+>ZTG(R+<77/;93*C9(LI: @%"B4@(3?8$=,QM
M)287T,WZ[:/<55504EI34E T"KCA\R8)\R8JOXJI.($
M                                      '+FWPRT]UI3#/N]KDGPO)Y
MI60V8;7TDLZUE*(Z7M3JFE-V\;H5U%/)Z%C&IHX3)WBQ?2Q>UO7*-RK\4 T7
MPRG^F7EIAN]KO9&+J!M),*S1<"2Y$RPJD-:-#R9>/HQLZ5M*!+6[;T-DJ[M)
MDMK<HTO6Z/'I\('4 #PE!T-E).):<JN)"3%!<6-&ZBD5!73R1Q8<&J7?7-$-
M+*F3%J^H+&J(5,K&B84HO'=4LO?4-PWI:N7J0/= 'AN5SMIF(:BYW@X4-J-I
M(LTF%9PN56((2&EEZ[MLO1?4594,%2!*S7?O6K--TR8M457;MNWI5K7733J!
MY;CD-@,^\UB[N?+/:U]\+9%LLJPXW,BHEYX.13UIT36^UK:F=*UN!;4-:Z-"
M*4DTFSYO6NG0N7N:U:>$#J[-^R9LVS!>]:,6+U%-RS?LW*+MF[;KT\--RW<M
MZU45T5::Z:TU4U:TU::^'3770 ?* (K9<ZPC)"M=0([F.*WZNV"]TW?167(3
M1=*M9*V*J*+YFZG(:N>.6R]FNY11=O5V:;=NJNBFNJG6K334"5 !_-RY1:HK
MNW:Z+=NW15<N7+E6E%%NBC36JNNNNK72FFBFG36JJJK732G337777330 >6A
M+R$Z49,<396DEQ-]:)V5%'74)1)JZ,K)YFC2X7/)BHGWC!(^3OT:Z5V3)6_=
MLW:-=*J*ZM-?" /6 'C6'&WC2ZH-8LNHQAS)">G*ZJW;"H1O+J8E*]XZ725-
M02+=^I0))ZI?35&PG'3)>T6.WD\[;+7;M96_3; ]D >$<=+93E5'0E!QH1%;
M<)XZEH".<5T\LJKBFFI-U>44Y'3[YB@VIGB"%8OK1TH2LWS!5)LW5&_;MD[=
M=[0#W0
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M%SQ#I.S:%.C!4P1=#5U_+HQ\NPNE/(J8Z,%*\N>2]H2A0ZYY1=L1YRJ$\O3
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M
M
>                                     __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g383770g24x25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383770g24x25.jpg
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MDJ&QTM?P&B0F-D)S=WB#LK;!X3=6<IBSM+7")2<U0T9'=826V/'_Q  < 0$
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MCC&.,8XQCC&.,8XQCC&.,9CK=>KWI7UOM(#I#8'47I6E;BM$\(+KVK[1LFI
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M ,UM1VOI]*5741:B(N"5#(ED T2*D/CD3?U]#I5_M3=4?\7U _TK\R?B2?\
M=.B_G9?^3FO^B'L_SF_D+_7RUZAZ;CI?!B9<*9JCJ=6\_:+P81F/0:&M&(MA
MNM@/P4J4O:C></(A$XZ)*,)RAN0EUM#CJ$I=6_$LYY&JT7E^FR]1P?\ P?,9
M)[?T"FCWP- _,7HP# _IGB"#].7F/].#TPE9\(6/T_U32YY*7&@08K6O=?\
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MLQ)4*H LDDB@ .22>!US'?\ JO\ I(_;@]/G\=^G/M?G?_0A\+/_ "O\(O\
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MM)4XA*D8SGG,U_97:G93QIVGV;K^S7F4O$FOT>HT;RHI 9HUU$<9=5) +*"
M2 3>9XIX9P3!J(Y@IIC%)'(%)Y )3< 2.:.2#ZG(^=9_T8O[-YH9EH^9^K[,
M>IR/G6?]&+^S>,4?,_5]F/4Y'SK/^C%_9O&*/F?J^S'J<CYUG_1B_LWC%'S/
MU?9CU.1\ZS_HQ?V;QBCYGZOLSF98=:7E2YLF3C*<IPAY$-*<9SG&?'C,>(PO
MQ8QC.,8RO*.RL]TYSX<I8^DGVU^8#.SQDXXQFJG?FL1EVWVU5KGO'ISK6R+@
M]3Y=3#JWCU):EV%)$5VRGB.K''.GW6_4]18&RK%7RZBB0-[AG:Q,G'($F:+'
M#%C8XV RPZ77'L!]O)''JZYM40GP(0C&<YPA*4]U*6M6?#C&.ZEN*6XK.>W?
M*EK6M6?>I2E9SG+*Y]<8QQC(IW#O'4^@*S"N6X[N)H58(G(U;A&#*9JHL@Y,
M@D244:C$&+,>\]Z"()24Y4TEORXCOB7A7@2KJ=D=B=J]O:E]'V1HI==J8X&U
M+PQ% RP(\<;2'O'1=HDFC4\W;CBKK!J-3!I4$FHD6)"P0,UT6(9@. >2%)^C
M,;/ZYCT(_ME*)]#8_L/GH_[F_P ./_+NM_E:;_GYI_CGLO\ =D7_ /O^KEH4
MCTD'0\+"S8Q#J,H\5]VW[!(MM.,V'Q*A%[]92PV1CPA%8\$P=-BRVN^?%Y;Z
M/&E*NZ<57\'?PUE!:/X/ZQE#/&2&T_#PNT4B\SCE)$=3X6IHD4<D]L=F*:.L
MB!H']GT8!@?F^((/TY+U"Z].D':%P!4&@[VJ%GN-GF*@ 0,!HXF83F)8>E*8
MCYDB6&,+PQ'>=_1'FT^%O/O[]L9UM=\!?A;V9I)]?K^Q-7IM)ID[R>=V@*1I
MN"[F"3,U;F X4]<O%VIV?/(L46JC>1S2(-UL:)H6H'0',NN>3S?QQC'&,<8Q
MQC'&,UQ=><F\3\U(528NP9TD;7;Y.DBZK<MKZSAQ)$^. CC-M.VC4"G#]KBZ
M><9D-E-96*/'U[:57T>NT&@TX=7I2F2/'^ROK_*.>O&9[-,EB%6%H'6)+9-X
M>(=S8EB8<A,WLU&=E2LBD/MPF<DV\.YPVP]EF'F1W8RM+2,99&8=VKI[O5H?
MNI-ZE:HCRK(5M,*/7VSLQJK>Q2E-M]1K%FDQH] ;RJXA73[Q4W.=BRIY1JSG
MH4,Q'C5\##F6!JN30KPYOQ'7IX>5>%Y4@GU7]7N\;Y]OC69P0([D.#"B.R')
MCL6)'CNRWO[-*<890TN0[[U?HCZDY=7[\_?*S[\_'RN6R >JJ*^GI?ZD%9)3
M5XQH7<"LH4V.PE6,:]L6<H5E$!*\)5CW9RE:5]L^Y6,]LX[OP7_7-\'?\^]D
M?[PT^:>O']XZWDG^]-3Y?XE_(9_/XY^\\^5XXQCC&>QCT*D=YSH<!*1.E1T_
M=)V%CRV40E([XGP^^>[\-]SOG\/Z)V_%C'/R+^&7]>LW^;>S_P#4DSZ#\'!_
M^F)R1\M-Y>8\P<VT^IR/G6?]&+^S>?*<[U'S/U?9CU.1\ZS_ *,7]F\8H^9^
MK[,>IR/G6?\ 1B_LWC%'S/U?9CU.1\ZS_HQ?V;QBCYGZOLQZG(^=9_T8O[-X
MQ1\S]7V9VVFU-HPA;SCZL9SG+CN&4KSWSWQC.&&F6^V/BQV;QGM\><Y]_&3G
M)QC.@5()$BR15<6?.0,@3""X0J&\1*3$PX[DE44:/CI5(G3Y&&\LPX;"5/2I
M"VV&DY6M..,9K4Z09-BF]0.SR4J594 BS.X'F31\SN$C#W#*@;A'18-HKM2V
M15@5)U)"U7 =D4N77M,%;'6[KFUP; >D0W0E=Q+9)\/8/+Q'MLW]73-G7&1C
MC&.,9X<_2H_J_>HS^$%3_DYIW/VI^#']8GP>_B^I_P!X:O/FG;?ZJZS]^G]%
M'F #']G9_P"-;_ZZ>>N[4_4WM'^(ZO\ V>3.?!^GP_PL?^NN<7-[,6;2?0V?
MJ^M7_P &MG?R?G^?,_PO?K$[4_C'9O\ O#3YV_@]^JL'[R?^B?/:/S\=Y]%S
MH3!(LBI"R T?/6TG*6U3(<>4IM*L]U)0I]M>4)SG&,YPG.,9SCOGW\FR.A(^
MG*E5;YRJU=+ ->\9TO@Q6O\ S>!_DF!_1^+/F?><CNX_\6G\E?LRQ-<UJN+K
MY#*@ 16<7S::<94*@YSA*-G6]"$]\L9SX4H2E*<?$E.,)QVQC&.22;ZGH/$^
M0QW<?[1/Y*_9E^IK5<0I*T  J%H5A2%I%04J2I.>Z5)5AC&4J3G&,XSC.,XS
MCOC/?D6?,^\X[N,=$3^2OV96N1E\<8S2QL/874M ZHHE0K>]=:;6LS.[8B]=
M:K';,,-Q:, =NA(S:*UM&NZFZ%]@YHKTKI[F*I+!+;&U)DH!,9/;%#V%^188
MX,2RW%=".!9J_5^V Y/J_)F;?5YLVQ:;UUK+-0M#VN7[+L:OZ\E(J&NI&R#;
M8,O5;.B;$H8=%<* AYVN-06S]8*6\/&I3<X#!@V2-,&37:V89 \>+H>=>(_[
M?3DAU/;DH3TSZVW%8VSFQL2]0TV\VX]61U?"2IT630HMF/7/(*Q$Z;'@PI/@
M?FY!0&4%F')T>#"!?H;C4>0+-9!X\/[,R(2K"DI5COC"L85C"L92KMG'?'=*
ML84G/X\9QC.,^[.,9Y&,A[>Q$?G2&Y4XG0\JSJK8:<)Q)9RK*LU$QC&,8POO
MG.<^[&/C[^[G5["_5SL;_.O9W^UPYK:L@Z74@$7\7F\?_P!ML_GH\_?>?*,Y
M6_TC_P#Q2?\ V[/-'5_X1V7_ !Z3_=O:.98_F3_P2_T\.<7-[,6>H3T TJ+'
MU1U"8?DL,95L*I93AYYMK*L8K<S&<IPM2<YQC/NSG'/S1^'?]5/@_P#Q#5_[
M1'GM?@L0-/JK('RR=?WF;_\ VD.^7POK3'YSGP;/56/,>\8]I#OE\+ZTQ^<X
MQ8\Q[QCVD.^7POK3'YSC%CS'O&/:0[Y?"^M,?G.,6/,>\8]I#OE\+ZTQ^<XQ
M8\Q[QG*U+B2%90Q*CO+PG*LH:>;<5A.,XQE64H4K.$XRK&,Y[=N^<8[]\XXQ
M8/0@_3G8XR<<8S6-M(J:$=;]2G5E^QQTV+&H@DVM5[&[7J_LV#"M-N#VNQV"
MZ5*]#M#T"5J,;)(39U5V=2#=LVC'#QZ@&)IDR:W'%,GP/]E^'A5^X^?'GLYX
MR,<8QQC-)OIY?U'^O_\ G%5#^3G;'/LOX#OUVZ__ -/:O_>/9.><^%'ZGQ?Q
MN/\ HI\\D//U7G@LY7OTZ?\ BF/_ &#?-'L[_!Y/X]VI_O+5YEF^>O\ !0?T
M$>9R^C-_5W=-?\.G_P#LV=YY?\(_ZR/A'_$1_M$.;W8WZJ:/^%_X&SW3<_$N
M?3<<8QQC'&,<8QQC-57I'M:U:YFM;3$#NFQ.R\4/94:IS=\4K5Q^;988^Y:<
M=*TL&9W($+:_A0$ #%GLD@9,<C62<8&B$@7HE;<V#,:992?61X@7U\#P1][S
M:$$0\T&$-2,0L2&QD!#^!JD+'8>1%:2[B MN-#0N%A>%8BJ1$BH4QY>4QF,9
MPTEE<J?&,<8R ^JS]2[U)?\ ('N+^3RQ<[OP7_7-\'?\^]D?[PT^:FO_ ,!U
MO\4U/]"^?SZ^?O//E6.,8XQGLB]"?^H9!?\ *5L/_P!_A<_(OX9?UZS?YM[/
M_P!23/H7P;_4Q/X:;\HS;=SY3G>QQC'&,<8QQC'&,<8SX=:;?;<9>;0ZR\A;
M3K3B4K;=;<3E"VW$*QE*T+3G*5I5C*5)SG&<9QG/&,U.=!^MP%,W;M*=0H/3
M%%H[D?9PAB)I>G:MJ%JK$@;M,<(CT@O$#5P;MS/L T O&+8F^$EAFWWZ&P)8
M?*QC+8=EC="[^F_SWUXZ5X\=,VS<97'&,<8SPY^E1_5^]1G\(*G_ "<T[G[4
M_!C^L3X/?Q?4_P"\-7GS3MO]5=9^_3^BCS !C^SL_P#&M_\ 73SUW:GZF]H_
MQ'5_[/)G/@_3X?X6/_77.+F]F+-I/H;/U?6K_P"#6SOY/S_/F?X7OUB=J?QC
MLW_>&GSM_![]58/WD_\ 1/GM'Y^.\^BXXQCC&6%K?_>\1_A[M7^5"X<D]?H7
M\@QE^\C&.,8XQFM+;^L\::VA7M\F*SKN\3)6QI,X.9I4?96B=N(F+"'3,_%[
M+:OQ;=:[SB0Z.&/CY4O<%<U53PM6&NO62YM.J<(.,D7S[/SW]'YSD@=3VS+E
MBFZRM]*KFN-C:.V8F&+/YM6CMM;M)P!5[HMP>$GTT/6J2-D, +>S*!Z[DAVZ
M;)DM8O4MTU+;%9DCGV !S?4>L#Z.A]>3C6Z@YM326G&[H%(ZQ*MU?6]O*4>J
M>0!@U2S0ZU"E_!!P+)8)0%!ZB9D80."S&); XD"#S&58F"HDAM=?DR#ZK'EY
M_9D\MHRVVVWE:W<H0E&7',IRXYE*<)RMS*4I3E:^WB7E*4IRK.>R<8]V&,BK
M>Z$?</W+]ZG_ ,E.P_\ @X_\T3'[G.KV%^K?8W^=>S_]KAS7U?\ @NI_B\W]
M&V?SQ^?OO/D^=EIIS+;N<)QV6TGP_?)QW_1FL]L8SGOW[8SGM^+&><C6ZS3+
MJ= IDYAULC2@)(>[7\7ZZ/<Q"D!2[HH-T6=0#9&;$43E)B%X:(;>0+^6B-"S
MR:!->0)Z#.NI.4YRG..V<>[..=1'25%D1MR,+5A8L>?(!]XS 05)!%$=1GJ)
M] "E.=4=0O?&,_\ UAU+X\8S_P#AN9^/GYK_  [_ *J?!_\ B&K_ -HCSVOP
M5_P?5_PR?ZF>@3P(_6I_P<?S<^#9ZK'@1^M3_@X_FXQCP(_6I_P<?S<8QX$?
MK4_X./YN,8\"/UJ?\''\W&,_<)3CXDXQ^]C&/\G&,_>,8XQFGW:E (5+KPKU
MAC5S9)6L7BXZ?G^UAM;T\( @CL.V,RG 5;+PNF.X[+*"9DLJ>V%>W<;IU[)G
MBQ^T%%RKPR+Y9%D^'07SYW[>M>?AX>O-@G4#7+?8P8"-5P]AL,9B=8LE@U7L
ML2J%5R)E%M(ZKE,DIM@K32X@:URQ$W+2">9$*?@<?C1'GPC;C$BN>G3B^>;'
MJ/A>5/(_*//ZQE-*"[V6NNG5RJ=<D)K#DMZX7Z%9ZS&'ONCHQ$ T-Q6FKY&>
MD!;?*D_"XB057R1!@'#"B'P;1^4YFG.*/(]E>SQK[\_2\NOKH\>SGV^ S(US
M#F4*PTI"',X^\4XVIU"<]_C4VEQE2L=N_NPXCW^_O[NV8R<TC^G?1,3TA4#,
MA^,ZC^J(J.,)9B.L+PO[G6UNRLK7-DXRG&/%C*<(QG.<XSX\83G"OLOX#OUV
MZ_\ ]/:O_>/9.>;^$]_B^*R/\+C\*_\ "G]9SR6)SC&>^4X5C\6<YQC]_P"]
MSC/^/GZGE1Y$*QS/ Q(J2-8F84;( FCD3GH;0FNE'G/"J0ILJ''[5BP'O4J>
M/;GVXXE?_P!TA.?"A.,IROOC"$I3CW*7G'Z5.._N_=YJ:312:4U\>U,\9DGE
M,<J:0*7U$LDSDM#IHG $DC%0'  H&P.<DDJR?^$B&D7<ID)I%"@4SL.BBS7N
MS.+T:.',]=?3;AI2$.9O+_@4XVIU"<_!LY[U-I<94K';O[L.(]_O[_@SYC\(
M_P"LCX1_Q$?[1#F[V-^J>C_A?^!L]S7EE/ED#\FR/M7GXESZ9SYCW'[<>64^
M60/R;(^U>,<^8]Q^W'EE/ED#\FR/M7C'/F/<?MQY93Y9 _)LC[5XQSYCW'[<
M>64^60/R;(^U>,<^8]Q^W.RRE]*<XD.,NK\6<X4RPMA.$=L=DY0N1)SE6,^+
M.587C&<9QCP8RG.5,GGQ_)7YSFLOK^>D0;AJ-3NX"^N1M@I^U .8!BY:)UYK
M-4EF90)+Q>7;MK]/'4 9B;#7$D^J51D&#@-H$QK%+C'ZY.9<AVYEEOFA](N_
M'R(^_7PS8JF>V"K0V2B*4,-1X(J.VT)PZ?GR$.(C1D2$/)0PX00G"\/R)RFV
MLN,X<E+;1WRC#*YA">ZH[ZT0V#&PR)H$8(0+3*Y(V#0KB&RD<,H%IL8&N$<V
M"95VR]AND^L^V<8#Y0Z+ .SP46)-)-0[$Y8+9'T="#^2ZKU]?,<#*DU]?@1]
M'T].#U\#F?$"0[+@PI4B,N&_)B1Y#T-W/=R*Z\RAQR,YGLGNMA:E-+SX<=U(
MSGMCXN5RV0#U52GU=+_4@G(V:C&="[@3E:G!V4IQG7MBQE:L(GJ7E*<>_.$H
M4OMCW)SGMC/=^"_ZYO@[_GWLC_>&GS4U_P#@.M\/[TU/]"_EG\_CG[SSY5G.
ME+.4*7G#O=.4)SC"T=LY5A7O_29[=O#\7O\ C^/W>_F2R=H+JHX$ET6R:/4R
MJS::<LBP/ JJU:M0[,)Q;#8 4X6F]'.JQ&-G*R6I12 ZT2X<V/D^@*=#Y]>.
M>#/;OGMW[=_=W^/M^#O\7O\ [G.DN[:NX@M0W%00I:N2H)) )N@22!P2>N8#
M5FKJ^+ZUX7TY^C/8QZ%20\WT. DH@RI"?ND["SYC*X24=\SX??'9^8PYWQ^'
M]#[?BSGGY&_#+^O6;_-O9_\ J29]"^#?ZF)_#3?E&;:?7)'S5/\ I!?VESY3
MG>QZY(^:I_T@O[2XQCUR1\U3_I!?VEQC'KDCYJG_ $@O[2XQCUR1\U3_ *07
M]I<8SMM.*<1A:V7&%9SG&6W<LJ7CMGMC.<L.O-]L_'CLYG/;X\8S[N,9R<8S
MX=0IQMQM#JV%+0M"7FL-Y<94I.<8=;P\V\SE;><X6C#K3K>58QAQM:>Z<L9J
MYZ&G7)>U=DMS]P%-ADZOG:-8<&6N_:/?V(VN-MO(\B=O>M=0]/&KI8Z5)E5]
MC((S8]E;$B#Q$_#%>C#8UDEY0RQ)('%?0:^@DG\G.;2>,KCC&.,9CC=>D#I;
MV/:"UUON@=56^W'G6'S-C/TX.2,$WHT2/ CN39TF,M^0MF%%C16U.*SE+##3
M>/O48QCT6C^%OPF[.TT6CT/;O:FDTD 98=/!JY8XHE9V=@B*P"@NS,0!U8GQ
MS3D[/T,SM)+I8))'-L[QJS,0 !9(L\ #V#(DV+T+]' S7U[)#^F;3$*>/IMG
MG09D>A@FI$29$"3I$:2PZF)A3;S#S:'6EISA2%H2K&<9QCFPWPV^%\JM')\)
M.V'CD4HZ-KIRK(XVLK#=R&4D$>(.5'9G9X((T6F!!!!$2V".01QU!R\OZ@GH
ML_:NZ2__ (  _HG)_1U\,?\ S-VS_IT_];(_%?9W[BTW\TGV9>E Z3NFC55G
MAW76VB]8T>VCF9D>#8ZS41(DO$8(1784YJ/.B1VWVD2XCST9]*58PXRXMM7=
M*LXYIZ_X5?"3M33/H^T>V^TM;I)"C2:?4ZJ66)VC8.A9&8J2CJ&6QPP!'(S)
M%H-' XDATL$4@! =(U5@"*-$"Q8-'U9D'S@9MXXQE+,)**@/9#D18N:C*7,3
M3 R27@-,HSXG_.AQ3(!U6<MX5X7?:32&<_HBT.IQE&0]_L^YQTZY9M4!62I(
M6P:M=7GAY)<^34VQ5IX.:LI:[ 0/+:9(R[L7BX801+/L1(N1KDAR/B.SF2M]
M*WW9-'H#[[X ]F02 +) %]3P.>@Z]>GMR_8\V'+RZF++C25,*PEY,=]I[+*L
MY5C"7<-K5EM6<H5C&%]LYRE7;'WN>P@CJ"/;@$&Z(-=:(->W.SR,G'&,QMZJ
M @>S:N=KQ*T[AIY(R2DP:J7TH[M=NRYLKE6LZX\0SG45=M1OX*2!B"OM59D#
M.!1I:!LR/AFUQJQ(:9(Z^'TU7UYC?UTCA=TT1HH^+:.!5 ]G439M-M9R[ZQU
MZ]JXA5Z%;K2&OVQ9>_:M?1RZ[4(T94S8N8]>,;"KX)LW91<8G("$11)@=?J\
M3?JX/YZR0AUVF4#ICZ8L5TO!UX$):QID!P\1* K[& 1A&C2%AK8+X3-0Q]<L
MKA8T$$!E6*$-A1K/%]:8KD864/!I,"0+\+KFO/D#P]N58U?0$W7@ >?=F0]G
MN.R16KAUMJ6JW;_L"4,KDN1K=%K#TAQ$HFW#4;8R?LN%CHF0>'Y+BF96,O2?
M5<QV\^>M.>7B6-W"RR]RANY-C250X]%?2-GCU79RLC.J$HG>,*I P2^>?2;@
M4.>?*LQ.V%M+K+NE!O%.C]"\F#(MM0LM98FO=2NH7F8;QX+-%M2G6D-)6ZW'
M7*2\XVA25+2C*4JQG.,XZ_9YT&BU^AUC:[O%TFLTVI9!IIE+B"9)2@)L L$H
M$@@$W6:<SZJ6&6(:0@R1O&"9XB 74K9'C5WGFK_K.WI$O[3-1_CBU_\ ://T
M5_=O^#_^3];_ "A_RL\=^AOM#RC_ ):_UL?UG;TB7]IFH_QQ:_\ M'C^[?\
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M9?P'?KMU_P#Z>U?^\>R<\Y\*/U/B_C<?]%/GDAY^J\\%CC&9U>C-_5W=-?\
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M4D^VOS 9C9@:I%3]Z7-^W<S?56;'O10?JW=:?_H6Q?\ L&?YI=H_X*_[Y/\
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M_P#JZ;W_ /[2<^6[NRO\3VA_I.F_Z3.]MUO^-TO\Q+_U&:V.L?KY](%T@[+
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M5H=T4=)#H^ XYTZ:C6XY"BK6M5,$94I:V&U*4K/J_ORI6<YSG\.<\CXWJ?\
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MI$0-4[ ;+XB6A;^MJN3S: =?KDBVR2<P9D@R)JL,30&6W)C9.\4-'9#,5]%
M6=56T^5==C,^P &BUFD<2B.E <-M8AJ!47RQI68^E\FIW!5+$U=7OIV\'KEJ
MP)L.Z?!Z V?A3K,,EA6I\ 6_1I+K\VJ6"1&+S)LP:^:JWL^P31\J2IX3F?D?
M*\,F(_S'/&L<S11[CM(0[J)[P !U!  (5[4$"FK<.",M$[-&'?:+!8$ @;.J
MM1)()6F(OBZ/(RP-MV^B6NG"K6&7I&Z#]>W43:OA)L2,FVB]?V06.*?!@_5
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MQ&@6B:_92)2G<2,+SQ1,H3NMTKJ7(*J2&<1;S0MFNP+\$:SP 9/V/M>YTG9
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M0EB$9C D#B2-7W4RJ+=E(Y](J"MV54D?L1D)(7$A*%3&Y7;88FE5@>.+(8<
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M9UO)ZVOAQ%8#EKWKZQ7*HRA<8M(!U4\3JA)49DU&*RXIB<(#3A3D0R4A)BV
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A-62;/   ]@   Z   4!F0*% "@ #H![_ *SR3XGDY__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g383770g31v63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383770g31v63.jpg
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M\H+:.8[_  <T7+.O.K% OS!<X[K<8J_/EJJ-&\>,I F.+/J19+,*KP0#)%]
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MDFC&M!))-Z[=GV9(65!= D)9DO#?$=%B4<^(^)$=0&)%BQ71(L1Y  TGO<0
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ME9J?TW^*81>XTTQK&6S:;)B8FA-.,>:T#,.?#A1&Q3#IS9?"B0W0JPZ#FB&
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M1K0ZC6M=T;#EP(-JPXS9:-*CD=%AQYJ1E8LE!EXL&L00[2;%@0FS%JL/XF3
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MU&SX:"7$DT %3J6$&9Y0R\&%+P>3DBR# ALA0F?^('.T(<-H8QH+K+<XAK0
M"XDT%Y*S7G0[H?=)J[]5NW]#<X^B6'ZYFOA!_D%R]/Y2_EZ1^/\ ]2GG0[H?
M=)J[]5NW]#<=$L/US-?"#_()T_E+^7I'X_\ U*UF8G^U5@1DQ#)ETSJ8_%Y
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M<1E-0@&FU8SAD8"F8@?<8V<O [,B(,,'"3!P'D[!TQU75(+OO]-ZHJS^"<K
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MFPEV:$MGZC=8BST65.[@,DI[>)S6?\V\*^Q-?\\I^]XJ=W 9)0;^)S77T@4
M4=+L=!S7=ZV1;.7+30J_V=-V[S=RFT<+M\/\JI(NE&3S1LJIIJFONT<ZI;;;
M(*XT5.[@,DH-_$YKL>;>%?8FO^>4_>\5.[@,DH-_$YIYMX5]B:_YY3][Q4[N
M R2@W\3FGFWA7V)K_GE/WO%3NX#)*#?Q.:ZZ,"@#E1VBW'-5U6#C5H^21*OU
M5&3K=JV?:-G>FC_;9LXV9/6;S5%;&BFS5VV<8URDNEONJ=W 9)0;^)S78\V\
M*^Q-?\\I^]XJ=W 9)0;^)S3S;PK[$U_SRG[WBIW<!DE!OXG-/-O"OL37_/*?
MO>*G=P&24&_B<T\V\*^Q-?\ /*?O>*G=P&24&_B<T\V\*^Q-?\\I^]XJ=W 9
M)0;^)S3S;PK[$U_SRG[WBIW<!DE!OXG-/-O"OL37_/*?O>*G=P&24&_B<T\V
M\*^Q-?\ /*?O>*G=P&24&_B<T\V\*^Q-?\\I^]XJ=W 9)0;^)S3S;PK[$U_S
MRG[WBIW<!DE!OXG-/-O"OL37_/*?O>*G=P&24&_B<T\V\*^Q-?\ /*?O>*G=
MP&24&_B<T\V\*^Q-?\\I^]XJ=W 9)0;^)S3S;PK[$U_SRG[WBIW<!DE!OXG-
M/-O"OL37_/*?O>*G=P&24&_B<T\V\*^Q-?\ /*?O>*G=P&24&_B<T\V\*^Q-
M?\\I^]XJ=W 9)0;^)S3S;PK[$U_SRG[WBIW<!DE!OXG-/-O"OL37_/*?O>*G
M=P&24&_B<T\V\*^Q-?\ /*?O>*G=P&24&_B<T\V\*^Q-?\\I^]XJ=W 9)0;^
M)S3S;PK[$U_SRG[WBIW<!DE!OXG-89:-52WD ^).-PB$J+!RTA%1E:1K)2 D
M  O PXZ<'AMRFI)X'"D)%'V)8FV;*,ASPZ&:O%T5R;+1=4[N R2GMXG-=7<1
M3J<N;0!1_&DYX\CCR8-(3O*LZRYU$AQ-B%(2EM&]B^#*\<8&"@P2\-I,MAC4
MF18L%W6CIVW245.[@,DI[>)S6Q^;>%?8FO\ GE/WO%3NX#)*#?Q.:>;>%?8F
MO^>4_>\5.[@,DH-_$YIYMX5]B:_YY3][Q4[N R2@W\3FGFWA7V)K_GE/WO%3
MNX#)*#?Q.:>;>%?8FO\ GE/WO%3NX#)*#?Q.:>;>%?8FO^>4_>\5.[@,DH-_
M$YIYMX5]B:_YY3][Q4[N R2@W\3FGFWA7V)K_GE/WO%3NX#)*#?Q.:>;>%?8
MFO\ GE/WO%3NX#)*#?Q.:>;>%?8FO^>4_>\5.[@,DH-_$YK#.(U530\+BSO<
M(UDYP<6,!8XXD2R)XN) +"VQTH+$*%-2! <%<' B!9\T;K-AJQ@6D\51W(--
M5E3NX#)*>WB<UJ(HUUN.V <J<).*V,VG&6>2$DK058PPC8$>88U8[Y?'(:TD
M*TC$L\:$QNV7+\:W1^*08[?'\#MOE17V<!DFCMOIC5V:D?S;PK[$U_SRG[WB
MIW<!DE!OXG-/-O"OL37_ #RG[WBIW<!DE!OXG-/-O"OL37_/*?O>*G=P&24&
M_B<T\V\*^Q-?\\I^]XJ=W 9)0;^)S3S;PK[$U_SRG[WBIW<!DE!OXG-/-O"O
ML37_ #RG[WBIW<!DE!OXG-/-O"OL37_/*?O>*G=P&24&_B<T\V\*^Q-?\\I^
M]XJ=W 9)0;^)S3S;PK[$U_SRG[WBIW<!DE!OXG-/-O"OL37_ #RG[WBIW<!D
ME!OXG-1B9DO62.6""J60V#5X&U90@DZC-9&;,$"[!D39?YUA!P"ACZ1H2,N@
MMEB]PDL/&N$U/F;KXFV?FZWQ%3NX#)-';?3&KLUM;P13H^3A80_?QIC,Y*-,
MF8Y$7DJRVDY\/'5!Z4@+!0"Q?0J5&@E2XI,R^8M%VHQ0F/T>JH;/6V%53NX#
M)*>WB<UL?FWA7V)K_GE/WO%3NX#)*#?Q.:>;>%?8FO\ GE/WO%3NX#)*#?Q.
M:>;>%?8FO^>4_>\5.[@,DH-_$YIYMX5]B:_YY3][Q4[N R2@W\3FGFWA7V)K
M_GE/WO%3NX#)*#?Q.:\,&M'7#5+&&&(36DU*0KLC\) S/7?$6$=*X?U_-*Z^
M$\(V/".R;L3LV3<MH//*#B^(E8,GW249[,8Q0A]AKH#<28WO/O[^]BY+C6_4
MV[?^&E/;4UX[EDI9;/:XY6P* Q+/:EA:E>]9NY8BU) WKVT1VC:Y65ST:*J!
M07*#D9UCM@RS:)HS\S7KV++RQBM#G#HJDKD,>8Y)$H*UJ/\ (4]AK6HP%U:T
M4[^;ZZH+;4Z(QB7=I"H"NN\W6V&UD)D=DW#.8L[H:S*SI-Y>S@JWDQ<RE9T2
M2E<ZLAPI*)RXEJ-5% &HZ$%(2TC*XY,H3<-5XON%0=(X:KAP-^Q4EK%GVKK[
MJU4<.ZX:]K1DTB70Z.1KLY';(C5U.6]=S^/SCK%'A;.C8M+1B+)K8<?I+/9W
M,/C?7IDHM)AH2'&C[8G.7L *&H+@/8%;B36EYN-<0;]>--PW7JT5=1F]IX;I
MR(ZVKV0=45)>VA_!Q\$T[05T;85F$ZASJ1.XRXMBY9$\O\A5YR[Q,770E9LX
M'W;S(F9@4,DGBI,*R'53$W5IN.T;-0--GO5FNYI,^UM6L&<R*=D077ES3]XN
M79+K"E<^)@KV&:%JLUJD>?=4,V<SC=-2'+VBO!P!C7:M)1*45ATT9%C"4(&K
ME![JU&NE+ZUUW8>S7<M1Z$5?;0:U;=M6_AD_'75-J(Z=-[*7)RZ?/*[?V?M3
MR+VX6L0C+P^[K336/V$B_9MMXD)T2BJ3U^)#*C1QPDU?E2104V$@>S6-^TZU
M5N4-;4DUS52_/LNTA:^X5W![TG9@Q6#72^HB&T\WZU=[(3U?/PW5R/5I(+XW
M@<FI<5%C,#5;RB5RF42AC-E2$U3*,196ZAI2FB,*U);75O!UZA[EW!IOL0(M
MGKTJ<<=C9RM(HQT]BQZN6KCM/5#R&BI7"89&;BES I%0LEZRV;'P#T_*9O;:
MEN(5Q<T'? )&,C<W$%FU2[/"AI?2G_NW^R_77"EVJO\ [BHY!1Z]*SZZ9@%'
M)=FH[*X7UF^$]'2'5=.[),?CU^-K<Z];4ZM&R-B:']WQ5W&G,D/5AI&'#^-R
MA-W+9!'$BR[^3/5RI()K=>6X5I?6M/'W*Q=DAK3K&URU=$Y+VT>]06UW5B:L
M26@9CV&G%EM8[).N=MK/F@"SHB_+W@PKAS?4=JM>8,JQ/(-H<5+HB]D(W7!R
M5,M&K[^_^O8EU ;JT.&PBEVJM*[RI$ZFP]*.]NYG.3FG:3=[:W37JPG##=\N
MK4U=2#R0E_9!*7L)Q'T7[BHXQ9$<C[NL")..%1H.: W4P)F-Q(V46!8:ADL3
MJI=K.KW;?^[_ '*,'^G9Z2]Q)R D4_N*&*K]BQXB%AXO%>QKR O.JCFN0:3]
M4>6!F!?6 4D11<2YZ0LV1).;@A-QX:BQCY;1K"HF])L!%-]X)K7#7[L/:5%)
MB2][#M>PHA.'EQ1&/5G<5>=5;_)-0USLRL[C-*U[>"\V[2QMK2BPVW-(#?\
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M&X?[_P"*#$>.25=V?,$\I91ZNCOXW#_?_%!B/')*N[/F">4LH]71W\;A_O\
MXH,1XY)5W9\P3REE'JZ._C</]_\ %!B/')*N[/F">4LH]71W\;A_O_B@Q'CD
ME7=GS!/*64>KH[^-P_W_ ,4&(\<DJ[L^8)Y2RCU='?QN'^_^*#$>.25=V?,$
M\I91ZNCOXW#_ '_Q08CQR2KNSY@GE+*/5T=_&X?[_P"*#$>.25=V?,$\I91Z
MNCOXW#_?_%!B/')*N[/F">4LH]71W\;A_O\ XH,1XY)5W9\P3REE'JZ._C</
M]_\ %!B/')*N[/F">4LH]71W\;A_O_B@Q'CDE7=GS!/*64>KH[^-P_W_ ,4&
M(\<DJ[L^8)Y2RCU='?QN'^_^*#$>.25=V?,$\I91ZNCOXW#_ '_Q08CQR2KN
MSY@GE+*/5T=_&X?[_P"*#$>.25=V?,$\I91ZNCOXW#_?_%!B/')*N[/F">4L
MH]71W\;A_O\ XH,1XY)5W9\P3REE'JZ._C</]_\ %!B/')*N[/F">4LH]71W
M\;A_O_B@Q'CDE7=GS!/*64>KH[^-P_W_ ,4&(\<DJ[L^8)Y2RCU='?QN'^_^
M*#$>.25=V?,$\I91ZNCOXW#_ '_Q08CQR2KNSY@GE+*/5T=_&X?[_P"*#$>.
M25=V?,$\I91ZNCOXW#_?_%!B/')*N[/F">4LH]71W\;A_O\ XH,1XY)5W9\P
M3REE'JZ._C</]_\ %!B/')*N[/F">4LH]71W\;A_O_B@Q'CDE7=GS!/*64>K
MH[^-P_W_ ,4&(\<DJ[L^8)Y2RCU='?QN'^_^*#$>.25=V?,$\I91ZNCOXW#_
M '_Q08CQR2KNSY@GE+*/5T=_&X?[_P"*#$>.25=V?,$\I91ZNCOXW#_?_%!B
M/')*N[/F">4LH]71W\;A_O\ XH,1XY)5W9\P3REE'JZ._C</]_\ %!B/')*N
M[/F">4LH]71W\;A_O_B@Q'CDE7=GS!/*64>KH[^-P_W_ ,4&(\<DJ[L^8)Y2
MRCU='?QN'^_^*#$>.25=V?,$\I91ZNCOXW#_ '_Q08CQR2KNSY@GE+*/5T=_
M&X?[_P"*#$>.25=V?,$\I91ZNCOXW#_?_%!B/')*N[/F">4LH]71W\;A_O\
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MK#Z[ #!+AZB]7C0-PVE<T-2$MAB#%"1+H.-'-U2A\W(&N!8\+(2MU]3[+O\
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ML'Q 6E:T\4(L&)51^B+>/6.DLRY:M22HHFDP<+I)HO%!S_1ONILS<83(N[K
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M8P838PBH(W*MUCQU:J[U,7:ZQ6,KZ.7[8%:'7+P$^J&>[[245H3%D&,5:-R
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MG")PB<(G"*DO=JSZ?I^.U=/+)JXI;LS"V$MM1L8;B9 _!#;*(Q*1 =Y9+2[
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MNFR,D61-II-&^V=V\OT;/:W71UE"&^VVZ)_73!9+;;.VCO7.<YXNQ/ 9I5V
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M1FHL2A/$#WG4H"[%=^JVH)&V'B31:P=J9IV\K*EL3C NPW<U>F:98=>C3L.
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M1"2$0Z,1E&0Y*9ZP5JI[OCU[:#!6L>E!8[*)/!K%G,?CWFXM[*@H359<[%+
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M"=7ZC;[5LMDW,'AD'ALMCJ3.9.+,EU;0NN&C0EJV820A9IL8P&%]":39]G
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M$<$:NFCM<? Z^KB$UC'W+]5@NZ9Y=RHK%9+.VB>B_P \'QZ6 0IENR."B3-
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M[@,D3R#9>D,X]LS_ .]XJ=W 9(GD&R](9Q[9G_WO%3NX#)$\@V7I#./;,_\
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M?T%,GZFA<@J"'V]()I<XJ,:6G('E!SVFFI2[8A-B4GU=$)-05M W=8,@4A9
MX(Q-10LE)"R('XJ"ZKJ&_4-7L(P(OQ5M_A.(9,NQ0R!=3H#$)/,7DF V;<DI
MS$Y#$XX]BJL!BZT2I&0.R$P/QT8D[C_8"P();T70T>K/'Q6D'>$F#QFS(Z:E
MBTTOVZN.OP%/?K5 F-ST!>';)A<W9B6]"*J\MNAO1$C*8=W<@\'DAY&5B[E[
MQ#+O@-0%IQ:U?L8L=@LL9$HG-7J(B=--2FD2<OV&C=BW;F"RH[1_"''\3O\
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MP7WR@E_H Y]I 7^[B@Q'CDE7=GS!/*"7^@#GVD!?[N*#$>.25=V?,$\H)?Z
M.?:0%_NXH,1XY)5W9\P3R@E_H Y]I 7^[B@Q'CDE7=GS!/*"7^@#GVD!?[N*
M#$>.25=V?,$\H)?Z .?:0%_NXH,1XY)5W9\P3R@E_H Y]I 7^[B@Q'CDE7=G
MS!/*"7^@#GVD!?[N*#$>.25=V?,$\H)?Z .?:0%_NXH,1XY)5W9\P3R@E_H
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MX-1X]S&39P(U7>Y<*,1YPTV9[()E7^JY/W4#1#I.TA/064='VECR.2Z2.A[
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=MN_F3,O?7'5UG^@R?=H'R)UM:OK.T.^S/U%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g383770g36n42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383770g36n42.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X85.:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(Q+3 T+3$W5#$P.C(Q.C0Y*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3 T+3$W5#$P.C(Q.C4P*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,2TP-"TQ-U0Q,#HR,3HU,"LP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$S-CPO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%I045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q-T95=697;U9U3&E!
M4G97,B8C>$$[8U)Y365)5W!J5U1A<#958V1C1G!P<'18445G<5%1845&,$9$
M>#55*S$O3'9I:&%D5DA%:TMX-#=':DMD-CAA9&8U:%1!=$MC97%M6B8C>$$[
M87@Q22M%:T(Q2DA-5E=U+V5U3D982%5*3GE3444U8WE807!15DYD*S%C84MO
M5%=.8F$Q,&DW=6Q9.#162W%!,5-82C1"5F]F=$9T=B8C>$$[;FLX67511$=:
M;TU4=716,4I:5VIJ=DHV2U%&4'%0,%5!9&HS<&UC24-U5&=3;6(U<5HQ8E4Q
M+S0O3&=N=BLY9C4K3TAG2&-J:E!E,R8C>$$[*VPY54A7-VY086YQ4"M/*U!!
M3S502$QV6$QR97!S4#DV<&@O>C%993-7=41G2&-N:E!E<E$V;G%N3&DQ,4U2
M4W1F56,O=T%C2$-/-28C>$$[;'AN=E%X.#9W4E-Y5S=A;3!L=W!O.79#.&LX
M>2]W1%!/3&TO-%I';W-R:W%R-7)V5T9,94A5<'A50W9#4TPO:RM9;2]$05%/
M-4YN=B8C>$$[5C,X>39O=#%B>$Y:86M&;F-2;5941SAC9%%F:FM+5$Y29'-&
M1'546C<P0C4P,6)8<DLS<S5,4SAU;S=I4U5R1U99;41K3S!X2&)I1R8C>$$[
M;U!(-5IG-C=0-%%"1EAZ.2],.69L*VAY.4I(:7-%6&8R968R96%!9S$S>C=&
M37-S:S!C.78Q949*2FM:=FLW;5AJ+W=/87-D<U-R:R8C>$$[3#EZ:VY24C=Y
M<5AF;D<X34TO<GDS8U)G;S%053E&;E5J-'5.6E%$4W1+2S-,=4%$,'I).6]9
M8W-E1U%-5#5F<F%2<$UK6F)%5C4S*R8C>$$[,6995#9Q=#%(3F,V=&1-<U,P
M26%D>4<R-FM55V=P=E$X=CA!5WI+,'5L-%1X8V9'3VXT<W50;'HX47%U17%&
M.65A<D%Y1TQ6-S972R8C>$$[-%EX071--6]:=E5K:DM&04MC9E1B8VXK541P
M;74W5&A02$LT>4Y(9FXU+W1',W9C,U0U4E!9>$<Q1&PU8WIZ-W0O3C!M;V$X
M8F-8528C>$$[5W!85%-'551'2DAK<7IX:&ME36]H2E974$U+<6IC.$-A9' X
M8W-M;30T+U5.:C=T:F9V-5=E-VEA9&]:=44X:GDO2#0V3')V5SE69"8C>$$[
M66(R,W9R=5)::T-2>%)33WES-R]!1V%Q0U-A9SA25'5193)91V<Q:V]:4GAM
M>#%T>614:$5O1W5B1T8X,V%X<&PY9'!D-G1D:3!M-"8C>$$[>G!,3&-31EEX
M269H0VMT,"]H.',V*V]G.4=R5&9V24$Q=GE+4BM:9&8X,U%8.'-H,5A61F(Q
M54-2=S-5=C%:5DY+8S%6*V134&QV;28C>$$[9&IX=TDU1#5*;$5*:&9R-35T
M-W1);#AX6')H560O5DTY=U%&:4E,9W%R-W4S<69!=EAB:FM"-%HO:$@R3513
M0F@Q2#AW,$8P63E:=B8C>$$[<%HT,3E25657-&]E54AR2W%H;E9T+W-G538Y
M8VM9-"LT2T-G9DUE="MD.4=M=#1X<CDO95)44D8T,VEU8FEN24U664XX5F1J
M:SAC228C>$$[4R]H02M#3FM!+VY8>FUZ<C9'=%@W5$]F4V%L,TU5;W<O=T--
M:$%92'=Y47=1-V@X;5,R8GIP-7)%871*<D]O<3!40D<O=T).;4(R228C>$$[
M56QL5FA89795-&9!:#-$-4I)0T10;EAZ:UID=DU'<'%',E1J9'I-<D5D0E5V
M,3,S>$=#2#@P9DI&0F5V-6=E8F955418<CEM4U!I-"8C>$$[1C%0=5$S=3-5
M:D4T258Y25199EIM8S0T-C%J:7)',FI76%5D5U(Y,6%D47<Y:F)19SE-:65A
M435,3S-I.5@P67=H;49*849Q3E)3;R8C>$$[<G8W-&U26&A$:UIM36@T9G98
M2V]2,4]X-41A<' X5&LU2&E,2VQ.4%%T1VM71TE#5G%%<6=.5'AP>%!8-58X
M8TIM56-+=D<S-W1W>28C>$$[2U1),T]4<E%S865*.6AH-&EI;4QA-4M98C9-
M25=64%1,2D)5:4I86C)9='A(5G9N.6YT5$TS0D=X8FEA:59':V],:W539&I5
M5D(R-B8C>$$[1$UL>$8T549U9310.#%F;W!G4W8T;'%524<T035E3T)+5S-U
M='!A1UI,6D9U2'1Y0F-Y='E&=D%Z54$U=7%S5V)C9D%G2C96-&<Q>28C>$$[
M0DQ-0D)287 U4'9*9E4Q4'I(639J.$Q(,$)D=TIA+T%/5$%1;R]X<48S4'%L
M-F5.36IS>F\Y>60R2&UB>5=)+W$Y=G%D:$-I8VQ32B8C>$$[6EEO<6-1>$I#
M:VHT94M-=TE&2T-O,GAS3%)4:E-,*S$Q2WEH=DQ'9&)I>FU(3T=:83A753=!
M9VM#;S)W5W1*:'I#<E1E;G0Q-C1P0R8C>$$[0C%E>6$X=%I,8T])-4MQ5FQ:
M1FLT.%=746IH2E931S1I;TEP,'EJ56%E3U=00U<W1&PT2EAZ.&U00WEU66)I
M6G)/6C5K;DMT1&)R2R8C>$$[>$5944%-141R3U=$53,S1DTQ,F\W3&A124E!
M2&9T9G90-U!*>4EA>5%/-'8X9'E8,W5R5VI!=WHQ;&Q::$=S2U)*37A:='%%
M1C0K228C>$$[-U8S>E=Z,$%H=4IW*T5V,D]::'HK25-+26]%-VEU6%0S;F]O
M<F%.-C!&<WAL<WE5;%=+03A40W9P;%)*15E*3U,O-W-5+UE+-S!R5R8C>$$[
M;WE'6'AC3C-,;C-(-G(V,E Q,S5*>%-J3VE">2MX2%=T:GAM4S5U-S%:571K
M-%%X2TDT-#!#*T-2<6E!.75L93)9=6).3V5X+T%B4B8C>$$[14%K.2]0,W%B
M,W1V86U14$XY6&UN:TUA0BMG;$Y71D]*<4%N3E))>$E#3G-333,K:7EX=S1/
M1V97>CA$,3-Q+V1Z4%(Q=69'8VU3>"8C>$$[,"](;7,P,6QK=&AA>F-P635X
M57DO0WE,4#EQ:7-V,E90,F\V9V1W2SAA-7%D5G U67!C44EO-V=J>B]'-VY9
M.'-:,D%$<V52+U-X,R8C>$$[>E U6B]3<W)836-Z=&5782MJ3$9C2TA34F@X
M5E)X<%9H>D).5BMY44(P<60O=T)M-69&>&DO<4$K6358*VAO+TUN0DEX+VAK
M8G9U2R8C>$$[5C8Q1TQU,&=U,6EN=55L:&IJ5G)D5VMK:FYH4'A.34%1875!
M2V94;2]W045T:WE'-T@O5FU&,4PY6G522V\T:T=934<U2TM6:U$W:"8C>$$[
M;$@Y8WEA,C)9.60P16AU;G5#>7EY1U5O=$DP6FM*5D%!1C-P*W9*8E5G3&)A
M-6YH2VXP56$S6#1H1C%)0G%">6)O2VYE;45I,71-;R8C>$$[9DQ(;55734]O
M,C%O.7AP<V%35'108CA855)1=45D=TLQ2WAS=S5.4V=/+VIL6GE2=6IZ6&MU
M;3AN*V-,:49Z2G!&-U=-;%AP8E1!<R8C>$$[=RM+:"M$8S!(23%W1$Q!9%%I
M,$A,-64Q93!T-#=Q*W1:<DM&<$A%0G4P94US,T9'2E5-3B]H9%18,WE9>5)*
M;T<R560P<VM.8FAU328C>$$[4T%L86U0;%AN>5!99V139'-L,%%E8C=M2GIL
M,FA4631&4TM&839J<6XO35%N+U5.1&=+47)/46@T.%=9:T4O0TLY3S,P.7-6
M63=D428C>$$[86EL:&4V9D0V8W0S2CEC94\X3'5S>4,T9#5)=T%53SAA=497
M:CEU,E(T:&)/05!W8CAR>%A-1VYX43-0=W-E6$50,2LQ<U!X3T%N9"8C>$$[
M='HP5%E4=FEC:S!-3CAY;5@Y3T]G2#=P8F5%,2]W07!N;')4+V=2;61P=G!C
M2%4O56=&;S=%06MT,W(Q>DIC9&-&1$E&3F1Z=E$P=R8C>$$[2V=R:64V=3<S
M.48R<G1'<V%H<BLV6#=584XY;4].=3!J*U W2S<Y4W523$E,.65/:#9*-5IM
M*W111F1,:4M,-D5.15!X>4M!05-Y2R8C>$$[;S5K16QM2#,U1U9!36\R4S@T
M3GHK5F$S-E!,<&5Q42MP0W5N;4E31# S1GE':VI:=44U8G!*5E0O;%4S6E-&
M<3)B:&%6>6$O*U5.=B8C>$$[<&-F<&57<FQN:%EZ5S!$,T-Y34))66)1:W9(
M3D\X8C!64&A!<CA(:F=S37%,,T113'I28DQY<&$S:T)E2%140W-K26MC>7E5
M:W!X0B8C>$$[2W1)>G5Z3E%!16MK,$<K4UE&0S-D-W$O13-6-C!U;5%I:%<P
M=&\P;75L52]T>74V>4EO-#=S<6]A9GIN25I-;V=,:V%$6FEX1UIO8R8C>$$[
M-B](-T5K,4159%%E-6I44F17=6)H:V\X,W)*1$QA=7)G:FE:5E971D)1+W4R
M3RMX23-'83-5.7!I2#!B+VIU-2]D.%A)>&%->2MR6B8C>$$[5&DP=3)29E1U
M6FUE1S9)5DQ+37)(83%J,V]%4$9+:7135S-R=5183DYX6F-W:D5$;#<O>#AN
M651L15--<$AC.#=A;',Y2U-*+U0P-B8C>$$[3U%G3C9I3$=A,$913W%,>G%/
M>3%Z2D=I,4\Q13%(;%IQ=75W3R].<"]--&EA-R]X=6AP8E=+2E9V23%C:&]4
M1$5Y9W%)5F]8-$)(0R8C>$$[3T%O0DY60E5E3UDR5%-:25(T<$0W+S=0,'1O
M>E$T=45(-W9X*VA-3E!';%@Q=T5%56QN3F1.235K=#-#*VDY969*05<U3'4T
M-$U"428C>$$[;C-Q0G1T3C1'65)J2U!R<FXW='9X=#EJ:D5:35)-=U)W9SAJ
M,2MZ;#,W<G1:,'5Y<S=M>F]Z>4)2.59,=CA:64]"=V5O1DYI:$1K.28C>$$[
M,EA+*S%.3DQ9:C99>')N6$PY3R\S<G!C-$IL9D]5<C)(9CA!;U5O8DQ5;TQK
M*W!/<C(X8G!-039K<T9$3$%O0E)(8VA224%Q+W="328C>$$[,6-*4WEG44$U
M1#=F:65V6#=R8VU1:D,U274O+T%(,'),1DM)2DI#<TUQ=# U:V=X4#%&03-+
M;E K4FI4<F<P*U-73$HQ2#0S+TAE>B8C>$$[;'=Y1C!*92]K:U1O9$8Q9'A)
M6$]M,W!O-5AI4D<T*TE%5C0P-49V9F8S8D\T3WAT,2ML>F-C85 Q4EER-6XP
M5U-/*W)D37-C9%I(328C>$$[-D%U,#-Q=#A!5V]686]T3W)5<&UF:6YT<S-3
M0U$S<T1W37AI5UAK6D9(,6DT;TI$=T9/3WI624%/-$E'5V<R9V]V>3DU4FLX
M>'HS<R8C>$$[5FYD<&%I>7-N=DHR=5$U0FIJ:U)(2453>4U+0GEF<VYP:V-M
M8F=R>DQ%;&YX.'%F;6Y:5V\P:$Y5,#EB4EEV<71V8E!%-4MO241C128C>$$[
M>#@T4&=:<559<6%L+W9Z13A8151D2#AF1FE3131S.4TO33%R:38Q834Q>7I/
M;S)):6QK16M7>48O6&A2=51X0F5.87%'<58R-49G;"8C>$$[1TY:;&DU04=I
M;W!*4$Y(:UAZ<G%&<$E,<E4W1S9T=$AE5S1":U)O1S54;%%Y<7%X1G8S:C!5
M071T449U3E)7,TAN9T1S1'5O2658>28C>$$[,C!S5"MP3T%J96]1,$I".59$
M6#1L;U%.>#1%6FYC5$UH.75S8S5:;U4R86TU=T95;W-X5RLQ42\X=DLO.5$P
M3T97>7-3>48S8VM-928C>$$[35HU1V=09&1J-'(O04%W2G1$4S(V:%1C>$M&
M5TU&;$QC:5=(5G$Q+T1+>DAQ>D5U:3EB9'!9>$\U1$%G37-A9T93=E5$8V14
M:$5E<28C>$$[1$QO=6E316=-<6M/0CA1879-5B]M<G9K9T57>%!Z4E$V9W!'
M>&%)170W8VUP;69P=G!C2%4O56QE,TMO<40P24=:1&I,2G T-$E:2B8C>$$[
M,UE#2TI423=$96EQ2VY!56A2.'97,'-.:DA*8U9&,60Q=6)O9SE*2F%-450T
M4FEI1#)!>4E:;$PO3F5Q969B9E4Q=#E!,'DS=F)"-R8C>$$[64UB:5E"=4YX
M-G1/0DAR=VMJ,'=4.6YR5&9)4W1N141Q;R]8+W=!>&]R92MN:3!E1S1U4F9#
M3WIH2WAG0WI323A31#8V8W8S;C=43R8C>$$[3W8R0C)J6EI!0E-S3"\X04TY
M>GEV3D9H:$5C851.2$=S2EIN5D974T9A>D=I8V=E2%9J5VY.95!X4G-S<4-J
M0G%F-6U4,S%R*VPY2R8C>$$[=$Q55S%N3'%%8T%*5E5U275-9$=C5'5'-&@R
M<%1J=58S,G)L1W!L35EY63@R>D9'2FM!95-),#E6,5,R;'5,=64T=FU9:6%D
M2CDP5B8C>$$[:CEM:T-$+VE+8EIZ,E1";GE3<7)R82MF,G5Z1U1(060S,W0S
M=6\R3VU2>FUD;7)'27A*8E%+:VMK2'%C4GED4&AI:5@T:'9+-356<28C>$$[
M<$(R1V)(430T1#$K;RM8-E0K<G5C4$IR2D@V9&=K8U=U4S-7<%A-0WE#,VEK
M5DEO6G)::DI5<6I&65AV6G=9-'IT<WE1;79J46-S=B8C>$$[3UEJ95!P.3)Z
M:6UD9T$W,&<Y3G8Y66AG:U,T;&YU1F%%5#),4U0S>DMX-FQ0,V,P1RMZ2E5,
M.6]E1RM64VQB1S P=$PK-6EM:'5"3B8C>$$[2W=U64DW='AC5%-3;W-C4EE4
M*VE'2FM74TUX3S96:V]5-B]&5$I2>6U0=3=U.6)4;C9S,$XQ2EIW8S1R:4Y"
M3%1K46I597!I1$QX2B8C>$$[43A6<4]X-F1";78Q8U!">4-59&=D>#AF,4\R
M,#@O1FA2.7E:86YC5T9X6E)M4V57,5IE36%O5W%*2&M1=6MB.$9+1G%,>4=W
M;WDW528C>$$[86UB6$QN>%IS565-+U8Y:#<O9"MH>&-C6C0U4T511"MQ*VYY
M47-K-U-).%-L>DYB;'A%>4]!>F5M>$11335685-R4F59-#=652M'828C>$$[
M3'=Z:'E!.%$U*SAE+W=",V0W:34U4$A':41U1D,K=6)A,C O,7)Y5U-31F5*
M<5DW9'!I1$E/1D-4.$1";2M,:$E/3&-V,FAM.%!H5"8C>$$[>&I-0F,K5S%I
M>C%V.&)H,3%41U$T>'1(>C,O2#9&:W-.=G%Q>3(Y-T5)23-#1D5M2V=K,$I)
M1$5N;'A#.5%O<%AP='EY-U)D<41,3"8C>$$[:&QT9DI/6%1E0T)/1CA1-3DQ
M2D9,15HT6DY&,4%C8FU"5U,P;%!':V=)3S%453=52&)9+TU:=6-5>D5U5D=C
M6G@T:'E9;F5A6F-L3"8C>$$[94<Y9C!R849L0T]Y=$A023!N,B]I25E%<G98
M<#!Z3T5U-VUX25IL83)0-5EX9EA,3DI:-SE1<GAT8U-V3D\X4VA'8WEH;U5H
M-&]8228C>$$[43%5:G@V,4=-6EI4=GE95U5&<5-F;'I.6E-W5TXY3DAF,T4P
M4WAW5&5O:GAQ2E-:56M,2&=&36-G06)J43A".6UU4VHT;#=J6F0Q4R8C>$$[
M-3 S.'1R4U-7,&DQ*RMJ.5=/3S-M:VAL.5)(4G!#>G@O1$%P:T-T17!R441F
M:T%F5$-U0DQ)9#9(-"M0-"LU,U5";R\U56@T,6TX=R8C>$$[86QZ3#%E4&EE
M24IU3T)O>&@O,W@Q-4%D3U90,F-02&PO;6HX0D<V=F-E6'9Y.#%'4U8W9E8U
M1&1W5V-L,V1L-V=14FTT56AA25HT928C>$$[8E-(-UI!3E=R46-A65!%>41M
M3G(O2%9*2F948CEC,%15;W1G46Q.<$M%=7158V=L9G)3,31G<V8Y-6]E=S,K
M-T-&63%Q9FUE3S%U;"8C>$$[:E1I5VML*T)A37I&47=)66M!04)M6&Q3;&%N
M3$E96E-"26-E96%T:S13.75R;7=&15)%:F1)<FMG:T4O6DI#<4)103AV2'!K
M270P2B8C>$$[16\S4VU:-T--<V%M<D-P.$$U02]6:DEB<S%7-&E7=G%F=$%C
M4E1B<5%D+W5W04IT:4AM:T4V;6Y(;TE6+W=#2DYM8G O<&-(52]5;"8C>$$[
M0VAA8CDK:$]:1%%G=&1I539"<6%+<$QM,6Y!541K4U1%,4%&,D(K5U%02FQ(
M;6Y%4TM9;&Q59D-13THR,T)X5FAE<V51=DUT-W(Y,28C>$$[<49J-6=N<W)A
M+U%23TDS;%8T;S0Q6F\Q:F\O2"LK-"]:-&9$>7)5=&Q::5<P4T9+5C,K6#-N
M>4MZ;&LP+W=!,%A.>F5Y,GDR-6=N=28C>$$[8G%'17DK=4A--G-S:W)O=VI8
M:E)A5C<Q<6%X35-Y16=Q5&9L4#4R=4QH<#4O3C P:GE7>3)L=U-S-BMO:V%3
M;W).>'5&-WIL-F9Z8B8C>$$[:6U2-%-Y-&@S25A6+THO;41Y-#A/='(U;6MU
M;V1*:EI6,"LT37-D=DMS<&I6:V-Q>FA5255+14-%5D-':&5P65-):G539U-6
M-2]-<R8C>$$[3G)0839817(V6%IF5T)&-EE%8GIE;GA6;F%26#5E:%%Y5BM*
M6%IV0D-$;41K,4)Q;S=$=5I:2FU5:DM2=5)9,UIX4S-L;4Q3.#1W5R8C>$$[
M53 S24UK6DII;4Q&=51N;#9K<#0X:"LY6FI3=DAC6FI%=&%B46%C-E)06E)R
M.5AL;E1J3&%C4S,K:U<V:VAE4C5+9E9+17%W4%)M028C>$$[*TAR1S%2<D@V
M=E!&8S(V:5=Y<S=L-5!43E9O:S=Q57%32SA625939#EZ:7%G:U133%HR36-A
M=F1#,U-$,$$Q1RMR>7E.>F--84%.2R8C>$$[<W!J4F1Z>&(Q3FA1-5I'0DIO
M2E0V>4]O>BM:2$XQ1W%'1TAJ25992#0R97133S-.2U!4<T1M1C)R3TIO6#9O
M*VUV9#%V.41T9$I$:"8C>$$[1S(T3SDK6C9F1'915W-V.5E45#=7:71#.3-)
M:V=R<U%K,#8K2%5C:FMP66A(5$%M-W8W-'A09BM/-45*:S5I0C-F<$M.=#=1
M5WI4,B8C>$$[-T0P,TQR37-N-S,T9TM)<S=C9E5&5DUN<'-#=GAD4E9M3$Q8
M:&I$3FHT4#0K63DO.#,T,5E0=V)-,E=C6D-23GA',W<W+W11-U)78R8C>$$[
M:T5S<W--8G=Y351C0C),0EI61D=8:VQA<2MY9V=J:69I5FPS<D13-G%E33A"
M2FE03%DK+S-J.6YC:DYH16AX1&,O:EI%<$LX<V%7<B8C>$$[4TY"9'!T1F-&
M541C9T(V:4Y',TU53E-L1T9'1F9C0W)*:&QG;EI!239C.2]086UC36=Y4C(R
M44]T,D5E<'A02W8K:C9L8G-A365,<R8C>$$[03%A06UI9R]"+W=86'%'-#E0
M,F9R0FYH4BMS3W5K1' U,R]"2DEP-# Q5S0P=4\O=7AP1C1*;3E'95--6$-N
M66AH-F$X87-&-F8U5R8C>$$[,G@V8D]'871Q-75C45I2-&\W:&9P6&UZ4TQ/
M-#%84V8P9$9E5WEW4$%K5GAW5V$V;4I"5S5K<D<Q4W9'<6]V,F%J8VUR1S9E
M2U)O,R8C>$$[6#0U3DY,8FHX>$Y&:W5B949D1V=T*TYX8C-C.'EI14MF<3A,
M,CAG2T-!.'54>DUW52]!3W<S2G=J5'DW*V@O2$Y(>%A84&Y844=S,"8C>$$[
M;%1Y<F%K5S@P:GHS4WAW3'II3&MX04ES0V-E06].='I19VUL8U)H;&8Q1F5&
M=30O35!Y6D\W>3)(;%,P-$\P6E53<$%+=5%P:VEO228C>$$[=T]02W(X;3<O
M0V8S9G=9:E1Z2$]2+T@T+T)503DW1$YE,4Y,<E5P2D54,%5N:E5R16Y(*SE2
M0D17<V%Q2TAH555'+V5V9DEH0V=Y-28C>$$[8E!S='I1+U1N36QO55I0.7))
M;$-75V9-6$]Q1D9$4#E:5V=9.%(O=DY$,T%0-G-K1E-C-D=96C5*:&%P8W1#
M4TDR86Y)8E8S5W K9B8C>$$[,&HU6DM-:4YG5VYW.3=435=J45<X>3AI5TYE
M9$M58TU0=&-46&IX1S(S:&M1,GA&2RMM<WI755I087%I;3)Y<U%/;G--36A2
M6DMS>"8C>$$[;T9(:68T5GA#<TTX,4@O8VEG+S1Q5V@O,E1:;39F-EA#,4@Q
M2E5Q06IK5'-25#A+6F-7:#4Y<6YL93,P*S=:<FYZ2$)P:'9M94UW:R8C>$$[
M1DI,=C%N2TLQ=T1,4U8Q959&-3AD9T%+:%-2;%)&9%<P1RMI5DAY=&)857=U
M5"M9='9*6DM*5W5)=G)(2DI:9E)+>5-Y2#9Z>#5+:B8C>$$[2W@R;W939U=G
M15-03FYF:WI8>2]O4&UV5$YD83=J,6LV.7 X;&E5:VEU<FAO,%<T16=K5C%2
M235G3U-/9'=E;C!9,%571U9W82MB4B8C>$$[:"MM8E8W0T5';C%S1EIR5W8K
M5DMT1VI(*U9):6HS=S)O0W8U:C$K1%1,5#%'65!,8U V5FI#4U9$>75R8T9,
M,$MJ:WDP*TQB=61G8R8C>$$[<7DU0D%7:T(U3'$R=39H<3@P;#5$37%Y5VA"
M13!4,$5-539H2%=%14EZ3GE)5U-48VYB:E)";7)N:TUJ6E-4,TLQ<G!A2EE/
M;'%R3"8C>$$[8GE-:&U5:$AA2U)&<$A)1TI"64UZ=4]G<%AI5'5$;%)/-D5Z
M:VIJ24YZ3W9+<6]L.'9Q37!K5%E)-% X>6M*.#EM<'-X3%-Q1$<X="8C>$$[
M6FQT2DEP27!R=T4Q:55Y=DPV6$5Q,%,Q030P545/5U9A03<W15E1059P33=(
M5$QU6C=3-T)84G)216-8059Y>G)%5DM356MF-THT<28C>$$[5T)61C1G+V(X
M36=A66E01DQ936]I>E$U<3EH8U)242]69DQL=5=74EA74R]L3$)6.55J:U53
M44AM86506&%R<T)436),<EE9=U)(;B8C>$$[6%!N*VYB-W@S3V)I,&AU>CAV
M>"M03DYB3TM$5#1:84@Q8G!U8S U04%Q>#-D,D]Y<4LY4V%!6F]Q;&M,<U-2
M14E$:#EF=#%.>$$P1"8C>$$[5SAN<5=,:&Q,8U-1-U!X<4LQ6G!+2S%.:C%(
M8F]S9EHP>G K03=3=2]S<C1/=7EA:45C9VQ%.%%-9"],8R]0-&0V<3$S2&57
M>$5I+R8C>$$[=C=757A#56,Q4G!553%7;S1S;V-6,DI"2S%Z4E1X>7=Z-W%,
M<TLT;VDO-&@Y:E13=GI3-F%O:4E54W=U>70K-UII;UE/06Y-;S5#="8C>$$[
M.#EQ0DUY.5I!6DEJ3$AR.5@Y8CEV3G@X16I'4GAN-&4U8F-W5S%P8C-%17I-
M='5%-65O:E-",6A9;W115DY'.4M8:'A8=E5F<W)H,"8C>$$[=6)J>&U%<3(K
M;38R4% W9FPX,E5S17!:05E#>659.'8R3$QN,'(S4TDW.6]J239G3%!#2&%)
M<VAC0C$U3#,K1V\Y=TUW.5!-=WEC>B8C>$$[2'I'+S9M-EES8V=F97@W5V9*
M:5AR3&8R.'!35U=+3FYJ27%#1T%:9W U3'A,5F]F2#)Z=79$171W-FI4.6]Y
M>%(X3U@P;UA5,'9.9B8C>$$[:FI70F92,64Q2CEE0V]$175J0W%S449"04AX
M3"]%548K2$M"<UA03S1S8VU-,U=L6$9N8V=P6#8U8U1'2#9J1T-/8T1J:U%:
M4V5)*R8C>$$[>#E'6F=K0W=-85%5:6%N8E)R-DQE;$E!47EG<CEI069&6'16
M8VM+4G5',W5':VDK<VPU1FY25VMJ2FI7:%4W8W1H5"]!1U=+8E59-"8C>$$[
M;WIX3G1)>DY4-&Y7<DQ4:4%78FPY;'0V8D@W<THX,3EZ-U9F<6,U675/:#5"
M6#<X0E%K33DS9E=L-V9E;$=X17).278W;5=25U!O428C>$$[;VY&:U)W0T=6
M=78P*T]4:5(Q5VDQ6C9N2W$O=GA/2C5),F%::&%Y.$1,4E91:CDS>3)69FDW
M5C9B66MX54%R-'18:B]!2'AU24HR6B8C>$$[-FE-2F)49C-:4'=Q-31!.'AY
M3F%(:C1B-#)&;W))3E9%23E/3T=C24)*=W)B>G-G3S-!=%--4'515U!8<CEY
M6D)A2VQ.-6ET6651=28C>$$[5G5Q>5-5=%$Y<S1.0DA6=G-O0CEO2#A-;D58
M>5%46$YJ*W(V:F$S.3!K;'5Z1TEX<4-(4FM0249J,%E!+W1:;%E144A$>D5%
M-TE1<28C>$$[2T%J-U!59E1L<E5L5W1E579,*W585G)D86Q!6C5,46HV=2].
M,#0P9%I.=VA&9FIJ0C-Y2FE#>6I):$)F.'%S.&MY3SAN-E T=DLP<B8C>$$[
M<S9Y4TM3,#8X6D-A34LQ<%AF=FM404UH37 Q3&\P;'1+;'IP1$,R=4DT,&=E
M3U-R=WIX4C=+<VTO24U"<W)J8V0K43)X25-#:6XQ<28C>$$[-VEJ:6IV=$MU
M67A,27-,4U%+=#%$.%HT;'8S6C4X0EAC=D=U0S P=V9Z1F4S:VQZ1F1A27IW
M5V1N8V9O5WAJ:31Q12M!3DHV64ER1R8C>$$[>$A'2E-O-DMF2$Y2;FYC>4=2
M2T)T235V<D-81G5/1C9K9S5/27AB33 Q041&3$=316I98T=+:V9B,S562E!'
M:$-:3$-V,611;'%*8B8C>$$[4F%V8GAI6'!';TQZ>&-M2%!B;'I4<5%32T5N
M;%5+<V4R8VUO:$YX8U1&:&%!8V\T<FQ9<6AM9'E">%=)9D5X<4-".$YE:%=1
M,U-!>28C>$$[,U%02V-L<6ML,61U6G(R6F@V:W1/2$UO>D)#>7$W24M+4E)1
M2TQ18E9'8E1"9T5D>GI5<%1F5TYP9"M98C,Q13E',6A-17(Q8W-*;28C>$$[
M.4U.2$EY,4%(1D=!0S X5#-Z;G4P8S-&:U!#9G=.;F0V67DX3TU4>6ID9DAD
M3DQ3,VQV,&%/1EAT-V50,49$3%1C<65)-S%0=S%.4"8C>$$[,E13=%1Y55<V
M4'-W>3E5=G!)+T@Y=2]X8V)0<38R2$Y*<FDS=F8P<$I:>'IJ-GAB4$=Z,TUI
M;S-#26=/<T-X;%%H-4MY=7ID2VMI;"8C>$$[9'EC=7)'17EH06)B:F)N.'IF
M3'5&3FYG>'EI36HS0S<S1CE4,#4O1D=*65=S,'=K3W%Z=F15*T(P=4I62VIW
M5&EW0V=(<TYS,4US:R8C>$$[<G,O83580TLR8WE45U5J<F-33$I$24XV:C S
M:V]#2%8U54EQ6D50,C)5='E!,SA.:'!T5#1G.$M82U(K4E!)+T0S,5)C8E!J
M23E9-28C>$$[>"LW=5$Q:%EW1V(Y2#-%:&ME.&ML5T9P2U8Y2W-A>%1Q:6Y9
M.'!(8FI8-U%)-TA-:D-:949K>$AA="]I3V)83TYY:FQJ6DA++V5R6"8C>$$[
M9'I).7!P.7=P-'-72$PS1E%A9FAM2#):3&@Q169F6'IB9%=,>$9D1DY-<V0X
M56I*2S-D.4U+140P,FAE85I#469T1&UG0D@X37%W428C>$$[17-G0E!D.74S
M-F(K1%!,26E*2VIA;EA054YO:W-5.$5584Y-4W)+.'!N45-I<$0P6#!W+T9D
M=3%46'!M>'HY<359>DEV:V4T9G$O4R8C>$$[-#AD2&EK05%+0D$V;$%3-D4Q
M.6%Q>$Q2-GAB0W!K-#%)951K04=015(O6EAT,49/:F):=4Y*<C1:.7(Y6#,K
M8FI3:DQ4:VM$,$AP,R8C>$$[9E X04)3:E5)<F966E9H,7!$8E@X6C516%--
M>6AW1C9$:GA(-U1D>5%02')M>G@U5$A9=59'56-G=4IS35DQ0WIL1G=B0DM.
M2THR:B8C>$$[.4%F03-O2#1M67EN<4='=TI.8WIG97%#14AB9E5H2$5W56LK
M;T9G:%)G>C%**WIY5VTY0C=94U-X43EU67!:<$)*14AD-DY+-V-L.28C>$$[
M36]#6%5O9G1&4C-W;EI8,G,O535Z0F%54$E105-45$EL0VE31'17=$\K0DMM
M5CET=75"0S)L05(T-'$W661D<U99-35K=5)*<49V1"8C>$$[1W=*<VQA831(
M97-Y1T]*9G K2G9O.3AY.5!(82LY;WI(;VM*04EO5#$K>65N-G-Z2$5A4VY7
M;S0Q<%1R:7$U4W!)461A,#)W2E9W-R8C>$$[3%@R+S)S4VQ85W)I;%!I>4Q)
M3#5I,W!C4V%%:F(S-UE%=DPW*WEE=S%+.70Q6&U3-S--:D-H16QP9$96:S5R
M5W$K;%!&=%1F9FM+528C>$$[<FUL>D-P;C-S9W%24DED5F5!4F-%:55)8F--
M3U5I4"LX0V@Q3E=!8C1O>6$Y=G151F%U:6Q7*W-#3S)7*W0R2$LQ2W-Z36=6
M:79)2R8C>$$[1TE$=6\T4U5&3S10=&A+:&M(:W$P:6EU;E9,<&)U2S%R1D9)
M-DMP-'%74$MN46-P2VM(-U9!3C9::S996$IZ>F=%8UA%96%E6&5J4"8C>$$[
M<#$O8V%Z<$UB4WDS0E9T47-/5S T:EAI<E)C>GA36E9',U)7-DYV4FAS6$-8
M43)/:F%V84<V=#%#<&,X=E5K5E1&3W)B:#!*;TI),B8C>$$[5G1M5&%H>DAN
M;SA5>EI'+W9,9$A03TY595AU5$MX<V],5WE3,6A&24EK14U8:45284M->4EG
M055'=6-J2U)K95I.;T,V,$I*:65,3B8C>$$[1DDP;DPQ,#1M44QY-4UQ37=9
M;T=*4#)A8C<Y9#AX.&UJ>%1.:V(K5$]'955D=6DV-3!/,FIT-5I%:45K<DM1
M>D9N1'958F@U05$W8R8C>$$[=FXW.6--.4IJ;$5X;T0T9F%X1U=55'A7>&%.
M-7)Q=VQ)9&]:<D=6:$9-9G1R-DHK0GIS0EAV5$]1>EDK0UII-W9(3&EJ9F5H
M-TYT4R8C>$$[=3!J='A*8G<X-&=R>E)236LW>'-#2T=S:%90:W%,43E/3UHR
M;S%U6&@T2DAY+V@K.&9R,V%-94-&.%$Y+U@W=C)*:F,R14IM<W)-4R8C>$$[
M2D1$05!6654S;W)O;U5B+T%/5FHR5DAI>D-2=FXY=34O47@Q:')'46MC;7%7
M,FQY4$QQ*W!1>$YC8S)L=#1/56IU>B]!07E-1DML9R8C>$$[2D99,4YD;4I)
M.$TR4#5(1TUG36IY-D0W;D=N<7AW,45F3D91-G!B6$XQ1'%':T]K,&))+W)"
M0T9P>#5/16MJ04PX,DYE0D\O:CA/-B8C>$$[=78P<V,U=D@Y6%@X2#E(9#@S
M4C5X0TI%:E9C=FIZ*UAM;3%X0D1Q2V,T+S-6-T1Y56-L<59,2U5.5F)9,55N
M.5EZ;C14;&IL661K428C>$$[2D1Y4VI617-R>4<T:'9O;E-:27!:;FEP>E!P
M;S%/44M!0G5+<T-7;TM5<5%+0FHQ5VLW56AK:#8Y:5!X."]*,4HP951(:TAH
M;FXK3B8C>$$[-S9E8D5.4S%7*S!Q-&IS2E Y3'-N<F-Y4GI)0W(R>$%&14IQ
M-&-T+VQ6-VXS,E)M66M5-2MN36-K0U1S4C U<5=U-DMO34]P-F9:1R8C>$$[
M9E-P-# Y94=-,$MU4UA+3GA!4%$O8G!4=EA-+T1L16AU9#)U45-'6&YP<D-+
M4S-%6DE2+U$U0C-D6%IG07),569%=%%A-S=:9%A%>"8C>$$[3WHW3&8W4GIM
M4S!+1#EF8R]F9TM&2G1Z,7=+<&M91E=-2VM!;6DY>#1N=&ER9W1#04M53TMS
M4#%E,V4S,4\Y1&<O-EI)<S!,,$E"-"8C>$$[;VMB0W94-&%$+T]L8R]4>4A#
M2$9Z4DYP8S!F26YF9G508G P>DEC9'-X<E$X45!C*RM+=%)U9S,V13E.+W=#
M=4)+<4)6>G91155)*R8C>$$[92M*4T9E34Y79T9627E,2D5+5EA9<6%(86A&
M0U(W645H2U!-3V=1,SEU<SA3,'5R5W)W1VEK.'%!.%-'0D)$8U%#1&U*<7-8
M14Q(3B8C>$$[>61.1TIL56U!5%%81G-Y5U1+<V%+43 V5$MZ=W@P;U%Y1TU0
M3$AZ,D1H9G9!,D=R3S-.>G,S6G-G3&AU2%-,2D)E=DIB>G)F5VMS828C>$$[
M<3!25G=5031T14IN.4].4#-C;U=H0C-#9V)$64,R3VXW3GE3;4))8TDX,F,K
M4SE-;&ET:TQ&:T)!;T<R2V=!-T0R-44U;F%30G%Y-28C>$$[+V$X-'@Y02](
M2FPP9$%15'5Y.3EI835N=E!P4'%';EA-5C0K<&%785A452MT5U))5TLV06]"
M5W5Y>7%"4E@K4W1T47%R84PP<E5R5R8C>$$[+W1Z4&)S5U5-56QJ6E-K:U1Q
M9FEJ:U$W<7DK0BME3G)326YU,6I'-4A)8C R.7HS>4I.3G--6FML=#=E=3EJ
M3D1B>F5L4$ER8TIG028C>$$[+T(R0F\Y1#%O9#9(24=88S5)=U514TQ$14Q7
M5U,S=3=Y3S9K1&U/94)R;5%!04]V;U)/-4$W0FIN2C9G9G9D>EIS+V586FE&
M:31J:"8C>$$[2%%C-E)..49D5W0Q<'AL9#-0<7%K9T\O0G!,9'57+RM5,75A
M,3<U;F1O475%6D0K65 P8D0U=49P-5532S8O<C4O8V=V3CEZ3TER,R8C>$$[
M,#1H3#E59RMT>'%2>4%K44958VIU13E1<U%D='0X<C=-9T]'574W.6)(5UI:
M4G%J5G-B=CE/-%AS,FQU6DEB5S!M:TET07IV=U(S628C>$$[:&YQ4C9K<VDP
M97!B=4YX,$=A1&)R0U979#=U,G9,63-A;3-H=$)*2&)2>'-*8G$R<4)5=5AO
M5S4X=G-0.$I(2V=7;T]+,FY&<&9N-B8C>$$[=F$S5BLO;WEE;5)(9F]R<D$S
M3C9(9S<O04=8-5)N;$A)04-E6$AR>4)Y=VIM1E,R;#,Y1#<O,2].=7<U>D0S
M2FQ,94I08FE054QC<R8C>$$[>DYW2'!F131L,V]G4F%/5W!V5E%2,G)88DY:
M:S=/>5%/,V8X4&YY+T<W<V]A<45V>"MH4750531Z:#-7-FE.5'E58S5U44A%
M<$E+9R8C>$$[34=P.%1F8G)5;FPP>DHP6&%M5$521U<X93<Y6#9U6'5A9%)O
M;UI.-#=34V5B5$QQ0U)R,U)P5FIO,4<Y3W)24W-">4M-1'-R154U2R8C>$$[
M5D1J.7)W>G!C5U='45A!-S@V4% X969,=4QI=S%%.%HT8W4T-R]X+V%H:6UH
M,V0V<W0S06)(5E9P0W)U5U=.>GA*1$Q7:3AV,V@O6B8C>$$[0DAG37E9-6I6
M1GI9;4HS1S<S5'HV+VY*3DMI8GEK:5-A:THK56E3.$%R47)&27A4;$IS<%IW
M<6<Y:69#=6%L>%=(4BM94'IV.5=/,B8C>$$[:S!#>DA/.&5!6&I58TIA26=#
M,T5Q<F-25F1N25!&2T-L96U23DE116UR9FXU8W9C4F9O=7IS16QT2$UD>6EP
M2UDU=W-T0D=J5#E1-"8C>$$[5F%V>E9X4G5+,4MH,E-O86(U9R\U>4)84S1L
M=61!<S-V64EJ-G)43$AY;EI)1E!72S=73DAK;$1G:TM&1E)293)#9W%T9&59
M4'HP1B8C>$$[<D=I-D9:;6%62E=A849&<D51:FE)0DI,>'%T-F=5*TA%,#(V
M-$M#16(U8C%N.#5*3E,P=3,Q<E)R4TMW.4=*=%5V0G@Y55,X23%D5B8C>$$[
M-%0X83%:;C5H2V)&3T]W9&Y:5UDK86]23#5E=DM)2&M20S!/,5=$:EI76'=/
M5S10<41(2GE,1C=I34LV.&%&0TMQ-CE#2V114FUE0R8C>$$[-$I&26-&;%5!
M;6UX<4(Q<C%Y5$9A5C1J;#%.9'@R>%-K,G0K8F].1W5O-U9R4S1U-6YH860Q
M=#!$1EEK3S=.=C!(13$X371X-%1-6"8C>$$[9$E-<5,K-B].3S$P-F8P<C=3
M8BLQ;$=X:6U14G1T,3)C:DQ)-E%N:U%G-4LU9W5K+T]44V]*44IT375K8FEK
M:6@Q4E<T=6]D5'4S4B8C>$$[:TE+;G=X1VEK96]8>'=&5E!Z9S!S=RMU;6LS
M>E$Q96MV1D-V2TU+6"M+=%!H1')8=W%-0C!2-5=%:D]/9$9-=$(X=V%2-7)U
M6E9J<R8C>$$[-3=/-FA26FQA5E%P84]1,$1)>6LW6F<V<E%!8FUN6C98=$M5
M9'59.# T9SAR5U,S0FML6#%:3W174$IQ,&]$=40R2#-::'@P9W0R1R8C>$$[
M5'1I4D9!058S2C1I>'=*<W1%;V$P2%%$36]2<# X.&AK8DQ8-E%S;5 Y+T94
M<EAM4#8U4&A,0S%R6&1K9FDK<U)!9S=59&1V>'=C2B8C>$$[4VQ/;U)(-C).
M43!M-FE7+T-H6EEI>2MN8V]V4TM7;%-R0W9W4T%653EI=%9W1TI41DQ*3F9J
M=F],:#=D2$XQ0WI*3%IK9G9K;4%(-R8C>$$[=#%Q4$5D1%%J9%-146-P,DUG
M0V%$=$U-5$A'6D%747@S5%!.1CEC6&,Q;G%%4W=Y33%,67AH9T]22V])>%92
M54QV>4I9;FPW9$UR528C>$$[84]):'A14$QM-"MJ,3AP6D]$24]F3&(S1#5$
M=F1+,"]+.&M71G)Y-&YP0TE62SA1>55I9C%35U1J4DEZ,S).334O2&\T2$]4
M;%!"2"8C>$$[-G9F-W4O;3=R5C5I34@W;5!I5"MN,V4O=51E-U=75WE#,GIR
M9'EX.%-G:V%S;DM.=5=W,U!-=#9I>&IU1TAJ:FU!>39A>"]!83DT+R8C>$$[
M<S4K-3%1:6-E86HQ5F)U5D-I,VEP2$Q"3$=W:S5%04Y24T%H66=J:31*6&ED
M:6%6,D=A,U$U:$-64W5J*U!V8G14:31W>$=C4&%&-28C>$$[2U1T34-I5%@P
M<FA834MC4D)*17E(6GA256QF-'0V55!X-71:4DU44F1-5F%20V)E5T=-2CA+
M2T972FQ3>E!34C-K648R;$MS=%1Y2B8C>$$[05!1<E-M2T9+2WDU>GE88C%M
M:6UF,#0T259#:39+3T-);V]'5F8S65IL2G%P;U!I4'A%2U%L9DA0<4LS-GIT
M36YO5E=Z.4M#5#EX2R8C>$$[1%9M9$DW:U-X96Y(<W)C3T$S1D=O835+37I%
M54-T<7)A:&1&<G4V:SE#-EAM,$]M:40T6C-287!%-E<P<FQZ1WIF0T1&2GDV
M:FED."8C>$$[12M'46]J-&IB.6XR3C),2UEY0DHR+TA*17=C6FYJ94-K,&MF
M2#%E1%9,>6]25D=4-$@U9G9+*VU2>E=T4'1::6Y3>G@K=D5F,6HS*R8C>$$[
M6&YY8WE/<&AK.4UW<W5O8F962&EH:W0P57-K9C<T:S%:,EEQ=G!S>2]&=5(X
M0DIF9F\Q0S)B6%-D<&E1<DQ6.'5F9%@T=FLT*U14;B8C>$$[1C9S6E!F6%-V
M>%<S3C9H-34X:F$S<G5P>C-L;G)K;6M29E5"8C(X,%132SEV3VIY35IL36)X
M2#1H279,-'1W;$1S8VUL-7)P4&LK,28C>$$[<W!,97IT+WI4:D=N<%9V<3EJ
M8WE1>"]V3&IN5U=31S8T*V\U=59535-P:W(K,%)807$V.#AN6%8U<$@Q3E!Z
M8TAR4VUL,V1F6%AC3R8C>$$[<%E15590<FY&954Q56].<6YJ,7!12VUC96HV
M:#5F.$%-5457<F5F:$=R5%<X<W1L9%AC,75O=&]Z3$DV4DQC>E,K;S!Z<$=R
M8U=(0B8C>$$[45(P86U"0U=384109C-%3'(K6C%S,79P<4Y,-CAE;T]7;&,X
M;'5(;$-82VU)8T%I;FDY1G$S05(W67%V='9Y>3$K8U@W*UAF>D%L=B8C>$$[
M2D)$1T9J<W O5&16;E9N:F51>%-T16]:2F559$EG2V9%=$=9=&IA=E-,1V)Z
M9&)A4$1:>F%5;6]4,CEU<TUS,'0R<71C3VEC5UIQ>"8C>$$[169V1'5F;FEQ
M6&%N8D<Q84-0,&9233A";6YT:$E:;'0U439K;W-H0S=-6%!B96U:;4-:23-C
M8DY%0DPO04EA-V)(,WI)8UIW645D3B8C>$$[=6=09D970RMB4$U&+W=#6'9/
M*VTS,6Q$1%!/,6]94%)U451%>7I/>4UR54LW16)D8WI-3TE4>&M(=E)X;4UH
M5$Q,*TQZ+V8S,&YR>B8C>$$[-E=%9')3-6UM1%AS4D12;45Y3$A!0T=R2#A,
M<U-Q;C1L655.2UDX5&I!,C1U=F0U=5=E36YO:$QW9FU!.'!A,VPP-6]B;4I"
M<#AT8B8C>$$[,D]15VQM5VI35EDO:F)F:C9G4W).>5E&05=Y569#-C,U.'5:
M66YX4$PW559C6&9N>5-'=W0W5U13;71R-BM7-FHK1SEH57I335I"0B8C>$$[
M46-G:U)C3'0X2DQF2# K4$EI3U!C;FDR2&PX+W@W;5(T*VQF87A(>5(U<3%Z
M5DYE,7I76610:G5T4F4S-4-Z:68P:TIA675A1GDS428C>$$[=#!Z2GHT67AJ
M1TI/>FEW>6U22G V1&(V<C5W:V=J639"1U=95G(Y8U%5-E9&3T<R65)H1"MD
M.6ID6C=M4"MD=%8X,%-E5SEB:'9.228C>$$[*V]W0S-J4#%U3S175&-Y2T=3
M:6A387(Q<#E/6#1)431X4G8T34UH3D9H='E0>7=':5A#>'AW+W!&<DM!5VMI
M4&4X:&,O5G!8;F54:R8C>$$[>E)H=E=73E%/4$AE;$)U>351.&)I.'(X=2\X
M054Q>4=+=D]V3E1T9$HO2UDR3VXO049N5DQS6$UV;T<O6D=O,%)C1#%L0T<S
M2TU&2R8C>$$[;6@U-U9"*TQO0UHU<DY!9FHT<4E9<4<V0S$W5%!Y+W1D3#EF
M44Y7=7)R5E9A27A2>4%P,61W-6]);&]11E%J-#EV974P<V-S:$Y3028C>$$[
M-%=%-%EW3&ED,F5E8G16:C!3-6IV63=+3U,T;5963C5)5T-#:FXY,G=50FU)
M<GE52WA06%ED8S K;C!S8W!.;C1/-3%'=6QP=T]%1"8C>$$[,W%7;C9Q<V-#
M,VUO>5=M;EAK-TXV45I6=#,K<D]&2V=Q04@Y34U$=3%2=#%06$DV;D9/4C19
M6$M)-3<S=BMT=3!';W=W:G@U86I-."8C>$$[='%00V9,=79R*VID0G=M,FM2
M-7)+831)=E,W23=S441)-49A1FQ$8TMR56M.5W R6E-38WAT5G%$:GE2:FQJ
M17A(;'DO2'5R>4]Z:R8C>$$[86934GDT6EI.4$]92G9M83DO.$%B9#@Y=V)2
M='1W5SE&=#9V<5A.=6%42F)G<3=0>%9836E.4GEG*T9K8F5H-E8U6G)S94]7
M4$QX128C>$$[5FAN9CE8939V;WHQ1U=">&U)26QL04%0.#9X5FMD9"LO<6UD
M<D9"8G4K;5-P1VQT34,Y=D=P<7$Q2DQ*>&%H07)U=E@T841K4T1M<R8C>$$[
M-U%W>G@U0UI'+TTS=CA7=E1Z16\W0W%3>E5R3V%N;WE)<VPU07AE,UHT:$E*
M47=#0F9S;T=,.4I62DI0,G0K<35U1%52>5%%4V%)+R8C>$$[0G9F;"].4'=C
M8DIP=EAF47!(3$A(0VQT8F]*,G1G=U,Y=&=Y4U-%.&=65E9(1#%&1D]1.39C
M<55'5$5U.4=F<S)C0EE'>%1#2V%A528C>$$[=DLY=&-P=U95=4DT-"M$149V
M5%<S=&<Y5U)'-3%F9FLS>$5G-S@U5S1N:%-(46]2:&$S2FYA4U=%>CA$17)7
M,SDS6&EI>'AW2U)6;"8C>$$[5GI6,TQ';T915%1C=%)8>3)W4S)K5V9J2DI!
M630K3$%C04EM249U0W9*;S5'84]P1WAP>EDW2$91;T15-4QE*VQ&>7-K,3(P
M=$QX228C>$$[9UDT;4UR5FM*4VDO=DDU5U=/<D$O0GE8<W!Y94M2:$E(<#$Y
M>4-,6DQQ8V))67!G:VMK9'=">6M#<7EI47-76C,T.%<S1%9$:FLR,28C>$$[
M2TU46$)R=7ER3C0K=E0X9F,U*VLQ97A%>4)89C$V4&-P-&ML:F5+45934E-R
M:G!534M(<&UA=V5#95ER8CAL<F)8<&1+9GDS8UAE<28C>$$[>7IF5G543BLU
M2C K3E!J6GA)-W@O0T]+;&LU3G8K>7=9<7!0<FQZ*U5E;6Y58D9V2S$Q95AU
M;7@R0EI(=3-A06I55VAU63%A5U)Y+R8C>$$[3&Y/-2]U,C)",TA+;4)7.60O
M35 X<G(S4T<Q>EAD0S%'.'5Z85!P8VMO=55B;7-H9&949&A.13E73G9U+W!6
M06]E*S1P55A$3"M5:R8C>$$[96]X5VDV0F9,<3%T84Q92GAU4V)C44@T66MK
M:SEA;U5V26\K2U!L6#1Q14QY>&]O97$K5"]++VQB5$EM,6I23$TR>F%X8C)R
M4W5X628C>$$[=3!C55%%25E-5%%H5'9G2E-Y4G$P,C8T1EE&9'IF5V)I-'9)
M>7AE-&Q:6$1(64Q!,W!Q<3<W3%9786YI8S)73TY#;D)Y;7EH,F%O628C>$$[
M9'AU3GIK,G!A2$I006EV8S!"-F94:7)(4$Y0:VDP.'<S349Z3&-345!!:&EO
M9T1!<E5K9&4K*UI'2%5'07!J2T%+5TXK5CAC,&-C3"8C>$$[87AD4$9#5SE.
M4T%66&M2>4DS+V$T:C=S;BMB.&=V0F95=$XK54YM<6QV,&YC<WE,.$MH1G)S
M3V<S.7-0-3 Y=U59=DUU<U!Y:G-R=B8C>$$[5#=A-D=Q6$-R4$9(2W%"5F%N
M2E%W04Y25VQC:BME4&-%*T-/.'-N.&PK4DQ8>7ID6$TP1GI*8U-Z<7%%>4)6
M055'=7=&9#8U5&XQ0B8C>$$[>6)%33AE35)::7!);V\V0W94<'9M35<Q,'!J
M:U)O,U%/:F=R27)$:T=5-T5%2')I;$ID5#!Z>3-9,DUT>"MH-U-2=T%S35%G
M:D102R8C>$$[-T));W@X3WAK9&=O*V533U=8955C25-F>5HU87-B;%I:8C(S
M9W5L=%=K<VQL93)J:D4P,&-H3GI.=S1+3T%K+V1X-V)+=%)S,D%:6B8C>$$[
M.35:1TE44V929$IG.'@R54U/;C)Y4G9A,T5Z.$QE255E1U<S0TU'0S%"2'%.
M9T]34C9L35%!<&%P1D@X669G='-34DE:-D--2W=+128C>$$[='DR;U999S$W
M1VU9-31G9E1Z9'1I;$%X=6153SEG,G12-F0U9VQJ1FYE4E)Z<D(V8W1N3S52
M:#9%>D5-1E9*1C556G5)<4=!,S-5-28C>$$[<TU*3T-*36=33#5G9"]X2&PO
M838W4$5A<5EJ06E*27%I835(<'-E;G@W=&LT5WIU3&E/,E,S:TYT8E<U679&
M8E)H5VM*6&%N26QA1B8C>$$[-DXT.60Y.71B-&]):U-/2U(U6#!D>&TP,&]C
M045U1TUF<7)A*SEF<#AC3GI033!T=4QB55-X1%-!3D=Z145(,45"23,U2E1L
M5&Q5528C>$$[3S1Z;F16<6-W:4UC:C9E-S5I:BMP=31-2DIL16)Q<SAL,U!(
M4&%M0U-3-G1X-FE*1BLV4FYQ4W9P<WI.,%9Q02]S;7$P-&UJ8D1$2R8C>$$[
M3W!W.$5I1$]T=2\T+TPT:6IZ9%A+4&@U8D<P0V0K-S=%5&9*34Q,,#E3=#)+
M=%99-2M+<G5$.$]Z1FA7;$0X2EE$<%=U83)E9WI9-28C>$$[8D,V8VE/;VA)
M8S93-U5)9$=K,&%/.755831684QZ=$-"-C!G65)0>'(X3&)G;793;C)E,F)1
M>7AJ1$=5-S1J9C-T,DQ66F-E431Y3R8C>$$[5F96.#!'<6%/1VM%5FYF5W-V
M14-/-FQ*:FE"-B]W1$AS1V)V5'=R-&)N2T1L=SA)3C=N<"MT:TY236YH4# K
M-&99=7-03#EZ16PQ928C>$$[5W0K=#EC07-N<5-S<S,W,FQ6:5)W96%0,T5I
M5$%J=S<U;7AW=VXO9'E"*W=U:WIC5C)24U=8:U9X;S)N=R]U<FAB,3-+1G!(
M3'=2:"8C>$$[:W!).$E!:FM3545,>$Y'6&)Q,GAY17-C:'I$47-S<EEA;UER
M<'A*0VM:354Y,D1';D51<'I'>$E**TPT,V1Z,39$635+1TEN8S=2-R8C>$$[
M,EA08G%N>E=T,W%3=D-T,TY&<&1U-RMH>$MO.&ID059E358T06))2S<Y5#)!
M,75R-U%N2U922CAV9#=N8EET4$5!5T$Y*UEB6G4S1"8C>$$[47IW449U4FI5
M<U18;'A&86MC82]C2UE#<6Y*8G='=%DQ2DY+,4$S<#!W255M=')9:F5*0T)V
M.$%:2%5!:CE2=TI5<&)+>FYI9$I9128C>$$[:VIM57!+:DM#2%9T:4="1S1W
M2W)"44%!0E%!8D%D<U9C4&)F=&ER>C596&EH*TU54'%43CE$4W,S-FIM,$)C
M0UDS57=I;%1S068X028C>$$[4')H87EP<5=$33%13G%E4# T5EEX-6\X.6%F
M-61V<F$Q=5E:2FMN4C5*<%EY;T50845/>FQ9>#9Z2WER>6-B-4=5<5I2:F%6
M4V9N6B8C>$$[-6)G0E=/>79:6E!186152U))1U9!4&E*36QF=$Y4<# K4#A!
M=2]J>5!'1UEX;$90*V18;#51;D=X=E=R13%W5DM2:'9354UA<4$W5B8C>$$[
M8C1"5E14:E@T:7!"1T%Z0V5!<W0X;EAS5#9,1&)R5695+SA!4C%6=&U%87%$
M05-..3)G6D<K;D-%1E!9-4M6,W%19C$Y.$-725A8:R8C>$$[2%8W:E9J8S(R
M='9:4FDV931#44-33C)J:V%75F]P2D5L6&MV<7E+,4M5;W1#1%A)14UW5TAA
M9#5(,#=4-V$P=&XO34<S;&ES5'=L:"8C>$$[;&Y5231E545J*R\U3%=717%%
M-6-#5C-5='E*:EAM>79Y5$-Z,&<R569Q3BM914=O,S<V93%J87I4,VA2>3$U
M8WAZ4G5R<%!59D1B1B8C>$$[5DM$;3,X,49&1W9.8CAK6%EE5&(W53)63%AZ
M-#$O9%)1<$PV<U9Z3$\P8G9+>&IN4TU83%)G8U!H5W%B;&0V,6%P<GI7+TI&
M*U)02R8C>$$[1W,V5C5Q=F(V-S$V-3%I0S%I1FXK+T)9=$TX551Z8C@K3$5E
M;DA747)Y4#)4.6Y%0E-766%X<#!..6)3=U11<DQ"4$=Y=6II=G=S0R8C>$$[
M2VIP=4]X<F=S>$YJ;35'27AK1$=1,DQ&<E!Y6&)7,G!Y,V-!<4AI361*5D13
M2S%6*TE39DE(=#,Y>FQM6%5Y>5$T4TLS8G-';7@T8R8C>$$[=FE!,U%04&YE
M,CDO:C<W;$=N-E5K8V9'9U!(<G0S-E5Y:4U+5&XQ4FM53'$S;&DU=7)X3&TQ
M=55G0FI:6E%99U-X3D-R<31)2W-+0R8C>$$[=FE.:G1L1V\P56-X1C=.5U!6
M8T532W,Y3B]M=&LX=#-O;E<W:W95-%)%56EI*S!5-4%L2&M*6&U0:"\S,G4O
M>3-X9$HR86-74TUU-R8C>$$[;G8X07,O4U4U.55*=TE3=E9D9#AZ:E9J65=I
M45=S4$1L13 T36YR54I"6F%&9G,Y0T18>#=J2%=A+TIJ;5%"-E)8,FAC1VUH
M3TE*3R8C>$$[-5$R<&%T26QM='1D,D%74G=W6C%4,6)B66AU56=!-55:<4=G
M4V])<41503562'1'3U-%=5!9:FQ84&9U+U1V>6)"<$]'635M4%@S9B8C>$$[
M:FMQ-F)$.6-H;%=++VIK:F]O859#4W-(:GEJ8TY*4G8R9E9+9DTU4DA1-' P
M65,S4%$W9DDW<W V:5538D<S-#5P3C9-:7HS155J1R8C>$$[0V19,$Q45WI-
M:E!(2VEY:$=)-&LO8C-"-S5G0V-S37E/=30O2&XU=591>4%&5U<W=359:TYX
M3D)C>#)Z07=M8T5&1$A55DIH35A):B8C>$$[9F1Q-68K97IG,6-R+TAE,6I"
M:C-)-C=+:U9V3F9"8GDV=6UA>FM!0T--96IB;%12*TI)06%5-U8T9D5X.$UN
M;'DV:6-U03-X8W0K+R8C>$$[.&1Z0T5-54)X1&MR>3-6,V%*1&-&;V\W2TES
M6E9+.%AQ1%='2TI#5%=2=5!8:W V-TQ1=&U39$1$05EZ>68V6&UB<C-C<BMZ
M<5=U3R8C>$$[;SA54VI'-S9(<'HV-SDS3'IE.4A.;S0W1U!/-V%.96%48V%,
M96%V839B8UA%87IH3&PT-DY&1DUJ3C9K5$]H94)Y0DA)2S!+=%-U*R8C>$$[
M2W9'<E!Y9&$V9&18*VMW9FUD87='6C1,,4Q60V)E0S-K=#55=&=)>D1C4E)F
M0S9#3&=+2#160DAI1E(P96=46$=K33EV*V%J>7IZ428C>$$[44ES<V1Z8WE/
M27I%<#4K9W0P6%=2,5I(2G!Y,W%D:6-52C,U04YP;W5P-G1*+VI-*UI2=U0P
M=$I36F944G)I57EO,$1Z>F5M>E V=R8C>$$[1E)*=51486='07%Z<CE087(O
M,4QM;U4O-'EA9B]W0FQE0DMY5'I"<7E2<WDK5SE26G=P2W V;6XW:T199C<Q
M2$9#45@T;E,V:TYX0R8C>$$[,7)*8TMT,4AA>4UJ3VAC2TI5-5)L:U!&9T]H
M>D]W>7-/3&UJ=6=78V-G0TMS96=Y.7@Q;$<U555F0V8Q67%P>E<P33AB=WIX
M3$Y'*R8C>$$[>GAU05%11%560GA6,S90<W!*,'579VI-.&%.1VMP449G:VY(
M;6]054)V5%=O.6AG<$YO9U<X0DI(<'%624EP>$AF<CDK0VLR9W135R8C>$$[
M5%1R:S9X8GA.3$5%165P=U)I<G1%=39Z26\S6F]Q;6]'-TQ8<5%O>4I::$XY
M3G9B2R]T66(V,&U793!U135W>GAM<75R9$-$:7%-:28C>$$[8SAT.7$W94YC
M0U=%*UHO>34O3&%45#<V+W="5'1V46I&=G=M=D9K:U8Q5F%K54IB9&EZ54$W
M-T1)1TE::5)296=F;&0U6FIT-V4V=B8C>$$[3$TO<$EZ1S=K<DDW37,P:C@R
M-45.4FY)0TQ),S=:544T:4ME2G4Q.'4K5G9+=6]V6BM7<E)%.'E8.7-Q<$=Z
M3SE)16)J-CAX66XY,R8C>$$[1V%D.7E!;S8T,5-K:W-R,&EX:'-,3T]Z:F)M
M639S-W9U-WE335AK:UDO>D\W1FHW;D-H6G%'=&%,<'(X3E(Q0S)S,UI(;$-4
M>7AX128C>$$[>'AI<G-/8D0T5D@R:C)W1DEE3U)E4F1,=&17=7)Q1#AX<F%&
M-WA$0F%*1F-*1DI'<S$P;#!%5F\W:%@S.5)W2V11-"MM1F5B4&E+,28C>$$[
M=DIT:&%T6C)Q+VU&05DT3%DR2G15;'%*0S=2<DEX5DIY54)L:4A*4CA*24A+
M<%HK6G)Z6&DX:S9S3E!H9VED-79Z0FEV3&TQ,'%E4"8C>$$[-CE.3S=#33,X
M<$U.=UI"3W-3.58T9G1M9V\Q2UDQ-6\K0VY(<%9T6C9T<#!T.2M98U8U1F%M
M,V%A,'5,:VQ(;7-Z23AK>D4S1$)+<B8C>$$[8DU#2"M!144W=E%G+T9(=UIH
M2F-A4C5J=6]K,&Y63&$T:W-M9&(R,VI#4$EE3&Q9*UI$2DI';UI8;U)4:T-A
M1VU9,G P:V,Q5V56="8C>$$[*T1594A'431B:V%O,WDW.75T+UER,V5L,SER
M379P5$<V=%-$>F]Q;'<O9V]0<&IJ6'A9;C4U<3AV67AQ-&YF.&5:8C0V-&11
M;&UP-B8C>$$[5F)44WE75W R1E9!1&5O:&%J,&\S-W1316MF:C%B:71",S)Z
M04]N>F%C.%A)+VHS:'E2;&AK1DQO3D<P.6)A=6YC5F1717-B3'E!-28C>$$[
M<5%W-D94,4A9-6<X6G5Y,V]E,'1D3VMV1RMS,G!T-VE.1U9R8T)P26I%:V<O
M9558<G,S5V]B63=!8FYO.$=O>%I">6HT=D11,C)V-"8C>$$[9T,O<S@K:G)C
M<UIW:G<O=V-6*V9Z-3$K;$QD371T4F@T;64O4S-E46-L:E='1F]I0V0K2$Y$
M54$W8C=J;V0V-6A:=&9N9U1'>E%0=28C>$$[*S=K,W<P,DUG1W5F-#9P<$):
M-F-K>'5P<%AV8F]!2S@W,4E51&-!=#EI2DLY0G-O>D%02&M*24@T*U!0-U,U
M1S!25#-03W%D67AN>B8C>$$[1BM89FQ,>D)Q:39P<6QL-C$K:T%T5G5&9#0S
M15-Y97%O0E%Q4E)Y5'1I<59Z9FLW-4)K;&ML97=K6C59;6=C;31N24U,3E@P
M<48Y:R8C>$$[-&MO1D<S16MD>F=T5FQT*U50:U,P:VAK=#=",4YU:7A11#$U
M:49J4E-Q;T)Z<%%C,D\O9&U09D)A1D\R+TM0>61:-FQA-FAA>%12>B8C>$$[
M5S%Y;#=)2&UK;44P,%5F<'A.25I3-2]D,$)(1VTK0S%::7<U9C%W2F$S<'5+
M3C@K*TMP6G(K;FTW<W9543AB;3-Q.$0W14-V,F=19"8C>$$[=G,O-V57-' P
M9DES2GAS34QN35)C36]R1W=$:G-A159(-C@R26-!.#%-+T%+,4(S1D)4=WA1
M,GHK1W<V;D96=V1A0V@Y-F(O04LX5B8C>$$[5D9C16IE=$\R0DMO2DM522](
M9D%L9V=T9DUM<39N<6%A9'%K,6]S1C,Y571,84)#259*0EI4339L4D-J57!Z
M;V%T;D\V:E5:9D5K028C>$$[4TM,-DAO3DIO;V%82$Q*:45J2TIL26MM*V1E
M:V9X2'DR,E)&.357.#=7670T<%!->$TX>3-*8FDW=$%P='!927EF555S>%9V
M<D9F<R8C>$$[5D9+57(P<6QL>E)(,2]A-4]+4%HP-TDP*W<T9F8V:$DX=CA!
M3C<V.#%U;RM34'I%:5=72S0Q>4TR.%AP96]:-5I21UHR;%=.15@T2"8C>$$[
M56M41E%R1VY536506DTX*SEY-65A-&HR5DMQ=T=Z9DQU074O<3=V,4,Q3S X
M=69M9&,R:S$S2'(V<DAB,TPR8VY+965V<DIS5D9)>28C>$$[1#A8=S%R,3ES
M07DU:4PT:GIP<WE2-TMJ25)/13)9.%AW4#A!;F9&4%!+:65:3E X>E1A5')'
M;VY55V94>&1V6&M21S9Z;5!I<G91<R8C>$$[0G9U0E$Y<6EH3V1O37-Z37AK
M8C)D1#(Y:#!P=U)Y-$EC2')-9F5/14@T9F8S.7I.<4M+1F1U5S4S>F%V2G-D
M.#(K4DY'.'E3=S-&,"8C>$$[,#!/;S)A3W1H95%Y14Y#.&UX9%902D-W-T5Q
M9C%50D9P0G!J*VQF:VHU2# K2U,S=55N=C1M16%2>#--9S1X=WA.-F=24%1#
M1&51<R8C>$$[>$I&9'IG-%%N:4M+,"\X04IR>6)B5S=I9$QI+VQA23)X;&YM
M6F8X05(K44EH-'AE;DAW0W%Q8DPY:U4V63A+5$EQ.&8U5RM5-#=2-R8C>$$[
M2WII;',W955W<WEW4W5O+V-U<E555E!$;G=(27)1;D1W:$A%5E<X+TMV>5)Q
M3$LY-UEE;S9",5%T3$E62'%P=V-H959+<W1!9FM01"8C>$$[2&A#9VQ'*U9F
M26YL6'EZ3D\R:5=F,5E4<WIY1#%(:TA**U!,6C)B:CEH96U.570R>4UX0455
M06]V,D)4-SA+1G%X9V]W9C1L96]C128C>$$[07)1*TMN<FER1DY7,%,O=#<V
M,FUS43 S265L2DLP;$)%9UE(-&Q0<4Y)0TYG0G5+0VTQ4618<D]Z:$UF=30P
M9G@K3S5Z9%!Q04%E3R8C>$$[6$QL='HO2$Y3:F5(55DO5&Q":'993T1K9D5R
M>'512%)X.6QH,7%P>FUP-#59>G4W1TUH3&MH<E-(5$Q4-GHK:TQ73TIO96-Z
M3VE&:"8C>$$[26QA=$EI;T-6<"LR;TAW.58K1V]4939(5UEJ05%N=C=X,3=V
M,#,X4&9I6CE0;'E:05DR4V%I3B]L*W!0.4LP:E)R83)J97IJ4$=8.28C>$$[
M-&ML4S=.>3-&6&,X:4XK:'IC-&]2:$=O:EHQ*U=C<%-U6$XV:&U/,W1(1E9J
M1'9G5EEW3DM$8D%Q;7<K+W=!355,5T@Y;4)6=%1V="8C>$$[.4%W2E%'=5=6
M>F5A4F0R=')*-E9Z3D=Y4E-%,&]X-SDX;D-6145S6D-X5$,W:7<Q2T-73F)M
M1#!';$@W<%-Y:VYH<V5817-Q.7%F128C>$$[8WHT6D%E5&AZ>&MC,$='3$XX
M='@O=%I9,4Q0=$]A:SAE*TM&,&ML1E9E>$%X4S!09V]A*T9-5D-+56)E>$\U
M2#9V=W=&265+96%79"8C>$$[4$UM<&=-441C4%=M,6%.55IY5W,O=EIE.3ES
M.6Y!1&]-6#E8.4I24&Q!84)C875F.%(S8VM6:7%--&]Z:FY)6%=Q<U9$3CEK
M<S-B:R8C>$$[4E-O<E55445B.51L9&\K3DA&*S1I1$\O:TM0-T(U6&1(:WIE
M369L9D)D4&9.-6EV<C)E,EI&<S%M;6MJ67)$0VI)=V%/13A3<DQX6"8C>$$[
M="MV3&%X8S=0-"M$;UIF;C52-%!#:$53=39!4$UN=FPX4S@S,5HT6714=EEB
M0S9K=4Q"8FU8-G1/-4EA4D$U-%--2TPX5$M!5'1L328C>$$[9TPR-5!586-%
M-#1M8U%*.$ES9'AR8TUY+TIY4U9V360R-TUZ57-M5W S;U!6:F]..#)86E$O
M94@S9G%E3SET=T)H>#$O4% S4%AW1B8C>$$[0VMJ=4LQ<EAB3C8K8G51<#A/
M-'(S-F1C5F1),%DK06)-9'9O>%9C16-Q<')59$YV1VU+5R]107)T.%)(,F$T
M<3!66B]H63=$9G)7="8C>$$[8U9C:V%O1C-)-FLT<7!L=U%R3DEQ35!T16QA
M:78S9&-68E-33&MR3DM0:4AW-VIF>"LV=4I68T1B<%)#5F]A.&E44V=!.$U#
M<V,Q>B8C>$$[4VUI=5 P;&$W3D=736A&4&E!1$AI4U=555IQ5C5D3W4S>%8Q
M;F%7:3A34$9(-F<U5VQZ.$)O.&M+:W1R<6M$;4YH.5ET6D-P<4$S<"8C>$$[
M>GA(<%)H>%!&=F]Z;7 T-5EY3#)S6#A(84-1;'E45'DY<45K;'-T=$]4.5EG
M0FE9.%%"4TUQ3G5.96=:5'8T,#-O5&Y68416*TQ$9B8C>$$[-F<V;E5994-7
M,THV:&QJ2C)+=$59<7-+2'=W2W0Y3G9F1VQ7;4II83 V9$U&25=M1B]$1VMT
M96I,+TQV-#1+5DQ034=K>E@K:WIW228C>$$[;C<P9TY%97!6,4E)661.>&QM
M23%)5WAM3$1&3&IY-W)2;5IO8DXK0F]6,D<Q4C<U;6I*2'9C2U=+6&-P<#5C
M,7EU.6Q*6')88F9F-28C>$$[-&9%:C-O.$M88S%,-5DQ>'1X6G5$52M'4&EX
M-S$X2UAC=%AY>'(Q4E=Z8S K6#EC9D5J,W X2UAC:30Y0C%K0VAS-4YV;SEV
M2$(T:R8C>$$[93EF1&PS264T.&QV8WEM5S4P94]A5FA1>7E1>'4U;TM$9'%N
M2W!2>%-.:T$O0GE-96)0059'56=026QT4$ED<T1V;U9V+S!J>&8P>28C>$$[
M2&@T9390>41B*V$Q2#@K9BMM2W9(-4-S3BM7:#(Q4C O8U)F,'=E2&DW;R]*
M23%7;R]N>B]W0DU7,3AG,DA1-DAB04$W2#!)=C99*R8C>$$[2&DW;R]*4#5R
M569Z-2\V62]R4F5N*U9266AJ839:2&)L+S=Z,&\P:DIP,')X-C!Y55)#4$MG
M,5I*-5HO551,,VTP9"MI=%(O,W<Q2R8C>$$[54$R*VI*8UEA*T%T9F]R56%G
M:4)H.3)01T8T0S)U;%@T4#A!=D]W1U!'13A"6&Y43#<P>69Q>$Q$;TLP=V-9
M6&=+;75L86EV12]6,B8C>$$[24$S5V]Q5#@Y<U!'1C1#,RMI.5)A36-O0T-#
M9&@S>#1W=D%7,3!Q.7%!,74Q0C)0>7@T=W9!56QL.&I3>710-G-,35I';5I8
M-$I5928C>$$[=41Y<5)U,4,R>&(R=V-16&A+:&-F;'=:8F@U0VMG-4-5249#
M:%5-:F-U5D)4:U)U3BLQ4$1(:4-E170S9C5D,TXQ-FIZ>7I'4UES>B8C>$$[
M:TML2W-/2DE(8C1E22MJ-VYI0SA*5%!3+TLY,UDV8D990THU:VI,=3!K;C)I
M>G-8+W=#3G-2341Q9WA+1'9F2D8S3%!*8U<S<7=Z<B8C>$$[159I0DI+8V=3
M>6IF;%)35'5+9DMM83=6-D1(;$YJ6754:'IZ:'1Z0S=19DQ'=E=:=4HW,DY:
M2G)G2VI,2%AO;&5,8C!!<'IF>')59"8C>$$[2V)X,$]I.$4R5#,O04M%-3@S
M2'-!+R]:/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM<#I4:'5M
M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F
M/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D
M9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U
M8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT
M=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C
M.F9O<FUA=#YA<'!L:6-A=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @
M(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @/')D9CIL:3Y$:7!A;G=I=&$@1VAO<V4\+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^
M"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^,3PO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z
M=&ET;&4^"B @(" @(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @
M/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M
M<F5P86ER(CY&:6QE($YA;64Z(" @(" @(" @(" @(" @,2YA:28C>$$[57-E
M<FYA;64Z(" @(" @(" @(" @("!R<C(S,#<R."8C>$$[3&]C86P@5&EM93H@
M(" @(" @(" @(" @,3<M07!R+3(P,C$@,3 Z,C$Z,S0F(WA!.T535"!4:6UE
M.B @(" @(" @(" @(" @,3<M07!R+3(P,C$@,# Z-3$Z,S0F(WA!.U-C<FEP
M="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO
M;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O
M<FLF(WA!.R8C>$$[XH"B(#$@<F%S=&5R(&EM86=E<R!H879E(&$@<F5S;VQU
M=&EO;B!B96QO=R R-C4N)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@
M87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($%R
M:6%L350F(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E
M;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@
M(" @(" @(" @0TU92R8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&ET96US(&AA
M=F4@8F5E;B!F;&%G9V5D(&9O<B!#4SHF(WA!.R8C>$$[16UB961D960@:6UA
M9V4@:7,@;&]W(')E<R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS
M.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM
M96YS:6]N<R,B"B @(" @(" @(" @('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1F]N=",B"B @(" @(" @(" @('AM
M;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @
M(" @(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^"B @(" @
M(" @(#QX;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y4<G5E/"]X;7!4
M4&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM<%109SI(
M87-6:7-I8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E
M<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^-3DU+C(W
M-3,Y,3PO<W1$:6TZ=SX*(" @(" @(" @(" @/'-T1&EM.F@^.#0Q+C@Y,#$S
M-SPO<W1$:6TZ:#X*(" @(" @(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S
M=$1I;3IU;FET/@H@(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @
M(" @(" @/'AM<%109SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^07)I86Q-5#PO
M<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M1F%M:6QY/D%R:6%L/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=$9A8V4^4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\
M+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R
M<VEO;E-T<FEN9SY697)S:6]N(#<N,# \+W-T1FYT.G9E<G-I;VY3=')I;F<^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T
M1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&
M:6QE3F%M93YA<FEA;%\P+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@
M(" @(" @(" \+WAM<%109SI&;VYT<SX*(" @(" @(" @/'AM<%109SI0;&%T
M94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @
M/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^
M36%G96YT83PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/EEE;&QO
M=SPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z
M4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @
M(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM
M<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P
M3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM
M<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'<F]U
M<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @
M>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B
M/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.CE".$,U-#@W
M,S$Y1D5",3%",34S13 R1#1",S0X,3)#/"]X;7!-33I$;V-U;65N=$E$/@H@
M(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.CE".$,U-#@W,S$Y
M1D5",3%",34S13 R1#1",S0X,3)#/"]X;7!-33I);G-T86YC94E$/@H@(" @
M(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z-#%&-C!"
M-C8R.#E&14(Q,4(Q-3-%,#)$-$(S-#@Q,D,\+WAM<$U-.D]R:6=I;F%L1&]C
M=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U
M;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ1&5R
M:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.CE!.$,U-#@W,S$Y1D5",3%"
M,34S13 R1#1",S0X,3)#/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @
M(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.CE!.$,U-#@W,S$Y1D5",3%"
M,34S13 R1#1",S0X,3)#/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @
M(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z-#%&-C!"-C8R
M.#E&14(Q,4(Q-3-%,#)$-$(S-#@Q,D,\+W-T4F5F.F]R:6=I;F%L1&]C=6UE
M;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U
M;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E
M<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-#%&-C!"-C8R.#E&14(Q,4(Q-3-%
M,#)$-$(S-#@Q,D,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,C$M,#0M,3=4,#DZ,C$Z,C$K,#4Z,S \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.CE".$,U-#@W,S$Y1D5",3%",34S13 R1#1",S0X,3)#/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#(Q+3 T+3$W5#$P.C(Q.C4P*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU
M<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1
M" $^ ET# 1$  A$! Q$!_\0 'P   00# 0$! 0          !P0%!@@" PD!
M  H+_\0 1A   00" 0,# P(% @4!!@(+ 0(#! 4&!Q$($B$ $S$4(D$540D6
M(S)A%W$8)$*!D3,E4J&QP? F5)/2)S0U8G+1*$-C_\0 '@$   <! 0$!
M          $" P0&!P4("0K_Q !D$0 ! P($! 0#!00' P4)"!,! @,1!"$
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MVZ3?;?H$Z@")M;T O>=S[$W$]L;4.I*O<!!Y5P%$) 2> /L)Y('!(X20/!'
M\#T4J*@28DBT^VX/?\;D6P"00KS=]H]=IGTZ;B1OB@7\0Z_D#3IP^%)6E[-;
M.DQ%:$*5[BF<OR2HI7BWY[@LU+5\.X*3V)[B>.%>KKP6VHOYA4%*5I9*@D+2
M%)\XY<D&08U2+7-[QBO<1.!+%&A*U)2J H))23<=001OWO D1@$YE9NTZ,2Q
M.*4?0UM9!AJJ6VB2SVQFF_J5$)25+ !Y21X6">//!O="VE0<6I+?F.W);@7(
M@ I_TVZ@#/\ ,%*U)0%NC1*@4O.220)DSL.@[CK;$&R5/T@BF-(2A4<J4E*
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MOY;>G2 (Z8$ S=WH0.>Z)GL=6Q]A?<",:S.0AI#J6W)*FG"LHX[4.(2E2E*
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M+#>A)DRX$O'Y=+C[D&/:*2?7G'WAGPSQGP1FG%G!=&/ZQ5[%/QAEH%0ZE%0
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M'GT,%._I_*?XXRY\@?D@G_L"/_[C_P"/QZ&!-X])_'")R3PXEKN[5GG@#GR
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MCDD?'((](+BNB5@]/)O_ .L=O3YX')3T4GIU5U[>7YC"=S.^HDN(6G']>(*
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M>T-F?D8"R4DJ !IC^.>0E/X[N/'H%(L0%@=/)UWWU"?3VP7)$CSH_P"TKO\
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MD<618Q!)@K><E3F(:$-.-NH6E92RH=@]SL0>X]QX'GD@\@<-!H)2M)F' D+
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M'WG82V8G2]J3R%@&TH?#2[B"4 %,3-D*2=7YU;7LU;<>!6[?P+#-S1HC*?\
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MR18<?J26_M"&%)!%Y2I:-2C  DZ4G8!-X422$Q6'S1YBT]4((TK!4V+";@$
MWL)!Z$*F=QA(_>JM\P<M8,*\A19LF6I4AB'[OO,OPJZ.PB4TP'V7V6W8TCAB
M0"CE25=R.Y2A*#%4RRE*&@%A8,*,)4D =22 20J]C\L+<J6JS,:ET_9-K! 4
M3(38[WB+@7Z]\'O4TFPKI>2JJ538C4B)COU8K6H;L#]09_6DR&8XD.>VW["%
M,AQN.XXTRXXJ-_3]@(%2XL73*_9X?TMO)%4%H*B=-V($@;[]!:")W,)P5=.
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MTER45)6$K)]M"CVA25CN(*U<]W']OGSS\-$Q(]@1VF1(Z1MZ=X).'T?=!B
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M[8P+Q>0VEJE<2L$JS:M;/_6134Y(C>;FY$"P%Q@A7T^#12&LRCQFL@C5L2?
MR>@>C-B+E6!745=9FV(S4OJ1'D,VM*IQ^(F4XW$;O85/+E.!B&H#T#XG\&4_
M'7!F9Y.XH,9BVINJR&M,E.79LP%.MU*X(("FT.,Z@#!7>)QE?"^>.9#GM-4
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M8,&9(CTC\9YK^P529"K]6J;%<>0U:S97;7RRB.Y.;BLQFW&BPE00IJ LNO\
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M2;*9([RJWNK4H<LLCNY#ZENV-_>S+&WGO+6],FO.N%9D-LM,-J2TVAM)LK3
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MIF G?8?Q)M-O>H38E)JS )5M8Q;2<T'HU>B-41X\B6Y*GJ+4<J$F5#BLL^X
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M/^FX;FN-HCUCN,PGDQV?:K[.<)=-,6M+IFQ<HQ2QBH:+DHKN"7>16A&E*V%
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M?1QU(6N82HJ<3.?B+A **HJ%I5WHFH33TH^'IUMJ?22H:R2VE6X! DJ"3 )
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M1R;R!.KZJ<$0Z%3$J?*R%SEHBV2VRPI-LA*6V6$L%302D-..*0E(1VJ5P<^
M7\.TGE(0P[5!.NVH.)I7 ?*DDJ 4$JD[BUL1ZD/RWS%I!TF!Y@0+65<"1Z3O
M?']04\)!)/ 'XX\#_;@<^?\ O_CUXCQ6"2DVZR;G:+VO;J<>^A@BN -IZB^Q
MV_AUP@?6I8^T *3W $?/!!!\D*X_?X/GT2I M^K'^,?J^%A(!)O?>_K/Z]SA
M$M2NT(5Y(//)()_( 41X*ODG@ <$>.>?39D@)W(D^L;";_H1&#PF=/"5<*[5
M=JNT? *B"!SXYXYXY\^!Z!O.JQ MM?\ C^-NW<8IIE@='4%8ESDJ&M:G[E!
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MWF03RUMI=4-2"HZ1JDI6TH  I*@0)2% @A201CJ.U@JZ%8<'VZ00T5"%K*9
M"P1O8 0 (CWQ <RR(3]>813K?C4D"[9^KO;-+16[$CU\<.S'>"IIR7.E.@>V
M@.LMH0I+7<TI\N-2J>F":BK<6"I30<)$QY 2H*!@E-NI"H,DB!I*:E:E4##0
M0A!$$K2#JD"^HS$ G:!;Y89Y,NLPNDD?I$"QLHBVVE+<R-57-='#Z_;,"351
MX\>E??=BGV8O$V/(6I#1DMN.^^'VTJJG %.K;6E)+323I;7$#S:DDK,& 0I
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MCP%<J!//!)\<D\:5P/']M[_9=O\ B-^NTB\XS?CVRLNBP)=)Z" $>G<][?7
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M2B@9$FH?"6RHM3]P*69"8,NHJ&::G6[4OL4]( "^\]!2A&H04&8"]8%Y%C
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M&I63P:=[N2J)B&89=B-5-0HD>Z]68M>4U;,4M!!6J1$62%!*CQX]>E,P\/\
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M24P4WB)(PG,*45=-J("N6M:UI($**TE)U"!(4"4D=C:<#.)I6WQG,=CXG89
MB_QK$H\K^5+&196-[+V)K;-S$R;#\GFKDN+;GR8=)8/49O6'4K,Z%91(+;+#
M*DCZ&_T?ZG/,[H<RXDSK/35#,WU9=5T3[BG$IS.F445*M))*7%5 6H$0"2%
M ;9)X]<7\$.\-<#\,<+<&)X<XAX;IJ7,\WSEFF::=?9IV6\NI?V,\@:DMOUC
M8J<P"M:UKUF?- H/MW'IVE]D#.4LRY.)Y$8=-L%B"5?4O(EO=U%F<=#*/:;M
MI+T-+K$E,6.D9WC\^)$2L9F'E;57,JRZJYHL@^520(!*K QT'UZ[;XZ7!G$S
M7&'#U+5D!-4R@4V:,VBGS5@!+E.D;\M5/HJ/5:S[8Z=8%E+6Y]>ICB9'D9_A
MD.&Z9D)Y'TN2T[\82JO(:P^XXB3 MH'8^VIM;@:>4[%4M3T=T(Z-*_REH4HC
MDU O:2E5@3%[21(VWDF1B>J*9PH A*B=*1$>6Y'N-1_.\G',G/VZJ@ZHY^:9
MX]*9KJW$%U](MR*Z_P#1L3(Z6VIZ1';4XTE$J1E,*5* ]J&^_";DK9,V&7M.
MH><]D!I*(DNKJTK=2E4!8!U!*O\ $;-J2G<C40(28B*=2BO+KJ0EE*4$$B\Q
M?KT!(OZ;",4FK[O965[LRC(M1XZY9M.5L['ITNPKEOU@@/-5L=N1-;<>B!B7
M.35IDL,O^\ZS!0PJ3#[5A*+2\W1LY524N:/&F<:=#K8;5YDRL*TB),25 Q>3
M,29$$K?J*]Q=(T'&E)<#BRDW:5(()CJ@JD ^X[,TKH[W2U&?G2;/%:]J0HNN
MU"+6<9KD5T@J1]&ZY74\@LH2VAIB:XZA3+02\IPI3[C#G$E&7&6T-,N(9\J*
MM]M3BDD3I( (3Z;*-H,F3A[]F53J2J="/WA($]D@3%Q;[NUMY.'UA:]64LW$
M;"CB1ZNRKI,;('ILL!V4W)B.LNS94J-&F,(<2TV5(6D>VEKM;2 V&N%N<JN6
M*KXTOU(*0TE @#:4E-B$F$B-Q'7JM@(HTK94$A*TRH& #ID ]"=[1M-KXK5C
M=3=9,U;TM!$3/BMY&+UYTK:C1H[4=IZNKYKW<ZTOZFV<=2XXTRV^M24I(:"'
M6@GKNN-TPI7:H 52_NM#[K022 H#=.I(2LR3)49"08/.:2Z\\MQE""TTHJ/_
M !0.L"\;3,$?(X(^S,*DNX)"B0;-,R7@K0=L&D0%Q/?K7E1Z^PF5CZI<@6*8
MDM-?+<;=C0'5L)4ZTV\RXM"(E,I?QCCCLE%8DLQ.J X(A21!$'I<$I*3N!AV
ML"G*9"9(E9U 3(!(V%Y@P8.\1L,!]J=:+Q9>.QNU;MQ(CM/1W6G'2PS!LV_I
MWJQUM)[&9%LMN#-B)Y)*D/1@&GUH3+66U5"UJ(;;HVE:@FWF1I(Z=;C;:3A"
M%.):%,T I;A2@2>D&8WN2!Z028Q:C3>XMP]$[.?5>&U\V%DF>X9,Q;"<_K[:
MRI,CU[*RJ740)F6X]84KC;L7(I&*0;7&"I-A"=K47]I8P'I+S4-:.)7Y7E7$
MB:'XA0<I:>J0]44SC:'6JT,H<#3#X=&A3*72S4J3I(<73I1&E2@''FZFCIFZ
M%U)4F4N:5 *"PBR4J)$%(7I61%U)%OW<%;'/XB>X[_&#B>X,%ONI&8,9V7K>
M;GN;Y]D3F=3M?Y_D>N<H;HT7"F;V<VO \IP2QO\ 7LJ<9T:HG9E<-6U9=U+$
M6K'.J>#,H;JE/Y<\YDZ _1U:6J*DI!2?&4;-:P7DTZ"VD"J8JT,U2 $*=12M
ME#K3BE.""EJK2-33)1"PN $Z2M <3J  (A25 *V)"1]WI/,1_B1[?IF++"/]
M),@J=?HDX$<*Q/"]Q[&U198O!U]B:<*K*_),WQ>[AW68460UX19[#>M6ZV7-
MOC^J8I-P>/S7JBO\$92^D5(S N5816&L>JLMR^M%2:M\U3BV:9X%%*ZROR4A
M05I0T>74-U1\V"4AP+"'&O.YJ25+0A?]XH*G[T(*3]Q2;@2"E0MALINIW9>,
M9C6_S%CM)<W;>D>H#4#RJ>XLK.+:'JMS+:63Y%D'O74U=@NWQ;_5+(50/U&X
MD*N6*"LE6T_WI4UTNKR&DJJ>L=;%2TT:_):[4\VTGR\/LY>PQ3I"$(04.)H$
M<PI;;2WS7 VA("$X>70.L.H94M2DNZ'4Q<)4A3>DV%R$@)F!N82!;!\B]8E_
MJ32T74='KRRO)<;3VS]5SL>J=A9!#PIRFV?6YG$L]HYUAM4Q6XA)V@W)S!4%
M.47:[2!(HZJLQ^%3HL(3-VUR4\.)S/-A7KJ$(0YF%!F*77*2G54M.T#E,IN@
MIZMPK?;R]0I0LT[/+6EYQQS64*4V>@_0-TFEYQP*<6MNH2VI""L\I2?*IPDD
M(44W0D)N3YB"00+4=8>>.;%R_8$/"<=-SD^W>F[<,#'UW,EROQ^WZ=9_U4:*
MJ16_426\9R..D(M \]W,/!"HA]Z2I*>Y4<)TRLMIZ2IK73345%G% AT(0%K1
MG"(6H2-(=8)/* "M4G786YK-,JI=;2V%-AQ*TK*>RR09M$!,^\B)&],MEWN.
MV&?WF15>+3<<QW);N\LXM*S8V-_7P?K)B)S:V[>?&KEY0Y%LTR8LJ;#K&F'(
MRTLML!QIQ!L>2HJC1M4SBPX&6T-N+"$M%92B"OEA2N7JWTA1WN3AQTEMQ+I\
MZT@:E6\T#?TDWC?;8&<-.>7>.Y-6TMG03I4/)_J!"E1&X;ZU,Q@^XC_TU(Y4
M\EM:T0F^QTSOJ_9+"T\N113-5+*JAI3"$4+FKG.&Q2B9*DS8JMMI.YMWZ3U2
MS4,M+0XHU>H)5U*&P"3  \WFCZ]QB&RGLJ6ZX(U-%8@0$AGNN(D&UM)20E*E
MOSI,F>DJ4X#W_1M-!J..&T(*DDEX*0K2W3./M-H "%,40J$. $W"]:0E1(@)
MTZC 43"HQ 4AQ,\U:G-9*O-<Q)%^O[OX]2<6VT8N\L\4>ML-OIV.OKEBJR&I
MHK^RAT:K"L2J1'MH$%+H%>Y81+-#$^ E*6V9=>MUH%N0E1J/$"@I5,'$:_-5
M+2XXR&GB%*:04.MJ)*2E394!-@Y'23!J)04I%HU".@VV!V]L?TNEK#:21Y43
MR!^_)'/'Q^/7C+'!C453T-H^0._H!VO^#<X^KW5)+94 D*+B00@\>"GA7D'C
MC@>02?)'QZ0502(Z3/RZ]1VCKZ86+ =([G^.$A5Y Y\DDCCGR?D\?^/38W'O
M'RP>$2U%(4D\ E:P$_N.[N0>[P>5 >02?^W@>@HZ9!L-HN1WM^CUP7K^OI)'
MZZ8;B5/!27$#E+BD=J%E*@"/[CV+6?M! /E/)!''!X],K(,09^OZ_7M@_?%5
MKYE"=_VC25DI&M:=1*U!1_\ X]/''QSR /D@GQYY]!/W3ZJ2/JE8_/$EL^1)
MW_O>W0M_B(GY8(*(P;/*CR1Y2#R?_)/[?''CT6DGMU'H(^77TP9(/?U_&+[D
M@&-OGC?V<$?: 3\? _\ C_W]%&_6/?U]/0SA.(C8R[M,J240%3Z);+L1:JJ6
MVY9LOH/:IYEM*6'&W@I;L=QE+KRFULM.AQ@^ZA9*U"802F!)3IF^Q@F0(@S
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M)6D932J6]\5F*&P.:ZEDM,0&T.<TD!*5 $BZYORE996/&F.9N"G)33)(0JH
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ME:D:DB$R<<^]1T>::IV#L;3.R)D:;+PW)'*FBEI;#;UUCJT&;C^1L+;;0RY
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M&\8O=JSIWZ<]IZ+Z;G)MAD.+Y9E.R>K]>QMC8V(%J[6XQIK06#;Q:JX]'/\
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MU#E/3 F-1WUKBU@]+@S_ .I5I$N B1'5',U,+F3 D3G$(6\;K3UCV<9/1U:
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MK!,ZD)2"G0+JU?XB1TG?$UPU]A^*N!.6ELH^WM7XY'@<CR.#P?GCGGG\?+]
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MATPXIC*C/G1HPD.+,B7(<:0M^2^""7I+ZP7'WCV\J=>6MQ7/E1)\U)_.''0
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M3EAIV@*!A"*D,,KIV4Z6334P4VRVXWJTZ4:](4G2L:B0HE1.%+I:94<M*DA
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M5-4+;RT-TZ(2 XTTI:E $J+325$'0K"FF*=;:@A4/*; : .E,H"B" ;J&B9
M[#:#BM>65F:6T=H65;:-5$8F&[*DA'N28:)7U,B/$<KW)29B%S(\5-E)8>#K
M;312Q&]SWDGN(=I6UNI8.E3QUJ7J&E!*0DI($*$@$CN%03,$(J#5.)90^D@-
M#25"P5"B9VW,QWL)CH<M*Y7DTU%^FBKH3#$-FDAR6X\>5):,IDVZ?> D0XJ(
M[CL;Z8R&([80927Y"@A3_MHK7$-/2I;HB7D+*G:Y15!2))II@22;R23W $Q)
M;=4XX1H4 A$I2"8@0#LD$1C^E*^I8=)[04E:B>?/C@ >.?') '/'(Y^1Z\4J
MZ#O-K7,6_P!1&^XQ6)F8Z6^=[?EC0XD*[AW'@D'GA///R1R4^0#R!W<^. #Z
M*)44]-YM,^IB^YP>$!2$D\?DGD_ )_)XX''^?Q^W'IM6Q^?Y8&$3Q+BT@**4
M<'SSVJ*DK0?M2I/D !06H^#R$CGR1'P#Z>GYW_#"!R3W=Z.YM1'<DI'E21R>
M H<K//')Y*>" 5 $<GT,$1)![;1_']#%:W$@]0ETI/W!6LZ@_P!Q4!V9!9#A
M)_;E2AQX(((\>I"0.229_O4V@;E*@#?T,_P[NI-T#T<[]2CY=/3?VP7T-A0/
MD<\#GD^?/'QX^?\ ?\>F@D&;G<C:XWB?IVWM@U+@V@_P/^GZMAKL8D>7&*'H
MXF(0MM\1U!"@MV*L/,=H<[4%8=0DI[U!//A1[>01H %_-V21U%_6;CH#O/K@
M@LS-@3:>TP#UVC?O:;88JC(&IS_T4R+)I['[W$P9Z?:<>8"E$/Q5J[&WT!(3
M[B&NY3"PL*!;"7%(2K5,I*5BQ2J+[ %,""/G(Z@;86ZD@ A25H/[R9L;2% W
M%S%P).'&RLH%6P7ILEMAOGAI'<%//JX\-1V1RX^ZKGPAM*E<>5< *4"6I*$E
M2SI $WM?H +?JV$MAQPI0VC43:P-HW)O%NMQO@>1ZV1ETU5A*6]%K70MA!0L
MI>?BMJ"_H(3J5!3,9U:0Y8V314Y*>3]/"=####[<0M"J45N:DM"0E,:5*@"_
M_"#.T P;P21B8'TTB-#12MTPI:I2M*5=IDA2A;N 03M&(YDN&BCL8,BHD/-U
M=B\Y#=C.ONONPIJ(STEAQF0^MQY<60B.^EU#SBUL/%!;4IIWVV(=70H:4VXP
M="5K"5-F2E)7!"@=DR?O$D VBX,S:*O6^%M/@+4A!4VJ(40")20/O18I $[S
M.'_7M E##N02G"_*G./LP2YPKZ:N;<+(6VKQP[-<94^IP*(,7Z="0D%WW)&7
MTX2USU J<>G3J,Z6P82$@S&J\D1,]1$1,QJBMWD-F&F8U #[ZR).HBQBP %A
M>1))Q,+RAAW,3VI"$ID--N&+)".YUAU8 (^>76'1PB1'*NQ]L <I6EMQN:XT
MEU)2H"=TJV4DB2"#N+Q/2U[#$-I]QI16E4 P%(GRJ'4$3V)^IN,1?%+YBUBB
M&^Y_S\3O9(6KN6\VR0DE2CPI3[/VHD%0"U_9*4E*9(2AJG>Y@4A4\QHE"B0!
MJTV"AT(($RGR]MIP\\SRBEQ/]TZ I,&0G4-6DGNF=,*,FQM Q*5M\>2/G]CS
M\?CD>/\ 'C_/QZE0""0;B"9@#V$>NWTPV#Z3$][&">_M["XOAANU$1_:0!WO
MJ2PW\A7+RNU1'QX0CW%'CX'Y''IUI NJ3Y>G21._MVL?6",&N !MZ?.-[1$D
MW%HGMCG+U-MN#<4&!&CEPC5],L=J_;2GC*,H"B5?)X"?"4_W#N'/CUH7 Z"1
M7K !T\NQVN#[?(@R#&,\XY6D"@23]XNSWMI,?.VPG; <9+TU45IV/"060M+3
MJ"7'5AL'D]Q\ CM\'D<*!\>.!?\ &>*";@E7K]0;=.M_17OAP,F.I,B(]W/-
MK^PLJ 46U!//N \$GM"3SVG@?GCX]#KZ_P _],)2B(*=S?TM-H($?JT7&I:&
MX26&XK"&V4]KC*PD*2E*OM6MT?\ 5V\^1\^>0?0PH&09)]1TMZ])ZFP-QAP8
M#%A'7(>"%-LE38<0E/8X4< .(4."D \]OD<?MQQPT7"%%-NO>;'K?K\MHP82
M =S)%]I]>X@^O4;F3A*&8Q[5LMON)[E(< 4>P?![^SSVGA( 4!Y'YY/HE+)!
M!B-^HV@]_3V[X6C<"T7B1Z 7^?UFV*]]3D1K+:;5VBFW$+C;XVM0X=DJ I1*
M]98M7VVTMGPIZ@3Q69-B&"SM=RR1Q[V;QF4A+K[2T\S, 7$,TPN*M]+:P+_8
MMI6^^#;[JVVE,G>[H @XZF6GE+J*LV-%3+=03O\ $.*13TQ$G[S;KR7AL &2
M3:PM &8$="?J'$.&.\GE+D__ )=E)) [V^>5I*>TI2 5!7 2D?(DKG4>]C&_
MSDP/;:XMM&(K<E-O6\#>W<]9GH# (F^)?22U32AU;;;2$CB*MP%#3G"N \R5
M'N0.1W(Y)43^>0.6B"! ()B_<6[[@1 _RM@PF"+@F1\O7\H[GIAQOJXOU5D]
M#2Y.MS FOPV([K$65-GM,NNL0$3WR8[#TR0A+*7Y0]AHN!QT>VE7J->"0D$@
M&!W,&(.QD]]O82)#8!6D*( FY(*@!L20+D#>TD[#?'!?&L1ZF)T*PB5F-;PQ
MN!F.B\?BYC#@5'4+BE[4[0A[YT)(GP+G.=CYY966=[$I<,G[%*]GX-BF!XY>
M4RKY>/2KRN@N1,;KP;JE@PFH0'*=.N!4H*7DU-,2DN.N$NNI;+IYS:&TJ3JT
ME8$(MRET:""IRE66ZI9;)51K2I@TE4 I#3+20RRIQ+,,.N.K2K3KTJ(*[47V
MLLHPC8>08U;T.Z;+I3J^H:);S<2Q6RVUE]JJDN>F7%VJZQJH>.VMGLC)-=5F
MZC=RL@QO%W;6)#SR;%R.72_15EQ.A/.,K;<4A27S2)J HH077%:%TJ"" DEU
M;*7YUI3(#AU:8"CB.T\VZPA873)KE4I2'' PV I%8LE*M24M(=-/IT+7!+8T
MI5) )+UUB>YJ7H LL"P*JV5CN<A6<24XU+M)-9N9K$)V]LAOKRI@Y,_:BR8V
M/>:OF60I+E-\BR=R.T@6<.Y3,<8GA2&7DY<I*$N(=',(2HD/%!J%J5<JD.*:
M*M)U25D*"I@X2MUA>;!Q:F7&OLP5@ L%P4R4).G206DO@:DZ8"4D%,6Q!\NI
M[5V'34.MM.]1]=I.;L++;5=CM#'>IW.Z>'<Q==8?75;,7I^Q+*M?[KC8WDEU
M,OT4LS/LGQ#7=!G..Y%FDA@.9)C-[(B/))"4M-5"6"XLRXFI6D*#: /[.E2'
M@E2BH)*U(;2XE:]UI5B8TH)*UO/TRZ@--B&ETJ%$%U9,U*D+8*D )*@TAQQ3
M:DH%D*3@>ZXP;?;E'AUOMW%]VRJR7K[H7QSJ @Q6,V=VGF&+Z\?ZN(F<T3"<
M=M+3.\UFXWEF0:AN]@U6.V^1Y'E&$2+&.I>5,W;[-LPVV^$I+B'M/+HTO@:R
MXI"/B0M/E)6LI4IM3B4E2EHFRIO(<<IEJ6&EL!27*XTUVPVE;OPA;4=8Y:-2
M$/);4I*$)6!(1$@ONX[MK'KU_*-<Z^ZG:K5F*.],62U&*Y+*S3(\ZE87AO73
MFV5['9K\8?E2LOE..Z6,"TBZRLF)FPXNL7<=P>VIG+.*QC33B@[NA%0&DBG(
M2K45Z4UJUN0DG5_=&0@@N<O2A0GRX2DLP$K73%U7Q"5+2$)0'%T2$-DJ@( Y
MT@N)AKFA:P8)5A9!UOLW>VW56&QL4WO6ZDR';G5!D,.LOK'8NMF).,6&KM#P
MM5.7%?7VU-;U%-.O*[*KG%L<N45TNKO8L[ZZGK,BA6,&.80MUR5I>2R7:A4$
MN-GE\MD-D@:5)E25*0DP0H$0%2 1<;9: :53J>2S2HD);=AP.U!<TD@I*@DH
M"BDD*!$*4"":C=$F![A_XA=H.[!E;!QQ5UTE:3T'LC/]@6N37%IC74=F73?B
MN;6UM?WF03K"RK\C8R[J#>II5+%>AP:6%-4E$*)6UQ2SD/C%09C6<"YB]3LN
MOHR^HR*IS%LAUY;K* &ZD*0DE2PAS,6W5MW2&VE'3I0(MW"]51,9U1!Y;#0=
M>S 4I"4(;2V[5I:8(2-(4G122%3J4HDD@JU&(:GBIT;F3FI]JX7<87FU(RN-
M/K[BO;CQ&7(1<92(LEQQO]1K7VH[CM5;P&9%)9151'8MF[]2PESS#G7!&>U?
M!=7XB(J*&KX<=SQCA<#XI!S2JJ6V?)5*RU"0I5&V4EO0VXPXVH N%4%0V3^M
M.6(SY/#^NH;KG:1=6U4Z-5$Z&%)0IHC1*&SK_>49,#5-CT8QR7E.4P0K!,#O
M[B&E']2\_34UV-PT)2K^I/RFT5!QRO:X'<%S+1E*FP2@K5P/5#1PKFSI;15-
M5%"7!#9S)KX1!0DZ$*2L*=EM2$A3?E!#>F2I7F/8>S6E9#J0Z*M]L(U4](L5
M%4E10%PMD);";$*; 63H*03)42Q.JHY<U4:RNI&V+M"PA6$ZCF*1B$)U*BA4
M7-MR2HR*.(&7>6K.IP:-DE[[14[7S&W$^XG7.!_!S.N(5)&69<*Q+:DE[,\Q
MFBX?"9%TU#B4KK@(3]DT6E*5$* MC/\ B'C_ "W* M+SP96$*)IVSSLSVV53
M(D41O'-=YR0)E-X$L1A5_F-3(@YG.IZ7 Z)+=C8:WQ)YK$M38V$#W$S]B9!;
M2V595,#()DVN?6TM=VADJKL:$QI+:_3V5<!<$\!M-YCQ14?MC.VG&WFJ:M,L
MTSJ$'0<LRI(4PM*0DI15U(J4A"E-EHJ="DXUF/%6?YTDTM \<KRQ.I5FREYU
M*IGG/O*<)4I*ITH+:#$A'E!35+8'7'KJ@O&=6=,6 S>J/;,A:JVLB8M4W:M4
M5LUE(C%JOKZB&,JV<(12XVXEJ'3XL\PGV)U4 /J4-YWQ]FV9%?[/:5EN7NHT
MH"@5/NM D!3;!6:)A(3  8HVE @JL3;AL4C33GV3:GZA<E;SWVB2HS)@C?:X
M@$&Z9VJ?N3%<YRF2Q<_Q$>JV)A;+#27ZCIFU((&;9G AH_\ 1JF<%Q*>WK3
MHO:6Q&EWUUD<V$L+1/J&%I"303I6HN(*PM9E3JW%O/*-CYU.J<23,BR8
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MNLN4I?TI>4Q64<T[S"%H"PAH-EH A43-,FH'J!RG13I11J9?IW$-)0W%)4U
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M,!IJSDRV(UNZT4N6#;+;DFIB!EAQ#5E/>,+KU^;U--3H<;U5M6Z0AM2DRTT
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M<L=ELJ)&:*E,P2U/AIDOOK+;#:2][B4)4Z'%>TLA':.2EZBJ:JG5R$)*N8@
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MZRO0=CI"TS&VH2;XA9@$<RG"KJ+U)8D:C#@((!()C<6,&9V&&B\EN?\ %]M
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MA3](\ZVZV$..L+8=:4E;;C#S"VWF'65H2L.M.)4E5@H$&'ZFAHVTH&HI=0V
MX02%:@==B+@W$0?F!@YTN[,TR^7$O\FL&8F22<%Q-@5$:#B>*P,=PZ/=9L<#
MQ^JQS%*K%\6I*B!1N^[5UM!054-J#+8D+AH?E.N.UC-,N8IZ>E::946_BJ]P
MJ6Z]4N./.)HB^ZZ^\XZ^\XM8 4X\ZXLE&DJ\L" E+;0T)((!)!(U$R20HD@F
M2(N>T7C']$1P\K4?'E1/@_CD\?O^WKR- 41?[I_4_KOBM_K]?7#=(6ALA;BD
MH!2GDJ4$@*X(X!)_Q^Y^"?CTVJ9ON1?\1^0P,-SRU.) ':4K62"DD@M_])Y*
M""0?(\=I_<>?47!']=<-7MJ;<[E*XY^X#A)(4#W*X/"N >2% '@C@#X]# L1
MZ'"-]Y*4*7Q]Z4+* D*"B$\$@$!9\<I/@<_D#@$AM>X]OX]]O]<$ !,22;WZ
MQZ[;_G?%>*]7O[[OU.)"%KUG2%?)!^Y.0V:>5?@DA(2KX/">/'I]G[CHF/,U
M)M%@Y>]H(ZGO/IA9^ZCL0N#ZA2-^]@(Z=1@V%(2R4M_>L<^ HI/)"E< \\CR
M..2>/GD@GGTH)(!F=Q&U]HM,CWL+B3; [SVM^'\,5#V3D7\OQ)>-V6&W=59Y
ME?.VL.^*Z6571V:^<Q8R6E6%=/?EL.L(1VQ&'HS*W3/][A'9(2A890VE3B5I
M62;C2I)UJG2D@B([E)TC3$[ \G-<P<2R&5M.ME7E9<"FRVGED+4J0LJ!@$@:
M=1) /[P ;V?N;+5TE- N)BZ*G6X^B=/A-/07,MC+:#+$9]3R^QJ,H!Q4QJ(%
MMS%**0([',?T\AE]P%;3#BK$J4@*4&[R8(28$;:H@"),R>#69R_R6D+"FDD0
MMPPCX@%( TS  )DG3(.T1(PT8GL^XD/8W7MVCDG!:VU59VF.Q$?2V,\CW741
MDVR7$%< 35-SW*QP-,S'2XW(E!EQ*664N)3*5 !4*3K%R))()3T(!*9-]B 8
MP*3,7)IFRM?P[:E+6V!YE"#I3K)DI"B%D#<R%6,8MR]O"HE-KC8Q09%D5REC
MW4UL6O5W,I' +DHQ53GT,A7""ZS&?0%E*5+05I))+:%>;4-/_E"2=AJ/EGYC
MO<8L?[0;4"&4.NK !TA!$3U)VB>P.(JW+O)\^RL[X(8LY^(U#SD-N!)K%5K;
M\BP<-8XS+<<DK<CN./)4\^EI3B5#N93QW*ZM+I#(BP#AM]ZX;;!5[:IL/D3
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M2E/ /DI)\\ $^#>N"S>M$;%L]HF0??86.T3BA<;#R4)F)+N\6^[?W'2_; 9
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M@0[%EAK),F;IJB+"9^$=6A06Z@DTM13ZM;J@I;P;AP-E*4,I!;NVVF!.Z@
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M+U=/N*7"L2-A;-/$AD^TMT*!![$]H25<=W@%?)'@ND#@=H]8]QM2TK.>O+I
MVEMQA"G$MGRAXE94=[*5*9$  @B)Q<<B9?71A;B5'2#YB()'E(%P/>+3ZXO1
MTYQHB,8R.6M -J_ELQBQ=)!>#4># ->P5<]PBM1G2\TVGA(>DR%]O>ZLFJ-W
M;1V.LFY!)UD3'0P(,;@#IB[90$_#*/[X=4E1ZP DI'> D@@$FY.%NQ)+-=?S
M7W7 S]5CL/M4Z>T.JCS+)"T(4K^]: M"E!))2E2%'@*'KJT(*T:1?[2(Z^9*
M57Z02(]_0#'<:*$I.HP 9]HGM?V!_EAUTC'4G$9DE:%I_4L@L9C2EH4@/,AN
M'%;<;40 XV3'5VK22DD* )()],YPM*JL)29#;#39B+$!1*9'8DB-QUQ%0(UF
M0=3BE C:#$1]/UM@Q^3\>. /'GR#RD?OS_GS\^N8!/SZ_KK /ZOA>,E#[>PG
MRKCSSP/M(/)Y^"1^!R.!Z7]X&!'Y'<D=COO8R9MA22 03TG\L,ETI,.O?>3_
M ');=<3Q_P"\&R$GQ\CO4!Q^.>1\ !]@$K@QY;_2#WWOWW/I)-2Y$7'?\;?E
M^(]XXB/]/"BLGQVLI[O/'<2E/)/^3R?^Y'IZY*E=";;6/4'\=ML(Z#\;_AZ[
M;_RQSNZE#[6[83B6FW5)U;4$(>4X$!(RS)SW'VVUJ43Y[$\<$C@D?/J]<&?>
MKNY#1W[R>FT_ABA\;3RZ$&8U.W$#HF=SM;OU],!1+\2<RX^EIOO"W"65CM4E
M*.X@*3X2A*2 4@>5$#D?)]7W&?C5.YVB?4'V.Y!N18&?3&,=1AJBO.(92B2A
M:E#D-HX)X0M9[>00//X\\^A@'S=[2-NN_L-H$$G\<*WG'/=;4B2P^TX724M.
M$",MM*@"I7CN1_U \*!^ 2>/25*TF(FT[_Y8  BT[Q?J#$_AV[3:^$]QD./4
M]7)O\DMZJ@HHD7W)U]<3X]56P^U0;0]+ESG8\5A*W5);27G$#O6$CRH),9;B
M4!2EJ"$B5$K4E*0)_P 1(@7L3TVP^VPXX4I;"EE40A"5.*[PD)&HQ&W2#/IY
M17D.VJ*ZSQZQCW%=.BF767]--BV,&R:#JE-/19,5YZ%)C$I* IEQ0)"NW[AQ
MZ2%!8UH4%)-TJ"@04C]Y*A((!.]Y$C:075)*5%#B2A2;*0I)2I)/10-TG:QB
M_N,#B;@UM*ZGL)S:F*45"='[ Q3:"&;&I%A&5?9IKJ^UG8"I4Y]?]!*=Q+9T
M R&XZDKDM<)>0J+*0J"ZA8K&74Z2$TSS;@*O,G6XRI@A,R4GEO@$2)'0@C$U
MIU(H'VU2"JK8<9(2HI5H:?14)U63J <IU02+1W2<6G@6%5,;?3$>@RF(4G],
M=7#D,34(GQ72B4V^MEQ8CSXZP&Y,9WM>95REUM!'/H**2HB9 @6((D2()&QC
MVOO'2.6U6U2F4@@$=(L1>X(N"+7PU9+;P:RR;6_85T</+AUS<>6\S"9>E7$I
M,*N:#BQ]\R;-*8D**@%<E\AIA*W2$^F[)'F($D $QN9$02+DF!UU"!?#J4E0
MA*28DR!-DB3[ "Y,V&^)+ B--I2S([P^CA24I*@ZH\ ]OW?:.T'@ )[B!W'E
M1/HU" 0=OGM!F9B\$3M^>%A)29GWD=^]_G_$;X>F6^2Y[$M82XEH".M(6AUO
MN!6TZL\'D@\>/'/(\  >F5+@B)FY^0BQ![V(L+=9).'D1"B?3OW]-MIM[G"L
MAUR4V6R$.%H^XPV.TM%"CV,]I [RE0 [B3X_WY])URK:;'O:\B2?PCWVC"R#
MTC>3OO;L!/S^=MI.@V<MGN2\PQ(=4E;PCLA)"!X[5N#GVY"2D'N!Y^?)'/I"
MC97J#;_2UOX6Q(3<""(  []!ZC^/\,2:@^HD.MJ5W*>KF"EU2N4!^0M(X\A*
ME*3V\<.CCD_//D>HRC !B;_P/IAY))49,V/\,/1AMK9<>*R\M]I8M(R!RAY"
MDEE*'7$@*"$_: 5*![?'CCTTI6J\7CWV[6(GL+S^.'=MXVZ1[=)'K_GB/KD4
M%-#B/QX,)JQC.)C0D-H<=$8@\!"?N*SWH"E%:CY(_)\>C"-0F8FVU['I]?UT
M0I<':3[C_7ZB^^!YE.6EZ3%@1.9MC(4MEF#$#:9<AQ(=<?4VB0XTTRTRPE;\
MF9)?CPH$1I^=82HL&/(D-!RII\MIEU>8/)I60%*;4KSEU2;QI&DB8W/>3ZQR
MERK6E+9U-SI<5,!"9\RC_P!43U @;[XY.;[ZW[:3G$?0O25C,7>6^)<UZO5<
MUT+]>US@,^+Y?<K&WS&BYOD%&0]+GY#;O0,*Q,,"8^AAVL%W)R3/N,JS.G'&
MJ5]ZARQ*PTKD+"7WS"B/M-,I;(2HK!!5(204Q?H-4Z&X;91J<TZE/+,@)%SI
M2=S,'43:"0!N>>^8WNNM Y79YEL+(*OK$ZS+%YQZYN\DF/93I#4%NM?>EA:%
MAF/M/+J9[[FJQMF)@%+)[DM54F6Q#O7J6I2T MH;;0UYB%P5/N@FZG%DPI8,
M@$ "2>M\%SVV=:6U<UPJE:E04I/9(,DS>YM,B"?-B7YWEFQ>N#I6RBQV)<.7
M^Z>G7+!L:/);AQ*YW)M29!$%7D;GZ= 98AJDXE,;,J8_%CH,>I:J8[I>D3Y*
MW^*O32UZU-\S1F%.6:E2UE125>74W_AA($@029),896IUY(4I9U'<WWV!F08
MZ?/K.&_I4K<:N,2S+1V5S$5V$;QKZFO1;R![C>(;-Q^6N7K[)74N*!;@JM9"
MZ:X0WV+E,V$$//-18SJTNU0 Y;J/*&B"YUYB1-@1MM)F8]>J$+A)1'WA /K.
M_H)Z7Z^H.K6C=MI;94[$M@8+C60W^#6%A3WF%9I60K>EO:R;#>KY;+"9S3D?
MF;5353,=R!IIU,=QZKMV!)95[;H"B^RI;?E#@Y:7"9A9!-P!)L")L+29PI+B
M6#J4 L*&B"!UDS<'HG<0;R.F)WGVK:'6MI17V(2YMMHO:BI+V!V%HMUZPP^^
M:2LWNKLGDJ6IT7%$ZEX5;\ITRK6K8<<]Z;*J[*:IME94E33WWVE%*CT=D A0
M!N!>+R;6.$+2D'FILDB2GL9DWF_Y_P "3M>L1L/"8.ZG6VI.PM;,4>$;H;6&
MTKS[6=H[^EX?GCS03Q*OL>F<TN0/(X<>@?43Y"(\&-3Q@EL+;J#3@%33Y"D$
M6#5@(5,SL3;>?GA&K7YHW^@[ 'K;K_+#ILMN1F>O:3=K/?.SC4;-+B&UUDJ<
MD9GJJW<>C8EF\U* XN598[(5,I+^2>UQZ,+"VGJ1'CPFF44RVV*A=,M>A"P0
MWY205%)((V!)@B;=#@VO/YONZ3UZWBW<'\NF'#/)%A$S[5&_*&TDPT;,Q&JQ
MF[OX"T)DU&W]9M&L<ER%/M/,M2\HH8T>SB1934B+95D*:),:173/;>4PILL/
MTQ/G0LNID$:[Z=,6WU S)]MCAURX[21]8,GZSA5CN13, N6<Q;M&K'(6<EL,
MND29;$&LC6,^TFRY=Q!7%JXL6#7UMM$GSJA],:(/9A377"'WAW+=<*'F&VDI
M/,2FP)V-S,S;L9Z=8C$<!7,20)@=X[R-NV%>3Z!<Q?\ 4-MXWL'76 =->P84
M3.X%[L"]D5%IA35PV9MCCJ:")!F3+Z1!=4ZW00Z=:A,87&JY$V.]'59OBE<U
MN*IW##S7E=D&"0 H;=8(L"=B3-\3"R#=3B4:@%%,'5I)M ZF!Y8M:"=R0 O+
M\KWJFYT/TB4=SCFL[B,'-O[WS$-X]EN<8[">)L9EW/41$U;J**XA3R*-MU=E
M8$,M27;J_<CFTZ:G&&T(*RM!484$-*=6E1,)E*3>5J"(!$).J\#"DIYP+-(D
MM4Y/VCJS*@$^;S$Q )2$@3'F@ DR;Y]-O3-C PIC#L,#K6BZR;57^P=A6$1V
MJ=WQD-$E;U6Y609 2_7Z7QA_ZB1C%2]VRLTL'57%CWTBT,66F\'<)J14TF:Y
MK3V2K504H\[BGE#[-YYN24,I!U$K$(F2<(?<(0XTTDAAL K(!)<424ZE 7B5
M6 D@$DW@!)U39GB>O/\ \28A40&-Q[%Q^WU]IB48D=62XOK^X:<J\XVK*DJ:
M^L@5S]9(D4^$Q7U(8MK6TFV:(KM<ANP.9^.7&M#7&FX<IFZ"I?R]]MS/*Q"T
MU*'@5/BHR)I:-(-,^VFD<JU JL E*4K0=6N^&V39O3TU5\1F&94N59HI)5E#
M;P10OE&A;>:+;B]8U_=TZ[)3HA25 I"6KIIUPC%<>KF4,^TAJ/':0CLX#:&F
MTMH2#SW_ &I1V@*X4!\^0/7CC.:I5145*P\22#\,.12M\A97*SS66D// H\@
M4ZXIP@ K6;XW!(6E*4*<UMH2$-LE(#3:4@!(; \X @'S$WDP9(Q8#=46P7KB
M_@TUD*>VE54Z/76RXR)@KI;D?LCRC$<4E+Z6'5!SVBI((!\\CU$X:J,HIN(<
MDJ>(,I&>Y'3YOESV<9,:EVD&9Y8W5M+K*(U+"D.LAZG2X@N(4" ?-*9!B5C5
M;54.84V75G[/KJFAJZ6EK.4A[X9VIIW:=+I:7*5Z0Y)%E0)04J"5 08K46K3
MFB:6UF&QGU6E-0R)LQ326Q(7F&R]HV@4I*$H226_84E:D!;J7D.J +I]>Z_"
M^IRROR_QLS?)<K=R?(ZMJFI\DR=;_P 0<ERVFX4S!*,J34$!=0FF6LDO/%3V
MI925E"4QYWXR36_'^']/7Y@NOK6_B7:RH4TRTVZ\Y7I;#R$MH2X-26-*@M2A
M"00-1<)$N(2DR.I3J >*@%'>&T6^W]PQFMS'\>?'*61X_'C_ !Z\59D(I*-7
M?+J(>O\ T='X"W>UC>V/1U/);0)L $_0 3],7.R#%HF0T*F'T!86UX!;20"4
M%*N21R.2KDGY(\$<<^JPAPE:&QRE)34M.TX<9IT%@%,5(;=#<L+>J?MS4I\Z
MB/M^:9)DMK6AQ*@Z65LE2J9;*4G0I=G%.I4"7$KOJ2G25 D BV*U:9L\Q:R"
MVT#F$2)2/5F0WE_TN94_8QPQ*N+-;DG(]0W,U4EQ4/'-E-QV[&E_4(\!&/YS
M&2VRQ>,"A@O^F^#>-N&^!OZE\0<*\3YKFN8YIE;G_*CE571)I:>C8;K6*3G9
M2X:5(S.NR];CE4T^5.N&EIDI:4A+KK8R/B;AO.>(CG+-?EE+2TE)4"LX4JV'
M$+=34>:6ZE+:BMMFH>(<2A[24:^622A*R2+7$4[.P]G 8G$#)XEID&5Z0GV8
M%?+QG:)=??S?2U\Z]_4K*#8;T":%1YP0G'=AUOOS?K)ZJ6E1>O'C@K+G:5'B
MCPVTV[D>>FG?XD71(+K25O-MI:X@0TDCRK2I"<Q*0E*5C9)U*Q7/#?B*HIWU
M<+YB\45-"IRG8+OWEK:4I;U&OJMQI;DI=D)4A:4!/E)(RQ:33[:P6RQ7)84C
MOEQK&AO:V7[\&QA2&B]6V5=)0E;$RNL8<AM^+*;!9EQ)<=UI?M/-D#R=25^:
M<)9_19GE;S;.89;F+&84E8NGIJ]IE^F4EVD?HFZMMZG+2AH6L+0I+@)3N#C<
MJFEI<UH7:*N;YU)4T[E/64RU$07)"@A:"%!0L"JQN+#"/$W:+6-="TILJ5,A
M:=-G+L<!S]]+UM9:3RZU<2J=8RA(?3(MM9Y7,6LYU1KDLM5\B0,EAO5[["K>
MIU3AOQ=XIH.-JSCM=8W4YQF52X]GM.TTFGI<_;>=+M2U44K 2TT^0I8I"RE"
M&5E(2@Z E5'S[P^R7,,@3P\TRI-"PRP*$JA;E XRA*5*IUJ$AM]25&I;)\Z%
M.(&D$X(E_A-<W19-I?<>+O7VO3:Q[S(,=I%NR[[!+603-J=WZ1NX[#3TB+8)
M6;.RJHS2Z_+J]5A#ETK.1JR?'[KTY593_79C+_&'P=KDY-Q^AIY^L6RVP@9B
M6T+9=1F=*\CX&@SMME3M,EU;!76TQ;+J5ZDD8S2UZ^'%U'!_&J5562%:4Y6:
MTN*9IF&UA6I"T'XM5.2/M*=Q]26]F-%PIDQZ39ZLR5&J\GEU5E7MU%398)E%
M( G&<UP&SC'^6,FQTAUU#<&9&85$=K4O2356<.;7(DS&&8]A.\'YW2U#U349
MFZE::BMKLQ):J4BG?:J6N?5UC%8V95353E6JH73H6D)J ZI>II*0@^G:&IIG
M*5LMA+=,E5.BFY82ODTU0T&Z"G"U+;_LY%.^:5N%*0.9K4LD$*,XPV\KK>HV
M-KNTF8WF^+2OU2CNZY+0?BR$I*7&GF5I7'G5\QA;L*QK9K3\&=#>D1I3+C3J
MDF#15KC#CU.^RXIKF +IJQ*$+2\A*5(6GDO.A!23J!#A4=X23B34TS;X+52R
MHEE:@VAP 7[K2DK"DG<)U6! /7#]CNR(N489EV3TV.QZRRH&7+'>NF8(48>.
MAUP-KW-JR.\IQY&O["2''LMH XZYA<]:Y#JC3I5-E^T_ WQB<149%PEQ96(<
MHZKF,</9[6*U55&IQ?).5Y@Y8!HJ(8HRY!+?+4)&/./B7P":1-9GV64Q4:A"
MJG-\L0"JE2S3!3IKJ-E,*14MMIYQ0%*+S@ @$XIIMV1KC,,$O\I:MZ3(JZN>
M@T=]"ASFE"0S*NHD:'6V4^N>D.55I3SK!B?5V2$"QH)96\RV[$E3H,OUW7N9
M=7TKKM._3U"J<:7OAWT+4B?N*(2!]Z!ZV] <4SPW?XKX>XFRS(5T&99<QGU0
MV.1GE*[ER.4_!9J*5RH.FH94-^7ITB\W&.>G43MW$:/&\5U_@=/,=L(V.JQ6
MIJYT@S[1^LEO!2OU]R(U'9?;C2^]%9#A1VX<1"Y$6K:91)<CU]%?JTK++;"G
M4.-%<?:0@ D&"F 2+1N(N/3'N_A_AAZBJ*QW-*=CG/-.TK;86'FTMFRG9'EA
MR0I(L1!\T&<7@Z0>HK>UU@-;TNYOL_*:=JT@W4VD?QF[FUS=XTBOKXEAC6P(
M-4] 3=2Q"*&V9#[LEB1 @=KSR9#3GZC;,EK*9]\5-=04U36TJ$ /.M)6XE*%
MZT%DK"BRI(7(4FY422"8.,[XLX79RJJ354[=.MMS2&U.N(4XP1&HC5(2"Z5*
M3ITE(4 #UQ3W=?0EM.@M9=Q@&35EHB!/E6\&@G.O54F#)=<2^8\*0\W809H"
MF6&XZ935<6VX\=E^6\&0[ZVO+^+:"J:Y5<PYJ=1R.<E20 A2='F2$$G2"5;
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MFPE1S]6')28S[S0JD?3HER7T/S'YJ8[<9"6X_>'IS]?2N-%JE=\[M^=%U$&
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MI81*Y7=-LS4E<RW:7)CRGK%$:,DNL?2M34M/).;I<?;:%14H6P-5FF8*;D$
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M+*!Q'<8YBI+C@00 6TJ(22/400#U @F!!&(SGF&TZ\;72.,P*77S$27-RV/
M;$.?/BU_L/PJ^.MEK@-2WVU.SY?>)K@C-QFE*5,=>;-M5E*W<4 E -T)D$+*
MNPT^4#H#JD$ 8:J&$+:+:PE--!+R4RA2@F%) *2"/,))F3  G48$51H.YF0,
M;F1\EDXM"2D+E8['BMRC%J%1U&!#$V:'WWK&/VQVY9=[$>VX\GW7'V4N/DH-
M!2[*423U 2#.P$  19,;Q,:=H"<J*@TH/*9&J5-)$CE:3H0"J3K!TZB29E0[
M'! UEC[.,W.:X[,AJE6+4R%.-\["*$7%3/AH:AL(<<]U"4P'(LI#L5,A;8>D
M/*2CO]X^CT@-ME)\I!!D@J*M1,JB+Z2D#T$]1B71-<E=2T4J)"TJ#I3 <0M,
M@)WLD@@C:22!?#OAD1%#D^;8S&_I5Y?J,AJ(R0.R(Q=1Y;$IIE/(2W&1/JGT
M-M-]K;(( !4M2E$XJ4H7IF92?4B%3&VRA$"U[X?90&W'FP?+*74I[!S4#%]M
M2%=/\XYGK;C695;BE+4B3C4II*O(Y4S,>6M'R>>U,EOGXYY^!ZGT,<AW:0XT
M?6"@B9]TGON(ZXFM7F?7\"1_+^)$XPTFYPSEK0!]MNWBNCSX[W(ZD+/'[J#*
M/D>2!^>!Z/-P>8S.Y8!MU 5;I-I/\3&&=EJ[$@@#UF]O;I[[8.W:%*"TJ!"D
M!0\?W#^\$?MR%$\_OQY_?DIVB^XO;<VN-B/3K>!:RL?!([R>/GC\@?\ ?XY\
M>/W_ #QZ69"?:.L]?88,6_C^NN(K>DJG5K?/)$I1//GPB(M0\?'RX#^/D^/G
MU*9NRLS^_P#4?Z3'TC"5_P!Y&X(^E[G8D7]NAF(PWOJ'<OGD#GG_ &\\'D>"
M0>.3Q^01^_*XE*8W)OZ[_E_/"2?/M-H'OO\ (]/G/7'-CJC[D[IJU^PM3 UC
M5\OIX(CO#*,H4TI20?<(44J!"0?CDGX/J]<&CS5Q)DCE;[W"C^7;MT&*-QJ9
M%"(ZN[V_P@^NVQV_' -0]$D1BDN"/*2DJD+2I3D=?!\I2E02/O3VGXY[R>#Q
MZO7>;?J-Y_B#MMB@29O<&+CIUWZCKVCMMB25CS#K;* ?;7[8#J5H*RL%0'N(
M"E?VD>2.?\_Y"%JV@]]C[8*+F;@  'VW$=SW[W'3#N%LQ6Y#:BR\T[X<6E*D
M.^WY!2E0)"2#P1XY_'['TT2=SO> 3N/G]?3ZRXD2!*0+CI(!GN.O\^F^-'T[
MKLA3S'N-IE-EAIM2BKL8*#W+=4H<]SW:"2H#MYX3X(]$>^]R!T]/4>@)&_I?
M#@BVUA) %XWF;;&# ]=\;;&R@0%P(%A.@0G"OLIJ^3+9CN6$I*./I82'7$N3
M'D('NJ9:#BSSW% 3Z:6I( !4D%1C<!2CTB]S>\3?:1NXTE142 I0"221)T@@
M25&(3N""8MTFV&#%-I8;EJLB<J<HK;!K%LFL<'O4R5"!'J\JIEQ46-6A<U$4
M2'(S\UB-]1&+L9^0?;C2'NTDQDO-+YA0L0VZ6UD& %IC4#J ^[,2)!)B3<8D
MN4[S6@*;4"XA+J--R6UR4JM,&$DQ8@$2 +$HQ9]?(D.0F[&&],J$(791VYC"
MYE<9#:Y#2)3#;JGHJ7FPIQH2$H]QD*4@*0"0VX05J@@P(4 1()VD23<D$=[8
M2D*TI)20%3I)! 5!OIZ&"8M]!;&G^;*+]+9MDY#0HI'7 TS9MV4%$ +4\IM*
M43U2!$4XY)Y8 #W/O)+8'?R/3>L$:@I,$SJD1,V\QZ$V$G?<##@0O6$Z%:Q?
M3I,@;R4Q, 7)[8=W;2"J/V!#KJGT/?4OPW5MNN)*2WQ&D,K0\TL=Q/O,N(<0
MH)<;6E24J"E Z=B"=R2.H]+^O0SUFX=^DCN)OZ@_B/EBF>H_X</3-AUQL?(:
M9K;\F=L7*UY?;-6^_=OE4*Y?AIAS)$2ZJ,SJLCGJG(:9<EV&57.17/N--I:L
MFHR$QD\@993-*6H<XEU96J:AXPHI )"@I*CJM)4I2O\ BBV.NK.*UY+2%&G3
MR&PVDII6+I"B1*2@H2!, -I0(,D$R24!TFT]?&4]@&\NIS6DY,AQIE^/O[,M
ML5<3Z?PTRSC/4)(W)B_L]ZBL112MQP@K#:&^]2O1FD"8#;U2W<F>>MT"]O)4
M%Y/6-H&$BN4JSM-1O ]Z9MDD>BZ3D+$S8ZI^F'VLM.L'4$1B=(K<'ZJ<,C+6
MS*;QB!"TOO>-%1PMUV-67%U.T_LJT[0I09_5M&,!!2B*S.D-)1((FK:220W4
MMP;) 8?$_P#"26G".P+-]@3 Q(0*)[3!71N'3]]1?IB;;J"0\T/4A_U(%\6%
MU9U':YW'77TK#K:6++'93=1G&#9/4V.*[$P*Y<94\U49S@][&@9#CLI]M"GZ
MU^9"_3;R&A-G13K2J>8G.DA;=0"$*A2""XA0*'$* D)<0K2I)(VD0H722(.%
M.MKI2DN(2M*[-K24N-N3'F;6F4JC:QE))!@B 0)US$QNL&;J938W]BXS4XQ5
MI9!E3;%2TQ(Q:94M*'%*DO-LQDN\(+KC?N.-H!5Z#U6TPVZ[4JY='3LK6\Z/
M*4J3!;E4@!*H()) DB1MAD-EM272"LJ)"6S!*=0B0DW ];1Z[XX6]3&V\SZG
MML7W21I+)(D"G;5.N>J;=[,B0[CU?0XZ42LCQR'9MJ;<3@>$>Z&;5]MZ-)S3
M+),:J;$0SHD2KQ'/L\J\Z>Y]6GDTC*C^S*<&&G4(&DK4T(04O*!<F#KUZI.K
M$IM 3=)M=2W)DQ<B^X"0=(BX,BU@.;F[]UXSD]13:!T' DX[TZX+-<<KHLCL
M3>;6R@!F/8;2V&]'2VFPL+01T+Q^H7Q QZK$2- C1F6(,:%5UK*DR?+!*TI!
ML@_\ $ $'8B-C%@)BU=1K"6TBR;B+D&8U6_>)B_T,8LGE.$KZI]>XMM+$F#)
MZ@]/8)38KM' T O6VRL*Q6,B)4;&Q".D!=I>0(14C*:5MIR:^I?$+W%QJ5G(
M>4'W:)SDN-MJ8<"M#ND%32U%)@*(E 4 >HN!L=F0 4 F-=N^H]QU,;2#>8/<
MX&&"U\*WALO1>R2'FUH+02'5'^DM3R2C@^XD-)4I20%)6V"I0+841/(T)04W
ME*CK&ZP2)(5$* M)OVPD)43Y02H [ Z@!N;7 '?;?%SL=IVMYZ^@:HLY[#F<
M8I&F6N@LRD/!;S,R-',F7JFUGE?O.X]D42)[E$MUUU-7+BM);*DQ:Z!.Y;R#
M2/"K0DJH@9KDQ,$6EM-YE(!D#[Q.Q$AT'6D)7YH)G5YB/2]_;I(M!W&&+UU5
ME=:Q+NH<R/:4<V0BTK'Y,YA$"\K@[6RWK&H2^F";>"AMZ"J3+A+GPVVW8B'&
MD!2!/L9<1LY8*L-2=P)M-M^A^0.&M))T[$F!TN=HF_M;!9>:>I;N9C[OZACN
M58O+ANNPI,>157N/V;"8UC7RU1)S+4F-*:]V).C^^PIIYMQM2T.QWN%HTH+;
MC24I(<E!T@$!9,RJ)2%0")WO'?"5M*;,$JG7I(FX-R;$>E]QWWPT;OBQ6[[$
M=V5L6/!C;81:4&QJF)W1J^)M#&PQ'N9<1M+G='9S*F<CY*Q']P.A*7Y\E;LV
M:^LL48*2[3*0=*0H@E/EDB208B0?:3:<.*L$Q:UX$29.YZGKAWV5JS9^_#@V
M^-/5U;:6MG$?P/>$BQR#'\8ATN2X>Q%C-YM>S+B=!CBNN\7=K;6P7 $I^M:3
M61V(,A^6MI*:5SE+?HWY 6J&%#[Z1$G1%Q<G[H^I&'4L%P!16 %"25*"8/O(
M, ]A,$0.]:I.P]?:ZR9K%]&XU&ZI=ZR9[-:QL_(*&7=ZCQ?('7$M-UVH-8EA
MZ5LF]C3![$7*,H:>;>F,-3:"JI9)=AGLI0D$*4="+ZGA*0(&^HP!)@ DB?0D
M +0MM"@U1(6ZZJR7G4ZBDQ?3(,=1/6QL2,&ZFZ<[[+\O=S#J<R'*.H7="'42
M+#5]5E"12X&N0VVJ/!VILQA$F@P$^RO^I@.LZZPRQR$EMY-I FL2(S%ARK(L
MVSUX-T+*4L*2 X\ZC0.7J *D.* 2I>J#Y292K<&<(<<I6"5U3G.?-N65:D))
M$RI1,2 #(28 ,:@9 NWCNOZ21$3B&:Y=58[A=86)T_3&G0<"P:L94VAQM>1P
M*6:C+\SGR E0?OLWO)+-VV%OR*=OWG&DZOE? 7#]&5KJW?C:VB:2MWGNIJ*2
MF"B>7SJ996$@K"]*U)\PE()*2,-+>KD);=>IWV*5_4*97*6W3O!,%1;5I2AU
M20I(.DD@$%1 (F?;4ZC=7=.6"5&+5=9_I_56<-3^(:PUY7536ULZBKY2+CZ)
MQN/58/B\MU*4?S;?H<$PA3<&MF)D0)S^<\8^+64\/O'*.'FJ7.*YM1;JJUMI
M--E.4+23+!9TANJ4D:5'E(7!*@0-)(T'AO@FOS@(JZS504:D@M?#ZF:AY"KZ
MG0D(4HD&958@CN!CG5;[7ZEM]SI]#6QE:4U58Q5(ET&"V<I6094RLQRPSF&?
MR'$9K?J"%RQ+94JCKD>W&C-1YD=YQM& <9<69%F_#.3YI6<5YSG_ !J[F69H
MS;*7Z)%)P[0Y4A2TY>YEK;9Y;BW6E2M3H6XM0J4NAM+%-KT[(.':O)\SKJ-O
M*,II\E%)_9JVFK7WLQJ5*<:#9S!AY(9;6I!4%A@E044B5)*B"]JOI:Q7&7H-
MDNGKTSH;0;9E_2-)DMMK4MQQ"'N X M;TE9[3Y5(D$!(?=2O'ZWC3/*C*JCA
M]&=9B,BJJNFS)_)$U[XRQZLH2#25KE ESX=;]*4HY+ZFRMDI3H4DI!Q=4Y/E
MXK:?-7*.D5F=(R*6GKE,-&KIF";,MU!'-::)4K[,*"23L9,6XCKQ_$HW+SC#
M8:1W=OVC]_)/=R//)_ )_;SZIJE%TNJ5)*E*6XI4G475%1<42"?M5E1*U?>5
MJ,E6_2;2%RTT)+:2HH;&HMH)))*1*DIU$DDVWMOA#%R_+LU9DIU[B=I?0XA6
MB;=($:MQBK4VGN7^K95<.0L;K"!]P;GVC3BT=JTM.#P.A3</5[B15.%FDIP/
MLOB2AA*TD H6.< E5KS"@;F")F([F%%3*',U/*202FG <7Y2=25)!F1$'4(_
MQ6Q7W&I%OB63Y1:0=F0-P[5M[">,7M\>:1-U7T^QIKLQJ590<G437[(V)65<
MMJFIZ6@9<QG'+6L5?6UB_83F9'KUKPKX94_'=%P@UPYP0K@ZDRG*'LOXRXSK
M:^M?'$U0^\U4?$Y FH25?M)]A+M(^\PW1L4**NK8I'5TU*RV<4SCC1?#3^;'
M,LY5Q Y45GQN1Y(MJEH6:%1J0NF1F5;3J6X&*-2FWDT[86'33H0I*-:B8_H_
M0<?1-Y;Y!;;&CY',O:-FA4^B U43):6;A-P]<Y(LS7D6=VIP24M.DK*%V5L\
M9+AGF/']&<#^'#? C^9*;S8U5+5HIZ++J6.2W1Y=1EQ=.R^B$H=JT*><2IY$
MRUH1Y@D1TO&+QZ1XM\.<!Y$QP1E'#R^#Z*H;K,RRTFI=S7,JMJG;J7FE<E*F
M*$AA+C;.K^^6XHB8)L7-FQ7+2)E6+Y19XWF=<T[%@Y)2SF&+%IE;J75P9K:D
M2JZXIY"NU^537<&SJ)#B6I#L%4EEEYNR<3\$</\ &^5KHN(*$53;8_L>8I"%
MO4;HL#3O*E;+C9/E4VL$$P(F<8/E>>YKP_4!=!5N-%:Y=H5H66J@+$Z5MP4N
M\P)^Z4G4$DD0, :ZS#5UAG"J.[@3]49>NP8K']OZGQ>3=:?N,GDQV9JJW/M2
MQIJ[C%+%^-)9^HRC )3]'(LY$BQOXS,I#E:?#OB!X5-91Q .'\JS#^M-4MMU
MU#+39:S^B;1*@P\UIY.8K82-#E2ZOXIY04LA3RL>M.$F.+<P\/'/$JIH&:'A
MQIQ*>?4/:V'F4/II7,RHVB"&,OI'S\$\S=OGG4L B01Y6197@RZFKV#%KWJC
M)&2[B&>XW9,Y!@&<0U-*6F7BN414-QYA4PGWW:N<U77\2-VR+"FB1WH[KN$Y
MCDE10*?2 I'PJRBH2XE3;["PH!;;R%@.-*%PM*P"+@X[M-F#%:V%@(TJ0EP2
M4PI!("7 02%()'E6DJ3.RN\8PM^NJMJ/XI+FB'A>^H,77-M*04J:HLQD3Q,U
M-FT=ON0VJTQG._T^-"6ZL1VHM_9.OASM:]ON<*9Y6Y-F&7YAEZE"OR>JILTR
MQ6I2=52RLE3 6#_<UK/,0\D>1[E(24KB!R>(<LILTRVJI7PDL53#M-63I*12
M/I"7'1(NZTZ&"T0=225*21<XF$NID[6QG.-/RPFBR_8%+-HX\ASM,7#^H75K
MEG.PZ8W*DM^RPQ+MZR\PJWD("W+Z+,J*UI2V%!+OL3Q=H<HXAX:X&\8Z?+%9
MEE66_ 5'$] FK=I*BJX9S%P-UE,FK9/Q&7\JM#U,7*525A"E$E)1;!N!:^NR
M;/<[X3J*A3-<H/T=%4DJ%/0U_+4$/%,CGA;99>2A(42$J&DS&(-TL978V."U
M-7D4^3/NXB'&)RIC'TLN,\F0_P#\A*9\+^JK4E%;(4\!)<=AJ<EA,M;_ #XR
MX^>R*HXHS6KX;R-7#635F:(1E_#OQ*JT912-T6L/(KU^:KHZQ4+IPLRG4DK&
MH$#T%D;5?29/ES&;YJSG-<0I-164C"V-:P@ K6M82M39<"EI2OS*2;B<9=24
M?,L.:QW9.M*A-EF>)Y+3WM4KZE$5,-ZMD_7-2G@7XQE0G94>-6V,5M]"UUTZ
M:ZM$IEAZ&_.\+V.$<RXD51\=\1KX6X8715_Q^8)I*FM<=2FG4$433-,0\'*I
M1 ;<2"$.(%A]X,\1NYHSEA<R?*QFU6*A@&DY@:(8*CSJA"R0 MA$J29$6B;C
M#SEVY*;5FY\0L:FI0WBMS;8/OBC<GREL?INJ=MKKF<SJ(K3$"2S828R,DSVH
M$!2JZNJZ6+%8+Z7!&[O1;?%ZN)?!-O@O.J5S,\\:<K.'4OI+;RZ9W(WT5N35
MSBDLI<;+S531LM*>==4ACXK04!;FO@<%^#^:\3<3\4<4Y5F5)DC?#>4T5;69
M:^I"ZC,G*Q%>NJ:94"2H(7EX34 %1)=8D$!)Q"M65J]5;7V?IQ:5,LZ]SR_Q
MNL84?+5 W--AB?/("E*>Q2=2O]PY!4[\GCUY3SAOX@BL"5)-6VA\E2M;BG-(
M14%:Y)4I#Z5A1DD )'E  %RH7"XPA1;Y14@D-DSH0+("4_N)(\R4V 28'867
MVI3U>18/:5]O$9EP)U<_&EQ7TA;4AAULI6A7E)'/_0M"DK;6 MM:5I"AS,GS
M*NR',:3,\NJZC+<QH*BFS&AJJ=]=)5,OT]0ARDJJ=YM2'$.(J&VU,O-D$.I2
M4*U 8<>I6JUE^BJ&D5#%6TZP\PM <0\P\A3;K:VR"'$*0I2%)((4DD$08Q#]
M+Q(5#5].U2F.EB+6ZAZ@G2TDJYCTEAN%]B@#SCJBM2528]TN,XZI2W![A"EG
MN4OW+_1XKLWS;B/C_,\RK*C,7\UH>&,WJZJH?<J7JK,:JHSAMRO?=6I2G:JH
MIF:9#E0HJ<<9:8!44)1CSQXKTV6T5!E5%1LLLLM5^<4]*TTA#;35(RQ3J2RT
ME "$L(<)*&T>1"B8 5./I$-(*&G2OV?<<;64CCW4CRCW%=H5QR>?"DA9'!/'
M/KV;3R&P1(UBYN"H 0)VF-K[;8\V+-E-$C2K4.63Y5)/WA%P4Q'0C; "V]IB
MKSN#:H:K&)#\Z/'^JKY"D0X=S]..8BU2V$./5UQ6**G*3(HR52ZUQ2F)29E6
MZ["3'K:+XQJQ ,$ZNI -YVV(@GII,]<7W@?CVNX3JVFE!RHR@G0^TI2EM4R5
M$JAE*B4(4HRHA.F5*.YOB@>-Y9F/3??5E9<V%PK"(%@Y68MF*8+AR#7DLH,B
M7B.34["UIF5 2H2G:!#RHSM7VY)@DYZN"JJJK+:JBA4EEP ,%8E.P*28) $"
MX]-^AQZKI*K+>(:!.8Y<MMYM<&Q2LH)3(N"K2H21T*8M><7;MM1ZDZHG!EC+
MK6(;3-;"ES9%%)I[6DSV TP4Q,@K6[6!94=]$?:($:R_3S8Q4\P75Q"RY$1;
MLMXBK\N82P=-11E9+:5J42QJ,^12%)6C4)E*5 3<@F".<Y1-\PE:O+]TZ2%7
M)G203&P-C8P.F*]99I*DU?=TF80\=D9'8X\I^),=N2I4Y#,=E_VU04L,"/5P
M$)<6VB'3PXL-AQ#2Q%2A:U"S4V9.9@EVG<>#/. 4TI/W!J()!U$DJ-I*E%2@
M3))$F5\/3L)#C;6O0-]*21M,#>^]A'M?%#>IK8^P=JW. X="K17N9791XF-P
M@0AN"[)36I;,B:4>^_.9A7,)^P<881#IX\AUM L+"*Z^Q:LBI*/+&JJK6HN*
MITZG!,E4R-0$$)22#!.]SL0#P\P??JULH92D(5 N" 22!YB1.]K"PM&\^Y9T
MO-:6JH$UO+ZC+0_$A)R"%9UPBQ8RGGF'2S7J;EO.QU)DI^K:=B.PK-A$=$A4
M]]P@/'3YVO.24.H<I%)4?ABU*6]8"H*FR$ IZ'[P))!GS0ZYEZ6 V'%(.FX"
MB8!,73!5IOOMZS<X:MR8M08[JO\ F/%7Y$V'E,6B,:09C<P5C5B8LNWH9!:2
MEA+@X4B0I3:)<D1XCG<0TM(<RJI.8YBS3/J:**=UQKDEG0'$MA6E<* *D*A*
MM,%,Z9ONU4-!#)6@S?=))Z$])O:)![;8#6Q=?X_A& :PS:OF/4EAD(C0[%MT
MON,IE0&V$R[6$EM^+-:F.3?J%(^GF1FI1CKE>TVZ[[RI5-7N.U&8TRTMO(:"
MPDN^=2%:U)2A 5*A"0"$@6)E(G=E82W2-K2 VM9!)'E4H$QO8W)(&]R;$X68
M])V!"HX6P'K9;^/2;1^N@357!=^J7!CO13->C)#TZLB):FRZU-@Y*GL-O3'W
M51UM.,3UR"K+GJA-$$+;<0A/,24:6E%82L@ @ C[I(V*D[V& %5""'4A#@(3
MI)4%+&XF3,'>([[R;R;+)6991K^?'J(TM^$F?5FRJX34J2IN3$>A3G*PJF36
MFU2EK2B6P:Z))0 MN&FPF)<!#*!04U8R[5RV_3GF)4V  NQ2"HI2)LJ/,H!)
MN1,ROF5;B5(4K4A0&H ZK2#<3>(D= 1L<(,>W'@T/"/Y)RC&,E@V-= :KT/P
M?TY40SHC7M,*>#RJZP@2%/I)$6Q9+?N<-*7)\I4ES+J_XDUC)852F5ES6"HH
M)!T*O%Q_B ,Q!$7EMU=,AHLU*%"WV92#(<V$[$""HD&9(B,-E57Y=G$;$8-7
M&#./8OC3EA.+\AIA+M_?V%BY83YI=?2H+C0HL&J;7VR_IJ^JCU[3;D9"VG'U
MN4](XK7*EU02O6D$Z4A(2EL$&-((4N 8EPG;$5AHOJ)49;U'3J,V,7BXZQ;M
M<1&+0Z>J8^-PK=F)9R:Y<DURY*Z^RD53<EYH34!*DM*2MWZ9"DM(2X"6DDE2
MR^[(2BH<1.'^R);)" JJ( N1)8F;;F+['IL 3.J*9A#3"2AL*"GI5Y4E0^SB
M\20),= 28Q_1.ED%P@*X(4KCCS]QYXY'CD?XY /'R./7CAU:3IOL(V/IBB)$
M:O4GZ=/XX;G4K4 "?N'R0.W@$>?')\G^WPK\\CX\15$$DC]6P9$^XF+QO[8:
M'NY*N5=P2&U*4HCN+G=RKM(*%*[T*![0@E2N_P"T?CT6 #,^\=?UUO\ G;#+
M(0E".]Z405+6?<=2RTELN'^U""S\K!6@EQ;BR5)422%**5[?KU_7X8%HCW'Y
MV@]OU;#>VRED..^XIWO: Y2MY]*O;'>5CW'7?/!("6PD#DCCN X;O]-Y/4R/
M2/6_OZ S'<_Q_7^9C @J"E[?UZ$$*YUM1)Y')'*<CM4_[>"//'^3^?4MF[+H
M_P")H>WE<!L3TN(^?KA1NAN?^,_.4'\\%YZYQUFHN+]W(*MNFH)LVMN+!3J@
MQ73ZZ4(<V')/9W)?8E*2R4!*BM:VPWWA:29'PKJBAO2HK<2E2!I,J"@% Q<0
M1?U].C?,1I*M0TI)!,V!&X]\#W:S<.;2MP1:Q$1H.:8O5Y&D%U:DI=,&Y-86
M$(4](DRX$NO?88CMO+<$AE2$]P/"F:=RX"9*FUK;,;@$I*I,  %*TE2C @S;
M#%3#C82%  /,Z][ +2N([D 6O8S!Q)W\KQ>&S&=DW341,B-)F)$N#:1/IX42
M3]))F3_?@-_ID-F1_3<EV0B1TD@J<"3W>DBEJ%*.E(4 0F 4'42)"4G5YB1<
M!,DWMTP]S6QNH#<[$6G?;IU./+6[H:J=]'.O(,:6@QC(:[EK:A_7$)A"QF-M
MJAUIFDI$/Z^1&^J[DF.7 H<MBE?6"M"%*!*H %R$;Z!,JTC?2"!UB,&7$ P5
M &WM?:3L)Z2;X:K"+C=;EC,^5;(;R+](;J7JV,9,L(@39HEPWK2/$C23# D)
M?^AE2U165)>E)2IT<>VXEEU;<I1]F"?,8 ) @@$D:H!DA,WP@J0'"2?-ITD"
M]M1(D DB]A(O?U&(WG< 36UY'!F5[D7#&,BBW:G'5)+*U?0HDH22CL)AN12'
MPI2>"M*FRH!1#]*HLK6VM"Y<#*D!(!)$F( ,DJU0D"V\QU>2I)O(@$@F8 C>
M3:!T)O8VPU:IQ]>.O/U]I8UJ+C+HS&0P:-,A1G,U<8&.Y(?"DI;!]^0EE26U
M.<%"BE:PESL57O"K2R\RVOE(;#2G%I@:U'6 1=2?*-E $&9 MA%TNN(44A1,
MA(,PE,)-X /F!V[_ #P6:]^-8#FO?:DM^_*B)<9*BV)$.2]"EMA2^#Q'EL/,
MN'X"FU <C@GG%"D*T*$'RDCN%#6F?0I@CWWZ84"%"09$D?,$@_0@C"15Y0MS
MY<']9B..5R9IL%L,S9$2"JNC.S)\>78,1W8#$N+':=<?B.R4RF@A25-A?"3(
M-,\4@Z"->G3)2%*DA*2$D@D&T* T]9P6M$D$S&J8D@$ DR181U!.(M,L:JSE
MU4N#9MN-2+!R)%+T6?$5*E+IY%@EF,F9$8]XJ@5\N4%(Y;]J.L]X/:E4IMA:
M&5(4(*2%*@@PG4$WO_B4!MNH2,(4ZDKU#K:#(DP56D=A.VWRPFEN,*<?;;D,
MN/QOIU2V4*/O1TS$/KC*=3V@ /I8=*.%'P@\^1Z,H(2DZ922=,[6W[S!(Z=?
MG@!8*CW[ ]R([ ;=[P9M QSWZAK01=WP6UQW'X[NJZY+I2AM?M]F390 I25@
MI(X*N/R/W!^;CPB!JK?=D_.%?QO]<4KC($(HC,SS9/2^DP/<6%@/K@&1*J,X
MIN0 M/?)<]F,5-+4A*W $N.I  X4@@)2?[?R /5[4M)! -[=#_*^QV[8H 0O
M8A($$G;?K-X[3WZ>CO$@IBRE_2Q_<<0I;"W'RI?<XL_:VV%]C;?@'M(41QX_
M'IDWV/6('N!?T%YVZ>^%I$22 )N"(FX)GW-H(ZR.AE,F/*><?;6I*#&?42A*
M@MU32$^XL>>4J6E7 ">? (X\ D%VO ,$D[FUO0&QN+V'7#D[B)[VM[=3U]?H
M+/$*1-9#BQ[2AR.>]'*BA0^P@'@<I (5P1QX_!Y] P9]B1-^DF#/M^,6V3
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M(\DI0GX ))X/QP.?SX_8<@4]ZK<6H)TNJ"G0A0;!)$QJ,Q9 $E:S" D*).)
MN7$H"7%I23H!$J6!Y-.Q*@N"F),Q$]8*_FN=Y#ETRIQ7&:FNU?2T)L<LW9E6
M1P\:P3$++ZJ8VJKM9\II3;S[49B$^FOKE3KV<BS0] J7F($IQS2<CX"R+-.
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M_O(FL/H#8)I;;"4(5H<BH221K.A)3=Q.DA"B@D64%I)$:3> XA;A44A2?(H
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MP=MC&T&=SM/;J8><7@7N@]J3\/K+']37B$F#EVM+QUU;D3,M:9 A3]*B7)0
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MFWR>3#Q'%.H+-L.A0VK#9VQ(57!@3L19O(C$)ZUIH-DF2+>RL%M0BE"F>R+
MC3A'=I*)RF<=6\N6G%RT@#5I, "/-< CZ'IOA\I67.4DZD>4!0'E40+F+2 ;
MB3MN!!&+3=-W2=08YBDS76(N19N(M28T+=>P(2G&/]9LCKI9YUSBDY;;<IG3
M.&RVG6+=X>S(V!?QY/U;;5:VN#$TSA'AD5B_VAF*-=&@$H;B"^!:9DZ4@B -
M*C:;3 -Q80GE-F--E.#]\R9(&\#83N?,8-ATJIZNNQQIMM=$T?99:CP8S48&
M PS%2AN(A$='9'92PA"$-A#?#:$I2E*4@<:LM20!R]+:&XTMMI@"X!':8.T1
M[3AA+0U"4=#UFPO<_KKA5,B2(N"3FXRD0['/\G@8G"?990130ITQ#=A-0AQ*
M^UNOC.NS2TGELM17!]H41ZKG%.>IX=R;-,Y=4?\ FK+ZFM8;2 7'ZU#*A0--
MI@!2C5J:*DR-24FQC'1RRC^.JJ-IMQEI3]4VV$NJ4%+2"5.(:2E"^:X4I5Y%
M%L1J)7;2> E/D9ZENH_8^Q%Q'VL5JK>/AFMHBDOF!4ZXQ)R;2XK6U_U;#"@Y
M(BP7<BGACZF.N3DHD";*#Z5,^#..,K?R7*>'\Q<XARO/,UXLI#G^<)R^H75/
M9;F&8OOK>R^O*PDT];2H0A#M+I5RTAM25D* 'I+ARJ-4[6T*<LJ<LI<K?^!I
MUU3:6C5-M,,NFH:;$ -...N:%:U3%],E(Z.0OTG#:,/.%IM+#1/:2&Q]J !R
M0/'A/[*X^>/!]8XZXIU82K6"M0$)!6J"J"0!!)W@09V$F9MX0M;:G&@(2"?,
MK2$D3$DSO$S:-HZX%>+VV79%3TUWN/"I-;DN2_43\#T?C=^VFWRNB0MM%=FN
M<9(T'?Y"U@Y+6N&JW"7\CRIB.J3BM4T9]<VYZ)I?!O)Z[B]C)/#[-5<9I1P_
MEM7F-964[F59-E#M:P*E*ZURIJ5/U%6R8:70-M(<+DEQ:$)4DYA6<=UM-E+M
M3GM%2Y(H5;]$EMA]M^KJ'65I"'J=24-%%.\4J4W5:5-B$@I45P+.4NK7K:/6
MY#M80\@G4J$_R1@M%7(J-9:Z<5PM+&*XLE;D<SF2KB1EERY8958/+E.?J%?%
MFJKF?6/!WAGDG!GPSZQ3YWQ(*=M+_$%72,.&B4% BBR9L)4U0TS:KRC6^N 5
MNJQB^=<7YMG;CB'5.4%+YA\'1NE)K&R5%-76.D2]5KG27 $^24I2-P"NI;!=
M9SXQVGMQNY&%Z6Q:9D>58SC\QJ&SL.$]:0(&,ZVE-K:+R7<DR^7518K\276*
M$,V_N2'5ICF/5/'9[**3)\GJJAE-;Q K,PC)TU;CCM&TZ\W%5F-73J62^*5M
MI"VVD*;#:CK2020K6? +Q&XVX&>XJROA:I9I*'/Z!M%;S:=-0NFJ8>IV<QRY
M3EZ7-44U14LJJY5J2MC[,%@$\_(E-G'5CDD7,MK.,"JB-,P\*P&D+];A&ML=
MC*0*RAPNIBIC,5B(C3<9+]M':CV5G(9^HD/)9$6'"\BT_&.><,9VQQ#D^:5E
M-Q%1UZ*YO.EN<ZN<J TZQ5)=4\%MKI:A#J@W3E);9:A/G)4M6AOY'1567U.5
M5S?Q-%4AM3U(X9IUOI(6JI?2F%N/E0UJ<"DDKDD:8&+X8+I7&<9KX<2/!B1X
MT..VPPWV@I;9:0E*$>03RVA"$A1[N2#R23W>L[S'/:JOJGJRLJ"[75%5F5;7
MU2U%/Q=1FE7\=4U-2I(*0^NI"4H6 E*&OLT(0"(ZE)24[3%/2T-*FGI*!A#%
M-3TR2-8D!:U)4H:_*5*(*@0;R2,%V/2XW$"4%V,"D\=J0C\< E1(_'Q\$^#R
M1SZY!J5N>;F)(,P6E%U).Y!4 D _*?H)=.K42$D(F I0T.:AN"W<I FQU7Z"
MV'16/TDQLAI4=Q2DGMY"""1R>T_;Y!(\'X_/I(<6E04O5,6A73O GIN>EA[E
MJ4FQ21]#'J(,R+[=KWL 7LG553>5<ZLR"D9EU4Y'#JFNY"TJ"D*:=#K2D/,F
M.ZAMYAZ.ZT\P^A#K"VW$)4FQ\/<1YMP]FV59YDE>[E^:Y)FJ,ZRZO;TJJ6JU
MND51(96IP*0Y1<E92:9:"A8^],F8N84=+FU#59=6MAVAJ6T)4TDE*BXD"2I8
M4%%"X\R!I.DQ(,'$"U)2S:FDR[IZ9#LJ-5P[';&B8KCCC\F)DV.L.2]@:ZIG
M'%./!C8V&BTLXE<LKKX^24DK(925VLM,A6L^'WB-6Y+QS3\;YA7U+K];FL<6
MU#[@<7FM%F+LU3E0E"4-ZJ>K=%6GR&6FA3@I"@H4?C7A6CK<@_9M,PVPS3T"
M&J$);UHHETH2XW\*)2I"7.6&B-:C"Q).(=O*FE9AI+'MBXVTJVO= &769*S"
M3[LNPT+GDUR]Q?*&T .+?KM>94;''7(C24PL>Q:S5:3E,0$ &W^./"(R?CRO
MKJ9EA.4<8TQX@H:UA"4I1GSK33E6*-LA;00Y1.9>I6I)(6"$P23CD^%'$1K,
MH:H:I3Z,QRQYVAJ&RL$:$ H9<>E(\JM"N6"#!"S,C$UZ>+5V^U5TXSW6W/J(
MNP-\XU2-J2 MS&)TC ,CL92 02N$G+9TJ*E8_IMOR'&>X$E/JT?T<WZBBXOS
MIK2&@YP73UU:E8+07F659F.4LH6I06]5L/*(4@H0D)\K9D@\'Q@8IC043CCR
M5)3GU/K?!+R6J=YA9>:6M(2&D+J$MB3*4F)!.-_4Q5O8[-T!;/\ :F=CF9;H
MU;,?; 0N;"DV..[+QIEW@@>S2P\CM:^*V.$LH>6@ ?<3GOCGE;&6<?\ $K+"
M4J8S!&3YRG2G0EIVJI:BG?5IO*G762](*?*Z$F2G6JV^&-8_4<.4**CRNTM1
M64[J=>LK"$K::1K@69@!)B#ID %5CW#>^NQ$J5RL&&"05#SR.#SS^/CG]_V^
M!Z\[:=-0VLWTJ-K[D&#Z1.W\YQIB=XL=5@?547F)^7KTP!IKSL?5.OY3*DH=
MJ]C;WQIDJ[@$1YV/ZVRLH2H>6PJ8V\\H)'!4M:B>Y1)]@?T775L<7U;!5K2.
M!:P+,P%NY77T2VG(OO\ '*"09*8)E6H1A'C+3 Y(SYAK3FM-3H5'W36L55/J
MWF$J*5$6U!)$C<1'-DD=:FX8WPBO<UQ7LCMX CP]18$AH<<^ 2M7;QP.$D#\
M\><<S!Y:%*.I:JC.RM6VI2:YQLJ/0ZM$SV,8V/*E!=.T8B:.G)]5%E"B>LR3
M-_??!FE3,J>W[TZ4,&EAV&(SMB8Y*R.S?EM-OPG:JWK[&MC-Q5R&E/(F/QRE
M2A%GH>2E49P05*1(5V.",MX/>R/BS.L]XFKZ#BS(Z)EO@G)Z"F;_ .?&ZUI2
M:Y5;4(;@KR]Q:EI?7"Z9E"7$E:D 8XO$55GC+^7M4&74C^4U$-9MF"7$?\WJ
M<4&TLN-*25O+?;7*5(4G2I6E23$J"V*H:I:[.MX2Z:%D&9:FU=N;J-PY-M&3
M)9B[%<5+::GJ;Y!<<I[G.G;WA7*([M-&D)1[\6.ZSZY\2'&LC\"O##*J9H+Y
MF7\-4K=<W"*NC<J<M=?JWT.WEYV=)5 (.J=4XQC@2LKU>)O&SC5=5TN7YJUF
MV7YM1,NEO]MTS&;(4AO,E)N^AEQIHTZ82&T!2)(43BI6G-"1MDO/YEF4N=DF
M47TY^YO;RTF294V[N)LA,V396JRH)G252TH?83(2XS"("(;3*0@H\I-^('$V
M29)Q-PSE&:U&69)Q/3IRW/,OIT4ZFZUBD=YC+J7'FW7Z>I)6XAUUEQ'.0ZX%
M@S;=SDN6UE9E.95M,FJK\GJ'JJEJEDA:5U+!IG6C$ L(:2W\.@A7*6@J!),X
ML&YI?:FF; 9OT_96[@N6(>:^N^G6ZU2Y#5]A;?K,EJE1+&JOHI0OW68UW4V,
M9"T%# B/.)G,,<'<4\,,9RV]QUD3V>Y&VS5I&4T#ZLO/Q"V$)HWS7E+]233U
M@<JW1J'-*N4DMH$&-GN59E59=\/D[[-+6-&E%-65+)J5-(I2$!!2AQE2]=.E
M#"E:]DE74 6*U+G55F-NNOQ?&*?7VY'8SR\FT<AP0=<[88ALK>G6>DI5B_V8
MSD28S+LR=K*TDM0TQF_<QZP#%98VEKZ"\,_Z0#N3"ER7BZKJ*WA:J<+F59V6
MS59SD*VW"E#6:(*M;E F!J<+C:4-"()WR+C3PK6\D9WDC+;.:N)/.RUO4QEM
M4Z"5+TMG6*=VH42%/JYN@DK4A<'"38VL:+8%!_,^&1E18\>59Q)[%G%]G(L+
MGO.*AW-':U5DSWOU[LEEVLO<;NHQ9=4VJ-81F9T..N+[/IJNDS>DI=;K3R*U
MM-525E,I#])4,D#EJ:J40E:X6"X@)!:-I5OC#Z#,\UX4S!57D[E0PBG=(S&@
M?"TN<Q*@76U()BGU*3+*M*^:@*4 -L<O[_7N<:9R6=<8# ;F5]C_ .TLEU<X
M_,<I<A8A +7<X/*C]]@Q-JV4I<;8BC^=L1<0PA#64XVFO<A<^IHZC*WY*2EL
MDJ21,+ MJO\ =WB-CZ8]/\*\8Y/QO2M&G=;9S130YU$ZI.M"@D:H<A 43YC]
MP?*V+/:SZB\2V+BST')E/Y)CL=J-%G3+%+'\X89[P4F,WET6.I3<JI6L$5V7
MT_OU$HH6'G(3[20YT\OK^80MI99=$DE1\JS)FT2"0#U(,0;3CN+I5TSBEB9!
M *5>9*8M Z00"HV[@2!B.;RU+"K,&R_,V+)VWJ86+6UQ%AM/1I3<M42N>E);
M?6J*XI\+"$=RW%NO$<_U>0"+ME>9EZHIZ4H0A;CS;:G#(A*E!,I@Z?;2 /0"
M1B/4<OD.*4E-D*-A&P-H.QD#ZWN,4VUY48U@&KV]PS<@J!8535O4UM3-]A;S
M*H<E\&-6L*+OO7-Y-]RP?"&D2GUS6F6I+;,9L"TYCSJO,D9*EA:FU<I9=$ +
M40G2I2O+#:$DHW(D%1!F_.I6D,4SE6E0,+*=) D$A1@F;'R[E)(]L O3;6^<
M<U_L'=>-N4M=0.VEQ?2'[:,V]+NYR$J8GO0$KC3O=CIF_7MQNXP4J=7**)*P
MZ5HGYHO*'ZVGRNHYJG6 W3PV82T$I$IU?O23(( [$=X3(JQSZL:%H<5Y41I*
M1%X-P022K]V3.YOCVB@W&5W[61V-:]+EP$3H-$\RFP1$1:3YCTO([]N/30)B
MFYLRY>># ?=:^FAQ8*&1&5&;E$ZA-/2++3=5H;8/VC11K6M)2"A"EK<2(T%(
M/E(G4J(.$-<PD.+9\QDJ\X%Y/9,VC?TVM.)Z=F,ZTRV'89+"DRY#^5QE0::M
M3!?GNQZG%+^-:K<[9;<%AVSM<T,Z4TF2ZPQ92)<(%3C*T)@HR]5<PXJE*0%)
M<7J<44(;4M:%)&HR=*$M0#8GRD7-B0^EEU)6F4ZI,0=DJ,C:\D'>#'7K6%>9
MX+G&4[(R7,W7JR2[D<NVQ:%(=0RIF.T+:!!A-Q(3KC<N8MEJF@SEH0]%BP6)
MCL7ZB?*8;?[H9K:=&4M4@2Z&Z=;BP@0W45.KE#[;49TH4X4@I428(("2<,)?
M0LNN."5J44I!L0DJ-P>P( $"V^XPT8-&S@4]_*QJ[R=6(_53'UL0IM1 #<-J
M6'%R_P!/ENV#LJ0VXH+DM1%,PS)^ICM2'%IDI0BI-$BH2Y7A)KW"/B%)GEM+
MU*"6P.NA.D$R9!L <.M./E"TMD%)78@D!)TCWF([]0-Q>Y.A[^@Q:)DU)DLZ
MVC9+#EUGZF(-<J0S)C28TF943E.HCR92G9M?);D.B;(=<2M9#1#/;S5N(W*U
M1I%LH0NG4JKY"Y@J2%,@@B2!I4"+ $F=1)V<*$+2@+*@X@%*SJ DS,@0.F/Z
M)3Z?ZJS]RB2KS_T)45$$ G_J /C]QX'KQ:L"9O*I)]_;W)_5L57#>I02XM02
ME)[>2L)X6KM^>3QVD<_/;QYXY\\^D82?^&)GK]#_  ^EIPW/\HX42$DG[?*
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M.7_P=;<IO_V9_7:V$,O1^LVEH+.!XV0I'<2(,;A3@42$N)6WRE*AV([T>V
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M<6X4@Z=1!CY;W[D#H.L8WP/887(@.NLR0IMP=_L.)B<]I(0R2.5+Y' *1SR
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MT_*9PX! &_SM^OY8=6%,,(+;3H;!=4TIKN4L@<I*NXCY2KSV'D\>0."1Z1$
MB+]R)@V/M'3<SZ X4-Q'<87-0&E.%;BT/1>U;@2XHA2/M[E!)4>X))'/'SZ3
M)($V]^A_S[]3!()P]T['U_77I^73"5Y31C-K=4I#0<2AL?!#2N>QM)0.XI (
M5Y/()'/YX0>@FYV&_;>Y]?2)[##C<>:(Z$_,G^1^D8D-6T7F5&,OVAV*2D))
M6'0VI*NPI7QRHC@*!5\>.T^FU;F1&TW^O7;KO?KAT*4-CW.W?8=NF_3M></&
M3BOOJ<0+FM@64#E(F5-K BR(3H6@M%+T24AUA]I2R24J0I/@\?OZ;Y:%$2)!
M4)28(WO8SM[VV&'M:TIUI44J"9U"4D>6T$$7V%COBKF*:"T3T_UV+PM*:MPC
M72LFV+C.1Y9-QRDBQ;K)[=.;0;..[D%[VNW-V&Y3[Z8+%I.DQX#3ZHT%J/&(
M9%7XE;:H^%N)W:9"6G$Y:Z I(N>8\RE9)-U1J(!GRDP(VQT'*NH?<I ^ZIT!
M*% +*C&F("19*1 O D_O&=^.O3!LG*=4T_7IM;$VZR1L&HN$3XAO8JYL9-79
M[ER 98Y)CMO1WW6(R#6.20A]OVEHC.DCVD\^?*VF;K/AV'E*2T7FZ?RJT$I9
M:06S.X,K4%G]XQ.QP%2"_8W+?T\Q/RDC<'N"+8=JVML&K6UZLNCFSNJ']5CO
M2MRZGQ]3,K+-<SK*2S99"XQCBFGTYCJNZL((M'D1X,E-8B.I]#$6LBK<QZ*V
M^MM3E%5(,M+4VP^@:-:$K(;)5/F*40F;&4ST.&6O*-2)U&9%K@=;7(L#>8]!
M,ZI&$8OU$5<W8&E:BDPK>U9&<OL@USBJE5>$[CB0BW-G7VO:YEX'#MB5Y;-C
M(HX*VX=E) D1'DSRY<R M;E,X.>>:PL@!5X3-@5$[@=08F#O?!+"5RHC2M(D
M1 !-]P+S;>-K$$XG>+Y(KJ8P9W(&$OCJ$UG3A5G[;3D.VVS@-,6D2?K&HZ6Y
M V7@:4H>BR6F1-LHR$1FD>](CMXR2FT41!0I+E'52E2%>8A:_,"@F-,!*K@&
M 2,-EQ1[6VL-NQW^4&V(OB<>^R'-,IV7=Y/)R6?FCD:;8SY+5:PZ\\Q!AUL<
MEFJAP( #4&%&92IJ."X&^];BN\>IP2EHH2VD)0E)2BP-E75J,7(N!T'I&&5J
M5J2JT@$1N(D=]]OT#B:Y-/R&^M]:PG8-**[7M7D51 O6YLM60RZ2[L(5C#QV
M="5$;B(JL<>9EMT[R9;SC$)]B"W&CH2ZMYA#3:/B"G5_:#YP28$)"1H&R;"(
M!_XHWPLJ4XD:MMK".I_'"O;KQ<T=C>6,*YG:>VLJKD+; 4J/@NVH+DIE+@![
M@'\_K)JD@JX9:"P"2H)],,A0J0E$I-0PJH<"=N:@PDIV@1;3,>\SB0D*4TM0
MC4D'3VW]_4F]S$"(DS75>X\MP'IZSV\C.M3)5MEE=KWI]-A&8F3,>S&[IK*5
MGMEC#TAM<VOJ<=H9U'8R!6OLQTR)3]9%4E"WXB9;5$IRJ;<UEA(5#H;E"%(B
MZH%@LDCS3,$_XL3*.GJ'H;;!4MX:(3(@=2#$#_""")F#L)L7TD]+[&*X[#5$
M4\WL#8U/*L;/)N[W+K#=:63SK=YD$:8Y]\?--HRA+JJ*RX7)CXW^J7T9QYBP
MFP3=\FRI%=F#8*B[1M1(FX*3J@GJ"/G%C,G'57ESM.PM#B%)4GRK)L=)$QW$
M['O83<C%I-^[/PKI$TIE6V[;$<H?UOIZ#1/V^/8!65EG;P<;=MJ^DL;R)53[
M2EC38>-QIR;>U:38M28]+ L)45F9(8;B/Z^76Z1GF(0H,MI Y;:1"4@I3(05
M 0#YC?8$@$B#RV*/XAY#*"$J62E!62$DW.DJ"203&E( B8D@2<$'6.WZ+=>I
ML/VQKY^98X1L6@JLJQ)V962:FX733Q[S#EA7S$)DP%NM<AQEU*5H/GRDA1<9
M6AX(6DJ*%I"DSY9%NA\PN;WD[7PMY+C2W&7 G6@E)TP1(^]<=!/M((Z8G^5P
M+-[ ZB\QZH?NY&#Y2;^=C,&2P;"UH)L5^NR&) 5)<:95:&GFV"ZI$A^/$-H(
M2),B,P7'D5#C_(*KBKAC.LAHG4LU]<PQ\(XMTL-!^CJ&:QI#CH!TH>4QRE _
M>U:3 )(ZG#%9^S\PH:R_+8JBMQ4)*4HTJ&I6I)B"1$09[[8X>XCH.9JBZLH>
MN]QZ6O,.8F2'*EC-=@P=8;!QVK+JC&K,YPG.8]-85UU!84EF4J&J8U.4U]:T
MU"3)^BC>%,XR#,R\AO,:>IR[,F7W/BZ)^CJT--OE10I3"Z7+*A%0PL)"VW5.
M:R%%$0A*CZ(H^(:!U@+IDN5:"LGFLNT]B8)0LO/:RJX5]U(TJ  !!)EF>;?U
MIJ-B'99IDD#?>:O1)]GB.M=;IL7M9SY50Y&:=EY;LF[A455D4*JDSX)L</Q)
M$R1/#\=F19+KY,AE;M%PHO*S0U3E)4MC,J@4;&<YM2/4N5,/2"MC+*%32,RS
MJJ&H*"^334LG3JU) 5=>#.$^)O%.LK\DX6:IDIRYHU>9..UB$N,M!/\ =.%O
M6EM1(C]ZRK1,8Z%:8Q"/*QN+L&QGG+LTVRQ#RJVR"RK?H79[5A'9?K8\:"5/
M_H-+70'F(>.4*''&Z*N;:8+TFP,Z;+]\\*9!DG"V0T>29)]HR&DU=?7NMJ14
MYM4+=<<YM2ZX%.O+"GBE)Y@"&DI0G2D:3XUSJIKLPSNN_:C+(S&G<JJ5^B0K
MFTN7TV5OBDI6:-^=+C:0Z>8$7<7#JC(O8XXPU6ULAHM!;K@4Z\P@K6EE*@"G
ML4\XHI"%-I45!')[B>!Y'JQ!2%J\A*4IORT^5 ,P5!/?N9V]8QRN3R1<223=
M5U1N$S_A'^'M'RJ)U%X7C&;83E>(Y0]:P<*V/B<?'L@NZ.JD7MCA62X_=5V5
M8+F9H(:DV&05='D%>MJ]HZT?J$VOL_=8<99A2WF\>\:^#LWXHR3+LTR2G^/S
M#AEZK>=RW5RW*R@S%MIE_P"%5I*7*ED,%:474@$&)5!N_ F>4V4YB^W5*#2*
MIE*0\HZ4Z@HE*9)Z$ F!L1(,XH7K_7MKKB(J.]OOI9E4T!*TC(O]9(=9%1%8
M"NQZ;5V]3"R"O=[!_7B/5:U-+Y;0X\D=_KQQF'"]2MYQ3RGZ2G39::C*<_+S
M2@!(46<K=94I"CI.AXI)!A43&]TN=,U:60PS65=15J+-,RR*4FI<;!4XXU#I
M6M! D)TDB\2<3*^9Q7955/QNOZFG[:?5S:]5H.F##\YV%(CN.>X\U4S<UF)U
M]CE([-:"WV?>N62MV&VZX7H;+S3V@^#_  QF66<0(SW*^"5^(%)3-U[3U)G6
M5JHN'ZL5V6UF7_VJHK%%Y'PYJ15,K;IG2E]EI1+*076^%XBO5M%EO[,SAW-.
M"GZI%)74N8.)JJ>I-.BKIWD\EA-&T5J>"!3JU.I3H=5K"TRA5A:?4-U:1$RZ
MG2G4+D#!;*G+++-I:TQ.3)2E(X?JZ?&,2RQ#;JDCN#5C<.)"NQ)[4E0'>;\
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M#CE):,A^NLVTJ27ZZ5-AJ(;DGN[&7/<IS2MOG-/RV\W$ZD+!0HQ>"D$KF"!
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MXF4. CMA\<_X[?!__J/[<\>?^WKRN=)?0%;J60(M?03UV$@;WZ8UX6*518+
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M&6:M-@AMER=*?BT-)+JDI$0#(A:@;D"3>(N3PE4#*''"LN!*TD!&LA 6HB(
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ML_QZX/\ UZ_KY8:+6,F2&SWN#M0XD^VDK[D**%E*OQVK4TA)'W=PY26UIYX
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MS'MH4&4XAI7A;-\A>IT//I6':>G4BG4\XV62A2$)0A+Z'$I+#I2$GE.:57!
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M/?:XG$/O8,^4R\]+]T&<&H(= #;CB@0ML_<@K7P.T*7R H<^5 ^93#J$%(6
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M&YP\IB(5 2MV3]4'?J7$R6UMN)#"P4M)(1SVI;[R0#YX!21R>?394E!3,B3
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M''?%?AQ6UU?P5FU1D5;F;#5/6K0AE^F=98=%0V'F7!J4XEP0RL3HUK)C5!O
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MTD[&TVV[^F&TWGU)L?7<;@[3N(M/2,,B%-(00E@)/<72VA)4HD<@+')4I;G
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M4KAU04"H-<A!^/)]$E6H>O<&8O86@G?J?K,$B2;; ;2.L>HL-]@.NUR$SIK
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MZS[A9G@Y=/0L92PUDU#'";]/2TK%*0<UY;BP5\KF.J<80IEU;K:2I"4K7IG
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M2$AUO]Y10HA0@VB;IV!%K$)4+@8L_-8<;DI03(() U)(!A29V4-@L0;D3!(
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M>HG!+"2# N+;"]QU]-]P2)[DXUU"^^*\\_(=3!$A<IMKCE0"/[G#P.Y24J/
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MM1&&(<:/"JHL!1+94%*@I3!!,:@!_AMJGL0=4Q%HDZBHU:>6W" 8!2/+(WN
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MK^T"%(5I6I*M!"3H,00#!./W?/I"O<Y_!61Y(\@D_CY^/@^LI7<7Z"WRQ60
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M .%))3V]H!)!(X\^I+0*GJ>( %0S<Q A8WG>>OKTVPT3"%6,:%6N38?R,G^
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M"LNJ5LB[C*X:+:X^NL\[EK0G@^YS1]I\CYXY/GXY](5X;<6F(H&?_3J/T_\
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MD#@<<GXY!)DCZ=>G;Y&VYZ6!P1,R9MTG:.LC?H8ZGI:<8L%V5-^C=E)+2/\
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MA]![3[K2E#L4V6W6EO-+0M70:>+2RAPD:5:=0V)!(GI(.X]+]SBN55.A0U,
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M&]'+2[3:*AQ@O--A+C:G6W2G XD]&^:0 Y>V6R=/UVJSAF)YS"W;*O\ +/\
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M_P!=+C+C@PQXQ@5#N4AO^9F?<4D?<E!<;"R DK0/N#1\&\]TJTYIE)5!B36
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M&VY'2GW6XREI3*QC#7PEQ_VVY-NRN2M,3'5I;B%$G58@$$D;;GN+6BV]NCR
MFA0@KA=2X1RT"_+*ITJ5,RH2(D#8:A/W8MCN LP$V'5%U;W]UD;^52_J*VL<
M=]G-=T70*E5N&:\K5.M/U.#Q%%+5SD<?Z:LKJA;T>CG/3WK*\H7%*  4=C)
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MPX*''I55&;:D9'CUD+&N@!*;"U=R.(D*$1]"J=!?I24N!6I30)4A9,"$@V0
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MJ/D+:_O+"X5N2! (WQ2F-DZ-0[ >U9F,&^A:DSA?\QP<_B0I$FOU!L-M4J'
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MZ#'(?1<FPOJW-.HK(FT/Y1M>X=<QQZ6A1-/@\%YV+BE1""P2PPQ4]DIQL?\
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M*F4*<42S\,5JD%*G33$TQ>(+OPY+&OE$HP!75J:<4B:I]-.-F0ZL( Y@=T@
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M*5(6D%*TD"0H*A*A-XBY@SBI:OX>O1<05N].^#)#B5%MUI-OVE?=Y/8W:A
M(/V]B0D$  #@>K+_ %ZXM_\ CVM BWF:FXMNU'SG<>^.-^P<G)GX!D#L2L;]
M0-4>H-YB-MMR/X=O1*B.I:]!X.M90%$%-T5)4#Y2D"SX(/P//XY\?'H_Z\\6
MC_\ CU<;]2U&VQ/*C?Y](P/V!D__ ( U<[RY;<1(7 O[[Q!(&*7]<6J^B'HO
MT)9;E>Z-HFV;9^V@8QB>"X6)K<VTR6VC3Y-<BVDNVK\ZNI6FJZ0]:S:BGR"Q
MB1T%YJFDM(>=8C57B#Q;2M<S]M5[AU:0E):NH@D RT83:Y *HN ;D2:3A?)Z
MM\,_"T[0A2UK670 E) @#F;DFP)3/4@Q) VCTH]).(R=,83BO3%KF\V?NC-8
M-?!II<B^37X]@&.IA7^W\]LG(UHI]-3AN*$UM6M80U8[ RC \<D.M(OO=0M?
M'O%R2VA.>UJEN+  EN @07%F&IA*2(V\ZD))OAMGAK)W ZM5$T&FDJ)(*Y*S
M(:1]^"5*@G>$)60)3&+#1_X>?1B^PD-]/F!+4@+0M]:+I ]P#E'N#]5' 4./
MN2./)^2!Z</'G%8WSVMWZ%J+FW^S'\OE@AP]DP$?L]@F;G4[ C?=S;\YWD1A
M%,_A_=%,=5?(1T[X>M)0MN;%:%PX"^>&TAMTVH205 *2?)2%<GX((5QUQ:!(
MSVMOZM'M:>7'>_IA0X?R4 DY>R1;JX+'K]^?D1Z@Q@7ZBZ3>B#<&%L9?4=-N
M%8W9Q<JV)A]SC=FY/LY=%D^K-AY1K;**N6H3DQ9B&<AQ&R+#BHX9E0W&'O:+
M;J>8O]?>+W6B4Y[7))+B%#6V""A2FU0I+0((*2000;2+G'69X8R%+S85EM,L
M>11*N84E*TI6DE)601"AN"#<&TXLA>8=54==#A4=8Q54U9&;KZBLKHC<&O@Q
M(C*8T>'"@LMML1HL9IMMEAAAM##32$(0V$ #UGU:I]];SK[BWGG%K<===6I;
MCCCA4I:W%K)4I:U*)4M1)49)))QM7#M6S3I98;0EI#24(:;:0E#;:4)2E"$(
M20E"4@:4I2D  0! & -F,*KR?'G<.S6'*GT2+&MNH;D.QL*2WIKVFEB947E)
M<5;T2?66=9*'U$*=%?0XVH%*BXVMQI</*\ZS;AW,/VGE+S+#X:12+8J&&JRE
M?I:LKI\T+S#Z5-++E+H :<0IM:I2NP!Q=LXX1R;CS*'<HSJG<?8<<R^IHZAF
MH=RVJR^LR^J57T];3OY;\/4JJFJAQ;*%..E:F5JUJ()3B,XUC6O,)D-,:\UW
M1U-]+A2HMEF[D1FTS[(8\^<JVGIR#.[%,K*+D3;1;D]Z-/M'8@D%OV(\=IIA
MIOGY]Q9GF?+2,VS.H<8IRXNEH %T>7T;;%.REI67951J30,MM,L5"26V"LMU
M+FG4O3BP\%>&7!7 H4[E67,,UP8S!!J*A2ZS-JP9I5IKGT5V9U"'ZY]U->/B
M="GT-.K0PE]2&6E%-(_XBN7;(D*H<8QY42B1JZLPO/\ %%US:HFS+O8&>7UW
MC$2PPNYKZF7E?Z92LUZ*^\K,3L:9YY-@[.L)5FW6L0H>[^!M%DK.4A^L2A^I
MX@5F[.8BI+;F69?EV7M,/LU=12NU"6!\0MZE>I:C,:92$2R$(2IQXM^4_P"D
MUG'$-;Q;5Y>W4&FRCAS*^&*K+GJ)I(S;-<VSBKJZ1L9>_EW,S%IW+::@>RJI
MI<OK<N74!]Q]58)<2.>^.8+7VE_JV'88E-QC(,IP6KMY]]>W&-JKKF-&R[-;
M/*,W3+R*"Q^E0;3&VK'!*7!H$U4"\RFCI'G4V"[5<QK>J[,_A6>(WW7&,^52
MYG6T2<HI:*L>50-M4&4(ILL0Q1IY+]3\?44>:U5>L.BC8JJUBF20TL-^3J7)
MC5U/#67TC59P=S\AR^M5FSC5!_SZEUC.FJU\5N9LN,9?2NY2C,*7*Z!ZEI_V
MLMNC75H?71NJ>[PXE)PRHQ;&[7'K',)43/:JOV+D%[L::Q?; GN7M7'N%LY'
M;5T.(W,151G3'@08,-$*,P@K@MK,M9<\&\?YGF.8\3UF2U;66%.4U#N3T=%D
MOQ-)E[-30/FE+U*]6U%85)JEM%*G'"TI3:M2RW>/K%X'<-91PYX<47%- O-!
M4<09?3\156:YXY19AFWP^8T::U--4'+\OID."D0X%)Y"G4E:"4<S4-7-C9VT
MMP[ZS6-_IQK/,,YP3,9N=,Z88F4SNN'X\'&VL<D2,XPJU@YUA2LNRNC81<+M
MZ/-WK^MAPW4S8-?#^I=BI]*Y7P;P?P9P^Z]F-?D>69QDU!2_ULJ:ABESP(<S
M2HS"I9RS,:2IRW,*2ARI1JVV/VEE**2H?7S*<U#A6VI7ACB3Q&XV\1.,>11T
M^>UF29K7UM3P)34M579!\1D]#1Y4Y79S0/T69Y7F%7G!4TW6UE'F[C]&^VND
MJVZ2G#;[ N#09%(>UM7:=ZAZFMR3+V\?L\;SV%/,&995DJTAV](\&+F,E[V+
M]O&+0ULS(*B0X[-4_,D,V,Z/8.2)?@;C7Q%RS@WQ+SG._#-_]G9&UG%+7T:*
M)=32454U1NT%6AFC90&F49<[FE,]5-4KZ7F4LA%.\P$%.GWEPEX<YEQAX291
MDGB<A-7G55E;S-5452VJG,FU.IS&FIZQ\TJF0BJ3EU8*558A?[0<>+E0NK=6
MV=3MA^B]78=G5=L;#LBV"[]' G2W<2R/(1D%-.S>UII.-SL^?>E,(DL7DW&Y
M/Z3,9A"-"D?2097LMNL."0QQW_2;SKC+@[-N&,QRGA]+F<4]/1O9I241H:ZG
MRFAKJ>OI\GIE4SH8:I#5,JJ02TI;2UK1*PL%-3X?_H[9!P5Q-0\0Y;F>=AJ@
M>JJX955Y@K,Z&KSFNI'*-[.JHUS2ZIRK33/.,% >2AQ*6B-*04X97<I:UMDE
MY79>Q:2M,YY91)^5)JFR[=8'E$)I,6FVMAZ?:>)NZ-A"(=_6M,NIR?%PNIEP
M;=N''J++ ^&>*<PRO/6,^R^J2QF.6U*ZND0LA%(^RX2U545<0/M:-]E2WT(+
M:TTSR@&D^75BP9_PK1U-$Y1N(;+)96VTI2B5M$H(2J2"2I-BE14#*1)Q9%:7
MK-ES!\NFQ)]HQ!J+S&\KH)A:@9)C\S_G<0V#A]I#DN2&(MB829]=+AS5RZBZ
MKY4%$UR75IG.?0G@[BC)/$?A9W,'VFG4U#1RWBC(JM"$O4KC:/.R64*<+2:A
MM0=IGTJ^Z4D:5 @>0.(:.OX6SA:$EUKDJYM!4K!',0BY:U1)#@\L#IO@=Y]@
MF0Y==/9EC,=N/U P&%S,IQ^(Q&@0NH;'ZN,V%9?BL6.EF#&VS0UK+2,JQEAN
M.G*XC0M:AMMU$>#Z\9>+'A=5\#5JW'U.U?#=94$9'GKS>EI@U9"J;(*KE)46
MUL@*31OK26W/MB^XSI3KVC@KC9&<4J!4+#-8VVE573$)!;;!(2ZV-1*T#S<Q
M*1KNDH0H$A+IK+:U7E4)#;CI;EH[F)462%-2(TEAQ4>3&D,.I0\Q)8?0XR^P
MZA#S#R'&7FT.(4E/GZOH:BCJ'*>H;4W4-W6S(*T'2"$%8):4I0(*2VXM"@00
ML@SC4=:7D(<:)6EQ"%H*8*E(6)2O2?NI6#("PE8_>2DC$OS/":K)ZY]IUII]
MMUOM\!*BGD>/W/SSQP4GG^[CCGTFBK':<I(<+(4-2SY5*;B)!0"1S#LE)(25
M>75AG0E]*D\Q)*@4K;25)=0#]Y1"D@0D$DD*-A:;#%1=1KS7%,WV9I:VK6'<
M/?JKS9.G'$R&GWH6<8C2N9-DE1&:5*=>@UN=8W$R>#<L.1HT.%8PX5G61Y5E
M:V-@OTSD'$W"N3Y-PEG^79CFE5Q14/ACCW+7J9E.5#+EN\EA_*E)>*W':?4T
M70ZTQJYB_/"0#3GGN*OVQGBVS3Y?EJ&FOV%44KBQ4IJ*9.O54_9@(#VE?W"Y
M!"4WF08KW2-7ED5O,L"N9^+6F1P67GWJE33T&[;D(2IMNWH;%B9C]PVZT4(4
MJTK)+R65>TRZT"0-VXE\/&Q4N.Y4TI5,4IJ"I%F@:E"'80H&;))UPGRGO:=%
MX/\ &#(>+*:CR_CK+W'G$T[*1G--5KHLP2I)<0%K<96C5I4U.@D@BTP<0*-T
M0;7O9"K*_B:PE5#D4,HIXTTZ\7,4H2O^==47,OKX4A)>C*2S5X]!@.(C+9<B
M-F0U(AT4\(9J5E#*5+2# "5*$?XKK0@65((O'?KC5J?CKA;)\GS:ERKB=6;Y
MI4O,)RY6:4+"DT=$E"$K:+RWZQ!<!U0L4GF@*6HJ))CM]_#9O9[;"L9Q*L^M
M,E)FNO['P^VKFX?MNJ<$6/'Q"GLG)A<#:&4K6EI(]Q3O>$H2J(OA.J3J!)0]
M,H0XW4RISHD%+"D^90 )*M/68&$<->+%+39O2-\4L\.NY&JF=:KPPF:EUPRE
MM3:>0RD2F"M:5(T&=(@ $'YUT6VV$-&3;5.XL%7&:[U75-B]'DD,O-H!<>83
M@&R/U[Z="PLM+34N/I8'>4!04A+2>&,W"B32\[2F2A(79(_>.M#:0$@Q8S>8
MWQ5\_P#$++,U0I+G#.4ALOOLH<H:E3H?IRHEA1\B5\T-@J4"D)2 J%'J/,;3
MU08M+;J=/]45/>JE>(VN\_R.1C-Y<-J)'TKF([WIZ^!):<1]I9C7JP\"L-K5
MRGT\,NJF4I^)H*RF3!TN!G4TM(MJ"DJ5M\CVZX\X<7JR5:J@4C8IG#J*Z92E
M:V5*,A"TKN@QY@+^4])$K;#9QUQD5?(ZONAJG6\N2T/YHP.+E.HH]L^5=RGV
MZ;&,@K=:9D7C_5EOP[(B;\+^H0X4E:6G_NTE9! ^YRT.+3'="2IX2;@*0#>1
M*2"<3>*F5'[%#J9)"A))W/0I%B8&XV!F,2K:V*T_5ELN7N/0&T\;R2_1CM)5
M5/3YG ;UUEN$T]!51:UFCUY!ME1<6L*13D9$MN-'ET[#<EY2(K]@E,7V$L.5
M5.R!6G[;62ZX@$MAHS!-@1%I2$6-A(&.>]]JK6''4+F0AT!"3VTZ21 $@"P@
M6%HQ#<5USU1[<R"BQ3/L4V9.H]40V*JLA; @/89K76%15L>VJPM;"Q@U&-0S
M$@LNR'+:P5:91<,(DNPG+>;++<CH)A38=2M 23H;451S%6(;0%#45%,J2F!.
MDQ>Q-+-0XH!12$IC4I1*0$@Q D=)-A<F  28P];3Z@,<_39W3WT[7:+YFXC?
MIVZMSU32ZYK*H;#B7'=<:V<>")-9@(?2A-K>*4W,RR1V/.$1408=*E2B@"4K
MF)(@:Q!,!P3Y0=PDD]R=L./.MH2&F(0) =6LA*E$;E$2=,&0"038GH GSVWK
M+W#\3Z6^G.GR"_@Y)<T<G-KM5'+H\AW'FE8DJQ['*;'YH;G4FNL+6M^;'_5E
M0VGI"9=U9+:A&UF+;4DE)<*2DS+.O?:"5&\0=41-NMY)$)< IZ9+BDIN%D :
MU&Y-B; E24WL))W)P195-0.[JZ;-#4MO M\3Z68B;#8^407BO&W\OA9"O=&\
MYL:<OVT+I*%NG=HJZP>2V'IBT0%I3)[XR4*"VU/.AO45(T(:(\ZBOR'R]0-1
M,SL#.PAY"4OU:&P4EBG(4"I10"$^94*O<DJ [V!WL2M5[0V_47NJ<-Q'"*^P
MO-KR+O:O&1+FUTMBLV7G.6YY>35S4H^BH8&!T%HS-R"PLX]BEQ:A"$2O<2W)
ME:]6<7#@+*^%LKJ\K%?0#+'JNHKWG%,4S*_[P-(>3YEN'44H9*4I42"2",:A
MP9X99/QIP;Q=QAF'&K.1UF45C=+DV0H9;55OA1"00F)A1_>U& 03$X:]J=:N
M6Y'L&5@O3=#I;U54Y)CW^_LPQ>'ETN^M8A:;?DZNQ_(XT[&<7Q.+)>D0*O)'
M:ZUNK]<>:XY[-<*Z7-PWCKB3B'/>$4\=UG$U+E>05N=+R7+.#<MKU9;Q =+0
M?-=F+C3*W4L'F!"J=#D! 0LO%;JVFNOPKP[E-!FZ,CKLCJ7:]O+1F#^<U:)R
M]94M:$!I86M*E+"/*E2$DG4F D:E27"=O]<B46'ZGOJ_F@B&8Z)&$:M6B..)
M(<2PC^1$)90H!OEM"4I'8D@#D^L@R3.F%FI*W\R<4I%.O6C-*PMJ\U2V="''
M5: %-*D)@*/F-S O-;E+ ;I]+=$D%3]DT3+406['2!K-YE5Q,6VQ^PAP\GR
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MBL5RV@0F7+0TP79+2U%QIMX.J9!2I+C#A:;<:44J!!5X5P0%.@DB(,D7OL2
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MHL@D'E9+V09#</.D$E3[KI/W%7J*SL^D3'/=O8W,*-K"Y4K>(,^F.BMX@TX
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MJ))5J;U%2VVUI\H4AHD)!Y8"9L5:2I74'76T0V\A5T5"$C2OS*1!)24+(E*
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M5ZLP_7OU.0V689'>#(5Y9;73BZI5'-:?I@VPHA:-9;<;2$-A(+K[K)0!YE$
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MI2HEAQ2!R2)V)H''/$*<Y=124*$MLMJ>4ZZ1*'>9RN7R5J$*".4K64F25@J
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M@^2.X=PX/*1]I!Y'')!Y/';PHC<'VP>Y!W[?C_#KL>D=65@V"W7A+2AMM*?
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MY!$"3VM,F!$CN+1 %ND7FQT.H+3JB$%Q"D=B!_:AM9\J<[./ \ ? \D>?!]
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MN@H)"@M!+8GK!$$81,Z?I$/I=;@1P0L*!#:. ?P1PG]OC_?CP/'J/\:Z"84
M@WT!2B$DCS: 94E!-TM24MR0G<X-(2@O$I:!=?>?)0VAL_:F0E6G[_+@!"B
M8'<SA1FFM(MCB\ZJ#:$ID,+;'8D< E/V@@\@>1S\?[?GTVBH4M\*  *">]YC
MTL.O4=QUPXA<&1!D3_V>L2)VO/YX%.M-M5&"2\<P39]HS@63XA6(Q'7^X;2,
MJ7@U[AL=^5(I-=;=2VTN3CL/'E3I<+%,\AH>K::M>>8OXRG(X%[Z&\,O%6OX
M/>K7$FHS;*\RJ6*S-,N<7-4BJ2E#-17Y>M<I-6^VA*.4X"C[I2DR8S3C;@BE
MS]%,XVAENKRY#@H'7&T%MEMPE98652.2MT\Q1(E,D  $22<NZ7]9[/V1%S'+
M*2QQ_8L&!5396+INFD8SF%=!F+E55S6/Q?J*[+*)3\A:6)]5+:9?CJ30W7N?
M3/54;U[E2> _$NJR_C%BF775N7MB=5:RSF>6.)4@I:JJ5D(<"K2%06U:=I*<
M4S*/$_Q9\-N%>*/#+*LS>R;(.("LYM2IHZ9;%8JK&BNJ*-\(U%%<U]E4I4H*
M;U ) (.&S>.02]/ZLW'LZCQ"GS/,M;T^'2<?Q[)(!N*2$K-,P3C$_,KVD+K#
M=[!PQ@-S?T^8X*M+D],RU,=B*W-C<GQASWBNHK.#^"N%\Q>:J.,JFM89<;K&
MZ:I6_2II6J7+VZNK066:A]ZI27$K4$A@*<1*X!IG >5\-MMYWG>=4[3C'#E$
MFJ+3E*]4I4P%E#3;;;(45N-$*"18Z$ZB;R*/8#U(=:NP8$>PKNH3+**))!]J
MKQ:@P'':Z)V*6VJ-&@P,32VTVPM*F4I2MY(2CA+KB>%GQGQ<QFG#^?YGD>?<
MQS-,FK7LNS%HYH]6)^-I%%JJ JV'N2ZDNI44J2D0F$* 4D@>C<JI\DKJ&DS'
M+FJ2HI*MAMYAT9>AA*DJ &D,.ME:-"@6U:I42@J!5JDSZUK.JK/&3&S'J'W/
M<1%@AR,WG-S0QW L<*2IG&'J-MQ"A]JFEI6V4DCM'/JFN9E2D+ IJ=14A:#\
M2IVKC4E29^W4L&)G3 "H 42#CK-TB&A"6Z<>9)U)IFD*\J@2DE(3 4)22)(D
MG>,1[ .CBOI9LVSMY<N]LK&4'WK*V D6"VDI"&TR)C@5(F2.T)^IF/N*=E.
MON)#JW5+M/'7B2KB\\/<C(<BX=:R'):/)C2</TB*&DS!=(A85F=4RA(!JW2H
MB0HI;0"A)*3..3D/#YR+]I@9E65W[1S)[,=56H.*I4.2$4;*I4>0U/EF"HD$
M@6Q<;$M04U"$%N&RCL'(6M"1VC\\<>?'^./'S\<^LS?KWW%**EE6J\;:1_A
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MWVZX*PDE*>NQ5]09$'>>]KVQ@KIGWRA"@?XBW5<A">00=;=!_:>%!(_MZ->
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M%!"T* (()(5V4%)F4D8*HI*BD4WSD:0ZDN-+"DK;<2%%.M"TDA256*>Z"E4
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MX'J1.UK$B(F(L9/M$_HXC$CH)$CJ8B+2>AM/IU.XQ+&)*WV6^QI?M]B%.*4
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M25)45)21Y2 L";%20H3.WD*;"8!BT X6I"DA"E PN5(@@@I"E))3!L0M*A!
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MIWV""?C:6J2_2O &Y9"1K;TA.E2'"529!B<7QI]FH*PA6LMP%&((D]K$&QW
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MQO!^EVOU?L6J<K\_OZF/F-Q2=0-<G<-IBVSX-13Y)$8<N*F9;Y79HK5H53/
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MZ5KR-;1)DN= N;'+\:U%FMO:5,N?!K)RJ>RO;^?-I4RZ^%+CU;\-E^.R\TI
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M8W@ F(O Z>N,FFYE?</M/^VPRF$VH-I4MXDND<A !X<65E14.SP>"/[E>@;
M$F;]@/PM'S]>UC.\DR!>+"9]/7?8G:8Z:Y./P((#5/5UK";"9*>G>W%9CO.3
MI;BI$V8/;;0/K);KKC\EQ9]U]Y16XI2RI2B$#ZS(N+FY,6$W)GY&UCNH@F21
M:Y!M)  @=+]H D1:)#0QG4.6T..XIVO9AQ EN03(?3,2"I:D^X>0G[O[@./!
M /@#T"8G<VOO-K#\9O$F;3!P_81(!N(F_3>YF(BQZ"3!(PZMQ([T)+$AOO"&
MU+#C)2A32DJ*B V#RL\@$@CD<^.#Y("@JW8"QB-^U_E?"H,=)FQ^0WM-]R3'
MJ",,+S?Z@9+4.0D. ]B/?<+824I[4)<*^WM!^[@)*P>U7/G@>C(!(WZ&#MU!
M]01UCK$C#"P28ZP-ON^]MB+7'?MA/029+3;\268QCA[CZEAKVB'._M6VM)':
M5 @<.(2 OD$\_(!-E#8 $?.+==C/I^.'18 S<";;G>9V$B3>]AM$@R8SV5,R
MHG"WNQ]+!<0>$\D)4%I/">\MJ" I*O'W$CG@ ,H,$3T[?E<[=O2T#!DWU#V]
MI!(Z0>_4=B9$9%IB/W3YKZGWGF6DM%] 0 @$%21RI2NXGA/@$>>>1XX-9!VD
M>\C;N1M;N?E; !O)GJ.AB0+ 1N#O ]\-,RI;1(,I3(;4_);>9>2I)2R7. M*
MTK2$!78D)2GXX)(/)]+2/*)M,[3W.Y]]CUVBYEM2"3JG^!M(OW(]#L+@;XV5
MS,FM0)#:#*9]]Y<5AAP-]SBP.$O*'  ^5=HX^#Y'HR" >MKD^UR(_&3>(O@@
MA0(-C/7VG: ;[F>N%OU\PA3]K#C]JP%-!I)/TJPO@I(\APD\%1^"21P?34$F
M$D B]YN!V@7WZ?GA1&H00"DF2)&^W4[]1>]X/:-V]+6RHS[JJNO;4\TM*7 P
MS[CCKYY!4.05E?*@!QSR1R.?B2EYU!3"A('K<_2(,Q?K:YG##K#*DPI(U$&#
M:WH28@@W-K](G'*_>G3!OG_B1QK;&HLZCXM5T:<;^@MF;2PAY#@S$-Q:<LIX
M%":Z;07-/ET=:7YK<M2V+B6EJKOVFJVIKG7<QXW\.LQX]SW*WZS,Z8\/TS);
MJ:%WFIJ&9)!-&VVRME50M0*TUKK[3K,I0EI0;"CZ$\/O%3PTX)\(^-.%,RX!
M?S#Q"S>H+F1\3L)I5TJFRNE<I1FU4[5LUM,SE:FJCDT5%1U;-=\4XJH=9(&E
M/FF(7%=87VP,%HV:3,*)B1D&X]34<1^-565.R_Q/W!J2MY<=70O+?;D9_@[2
MI-CC-E)-A#5.A3(=CD?D[Q0\-\TX.S=S+ZY:ZMNO<0]D?$"M*37TH!U976+(
M2PQ4?NA25K;6E(6MU"B0'N$N-*;.Z()U:'$&7F7 D.M&TRVE3GV943RU:B0(
M!@&Q*UKLVES"O0N#80YBD(9^J0Q(9><CJ?90^TEU#:U*0765I=:[TI#C2PM)
M*#W>L0K*!YDI6IIP(<*@T^6G&V']!TK##CB$"H"%66XQS&@8!7*DS>90M2T)
M<:+C93J0A]EQ2=0)3J2TXLHD QK"5=(FV"#=4<.XAK0IMI25MK"@4]W=R#P#
MR#Y\G]N!^1P.(#3JD*Z@ Q?H;7 G\\ *CRKO/X3 ,[ BW?<>IFD%UBFP-([0
ME[6U_-AV.-VF.C&\\U-;Q%N8IL+'%O6*K&JON'5QT*DQK$_IEE^FR+&AL(Z)
M$9^55R[:CL=;R7CC)Z/@E[AU?"E&.*$<1)SG*/$!BI6WGN24WP/PQI:5@-(2
M\ \%J#:ZMIE2'G%+AQ+8Q6LSX?JLPSM.9N9J\[E:<F5ECG#+K21EM4\I;ZC5
M.NA:RAP<U(#B:=;GV24@A!(-M86_=?X5JIG/46MK+U+8V;-3CEQ8QIUIFV!9
M@MV,S(U'F\*N196L[)HKTQ QB;&9L%9C1+B6#4BP6%6]QZ]\,?%RASW*30\6
MUS.7Y_EM/^T%5#B@*3-LL$-_'9>X#SW6=:D!2*JFI'I5(9(DXR&N\,<]K,_H
M<FX5RM_-:C-WQ2T%#3@<]M]2%+"GN:I##+6E"M3O.4AL2X\I#:5N)LIJ'9.+
M;3Q"DS' \D9R.EG*D=CLN)*B%J3!EKKYT*9!G1H-I66$":P_'=AS(C,AEQLE
M390I*UZ[2YA29O1LYEESJ:JA?)#52V905)-T$2%!1 )N-, R1L:IG?#V=<*9
MM6\/<19?493GF6.AC,,LJT<JII'BD+2E=RAT*;6AQ#].M^F<;6VM+I2X@K+L
MO(I#*FHT>)!?F=TE;XG<A 6M:$)2E0(+_*$J*4@I"$I[E<$@!X-!=RI0 L(^
MN\WWB^P'SQRB8/0VD3%IO>#?KN;S]5&,3$.R+=YVFA2"M<1!:?=5V1G&TR/=
M1'#;:P&EJ7W_ '+4HGY/CU#K4I26DW("" 3).]YC$VB! =(( *QN?3U'3'5S
MU3,7''WH8'S^5OY3^./O0P1V,]L-S[B0L(5R%N?:!X \^ 022?CCD\?:2/GD
M#T2C ZWM;U_7K[82F ;$FQWVW&WS[82EM7*DD$)2 HJ*4J[B 3PC@E1X^/(0
M>>?GTWI,&;#>8[#\#VVM,]L+PE>=#0[^ &^.2M9"..>. 4GSR>3YYX\>!Z 5
M B)CK^IZ^N!A XR70LCPG@>VX"%<I)!)XXXX)!3YY!'X^?2%#RJ,6 _1^H^6
M!AN6V$IX0$E0*@4-\^3R6P5I)Y!;!//;V#R"D>H^"/X[[QM_#H??&<A24H4I
M:@A"0KO*@0$H3R25$^$I*>>3P>/@@<CT,$1,$S(F(OZ#T[$=OD<-"E^^V%-^
MV62I25$=JC\E*FR4J"DD_;SWCX">!\>A@^I-_K8[7CIC2XVI*TMCGM)4H<DJ
M[B  !X''G@^2KC[>WCD@A&@=S]?\L'C2XP4J4XX K[4=G*!]I[E$\$\DD=J"
M"#X5Y'X]$I( L3V]]S^8&"$$FX.W\_K/Y#J,9<H5RGP>#PH?L1Y\_P#C_P"'
MINX]/Y8/#:M+[<DK6XRF.M26VV^U(<+BN>Q*3V]Q5R5J #G)[E<HX'(5(@ 6
M_*;;^\=9 ,7%\%?]?Z?A[7WG>XE:A]H"N>>?(!':%<<!0())/!X4#Q\?!!(?
MK>?;_41<S@7]/6YV^F_ZG".1$9>2@/MA1:=0\T"K[PXVKE*T=G!Y!Y_)23P>
M"0#Z CW@@GK8;_7UVZG FU[>F^WX1Z[>HPH6@]G:1R$J*T^1RD<D<D ?D?)Y
M _'XX] =QN(]IWZD1VV(MZX!CK'0[_3\<-DM2DDE1(:0D=W:%>XM24NKX"PG
MA ''!5SP!]H^0/0(%]]NIZ$7[?YR/FDW,29$ &^YV@"!/3:_L#/-#^(CL1N-
MB&,ZAJW0J]VGDL#%$$(451:17TEOELMQ/'<A**&&B,TZ"$E^\8840$\F_P#!
M-(1\76J0$D,AE$;$62"9DF1OT&_;%9XHJTM-,L>76O2%R;I 4)T[$3M/SVP.
M;]:V8E)![DNFNKXL=*^ KRAI )6H#R>X$!0XY^2/5ZI!Y%J_Q*(.T 7,R(GM
MO/7% JUA2D)!L#J'^*]@(^O2+1:9Q&7VH\I*4/$QU]O#C@2?</*P1V@$<)'
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MYY4H<\D?]((_!]8)_2&G^JV32(_Y^1[?_!]:3;I<W^6/I]_W*C_\O'&W3_\
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M'"?0G>]AZ#>T;^N\D1(V-\&.IM%A8"]][_CMTVZ2&,AE,=A:FDK=7[;G+:5
MJ"4^4J]S[@0?)[@"/((^/2H$1M:/X ?CB0)B1:!<3O:>A-R-]H(L=P,/U5;R
MW64+67'&RT@K4A*4]W/"P5#LY2  "?@D>1\^FPF"#>?I>TC:1;I%]YOAH*YD
M)-I@2!%Q!%NXF/:^(U)C,PY+J7'#*E2FF"%J;4IYEYHD_P#KQ_"04D!12 "
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MZ_AL8Z;@D8!$G?;<?KOZS(MU,[5(*N?L)!(_N2%<I X(X)'()\CX\?;Y'GT
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M+_T=/&@=_#SB3_[ <Q^VYA302P&G%.--NEIP(+BP(W?_ $D(6O[R0"H<GCD
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MU_G<WN<+*R,RS"GE+R279*Y 9Y4D-)/(2&N04JXX^!\<'CP?*A?L;F/3>/\
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M9,F<&>\383Y?6?2T6GK'2V%T^ X&ES @_6+J6XRD,R%&&%>^DI<9:/R[[:7
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MTW"78)J@'V&7(]A)KVGI<.-+0PN<TV5PP^ 06EJ2K3!ZQ,]>W<R ?0C @P;
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MH2X5*^_CVVVP4@$-H2'"">5<J'CGD^NMS4MPHDF\0$=3[NGJ3/\ EBN*IG2
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M*0$D)*B2=4@*2(@)3_BW,^QG$NDF7+$5YEY*DI8)<:D!26U%WE"2A+15V%'
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M$)D(5N)F.O6T7PRW3KUQJ3,&\'K&_>W6+X)/TS,B6/;2&YJD(0)':"VE+?W
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G-;4 J;,*,I)DD3OZ=ML/T31(<(#:05)L J!"8,22;[F^Y/2 /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g383770g39d73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383770g39d73.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2@D4&AO=&]S:&]P(#,N,  X0DE-! 0
M    * B^$"2#A"24T$!       #QP!6@ #&R5'' (   ( _P X0DE-!"4
M   ! WE^%):I?8:3)MB!G2YF9D.$))300Z      #E    $     $
MMP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $
MEN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&
M5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4
M!R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0F
MQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M   BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W
M!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;V
MP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $
M5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D
M="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M       $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M      0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&-JX4
M         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M  4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'
M0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E
M!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F
M]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      !  FU<*  $  @";5P
MH  0 ".$))300F       .             #^    X0DE-! T       0
M >.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "
MT    &       !.$))30/X      !P  #___________________________
M__ ^@     _____________________________P/H     /____________
M________________\#Z     #_____________________________ ^@  #
MA"24T$"       $     $   )    "0      X0DE-!!X       0     .$
M))300:      ,U    !@             "8@   U\          0
M                 !              -?   "8@
M !                         !     !        ;G5L;     (    &8F
M]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M  3&5F=&QO;F<          $)T;VUL;VYG   "8@    !29VAT;&]N9P   U
M\    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M=S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F
M5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP96
M5N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M      4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M    !"=&]M;&]N9P   F(     4F=H=&QO;F<   -?     W5R;%1%6%0
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MEC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M  "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M  .$))3001       ! 0 X0DE-!!0       0    #.$))300,     !VA
M   0   *    !Q   !X   T^   !V% !@  ?_8_^(,6$E#0U]04D]&24Q%
M$!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E
M0     245#('-21T(               $  /;6  $     TRU(4" @
M                                                         18W
M!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0
M 4<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN9    E
M0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0
M   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U
M120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#
M$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T
M(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M
M   %A96B        #S40 !     1;,6%E:(                     !865
MH@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M   "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V
M@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                              9&5S8P
M N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D
M="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7
M(@<W!A8V4@+2!S4D="                             &1E<V,
M  +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C
M$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@24
M5#-C$Y-C8M,BXQ                                  !V:65W
M 3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %
M<?YVUE87,          0                        */     G-I9R
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M$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U #5H-=
MV.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^
MP0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!
M*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7
M@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA &&48BA
MBO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:'
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MLNNZ>\(;R;O16]C[X*OH2^_[]ZO_7 <,#LP6?!X\)?PMO#6,/4Q%'$SL5+P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!>0(5 P$1  (1 0,1 ?_$ !\
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M!A925,'A0G*2\2,S-$,D1&*R-7."E)/2T^,E56-T@Z*S_]H # ,!  (1 Q$
M/P#]_%$2B)1$HB41*(E$2B)1$HB41*(OA<W!,T-KBZK!NM2-B)6XJ[K+1ONM
M3HR#%!]UMEN]UUP%%7"%MH#=<(;  B- V\ 7)CO)4$AH).@6H2WMU>SYN#?[
M-<@VAX".+Y1=W@VWW#ND#L'S\[@(> UZ]/86TJS ^G2:6NXF/G%H(6EZPPX)
M!< 6V,G]N-ODN7OTNSZX#[-\@[_]ZZ4_A_8/Z*O]W=J^X9XCZ]B>L,-KG;&F
MJCWZ?9]!UF^0?IQ=*?R'C3[N[5]PSQ'U3UAAOQM_J">_3[/G[M\@_P 5TI\
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MJ\0&-%FBFP ;AU 3\2N,?[;_ .8_,KK'@0VV\/,.0\_$!Z\!UVZ#4*JD.HB
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MO=YEQ5I9;.0I1%&N8WB>1;:"*TX1$XD _LQ879VXFB16 <#+P]ID$LIM<'.
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M;(R@YS'R "W+$SFZP)UC@WM,R"K3D0^6*RQ,2Q>0*"_;)4<](G9'$ZRV1'B
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M_ C\.-_+[4>H"&X[^5$3;?X;C\=^>..NX;CR(#SQN(411Y[\_MO+J(;<AO\
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M>-MQ ?+;<>1Z@ CYCQ1$#CJ'CUV 0VX#81#@?$!'^BB*>!M$ \/GZ;[[AO\
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MHM#W;? ?11[M'0/\E'#O\&"_RU0-H[1_,U!VN/[_ +)Z+0]VWP'T3W:.@C8
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M_K4L.\?\6"_#S_9:>LMH_FG_ -1WZ[D]%H>[;X#Z*/=HZ!_DHX=\_P"U@O\
M*_@Z4]9;1_-5-_\ $=^OCO3T6A[MO@/HI]VCH'^2CAS^#!7Y6I]9;1_-5/ZB
MGHM#W;? ?1/=HZ!_DHX<Z;?VL%_E>/H_HJ/66T1_S53^HIZ+0]VWP'T\PH#L
MT= X"(_K4L.COYQ@O8/F_9:GUEM'\U4UGVCJGHM#W;? ?1/=HZ!_DI8=\?\
M:P5X_P#*^'A4':.T3KBJG]13T6A[MO@/IOWH'9HZ!P_Q4L._3&"O+;_??I^>
MGK':/YI_]1'R4G#4#_MM\!QGAY[;J?=HZ!_DI8='QYC!8_C.IZRVC^:?_4?I
MYE1Z+0]VWP'T3W:.@?Y*.'/X,%?E:>LMHC_FJE_^HIZ+0]VWP'T3W:.@CY*6
M'0__ &P5^5_'Q\*GUEM+\U4_J/'7]4]%H>[;K.@^G[\T]VCH(^2EAS^#!7Y7
MZ?G^%0=I;1.N*J<?:*GT:A[MM^0\=.[][H'9I:" _P 5+#O\&"OYC?G^L:>L
M=HZ^E5)F?:.J>BT/=-'8!XI[M'01\E+#H<;<1@K\KS\P[@/B%/6.T?S53^H\
M9_5/1J _VVZSH/I^_-1[M'0/\E'#OA_M8+\/^6\?&GK+:/YI_P#4?IS*CT6A
M[MO@/HI]VEH(Y_K4<.<_\6"OYS:GUEM'\U4_J/T3T6A[MI[A]%'NT=!'R4L.
MAO\ \6"OJV]+MMX_/3UEM'\U4X^T=>.BGT:A[MI[0.[PT3W:.@?Y*.'?X,E_
MEN=^@_"AVEM$ZXJH>UQ^BCT6A[MO@/HI]VCH(VV_6HX=^']3!7Y7_/X[U'K+
M:4G_ (JIVYC?]?%/1:'NV[MPW=W+Z)[M'01\E+#O7?\ M9+Z_P#E?'QH=I;1
M_,U#NLXCZ<$]%H>[;X#Z)[M'0/\ )1PY_!@OX?\ "_#^BGK+:,1Z54C^8_1/
M1:'NV^ ^BCW:&@???]:EAWYOL9+VZ"'3TOZ#\P5!Q^.>"VIB'N:=TR#X_L@P
MF'#LPI-S<8'T6;91%A!=A)-@6E%66%EV '=MLLL#:RRP.]^UMMVM / +0"M)
MS2XDEUSQ'[K.!%@( %O/G5?35U*41*(E$2B)1$HB41*(E$2B)1$V#RI X(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HBP)U!:R9
M=@K5=I#T\&8(4R&#ZK)P_P"/DV:3\D,K*FB\EC^-I_DE4A;<?(F*12&3W)6V
M#DIG-2\N$$;R+I$WG,ZV07('=.B)Y\^?T6>EUP6AN/EO^+PZ^/.P<40F%BQ-
MM;^DG&N1VW%61=0F*('+W:*O<Q0%S":L4;8CF>//C3'70BZ6/"U'%B7\ET>4
M=I,6.>"Y(L1E.+FC:CVUI<U:3-0PV*Q0></A<57Z,P[H,-7K0-Q)ITW  P8)
M*UL1B\-A<IQ->AAFN$M?B*]*@TQJ!TKFR1;3B KBXZU$X!S K5H<29NQ%E)6
M@"T5J;'6289-E"/O67F@"DB-/3F:3N59>:'I++0$NVZ[?NVW""MAL1AS%>A5
MHDB0*M-],Q)$PYH(N"--00HPV-PF,S>BXG#XAK"6E]"O2JM#@ 2TFFYP! ()
M$R 03J%>&\P+ #<+A&ZX+0 +1'D0$0 >..GC\/ =ZURX"-))@!Q#"3K;-$F+
MP+Q/!;,BVIG> 71S.4&!Q.BBPP+[AM[MUH@'^$ A] ;@&_CTZ;<TEV8 M(!G
MK2"+;K$W^'- YIT,QR<.^X%EV592E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(M9VL715J$U(ZB=+.;L<:G<
M:XA8=*<O<,BP^"R?3.]Y8<'Z<R&(3#'TH6/<R0ZC,7$61Y=#)6*1I8DT1%8S
MOJ'VT>_.Z53[$3E%YTY_MVSQ\=RV6VVB._I  >@!OML(>/&X[;CSL.^W ;CW
M0&B '>9\/F -=XCO6B/+'9[Z),B=I[!8-(M+.$R8L_Z)\WY/?V:+09G@J>19
M!2:A,(,Z::R.^#$1M1(9"2W2F0I07O!ZT_N/"Z^Z^XTX;ZW,'M''8#.<)B:N
M&S.ZXIY3TC;V)<TD ZP)(),3 6ECMG8/:+6T\9AF8AK9REY=##&K0TB38:VY
MK"*5=CMJRTM9XR)+="VI698RA.1WEZF#>QP'#+4>A@K<\OC_ &-6.BW%_P F
MN2AZ*BS#<B1E/)B5LO7D*"S;VU*8 A=T;OM'@\51IC'[);BJ[:;6&J_&&FY^
M6X<YHPQ )<YSB Z+D3H%RE/[)XW"UZS]F;8.!H.<7LH-P@AKG0T@$XGK ,#1
M)RS'LA6_SMBWMP\+8KE62&G5MJ2R6XQZQJ%%!(U@]C5/C^8YOC:T&6("6!RE
M;Q>8@3KSG4\$;"O&Q(@/O.M(3VG*2<NSL?\ 9^OBJ-/%;%PS*;RX.JU<;4R4
M):8J$##M-C#=='21:%@Q^S?M)@\%6KTMN5\35:6BG0I8)HJU22! (K/L!+HR
MG0P0LP=/_;J6GO+7@K/>GR783RO!\71YVF#YJ0R/'<*72AU2IXZT+%Y#?.(X
MQJDZ^4*7!1($"$4_[.A*6G)N_8G,OL\_'_9PT:-;&X+$LQE-^+AE'"@U<E(R
M0YSA)#6@$$EHW:28W]G?:@5*M#!X_#NP==N'!KU<4]M,]*!!EI#;O(!]J^X0
M!.7'O@L-?]>Z?_\ ^8.'OR->-Z!C?RM?_P"$[Z+WQM;9\?ZW"ZQ:NS_YK]D^
M"J6&=JOC>=RZ-0Z.M^*'UTDCT@:4Z6(:D\?S=W*L5J+"CUUK#&6M<XGIT1-U
MZA1<-A)%EMMMIJDCTMEPU?@\539TC\/693_&ZFYK9X21$\M5FI8_!5ZC:-'%
MT*M5[2YM.G58YQ:T$DP";  R3'#5;6BS+;[1N"\+@ 1^VW 0$ VYW\N?'H/&
MX[;CK?I;P6V- 9U$B_G=]>:[ NM'< $!VZ_7M_-_/T$*@$'0Z*4"X!Z#OSM]
M//\ 14HIHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$7$;[0
M 1&X  -MQ\ WZ?IX;#OTJI<T DD #4G<B=ZT0W"X!#GH/EP-61.];YT13WK?
M,//]/Z.M$3O6^8?71$[UOF%$3O6^841.];YA1$[P>8?71$[UOF'UT11WK?.B
M)WK?/] _3Z?"B*>];YA4$@:]B* NM$=@$!'K^';\ \#Y#Q21,;]4UN-.*Y5*
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41:Z'W]UMQ=^]T9Y
M_E+Z<*(MB]$70>58;;:%XW %MX7?:AN(B " = &[QW^UV'< '?BA, WBVOGY
M7[%(<6D$&-QL#(X&08&DFW:L(\W=F_HBU'3Y=E/-FGR(Y!G[FA;&U;)7A5)"
M5JA"T)[4C<GN*;GI"DM!,GL FVXM-:;=9P9=?</>K;H;2QN'8QM'$5&-:X$!
MKH OK$7$P8YC<O(Q.Q-EXRL[$XC!T:U9P@OJ-D\IFT"=".)U5H?<U]F1U_6B
MX_Z_]?37\7V2UM>O=JQ_K:_B9\(_98/NYL?_ /+L)_\ ";_\JTJ=J%V9Y.D7
M(>"-6^@B#36--C5,X1B^882P#CJ73&9&)#S,A3*6Y432 '60'(RU#(R,,%]1
M-8DJ5,XJ6U:$B2'J;49_N[)VP_:-*ML[:F*:6U&/-*IBBW*#8-9[)<+2Z08$
M'>XE<OMS9#MC8O#[:V-0K--$TJ-7!X3"NJ%[*F?.]H#2#((;$99+2;A>S+>T
M?R@P1AS<V_3IVN+.L2%DF%K99$)"W1A-Z9405?>Z+DKH!I!9EAEQ95]MXW7K
M+R2[KKN_<(ZC/LU0:Y]4;:V2&N>0VD[%52P&=0T M%K"!?D=/2'VH#:8IT]@
M;<:]K0Y]:MAJ[3FU>"'$0T00" ! L(LMA^C3MK=/F=WQTQ+.XGE+"$_@L0C1
MRQ/EAO)N?)8O,;[;G"YN:&12[R$Q26C*+?52ES0)P,0."14)M_I1&L&U/LYB
M=G4:6*])PF)HUG.:ST6JYY;E <<X<! (]F#)O,6"W=D_:?"[5Q+L$*5?#UV-
M:<M=A9)<<A:T[B'18Q8VDRMPF.LDQ+*3!;)H0Z7O#(*Y0@]<-0.+;?ZRD"P%
M!?JSHD1JPML])8-IHD 7?WOM+[P$!KG^[2QUU[P%TNA<PDYF[C<[MXL=3?NW
M*X%%*41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$70-MMX76CT
MMNM$?'H(C;OOP(;@'F/T["&*QSAT1F&[F3'P[M47X =2^LC5ZQZCM0+(Q:K=
M2+*R,V;<K-3,SM.<<G-S4TM;=/7]&W-C8WI).2C0H$*0@E*C1)22DR9,4602
M6679;8'TK!8' '"8<OH47/-"FYQ=ALY)+02<_1G-.NIC2RY?%8G$>D50RLYK
M0Z W- %AS@7F=8)T5DOU[NM+I^N_U1?/^K[E7S__ !3\?+H''%;/H.SOR^'W
MV]#/(>Z_7B=%K^DXO\P[^HS,QQCOGX74?KW=:6_]^!JA#Y\^96\=P ?[:@';
MRW^GK4>@[.M_PU#_ -F>_P#VO'@.%D&*Q47Q#^YQ&O;\=RG]>YK1^6!JA\!_
MN^Y5\?GE(>7PJ?0-G?EL/_[,_P#TM>(W63TG%V_XAW>XV_\ [)^O=UI!UU?Z
MH?X_<K?/X2H>O0.>?PU!P&SA_P O0XVP9X:?Y.[XGBGI.+G_ %#K_P#43\9'
M;H. DI^O<UI?+ U1?Q^96V#Y_P"JG^?Z>0J?0=G?EJ'_ +,_/HHW)Z5BY_U#
MC_ZB)[Y@:;^4 I^O=UH\?UX&J'X[9]RMOSMU#[*M^!$.F_D._6H] V=$^CT-
MW_)GY=%-]_Z)Z5BM?2'?U$_K/*X&LVN% ZW=:7RP=4/'4/U?<JB.WGQ*NGT5
M)P&SA_R^'[L&?_I?)#B<4!_GN/\ ZSX1))OPMS4_KW=:6P_UX&J'CC^[YE;?
M?SV^RKIR''78/C3T#9POZ/0_]F>,>ZG=NG7P>E8K\P[^H^&LSS (T.BG]>[K
M2#?^N_U0^(_W?<K= \ VE7B'3?RJ#@-G?EZ&F[!__9U[.Y/2<5^8=I^(_$SQ
M_:;J/U[NM+K^N_U0_P ?F5M^?#^VKP'Q'CYPYIZ!L[\O0W?\G_\ :W[_ -$]
M)Q4?ZAW]1UYWF.Z?D@ZWM:0".VK_ %1#N'^#G_*P;AY<2L-PY\A\>O%0[9NS
MW 1A:#C.Z@UN@.XL%[Z@1X*OI6*!)-=\$ 6>8U,3>)_:Z_6!V$&4LG9<TFY*
MDF5\D3W)\A0:BI0Q(7W(<PD,U>4;*EQIB9<G:4CI)7%R7)VPE<XN*TI 2?8D
M+6+UJ@LFTU4==?Q6VJ=*EC,E*FVFP4Q9K0V3)DD  <NY=#LUSGT,SGEY)@DD
MDVMJ?-ENRKR%Z*41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$6
MNA]_=;<7#X^[HSS_ "E].%$6Q>B)1$HB411L'D'U!1//AHOG4HTJT@U(L2IU
M24ZT+34Z@DH\@T N"\ ,)-MO+O"V^VR^T+K1 +K0N#D $*DDDC2UC<</U*0.
M'GR2M"6O3LH)E.=0[[KGTMYS3Z=<JQW$;J4[,\9Q%;/7S(4FCT<=6TI2D4JI
M>W-C:N>X6D88*0C2Q)QO"UN*76 J7*C++^GV7MRC2PK=F;0P(Q^%-4$E]9U,
MT0<K06N#7EP-^J8CLE<=M;[.UJF-=M79N/=L_%MHU;4L.VJ:QRD@$$@-@@ $
M DS&NN*'8S]H5EI9)H?HDS?'G6+Y18%TD?IXNRNRG12=N]TBO>)4U)4#.N<&
M5<GO;HM?&SA!7$R^\TC:NMO/(4DJC<GVDV/2PW0[4P#:%/9V*:UE-E.IG<QS
M1#B200>LT@R!#I$@B#A^RFWJF*>_9.T15=M*A1?4-2HW(ZIUVP"R!?*Z021U
M;Q$E?J3)<$:D1M3JBU(V[!=Z XLX+>]N =\;.\%HCL/= =N]L.V^PUR1>P1U
MQPL09\ ;[[=]EVXD_P )^$6Y@_-??:/VH[CTW$-]M]OCM<._UAY5<D#73C_:
MZ@3O(/='ZJ;1W#???D?QC\1Z=.M!$6TW*5RJ42B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$75=^TO\ G'Y_IK%N>;>T+=AW\OW1?S;=5H_UT6I+81W_
M %?<Q!MOX_JB2/;CQ >GCX>0C7U7!_Z3#?\ [>CQ]VU<=BO]15T]L\//DJP7
M0 YXXV#81\-]OKZ<CX;;;5L2>*P( ^>P"  'CN&P"(CMMOX_#?;;GQF3Q-];
MHH$1X\>-[MO+X[?/]7._/$2>**0WXV'X!SOOUYV^;PW#D.@CQ4R>)_OO[>:@
M@'4>=5&XCSTZ=-]@ .=_$/#;D/FW$!J%*#OQUYY#H(^8<? =^=NFX<=*F3Q.
M_P".JB!IYX?)2.^_4=_(!';IX\_'PXX'<=MQI)XE(' *!^<-^G(]!  #GGS#
M??G?8*A2G/&PCS\_7RZ]=^G>#H <[!23Q12/SCX;;C]8=0V$.0Z[[;@(\AL1
M2 CL' \CQ\+=OTV_&/C%3V&R8FIK/9K>;SKNO>ZJ[?\ RGS/Z;Y7[)_]#O?W
MF>5?#^N>E_3XXIPS7#?:/_Q#3_:'_>_7G,^"Z;9'^D'\Q6^RO!7J)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41:Z'W]UMQ=^]T9Y_E+Z<*(M
MB]$2B)1$HB41-OG^L:@B>.LV_7DBZS"K#>Z%X"(6B(AM<(;#MP.P=1#_  1Z
MVCS:(#4S&AO> =#VC?X6U2^Z1,@D$BQ$$6(-](6B'75V,[UJ<U9)]6>#-0R+
M35/W"&-D=FBI/BXZ?KY4^MJ V-E28U8XSUC;4)ET&3QZ)"WI64; 3L1*Z\^]
M6I/&[HMF[=HX3!.P.,P3,;3S9Z0J0>C<3)RN+'$ P29=J3V#E=J?9VIB]H4]
MHX+%>@XAK#3?4I-A[FQ8EP<TS[+0=2T928"P'1:1>THT]2'(S,P]H)FMB8FY
M998NE<3TF1]Q8WUO8BUQ@O"M2[SAO1MJ) 2I/-+.+7K2+BSE)QIY19 !=DJ;
M7V14C_\  Z1-S J%@!,3!;=VF^.Q86;"VZPDC[08@\"[-4,"=SSU9T(:[?<V
M5W-%FJ#/N">T&6X3UFZ]$F2L1/>CP,Q1A_RVTXVP>PDS&13Z((&5MWO=E2<U
M^1L2:2 2G+E2DM:E/7G6-X"@$TO-B,%A\=L-F-V?L[%4\3Z93P[LC:E4=&RG
M6=6.4ML7/-$V80V)#H)"U<%B\9LS[05-G;6VE2?AFX%]>G6K]'0::IJT@QH=
M(:2&]+ !O>9+0OTHPN=0W(L;02^ 2V,3N*.ERRQLE,,?VJ3QQQN;UREM76H'
MMD5+FQ7<A<$BIO6@G5&>K+DJE*=W#R#;+.5J4ZM)Y8^FZD\ $LJL<QXS .!+
M2 1(,BUP0X&"NUI5J5:FVK2JTZM-Y(;4I/%2FZ'%O5>V08(@QHX$&X,54%X#
MN.PAMY\;_-OMX;#_ )JQW'M$ <OW62>WY1XP;J>=^O ^&P?A'\7U#\4F;W!T
M/#4PIX7_ '7*K(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HBZKO[&9\X_S5
MBW/[1\T7\VS5;SJCU)AQ_=\S%Y<!^J+(]Q\-AZ;^8==QVKZI@_\ 28;_ ,BC
MS_VV^>6BX[%?ZBK_ #GY!6" .H>0[<>.^X>6X?BV\-^NRL"D Y#C<0#?;H(;
M!TW\M^ W\.NX;#0Z/(N0Q[AVM82/B!/*2;*#H>P[IB!,]RREQ_I-R#D?'F-<
MD,+BQ^QLG9\0Z>FU(;8]GN#-)5R5D66R%[M1-*E,1&"2GQ/:>H3J5"^T25&R
M'NV%W&:6(Q]&C6J4R##<(*P&_I)=8;S(;IND<UM4<,ZM1#P2"71W#+VB\F-_
M9:<DFCLO,G/+4>83EC%">4*99J'AT5ARLC)-JN6.&F9T<$&0U2>1IX"JA<<1
M&E-]RQD-F4DCOM$A2058%JLM203HU-MT0]M)M&IF=1P3P^Q -=E(O)&;>7FP
M!B;6!C.W .$YZC3%7%M[6T750P6G0-:9U,'4E8,Q7".9IRP*I5",1Y/F,70'
M*TZV212!2J2,"0]O)L4.!2EY9FI:V$'(4YI:A67>KMN3D&6&F[%WVW#ZAQ.'
M;4IL?6H,+P):^H&N!(F' D$.@BT:VLM(4JI;4+6EV4D ]'6,P)F64RTCL.XW
M!5[M/&CN6:@XZ?+29_CS&<=49"CF((HYS]1*.[-LKRU*>J8(0R$Q6,R,]*K/
M(("Y4]/Q;1'D/KB0%+K9<8(6:^+V@S#56TZ;!B 6FJ]U)V84Z+3#G.ZTVL8B
M?DLU##.JTRYYZ,R&-EM1N:J1(;%1C3WQ'.;+Q,,:1LH9GRK/\4-MJ2.NF*4L
MD69(=E[?))$EBR>+O)<<76V,L"8Y9+)&O4ORA*TM[7%V!W<5JD_TB=/>G*--
MMM6Q]'#X?TEPSLJ%K: :3+PX.)>!(LR!J1=PD(S#.=4%,$%S0>E;>63&0F(U
M,S$\P KAP'03DG(;SGI&QRV(I&/ [;)5"^32EMG4.)FKQ&8N[S-PBL3C<JB3
M/-2Y(1&V!V<EK=)8TPWM!:8BUYO07KT-JC5.UJ#:=$@]+4KN:T,$32SD-!=E
M,6+@=7 QPUOZ%4+ZL'J4V/>1%X:">&D"3OW&"L&1'G80YWZ!N'PZ=>-A'?G;
MCFO9: 6$[^/<#IS[%IJ/'CR\[?(=^H==]][N?'YJJBY!TX$1Y#H/AQUXX#;G
M;Q\^:K4/^&WAG^)#?I95=H>,'S\>Z5^R?_0\']YGE7_\STO^C_6JPS\?Q?Y1
MX?[1_P#B'_\ $/\ O?Y^.^W3;)_T@_F/R\_K=;ZZ\%>HE$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1%KH??W6W%W[W/GGC_QE].'C1%L7HB41
M*(E$2B)1$\OA^GZ=:@@&"=VB*! 1\?JW 0XVZ[_S;?"A!-B1'(1^I4$7F;Z<
MO#Z0J1GL7OFD%F<.L7 WWRR*2*-6+[R!4V(KWQH5MEJNY,!Q J+4URH#KB0.
M*$T+.X!I8W=\(#&SO[C!YP8.O9]$ZPT@G=(,=][_  6@G4!V=NG!WSW$&_5&
M;%IV8Z88>HVSSQ^(?XZFB2-K;I2AA*<433)DY*WV)(%%B]-<<;:8LO.]54F7
MV;#7JX';&TL$!29B7F@*QJ]'#1=SF9X.6 7,:6S'5+B1(LO'VCL'9NTW.J8F
MCTE046TJ;WG,6$"IF<2,I=+GM<!(]FY,JU.F;LY=:V.H*UX4TQ=L<S-,$A-C
MJX-L-C.G]B="&0N12!>^.B@#G26KE_HUTA>7!7?Z=6;W#E5Q906%6V66>YB-
MO['Q5:I7Q.P&5JU1Q+JC\75#BT=6FTBFUC.I3#62U@G+)DDE>!A?LWMO!4*>
M%POV@Z##TIZ.E3P3"QN=Q>XCI*KWR7.<XDN-R8@$ 1,Y!KQT#ZV-!L0U-=HX
M.9L.Z@Y?E%/,RW^ 0;%,68V;',>CYYA<A>EBI=_I9V<)BV"0I+<V?U,]LM*O
MO5^O6V%Y"W9&U=D;5J838SL+BL)Z+T/0UJM;.:QJAV;/FRY13!&4&9,B L+Z
MFV-C;8V/2Q^VQB\-C78IM3I:+*(I"@RF9ZKNMG+P))&6-;K]+$6EL=FC*VR.
M)O31)8X\)@5M$@C[HC>F5T1B-UI:MO=&\T]$M3&#:(6'ICS2KA"X O'NC7%D
M.IU#1<"US&-<YKK/!=_"1J(XG4<"N[IO;58VLQP?3J%V1S8+2&DC,"+0Z)$:
M2.,JI*E72B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41=5W)=X^8C_-6+<_M'
MS1?S;-5@A^NCU)!XCGS,0;[ /_OB2/<-M]O+PW'GCFOJF#_TF&_\BC__ )M7
M'8K_ %%6?QGY"/@K!VCY;<]0\]@Y  #8/K';QZ[ULK @"%O.W@(<V[>7/CQT
M#S >?&K-(&:1(<Q[=8]II;/.)F%!$Z\_D1W:_IO6P+ FOJ=Z?,1XWQ= SYS'
M BNI!+FJ9N<0R"XQ4C(40L;X\@78R>4#:EM],@<;&0ZX]2XJ7-"-BP;#&>\+
M+_2^5B=FT\37?6<6PZ@*+6.9FR.!<>D!)U.;0 &VJW:&+Z&GT89-YF0!K(M!
MT'S5]TO:FGE-Y,-4XVD!^*))-M7$@R[CTN?BF;,AL&IB0'O[ W"),? EMD.+
MU9YAS3)+TJXU2>:I%*F;"%JHD[6=L6>MTS,_1X5C7]#H<,QC"[_,OGR7 (+<
MQ$E7]-!$%CC_ (F(>X"I8].ZHZ",M\N> 3K (C1888MU6O>)(&\X\9L:X_D;
M8ZKWM:#W*W?,A$A36/*,E ))94$RW!XH9:C*(+-(N4Q=2<8?=>"PU8E I,3N
M5, :E1E4UWAS8D!E B1P+Z3W7&H<X]UHP4L2ZDQ],-!#I@ESY ,QHZY$ZB%<
MK2_K"AV$8$7 <C8F=,EH(QFR':B<<*V.;$PI2QY.AC:<VH"Y$)\7DOMZ)K;;
M49JYL1BS.5PI1+)=B[#1MMKBL!4JO:^AB32)INHUC4I,>7T7EI+&='T08;$!
MY#M=.-J.)R->VJS.,W24LKG-R51.5SLQ<7"]P"W2QDDJJL::W8%"Y)/9(XXG
MG0.>=X5.&'4"]P?,2V(2:2R>3Y*(R(V2R NAT:>T\"N9S4:5H4MGJ+RF=D=R
MJY1=9<HNMNQ5MENJTNBZ<!E-P]&::>84F%I%5C@'@U,YREK@6%D$0X+-3QC*
M=0512/2/$8AV< 5"#U"T9>K D$$NS3J%==-VMF0+LC3A^=L70%ZQ\^L61VR*
MQ!ZC</D$GCSG-L=(L=)WEUR&_P 57ODC-/;V9DOFJ0TI&DF"9$:U*B4Z _T5
MF ["I-;1Z*L]CV/8ZH^_^)D(<8#7-RDD6.9Q;:[H08]P=5(9 J->T-)!@/;E
MN2VX&I&^XM*U'J#A4'FGW6%EB<::=<6278259<:(W#8625:!91=O2PNRRVRV
MS:VVT+;0"O?!AI; OX7Y?*]EYZZ>F_B([;;[CN&X;=//X[#QTYVJ$7*T1VY$
M=]P#GKX<<_#Y_/X5#XR-CVND'<.K_?N573?AE/BOV3_Z'?\ [S/*O3^^?E_3
MI_<IPS7#?:/_ ,0/_EC_ +G+IMD_Z0?S'Y>?UNM]E>"O42B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(O'D+TBCC$]2%R,$EM86AR>7 X.1*1-:0Y:J,
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M IA6M3B4!Z-4*140N3>F*$0"_P!"K3$*+-^ ,*LN\*(K4CIDP /7$T,ZB/\
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M]CQUCU*2RF #Z:60X7O*9N. 4QDOK@TZ;6SF# VI(@2TDM @W !C0::75:=
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M>CBZG'<0.CR:XLV\\H4[*8S7MI E'FFF%"6EM$N^^ZZSNC=3,\2YOM0 8,3
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MVPE^1J)@^VM;%<C%<2K3-"5P2GDV)+SB;B@3O$>?)[UL2            #H
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M_;N2 3FCK$:P ?[\5U7IBMK;>Y=?O=WM_MA^V#H([[^ ^/ _; (;U?,ZP!@
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MY9%"A0VI[7V4P^7MSU'(H6+D<18:?)7),2UD)DEU[D>8?:6@*,4#98*D7,S
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MB/9Z!@--OE41O07:6F%=<GL:C /'&-RF\$,;MN]C;#)"#?[,O RVV\!#==<
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MHB41*(E$2B*S:G!4&5Z@(_J4.!W_ %28UAV88-;+K7  8@@\XFT'GSZ![6)
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M6(+T^(%N29O#[H#FQFLD7ZH[A&&R)*LE/2?&S5:H-DS+%VM0XOPVV*4!;*F
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*HB41*(E$2B+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g383770g80r72.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383770g80r72.jpg
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M 0$! 0$! ?_  !$( 1H"70,!$0 "$0$#$0'_Q  >   ! P4! 0
M    ! <( 0,%!@D""O_$ %,0  $$ @(! P," P0$"@<!$0(! P0%!@<($1(
M$R$)%"(5(Q8Q,A<8)$$S-%%X&24F-S@Y0D.VMS4V4F%WN+D**$1Q=2=%2&*!
MD4=46&.7UO#_Q  = 0$  04! 0$              0(#! 4&!P@)_\0 2A$
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M8;]E5C7X7:"^]&>L7FGWX+;;4A''SCJF!G)P)V_W\Z<_^VGG-&_U_@W@TOI
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M#C;@$H&!BHF*J)(J*J>E*UZ[PS#\FQ:9@^28IC60858UPT]AA]W15=KBTZI
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M:S_Z,^H3SAK/R\D3W^(UYTBCXF/_ "MXD9$JB:]'\JI-DG[)- 1B2DCH/O\
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M0+'_  S\S4.GH<ZLU#Q'U<\:K5S-KYE:XB=M$!NLS_<^<7(,?<J9(Q 3.?\
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M)<XQPO\ DJTK.Z4MJXBH*!4X2@A*=-<=CN#OZN[8?MR9(4TZ00.B6E)6DD1
M*R@$G) A5/;2\U)\:.L7-<+AR7"8,79>)SS!UO\ :)/-:>>4P$$E_FGZVGMJ
M2 J+\$OU+V'_ /J.=GN(E#/;CZ/^+<+R KB?9R^MN(6:R=(A%GQ97"GP4DDD
M"[>44#4V%JE(Y^Z[!7 ,V-VET$"&[A!2N3U6SWC<?(^602GX&[)P/6W$/BCI
M#-<JJ<>SW47'#1^J\MB69OP:L\HU]K#%L3O3J+J8S'KI]8=M43/L)).L/R8R
MLNG%8-SVD^N^Q?\ $I]"/;LH9X%]('!&[PB#P_C#J^!WJ5@H06PWQ5%JAU86
MM* +=UY*E&$*7O7.7O9KC=B"X_P]\MR?K&DEY(Y^+N]2D_\ R2GKM70J/)CR
MV6Y,1]F5'>%#:D1W0>9=!?E#;=;(FS%4_D0DJ+_DOKW)"T.)2MM25H6 I*T*
M"DJ2<A25))!!&002#6B(()!!!&""((/0@[5>147Y1>T_VIZJJ*/2E'I2H/\
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M6UHEI"<]Z]87R(0$@%9+=PN"0-;BH2)F(2D)J>X:2-14I1(R$*3O@@0I($=
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MMJXKWMY;)?R^]PRGAUUG/S[75$=B *GII$ C))\R,G'3H)Z;5.+^S7E3RO\
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M$PG5C)7]J!@JLUE?A<2-XA14?(C&_P"R"1)H$E%4ITGR'R$O:;<;O)PQH_\
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MTI4(.*?_ #^_4R_WT]>?_3GX$>E5*V1_A/\ YJJ;_I5-'I2CTI1Z4J$&!?\
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MB6'1Y'[]9K;7--AFM:-S\Z7$*]PW#<5!)/IT&W[\ZDUZ5%0AW?\ ]-C@M_\
MB/E=_P"!,$]*D;*]/S%6LWYFM7^67NHN(V!N<H-OX_/>H\NLZF\'&N/6FKEM
M$%Z/NC>R5UW30+NN(NYVL=;U.R-OLE[2V.#4M7(*\C*1S./Q/H.GG@4FQ/AD
M[FN2TFU.9F>-\FMDT=@S>XEA#M&>,\8M06[)(]$D:RT@_8W<*[R2G>Z*NVIM
M^VV+LF')!V7BUQA4"65!'4GD! ^9^>^>8$#RI9RR_P"?/Z9_^_!FG_TZN?GI
M4IV7_A'_ )IJO$G_ )YOJ1_[[^/?_(1P:]*@[)]/S-3?]*BH0<R__6W@O_OO
MX1_Y);]]*D;*]/S%3?\ 2HH]*4>E*/2E-+OW_F)W5_\ "78__@ZY]*E.X]1^
M-:KQ(_Z*7&3_ '>]+_\ EOC7I16Y]3^-2$]*BM+S+8N":\@%:9WE^.8C 3S]
MI^_N(-<LI0!3((;,AX'YCRHB^$>*V](<5.@:)51%P>(<3X;PFW5=\4O[/AUJ
M@$JN+VY9M64QG+CRT)GRF3R%9%M:75XX&;2W>N75& VPTMU9DQL@$@>9Q4&]
MB?4BU+2 Y%UKCN1[/GBX@#-]I_#L710)$-?U6YA.7,@P/Q$6H6.2 ?\ E!?0
M512\.[5_Q(_1UV<#K5C=O]HKQLJ'<\,046TI!)*KZX2AG0/ZVDNH(R%5Z#P?
MZ+.T_$RVM]EKAK*X(5=+U.D&/=99UG5!PE:F\X44C(@]L+F)R1V:,B*.3,ZS
MQZ61^W3Z]C'!NSC_  H-R<HFG*O6G&NQ21+K'J1IQ%(7(L?R%OU\L=LOXLNV
M?&._M>SC%GV>M%RE+UN#=7Z4G("KU\!D+*=S:L@C=*P17L' /H<X!9%MWB:W
MN*/)DEMWZMC5!P;=I15 (V<<5Y@XJ,E/@M/5JZ<2OCNRI4J5927VVRDLE+L9
M4FPG6%O)$3ES)=A82Y,V2]+17ILQY^28F\KLCU\M=I.U7:#CUPY>\=XO?7KK
MV5/7]XY<N.&0"&$.+@( 2D'0GP^&<$"O5^'<*X?PYM+5E:VUJVF-"+5IMD ;
M9[I*"2!."3DF)!,[W&@@UV$56G7U\6Y;XHS*;;;)57VVF6G&I3"]=*# MJ3?
MPZ\)]A[O$OD*2%.!:&P"III<H)"IU++BA! ,03JU"0"#!K:%M"L@8)S )T;1
M"1GQ<Q@XYYK*@RT@+%;0FV -?N)+PJI^:(/0-.SFJM[W51/W'FIA>PG@ GY(
MGMZXMN("W1I4(\(3I(!D3J0D.)(($@% 20, \[?=$[",DF2<#KN#)//?H3BE
M+?MRD&.VXV<-E/9,4,9(NHG:K'9%&+PVQ%57WS]_Y+MI")SW5;Q5LJ1XRTI+
MI,I!2LE(4)"BMSV=!!,0@$F9\,14%I*I"6X,^,HF2!UWG(G&D2,F(I>*2):J
MVRDC[)E?!P5:L&V'S;4D5GVW9E/$1AKI4=0&$!UQ$:(2;!T#PW64HUEWN$O*
M*B5I4A:I45"5(#5RX%E8!\4@' /B2:H+""G0(2(R2"8V$ 2-O"/@3O!KV+S3
M\E"<5AEIDD!'#.EC*\^V2)\&JSI"L,."J_)DCDA%_D+2>[BKM7&V0AO4HK)*
M_!<J4B%1  1;H1,GG@&.>,<VK:AI1$)D DA!40(*@8@@@[$;;[4K284QQ$*2
MKC##I(W[4^SEC)>;)5\B:@16&E:8,504^4-X?(%$6@4\9RS+"%)2RL+4G4XI
M3##:6TJV"5W+KBBO())S&XZ6C;I"M 23R_J'S S$R# /EC%11);W;@MR(K+G
MP+M)9/>_(0B$^WID@@1N.2>">?\ 7(15441D5,+9:6@$I*72$Z5IO+9HA*B$
MD*;;084L&2$F-*I,@XDV:U)PF0<@$3L9!Y8YC8 >5*FT>D.?LQYK42*?2)'B
MU##<B2!)\=/$I(S%(47X^"D(@_!1U0\1=NTRE2774JN'?$HJ?N7%M"2-)[M*
M&]:P!/BRF!DDS;]G0G$$ 3A, #)F)F)Z',S !S55=D2Y"HX<T(L8OS5Z76,
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MA1TIA>0N$I]HTVVB^X:JJ(K0.J-]JPU-ZR'E-(,J#;K=ZVHJ)(D"'0G8'6)
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M$!!!3$UJ7+]%XO!#8&$HZ]%(DR#$P,[Q$8JQ*?%CS_%77W/P5LFQ^X04'_\
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M$+D.4Q);(0-6R439,Q5!<10)4540T45Z)%3TI2STI4(,"_ZR/E9_N0?3]_\
M/GZF'I4\AZG\$U-_TJ*/2E'I2CTI7,_F-S)W%QMV-=8[281K23@W]U':NYL=
MRW(;?(["WCYU@6YN-.L)<[,J&"WCU92ZKPVEWX]E^1.1,GF7V2Q:"P;&RP")
M4)/R!4@ ]=P,>AV\\?\ NF'XG?4MVKOSD7K'4&28MJZ'1Y;BMY'LOX8CY"WD
M]Y.Q^BSB_:Y 8@Y.RZWAQ^/V8.8=&Q;&ZJ357L]J^R6N<+9MHC UT]4E( )S
MRB?/EZB?CG'.NQ&499BN#TDO)LTR;'\0QRO*,,_(,HN:['Z2$4R2S"B#+M;:
M3$@1BE3)#$2,CT@%?DOLL-(3KH 2J::;^]1QA_\ ZCM#?_Y?U[__ +#Z4KD)
M]/#>HW7%_5<+A1I.'NKD1M# \/ROE!R@SV3=4.G8NW[&CC.97;;FWQ91+C.M
M];)HY\E^)_9EK <SG8VL=K#LFR/4-8W$DQ%5J&3JD 8 YP#L!R'K]]='M<\,
MZ@,RI-S\E\XL>4F^J*3^IXQDF95$:DU5J&Q,";/^[_HZ-,M,3UH\RR91&\XM
M)6:;EL(2G#O]I6\,@BM*I)Y 0/O^)Y_</(5-;TJ*A#Q%_P"=CZB?^^]#_P#D
MKX:^E2=D^GYFD>7\S2R_)[O5'#C QY.;0HK!ZBR[+8MX6,\:-/6[1>S+C[5W
MDU6W=?/R*H<5?U'5NIJC8^T(KX-1\BQS$JZ4E]'4C;5(&/4@] ?QV\ZN85PR
M'),JHMM\O\\+E!MJ@L&;S$:.RHDQGCGINX:57(\G3NBBLKRI:OJLRZ@;0V?;
M[(VVP:.E49EC]9(2BC*3R&!]Y]3^0@>6Y*A[_K(J[_<ANO\ SXH/2HJ;WI2H
MS[SY8:IT5:T^$6!Y#L7=&60W9N!\?=2U YMN?-(K3OV[EI"Q5B5$BXSB$:3T
MQ:[(V!;8?K3'W%1,@S"K4VT-4@3Z=3M_[,8&]<SMO:BWSR:Y;\.8O+TJC5^L
M<HI^2CE/QOTKG.7,9-&J*_#<-E3:[=N_<8ML8E9G_%++T.%E.N==5&/X)$B1
M)N.S\NVE264F;(5(@!49,;GU$P/CN<X!$'%=G\(P;"M:8I18'KK$L:P3"<8@
M-56-XCA])6XYC5#6L=^U!J*2HC1*VOB@I$2,18S3?F1FHJ9$JJIK:O2E<E/J
M \EL(P7D5]/;7F'Q)FZM_8]RNR?.6>.NLK7%I.TIF/VG!7FMAE9<6C&17U!C
MV%8^_=99727;_-KR@@EC\#);VM_5(V,W 1E5I&%3@%._+WDG\C3=\4VOJ$Y#
ML_GU>U%MQ"U9:SN8-._ENM\DP[;^Y%H<@=X5<.)%;$K=JT.R-.Q;B(QASN+5
MMPBZMAH.6Q,CL:RPG4<NJAQ6?WU]?]J@Z83N<=0.9\C4SE;^I-%[ZE\'KSKM
M$5:[?6*^78H0DH_JF8^'@7;2@A.>X*H^AM*BQR5'AQOYY&WEBH>\L;KZ@#64
M<-5R+6G#N:^SS%P]W& I=X;JK&K#(_['MVC&@7SD[CW;G3TOZ>5J^_;5[5Y.
M^\8KXK=+[$J3,B*D:?%O$=!U'GUY=.=3"38?U'(W7WG$WAU/'X\CI.>.W_=^
M15/QC7'T^*MI>G$13\IP^+9(H>Z8*!*CP]3_ )1_JH_MDYVQNOON$.LY?2 I
M_P -<QJ^Q7Y51-&_XBT+AZ&H%T:>XK(DPOEY(\GV_I2!UCU'Z$U3^\+R]B_Z
M_P#3ZS27T@>?\,\C>/-CW^2B\C/\1Y5A_GXIT;'N^Q[S:K[OVSB(VJD#K\P?
MNB?OCTI+-Y9[_I([LR_^G#RG9A1Q(Y4ZIVSP&E0H[;9H)O&[?\R,6<]H@5'&
ME5D7"Z(76F"04.%*2D%2E!*0))40  -R28  J0F8 ().  %$_P#C46=Q_4]Q
M&RPC/M;V/&#DQC^0YA@N9XU!<<N.(V85-;96U#/JHBWUGJ[E=GS%5&5^8RX3
MSR$I,^Y[(//-.,CQO&OI#[$=GTJ/%>T_"+=2<*91=MW5P#($&VM"^^DDD>\V
M!S) K=6/9SCG$%#V3AEVZ,$*+2VD$<X6\&T*B",*.<5K^MOJ#OZZT7I?6^-:
MCLIV08/J;7.%VMKEE]%JJP,@QC#ZFCLOL*RD:N9ES ^]A.G$=^^K/NV"!Q/:
M[^/&NT'\3O9+AVI'!.%\3XTL$I2\[HX=:JC[25.AU]:9V!9050=J[/A_T7<8
MN5 W]PQ8A1G0@&Z=SF(0I* 8WE6/F TN<<P.3>?@3,K.AP:JDN$HUFMZP*.8
M0H*BH%=NR+3(8:-^Y^X3=TVV:H"JC9J'7@?:7^)KMWQ?O&.$JLN L**DZN'L
M!ZY"#.]S=*>(< (E3*&X4"1$5Z+PCZ+. 6:DKON^X@Y@I3<$H:F8DM,E*2DG
M(2LJD5')ZH<LYYVEY+G9'=2T\Y,N?9R;BTD"B$ N6<^P>?LI;:]EVKY$)*JB
MVR9)VGS]V@[4]HN.O.7'&>,W]\HDJ[Z_NGGU:A*BVT%K(0,RD!.@*)@&(KT[
MAW!^&<-2ENSM6&$""$VS2&6^0@A"?$H1XBI1D0%'G6:;@C'($(1*2O@K1$+T
M#[5M>_$Q%YH6$\>E001TGW^D'S]L5]ODG5AX$%9T$:B5]XK4K, A!!,P!R3U
M R:W2"H%*4JC/()Q&T$# @@"><SSG(!TRZH1S;>FET;LA2;]\&_A5+_ 37>U
M)%_:92*J*OD1"B*:EA/6Q6$K<<4E*1"&]'=MZ2!D),+6,9(4.8!&YRB^I(T!
M*<GQ+ E8Y02# G.8$_><@'3JJPTR?NKTX])=C.NO-DH_Z0G/TF$ZKY]=-I]T
M(-]"2]-BVV>*JU)25:TN$3H1W?=@",Z2XX\!&,X'6<5>#C:28*QJ/,]#@F!,
M;^O7<E6;AA_@P>-L?A7B==;00 _(E7JPNGT*0]\J)>R2BI$\X*_@#FO=M.[4
MIQYLZB9 U%^4F8$-M-Z$H)\.25ZB?LU6EQ"_<< @"8\.).,S)/D-\\S%\7P
MPBPW8C*(**X3$NM:=:;Z3\ *)7//_</>)=$+IF ^;Q?G[:.8Z[%H)#RDN%U4
M=WWP>)]2AY]I.F( ($F/%@S6253&B#C,>+;F=,_(D20,<J5?<(Y_@XRR8W@
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M6O>+W7U1]P7._-\4#VW_ (\1)E!5J&^J>(H^T",RQ\0?0T< BZ-AI-J EM*
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M;P08JXR^R:E*?C0Q[%49$J>?(]N/WY*XJJV"HZ_TAN=J*@ M@J"0F1X[E@"
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MIS\7"PW7=Y&N\.XW4]@RJE$R+9\'-ML_;N.,O:IUC=LQ+EM4X$<S]P\O/SV
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M$X:M101 $112_P @!!;;%?P#T%L-!/<RGF$H,0.H*E$G$DD\H@9%2;V?=?0
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M(R>FPU7[6T86+]N<CZDX)QVTXU;I6T>ZN4)2;BU41K;40)*9RMK5(2L 3$$
MXKL. =I^%]HF5.62M#[1A^S?\%RT 8"R@*\3:OLN)P>>DXJ5']UCD1'[6O\
MJ4\MW4420 R#6' :S$5)!(2):KACCCY$!HJ=*\@>T9-J'N(#P;RNAD=!]_ZU
M7^[SRZC*OV7U!LZE)Y?"9%QUXYV'XJ'2HJX_AN)]D+B(;1(@H(*3;@/$HN@I
M(Z?(_K/[Y4UG&3%=IXA]0#EW6[<VS$W'D3_#S@+.@9-#UY4ZU"!1N;H^HY'C
MT3E)37%U$FNQ[&+9V*VY2&'G@M&X)11;KVWGU28@0(RKG/).*Z:>E4T>E*X6
M?_:+]:Y)L;Z7^SUI]DW>!4^([%T;?Y34T4!A\]A0;3<>$8/6XU;3W9;#E=3T
MUWE\#/A2(P])F9!A^/-*]&B!+&1!, GH)JMLPH&)WCUC>NS6L<8R'"=<8'AN
M6YK/V1D^)XACN-WVPK:OCU5OG%K2546MFY9<5\1^3$B6^0/QCM;1J(ZL1)\J
M049MEA6V6YJBL)N_5-9O#4V=:GM[-^E@YO1NU*W42IQZ\F4TH7V)M=;PJW*:
MJZI'IM98Q8LZ&[)KRDPY3#4VLE5MK'A6414@P9_?[_9FH8Z)^F;J/0.R=-['
MQ7+\DGS-+XE>4=0Q-Q355=>Y)=Y5%S2-D]QF&Q,<P*FV-D>/6TG8&17[.M[;
M*)N#TF4#1W=%55QT,","DG/G^_RWWZFIV;$QS*LLQ&SHL+V%;ZLR.8< H&<4
M5%BN2V=0,:PBRI;<>FS6HO<<E)90V7ZQXI]7(*.Q,<DQ%9F-,/MJBHO/\=>4
M3RBK?U!MOQ4%%148T=Q5)#[_ )*7W.G)"HJ?R3P44^?E%7I45,CH/O\ UJ,'
MTHN)^J<:XJ<2]]Y"WD&UMUV/'K7JT>QMK6_\76NM,>N,4K"<P?3E2Y&BXQJ7
M$&H_A"E1,%HZ6WRAIEJ7G5UE=LA61*E1R< 9.WJ=^M==O2J:/2E<<=6\K:K7
M?(/ZA.HM8Z\S7D)R!MN8M=?5FJM>1V8=9044OA]Q(I(F6[:VG>?;:]U+AJW%
M+;PDF9%;2,MO'*>ZB8%A.;7%7*J!55&$DX$'/Q.W7I^) S4BH7$/.=]S8F5\
M\\VIMHP&I+%E2\4M=C:U7%+$I$=T'X@YG M&XF5<F[V$;;1.V^WV8>N#F-,V
MF-Z2P^S928:HF-L>?/\ V^&<F214P,YS[ ].X:61918P<9QFE98@08C#+,?W
MR9:]B!24E8T+:ONJVT@1(4, ;9CLJZ2LPF'G6]=Q7BW#N"6+_$N*735G9VZ=
M3CSIC)PE"$B5..+/A0V@*6HF *J;;6XL(0DJ4HP /WM7!W>7(_(]F[BE;6Q.
M5<Z\?77CVIX#./WL=NUGX<_DP96^W:3&'F7FK"7:QV''OTR3%CL0VOLW#EM^
M](?^2.VWTV]H>,+=M>S*E<#X6%*2+I)0>)7:)("U.N)/LB5ISW3"0Z#@W"@8
MKJN'\-X>W"KA2KAT[)TPRE49$ZI7$$ P)4!B*C#)@'*==G6/E82)3IFX+C4M
M]Z0\Z1$X3[C227)K[BD1N./DH](KG0^)'Z\.N;J\N%NW-R]</.NJUN7%TZ]<
M/+4=U..O*6MPD#2G4LA* E*0$I K?H6V"$-A*0,I2D0$C?G_ +YGSJQ:XI47
ME:]6W<)^3"DJPBPF3N8*=L/MR8[8.L0F)). \PV2JCXAT'BHBTKOG:M[MVU?
M3<VKI:6&U(U]VVN-8*5$(>0MLQ) UMK F4@&"+\I*="TZ@=Y,3F1ORF,^N]9
M\8SC(^Z^#A(BHH-*TKH-DI![8BCM:/NO>?2"9*GY](T(JO98*V$N**D+ !DJ
M,@$J,E2B1 23OX4A(W $8RD7BD!(6G6H;DG3/P@F8\Y Q)S7LXB&OW$R+\!T
M0-E&;46D[3^I6A;1UY5^$5.T%5\&4[[<<M*MU A)?R=OK@(D1,1G8GE]V+AO
MA()9,B/M#D?-/^PC H2$#G[LF,ZVV">8,^,D1!![5''?"8(J?QY"BIXMKUU^
M8H7H;8@A/?3,?]>#C'3?F8C?.:GVI*P5*;("?[PQOOX0-MS$SN:4,1VW40W$
MDM-=]M,D%GV7\B1UWQG$J(J_+;7BGBBH;B*?B+=HM*"E)2I"].Y4]!@GT,=2
M)F<DBLANY9TRI<2,2<CD<_["KHH$E>_<E_;)_)%&Y7[@D3Y)522ODQ_D/\T?
M^57MKQ\[:;>/L-D;?VQC$1]DQOC J?:K:#"S\M\CECX3U//:BN-/FH><U8P*
MHN$#=_\ O$G8DRG@1?MBJ=.JG]:]M?R1Q/5)MR9 2UO&751C?[.W(S&^*CVJ
MV@^,^6,C/J!\-^>U>B>]XE89.4( B(^X17S:C\(J1P4A1!,@5%(T5%;;5$#H
MS$PMBS2))MIR=)*P0#S("U-@],$XWY5F)OE$ )?3MD'&#@9G/+!VS(C)#?5%
M2,T\K2H(>9??VH"PRJ="@BJ=>9()"VG2H"(IDBH* ;V912%>S P=. T<YS'?
MB!T!&-MHJ3>+YW(&^SHWGD(P,']:JX\#8MQV)#8FH?@I6]DHLM_R5P_).E7_
M "%#5%<<5.UZ0R%[/ \5N4CJ6T*R?\+ZE#;>(ZD4]L7/_P!R-B2"Y'48)3UB
M,&@G&66A::E,DX:]!_Q[.[)57LWGE5/E![5QPEZ4E7P'\S%%&W2"/J2 =CW2
MLCJ/&#MZ GX5'MJO_P"Z_P#^H_TU[5UB,TG4IMQXU3KN]E^3[Q==DOX*@_"=
MD2)XM-!\= '7J!;CDP3//NE&3U/UF<[XH;PJ !N9 S_:@;2<8_"?3->T?8C-
MFXY)9-PNE,AO92DZXOXMM@G2KUY*C;8JI>"?)$7Y&MA5JX5D)04I)G3W*NDQ
M.K(YC:)C&]92+]O2)(4>NL&8\PD;;;=*J+T=D3>>D1?<)$5POUV47BB=J++?
MQY$ =J@H@^1F1$@H3BHM/LCP.DH.DQ/U)VS ]_,].9V\JOY@U/G_ (A/X51N
M0P/D^](C"9)VHK?2.F&A^4;[1%1%3Q\W2150S_S4 ;01M'4F WC!T]RKXCW\
M1F=NM/;VO+_,/TKVU)94EDFZP)$BHT*WDL%;9+I>R3K\7'%1#/M$\4\ ^/!5
M*A5NE8"0-1G*>Y5@XE \?S)&T54CB1;.IK6DQ!*7(!WQ&GTYU[:EMODD@GVO
M 45(P+>3/Z511)]>T_J=3X#_ +2,]I\>ZX'JE-JV)"1N2" R04JYQ]9N !&T
M?&KO\V?.275&3!+@@>IT'',SY'I51D"^:.K)C(P'DC(E<S%1PT51.0B_'8_]
MAGKX(?)Q/(7&U&A3 08DJU;:FU2(\M1]8)!&<B:OB]<<"5./$$\N^!@3,>[G
M.3^6:\^Z,AQ.WHQ,,.?BGZG-<%UX53LO'Y11CEWTB_U/)Y)TK0*M/<D$:4D@
MF" RF)ZRH.<NFGSF*K5=;0\?BZ-CYZ, [9WG%>T?8?>\/\(XPPO9=C)D(X\G
MY(VBHB^3;*HAN)TBJZ@-JO[3H+4Y;J@I0A0"MRG0G:8D(;1J^)Q\3-U%ZT@A
M2GPL\@MY)1C?4G2-7+H!GGM[?D-R3]E&8BL-JA/^-).>0B^"!CL"15$DZ-[K
MKL%!M447#0;7<:<.:@H8*5$I..I(\6P)P(VS)J^CB84"IMIN,B00)CR@CT!^
M5>2(9+A,!'A(VG12"3')C1*A?(Q_-UWY)Q/ESOY%KI%1%= D>SMI()5J/*'"
M-)W$DISC>(WWR*&_<@>!L<P8!C;E'0>N]7C57B2*$= #Q0GW(]:PT3;2]H+8
M*\\J@;R>2(J(J@VA&G2DV16EMD9U:Y.RG" .GNJ09^)@22"=KK?$),.I"41'
M@!.J"!I@$0/M'TS2IQY_H8[/W[8" HZ;8T[*,L)TB"'D72&:(H B**MBA.(J
M*V*%;+24@J5!U""$RX?%D"$I6LP09*IP)DXG-;>;=3+)TI00 IP%"1I^Q.0<
M==XYT%8$2C#9FM-IX(AHMC"9.-'3H4$1BQ"07#1%;91%_#HS3M&T$L<VB1*T
M,B3D*+1VZY 5F.8!P=JR?;5#P+>;2D$>ZO) Y:B(@\O+$[$!2$Z"+#1WX'HW
M8\VYE?;LHG78BPT@>9=*+2*O\T)Q!)&U$K1LE:=2^[03D$M-C4)B3J<<4/,%
MI1/EDC)%\V8#0U ;G4E7+)U0"J3N8]:]J1(B1F&P%H11'77XA=QV>E1$1RRG
MBJN&J*+:* ^/9.E\(@G:<M&T)#FI949C0VV!.R=/=M:YYP!N#. :NHNKAPF2
ME+0V"S*<9S &)QF=A\:B^*>W&@*RVK:)[CD=*T59:_F@@$.'9&3S@]^*(2$
M]O&JJK8NX*K=,%:RO69@K4Z M9B9:A !,\TYD&2<UG)O#J (;(QXFYD_X5'8
M^8! /I(O.RU5 C-D[% $$3>63-91KKQ7VQ;?*G$GR1?)30E4 +S)4(@\SEDI
M*0H$*G$Z$)2#N)4L$@9R0H1@CG5]-V-12HJ2F 1)[Q2CM R-^74[SS3D:.@K
M,<1*.UTV[(]DGT1$14)J.ZAW2HH]*)N?"-*BBBJ\B^WC*:6@P2@JB820H#)Y
M@Q,Y@9&T1BKZ' X)&J)^T-)P.G,"0.?*1SJC+S!]A'2,$1I%\G62KF^Q!%\F
MV52'7N@B==&\BHHI^+1*?;C4%"R !!<,P(!)$;^(&2#N#\1F*O)4$G,Q,G)
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MV@9P:UJ[]U;JBY"D3(1L$0G[&\$Q)]3M-)GI?W:(H=K$ E%7U<*4A]HO:,3
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MNOCD/77[3-@0E^2$ZX"JB7)4TI24M0K(*E!2E#)$IR #G<CY'>REU*R84@$
M[D#<8B1'+IC!JA!\*$5MH&E04^Y2.PC(('XDC+Z,VK9&'2IYN2@9:/X53('!
M&MEM.K6\M,<D9*E9$ZTE((2<[&"<15IVY0 4M*"B9!6G.GH4G )!!GX=<^%5
M([?D(N2E=)5$E7[SWC .E(WD<MF6@;14[<6'&;:'Q%$$? /65[.E]7@08D%2
M\H;",X2""%*$@B!.D'.#6&J[6R"HNJ.(2E49)RD @""1)Z&"<YBJ"3P^<AQ'
MQ140&0)7(+2@O:KXLI-B$8I_WTFLBKY)VV$?R,?5Q5F6P.[2%G5IU$@0F"/
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M >GF"[3_  DEI$3M![57GO$5: _P5ESRE-Y-IP9QU N7V=2$+A"2""H &#(
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M8=)03IQU3,&R0C+R,OE.U555%^/5EVPN7'#JLW2G4!*FI2(,$A4%,2#$9G$
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M)VJREYKNB\IU#;:1J6I:@GN]61JR-SB0<D9.]!&[(\'7D$&C5";;)%"(ZI_
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MS>I!*8<;;$0KQ9#@.X.01N#)B,G07O:5Q@KM>'N!6%!U\C^R/]34D@DQ"B1
M2,22:U]4_J4U7R4_-\WE)'/=+^3LIP.R%\OGV[-GS!U$Z?7R 5+IT(0TA+;:
M$MH3@(3A( Y>8D ^( CXXY):WKA?>/N%YXDJ4XX=P3[T_8 Y0)/3-3+XR<(M
MQ<E)\>=6UCF*Z\26*6V?9#%-BN-MLD5YJC@H34B]N1Z+V9%4OZ<#WA^H6$1$
M:1;#EPA!A("U02",I'K(^[?&?+VGZ-_H.[4=NG&;ZY95P/LZ5I4OBEXR4OW+
M8R?Y5;.0X\5GQ)N'$HMH(.M1&D]A>(VBL*XZ<WN3FML%&Q=K6>%G :XM+.UD
MI)L;N_F[P^I'%GW$U11N.R[)8KX4=N-#89C,1XC("!.(Z\[@*45J*E&2?W \
MA7Z"]DNR?!NQ7 K7@' F7&K*V4XXI;SJGKBYN'=!>N;AU4:GGE %6E*&T@!+
M:$( 2.I'JFNDH]*5S=Y!\WM>PL@RS2M+PSY:<T Q^SC56PH6I>.U7DVJ*>^J
M9<.X:IK'.-VY'K+6.67=),CU]@Y!PV[RY^CMF8C<Y:ZUC$W&54!MX@G>))_(
M&/C3_P#'/EAAW(QS(::+KC?.F,_Q*- GY+K#D+I_*=69A7UEH[(CU]O5S)[,
M_!\UII,F'*BE;Z^S++*Z'*96-828C[K#;JH(CF#Z$'_U\:E'Z5%'I2CTI1Z4
MJ$/TT_\ J^^&7^[?J7_P?5^E2K<^I_&ILOOLQF7I,EYJ/'CM./OOON TRPRT
M"N.O/.N*(-M-@)&XX9"  *D2HB*OI45 6SYB95NRRGX9P/P>GW8]#FRJC(.2
MN93;&CXDX'/B/%&L&JS,*IL[[D+D]6Z+@EB&DFYV,C81WZ+--M:WL/$_3TJK
M3'O&-L;G]!\<^1J&7&C2>$:JS?Z@W)SD+91>0W(/3G*-Z+0;/S"D:J*"CO9W
M$?BE8PGM5:F8LY^"ZJM;";D\3"4RC'6'ME76'UF/4F9; RUZN*?(Q+^\:X?9
M75Z\8:M67'E=3H22$@2)4M4(2)$J4!.:QK^\;L;.XNW<-6S#CJA(!5HU$(U&
M)4M4)2-BH@ 2:@)D>37MU96V17EF$JUN;"993Y9MH+LVQLI+DAYUPWWWT4WY
M+Z]?BB#YHB)TG7KY,XA;_P RO+GB-TIRXN+IYVY7&N-;I)A.J2$!)" F  @)
M3 2D)KP97:2\O;LK+;7>/N%2B')2D*)5I3K A*00  9$0!S&$6;'A1NWKL%]
ML%,R]ZN$GG%52-4%8Y=FZXJ])\]J72?Y)ZUOL25X%NHYU!)U8CGE,&!\]JSC
MQ-29^N93&-T*.#YF)._D<\IJC,^&PPGNWK2&B$[(,)==XDX79NFB>T1**$I>
M/\_$$04Z%$1+W\O!( M5@2-(()"9Z:2(D]!BB>*K)\-PT5>7=))CU\O/K5V$
M^!@K@VKBNR%]]P1<@&H^?2 '7VY+VTT@-?!?/M]IVJJJVU6;:)"V5B%$*2-?
M7R&VV0!TWJM/$W5D1<-+)P DMDD^6DZL9V\P>8HCNRR)Z2,MPT?/]GW&&%'[
M=I5%GKVFVE43[-\?GKI]45.T[]7_ .76RTH"4$$Y*_&2 <Q*DIVF",#SS6M>
MXY<I=6E*&UH2=)*DK2LD8)!*YWV/=Q'4":]L/SW'WWB<BF+?<9E5C."BH*HK
MYHJ2E_J=_9-.D3N.BI_-?4*X6T -+JTJ$F @$<MSJ!(,1D<L>=">T3PPNW;(
M)V"E3IYB2 0>6,?<:]C-EN2518\8QBCV/B^ZR*R'A^55%CO=$W'5.NE^1DJB
MKVB=6SPT;AXR-O F)^)/[Y5D)[1H \5L0#$A+BB2"!_41G[IQ(Y#M@\Z^U'.
M$A(TGW3HLOMN)\$HL"JO-L?U.B3O?^1QT1>^_5H\-<& H'XE()&Q@#K)Z[9Q
M60CM#:0?J7T3&0$D=))4[/*, QRS7F5)CR":CE6N%[Q*;OD$(U]EE1-Q%)7_
M )1QPFF2_P!H.F2?(^K?\M?/-LDG.521T$I)SZU=;[0V)!!<<!V&,?#Q$\^4
MR=O*DJ3%%L66ZQP2DFC**VU!0A#Q4G311D(J$#*&H+_DXH)_GZ?RN[@_5R20
M))&//)Z5?1VAM$R _< F,%#J-I_JTR/0&!O&*J[)BMMB#%>^+KGBPP@"P*"2
MHJ"J(DE$\600G2%.OP;+_P!_JTKAKH2264B!NH@?N.E9#7'+5U6EN]<)C41J
M5 "8QT$[8]=A5PGF8L=!:@325M!;:0I#7D9DJ-MH1+.5>S-1\B5.T[4BZ^?5
ML62U A2&0 /"=Y/^7X]/6*O#BR3DOK C "E^6^P^(!GX547&HL9%*)+=($_,
ME?:\W7G%^>T2:J>3SQ?"?T^9H/?\D]!9+,I*&A$Z3&\$?W>?/YS4#BR<A5PY
M F(4LG/QC\=OB?+9"PP1.P34NR>=(WP7S=->U$$0WB5._%ID%55\!!M/\NGL
M&F5++.D)YMI5\ 2B<<B<;>8J4\8=!#:;BXT%2@G2HH$J,ZI2L$R)DQF9-7P3
M[6.;LN'7MJ2D\\3DE7/$NDZ;%"AHBHT""T""7Y>*+UY$O>"Y9ZG"4*VU>%+0
MC<#"2(A(P(_.MVWQ)24)2>]7(&M3CY/CC, N$@',2D;<MJLM/166WGG2IVW7
M%1UT0 )+@CUTVR@M$!E[8IX_@*^;JF2)V:HLBR60$Z5$\R!I@#<Q(  '3H<=
M*5\6,%.B9($]Z9^,$G!GD3&!YJV'R9$W7>A<<%"-&JB0/@">7M,"Z;AM*H^7
M7BBEYNN.*B>)B*8CMHI1V4 DG5JU)D"=)D3(V(Q\IK8L\5;0VE!<1KSX HJ!
M))(!) )WG(P30LMZ,)R)+S[+KG7X..U3:BVJK[++?0ND1*I?/BBF;IJ@JJ>V
M*6 PRE,YD3G6LC?8 I@_J9K,-Y<QX5MI2J#ITI.#B3ON,QRYYFJ$^K8+(E*[
M[SG0@H2K(P0?YC'%6&X<52_F3AJY[9'Y$1^T ^%@H44K^K<" (E6$GR$&">>
MPYR(B,]+J/"GO4K60"0!D$\H @ =9]8JRLI&%0S%J1(?14 31'1 /@O;&04F
MR;%MM?EUTFT\R7Y%25MH<%QI!PY$ :DI1.HD28!U "1B9F>G+86Q490@>*94
M=M*>LQ@#2><]-Z1E.=;5PHD?WW_#IYU8[#<=M$55\ =89CN.>'QV+:^1%TCQ
MMDK8IA%*$R<IW/O$P!)A4@09&4Y\S)K=,LK6D2I*=@%**@5D\D$!2B1B"8'.
M9FE3$._>\2.6U6)),6T17"FO%VGD:M')4F@;!L2-MAF/.0R5&U<%X_(M6]=E
M(4M#)6I/A2D_;G^B3H)$:L]!SS71V-G:I6A+KLDR5'5[J0,E1)F.0,R#6UP:
M.(T^P"-J\]X*](LI[;;DIQIE0[1MA41J*+CI-$@F/@ "\(Q6Q\D]:*_7=+0%
MW+JDEQ00+=H%(@9!46X*IQJA,3.]=3PNXLT/%%FPDI83K4XXE)!5/@&M>=,!
M9()DPDD'EF2L(ZS02,A37([9.NOJ:^!.NJ3+'G*)#]P1#[M$;CBXVV7B* TB
M)UC-<%O'FD*"!:M..:I6(*@F I0; *5 @CWHF-C!B[=]JK*W?=4[=&^NT( 2
MRV2$ JDA)((0C24CW"?/E-KWI$N9W(>518C)^RUY,L_XESX\Q%?)Y/&,2$CQ
M. JKV@A_+UM6^$VELVE*FP\X3*UN@+22#*"E"PH)*2"01UY5SR^U'%[M3O<N
M^PV\%D,VRE)6I)][6\ E9U YWS/E7L11)8H"( L12'P1$04^Y=!0413X14^U
M<3M$[3R_]_JB[\+*&P !J)( @9!Z$#EM$=*HX<"5NK.<:23DE1(43//SG<GR
MI6TOG+8%551:9?=).N^C)6VFU7X7^8&^B=JGQY?_ (4U5RXD,I!F2YDP2"-*
ML2)/0P<8KH+1,N+4 !I3!. 9401!^!I6^OG(B!_)!5Z2O?:=BVU[2?SZ_P"W
M) D7O^8]I_+M,1,D:AD&1"2%*,\RD$J '.4X, @&M@0I)$D@J&H*,I29Y:U0
MDGG@F?/>D\R9%0HS+DAAM') $?F^T/B#"&^BKY$G2*ZVR*K_ /W$Z7_-);96
M1*4*)3.R5!4@$R"0-CC)!QM5!=2GPJ6F-A]8F 1Y!7+TKQ*L8)@VT,ID_N'0
M9567$=7V^U<?']I2+\F6W1^$3Y7X^?4^SW.A12R[("AJ$ ^*1,A4\\QY[BI:
MN;5+J.\?9"4D%25J$8&<01DS'WU?F6,16" #-3>466U^VD$J*Z2 IBGLKW[8
M*3JHB+V(+\*GJS[#>A)6;=T(S*C$29$Y5U//G-;8\5X:3H1>,E9)TH2HS$D@
M8$"$CJ ,<JM/RZYEE5"(ID(BVR/Z;)45<)4;9#O[7H14U$>^T1.U_E\^K?L5
MP<]R8G<ID8ZF#_ZJZCB5L!H3= *,CPK,SR."!.0?+$Q51?@0XZ>+4T48:_(V
MH,]DW/ ?DNV66Q4W%15[1?DB[7^?JPY:+==DVZ5[(UK0"H <@2"  <CQ0-ZO
MIXIH&+MT&9$..#,XV(Z>L17N.\TRR1%)L&GG$)UXS2P=%'#12+Q^\:>! ;3H
M [%/%ML4^>D]2JV4%D)9(R,1X) 'A(S G!@'&?2X.**69-TF0K 6E2Y*8.YY
M&9@F,U6--4/<D.63'N2?!/;L&F@-MD4+V61$5A$)>!*;B*CB(ZX:?R1/5"K8
M"065I W!))YGEIR#,3M@ @#%]/%)B7&G"#@A.G&!$@>6]6?))KWOI'9)ADC1
MIV!(6.;KGP)R#%%;!P1Z5ME"D$BBCI^)@Z"I6FUA(7KG4,(<!<]200H Q$?/
M.*P[KBP>/=E)"0/$1X@28B),0,22.E69$CR5&/<_-"3S<GM)'<8[7H09G,H+
M0R#3_1$V+K@(A.D??@)WVT)*@I:5!$$H,ZM2QD"51"3L9$F>=8JKU" >Z62H
M[*02#C83T.<CIO7IQUN,SX/+XLM>"-M3D[%"7\6QC3FD<4G3[5&Q<5Z4Z:CX
M^!+ZO>S!UQ*&8&I0"0E,A$[J4%!((VWD^1D"L/VXM KN5!;8U*>693IYB2""
MI2L@ [G%(D,Y#HD\)&O2^S#E$B/L GSY198JJ..JGB;KGF9 2@"R&T#S+:,V
MAM$@*&I:R=;VDA!CW4)2 "$@$*RGWL9K2O\ %D<07]4HMMMF&FS )YZR9*BK
MH).D9!!W\R99K_@VU609"ANM.]#,A-*JC[K9JJ=F9(K<5PB12<1QX91^SUZR
M&.'I><UI1X$JU$D0E1!P.A!!D @".6(&ON^,>PM*1JU/JD)$DE((,K5D!0'(
M&8403(((JT8(RJ!U)C-IT33W3<F.(CVB>1]*J@B"0H\H.]+Y_<+^/K+<M$E9
M2V$I*UZ4I(*1))(0 ) V@ P  >< :^UXHL:ENK)205+<$!?]6I>08WD DR1
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M<U]^?19_#QPO@+=IQOMJRQQ;CFE+J.$JTO<*X>M201[0A6MOB%VV<:U3:MJ
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M]L>WG$]M%$OMR_S^,6ZM>Z"4%3:5*@^ :I!Y&$CF<[Y$5E6?$M9+BE..$3I
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M(U0/+7/LJ(UJ6=""G2@I)4HGER5&V95@=*Z"RNVI0VVDJ=*07G"1I0F-S_5
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MWMY>>25N)U1K+BX!!R))3@;8Q'*K\68^Y[SS<< 1YXT I#O9HVS^R'3;(D!
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M;5'6R_%B8R/0]H/2B*HBBG\E)@E05563%5VMW9*ME)!.IEU1+:],)21(*3.
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M I%)%=!")(]FXWV)&/P2*D9%\0[\U![LR1YD6C7/X%V>]D4GB=RWK<>0H6I
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MO,M$BOQFV]B9&V+2BJ)(%!;OO$14G&W43Y4C==[1!%%7E4WO:D0!QN\]/:7
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MRK0P&1]\VX_92R,O%XQ%U5 8S:+X-*X?XN=_BO\ EVOK,:[*$A17>\Q[C6J
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MAB!)SX1B< #%>;V\6R?C5KAB$F"RDIU0Z%3<>/Q8D@/7X$R#:^8*G0F^BH*
M0HM/9KLZFU5?W+B0JW? MK91)*0A*@M82L&=044RJ0HIA.HI)!N]J.T"KECA
MUNT2AU!7=O:3$E*2A!4B2"E2=1"3X0H Z02(O0;!4;62J@#\0262*JH@;7CY
M'\JA*++P@I"2>7M&'2^:MFA4\2X<M)+."X5'N%Y3WN90@%/.<0/%.><F.&<1
M;<;[\R&\)>3(^J)'B40HQ[IF<B!SC&I.V_ZI*.::D$6:XB,"J].0" ^F6_\
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M7MK)I##QL+9ND"HLAE A,NCXJO3K:*W!)54'%0T\21$!T0'I ^)'9=L^Y;W
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M"XDJ #>H?&,C,3\_*M:[VE4VXM";0*2T$A2@LD QD3,=>D3ML:&LBF'(??\
MLHQH*!'#N4XVBJTI$\J=17%'MTD;).U_)A%52Z1$@=FB9 NQ@#(;$&<[YG[X
M@0*N+[2-I2@KLG!W@F ZE)(!Q_::>9^R3RG,"EL>WFSGE?&%'!(H^T/G-<02
M=?\ !P_E("_(-@UT72)T\J(JKY(F!<<'-NLM*>2I:?>CEM&(S,[3RY"L]KC#
M3C86+:Y0'%*" L)*B$Q! 2)&^9QD 20:S5<_:3YP!'C,JZRG@TVTC\XG)<G]
MMIML&VXQ$Z+2DA!WVJ/M_A^7SJ[VS;"0WWBR2?$ C(B""#M!SGX=*WO!EW5\
MXKV/A]Q=.J);::MVW;A9))! 0TDJ4H8! !,QB<&5>J^(?)+;=@R='KC*8U4H
M*07>31#Q#'4)X?$G6YUHU!.:TRVA 3<(+%XTD$G@:B2>M5<<-[_NTAM*T^\Y
MWNQ(./GN1T)CF*]C[+?1?](?&BMQG@K_  AEX!'M/%@OAR4-R"7$I>0+E0)$
M0VP\H@^Z #'3+4'THZV ]%N-TYY]^0-_EBF"-%#@@IN"9A*R6RCA*?!T0:!Y
MJ%2P'&S$_M[$A)#6L<$97 ?7J;$?4MC2W ! !/O$ $B,8Y]/>^S'T!\,L!W_
M &EXF]Q:X6$ERTL]5K9 I,A*GU?\T^,#4I(M=1 \ &*D!PYUYAVO-_<Z\4Q"
MDCUE+AFV-/4.+LNNRK*334]GQ@TSD]E6Q+&S?EV00I^16]G>2XWW?LOVD^5,
M,%>=(EVC%M;VR0BW9;:2!$(2 2!U/O'XDU[CPO@G">"6Z;;A'#K3A[,93;,I
M0I9!("G7(+CRL#QNK6H\S71'U?K9T>E*/2E'I2H0ZO\ ^L&YB_[M?!O_ ,:<
MU?2IY#U/X)J:\B+%F-$Q+C,2F3\?-F0RV^T?B2&/DVZ) 7B8B8]HO1"A)TJ(
MOI45I%GJG5UUY_K.ML!MO<\_/]3P_'I_G[A(;GG]U7.^7N&B&???D2(1=JG?
MI2M L^*/%N[\_P!9XV:"M_<]WS_4].:[G^?O]>_Y_=XX[Y>]XC[O??N>*>?E
MTGI23O.>M-_9_3YX$72DMQPAXAVRGY>:V7&O3,Y2\P0#4EE86ZJJ8(@$JKV0
MH@KVB=>E3J5_4?F:@O&^GEP13G_?8=$X>\;Z?$F^'>+9*WC..:>P7&*)K()>
MZ,PJ95TS58]2UD)FTDUL.+#?FMLC(>:C,HXX2M@J*F3!R=QS/0_H/E4Q/^#;
MX0@O<+C_ (U3+Y>7_)V[S3&NE4/ NOX?R:MZ1P>O=%.A=(1)Q#(1)%1J)Y_&
M!/SWJ@_3GXHL]+ QS;=*HJBBN.<I^5>-**H'MJ0KC^ZJU1(V_P!MPDZ5UM!;
M<4@$1123MCY _E5$^GKH5CI:W..9U,0H @E5]1?Z@,:.*-JJ"BUY\F'JQSH"
M5I/>A.>#?BC?@K;:@IJ/E_E3^E5_N'83'1$JN0O.*J\4% 5>:'(+(%#P7\%5
M<RS7)5=4150+W_=]Y/SD>Z\B.HI/I\A^0KG-R*X)2G^4.O-6Z_VWM'*KW:O&
M+E#MRTE;DR]G,I%GE>BMG<-L-PZL9R%RFB7-7$F8]O7-XDV4_*GR)$YC&GY,
MD&:MWWM7>\'X??.(>N+=*W6Y@R4A8(@I< @+!&,Y\P*\X^D'L!;]K^%W2[!3
M/#NT2&-%CQ(MH*5E,J3;7@*%E;+D:$O!)>MB0XT?#H/$W9.N+;6UQ>8W98V[
MB\B'D%B_EE([ 2NF,9)(<0)MK.8$&R.5)>579\GLDD//#;B;HOO.L>B]@;KA
MUKQ)5I=([M;S(:LEF TE68:D^ZN!I01$C2F>OY??3#PKM:EQ]KBPO1Q'@JF[
M7B%M=N+7<IM64J5;):*]2GK0:M:' 5-K:A39T0*T>-*)5\''/!^.GNMOKXCY
M"/:(]TJ=>0=^,@.O$O+^2"\@IZI>V:?$P\C6@RW)W4H_9"L'5J(&H1XLSO7A
M%I=%"V[A!*5)4G6D[%0W!2(F0#C/GFM4_4W9\MZR%1;ED][B)Y$H^UXH$<"_
MFOM/1@;0T^50E5>T<'M.XL. -6O!V>$O)25I0'%.#P@/+!4'$XD:04H4.902
M9,UAWU^JXOW;L'WSW:4@'+2("D">DDDP 3D#2<Y*VM$.N:*(JH_+,X\AI2$2
M2.VGG-CN=HJ*A( ,B7P/D\V8DK9]'H^%=GUW?&4VMR-2N':KHB("EMCO&0DQ
M_P!120$B8/,3,7UW_LUJ\XDD-7*0Q(,I\86DJWY#49B1I(@G!QD20V!(2]%#
MF(B.)\J(.'XH)J/SXH:=-NHJ*B*@FOCX&J]/QCAH=2JX: "R5=XB/$LJ)"E@
M*@@HW)W 3&TUJFRJ @27$>)F3*2%*!*=X().H&3,G?E:MK!UV0U 0E0J_P#<
M;=555)+I(*BTZJ?*^PR0H]\EY&XT^*^8(B4]F>!-:+CB3DPM*F[,J3J*7$G2
MMSI)R($0"3Z7;V^*&&4A&I+L%](44E*<@:2,@K4E2DD@CPZ3()A*#@$)/("J
MT:?XEHD15;/OQ(_'^2>/_>]=HJ*+H+_-3S[ZT4A:U1*FQ#H@QY$I!WF0J 9(
MST.,VH& "5*QH7&% DXC>9 (&"#*2)B$3KSLUYM2<5%;%1@/=_B;2$OF3O\
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M2.]%V2HMUOLY?P2Z$,HC4(*'5QN92C4 !F<S D@5?%U;DEN5+4HRDIU*2%
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M^/2LVJ^E*A%QM_Z47U$O_C?I#_Y1-$>E2=D^GYFIN^E11Z4H]*4>E*A#J_\
MZP;F+_NU\&__ !IS5]*GD/4_@FIO>E11Z4H]*4>E*A!$_P"LCR#_ '(,/_\
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M2DG?DP2]?"HJ=(9*OHURP4+6VXCQ(GPG$P.>-C$XCK,5R39TD!2BMMP ZC
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M#-+_ "BXW#DU)CEYG>1YY:9#*SG)K:?25Y,Y!D=E6L,K%@L.&JA1DG,[08C
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MJ+T*$O2+\=(@JORO2)X%VOP/R&U4E(2< I4!*09T&)^ !D"9,;SO5]YEXJ6
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M"(+GEWYBGB7:?'I45H<[@[PML7@?F\0^,$J0#@/-RWM"ZL*;'D-!X,28TO\
MA3[F/)8'X8DL/-2(ZH),N 0IU4E2D*2M"BE:%!25),*2I)E*@1D$$ @C8U0X
MVAYIQEU"767D+:=:<2%MN-N)*%MN(4"E:%I)2I*@0I)(((-?*!]1OAW.X>[O
M>CT<:8YI_/7Y-]KZP<171;A-&V<_%);Z*7E98A)D,1VW'_W[*E.LL#57/U%0
M^U/H:[<,\=M66N(N!?$[#N[:]0?>N$!)%M?$J)*E+(TND92XDC 4@'\BOXB_
MH9/T9]KUW/#+=1[(]I'+J[[.N!.I/"+Q92YQ#@;CF2&D%PKX?J*1[*I+?UBV
M5$0,'I%\452:=%3:)._A"%2($7O_ -GLFD1>T%"%$%&T3U]%.(2K"@0RZF$Q
MGWI $[ 01F(BOF*Y:*%]ZE)"FB \!'*0E<<Y(TN#F2"3*R F)])DA]%<Z>AH
MTRT2(B]JVBD3H_"=J;A.,NIVG:MD'7BH]Q8,%IIQ1()<4<P,)  3D;3DD>L8
MKK^"\):3PSO5MJ2>(:G4SN$F$H2C&THUMDR2%"9V-QR>K$=R<(]NQVS%QE$7
MLS1$\H_S\JIEX^T72>1*VJ?B2]UOM)=24I [U)A))&V"<XA) D&1$S.XK2'A
MCESQ!OA2T*+EPZEME0!*@J24K$ S""H* R,@@&L1'<04!\20F9"(3Q]_]\2H
MB/K_ +/<7M'O+Y3\"+Q$#5<MJ$0WN /#R) W(B!/,''.#D5VO%.$'V1"V$%#
MUFGV=Q(F0ELD#4""K4=M@/"1DFJ6+Z(C%>2J(OD;Z=+UXC&5#1I%[[$E=4#9
M1/\ LM."G2-)ZL/-AM82#J0""A)@C45)TJ]4Y((VP01M6)V3X$+[B3O%"@]U
M9-J6_*?!WRTJ[LY3I4I00M*TD[$&#)I9%>-\/!PD&4RB&T:HB>8+V*&J(J)T
M2*H/ *HO^:>"$'=Y.E8B,IWCD1N1SQC)'SBMSQ?A8!4'<L/"6"5"02H $B0
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MN:[+O<MRNY>%)-YE>3V5OD=W+4I=M:3))$ZJJ:=3TI1Z4I!:6E91UMA=75C
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MW2$)0V/Z0CW,<PF3CG."*K-E*X[']M$]R.A.N@JITA&J@C2_S^"%'2$D3X[
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M6ZZM%.&BGD(@G<[QMGH/@/C4^VN=^N*]EN/,T#S>I&(S2,M,,<&N3ETRPTP
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MB7)19#T2:F@N-6=9/CUT\ON-.LP]E;Z:Q7'*^8#$^HU5M6CD"X2JM!&2E1Z
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M?!'QP6^41Q"U4\R^R6G>\MRPZI##7?+/=71=0%K2XSJ;[O3*U$U@7)A3'W9
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M#>.P LGL3UW2?K%G#I@KCM[)Z1-B55545BW%C3TS4^XN+"OJXDFZN*BFBOS
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M5'Q]4G8).-B))RD3 .(.HYB#[NXWKHNS]@5"YOR#*3[,VDI^V=*GB#!)TIA
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M62$2HXB."3JN&':LB21B5A51(Z#[_P!:%XE[R855K?J4\UHJ*O:,S</X!W3
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M#J+<<3MBG3<JX;>+!=6IDI3=(8;>:N.[+S9:>A"QQ?">S0X)Q)Q/<B]X==I
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M^O[]/NJL"-]S@1!CSQ((Y$3$'.XB77&GZ;N?YE)PW8O*783F3XT&Q]F[=O\
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MX6Y"JB?2%T2DK9IVPK2*2+'Q/W?I21T'W_K6=USPMP'&L]KMP;9S?9'*?=5
MXY_!VT.0<K"[:5KEAQH6%#5FO->83KG3.L+)^.BL6N68+K:BS?(F3*/DF3V\
M46([,T)\@!T$Y]9))_+E%3#3X_FO?RORO7^:JJ)\=?R3X3_/I/GM>U]*BJ^E
M*/2E'I2CTI1Z4J+^]^6>K]'.S<6*2YL'=#F+9%D^(Z%PF76RMFYXN-XY<9@_
MCV/P9TJ'5Q\JN\6QK*[O"\=O+.JM<[B8CE:8?%NW,:O!KU3$_KR_>:X)7L'F
MM]0BNE;@T_N.CR/9V&7F:8+4ZJC8E2L<7;+CWOG'<HM=(;VA/9]F81<MU[L?
M7-FWANZV9V ;&W+66-?FNO,4@Z_RW7EA,O8Y_P#O]_C^-5>$8C'KG5&=AR)\
M.PQ)F:[F<7>%VN^*\G+K7',RVKL:_P PQO66#.7>WLO8S2QQG7&F0RU-5ZUQ
MF<%-4S"Q;!',\S!RHLLH?R;.[$[MUS)\ROW8L%R+-4DS& (Z?>?C\N@ J8/I
M44>E*/2E'I2CTI1Z4H]*4>E*/2E'I2CTI1Z4H]*4>E*/2E'I2CTI1Z4H]*4>
ME*/2E'I2CTI1Z4H]*4>E*/2E'I2CTI1Z4H]*4>E*/2E'I2CTI1Z4H]*4>E*/
M2E'I2CTI1Z4I+.@PK.'*KK*'%L*^='=B38$Z.S+AS(KX$V_&E19 .,2([S9$
MVZR\!MN 1 8D*JGI2L!*P7"9WZK][AV*S/UZTK;N\^ZQZHD?K-U3?:_I%O:^
M[#/]1M*K[*'^FSYGO2X/VD7[5UK[=KP4K:?2E'I2CTI6$R7&L=S/'KS$<OH:
M;*<4R>HL*#),:R*LA75!D%%;Q'8%K37518LR:^TJK*$^_#GU\V._%EQ7G6'V
MG&C(54VVIEX?$OBW7K0K#XYZ/CKB^&Y)KO'E;U;A7=/@F8KD"Y;B$%5I5]G'
MLG7+LN7(*H?\'<+EV5K8-2%R6\^_5,GJ?G3K8+@.$:PQ.GP37&(XW@>%8^U(
M9H\4Q&EK\?Q^J;F39-E-^QJ:N/%A1CG64R98SG&V1<F6$R7.DF[*DO.FJ*VW
MTI1Z4H]*5R;SSZ46*[4>V?.V1R(V[E5UMC8>793DN1R*36;&1+@>P-?9WJ3+
MM+,6J8>\^WKMO66<+C&#1 ]N9KU^AAWV/OC<7N:R,I55J(CE &!.X,SZSO\
ME4I.,?#?"N+V4[<RG&,NR_*9&TI-?"C0\G2A"+A6$TFPMQ[1Q_"*0J6GJY%C
M#ILQWWLIYBZOGK&]E5,ZEK9\V2Y3??3503,?OH/P J8'I44>E*/2E<\N2G!"
M'NW962[:Q'),4U_FMYK[6-"_8/X(-NYD67::Y%:CY!X%8YU.KKN@M,CQ8']2
MPL&LJ(IC$UK'+RQ.KM(AC]L^J02/O'P(@TT_%+Z9EKQHW+K_ &._N:!F5!A6
M _9R*-K Y=#=V.R[+4VL]/7]A#NSS*XAU>KOT'6S-WC^ E43K2KOK=2D9;.C
M5323E253RZ\]I).//SZ"NLOI5-'I2CTI1Z4H]*4>E*/2E'I2CTI1Z4H]*5%#
MEIS3T'PNQ"AR?=63O1[?-[IC%M8ZXQQF+:['VGEDJ;65D;'L(QZ3.K8\@TL;
MNEB6F07EG18;C)6]8_E>2T<2;'D.*D F8Y9)Y =3_MD\@:A9RX^IADNGMPN<
M>,&T3GC^;E,Q[]'MLNBUM33;B,:;$LTS#4^HIT#+8]K2[)RO!<FN,?T%L;)Z
MM[5FR>0F!Y=HNDFS\II[&76*D)Q)..HY9B2(^8&8(-1ZX1\)\GW?3[FS7>]=
MGT?6>YLKJ;JOS#,Z?+]#<F\VV5QYR*%2\=>:>+G7GB6T-";.RK6:RL7V[CMY
M58I+O<UP>+M'$ZR/BNY,NJ;!4DP1L8^(SNG&"!RC:>>([A:FU+KG1>N\7U1J
M;$JG", PZ"Y!H<=IF5:C1TDRY%E93Y3SA.2[.ZO+>;/O,AO;.1+N<AOK&RO+
MF=.M;"9+>52229.33B^E11Z4H]*4>E*/2E'I2CTI1Z4H]*4>E*/2E'I2CTI1
MZ4H]*4>E*/2E'I2CTI1Z4H]*4>E*/2E'I2CTI1Z4H]*4>E*/2E'I2CTI1Z4H
M]*4>E*C3C?,_AYF5GE]+B'*_C7E5QKZDR/)L]J<<WIJ^\L\(QS#VW7<NR#+H
M%9E,J5C=)BS3#[F1VMRU"@4C;+IV;\46S5%3!Q@YVP<SM'6:D36V5=<UT"XI
MY\*UJ;6%%LJNTK93$ZNLJZ<PW*A3X$V*X[&F0ID9UJ1%E1W7&)##C;S3AMF)
M*J*6^E*US+\PQ+7V,7V;Y[E..81AF+5DJZR;+LNNZS&\8QVF@MJ]-MKV_N94
M*JJ*R&R).RI]A+CQ8[:*;KH"BKZ4WVJUC&<87FRY F&9?B^7+B61S,/RI,8O
MZJ^7&<MKH=?8V&+9 E5+E_HV10:^VJITRDL?MK*-#LZ^2]&!B9&-Q2LO:V]3
M10CLKNTKJ>N:=BQW)]K-C5\)M^=+8@063E2W66 =F3I,:%%;)Q#D2Y#$=D3>
M=; E*R/I2CTI6/J[>IO(:6%+9UUQ 63/A).JYL:PAK,JI\FJM(B28CKS*R:V
MSA3*V>QY^[#GQ),.0#<AAUL%*Q]SEF+XY88Q59!D='26F;7CN,X;6VMI"KY^
M5Y%'HKG*'Z+'(DI]J1=6[&-8YD&0OUU<W)ELTE';VKC0P:Z8^RI6!V5M?5VF
M,7>SC<.R<!U1A<>= K'\OV5F./8+B[-E:OI%JZ]V_P HL:NJ;G64HACP(ART
MD3'U1F.VXXJ#Z5(!. "3T FM>L.0>A:G-[;6=INS4M?L>@?PR-?:_F;%Q"/F
MU&_L:VJJ'7S5SBCMP-[5'G5Y>T=-AZ3X$?\ B6UN:JOIOO)=C$9>4@[P8SF.
MF3\ADT[_ *5%'I2CTI4/-E<LVM<;SJ= 2<!>LLVSFQTJWJ,!R4(;&R*;/,ES
M6'MZTAB=$^==+X\X/KS)=DYA5BMF%M02L3BQ[&JF9&7Z8J8_/[OUV'G4P_2H
MH]*4>E*/2E'I2CTI1Z4H]*4>E*/2E'I2CTI1Z4H]*4>E*/2E'I2CTI1Z4H]*
M4>E*A#Q3Y?67)?8&^<#=U]2X<[QSRA[6V<V4/8];F 7FQ8F4YE42W<)A5]-
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*'I2CTI1Z4K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g383770g92x08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383770g92x08.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[14.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %/*^4V(X0DE-! 0      #\< 5H  QLE1QP"   "V  < E  #T1I<&%N
M=VET82!':&]S91P"!0 74&]W97)0;VEN="!0<F5S96YT871I;VX .$))300E
M       0LT,+V'L^98WVR ]+Z_Y]=SA"24T$.@      Y0   !     !
M   +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M  !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I
M;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
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M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#
MO_XU  (  3A"24T$)@      #@             _@   .$))30/R       *
M  #_______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          (X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      T$    &
M      $)   $\@    8 9P Y #( >  P #@    !
M      $             !/(   $)                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     "F<    !    G@
M "$   '<   ]7   "DL &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( "$ G@,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M       #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*
M"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R05
M4L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C
M\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 "
M @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^$_)&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M)18R.]P^S6^N/ :;P249E.C67*X)0#4N#IRW,[*=JU+VY:TA\98C* RJPU:
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M\@  ]@ /P /D&NA<_6J5R]*Y_P!JN<Y/;/N2P?GV)!4Z^*,EU6X/6B B"DI
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MX2U>B(<4PF8ANN+6S5Q90#$,1K9ZRZEZZ],4Y# TE%^TY1X,'U<0K<02P/\
M1E1DS]DD>5OW&"L/4"OF"5H)HYEYQN&QW')E_>4E?<:M7J/=*WD>EU'(5-DT
M)NHWJLP5PJ\PU,!F\K7K)%M9B&D$# (@*3R/>-W!/?D 4 !]P'7-W1HW>-QI
M=&9&!Z,I((^!%7E65U5U.5=0RD<BK#(/Q!S7MIN:BJY#2]AG7[6*@X&,?S,S
M*/52H,XV*BVJKZ0?NUCB!$6S-H@LX75,(%323.<P\ .O "Q"J"2Q  ',DG
M]2=J]) !)(  ))/( ;DGT JK WQ;F9;>#NOS=N(DO5),\A71\XJD<\,/GPM!
MADT:_0H94G/EI.8ZHQ<.C( B4B:TF#UUV][@YC=&M+<6MM# ,9C0!B.1D/FD
M(]"Y8CTQ5'NIS<7$LV^';R@\P@ 5 1T(4#('7)ZU]]TP908CJ)[*793=HK;E
M,2Q8B/OR$W;XR%,7W_U@?B4/P$0$/< U\<0&;&['_EY3^"$_\J^[$XO+;^V0
M?BV/^=6BFN=U=JUY=4C9LTWR;,LHX=9LFJ^1(QH7(6''SD2D-'Y0J#=VYA&Q
M'!@$K5"U1[B7I$DY.10K:+LSQT5,5VZ!B;W#KLV=W'*2?#)\.4=XW(U'WJ<.
M.Y4#D36G?6WM5M)& -8\\1/210<>[4"4)Z!B1O58FZ:N63ERQ?-EV;QFNLT>
M,W2)T'+5TW4,BX;.4%2E51705(=)9%0I5$U"F(<H&*(!T+U!SV(_,52_>,=P
M>?N(_.K'#H;;OAW8[#: A8)-20R;@4Z>$K^=VL"K]^E5X]H>BV1<QE#N7(3E
M'7AD7LDY JC^R15C'E043*&HG&;7V:]<J,1S_/1X!P"Q/B+^[)JP!L%*^ZKA
MPRX]HM4R<O%\T^>9T@:&SS.4*Y/V@PWQFLRM^NZ.*V:;2,U[A7XM%92DU)=&
ME1CLP E.9$L*R->HD0=/GS56SFSR4<K*>0515O#(23WL%-JH(:EE;&[NH8!D
M!VRY'U8U&J1O>$!QGFV!UK8NIQ;6\LQP2B^4';4Y\J+\6(!],FJL^9F)2P2\
MM8)V0=2TW.23^9F99^J9=])RLFZ5?24B]7-]Y=V]>+K.G*QOO*K*G.;W,.NC
M   *H   "J-@ -@!V &PJD,Q)+,22268G<DG<DGF23N:L=NB;LL-LUV14IO9
MHE2-R[FX6V8,I)NTBIR,2YGXYL6H4UP42%6;C4JF6.1D(Y4R@-+5(6@Z1NQS
MP%#XO=^UWCZ3F*',49')M).MQWUMG!ZH%VS5OX;;>S6RAAB27YR3/,%@-*'M
MH7 (Y:RQ'.MO.HNI"JC+(_\ 2'?/VSM'^>/M=.3Z"_=7\A5 ;F?>?SJ<]X8S
M^K_R'_>EO_[ML0:IWRA_7H_[M'_,FJS\%_57_MF_R)4B_4%4Q32E<6YNP_2]
MP&(<CX3R(P^)4K)]/FZ;86Q>TJY&4RR4; ^8JF*;TTI%N#(R<4\*'F,I)HU=
MI""B)!#+#*\$L<T9P\;AU/J#R/H1L1U!(K'+&LT;Q.,K(I4]\$<QV(Y@]" :
MJN=Q6#+GMFSGE/ >04"I6W%=REJG)K)IJ)M91!FJ"L18(\JH%5&)LL(O'6&(
M.H4IU8N3:*'*4QQ .C03)<0Q3QG*2H''<9V*GU5@5/J#5'EB:&62%_I1L5/K
MC<,.6S*0P]"*EY>&/W?C;\4Y/V8VJ447G<3/7.4\7(NE0,8^.+9)MVURA6)!
M.)P;UB^/D)I7N+]Y3(0D3$4VHE3K'RAM=,D5VHVE BE_M$&4;]Z,%?\ AY/.
MK!P6XU1O;,?-&?$3[C'# ?=?!.?MC'+:4)<+97J%4[/>;;*-H2JTVO3-JLLR
M\/Y;2*@:_'.967D7)Q_BH,F#1PX5'Y]B8\ (\!JNHK.RH@+,[!5 W)9C@ >\
MFIIF5%9F("J"S$\@ ,D_A55IO"W&V#=MN;S1N)L9%V[G)]VDIF*C'"@JJ0-3
M:%2AZ57!/R)3#7JC&PL.HHF!2+JLE'/:!EC<]'MH%M;>&W7!$2!20,:F.6=O
MWG+-\:H]Q,UQ-),V09&) /U5&R+[U0*#CF03UJ6OX9[96-"Q'>MZETB#M[1F
M4[S'F*3.TRE5:8KK<LB>S3C4#%!5,MRO,45@(*>YF-%9/&H^EE1.M6?E!=ZY
M8[-#E8L22XZRL/(O[D;9]\A!Y5/<%MM,;W+CS2$I'GF(U/F/?SN/P12.=2EM
M5RIRH'WB5=K/Y*=W=2W&5^+,VJFY.GI?:!RB3^#DRGCA!C7ISO OW&PRU-6I
M#Y(H@4SV0;SSODZ@+FU<^ 7/BVK0,?/;N=//^BDRR_@^L>XBJOQF#P[A9@/+
M,HSV\1,*?=E-';)#$9.:Q6Z#.X\^WOJ-8HCY!\1I4<],9? ]H\Y002]3<!:2
M5$633,<B(.S9(@:E&%<*<F0CI:4*G[KF*;8XS;^/82D#SPXG7]S9_P#XV<XZ
MD 5@X7,8;R,9PLV8FSW;=,#OK"J.P8\^1L:3&*4HF,(%*4!,8QA "E* <B(B
M/L  'N(C[ 'N.J)5OJK@ZD>XL-UF^'<;FMF^4D*W/Y#DH.BKF,(I&Q_1TD*7
M2EVZ0F$K=.1K\"QF%D2<!ZR1=*G 555#&Z+80>S6=O"1AEC!<?\ B/EW_!F(
M]P%4B]F\>ZFE!RI?2AZ:$ 12/0@:NFY)QDDU(4\+KM?%5]GW>).LBBFU1;X#
MQTLLD(B#AP,+=LDR"/F!V@8B!*%%M'B'!P*XGV1C]IUDQ@_E%<[06BGF?'D^
M&I(Q_&0D'LIJ7X)!O-<$=HD_@TA_R $?M"I+FZ[;I+9YKU?=T^PQ-=O=/1N\
M6Q2L[26?TBZTC)U-DJ'DC&UW1K\E#V5C"6B#D&[^/L=6EF%AJMNKU8GVP2T<
MQE:W.0%K<"!FUJ61]!)7 ='B<21R)J!4LK#!5@59&93@D,LQ/"90I1@KIJ #
M E'1U*O&^DA@K#!#*0RNJMY@"K8.&Z2&.\V1;!KNF85)E7Z@_LKG$F', R5I
MB\=8O^W5@?6S(\DWL%O3-.V&7OMC=,7CQHU@ZC5:XP@8J/@*ZFX6F)24W/TI
M)"2;8L6<*)9KA4:230H6,:5\JA%R,ZF9BQ+-@*!K?H])0!<!-*EC'%#J"1EV
M+R'4WF8NQ&=E50H"KG46W)ZB:D::4II2FE*CA]?7I@QVY#$LKNYPW7"AN PU
M7U'EYC8AJ(N\KXHA457$BDJT;)&/(W.ALP5EH!R4!?2E=;RM:$LBY3J[9C/<
M$XB8)1:RM\Q,V$)Y12L=MR1I1SLPY!B&V\Q,/Q6R$T9N(U^>C&6 S\Y&.8P.
M;J-UZD KN2,1/>EWNP>[-=[F$LO*RBT=2'ED:X_RRF502M'F+[TZ:PUE7?I@
M8GJ$JTHI'W=FCWE[I:KQPB(E*8AK+Q"V%W9S18R^@O%W$J>90/5L&,^CFH&R
MG-M<Q29(0L$DZYC<Z6R!OA3A]NJBI:?B;*@O/[ *-96R9E HFY.B2[TY>!(C
M&S5*R15S*G'@1X-*3,0B7@0#E8.>?;59^3S8OG7/]);R#WE7C?\ )3__ )FI
M_C2DVBD?4G1CCL5D3\,L*@5>X>X"("'R$!$! ?Q 0X$!#Z"'N'TU<ZJU9;8T
MQUNDZCNYF/J<.^M&9\YY0DO4S-IMLJ]?$BXEIY1)&S6R<7(Y3KU,J[(Z?F"B
M@5I'M2LX2 C%WKF*B'.M));V%N6(6&&(85$ &2>2JOUG8]SD\V. 2,Z)/>3A
M06EFD.[,2< <V9CG2BCX#8*"2 ; +IN]*? /3QI;5S!,6F0,^S465O?LW3<>
MD$NY.X(D=[7:.T5\[['4I)=, 38-%#2LSY:3JQR4DJDS184F_P")3WSD,=$"
MGYN%>0QR9S]=SU)V')0!SM=G8Q6B[#7*1YY2-]^:K]E,].9V+$D#&TC4=6]3
M2E-*5$7\4GN)*W@]M^U**=CYTG(R^>;HV34* D9Q:$G1,?D6*4W>9)XZD+^N
M9,Y?+%6+:J@ G3((6CY.0;W%RPY 01GU)#R'X 1CXFH#CDPQ# #ODRL/0 HG
M7.Y+\]MAUY:?^AMLZ@-XF[ZS5Z\LA>8ZHV!\MREH(=$JK9P[OU8=X@@61^XH
ME*]05OS^TQAN2F*ZJGFD-REJ3XQ=-:VJLAQ(\T03TT.)6.1N ?#"GT:H_A=N
M+BX8.,HD4A8=#K4Q $$=G+#U45J-NM0G<?7*W4&T-3,;-1K18*=8V)BG(9G/
MUB6=P<PT,50"G*9M(L7*(@8H& 2>X<ZDU97574Y5U5U/=6 93\00:CV5D9D8
M89&9&'9E)5A\""*L:.AUN))N(Z<6#G#Q^9]:<.-'N!;8"JGF+(.,; U:5,%3
MF,914[C&[ZE.U%E.3J.%U^XQCD,;5%XS!X%_-@86;$ZXY?.;OZ;2!QBKAPR;
MQK.(YRT>8FST*;+VSE"A^/,\ZVY:BZWZ:4JIFW(2A9S<3GZ<*83%FLW99ERF
M$>1,63OU@>E,(_7N*N _,?G\QUTN :8(%Y:8(5QVQ&HQ\,8JB3G5/,WVII6_
MQ2,>GOKXJZ4&U8^<UUM:HM6.&V4JIY"KJQN3-Y>IW2(0F(249+=I2KI&3568
M.^SN*UEH^2CSF,LS5U]JZOJTG.AWC;T=#A@?S]00>1%?#(R:=0QJ174]U<9!
M'Y'L01TJ=UX<;=?^6[9<]P589))S=]KUC&K-$5%>]\ZQ9;3O)^AO50.<3&3B
MY MJJ#<B1 2:1=<ATC<&5*)J;QZV\&[$ZCR7*ZCZ2IA9!\1H?/4LW:K1P>X\
M6V,3'+0'3ZF-LE"?<=2C&P517V_B$]V7YO&Q28QA 2 -;_NBE3XJCB(K^4\9
MX^;H)RN4I8J8" JM'4'Z&C.RAP)/MTDN4>4!X^.!VWCWHD892V'BG;(,G*(>
MF&R__#(ZU]<6G\&U*#&N<^&!^QSD..HTX3WN#OC%5^32"F'\5,3K..=.(>OF
MC234DFGRTCE)A=9M%(N51$"D6D%F[DK1$.5%BM72A2BFW6,2[Y&0,C)S@=3I
M&6([X&,^\=ZJF"02 <+C4>@U'"Y]YY>X]JR*V0S)J[O1VB3I3"08G<]@-^)@
M'@0*VRK5%#CS]/N%'WUKW8U6ET.]M/Z_U3X_C6:U.+JV/_F(/P,J _PJU@US
M>KS32E5\'B!]EAMLN\U_ERJ1)VF*MTA)/(T:=NW\N/B,FH.DB92KY#D*!"J/
MI1ZPO20'$H"%P<LVQ/)BS]MXX)=^TV@C8YEMB(VWW:,CYIO@ 4/W 3NU5/BU
MMX%R9%&(YP7&!L) ?G%_>)#^I9AR%=GP^.[P=N&^.)Q?8Y(6N.=TD>VQ;*%7
M<>4QC\B-G"TCBN:.0P\*.74TM(T1 A0* FO0.5C=C(O#C=K[19M(HS);$RKW
M,9P)5_PX?_A^IIPFX\&Z$;'"3@1GL'&3&Q]YRGO<9.U9R>)WW=A8K_B79;5I
M)-6+Q\V;YCRHDV7[P^VMA8/XF@P3TI# *+J"J#R8L"S94HE6;7>&<\ 9!,0T
M_D]:Z8Y;MAYI"8HB>B*09"/1G"KGH8V'4UL\;N,O';*=D ED^\P(0?NKJ8C?
M.M3TK5;T6-EA=Y^]ZCQ=FB2R6(<,E0S!E@KE,QF$G'5Y^W+4Z:X^Z*2XW&W'
MC&C^/5.D9Y4V-L60/YC+@9+BUW[)9NRG$LN8HNX+#SO^XF3GHQ3O6CPVV]IN
M5##,<6)9,\B%/D7]Y\9!YJ&[59)ZH-7&FE*J,LC_ -(=\_;.T?YX^UTY/H+]
MU?R%4!N9]Y_.ISWAC/ZO_(?]Z6__ +ML0:IWRA_7H_[M'_,FJS\%_57_ +9O
M\B5(OU!5,4TI32E0_?$X;+1*;&V^BEQ)A*/PW#N;19-A$I/=XYQG=)$R1>"%
M,89"BR<DZ, "H:AQ20]QR%&T_)Z[R)+-SN,S0YY]!(@_A(!_:'OFO\:MOH72
MCEB*7 [_ -&YZ#?*$\R60=L1S>GWNIDMF&[W"NX)LJ[&!JMG3C<@1S0QQ-,X
MULZ2E?O$>+<! CQPC!/W,M$(+ 9).P1<0\X!1JF8L[>VPN[6:# U.OS9/U9%
M(9#GF/, #CZI8=:A[6<VUQ'-OI1O.!UC8%7&.I"DE1]H"I@7B*-Z$;BW956\
M)4&P,G=FW=.VS<7L8[(L/Y$8$D=8K3,,EVZA@,UMCUS5*JD90AFDK7IRRE14
M\QMR%7X%:&2[:9U(6U!V(Q\\V54';F@#/T(95[U8.+W(CMEB0@M<'&0?ZD89
MR-^395.6"K-VJ%SM-VY6[=MN-Q'MVI'<E-Y/MS.%7D@2,LE7ZZV27EK=:')"
ME-W-:Q58Z8GET^.Y<L?Z9,#++)D-;+F=+6"6X?=8D+8V\S;!%W^TY5?C5<@A
M:XFCA7.9&"DCZJ\W;]U03[QBK3_&..*AA['5&Q3C^)2@J1CFJ0-+JD0B/<5A
M UR-;Q4:@=00[W"X-FR9G3I43+NW)E7*YSK*G.;G$DCRR/+(=3R,SL3U9B2?
MXG8=!M5Y1%C140:410J@=%4  ? "ON=?%?5:?^N7M;_.?Z>V5BQ$8I(WW!QV
MV>**1LF*CI1:CMGR=TCDTTRBNZ^)8XD[<FU8)#PYFT8902*';)%U*<'N?9[Z
M+)PD_P P_;SD:#Z8D"$G[.H=:C^)P>/:28&7B^=3'/R ZAZY0L .^#TJN4@9
MV6K$["V: ?+1D[79>-GH22;F[7$?+P[U"1C'R!_[*S1ZV0<)&_LJ)E'Z:O9
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M:>$IQ)<DQ^HC&#(1[P53W.<'(J.X1;^-<^(PREN _H9#D1CX$%]CD%5SL=[
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M+R*\,3)&Z,@8$L5P5."!L3R(/XFL+^GCN'#:KO7VXYS=.SLX&H9)B6=S6(8
M E MZ;BF7Q0Q#&*FJ9M4;!,.T$U1 GJV[=3N(8A5";=[![5:3P  L\9T _[1
M?/'N>67516K:3>SW,,I.%5QJ/[#91R?<K$]MLU:8E,4Q0,40,4P 8IBB E,4
M0Y 0$/80$/<!#V$/<-<YJ\5X4HZ38QDB^6'A)FQ=NE1#Y@FW;J+''W]O8I!'
M7H&2 .9('XTY54(K+BZ65<F'DSA0ZXC^(K&%01_Q$W.NGXQMVV_"N?\ .K(/
M;;MTKNZ#HHX+VZV,4V\=E?95CN%:OU2 K\$LCZE1,Y5;(F0Q#@=>MVQ&(L#<
MIB'*9>.3 Q3%$0&AW%PUMQB>X7<Q7DC$?:42$.G[R94^\U<881/PV&%MO$M(
MQGGAC&I5O4JV&]XWJN<LM=LV/;A/U*QLGE=N5&LLK7)Z.5$[>0@K/6)5Q&2C
M)0Q>Q1%Y%RK%= QBB4Z:Z B40$ '5[5E=593E74,IZ,KJ"#UV*D? U3V!1BI
M&&1B".H93@CT((^!%9,[(=M=AWK[O,/8&3<2*X9)NY'=\GP,LY?1M)BP<6;(
MEB7=G[^)!.N,)8[%=VJ4KR=<1[0ZHKO$P-KW=P+.UEGP/FD\B\@7/EC7';41
MD#DH)Y"L]M";FXCBW/B-ESN3H'FD)_=!W/UB!S-3F^N]48J)Z1V>*]78QK%0
M5,# C6$BF"0(,8F&A<U8RAX]@T1(':BT8L#I-&Z1?NII$(0.  -4_@SD\4A9
MB2S^/DG<LS0RDDGN3N:LW%%'Z/F"C 7P< <@%FCVQV JNZA'QXR9B)),W8>/
MDV#XA^>.T[1TDN4W/T[13 >?U:O!&01W!'XU4@<$'L0?P.:MZ$5DW"*3A(W>
MDNDFLD8/D9-4@'(;_$I@'_'7,.57^N[I2FE*K@>N=M>KFUSJ$Y'C*81JSI^9
M86*S[!PK1$J"-<<7Z6L+*TPR:1 *BFU"ZURR2D8W;IIMV,/*QT>D0 9B(WW@
M]RUS8QER2\1,#$_6$870V>IT,H).Y8$GG5/XG (+QPN LH$P &,%V8,/\2L1
MC;! Z5P3TJ=M5:W:;]]OF&;N4BU&?V23N%T8'[A+-UO'5=E[T^K2@$X,#:TJ
M0"%<?*$4150CY1VX05*NDD Y>)7#6ME/,GTPH5#V:1E0-^[J+#F"0 =C6*Q@
M%Q=11M]#46?U5 6*^YL!3RP"2-Q5GD0A$R$33(5--,I2$(0H%(0A0 I2$*4
M*4I2@ %*         :Y[5UK]:4II2JC+(_\ 2'?/VSM'^>/M=.3Z"_=7\A5
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M/#C[ZWSN/55#./NU6J1<7(34E'0L.R<2,K+/F<7%1K-,RSM_(OW";1BQ:HD
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M<0U21CNZ#\6 K9<X1CV5C^ )JH[1+V(I$_U$R%_]I0#_ .M=./,^\_G5  P
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M*959=4Y2D223*9110Q2$*8P@ UZV&;FW&PS/$,GD/G%Y^E34_P#0S=?FI/\
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MN?PJV"VJRJD[M>VW3BJ2B"LS@3#TJHBJ4Q%45)''E=>'25(< .51,RPD.4X
M8I@$#  @.N:W0TW-PO:>4;<MI&%7N$YAA/>*,[\]T!]:Y[U@K+32E0//$Y1[
M]3?SC5PFQ>';K;6Z*FBN1LL9%51')>7O.(FJ4@D.=+S4_,*4PF)YA.X [R\W
M+Y/$>Q2#(R+ER1GD/#BWJK\;_6HST]G7^9+_ *BN /#VQ\D3JB8>5^&R!D6U
M*S(J\6*S7%)D@;&EB;D<O%!(!6[<[M=LS*JH(%,[=-D $5%B .?C9'Z-FW&[
M1 ;\SXJG [[ GX&L7"/UY-C]"3X>4\^W;WU8A:HU6VFE*:4JI:R31[LGD*]&
M/3K60I[G:!(8]=F"@8/C;X>2B+, ,' @/MS["'XZZ:C*47SI]%>;*.GJ:H3*
MP8@HV<GZK'D=^0-?$_8NX_[)6?\ X!+?])KZU+]M/\:_ZU\Z6^P_^!O]*?8N
MX_[)6?\ X!+?])IJ7[:?XU_UII;[#_X&_P!*DX^%^IUHB=T^XB9EZQ88N/2V
M_-HX)&2AI-@Q!W(9%JCINS]4Z;)-Q=.D(MXNW0[_ #5463M1,IB(+&+7_E$R
MFU@ 92?:,X# G C<$['D"1ORW'>IO@BL)IB58#PAS4@?3'<<_3W[;5-JU4*L
ME-*5%0\4ZS>N</;1U&S5TX12R7DI-8Z""RJ2:JU6KQFY%3)E,0BBI$7)D2G$
M#'*DN) $$U.+'\G"!+<Y('S<?,_M-4%QP'P[?;Z[CXE1@?&HKNR",E_ST=HH
M(Q,BNK^<W@@Q$4V;DRB@)Y1JQS]I2I&,(%(!CF$"B!2@)A]@'5DNR/9+HY&/
M9Y]\]HG/XU"6H(NK78Y]H@Y@_P"U3)^ WJU1USBKQ32E<$[G<ZP.V7;YF#/E
MD;+/XO%E$G+4$6V(<[F;E&C84H"OM@( B#FP3R\;"MSCVII+/R**G(F0YRYK
M:%KB>*!3@RNJY/)03YF/HJY8^ZL4\JP0R3-N(T+8ZL1]%1C.[-A1ZFJJ6^72
MV92OUQR#<Y!S/7C(%KG[A:9)4IC.I2R6>5=3,P[%$.XQ!<R#QPH1 @=B)3%2
M3*4A"E#I"(L:*B#2D:A%'0*H"@=!L,9/^M45G:1V=CJ=V+,>I9B2=O4YVZ<A
MRJ>QX=S:.^V];*5\L7""6ALA[FK,:\*HR+)9E,,<:UY->"QS'/$7*22Q$9 !
ML5W8&X[5XVY,3CR)2@6F<=NA/=B)&!CMET;$$&1O-(<CJ/+&>Q0U:N$6YAMC
M(RZ7G8MOS\-?+&/0'=QZ/OO6_C4)4K44;Q/&TQ[:Z#A/=Y4(%_)2U!D5\.Y,
M5BV2[U5&EV15[8*-.27ITC^DBX"V$G(([M4W:>1OL2U]A,35E^3UUI>:U9@
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MX^7FY%J:(#[?42PBW'O[?7V]_G]W7S_V<E_WJ/\ ]-O_ -J?IR+I!)_C4?\
M(U(LVLYFM>X; ^/<U6[%$MA5YDB&2M$3CZPSB4[8HRLR0BM77\\LA$PZ,>_G
M8L6\T2(!!9Q','S))^JE)"\8,X*YA2">2%)1,(SI:15TJ6'T@OF;(4[:MLD'
M&1@F8@D::))6C,9<:@A.2%.ZD[#!(P<<QG!WR*R#U@K+32E=L443"(F23,(_
M,1(41'Z>XB'(^WM[Z4KJFFFD7L23(F3D1[4R%(7D?F/:4 #D?J/'OI2OWI2F
ME*]>^B8J3[0DHR/D *'!?7,FSOM#GG@OGI*<!S[\!P'/O\]>@D<B1[B1^5,
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EII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g383770g96o04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383770g96o04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[27,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    );"^ED@X0DE-! 0      # < 5H  QLE1QP"   "   < E  !$Y3,C <
M @4 $T-E;G1A=7(@1W)A<&AI8RYP;F<X0DE-!"4      ! 8]E!^\8GB1PRJ
M_4/P1XYM.$))300Z      #W    $     $       MP<FEN=$]U='!U=
M  4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0
M  ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    *
M $$ 9 !O &( 90 @ %  1 !&       /<')I;G10<F]O9E-E='5P3V)J8P
M  P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M    0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-
M!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M    0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N
M0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M     $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M    4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!O
MX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M            0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL
M0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G
M4',     4&=00P    !,969T56YT1B-2;'0               !4;W @56YT
M1B-2;'0               !38VP@56YT1B-0<F- 60           !!C<F]P
M5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M  QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M       +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU  (
M 0.__C4  @ !.$))300F       .             #^    X0DE-! T
M  0   !X.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      ,U    !@             #6@  !V0          0
M                       !              =D   #6@
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   #6@    !29VAT;&]N
M9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   UH     4F=H=&QO;F<   =D     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    +.$))300,
M !M3     0   *    !)   !X   B.   !LW !@  ?_8_^(,6$E#0U]04D]&
M24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S
M<$U31E0     245#('-21T(               $  /;6  $     TRU(4" @
M
M   18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=
M @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN
M9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D
M;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P
M  @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@
M*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M$G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR
M+C$
M         %A96B        #S40 !     1;,6%E:(
M  !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:
M(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                                    9&5S8P
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="                             &1E<V,
M        +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV
M-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@
M:6X@245#-C$Y-C8M,BXQ                                  !V:65W
M       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58
M4    %<?YVUE87,          0                        */     G-I
M9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #(
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M(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U
M#5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/
MLP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%
M$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5
M-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA
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M.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B0"-
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M$7AN>,QY*GF)>>=Z1GH
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M9G)SLK/#V&=XI*6UN,7_Q  : 0$! 0$! 0$              0(#! 4&_\0
M1A$  0,!!00( P8#!@8# 0$  0 "$2$#$C%1D15!4Y($$R)287'1\#*!H044
ML<'2X4+B\2,S8G*"HC1#DZ/"TR2#LF-S_]H # ,!  (1 Q$ /P#^_CA$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A%S>O>VMJ4+J\WW4I57ZE3='V%TUZ%&Z'*:YU+=
M[_KD%M^/8NIMC8,A-I;#2]54*SN12.H5E9^PSM<!RHT>N.G2#8B Z_'*Q3YF
M:UW1XYX+2G0<CK,C>#]ZZ0)#[*X[M@/K$R_I78-VA[LKVVK9L.;J!QDO#UOK
M_:CQ_;U/L02XC8DIUBLWZ_ZU(7(_*_<8,0PD-P5$T(D3A$8>&.&>&)S0U(W5
M;.&%X344(CT*BS;JNO&13-E >E[[-&)JVPIVC'U!;=PP=Z3][UQM5 T<T98>
MAV4_7MD,"RUJD;%@ZO*;4:D70"418S="E#Q4(.\_GW[%%1$UC=AACOB1AE^,
MK/=/W3PH.D=LC=<R:U9MKZ]NO4=N1PA?=I5+>UGDJUV W:0UP$#!34FS;"&Z
MMK8+0]8$;5H!2R2P #:AFS,Q,F+%9?.<\>?3\!^)4,12?A&4S'C%9-0</*@]
M\+JC\+^(%TO)S2E3L!X]T9N[K)CX'3OMX/B/N4WH';6P%:T4[ L=K# K=K?<
M(G5&JG]?6NQ@K9?&RIV6(%M23L!5-*D"3C$Q,C#03@3AO'SGJ!O[PB ;: ^C
M7"@I(5L?M.S5T9>*ETQWLD+VV.1*T3/"B""L;32(T=5XM=O.V<*W#9[ :KDJ
M?0D(C0S)\!.I5T+.[,P-\5K,4$G?2*8QB-AO!Y;=ZMMR:KL]BZO=>BM=7:)9
MA4(2&@42_P"NI$7#]*K1*W@I(2_QTR#$.J7F;8*^%NM>GF*S9QD-E0PR;\@>
M/%R'WOGZ#\-,%O\ <(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBUNZ
MN]N6+1G3OL7950B1)5J%M5D%7'"+"I0L2;OESKM!&64Q$0MI4P+4YEG:LYF'
MW\9,L6(EQURXB7<R6B+AYM[PGO4?0+'UD H^UM2R9.O+,['UR@(#UP^+UI5!
M/6WI;I]F/;.(VW85;L^K+<SKS9LSW4B=0-"KE!MUCA3=A:QV,_KL#.C2"U'G
M@?G2:?/T,''H'TI]8QVUVC58#96W=97VM;3TU;K1!O 2SZ;(#Q&S*AU!5W5
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M=4R&S:@P9OV+ABI828C/C"TBA3ZP+M@[!Z.IT%#+BB5RK<#(>>1BE)DPFB-
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M%$ AH5-2T_")B2L1Z 1'RV%]J'HLR'(>C2&EXREQIQ:%8SC.<<(OY]9/@_\
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MC^#X_$\T'^K\-]3PDG,I]K'\'Q^)[H3]7X;ZGD@9!).9U*?:Q_!\?B>Z$_D
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M1>!:0[&I  ,@K9+I+ZG-A=0)O8\"Z:O9H$*IM!I0IQ-E!E"T>03-VX1,J-N
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M-"R#0T=)PK-*T7=K&]K^U:Z6Q4/I45&9H0 =Q.,0I+_=\Z@_Q(MQ_K6Z9O\
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M[N0[H>@L[-J53L0@_?!#,%;,E;CYFD#[ )9>BLKGQ7IB)0_Q9K,=2<OAK2X
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MUVI6>R6Z3=!,(Z2KI2G#ZZ[ +\[-\O>'!H !@%H%V#$G>"9O02Z=Q %>MI9
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M\208'--9AI><EP&GE2&D1U$!Z)2E-X\E7/@HD=TJ9&P[&77ASF .:QUUQ $
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M,85PK-/FKGV8]'HQV8^#_+C/O>_C/Y./QI]-WDIZS\\_/Q5JC@0L4R2L487
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M4]JIO4Q'K8*SDQF8T<W? A4_T\#)UO?DERT>762$T=9)\95@+'B+8?I+T7U
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MJ:.@6 94?)TV#)T:WMS+$'AC3"X\BOF$-Y0R3W[E9#NOIWM.U3])VP)ZF -
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MYJ^U&PTYX*0+U@@5*.T"G5XG0Q(J+C7^%C[#+<CGAPY18.;O5.($/B#) <:
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M8YI<3</9+&D2(:8Q; !)-36=P(Q72TM6. CK!#KYF"2Z#$.+C ;@*>)$E:T
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MNZU*)09M+I8XYK9C5%E)CKEN%HGFA#B.P$OTV95 1NN4N\UBYU^Y(&E&C$8
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M5Z/\G"0<C3&B>GXE>JKV<)!R.B>GXE>JKY\?%\V>$@Y'1/S9S\'H3G/\V.$
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MUZ,MYF\P!)"-8SBI^9<A)VP+AQL&R(,M8VQ0A9)8D*U:B-;"2K4T*A0T6-V
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M8$2%5L&@U8@]?EVVT)B28,E=6I<,K(MMF0R0'+6""D$X)#NW,UA)S.I2!D-
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MH:LA -S">JYQ1 @&':U8AG=%[BINM:<'#SBEMFQY\NP#"IDN0A+PY+?EI;1
M0U&B.8<-M#_9WW-[?628CX2 ,716=\&DYA5]DP]9<:Z6&R J73?!),0#0?O&
MZ*-9^$$VW9-I:8K=K*ZSAA-@'*U7)X4($C/V;RZQ7J\5E#D\(6V('O:(4^*$
M$8KUIUU1]ETX/*A6)6Q2%=CL3'P6&VSG.8"6P\Q %<708)DR "")$R"0MNL+
M,,>0UT@.<TS(AH;%8NP23(/:/\- I)7X0>]"MK[KUA^YE6K?.UGL.17@<)FY
MNU2W7(<?/V>MU 92*PY7["FVS 4ZI2YVQC3A0'&!!2T&?&'RU1I#"]=<0YXN
MAUUT"L.(<XAI:-\$0XS J:P5D]':6L=+FWF@GLW@"&ASKQD1,D- !)-)D@+'
M;!X6($X()':%J*8: 0+-[A-6JW6URFU0E!(4ZZ;*J1R 7;JA_#D"XZ^I4PR,
M<6TVB%*(1(A%;2&);[</26C!A,F.T2VE2#G!:)PSW E&]$),%X!B8 DT(!&.
MXF#BM@K'UI'Z_I"Q;I=U.QB%C<8O3U-"+M\EV0Y.(75NA/6"_P V#4Y<6J#8
MIQ2O%:">=_E"5PXZ93<B8G"-&UAA>6T#@V)S($N('9%:X_FL"P!>&!_\!>3
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M.R9NF!)$S()((@&6E0=-\)JF(*@DD4?7;JGY@"IOP)^V3E:,YNM@L!"O/E(
M.QZK'%96IZ7)&$<WZ_O1HK@3(*T+'!#<,&B:2QUX@&Z*Q0N(),@8$3=WET#
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M@$L79:]9*O U3172<F[F2A.P;8JY^4:4#/5&F&Q!H02"CHI9,&>N'R;;.+W
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MUO,COG,5AA^+<*M(9>LJLQ,)KS3K)I:'#><SX.,"D*S.SF9$QACMD,^.VF>
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M6B/Q6IXR%T;;5V ;E33[%NVCTGU<B/-7>RTRX5HL$K0$[*A6LD!LK@.KUJ\
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M#K6T!B:-G$2),0)& F2: 2LCIENYMX6;8F/B D[X!J8WQA()HK?:NM73=,@
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M)D)))G8462  HL<@,8BUG!TF-79)@DG$!IGR(,EMJ_<+ $--L^2)%!%<))@
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M:F0U6VB-, C@,!:7IT@-=JQ:X&P:J5!O2VA(( 2(DR<W;K.\X.O78 !(:"Z
M28#C4 G$5%! G'++:XPMNS\4$DQ415N!@X1!J9G!1;4^@V?K\(VJF[M--WBF
M[59O.EK):JB/LP/75#"5G8-+IFEB5707#R;72:Q5]IWN&S,C62L'WIQ:)/CD
M1Z1R(C\%D6CLO-X&6.+0;H (:T@GM!H)K0[L%H](#CVK,%I;#P"07.)!<\$"
MA) H;V'C3=[7U>L55J(D);;I/V%98WET@S;R(H2#<+3B1&83>3$"A6&8 H0.
MS,P+!CO'G3(8:% 8)ES1)$LO-Z-!  +KQWF(WG=N\,:165Q>X.=(:&B  !N
M &.)-*DXG+!9GRK*<(G")PB<(G")PB<(G")PB<(G"+07J,Z6>E>PWG4-HMV@
MNG\S9[OO@9'/';?7Q8L[:I<F@[ E.,^400LAV_FG_<]N1BKVEY029&AR#$AS
MW1!C,<XVC+,NLYL[,DV@!D"7=EQ.XR8&!@&,P%WLK2U#7@.?#;,P!4-J*X]F
MA-14>1*E#[!CHP_%2Z>?U/T'T_\ ]AYOJK'@V7(*+'76W%M.=WJGV#'1A^*E
MT\_J>H/]0\=58\&RY G76W%M.=WJGV#'1A[WV*73Q\?_ ,CU![?_ / ]O'56
M6/4V4?Y G76O%M.=WJGV"_1A^*ET\_J?H/\ 4/'56/!LN0)UUKQ;3G=ZI]@Q
MT8=O_P U+IY_4_0?ZA^'V_DRZJQX-ER#WY[Z_,.NMN+:<[O5:?[F\"-X.[>&
M]]2=05CTM"K=ITVH"NOU;7S0"GZU/YKUFE6J+B\T8?7E#+7B7-EK@D_+U)\N
M#H9&._W!I/;S=T:P<YKRP MP:T!K:&9(&/C(-*475G2[=C7,#I#IDNESA(BA
M)D>"W ^P7Z,/Q4NGG]3]!_J'G3JK'@V7(%RZZUXMISN]4^P7Z,/Q4NGG]3]"
M_J'CJK'@V1\V#\DZZUXMISN]4^P8Z,/Q4NGG]3U!_J'CJK'@V7($ZZUXMISN
M]4^P7Z,/Q4NGG]3]"_J'CJK'@V7(%>NMN*^O^(^M/DGV#'1A^*ET\_J?H/\
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MA=_8Y.LL^(SF;ZIU5KW':)W#_P @_P#0N_L<O6,[[.8>J=5:]QVB=P_\@_\
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MW]CB^SOMYAZIU5KW':)Y._\ >[_T+O[/'6,-;[,OB;ICI],$ZJT[CM"G</\
MR#_T+O['%]G?;S#U\1JG56G<=H4[A_Y!_P"A=_8XOL[[>8>J=5:]QVB=P_\
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M[!3QJPY.PHL%F%'-O;:W$BZ7QEZF1H;EL'SKX-K;(>-/*15HF6ZPXLC:YD8
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M.$XQC&C:,))-HTN)+B2\$DN,DDDDDDFLUDK'4V@  LR    &P  (  $   0
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MFVUG?^XML:JH4RGO)(01@Z=286MH5NV"U/%&VI2#LT)"R%<!8)DR+R6SPA!
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
